



# ADVANCES IN HETEROCYCLIC CHEMISTRY

Volume 70

Alan R. Katritzky

Advances in

# Heterocyclic Chemistry

Volume 70

## *Editorial Advisory Board*

R. A. Abramovitch, *Clemson, South Carolina*

A. T. Balaban, *Bucharest, Romania*

A. J. Boulton, *Norwich, England*

H. Dorn, *Berlin-Bohnsdorf, Germany*

J. Elguero, *Madrid, Spain*

S. Gronowitz, *Lund, Sweden*

E. Lukevics, *Riga, Latvia*

O. Meth-Cohn, *Sunderland, England*

V. I. Minkin, *Rostov-on-Don, Russia*

C. W. Rees, FRS, *London, England*

E. F. V. Scriven, *Indianapolis, Indiana*

D. StC. Black, *Kensington, Australia*

E. C. Taylor, *Princeton, New Jersey*

M. Tišler, *Ljubljana, Slovenia*

J. A. Zoltewicz, *Gainesville, Florida*

Advances in

# HETEROCYCLIC CHEMISTRY

*Edited by*

**ALAN R. KATRITZKY, FRS**

*Kenan Professor of Chemistry*

*Department of Chemistry*

*University of Florida*

*Gainesville, Florida*

**Volume 70**



**ACADEMIC PRESS**

San Diego London Boston New York  
Sydney Tokyo Toronto

This book is printed on acid-free paper. ∞

Copyright © 1998 by ACADEMIC PRESS

All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher.

The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher's consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, Massachusetts 01923), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-1998 chapters are as shown on the title pages, if no fee code appears on the title page, the copy fee is the same as for current chapters.

0065-2725/98 \$25.00

## Academic Press

*a division of Harcourt Brace & Company*

525 B Street, Suite 1900, San Diego, California 92101-4495, USA

<http://www.apnet.com>

Academic Press Limited

24-28 Oval Road, London NW1 7DX, UK

<http://www.hbuk.co.uk/ap/>

International Standard Book Number: 0-12-020770-2

PRINTED IN THE UNITED STATES OF AMERICA

97 98 99 00 01 02 BB 9 8 7 6 5 4 3 2 1

# Contents

CONTRIBUTORS .....	vii
PREFACE .....	ix

## Chemistry of Pyrido[1,2-*c*][1,3]oxazines, Pyrido[1,2-*c*][1,3]thiazines, Pyrido[1,2-*c*]pyrimidines, and Their Benzologs: Part II

ISTVÁN HERMECZ

I. Introduction .....	3
II. Structure .....	6
III. Reactivity .....	31
IV. Synthesis .....	53
V. Applications and Important Compounds .....	74
References .....	76

## Heterocycle-Fused Acridines

PAUL W. GROUNDWATER AND MUNAWAR ALI MUNAWAR

I. Introduction .....	90
II. Pyridoacridines .....	90
III. Pyranoacridines .....	124
IV. Pyrroloacridines .....	139
V. Thienoacridines .....	142
VI. Furoacridines .....	145
References .....	152

## The Chemistry of C-Nucleosides and Their Analogs II: C-Nucleosides of Condensed Heterocyclic Bases

MOHAMMED A. E. SHABAN

I. Introduction .....	166
II. Condensed Azole C-Nucleosides .....	167

III. Condensed 1,2-Diazole C-Nucleosides .....	177
IV. Condensed 1,3-Diazole C-Nucleosides .....	180
V. Condensed Oxazole C-Nucleosides .....	186
VI. Condensed Thiazole C-Nucleosides .....	190
VII. Condensed 1,2,3-Triazole C-Nucleosides .....	196
VIII. Condensed 1,3,4-Thiadiazole C-Nucleosides .....	197
IX. Condensed Azine C-Nucleosides .....	197
X. Condensed 1,2-Diazine C-Nucleosides .....	212
XI. Condensed 1,3-Diazine C-Nucleosides .....	218
XII. Condensed 1,4-Diazine C-Nucleosides .....	277
XIII. Condensed Oxazine C-Nucleosides .....	293
XIV. Condensed 1,2,3-Triazine C-Nucleosides .....	295
XV. Condensed 1,2,4-Triazine C-Nucleosides .....	296
XVI. Condensed 1,3,5-Triazine C-Nucleosides .....	301
XVII. Condensed 1,4-Diazepine C-Nucleosides .....	305
XVIII. Condensed 1,4-Oxazepine C-Nucleosides .....	305
XIX. Condensed 1,5-Diazepine C-Nucleosides .....	305
XX. Condensed 1,5-Thiazepine C-Nucleosides .....	306
XXI. Condensed 1,3,5-Triazepine C-Nucleosides .....	307
XXII. Conclusion .....	308
References .....	309
 CUMULATIVE INDEX OF AUTHORS, VOLUMES 1-70 .....	 339
CUMULATIVE INDEX OF TITLES, VOLUMES 1-70 .....	353
CUMULATIVE SUBJECT INDEX, VOLUMES 61-70 .....	365

## Contributors

*Numbers in parentheses indicate the pages on which the authors' contributions begin.*

**Paul W. Groundwater** (89), School of Health Sciences, University of Sunderland, Sunderland SR1 3SD, United Kingdom

**István Hermecz** (1), Chinoïn Pharmaceutical and Chemical Works, Ltd., Research Center, 1325 Budapest, Hungary

**Munawar Ali Munawar** (89), Department of Chemistry, Islamia University, Bawalpur, Pakistan

**Mohammed A. E. Shaban** (163), Department of Chemistry, Faculty of Science, Alexandria University, Alexandria 21321, Egypt



This Page Intentionally Left Blank

## Preface

Volume 70 of *Advances in Heterocyclic Chemistry* consists of three chapters together with the Subject Index for Volumes 61 through 70. The first contribution by Dr. István Hermecz (Chinoin, Hungary) continues with Part II of his set of three chapters on condensed pyridines. Part I, in Volume 69, covered pyrido[1,2-*b*][1,2]oxazines, -thiazines, and -pyridazines, and the present chapter deals with [1,2-*c*]-fused 1,3-oxanes, 1,2-thiazines, and -pyrimidines. The third part will appear in a subsequent volume of our series and will deal with 1,4-oxazines and 1,4-thiazines, fused pyridine rings.

The second chapter by Dr. P. W. Groundwater (University of Sunderland, UK) and Dr. M. A. Munawar (Islamia University, Pakistan) is an overview of heterocycle-fused acridines, classes of compounds which have not previously been reviewed and which show a variety of biological activities.

Volume 70 also contains the second and final installment of the chemistry of *C*-nucleosides and their analogs by Professor M. A. E. Shaban of Alexandria University, Egypt. Previously, in Volume 68, Professor Shaban covered *C*-nucleosides of heteromonocyclic bases. The present chapter deals with the *C*-nucleosides of condensed heterocyclic bases and thus completes the first comprehensive review of *C*-nucleosides.

As an Index Volume, Volume 70 of *Advances in Heterocyclic Chemistry* contains an update of the general Subject Index (in addition to the comprehensive indexes of authors and of titles, which appear in each volume of *Advances in Heterocyclic Chemistry*). Volume 70 contains Subject Index entries for Volumes 61 to 70 and thus continues the Subject Index, which was covered previously in Volume 40 for Volumes 1–40, in Volume 45 for Volumes 41–45, in Volume 53 for Volumes 46–53, and in Volume 60 for Volumes 55–60. Volume 54, as a monograph volume, contained its own subject index.

ALAN R. KATRITZKY

This Page Intentionally Left Blank

# Chemistry of Pyrido[1,2-*c*][1,3]oxazines, Pyrido[1,2-*c*][1,3]thiazines, Pyrido[1,2-*c*]pyrimidines, and Their Benzologs: Part II

ISTVÁN HERMECZ

*Chinoin Pharmaceutical and Chemical Works, Ltd., Research  
Center, 1325 Budapest, Hungary*

I. Introduction.....	3
II. Structure .....	6
A. Pyrido[1,2- <i>c</i> ][1,3]oxazines and Their Benzo Derivatives .....	6
1. Thermodynamic Aspects .....	6
2. Theoretical Calculations .....	6
3. Ultraviolet and Circular Dichroism Spectroscopy .....	8
4. Dipole Moment Investigations .....	8
5. Infrared Spectroscopy .....	8
6. <sup>1</sup> H NMR Spectroscopy .....	9
7. <sup>13</sup> C NMR Spectroscopy .....	15
8. <sup>15</sup> N NMR Spectroscopy .....	17
9. Mass Spectroscopy .....	17
10. X-Ray Investigations .....	17
B. Pyrido[1,2- <i>c</i> ][1,3]thiazines and Their Benzo Derivatives .....	18
1. Dipole Moment Investigations .....	18
2. IR Spectroscopy .....	18
3. <sup>1</sup> H NMR Spectroscopy .....	19
4. <sup>13</sup> C NMR Spectroscopy .....	20
5. <sup>15</sup> N NMR Spectroscopy .....	20
6. X-Ray Investigations .....	21
C. Pyrido[1,2- <i>c</i> ]pyrimidines and Their Benzo Derivatives .....	21
1. Thermodynamic Aspects .....	21
2. Theoretical Calculations .....	22
3. Dipole Moment Investigations .....	22
4. UV Spectra .....	23
5. IR Spectra .....	24
6. <sup>1</sup> H NMR Spectra .....	24
7. <sup>13</sup> C NMR Spectroscopy .....	30
8. X-Ray Investigations .....	30
III. Reactivity .....	31
A. Pyrido[1,2- <i>c</i> ][1,3]oxazines and Their Benzo Derivatives .....	31
1. Ring Opening .....	31
2. Reduction .....	34
3. Reactivity of Rings .....	35

4. Reactivity of Substituents Attached to Ring Carbon Atoms.....	37
5. Ring Transformation.....	38
6. Miscellaneous .....	39
B. Pyrido[1,2-c][1,3]thiazines and Their Benzo Derivatives .....	39
1. Ring Opening .....	39
2. Reactivity of Rings .....	40
3. Reactivity of Substituents Attached to Ring Carbon Atoms.....	41
4. Ring Transformation.....	41
5. Miscellaneous .....	41
C. Pyrido[1,2-c]pyrimidines and Their Benzo Derivatives .....	41
1. Ring Opening .....	41
2. Reduction, Hydrogenation .....	42
3. Reactivity of Ring Nitrogen Atoms.....	43
4. Reactivity of Ring Carbon Atoms.....	44
5. Reactivity of Substituents Attached to Ring Carbon Atoms.....	48
6. Ring Transformation.....	52
7. Miscellaneous .....	52
IV. Synthesis .....	53
A. Pyrido[1,2-c][1,3]oxazines and Their Benzo Derivatives .....	53
1. By Formation of One Bond $\alpha$ to the Bridgehead Nitrogen Atom [6+0( $\alpha$ )] .....	53
2. By Formation of One Bond $\beta$ to the Bridgehead Nitrogen Atom [6+0( $\beta$ )] .....	53
3. By Formation of One Bond $\gamma$ to the Bridgehead Nitrogen Atom [6+0( $\gamma$ )].....	54
4. By Formation of Two Bonds from [5+1] Atom Fragments .....	55
5. By Formation of Two Bonds from [4+2] Atom Fragments .....	56
6. By Formation of Two Bonds from [3+3] Atom Fragments .....	57
7. By Formation of Three Bonds from [3+2+1] Atom Fragments.....	58
8. By Formation of Three Bonds from [2+2+2] Atom Fragments.....	58
9. Ring Transformations .....	58
10. Miscellaneous .....	59
B. Pyrido[1,2-c][1,3]thiazines and Their Benzo Derivatives .....	60
1. By Formation of One Bond $\beta$ to the Bridgehead Nitrogen Atom [6+0( $\beta$ )] .....	60
2. By Formation of One Bond $\gamma$ to the Bridgehead Nitrogen Atom [6+0( $\gamma$ )].....	60
3. By Formation of Two Bonds from [5+1] Atom Fragments .....	61
4. By Formation of Two Bonds from [4+2] Atom Fragments .....	61
5. By Formation of Three Bonds from [2+2+2] Atom Fragments.....	62
6. Ring Transformations .....	62
C. Pyrido[1,2-c]pyrimidines and Their Benzo Derivatives .....	62
1. By Formation of One Bond $\alpha$ to the Bridgehead Nitrogen Atom [6+0( $\alpha$ )] .....	62
2. By Formation of One Bond $\beta$ to the Bridgehead Nitrogen Atom [6+0( $\beta$ )] .....	63
3. By Formation of One Bond $\gamma$ to the Bridgehead Nitrogen Atom [6+0( $\gamma$ )].....	63
4. By Formation of Two Bonds from [5+1] Atom Fragments .....	65
5. By Formation of Two Bonds from [4+2] Atom Fragments .....	67


6. By Formation of Two Bonds from [3+3] Atom Fragments . . . . .	68
7. By Formation of Three Bonds from [2+2+2] Atom Fragments . . . . .	69
8. By Formation of Three Bonds from [3+2+1] Atom Fragments . . . . .	69
9. By Formation of Four Bonds from [3+1+1+1] Atom Fragments . . . . .	70
10. By Formation of Four Bonds from [2+2+1+1] Atom Fragments . . . . .	70
11. Ring Transformations . . . . .	70
12. Miscellaneous . . . . .	73
V. Applications and Important Compounds . . . . .	74
A. Pyrido[1,2- <i>c</i> ][1,3]oxazines and Their Benzo Derivatives . . . . .	74
B. Pyrido[1,2- <i>c</i> ][1,3]thiazines and Their Benzo Derivatives . . . . .	75
C. Pyrido[1,2- <i>c</i> ]pyrimidine and Their Benzo Derivatives . . . . .	75
References . . . . .	76

## I. Introduction

The chemistry of the pyrido[1,2-*c*][1,3]oxazines (**1**), pyrido[1,2-*c*][1,3]thiazines (**2**), and pyrido[1,2-*c*]pyrimidines (**3**) (Scheme 1) and their benzologs (**4**)–(**17**) (Schemes 2–4) has not been systematically reviewed. Only Mosby's review in 1961 treated the early articles on pyrido[1,2-*c*][1,3]oxazines [61HC(15-2)1201], pyrido[1,2-*c*]pyrimidines [61HC(15-2)1203], and pyrimido[6,1-*a*]isoquinolines [61HC(15-2)1207], and a review in 1986 dealt with pyrido[1,2-*c*]quinazolines [86AHC(39)281].


In the present article the primary chemical literature up to the end of 1996 has been surveyed. *Chemical Abstracts* Subject and Chemical Substance indexes up to and including Volume 124 have been searched.

Perhydropyrido[1,2-*c*][1,3]oxazines, pyrido[1,2-*c*][1,3]oxazines, [1,3]oxazino[3,4-*a*]quinolines, and perhydropyrido[1,2-*c*]pyrimidines are applied as key intermediates in the total syntheses of different alkaloids. Other examples of these ring systems have aroused much interest owing to their valuable pharmacological properties. Of these actisomide (**18**) and trequinsen (**19**) were introduced into human therapy as antiarrhythmic and antihypertensive agents, respectively.




SCHEME 1

### Benzo Derivatives of Pyrido[1,2-*c*][1,3]oxazine




(4)

**1*H*,3*H*-[1,3]Oxazino[3,4-*b*]isoquinoline**




(5)

**2*H*,4*H*-[1,3]Oxazino[4,3-*a*]isoquinoline**




(6)

**1*H*,3*H*-[1,3]Oxazino[3,4-*a*]quinoline**



(7)

**1*H*,6*H*-Pyrido[1,2-*c*][1,3]benzoxazine**




(8)

**1*H*,3*H*,5*H*-Pyrido[3,2,1-*ij*][3,1]benzoxazine**


SCHEME 2

### Benzo Derivatives of Pyrido[1,2-*c*][1,3]thiazine




(9)

**1*H*,3*H*-[1,3]Thiazino[3,4-*b*]isoquinoline**




(10)

**2*H*,4*H*-[1,3]Thiazino[4,3-*a*]isoquinoline**



(11)


**1*H*,6*H*-Pyrido[1,2-*c*][1,3]benzothiazine**




(12)

**1*H*,3*H*,5*H*-Pyrido[3,2,1-*ij*][3,1]benzothiazine**


SCHEME 3

Benzo Derivatives of Pyrido[1,2-*c*]pyrimidine


(13)




(14)



(15)

1*H*-Pyrimido[1,6-*b*]isoquinoline2*H*-Pyrimido[6,1-*a*]isoquinoline1*H*-Pyrimido[1,6-*a*]quinoline


(16)




(17)

1*H*-Pyrido[1,2-*c*]quinazoline1*H*,5*H*-Pyrido[3,2,1-*ij*]quinazoline


SCHEME 4



(18)



(19)



In the following sections, the physicochemical and spectroscopic properties, reactions, syntheses, and, more briefly, the use of these ring systems are discussed. Within the individual sections the pyrido[1,2-*c*][1,3]oxazines and their benzologs, pyrido[1,2-*c*][1,3]thiazines and their benzologs, and pyrido[1,2-*c*]pyrimidines and their benzologs are dealt with.



## II. Structure

### A. PYRIDO[1,2-*c*][1,3]OXAZINES AND THEIR BENZO DERIVATIVES

#### 1. Thermodynamic Aspects<sup>1</sup>


Enantiomers of 11,11*a*-dihydro-6*H*,10*H*-pyrido[1,2-*c*][1,3]benzoxazin-6-one were quantitatively separated by chiral high-performance liquid chromatography (HPLC). The first eluted enantiomer had the *R* configuration (91ACS716).

The protonation constants of *r*-4*a*,*c*-5*a*,*t*-9*a*-H and *r*-4*a*,*t*-5*a*,*c*-9*a*-H-perhydro[1,3]oxazino[3,4-*b*]isoquinolines were determined in to be 6.2 and 5.6, respectively (80HCA1158).


#### 2. Theoretical Calculations

A conformational study of perhydropyrido[1,2-*c*][1,3]oxazine (**20**, X = O) and its derivatives by means of modified MM2 calculations suggested that the O-outside *cis* conformation (ca. 5.28 kcal mol<sup>-1</sup>) and the *trans* conformation (ca. 1.63 kcal mol<sup>-1</sup>) are less stable than the O-inside *cis* conformation (Scheme 5) [91JST(245)53]. This conclusion contradicts the experimental finding [80JCS(P2)1778] and is attributed to underestimation of the nonbonding interaction between the C(8) methylene group and the oxygen atom or to overestimation of the anomeric effect.

Conformational analysis of perhydropyrido[1,2-*c*][1,3]benzoxazines (**21**–**24**) (Scheme 6) by a modification of the MM285 force field predicts that the *trans* conformation of the heterocycles is the most stable for the *r*-



<sup>1</sup> In a saturated ring system, the stereochemistry of the hydrogens on tertiary carbon atoms is indicated by *r*, *c*, and *t* symbols (e.g., *r*-4*a*, *c*-5*a*, *t*-9*a*, -H), where *r*, *c*, and *t* denote that in relation to the indicated hydrogen *r* the other hydrogens are on the same side of the ring (*cis*) or the opposite side (*trans*).



SCHEME 6

4a,c-11a,c-11b diastereomer (21) [92JST(274)259], as is the O-outside *cis* conformation of the heterocycles for the r-4a,t-11a,t-11b isomer (24), which is consistent with qualitative experimental estimates (70T1217). It was calculated that for 21 the *trans* conformation is ca. 3.7 kcal mol<sup>-1</sup> more stable than the O-outside *cis* conformation. For the r-4a,c-11a,t-11b isomer (22) and the r-4a,t-11a,c-11b isomer (23), it was predicted that the O-inside *cis* conformations are ca. 1.7 kcal mol<sup>-1</sup> and 1.4 kcal mol<sup>-1</sup>, respectively, more stable than the respective *trans* conformations, which is the opposite of the experimentally estimated orders (70T1217).

The lack of correlation between cyclization stereoselectivity and the steric energy of the products (calculated by the MMX force field)

indicated that *cis*-7*a*,10*b*-H epimers of 1-phenyl- and 1-phenyl-7*a*-methyl-5,6,7,7*a*,8,9,10,10*b*-octahydro-3*H*-pyrido[3,2,1-*ij*][3,1]benzoxazines are formed under kinetic control from 1-(*tert*-butoxycarbonyl)-2-methoxy-3-(4-phenyl-3-butynyl)piperidines (90JOC1447).

### 3. Ultraviolet and Circular Dichroism Spectroscopy

No systematic ultraviolet (UV) study has been published on pyrido[1,2-*c*][1,3]oxazines and their benzo derivatives.

The optical rotatory dispersion (ORD) curves of the diastereomers of 1-(*p*-nitrophenyl)-3-methylperhydropyrido[1,2-*c*][1,3]oxazines, obtained from (–)-2-(2-hydroxypropyl)piperidine with *p*-nitrobenzaldehyde, are nearly mirror images of each other (68CJC1105). The absolute configurations in cyclohexane of the dextrorotatory *cis*-3,4*a*-H-3-phenyl- and *trans*-3,4*a*-H-3-phenylhydropyrido[1,2-*c*][1,3]oxazin-6-ones, containing 3*S*,4*a**R* and 3*S*,4*a**S* atoms, respectively, were determined on the basis of the presence of positive Cotton effects (85T2891).


Ultraviolet and circular dichroism (CD) spectra of the epimers of 11,11*a*-dihydro-6*H*,10*H*-pyrido[1,2-*c*][1,3]benzoxazin-6-one were measured in ethanol. From the geometry obtained through empirical force-field calculations, the rotational strengths of the strong transitions in the CD spectra were calculated by the complete neglect of differential overlap (CNDO)/S method and the absolute configurations were assigned (91ACS716). The UV spectra appear as superpositions of those of *N*-vinylcarbamate and the phenyl chromophores.

### 4. Dipole Moment Investigations

Dipole moments of perhydropyrido[1,2-*c*][1,3]oxazine (**20**, X = O) and its four alkyl derivatives were calculated from measurements in benzene at 25°C and were used to estimate the conformational preferences of several perhydropyrido[1,2-*c*][1,3]oxazines [76JCS(P2)418]. The *trans*-fused and O-outside *cis*-fused conformers possess identical dipole moments (2.08 D), whereas that of the O-inside *cis*-fused conformers is 1.30 D.

### 5. Infrared Spectroscopy


The appearance of the Bohlmann band in the infrared (IR) spectrum is frequently used to identify the *trans*-fused conformation of perhydropyrido[1,2-*c*][1,3]oxazines [66MI2; 68T4423; 70T1217, 70T3941; 71T2055; 71TL3361; 76OMR(8)258; 85T2891; 87T935] and their benzo derivatives (e.g., **21–23**, **25**, **27**, **29** [70T1217; 71TL3361; 77JCS(P2)370; 80JCS(P2)1778; 84OMR(22)424]. *cis*-Fused conformers are not expected to produce Bohl-



SCHEME 7

mann bands, since they do not allow two C—H bonds adjacent to the N to be *trans*-axial to the N lone pair of electrons. The weak Bohlmann bands in the IR spectra suggested a *cis*-fused conformation of the *r-4a, t-11a, t-11b*-H isomer of perhydropyrido[1,2-*c*][1,3]benzoxazine (**24**) (70T1217) (Scheme 6), for perhydro[3,2,1-*ij*][3,1]oxazines (**26** and **28**) (Scheme 7) [80JCS(P2)1778; 84OMR(22)424], and for hexahydro[1,3]oxazino[4,3-*a*]isoquinoline (**30**) [71TL3361; 77JCS(P2)370].

The Bohlmann bands are not suitable for recognition of a *trans*-fused conformer of hexahydro[1,3]oxazine[3,4-*a*]quinoline (**31**) and its derivatives because of the flattening of the bridgehead N pyramid, as a consequence of (*p-p*) $\pi$  conjugation of the lone pair of the N atom and the aromatic  $\pi$ -orbitals of the benzene moiety (71TL3361).



## 6. <sup>1</sup>H NMR Spectroscopy

a. *Fully Saturated Ring Systems.* In the investigation of the conformation of perhydropyrido[1,2-*c*][1,3]oxazine (**20**, X = O), three all-chair conformations (O-outside *cis*-fused or *trans*-fused and O-inside *cis*-fused forms)

can be considered the most stable (Scheme 5). Conformers containing at least one of the rings in a boat or twisted conformation are of high energy and can be neglected. The *cis* conformers should be higher in energy than the *trans* conformer because of the presence of three *gauche*-butane interactions, which are absent in the *trans* form. At the same time, the O-inside *cis* conformation has a lower energy than the O-outside *cis* conformation, since the interaction between O(2) and the 8-methylene group is appreciably lower in the former than the interaction between the 1- and 7-methylene groups in the latter. Furthermore, in the *trans*-fused and O-outside *cis*-fused conformations, there is a destabilizing dipole-dipole interaction between the heteroatoms, which is relieved in the O-inside *cis*-fused conformation. The O-inside *cis*-fused conformation may also be stabilized by an  $n_N \rightarrow \sigma^*_{C-O}$  anomeric effect.

$J_{gem}$  for the N—CH<sub>2</sub>—O protons depends on the degree of overlap between the molecular orbitals of the methylene group and the lone pair of electrons on the adjacent N atom (68T4423). The *trans*-fused and O-outside *cis*-fused conformations, containing one of the C—H bonds of the N—CH<sub>2</sub>—O group and the lone pair of electrons on the N atom in the *trans*-axial arrangement (A), have a more positive (smaller absolute value)  $J_{gem}$  for the N—CH<sub>2</sub>—O group because of the more efficient overlapping between the N—CH<sub>2</sub>—O group and the N lone pair of electrons than that of the O-inside *cis*-fused conformation containing arrangement B, where the N lone pair bisects the C(1) methylene group (Fig. 1).

$J_{gem}$  for the C(1) methylene group is used to estimate the ratio of the *trans* and O-inside conformers of different perhydropyrido[1,2-*c*][1,3]oxazines. The expected  $J_{gem}$  is ca. -7.7 Hz in arrangement A and ca. -11 Hz in arrangement B. The measured  $J_{gem}$  of -8.0 Hz reflects a roughly 10:90 mixture of the O-inside *cis* and *trans* conformers in a 10% solution of perhydropyrido[1,2-*c*][1,3]oxazine in CCl<sub>4</sub> [68T4423; 80JCS(P2)1778]. The contribution of the O-outside *cis* conformer to the equilibrium was estimated to be only ca. 1% [76JCS(P2)418].

The chemical shift difference between the N—CH<sub>2</sub>—O protons is sometimes a useful tool for prediction of the predominant conformations.  $\Delta_{ax,eq}$  is around 0.5–0.9 ppm for the *trans* conformation, while a  $\Delta_{ax,eq}$  value of 0.0–0.2 ppm points to the presence of the O-inside *cis* conformation.






FIG. 1

A *trans* conformer, as the major conformer, was identified for 1-, 3-, or 4-substituted perhydropyrido[1,2-*c*][1,3]oxazine, independently of whether the substituent occupies an axial or an equatorial position [68T4423; 70T1217; 71TL3361; 76OMR(8)258; 92MRC129]. Whereas the *cis*-4*a*,8-H-8-methyl derivative exists in a *trans* conformation containing the methyl group in the equatorial position (68T4423; 70T1217), the *trans*-4*a*,8-H-8-methyl derivative exists as an equilibrium mixture of the *trans* conformer with an axial methyl group and the O-inside *cis* form with an equatorial methyl group (68T4423). The *cis*-4*a*,5-H-5-methyl derivative also exists as a mixture of the *trans* conformer with an axial methyl group and the O-inside *cis*-form with an equatorial methyl group (70T3941). The *cis*- and *trans*-3,4*a*-H-1-aryl-3-methylperhydropyrido[1,2-*c*][1,3]oxazines adopt *trans*-fused conformations with an equatorial aryl group (65RTC1367). The *r*-4*a*,*t*-1,*c*-8-H-1,8-dimethylperhydropyrido[1,2-*c*][1,3]oxazine exists in *trans*-fused conformation with an axial 1-methyl and an equatorial 8-methyl group (68T4423).

The *cis*-4*a*,7-H-7-ethyl derivative exists as a 3:7 mixture of the *trans* conformer with an axial ethyl group and the O-inside *cis* conformer with an equatorial ethyl group at  $-90^{\circ}\text{C}$ , and as a 47:53 mixture of the *trans* and *cis* conformers at  $20^{\circ}\text{C}$  in a mixture of  $\text{CDCl}_3$ - $\text{CFCl}_3$  [76JCS(P2)418]. As concerns the other epimer, the *trans* conformer is the more favored.

The values of the geminal coupling constant between the C(1) protons indicated that 5,5-dimethoxy- and 7,7-dimethoxy-3-phenylperhydro-[1,2-*c*][1,3]oxazines exist predominantly in *cis*-fused ( $J_{\text{gem}} \approx -10.5$  Hz) and *trans*-fused ( $J_{\text{gem}} \approx -8.5$  Hz) conformations, respectively, both containing the phenyl group in the axial position (87T935). Conformational analysis of the epimers of 3-phenylperhydropyrido[1,2-*c*][1,3]oxazines (**32**) was also performed by  $^1\text{H}$  NMR spectroscopy (85T2891).



The solvent effect on the C(1) methylene parameters in the  $^1\text{H}$  NMR spectra of perhydropyrido[1,2-*c*][1,3]oxazine (**20**,  $\text{X} = \text{O}$ ), its *cis*-4*a*,5-H-5-methyl derivative and **25** was investigated in six solvents [80OMR(13)159]. The positions of the equilibria were not affected significantly by solvent changes.

TABLE I  
EQUILIBRIUM OF CONFORMERS OF PERHYDROPYRIDO[1,2-*c*][1,3]OXAZINE  
(**20**, X = O) (88MRC748)

Conformation	Equilibrium in free base in CDCl <sub>3</sub> (%)	Thermodynamically controlled protonation in D <sub>2</sub> O–DCl (%)	Partially kinetically controlled protonation <sup>a</sup> ( <b>20</b> , X = O) · HCl salt in CDCl <sub>3</sub> (%)
<i>trans</i>	90	93	75
O-inside <i>cis</i>	10	7	25


<sup>a</sup> Prepared in sodium-dried diethyl ether with dry hydrogen chloride.

The equilibrium between the *trans* and O-inside *cis* conformers of perhydropyrido[1,2-*c*][1,3]oxazine (**20**, X = O) was frozen by protonation and deuteration (88MRC748). The ratio of the *trans* and O-inside *cis* forms was investigated by <sup>1</sup>H and <sup>13</sup>C spectra and is tabulated in Table I. <sup>1</sup>H NMR spectra of the hydrochloride salt of *cis*-4*a*,8-H-8-methyl- and *trans*-4*a*,7-H-7-ethylperhydropyrido[1,2-*a*][1,3]oxazines show that these derivatives exist in a *trans*-fused conformation in CDCl<sub>3</sub>, whereas the hydrochloride salt of the *cis*-4*a*,7-H-7-ethyl derivative is exclusively in an O-inside *cis* conformation (88MRC748).

Perhydropyrido[1,2-*c*][1,3]oxazine (**20**, X = O) exists as a 98:2 mixture of the *trans* and O-inside *cis* conformers ( $\Delta G_{203} = 6.3 \text{ kJ mol}^{-1}$ ) at 203 K in CD<sub>2</sub>Cl<sub>2</sub>–CFCl<sub>3</sub>, and as the *trans*-4,4*a*-H-4-methyl derivative ( $\Delta G_{193} = 5.4 \text{ kJ mol}^{-1}$ ) at 193 K, whereas the C(4) epimer adopts exclusively the *trans*-fused conformation at 193 K (92MRC129).

Conformational analysis of diastereomeric pyrido[1,2-*c*][1,3]oxazin-1-ones (**33** and **34**) revealed that **33** adopted an O-inside *cis*-fused conformation, whereas **34** existed in a *trans*-fused form (96SL100). Both isomers contained the C(8) substituent in an axial position to avoid an A<sup>(1,3)</sup> strain.

Both the geminal coupling constant and the chemical shift difference of the 1-methylene group are indicative of the predominance of the *trans*-fused conformation for (+)-*cis*-4*a*,5*a*-H-perhydro[1,3]oxazino[3,4-*b*]isoquinoline (**35**) [ $\Delta_{\text{ax,eq}} \approx 0.87 \text{ ppm}$  and  $J_{\text{gem}} = -8.5 \text{ Hz}$ ] and of the predominance of the O-inside *cis*-fused conformation for (–)-*cis*-4*a*,9*a*-H-perhydro[1,3]oxazino[3,4-*b*]isoquinoline (**36**) ( $\Delta_{\text{ax,eq}} \approx 0.0 \text{ ppm}$  and  $J_{\text{gem}} = -10 \text{ Hz}$ ) (80HCA1158).



Conformation analysis of isomeric perhydropyrido[1,2-*c*][1,3]benzoxazines (**21–24**) by means of  $^1\text{H}$  NMR studies demonstrates that the predominant conformers of the isomers **21**, **22**, and **23** contain a *trans*-fused pyrido[1,2-*c*][1,3]oxazine moiety, whereas that of **24** has an O-outside *cis*-fused pyrido[1,2-*c*][1,3]oxazine moiety (see Scheme 6) (70T1217; 71TL3361).

Stereochemically locked all-chair conformations of perhydropyrido[3,2,1-*ij*][3,1]benzoxazines (**25–28**) are useful models for the investigation of the conformational equilibria of the mobile perhydropyrido[1,2-*c*][1,3]oxazine and its derivatives (see Table II) [80JCS(P2)1778]. In the stereoisomers **25** and **27**, *trans*-fused heterocycles are indicated by the  $J_{3\text{ax},3\text{eq}}$  values of  $-7.67$  and  $-7.55$  Hz, and the large  $\Delta_{3\text{ax},3\text{eq}}$  values of  $0.87$  and  $0.84$  ppm, respectively, while the  $J_{3\text{ax},3\text{eq}}$  value of  $-10.8$  Hz for **26** and the  $\Delta_{3\text{ax},3\text{eq}}$  and  $\Delta_{5\text{ax},5\text{eq}}$  values of  $0.40$  and  $0.27$  ppm for **28** indicate the O-inside *cis*-fused and O-outside *cis*-fused conformations, respectively (see Scheme 7).

The  $^1\text{H}$  NMR spectra of **25** were recorded in six solvents.  $J_{3\text{ax},3\text{eq}}$  and  $\Delta_{3\text{ax},3\text{eq}}$  were found to vary with the solvent, which is attributed to solvation effects [80OMR(13)159]. The stereochemistry of the two 5-methyl epimers of **26** and **27** and of the equatorially oriented methyl derivatives of **25** and **28** was investigated by  $^1\text{H}$  NMR spectroscopy [84OMR(22)424].

b. *Partly Saturated Ring Systems.* The insertion of a 6,7 or 7,8 double bond in perhydropyrido[1,2-*c*][1,3]oxazine (**20**,  $\text{X} = \text{O}$ ) [e.g., hexahydro[1,3]oxazino[3,4-*b*]isoquinoline (**29**) ( $J_{\text{C}(1)\text{H}2} = -8.2$  Hz,  $\Delta_{1\text{eq}1\text{ax}} = 0.9$  ppm in  $\text{C}_6\text{D}_6$ ) and hexahydro[1,3]oxazino[3,4-*a*]quinoline (**31**) ( $J_{\text{C}(1)\text{H}2} = -10.5$  Hz,  $\Delta_{1\text{eq}1\text{ax}} = 1.21$  ppm in  $\text{C}_6\text{D}_6$ )] does not affect the position of the conformational equilibrium of the preferred *trans*-fused conformer. However, the insertion of a 5,6 double bond [hexahydro[1,3]oxazino[4,3-*a*]isoquinoline (**30**) ( $J_{\text{C}(1)\text{H}2} = -10.2$  Hz,  $\Delta_{4\text{eq}4\text{ax}} = 0.20$  ppm in  $\text{C}_6\text{D}_6$ )] moves the position of the conformational equilibrium towards the O-inside *cis*-fused conformer

TABLE II  
SOME  $^1\text{H}$  NMR DATA ON STEREOCHEMICALLY LOCKED PERHYDROPYRIDO[3,2,1-*ij*][1,3]BENZOXAZINES (**25–28**) IN  $\text{CDCl}_3$  AT 270 MHz [80JCS(P2)1778]

	N-CH <sub>eq</sub> -O N-CH <sub>eq</sub> H <sub>ax</sub> -O	N-CH <sub>ax</sub> -O N-CH <sub>eq</sub> H <sub>ax</sub> -O	$\Delta_{\text{aq,ex}}$	$^3J_{\text{NCH}_2\text{O}}$ (Hz)
<b>25</b>	4.27	3.40	0.87	-7.67
<b>26</b>	4.56	4.44	0.12	-10.8
<b>27</b>	4.35	3.51	0.84	-7.55
<b>28</b>	4.55	4.15	0.40	-7.55




[71TL3361; 77JCS(P2)370]. In the latter case, the *trans*-fused conformer would involve a ring fusion strain that is missing in the alternative O-inside *cis*-fused conformer [77JCS(P2)370]. The rather negative coupling constant for the C(1)methylene ( $-10.5$  Hz) in **31** is a consequence of the interaction of the N lone pair with the aromatic ring, which reduces the lone pair C(1)-methylene overlap [71TL3361].

Hexahydro[1,3]oxazino[3,4-*a*]quinoline (**31**) and its *cis*-3,4*a*-H-3-methyl and *trans*-3,4*a*-H-3-methyl derivatives exist predominantly in *trans*-fused conformations [77JCS(P2)1592].

*cis*-4,11*b*-H-4-Aryl-1,2,4,6,7,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinoline in solution adopts the O-inside *cis* conformation with an equatorial aryl group at position 4 [76OMR(8)258].

The presence of a substituent at position 1 influences the ring junction in 1,2,4,6,7,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinolines (**37** and **38**,  $R^2 = \text{H, aryl}$ ;  $R^3 = \text{H}$ ) (90CB803; 92T4937). *trans*-1,11*b*-H-1,2,4,6,7,11*b*-Hexahydro[1,3]oxazino[4,3-*a*]isoquinolines (**37**,  $R^2 = \text{H, aryl}$ ;  $R^3 = \text{H}$ ) preferentially exist in the O-inside *cis*-fused conformation containing the substituent  $\text{CH}_2\text{R}$  in the equatorial position, but *cis*-1,11*b*-H-1,2,4,6,7,11*b*-hexahydro-[1,3]oxazino[4,3-*a*]isoquinolines (**38**,  $R^2 = \text{H, aryl}$ ;  $R^3 = \text{H}$ ) adopt a *trans*-fused conformation with an axial substituent  $\text{CH}_2\text{R}$  (90CB803; 92T4937).




An analysis of  $^1\text{H}$  and  $^{13}\text{C}$  NMR data led to the conclusion that both epimers of 2-methyl-1,2,4,6,7,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinolines (**39**,  $R^2 = \text{H, aryl}$ ;  $R^3 = \text{H}$ ) are present in a *trans*-fused B/C conformation (92T4937).

4-Aryl derivatives of **37** and **38** ( $R^2 = \text{aryl}$ ;  $R^3 = \text{H}$ ) contain the 4-aryl group in the equatorial position (90CB803; 92T4937). 4-Oxo derivatives **37**, **38**, and **39** ( $R^2 = R^3 = \text{O}$ ) adopt the conformation of **40** (92T4937).

Whereas 1,3,4,4*a*,5,6-hexahydro[1,3]oxazino[3,4-*a*]quinoline (**41**,  $R = \text{H}$ ) and its 1-, 3-, and 4-methyl derivatives adopt *trans* conformations [71TL3361; 77JCS(P2)1592; 93JCR(S)170], its 10-methyl derivative (**41**,

R = H, R<sup>1</sup> = Me) exists predominantly in the O-outside *cis*-fused conformation, because of nonbonded interactions between the methyl substituent and C(1)–H<sub>eq</sub> in the other conformations [93JCR(S)170]. The *trans*-1,4a-H-1-methyl derivative (**41**, R = Me, R<sup>1</sup> = H) contains the methyl group in the axial position in the predominant *trans*-fused conformation [93JCR(S)170].



The stereochemistry of the two 5-methyl epimers of **26** and **27** and of the equatorially oriented methyl derivatives of **25** and **28** was investigated by <sup>1</sup>H NMR spectroscopy [84OMR(22)424].

### 7. <sup>13</sup>C NMR Spectroscopy

Low-temperature <sup>13</sup>C NMR spectroscopy indicated that perhydropyrido[1,2-*c*][1,3]oxazine at equilibrium at 203 K in CD<sub>2</sub>Cl<sub>2</sub>–CFCl<sub>3</sub> solution adopts a 98:2 ratio of *trans* and O-inside *cis* conformers ( $\Delta G^\circ_{203} = 6.3$  kJ mol<sup>-1</sup>) (92MRC129). A similar equilibrium (ca. 96.5:3.5;  $\Delta G^\circ_{193} = 5.4$  kJ mol<sup>-1</sup>) is adopted by the *trans*-4,4a-H-4-methyl derivative, whereas the C(4) epimer adopts exclusively the *trans* conformation. The <sup>13</sup>C NMR spectrum of the hydrochloride salt of perhydropyrido[1,2-*c*][1,3]oxazine has also been recorded in CDCl<sub>3</sub> (88MRC748) (see Table III).

<sup>13</sup>C NMR data on the C(3) epimers of 3-phenylperhydropyrido[1,2-*c*][1,3]oxazines (**32**) were used for the determination of their stereostructures (85T2891). <sup>13</sup>C NMR data have also been published on perhydro[1,3]oxazino[3,4-*b*]isoquinolines (**35** and **36**) (80HCA1158).

The <sup>13</sup>C NMR data of isomeric perhydropyrido[1,2-*c*][1,3]benzoxazines (**21–24**) (93MRC505) are consonant with the predominant conformations (see Scheme 6) previously assigned on the basis of the <sup>1</sup>H NMR data (70T1217). The <sup>13</sup>C NMR spectra of perhydro[3,2,1-*ij*][1,3]benzoxazines (**25–28**) (Scheme 7) (Table III) (92MRC129), and 2,3,4,4a,5,6-hexahydro[1,3]oxazino[3,4-*a*]-quinoline and its *trans*-1,4a-H-1-, *trans*-3,4a-H-3-, *cis*-3,4a-H-3-, *trans*-4,4a-H-4-, *cis*-4,4a-H-4-, and 10-methyl derivatives [93JCR(S)170] were recorded in CDCl<sub>3</sub> at room temperature at 67.97 MHz. The <sup>13</sup>C NMR data for **37–39** were also reported (90CB803; 92T4937).

TABLE III  
<sup>13</sup>C NMR DATA OF *trans* AND O-INSIDE *cis* CONFORMATIONS OF PERHYDROPYRIDO[1,2-*c*][1,3]OXAZINE(**20**, X = O) IN CD<sub>2</sub>Cl<sub>2</sub>-CFCl<sub>3</sub> AT 203 (92MRC129) AND ITS HYDROCHLORIDE SALT IN CDCl<sub>3</sub> AT ROOM TEMPERATURE (88MRC748), AND THOSE OF STEREOCHEMICALLY LOCKED PERHYDRO[3,2,1-*ij*][1,3]BENZOXAZINES (**25–28**) IN CDCl<sub>3</sub> AT ROOM TEMPERATURE (92MRC129) (ppm)

	C(1)	C(3)	C(4)	C(4a)	C(5)	C(6)	C(7)	C(8)			
<i>trans</i> <b>20</b> , X = O	86.7	68.0	32.5	60.8	32.1	24.0	25.0	49.1			
O-inside											
<i>cis</i>	86.2	68.4	24.0	53.4	30.0	18.7	26.0	44.6			
<i>trans</i>	83.3	67.5	29.3	62.7	29.8	21.9	22.3	49.0			
<b>20</b> , HCl X = O											
O-inside											
<i>cis</i>	83.8	67.6	22.8	54.9	27.6	16.7	22.6	44.3			
	C(1)	C(3)	C(5)	C(6)	C(7)	C(7a)	C(8)	C(9)	C(10)	C(10a)	C(10b)
<b>25</b>	73.5	87.9	50.2	20.5	30.3	36.3	25.35	25.6	26.1	37.1	63.5
<b>26</b>	73.3	86.4	45.0	26.0	23.9	35.0	32.0	20.4	27.7	28.0	73.3
<b>27</b>	73.9	87.3	49.15	24.6	31.6	39.0	32.3	24.7	24.6	39.6	71.3
<b>28</b>	66.8	78.6	50.35	27.2	32.7	27.8	32.9	21.8	21.7	33.9	62.6

8. <sup>15</sup>N NMR Spectroscopy

The low-temperature (−95°C) <sup>15</sup>N NMR spectrum of perhydropyr-ido[1,2-*c*][1,3]oxazine (**20**, X = O) was measured in a 1:1 mixture of CS<sub>2</sub> and THF-*d*<sub>6</sub> [83OMR(21)203]. Only the <sup>15</sup>N shift of the *trans*-fused con- former could be detected (δ<sup>15</sup>N 66.8 ppm down-field from anhydrous liquid ammonia). At 27°C the chemical shift of <sup>15</sup>N was 65.5 ppm.

## 9. Mass Spectroscopy

5,5,7-Trimethyl-1*H*,3*H*,5*H*-pyrido[3,2,1-*ij*][3,1]benzoxazines were de- tected among the reaction products of 2,2,4-trimethyl-1,2-dihydroquinoline with formaldehyde and acetaldehyde by liquid chromatography–mass spec- troscopy (LC–MS) investigations (79MI1).

## 10. X-Ray Investigations

An X-ray crystal structural determination revealed that the 8-carboxyl group of *cis*-4*a*,8-*H*-1,3,4,4*a*,7,8-hexahydropyrido[1,2-*c*][1,3]oxazine-8- carboxylic acid is in a pseudoaxial position (81JA7573). The crystal struc- ture of 4-phenyl-2-{4-[4-(2-pyrimidinyl)piperazin-1-yl]butyl}-2,3,5,6,7,8- hexahydro-1*H*-pyrido[1,2-*c*][1,3]oxazine-1,3-dione was determined by an X-ray investigation (95ZK899).

The absolute configuration of *cis*-1,3,4*a*-*H*-1-(4-nitrophenyl)-3-methyl- perhydropyrido[1,2-*c*][1,3]oxazine, having the 1*S*,3*R*,4*aS*,9*R* configuration, was determined in an X-ray diffraction study [71T2055; 72AX(B)37]. The chair-shaped heterocyclic rings adopt a *trans* conformation with equatorial methyl and aryl groups. The crystal structure of *cis*-1,4*a*-*H*-1-

TABLE IV  
INTERATOMIC DISTANCE (pm) AND BOND ANGLES (°) IN TWO HETERO-ATOM-CONTAINING  
RINGS OF 1-(4-BROMOPHENYL) DERIVATIVE OF PERHYDROPYRIDO[1,2-*c*][1,3]OXAZINE  
AND PERHYDROPYRIDO[1,2-*c*][1,3]THIAZINE (**20**, X = O, S) WITH ESD<sup>a</sup> IN  
PARENTHESES (73MI1, 73MI2)

Bond length	X = O	X = S	Bond angle	X = O	X = S
N(9)–C(1)	148.6(8)	147.9(10)	C(4 <i>a</i> )–N(9)–C(1)	110.6(5)	111.4(6)
C(1)–X(2)	142.1(8)	183.6(7)	N(9)–C(1)–X(2)	109.3(5)	112.6(5)
X(2)–C(3)	145.2(9)	181.3(9)	C(1)–X(2)–C(3)	111.5(5)	97.1(3)
C(3)–C(4)	152.9(10)	148.8(16)	X(2)–C(3)–C(4)	108.1(6)	111.7(8)
C(4)–C(4 <i>a</i> )	151.2(10)	151.0(11)	C(3)–C(4)–C(4 <i>a</i> )	110.3(5)	113.0(8)
C(4 <i>a</i> )–N(9)	148.6(8)	146.7(9)	C(4)–C(4 <i>a</i> )–N(9)	109.8(5)	113.5(6)

<sup>a</sup> Estimated standard deviation.

Pronounced Bohlmann bands in the region 2800–2600 cm<sup>-1</sup> of the IR spectra of perhydropyrido[1,2-*c*][1,3]thiazine and its *cis*-1,4a-H-1-phenyl, *cis*- and *trans*-3,4a-H-3-methyl, *trans*-4a,5-H-5-methyl, *cis*-4a,8-H-8-methyl, *cis*-1,4a-H-*trans*-5-H-5-methyl-1-phenyl, and *trans*-4a,7-H-7-ethyl derivatives indicate the predominance of the *trans*-fused conformation [70T3941; 82OMR(20)239]. The absence of marked absorbance in the same region

of the IR spectra of 1,2,4,5,6,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinoline and its *cis*-4,11*b*-H-4-(*p*-nitrophenyl) derivative suggests the presence of a *cis*-fused conformation of the heterorings [76OMR(8)258; 77JCS(P2)370].


### 3. <sup>1</sup>H NMR Spectroscopy

Differences between the stereochemistry of perhydropyrido[1,2-*c*][1,3]thiazines and that of the closely related perhydropyrido[1,2-*c*][1,3]oxazines are expected to arise principally from the long C—S bond (181 pm) as compared with the C—O bond length of 141 pm, and also from differences in bond angles and in torsional interactions involving the heteroatoms. The longer C—S bonds in perhydropyrido[1,2-*c*][1,3]thiazine result in a lower interaction in the S-inside *cis*-fused conformer in comparison with the O analog, which increases the contribution of the S-inside *cis*-fused conformer to the equilibrium. The predominant conformation of perhydropyrido[1,2-*c*][1,3]thiazine (**20**, X = S) is the *trans*-fused one (Scheme 5) (70T3941).


1-H<sub>eq</sub> in perhydropyrido[1,2-*c*][1,3]thiazine (**20**, X = S) absorbs at higher field (3.60 ppm in CCl<sub>4</sub>) than 1-H<sub>ax</sub> (3.91 ppm), as does 4-H<sub>eq</sub> (4.04 ppm in CDCl<sub>3</sub>) in 1,2,4,5,6,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinoline than 4-H<sub>ax</sub> (4.68 ppm). This is in contrast with the situation in perhydropyrido[1,2-*c*][1,3]oxazine (4.70 and 3.52 ppm, respectively) and 1,2,4,5,6,11*b*-hexahydro[1,3-*a*]oxazino[4,3-*a*]isoquinoline (4.52 and 4.32 ppm in C<sub>6</sub>D<sub>6</sub>), which can be interpreted in terms of the differences between the C—S and C—O bond anisotropies [70T3941; 77JCS(P2)370]. A coupling of 1.6 Hz is observed between 1-H<sub>eq</sub> and 4-H<sub>eq</sub>, which suggests marked deviations from the chair conformation for the 1,3-thiazine ring (70T3941).

Conformational analysis demonstrated that the predominant conformation of the *cis*-1,4*a*-H-1-phenyl, *cis*- and *trans*-3,4*a*-H-3-methyl, *trans*-4*a*,5-H-5-methyl, *cis*-4*a*,8-H-8-methyl, and *trans*-4*a*,7-H-7-ethyl derivatives of perhydropyrido[1,2-*c*][1,3]thiazine is the *trans*-fused one, whereas for the *cis*-4*a*,5-H-5-methyl and *cis*-4*a*,7-H-7-methyl derivatives it is the S-inside *cis*-fused conformation [70T3941; 82OMR(20)239]. The chemical shift differences (1.13 and 0.49 ppm) between the C-8 methylene protons of *trans*-4*a*,7-H-7-ethyl- and *cis*-4*a*,7-H-7-ethylperhydropyrido[1,2-*c*][1,3]thiazines are in accord with exclusive existence in the *trans*-fused and in the *cis*-fused ring conformations, respectively [82OMR(20)239].

1,2,4,6,7,11*b*-[1,3]Thiazino[4,3-*a*]isoquinolone and its *cis*-4,11*b*-H-4-(4-nitrophenyl) derivative (**46**, R = H, 4-NO<sub>2</sub>Ph) predominantly adopt the S-inside *cis*-fused conformation in CDCl<sub>3</sub>, which is favored by the generalized anomeric effect [76OMR(8)258; 77JCS(P2)370].



(46)



(47)

The relative configurations and the predominant conformation of 1-epimers of 1,2,4,6,7,11*b*-[1,3]thiazino[4,3-*a*]isoquinolin-4-imines (**47**) were determined by the use of  $^1\text{H}$  NMR spectroscopy (90CB803).

#### 4. $^{13}\text{C}$ NMR Spectroscopy

Conformational analysis of perhydropyrido[1,2-*c*][1,3]thiazine (**20**, X = S) and its *trans*- and *cis*-4*a*,7-H-7-ethyl derivatives indicated that *trans*-4*a*,7-H-7-ethylperhydropyrido[1,2-*c*][1,3]thiazine and the *cis*-4*a*,7-H-7-ethyl analog exist exclusively in the *trans*-fused and the S-inside *cis*-fused conformation, respectively, containing the ethyl group in the equatorial positions, whereas the parent perhydropyrido[1,2-*c*][1,3]thiazine in  $\text{CDCl}_3$  at  $25^\circ\text{C}$  is a ca. 25:75 mixture of the S-inside *cis*-fused and *trans*-fused conformations. At  $-75^\circ\text{C}$ , where the interconversion is slow in a 1:1 mixture of  $\text{CS}_2$  and  $\text{THF-}d_8$ , the signals of both conformers of perhydropyrido[1,2-*c*][1,3]thiazine can be detected. The  $^{13}\text{C}$  NMR spectrum shows the presence of 64% of the *trans*-fused and 36% of the S-inside *cis*-fused conformer [82OMR(20)239].

The  $^{13}\text{C}$  NMR chemical shifts of 1-epimers of the *N*-phenyl-1-hydroxymethyl- and 1-acyloxymethyl-9,10-dimethoxy-1,2,4,6,7,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinolin-4-imines (**47**) were measured in  $\text{CDCl}_3$  (90CB803).

#### 5. $^{15}\text{N}$ NMR Spectroscopy

At  $-95^\circ\text{C}$ , the *cis-trans* interconversion of the conformers of perhydropyrido[1,2-*c*][1,3]thiazine (**20**, X = S) is frozen, and the  $^{15}\text{N}$  NMR spectrum of the S-inside *cis*-fused conformer of perhydropyrido[1,2-*c*][1,3]thiazine reveals a shielding of the nitrogen by 23.0 ppm relative to the *trans*-fused conformer ( $\delta_{15\text{N}}$  66.9 ppm downfield from the signal of anhy-

drous liquid ammonia) in a 1:1 mixture of CS<sub>2</sub>-THF-*d*<sub>6</sub>. This enhanced chemical shift difference reflects both the  $\beta$ -substituent effect of C-4 methylene and the generalized anomeric effect differences between the *trans*- and *cis*-conformers. At 27°C, a time-averaged chemical shift of 58.3 ppm was measured, which suggests the presence of a 38:62 equilibrium mixture of the S-inside *cis*-fused and *trans*-fused conformations [83OMR(21)203].

## 6. X-Ray Investigations

An X-ray structural determination of 1-(4-bromophenyl)perhydropyrido[1,2-*b*][1,3]thiazine revealed that both fused rings adopt almost ideal chair conformations (73MI2). A comparison of the corresponding data on 1-(4-bromophenyl)perhydropyrido[1,2-*b*][1,3]oxazine (73MI1) and 1-(4-bromophenyl)perhydropyrido[1,2-*b*][1,3]thiazine showed that the C—C bond lengths and bond angles are similar, with the exception of the C(3)—C(4) bond (152.9 pm in pyrido[1,2-*c*][1,3]oxazine and 148.8 pm in pyrido[1,2-*c*][1,3]thiazine) (Table IV). In pyrido[1,2-*c*][1,3]oxazine there is some puckering around the oxygen, but in pyrido[1,2-*c*][1,3]thiazine there is a degree of flattening around the sulfur. The lengths of the C(1)—S and S—C(2) bonds are 183.6 and 181.3 pm, respectively, whereas those of the C(1)—O and O—C(2) bonds are 142.1 and 145.2 pm, respectively. The phenyl ring is perpendicular to the best plane of the bicycle.

## C. PYRIDO[1,2-*c*]PYRIMIDINES AND THEIR BENZO DERIVATIVES

### 1. Thermodynamic Aspects


A selective reversed-phase HPLC method was developed for studies on the antiarrhythmic hexahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-one (**18**) and its 4-epimer (87MI7).

The protonation constants ( $pK_{a1} = 4.8$  and  $pK_{a2} = 10.3$ ) of **18** were determined by titration (87MI2). The protonation constant of 2-amino-4-aryl-6,7-dihydropyrido[6,1-*a*]isoquinolinium chlorides were determined in 50% aqueous ethanol, and their  $pK_a$ s were calculated via Eq. 1 (82KGS1095).

$$pK_a = 10.08 - 1.43 \sigma_n, \quad r = 0.97, \quad s = 0.15 \quad (1)$$

2-Imino-4-substituted-6,7-dihydropyrimido[6,1-*a*]isoquinolines yield an equilibrium system involving the tautomeric forms of pseudobases **48**, **49**, and **50** and anhydro base **51** (see Scheme 8) [90CB493; 91CB111; 94H(37)2051].





SCHEME 8

## 2. Theoretical Calculations

The electron densities, the bond orders, the first six energies, and the oscillator strengths of the pyrido[1,2-*c*]pyrimidinium cation were calculated using the SCFMO semiempirical version of the PPP method. Protonation is expected to take place on the nonbridgehead N atom, and position 1 is predicted to be most reactive toward nucleophilic substitution (68TCA417).

The bioactive conformation of 6-dipropylamino-1,2,3,5,6,7-hexahydropyrido[3,2,1-*ij*]quinazolin-3-one was predicted by Compass algorithm for 5-HT<sub>1A</sub> binding (95JMC1295).

## 3. Dipole Moment Investigations


The dipole moments of 2-methyl- and 2-*tert*-butylperhydropyrido[1,2-*c*]pyrimidine (**52**, R = Me and *t*Bu) (1.40 and 1.47 D, respectively) were determined in benzene [76JCS(P2)418]. From the calculated dipole moment data, it was concluded that the 2-*tert*-butyl derivative exists almost exclu-

sively in the *trans*-fused conformation  $T_{eq}$ , whereas the 2-methyl derivative exists predominantly (ca. 75%) in the same conformation ( $T_{eq}$ ); these conclusions proved to be in good agreement with the experimental data (see Section II,C,6,a).

#### 4. UV Spectra



The pH dependence of the tautomerism of 4-iminopyrimido[6,1-*a*]isoquinolines **49–51**, depicted in Scheme 8, was investigated by UV spectroscopy (90CB493).

In the UV spectra bands at 275, 283.8, and 340 nm are characteristic for 3-methyl-2-(*N*-arylimino)-2, 3, 6,7-tetrahydro-4*H*-pyrimido[6,1-*a*]isoquino-



SCHEME 9

lin-4-ones (**53**), and bands at 271.5 and 281 nm for isomeric 2-(*N*-aryl-*N*-methylimino)-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones (**54**) (84JMC1470).



## 5. IR Spectra

The appearance of Bohlmann bands in the IR spectrum of perhydropyrido[1,2-*c*]pyrimidine indicated that this compound exists predominantly in the *trans*-fused conformation (69JHC181), but the application of Bohlmann's IR criterion to perhydropyrido[1,2-*c*]pyrimidines is greatly complicated by the presence of the two N atoms and in some cases the  $\alpha$ -H atoms of the 2-alkyl group (70T701).

On the basis of the weak Bohlmann bands in their IR spectra, *cis*-fused ring conformations were assigned to *cis*-7,4*a*-H-2,7-dimethyl- and *cis*-5,4*a*-H-2,5-dimethylperhydropyrido[1,2-*a*]pyrimidin-3-ones [72JCS(P2)1920], and to 1,6,7,11*b*-tetrahydro- and 1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-ones (84JHC149). The 2-methyl-, *cis*-8,4*a*-H-2,8-dimethyl-, *trans*-7,4*a*-H-2,7-dimethyl-, and *trans*-5,4*a*-H-2,5-dimethylperhydropyrido[1,2-*c*]pyrimidin-3-ones displayed marked Bohlmann bands, and the *trans*-fused ring conformations were assigned [72JCS(P2)1920]. The strong Bohlmann bands in the IR spectrum of 2,3,4,4*a*,5,6-hexahydro-1*H*-pyrido[1,6-*a*]quinoline indicated the predominance of the *trans*-fused ring conformation with an equatorial *N*-methyl group [79JCS(P2)581].

In the IR spectra three well-resolved bands at 1635, 1625, and 1615  $\text{cm}^{-1}$  are characteristic for 3-methyl-2-(*N*-arylimino)-2,3,6,7-tetrahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones (**53**), in contrast to broad bands at 1661, 1645, and 1637  $\text{cm}^{-1}$  for isomeric 2-(*N*-aryl-*N*-methylimino)-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones (**54**) (84JMC1470).

## 6. $^1\text{H}$ NMR Spectra

a. *Fully Saturated Ring Systems.* There are six possible all-chair conformations of perhydropyrido[1,2-*c*]pyrimidines (**52**), which are interconvert-


ible by ring inversion and N<sup>2</sup> inversion (Scheme 9). Two of these (*cis*-*I*<sub>ax</sub> and *cis*-*O*<sub>ax</sub>) may be neglected because of the presence of severe nonbonded interactions, and their contributions to the equilibrium will be neglected.

In conformation *T*<sub>eq</sub>, the unfavorable dipole–dipole interaction between the N atoms may be relieved by the inversion of N(2) (conformation *T*<sub>ax</sub>). Conformation *T*<sub>ax</sub> is destabilized by *gauche*-butane and *gauche*-*n*-propylamine interactions, which are expected to be ca. 1.7 kcal mol<sup>−1</sup>. The O-outside *cis* conformer, *cis*-*O*<sub>eq</sub>, should be higher in energy than the *trans* conformer *T*<sub>eq</sub> by approximately the value for the *cis*–*trans*-quinolizidine, Δ*G*°, and should therefore contribute only ca. 1% to the equilibrium at 25°C. The difference between the *trans* conformer *T*<sub>ax</sub> and the N-inside *cis*-fused conformer, *cis*-*I*<sub>eq</sub>, is approximately one *gauche*-butane interaction (ca. 0.9 kcal mol<sup>−1</sup>) in favor of *T*<sub>ax</sub>, and they should be in an equilibrium ratio of ca. 4:1 at 25°C. The equilibrium energy difference between *T*<sub>eq</sub> and *T*<sub>ax</sub> was expected to be of the order of 0.3 kcal mol<sup>−1</sup>. On this basis, the equilibrium proportions for 2-methylperhydropyrido[1,2-*c*]pyrimidine (**52**, R = Me) are ca. 75% *T*<sub>eq</sub>, 20% *T*<sub>ax</sub>, and 5% *cis*-*I*<sub>eq</sub> [76JCS(P2)418].


The geminal coupling constant for the C(1) methylene group depends on the orientation of the C(1)–H bonds with respect to the N atom lone pairs, and it is suitable for the conformational analysis of perhydropyrido[1,2-*c*]pyrimidines. Thus, perhydropyrido[1,2-*c*]pyrimidines (**52**) existing in the *trans*-fused ring conformation (*T*<sub>eq</sub>) with an equatorial N(2) alkyl group are expected to have a larger (smaller absolute value) *J*<sub>gem</sub> for the C(1) methylene group (ca. −8.5 Hz versus −11.2 Hz) than those compounds in which either the ring fusion is *trans* and the N(2) alkyl group is axial (*T*<sub>ax</sub>) or the ring fusion is *cis* (*cis*-*I*<sub>eq</sub>) [76JCS(P2)418].

Because of the presence of the bulky substituent at position 2, 2-*tert*-butylperhydropyrido[1,2-*c*]pyrimidine (**52**, R = *t*Bu) exists predominantly in conformation *T*<sub>eq</sub> and has a *J*<sub>gem</sub> of −8.5 Hz for the C(1) methylene group (70T701). Later, a value of −8.8 Hz was determined in a more accurate determination from the 220-MHz spectrum [76JCS(P2)418]. As other 2-alkylperhydropyrido[1,2-*c*]pyrimidines have *J*<sub>gem</sub> values between −8.4 and −8.6 Hz for the C(1) methylene group, they adopt predominantly the *trans*-fused conformation with an equatorial substituent (*T*<sub>eq</sub>) (70T701). For 2-methylperhydropyrido[1,2-*c*]pyrimidine (**52**, R = Me), a *J*<sub>gem</sub> of −9.2 Hz was determined, which corresponded to ca. 75% of the *trans*-fused conformation, *T*<sub>eq</sub> [76JCS(P2)418]. There is a long-range coupling of ca. 1.8 Hz between 1-*H*<sub>eq</sub> and 3-*H*<sub>eq</sub> in 1-alkylperhydropyrido[1,2-*c*]pyrimidines (70T701). The 3-phenyl derivative (**52**, R = Ph) exists predominantly as the *trans*-fused conformer *T*<sub>eq</sub>, but *J*<sub>gem</sub> for the C(1) methylene group is 10.5 Hz because of overlap between the π-electrons of the phenyl group and the axial lone pair of N(2) (70T701).


For the  $J_{\text{gem}}$  values for the C(1) methylene group (between  $-8.5$  and  $-8.8$  Hz), it was concluded that *cis*-3,4*a*-H-2-methyl-3-alkyl- (methyl and ethyl), *trans*-4,4*a*-H-2,4-dimethyl-, *cis*-4*a*,8-H-2,8-dimethyl-, and 2-*tert*-butyl-8-methylperhydropyrido[1,2-*c*]pyrimidines exist predominantly as the *trans*-fused conformer  $T_{\text{eq}}$ , with an equatorial C-alkyl group, whereas *cis*-4,4*a*-H-2,4-dimethylperhydropyrido[1,2-*c*]pyrimidine exists predominantly as the conformer  $T_{\text{eq}}$  with an axial C-methyl group. For *trans*-3,4*a*-H-2-methyl-3-alkylperhydropyrido[1,2-*c*]pyrimidines, the  $J_{\text{gem}}$  values of the C(1) methylene groups ( $-10.8$  and  $-11.4$  Hz) and the long-range coupling between 1- $H_{\text{eq}}$  and 3- $H_{\text{eq}}$  indicate the predominant presence of *trans*-fused conformer  $T_{\text{ax}}$  with an axial C(-3) alkyl group. *trans*-4*a*,8-H-2,8-Dimethyl- and 2-*tert*-butyl-8-methylperhydropyrido[1,2-*c*]pyrimidines have  $J_{\text{gem}}$  values of  $-9.9$  and  $-9.8$  Hz for the C(1) methylene protons, which indicate the presence of conformational mixtures containing appreciable amounts of the conformations *cis*- $I_{\text{eq}}$  and  $T_{\text{eq}}$  (70T701).



The  $J_{\text{gem}}$  value of 9.0 Hz for the C(1) methylene protons of 2-methylperhydropyrido[1,2-*c*]pyrimidin-3-one (**55**) in  $\text{CCl}_4$ , when the nonbridgehead N atom with its lone pair of electrons is incorporated in an amide group, points to the presence of ca. 16% *cis*-fused conformer (**55c**) in equilibrium with the *trans*-fused conformer (**55t**) [72JCS(P2)1920]. *cis*-4*a*,7-H-2,7-Dimethylperhydropyrido[1,2-*c*]pyrimidin-3-one ( $J_{\text{gem}} -10.8$  Hz) exists as ca. 72% of the *cis*-fused conformer in equilibrium with 28% of the *trans*-fused one. *cis*-4*a*,5-H-2,5-Dimethylperhydropyrido[1,2-*c*]pyrimidin-3-one ( $J_{\text{gem}} -11.7$  Hz) exists predominantly in the *cis*-fused conformation, and *cis*-4*a*,8-H-, *trans*-4*a*,7-H-, and *trans*-4*a*,5-H-2,X-dimethylperhydropyrido[1,2-*c*]pyrimidin-3-ones ( $J_{\text{gem}} -8.5$  and  $-8.7$  Hz) in the *trans*-fused ones.  $J_{\text{gem}}$  for the C(4) methylene protons ( $-11.3$  Hz) indicates a conformation such that the nodal plane of the amide carbonyl bisects the C(4) $H_2$  internuclear axis.




The room-temperature  $^1\text{H}$  NMR spectrum of 2-acetylperhydropyr-ido[1,2-*c*]pyrimidine exhibits signals arising from both rotational isomers (**56c** and **56t**), as a result of restricted rotation about the N—C(=O)Me bond. The *cis* and *trans* isomers **56c** and **56t** could be distinguished on the basis of  $J_{\text{gem}}$  for the protons of the methylene group adjacent to the amido N, and the chemical shift of 1- $\text{H}_{\text{eq}}$  [73OMR(5)397].



The  $^1\text{H}$  NMR spectrum of **57d** in  $\text{CDCl}_3$ – $\text{CFCl}_3$  solution at  $19^\circ\text{C}$  indicates an equilibrium mixture containing 45% of the pyrido[1,2-*c*]pyrimidinium ion (**58**), 27% of the dimer (**57d**), and 28% of the monomer (**57m**) [79JCS(P2)504]. At  $-45^\circ\text{C}$ , only the signals of the dimer (**57d**) could be assigned in the spectrum.

b. *Partly Saturated Ring Systems.* Of the six all-chair conformations of 2-methyl-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrimido[1,6-*a*]quinoline (**59**), the high-energy *cis*-fused conformations (*cis*- $I_{\text{ax}}$ , *cis*- $O_{\text{ax}}$ , *cis*- $I_{\text{eq}}$ , and *cis*- $O_{\text{eq}}$ ) cannot be expected to contribute significantly to the equilibrium (Scheme 10). The *trans*-fused conformations ( $T_{\text{eq}}$  and  $T_{\text{ax}}$ ) differ only in terms of the unfavorable generalized anomeric effect present in  $T_{\text{eq}}$  and the *gauche*-*n*-propylamine interaction in  $T_{\text{ax}}$ . Both conformers are stabilized further by the delocalization of the bridgehead N atom lone pair into the aromatic  $\pi$ -electron system of the phenyl ring.  $J_{\text{gem}}$  ( $-11.1$  Hz) for the C(1) methylene protons indicates that 2-methyl-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrimido[1,6-*a*]quinoline in  $\text{CDCl}_3$  establishes a conformational equilibrium involving ca. 81%  $T_{\text{eq}}$  and 19%  $T_{\text{ax}}$  [79JCS(P2)581].

Of the six all-chair conformations of 2-methyl-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrido[6,1-*a*]isoquinoline (**60**), the *cis*- $I_{\text{ax}}$ , *cis*- $O_{\text{eq}}$ , and *cis*- $O_{\text{ax}}$  conformations could be discounted because they suffer from a number of nonbonded interactions (Scheme 11). The basic difference between the *trans*-fused and *cis*-fused conformations is that in the *trans*-fused ring conformations ( $T_{\text{eq}}$  and  $T_{\text{ax}}$ ) the perhydropyrimidine ring is fused onto the tetrahydropyridine




SCHEME 10

ring, by utilization of the pseudoequatorial and equatorial bonds of the tetrahydropyridine ring, and this increases the strain in the fused system. This *trans*-ring fusion strain is not present in the conformation *cis*-I<sub>eq</sub>, where fusion of the perhydropyrimidine ring can readily occur, since the fusion involves the pseudoequatorial and axial (or equatorial and pseudoaxial) bonds. The  $J_{\text{gem}}$  value of the C(4) methylene protons (−9.8 Hz) indicates the presence of an equilibrium between ca. 54% of conformation *T*<sub>eq</sub> and 46% of conformations *cis*-I<sub>eq</sub> and *T*<sub>ax</sub>, in which one of the N lone pairs bisects the C(4) methylene protons [77JCS(P2)370].

The  $J_{\text{gem}}$  value (−10.1 Hz) of the C(4) methylene protons suggests that 3-methyl-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-one (**61**) adopts an equilibrium involving about 53% of the *trans*-fused and 47% of the *cis*-fused conformer (Scheme 12). The vicinal coupling constants relating to 11*b*-H ( $J_{11b,1ax} \approx 11.5$  Hz,  $J_{11b,1eq} \approx 4.6$  Hz) rule out the presence of the N-outside *cis*-fused conformer (91MRC1040). 3-Methyl and 3-phenyl-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinoline-2,4-diones adopt a *trans*-fused conformation (91MRC1040).

The coupling constants between 11*b*-H and the C(1) methylene protons (14 and 6 Hz, and 9 and 3 Hz) for 9,10-dimethoxy-4-phenyl-1,6,7,11*b*-tetrahydro- and 1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines indicate the predominance of the N-inside *cis* conformation (84JHC149).


The <sup>1</sup>H NMR spectra of 3-methyl- and 3-phenyl-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinoline-2,4-diones in CDCl<sub>3</sub> are very similar to each other, and the magnitudes of the coupling constants involving the



SCHEME 11

C(6) and C(1) methylene protons are consistent with the *trans*-fused conformation (91MRC1040).

In the  $^1\text{H}$  NMR spectra downfield shifts for the  $\text{NCH}_3$  and H-1 protons are characteristic for 3-methyl-2-[*N*-(2,4,6-trimethylphenyl)imino]-2,3,6,7-tetrahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one (**53**, Ar = 2,4,6-trimethylphenyl) relative to those for corresponding protons in 2-[*N*-(2,4,6-trimethyl-



SCHEME 12




phenyl)-*N*-methylimino]-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one (**54**, Ar = 2,4,6-trimethylphenyl) (84JMC1470).

### 7. $^{13}\text{C}$ NMR Spectra


$^{13}\text{C}$  NMR data on 2-oxo-, 3-methyl-, and 3-phenyl-2,4-dioxo-1,3,4,6,7,11*b*-hexahydropyrimido[6,1-*a*]isoquinolines have been measured in  $\text{CDCl}_3$  (91MRC1040). The structures of 3-amino-4-substituted 1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinoline-2-ones have similarly been investigated by means of  $^{13}\text{C}$  NMR spectroscopy (90JHC957).

### 8. X-Ray Investigations



The structures of pyrido[1,2-*c*]pyrimidinium chloride (**62**) (91KGS1556), hexahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-ones (**18** and **63**) (85JMC1285), and 1,3,4,6,7,11*b*-hexahydropyrimido[6,1-*a*]isoquinolin-4-ones (**64**) (82TL-2829; 83JOC5074) have been determined by X-ray crystallography. The structure of a wild-type human immunophilin FKBP12 (a member of a ubiquitous family of proteins) complexed with benzyl *trans*-4*a*,8-*H*-1-oxo-2-propylperhydropyrido[1,2-*c*]pyrimidine-9-carboxylate was determined by X-ray investigations (96JMC1872).



(62)



(63)



(64)

The X-ray analysis revealed that **53** (Ar = 2,4,6-trimethylphenyl) exists as the *Z* isomer with the mesitylene moiety perpendicular to the plane of the pyrimido[6,1-*a*]isoquinoline skeleton away from the *N*-methyl group (84JMC1470).

X-ray diffraction studies showed that protonation occurred on the 2-imino group of 2-imino-9,10-dimethoxy-4-phenyl-6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinoline in the solid state, and not on N(3) as in  $\text{DMSO}-d_6$  solution (90CB493).


### III. Reactivity

#### A. PYRIDO[1,2-*c*][1,3]OXAZINES AND THEIR BENZO DERIVATIVES

##### 1. Ring Opening

The presence of a substituent at position 1 of perhydropyrido[1,2-*c*][1,3]oxazines decreases the stability of the bicycle (54JA2431). Hydrolysis of perhydropyrido[1,2-*c*][1,3]oxazines [56CLY1180; 57CLY927; 60JOC2028; 70LA(737)24] or their 1-oxo derivatives (84JA3240; 91TL4371; 93JA8851) gave 2-(2-hydroxyethyl)piperidines, whereas that of pyrido[3,2,1-*ij*][3,1]benzoxazin-3-ones and the -1,3-dione yielded 8-hydroxy-methyl-1,2,3,4-tetrahydroquinolines (87EUP239129; 90CPB1575) and 1,2,3,4-tetrahydroquinoline-8-carboxylic acid (64M59), respectively. The rate of the solvolysis of *trans*-3,4a-*H*-3-substituted perhydropyrido[1,2-*c*][1,3]oxazines was higher than that of *cis*-3,4a-*H* epimers (57CLY927). The *trans*-3,4a-*H*-3-substituted perhydropyrido[1,2-*c*][1,3]oxazines, containing the R substituent in an axial position, were hydrolyzed faster than the 3-epimeric derivatives in 2 *N* acetic acid at 25°C in the presence of dimedone [70LA(737)24].

Treatment of *r*-4a,*c*-5a,*t*-9a-*H*-1-ethylideneperhydro[1,3]oxazino[3,4-*b*]isoquinoline (42) with water in methylene chloride gave 2-(*trans*-perhydroisoquinolin-3-yl)ethyl propionate (80HCA1158).



Acidic hydrolysis of [1,3]oxazino[4,3-*a*]isoquinolin-2-one (65) and [1,3]oxazino[3,4-*a*]quinoline-3-ones (67) in boiling 5% hydrochloric acid


furnished 3-substituted 2,2-dimethylpropionic acids **66** and **68**, respectively [66JCS(CC)262; 67JCS(C)1569].

The reactions of 3,5,6,7-tetrahydro-1*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine-1,3-dione with amines in dioxane led to *N*-substituted 1,2,3,4-tetrahydroquinoline-8-carboxamides (78JHC645; 79JHC897).

Depending on the reaction conditions, treatment of 4-hydroxymethyl-3,4-dihydro-1-oxo-1*H*-pyrido[2,1-*c*][1,3]oxazinium chloride with  $\text{NH}_3$  afforded either 4-hydroxymethyl-1,3-dihydropyrido[2,1-*c*][1,3]oxazin-1-one or different ring-opened products (92JOC5764).

Catalytic hydrogenation of perhydropyrido[1,2-*c*][1,3]oxazines over Pt (54JA2431) and their treatment with aqueous formic acid (54JA2431) or with LAH [57CLY927; 58CLY2081; 67RZC1389; 71LA(753)27; 85T2891; 87T935; 93JOC5035; 96SL100] yielded 1-substituted 2-(2-hydroxyethyl)piperidines. Reductive ring-opening of 1,6,7,11*b*-tetrahydro-2*H*,4*H*-[1,3]oxazino[4,3-*a*]isoquinolines (66AP997; 90T4039; 91ACH375) and their 1-oxo derivatives (90T4039) with LAH resulted in the formation of 2-(*N*-alkyl-1,2,3,4-tetrahydroisoquinolin-1-yl)ethanols.


The boiling of optically active 3-deuterio-3-*p*-methoxyphenylperhydropyrido[1,2-*c*][1,3]oxazine in ethanol in the presence of 20% w/w of 10% Pd/C catalyst yielded *N*-formyl-2-(2-deuterio-2-*p*-methoxyphenylethyl)piperidine with no deuterium loss [72JCS(CC)1152].




The reaction of 1,3-disubstituted perhydropyrido[1,2-*c*][1,3]oxazines (**69**) and 7-(benzothiazol-1-yl)-6,7-dihydro-1*H*,3*H*,5*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine with Grignard reagents led to 2-(*N*-substituted 2-piperidyl)ethanols (**70**) (50JA358; 58CLY2081) and 1-benzyl-4-(benzotriazol-1-yl)-8-hydroxymethyl-1,2,3,4-tetrahydroquinoline (95JOC3993), respectively.

Ring opening of 9,10-dimethoxy-1,2,4,5,6,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinoline occurred on treatment with acyl chlorides or with hydrogen cyanide in ethanol, to give 6,7-dimethoxy-1-(2-hydroxyethyl)-1,2,3,4-tetrahydroisoquinoline and its 2-cyanomethyl derivative, respectively (66AP997).

Perhydroquinolines (**72**) were obtained in almost quantitative yield from perhydro[1,3]oxazino[3,4-*a*]quinolin-1-one (**71**) on reaction with lith-



ium dialkylcuprate in a mixture of diethyl ether and THF at  $-73^\circ\text{C}$  [84-JCS(CC)597, 84TL3247; 86CPB2380]. Similar products (72) could be obtained in moderate yield from 71 by treatment with Zn in acetic acid (84TL3247), or from the perhydro derivative (73) by selenium(IV) oxide elimination and subsequent treatment with Zn in acetic acid at  $90^\circ\text{C}$  (80JA1454).




2-(Tetrahydroisoquinol-1-yl)ethanols (**74**) could be converted by inversion into the epimers (**77**) by *N*-benzoylation, subsequent treatment of **75** with thionyl chloride, and hydrolysis of the tricycles (**76**) (92T4937).

Reduction of a spiro compound, dodecahydro-3,3'-bi-1*H*,3*H*-pyrido[1,2-*c*][1,3]oxazine, with sodium amalgam in acetic acid led to reductive cleavage of one of the two tetrahydro[1,3]oxazine rings [71LA(753)27].

## 2. Reduction

Conjugate 1,4-reduction of the 1,6-dione (**78**) with *L*-Selectride in the presence of *N*-(2-pyridyl)triflimide provided the vinyl triflate (**79**), which was chemoselectively hydrogenated over Pd/C to give perhydropyrido[2,1-*c*][1,3]oxazinone (**80**) (93JOC5035). Hexahydro derivative **81** was similarly hydrogenated to a perhydro derivative (93JA8851).



Reduction of the keto group of the C(3) epimers of 3-phenylperhydropyrido[1,2-*c*][1,3]oxazin-6-ones with potassium trisamylborohydride in THF at  $-78^\circ\text{C}$  gave a 9 : 1 mixture of the axial alcohol and the equatorial alcohol, whereas the ratio of the alcohols was the reverse when  $\text{NaBH}_4$  was used in methanol at room temperature (85T2891).

Catalytic hydrogenation of *trans*-3,4*a*-H-3-methyl-1,3,4,4*a*,5,6-hexahydropyrido[1,2-*c*][1,3]oxazin-1-one over Pd/C afforded the perhydro derivative in excellent yield (91TL4371).


Catalytic hydrogenation of 1-cyano-9,10-dimethoxy-2,4,6,7-tetrahydro[1,3]oxazino[4,3-*a*]isoquinoline over Pd/C at atmospheric pressure in a suspension in ethyl acetate yielded the 1,2,4,6,7,11*b*-hexahydro derivative

(73JHC435). The 5,6 double bond of 1-isopropylidene-4,4-dimethyl-1,3,4,4*a*-tetrahydro[1,3]oxazino[3,4-*a*]quinolin-3-one (**67**, R = valence bond) was saturated on reaction with hydrogen over Pd/C [67JCS(C) 1569; 71JOC2211].

The 7-oxo group of 6,7-dihydro-1*H*,3*H*,5*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine-3,7-dione was selectively reduced to a hydroxy group with sodium borohydride in methanol (87EUP239129; 90CPB1575).


### 3. Reactivity of Rings

Methobromides (54JA2431) and methoiodides [60AP74; 63AP38; 70-LA(737)24] of perhydropyrido[1,2-*c*][1,3]oxazines were prepared from the bases with the respective methyl halides. The rates of quaternization of 4-methylperhydropyrido[1,2-*a*][1,3]oxazines (70T1217), three isomers of perhydropyrido[1,2-*c*][1,3]benzoxazines (**21–23**) (70T1217), and all isomeric perhydropyrido[3,2,1-*ij*][3,1]benzoxazines (**25–28**) [80JCS(P2)1778] with methyl iodide were measured in acetonitrile at 29–30°C.



Copper-mediated 1,4-addition of Grignard reagent (**83**) to hexahydro-pyrido[1,2-*c*][1,3]oxazine-1,6-dione (**82**) afforded perhydro derivatives (**84**) (93JA8851). Reaction of 1,6-dione (**84**) with LDA and *N*-(5-chloro-2-pyridyl)triflimide gave vinyltriflate (**81**), which contained 10% of the regioisomeric 1,3,4,4*a*,7,8-hexahydro derivative (93JA8851).


The 8-phenylsulfonyl derivative **86** was obtained when a solution of perhydropyrido[1,2-*c*][1,3]oxazin-1-one (**85**) and tetraethylammonium *p*-toluenesulfonate was electrolyzed and the evaporated residue was treated with benzenesulfinic acid and anhydrous calcium chloride (91T1311). From the 8-phenylsulfonyl derivative (**86**), the 7,8-unsaturated derivative (**87**) and different 8-substituted derivatives (**88–90**) could be prepared stereoselectively (90SL48, 90SL749; 91T1311) (see Scheme 13).



SCHEME 13

From the dimethyl acetal derivatives of perhydropyrido[1,2-*c*][1,3]oxazines (33 and 34), the phenylsulfonyl group was reductively removed with sodium amalgam to yield 5-unsubstituted derivatives (96SL100).

The treatment of methyl 1-oxo-1,3,4,4*a*,7,8-hexahydropyrido[1,2-*c*][1,3]oxazine-8-carboxylate with NaOMe in  $\text{CH}_3\text{OD}$  gave the 8-deuterated product (81JA7573).




The anodic electrochemical oxidation of *cis*-3,4*a*-H-3-phenylperhydropyrido[1,2-*c*][1,3]oxazin-1-one (91) in methanol in the presence of tetraethylammonium *p*-toluenesulfonate gave a mixture of methoxylated pyrido[1,2-*c*][1,3]oxazin-1-ones (92–94) (91CJC211).

The 10-fluoro atom of 9,10-difluoro-7-oxo-1*H*,3*H*,7*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine-6-carboxylic acids was regioselectively substituted by cyclic amines (90EUP373531; 96GEP4424369).

#### 4. Reactivity of Substituents Attached to Ring Carbon Atoms

The carboxylic acid **95**, obtained from the methyl ester by alkaline hydrolysis, was converted by an Arndt–Eistert sequence to the higher homolog **96** (84JA3240). The ethyl esters of 7-oxo-1*H*,3*H*,7*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine-6-carboxylates were hydrolyzed under basic conditions (90EUP373531). The carboxylic acid derivative was obtained by alkaline hydrolysis of methyl *trans*-4*a*,8-*H*-1-oxo-1,3,4,4*a*,7,8-hexahydropyrido[1,2-*c*][1,3]oxazine-8-carboxylate (81JA7573).



The carbonyl group in the side chain at position 8 of perhydropyrido[1,2-*c*][1,3]oxazines (**33**) and (**34**) was converted to the dimethylacetal on the treatment with triethyl orthoformate in methanol in the presence of *p*-toluenesulfonic acid (96SL100).




7-(*N*-Allylamino)-6, 7-dihydro-1*H*,3*H*,5*H*-pyrido[3, 2, 1-*ij*][1, 3]benzoxazin-3-one was *N*-methylated with formic acid–formaldehyde to furnish the 7-(*N*-allyl-*N*-methyl)amino derivative (87EUP239129; 90CPB1575). Treatment of 7-hydroxylimino-6,7-dihydro-1*H*,3*H*,5*H*-pyrido[3,2,1-*ij*][3,1]benzoxazin-3-one with a mixture of formic acid and formaldehyde at 100°C afforded the 7-dimethylamino derivative (87EUP239129).

The side-chain piperidine ring of **97** was *N*-acylated with benzoyl chloride and phenyl isocyanate [70LA(737)24], and the hydroxy group of compound (**38**, R = OH, R<sup>1</sup> = Me, R<sup>2</sup> = Ph) was acylated with benzoyl chloride (85GEP3439131; 90CB803). The HO → Cl exchange did not occur when **44** was boiled in SOCl<sub>2</sub> (90T4039).

Oxidative elimination of the phenylselenenyl group of the perhydro[1,3]oxazino[3,4-*a*]isoquinoline (**98**) was effected with 30% H<sub>2</sub>O<sub>2</sub> in the presence of pyridine to afford **71** in quantitative yield [84JCS(CC)597; 86CPB2380].

4-(2-Piperidylmethyl)perhydropyrido[1,2-*c*][1,3]oxazines were reacted with phenyl isothiocyanate and benzoyl chloride [70LA(737)24].






4-(Phenylimino)-1-hydroxymethyl-9,10-dimethoxy-1,2,4,6,7,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinoline was prepared from 4-methylimino and 4-thione derivatives in the presence of HgO and 4-methylthio-1,6,7,11*b*-tetrahydro-2*H*-[1,3]oxazino[4,3-*a*]isoquinolinium salt with aniline (85GEP3510526). 4-Methylthio-1-hydroxymethyl-9,10-dimethoxy-1,6,7,11*b*-tetrahydro-2*H*-[1,3]oxazino[4,3-*a*]isoquinolinium iodide was obtained from the 1,2,4,6,7,11*b*-hexahydro-4-thione derivative with methyl iodide (85GEP3510526). 1-Hydroxymethyl-9,10-dimethoxy-1,2,4,6,7,11*b*-hexahydro-[1,3]oxazino[4,3-*a*]isoquinolin-4-thione was obtained from its 4-one derivative by treatment with P<sub>4</sub>S<sub>10</sub> in pyridine (85GEP3510526).

The 7-hydroxy group of 7-hydroxy-6,7-dihydro-1*H*,3*H*,5*H*-pyrido[3,2,1-*ij*][3,1]benzoxazin-3-one was alkylated with alkyl halide in DMSO in the presence of sodium hydride (87EUP239129; 90CPB1575). The 7-oxo group of 3,4,5,6-tetrahydro-1*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine-3,7-dione was converted into the 7,7-ethylenedioxy group by treatment with ethylene glycol in the presence of *p*-toluenesulfonic acid in boiling toluene. It was then condensed with hydroxylamine hydrochloride in the presence of sodium acetate and with allylamine in the presence of *p*-toluenesulfonic acid and molecular sieve 3Å, and the imine was reduced with NaBH<sub>4</sub> to give the 7-allylamine derivative (87EUP239129; 90CPB1575).

### 5. Ring Transformation

2-Aryl-1,6,7,8,9,9*a*-hexahydro-4*H*-quinolizines were obtained when 3-aryl-methylperhydropyrido[1,2-*c*][1,3]oxazine hydrochlorides were heated in concentrated hydrochloric acid (60BRP856357; 62USP3031454).

Ethyl 4,5,6,7,8,8*a*-hexahydro-3*H*-quinolizine-1-carboxylate was obtained in 82% yield from 1-oxo-3-vinylperhydropyrido[1,2-*c*][1,3]oxazine-4-carboxylate on the action of DBU in DMSO [88CPB1597; 90H(30)885]. Rearrangement of [1,3]oxazino[3,4-*a*]quinoline (**67**, R = H) in the presence of NaOMe in cyclohexane at 65°C produced benzo(*c*)quinolizine-1,3-dione (**99**) (71JOC2211).



Treatment of 1-cyano-9,10-dimethoxy-2,4,6,7-tetrahydro[1,3]oxazino[4,3-*a*]isoquinoline (**100**) with primary amine and aqueous formaldehyde in boiling ethanol afforded 2-substituted 1-cyano-9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolines (**101**) (73JHC435).

Different di-, tri-, tetra-, and pentacyclic heterocycles were prepared from 6,7-dihydro-1*H*,3*H*,5*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine (**102**) as depicted in Scheme 14 (78JHC645; 79JHC829; 80JHC1785; 83EUP59698; 84MIP1).

See further examples in Section IV,B,6.

## 6. Miscellaneous

The epimers of *cis*-3,4*a*-H-3-phenylperhydropyrido[1,2-*c*][1,3]oxazin-6-one were separated with camphor-10-sulfonic acid in acetone (85T2891). The enantiomers of 6,10,11,11*a*-tetrahydropyrido[1,2-*c*][1,3]benzoxazin-6-one were quantitatively separated by means of HPLC on swollen microcrystalline triacetylcellulose with ethanol–water (96:4) as the mobile phase. The first-eluted enantiomer had the *R* configuration (91ACS716).


The electrochemical reduction of 1-hydroxymethyl-9,10-dimethoxy-4-cyclohexylimino-1,2,4,5,6,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinoline on a dropping Hg electrode was studied (87PHA858).

## B. PYRIDO[1,2-*c*][1,3]THIAZINES AND THEIR BENZO DERIVATIVES

### 1. Ring Opening

Reductive desulfurization of all-*cis*-3,4*a*,5,6-*H*-3-phenyl-5-substituted 6-formylperhydropyrido[1,2-*c*][1,3]thiazin-1-ones with Raney Ni in boiling ethanol gave all-*cis*-2,3,4-*H*-1-formyl-2-(2-phenethyl)-3-substituted piperidin-4-ols (85T2861).

Reaction of 1-iminoperhydropyrido[1,2-*c*][1,3]thiazine hydrobromides with tetraethylenepentamine in boiling ethanol afforded 2-(2-mercaptoethyl)piperidines [70T3941; 82OMR(20)239].



SCHEME 14

## 2. Reactivity of Rings

The reaction of 1,3,4,4a,5,10-hexahydro[1,3]thiazino[3,4-b]isoquinoline-1-thione and methyl iodide gave 1-methylthio-4,4a,5,10-tetrahydro-3H-[1,3]thiazino[3,4-b]isoquinolinium iodide, which reacted with 5-aminoisoquinoline in pyridine at  $40^\circ C$  to afford 1-(5-isoquinolyylimino)-1,3,4,4a,5,10-hexahydro[1,3]thiazino[3,4-b]isoquinoline (79GEP2848926).


The 4-(substituted imino) moiety of 1,2,4,6,7,11*b*-hexahydro-2*H*-[1,3]thiazino[4,3-*a*]isoquinolines was substituted with another (substituted imino) group when 9,10-dimethoxy-1-hydroxymethyl-4-(substituted imino)-1,2,4,6,7,11*b*-hexahydro-[1,3]thiazino[4,3-*a*]isoquinolines were reacted with primary amines in boiling ethanol (85GEP3510526).

### 3. Reactivity of Substituents Attached to Ring Carbon Atoms

*trans*-1,11*b*-*H*-1-Benzoyloxymethyl-9,10-dimethoxy-4-phenylimino-1,2,3,6,7,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinoline was obtained from the 1-hydroxymethyl derivative by reaction with benzoyl chloride in boiling pyridine (90CB803).

### 4. Ring Transformation

The reaction of 6,7-dihydro-1*H*,3*H*,5*H*-pyrido[3,2,1-*ij*][3,1]benzothiazine-1,3-dithione (**103**) with 1,3-diaminopropane afforded the tetracyclic compound (**104**) (78JHC645).



### 5. Miscellaneous

The electrochemical reduction of 4-(substituted imino)-1,2,4,5,6,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinolines on a dropping Hg electrode was studied in the pH range 1–11 (87PHA858).

## C. PYRIDO[1,2-*c*]PYRIMIDINES AND THEIR BENZO DERIVATIVES

### 1. Ring Opening

2-(1-Aminocarbonyl-2-piperidyl)acetic acid was obtained from perhydropyrido[1,2-*c*]pyrimidine-1,3-dione by reaction with 30% aqueous KOH at 60–70°C (56CB1642). Treatment of 1,3-dimethyl-5,6,7,8-tetrahydropyr-

ido[1,2-*c*]pyrimidinium-4-carboxylate with aqueous ammonia gave 4-(4-ammoniobutyl)-2,6-dimethylpyrimidine-5-carboxylate (87JOC2455). Basic hydrolysis of 4-cyano-5,6,7,8-tetrahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-one led to a ring-opened product (82KGS518).

Treatment of 9,10-dimethoxy-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinoline-2,4-dione with LAH in dioxane at 80°C yielded ring-opened 2-(2-methylaminoethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (59-YZ1008). Heating 9,10-dimethoxy-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinoline or its 3-methyl derivative in a mixture of 35% formaldehyde and 80% formic acid gave 1-dimethylamino-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (59YZ1008). Heating 9,10-dimethoxy-6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-one in a sodium hydroxide solution gave 1-aminocarbonylmethylene-1,2,3,4-tetrahydroisoquinoline [81KFZ(5)44; 82KGS1095]. Acidic hydrolysis of 9,10-dimethoxy-4-phenyl-1,6,7,11*b*-tetrahydro- and 1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines (84JHC149) and 2,3,4,4*a*,5,6-hexahydro-1*H*-pyrimido[1,6-*a*]quinoline (60YZ1414) led to ring-opened products. 1-[(Acylamidino)methylene]-6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolines (**48**) were obtained when 2-imino-4-substituted 9,10-dialkoxy-6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinoline hydrochlorides were treated with aqueous potassium hydroxide or their hydrates (**51** · H<sub>2</sub>O) were left to stand in ethanol overnight (90CB493).

Reduction of 9,10-dimethoxy-1-(un)substituted 3-substituted 1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolones with NaBH<sub>4</sub> in acetic acid afforded ring-opened 6,7-dimethoxy-2-methyl-1-[2-(substituted amino)-2-oxo]ethyl-1,2,3,4-tetrahydroisoquinolines (92GEP4104257).

See further examples in Section III,C,4.

## 2. Reduction, Hydrogenation

Perhydropyrido[1,2-*c*]pyrimidine was obtained from perhydropyrido[1,2-*c*]pyrimidine-1,3-dione (59CB637) and from perhydropyrido[1,2-*c*]pyrimidin-1-one [67YZ663; 73OMR(5)397] by reduction with LAH. Reduction of 2-oxo- and 2,4-dioxo-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines and 1-oxo-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrimido[1,6-*a*]quinoline with LAH gave hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines [59YZ1008; 77JCS(P2)370] and hexahydro-1*H*-pyrimido[1,6-*a*]quinoline (60YZ1414), respectively.

Reduction of 2-benzyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-*ij*]quinazolin-7-one with NaBH<sub>4</sub> and hydrazine hydrate in the presence of KOH gave 7-hydroxy and 7-deoxy derivatives, respectively (72MI1).

Catalytic reduction of 1-cyano-6,7-dihydro- and 1-cyano-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolines or of 1-cyano-3-acetoxy-

1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinoline over Pd/C gave 1-cyano-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines (81CB61; 84MI3). Catalytic reduction of 4-(*p*-nitrophenyl)-9,10-dimethoxy-6,7-dihydro-2*H*-pyrido[6,1-*a*]isoquinoline over PtO<sub>2</sub> in acidic methanol gave 4-(*p*-aminophenyl)-6,7-dihydro and 4-(*p*-aminophenyl)-1,3,4,6,7,11*b*-hexahydro derivatives after the absorption of 3 and 5 mol hydrogen, respectively (55JPJ709, 55MI2). 9,10-Dimethoxy-1,2,3,6,7,11*b*-hexahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one was prepared from 6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinolin-4-one and its 2-chloro derivative by catalytic hydrogenation over Pd/C (84JMC1470).

Catalytic reduction of 4-benzyl-2-phenyl-2,3-dihydro-1*H*-pyrimido[6,1-*a*]quinoline-1,3-dione with hydrogen over 5% Pt/C in acetic acid at 50°C for 15 h gave the 2,3,5,6,6*a*,7,8,9,10,10*a*-decahydro-1*H* derivative (83M227).

Treatment of 2-substituted 4-cyano-3-imino-2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-ones with NaBH<sub>4</sub> in ethanol gave 3-amino-2,4*a*,5,6,7,8-hexahydro-1*H* derivatives (90MI3). The N(3)-C(4) double bond of 6,7-dihydro- and 1,6,7,11*b*-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolines was saturated by treatment with NaBH<sub>4</sub> (81CB61; 84JHC149, 84MI3). Electrochemical reduction of 4-aryl-9,10-dialkoxy-1,6,7,11*b*-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-ones afforded the 1,3,4,6,7,11*b*-hexahydro derivatives (87PHA739; 89PHA694). Reduction of 9,10-dimethoxy-2,3,6,7-tetrahydro-4*H*-pyrimido[6,1-*a*]isoquinoline-2,4-dione with Mg in methanol yielded the 1,2,3,6,7,11*b*-hexahydro derivative (90JOC5117). 2-Amino-9,10-dimethoxy-4-phenyl-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinoline was obtained when 2-imino-9,10-dimethoxy-4-phenyl-6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinoline was hydrogenated over Pd/C (90CB493).

### 3. Reactivity of Ring Nitrogen Atoms

The 2-methyl derivative was prepared from perhydropyrido[1,2-*c*]pyrimidine-1,3-dione on treatment with diazomethane in aqueous methanol (56CB1642). The methiodide was obtained from perhydropyrido[1,2-*c*]pyrimidine with methyl iodide (59CB637).

The nonbridgehead nitrogen of perhydropyrido[1,2-*c*]pyrimidines (69JHC181) and their 3-oxo (84EUP104647; 85JMC1285) and 1,3-dioxo derivatives (64JMC146; 87USP4680295) and 2,3-dihydro-1*H*-pyrido[1,2-*c*]pyrimidine-1,3-diones (57HCA1319), and that of 9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*- (77SAP77/06706; 78GEP2720085; 79GEP2801289; 80GEP2847693; 84JMC1470), 1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinoline-2,4-diones (69YZ649; 84T4003; 90JOC5117), as well as that of 2,3,4,4*a*,5,6-1*H*-pyrimido[1,6-*a*]quinolin-1-ones (70USP3494922), has been alkylated, and the nonbridgehead nitrogen of perhydropyrido

[1,2-*c*]pyrimidine [73OMR(5)397], its 1-oxo derivative (90MIP1), its 1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinoline (59YZ1008), and its 2,4-dione derivative has been acylated (84T4003).

The alkylation of 2-(substituted amino)-9,10-dimethoxy-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones usually led to a mixture of 2-(disubstituted amino)-6,7-dihydro and 2-(substituted imino)-3-alkyl-2,3,6,7-tetrahydro derivatives (e.g., **54** and **53**) (81INIP149457; 84EUP124893, 84JMC1470; 86HCA1671). The ratio of the 3-alkyl-2,3,6,7-tetrahydro and the 2-(disubstituted amino)-6,7-dihydro derivatives varied and depended on the size of the alkyl group and the alkylation conditions (84JMC1470). The ratio of the 3-alkyl-2,3,6,7-tetrahydro isomers was higher when K<sub>2</sub>CO<sub>3</sub>/acetone was used instead of NaH/DMF, and the ratio decreased with increasing alkyl group. (Earlier the starting compounds were described as 4-[substituted amino]-2-oxo derivatives [79GEP2801289].

Hydrolysis of 2-acetyl-1-[cyano(nitro)methylene]perhydropyrido[1,2-*c*]pyrimidine in boiling 5 *N* hydrochloric acid gave the 2-unsubstituted derivative [74JCS(P1)1611].


#### 4. Reactivity of Ring Carbon Atoms

Treatment of 4-phenyl-2,3-dihydro-1*H*-pyrido[1,2-*c*]pyrimidine-1,3-dione with POCl<sub>3</sub> in the presence of *N,N*-dimethylaniline gave 3-chloro-4-phenyl-1*H*-pyrido[1,2-*c*]pyrimidin-1-one. The 3-chloro atom could be substituted by amino and alkoxy groups. Treatment of the 3-chloro derivative with thiourea afforded 4-phenyl-3-thioxo-2,3-dihydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one (57HCA1319).


Treatment of 9,10-dimethoxy-6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-ones with POCl<sub>3</sub> gave 2-chloro-6,7-dihydropyrido[6,1-*a*]isoquinolinium chlorides, which were subsequently reacted with an amine or hydrazide to give 2-(substituted amino)-6,7-dihydropyrimido[6,1-*a*]isoquinolinium chlorides (82KGS1095). Heating 9,10-dimethoxy-2,3,6,7-tetrahydro-4*H*-pyrimido[6,1-*a*]isoquinoline-2,4-diones in POCl<sub>3</sub> gave 2-chloro-6,7-dihydro-4-one derivatives [81FRP2470130; 84JMC1470, 84USP4482556; 89H(29)1929]. (Earlier the products were described as 4-chloro-2-oxo derivatives [77SAP77/06706; 78GEP2720085]). The chlorine atom in 2-chloro-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones was substituted with amines [80GEP2847693, 80INIP147624; 81FRP2470130; 84EUP124893, 84USP4482556; 86HCA1671; 89H(29)1929] or with sodium butoxide and phenoxide (84JMC1470), or was hydrolyzed with water [89H(29)1929]. Treatment of 2-methylthio-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones with amines yielded 2-(substituted amino) derivatives (84JMC1470). (Earlier the starting compounds were described as 4-methylthio-2-oxo de-

rivatives [77SAP77/06706; 78GEP2720085; 79GEP2801289]). Reaction of 2-chloro-3-methyl-9,10-dimethoxy-4-oxo-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolinium chloride with mesitylene gave the 2-[(2,4,6-trimethylphenyl)imino]2,3,6,7-tetrahydro-4*H* derivative (85GEP3340773).

2-Benzyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-*ij*]quinazolin-7-one was acylated at position 9 by heating in acetic acid (72MI1).




Treatment of 1-imino-4-cyano-3-methylthio-1*H*-pyrido[1,2-*c*]pyrimidine (**105**) with morpholine afforded the 1-amino-1-morpholine derivative (**106**). Reaction of the 1-imino derivative (**105**) with dimethyl acetylenedicarboxylate gave the diaza[3,3,3]azine derivative (**107**) (75YZ13). Treatment of **105** with concentrated  $\text{H}_2\text{SO}_4$  or with acetic acid yielded 4-aminocarbonyl-3-methylthio-1*H*-pyrido[1,2-*c*]pyrimidin-1-one and 4-cyano-3-methylthio-1*H*-pyrido[1,2-*c*]pyrimidin-1-one, respectively. Reaction of the latter derivative with morpholine afforded the 3-morpholino derivative (75YZ13). Hydrolysis of 4-cyano-3-imino-2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidine-1-(thi)ones or their 3-(aminocarbonyl)imino derivatives in boiling 70%  $\text{HCl}$  gave 3-oxo derivatives (78MI1).



Methylation of 4,4*a*,5,6,7,8-hexahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-one (**108**,  $\text{R} = \text{H}$ ) with methylmagnesium chloride in the presence of  $\text{Cu}_2\text{I}_2$  or  $\text{Cu}_2\text{Br}_2$  gave 1-methylperhydropyrido[1,2-*c*]pyrimidin-3-one (**109**) (84EUP104647; 85JMC1285). Reduction of **108** either over  $\text{Pd/C}$



under hydrogen or with LAH gave perhydropyrido[1,2-*c*]pyrimidin-3-ones (**110**).




Reaction of perhydropyrido[1,2-*c*]pyrimidin-3-one (**111**) with 2 equiv propylmagnesium chloride, and subsequent treatment of the reaction mixture with LAH, gave 30% of a 1:3 mixture of tricycles (**112**, R = *n*Pr) with the unsubstituted tricycle (**112**, R = H). When lithium tri-*tert*-butoxyaluminumhydride was used in the reduction step, (±)-tetraponerine-T4 alkaloid (**113**, R = *n*Pr) was obtained, containing less than 5% of **112** (R = *n*Pr). The addition of 1 equiv tetramethylethylenediamine increased the overall yield of **113** (R = *n*Pr) to 70%, with less than 1% of **112** (R = *n*Pr). Tetraponerine-T8 (**113**, R = C<sub>5</sub>H<sub>11</sub>) was prepared similarly by using pentylmagnesium bromide (90TL4543).

Treatment of 2,4,4-trimethyl-5-phenyl-1-thioxo-3-oxo-2,3,4,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidine with Lawesson's reagent gave a 1,3-dithioxo derivative [96H(42)117]. Treatment of a 4-thioxo-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-one derivative with Hg(OAc)<sub>2</sub> in boiling acetic acid gave the 2,4-dioxo derivative, and with Raney Ni in boiling ethanol yielded the 2-oxo derivative (69YZ649). In the latter case the 3-(4-bromophenyl) group was converted into a 3-phenyl group. 9,10-Dimethoxy-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one was obtained from its 2-methylthio derivative by reaction with Raney Ni in boiling acetone (84JMC1470).


Heating 3-acetoxy-1-cyano-9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinoline yielded the 6,7-dihydro derivative by elimination of acetic acid (81CB61; 84MI3).

Reaction of 9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinoline-2,4-diones (84JMC1470) and 2-[2-(1-pyrrolidiny)ethyl]-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrimido[1,6-*a*]quinolin-1-one (70USP3494922) with P<sub>4</sub>S<sub>10</sub> gave the 2-thioxo and 1-thioxo derivatives, respectively. (In the first case the products were earlier described as 2-oxo-4-thioxo derivatives [77SAP77/06706; 78GEP2720085; 79GEP2801289].

Treatment of trequinsin (**19**) with dimsyl ion gave the ring-opened product **114** when a short reaction period (5 min) was applied, but a longer reaction period led to a mixture of **115** and **114** (reaction period 15 min), or a mixture of **116** and **115** (reaction period 45 min) (90JOC5117). Similar




ring opening occurred when other 2-amino-6,7-dihydro-, 2-imino-, or 2-oxo-2,3,6,7-tetrahydro-4*H*-pyrido[6,1-*a*]isoquinolin-4-ones were treated with NaH (90JOC5117), or when 2-imino-6,7-dihydro-2*H*-pyrido[6,1-*a*]isoquinolines or their hydrated derivatives were heated (91CB111). Ring opening did not occur with 9,10-dimethoxy-1,2,3,5,6,11*b*-hexahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one (90JOC5117).



Treatment of 1,2,3,6,7,11*b*-hexahydro-4*H*-pyrimido[6,1-*a*]isoquinoline-2,4-dione (**117**) with excess NaH in DMF yielded a mixture of the 1-methyl-2,3,6,7-tetrahydro and ring-opened compounds **118** and **119** (90JOC5117).

Heating 4-benzyl-2-phenyl-2,3-dihydro-1*H*-pyrimido[1,6-*a*]quinoline-1,3-dione in the presence of  $\text{AlCl}_3$  at  $180^\circ\text{C}$  for 30 min yielded a 4-debenzyl derivative (83M227). Reaction of 2-phenyl-2,3-dihydro-1*H*-pyrimido[1,6-*a*]quinoline-1,3-dione with sulfuryl chloride in dioxane at  $50-60^\circ\text{C}$  for 2 h, then at  $70^\circ\text{C}$ , gave 2-phenyl-4,4,4*a*-trichloro-2,3,4,4*a*-tetrahydro-1*H*-pyrimido[1,6-*a*]quinoline-1,3-dione (83M227).

The photocyclization of 1-aryl-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinoline-2,4-diones (**120**) to pyrimidoaporphine derivatives (**121**) has been studied (84T4003). Reaction of 1-acylamido-2,3,6,7-tetrahydro-4*H*-



pyrimido[6,1-*a*]isoquinoline-2,4-diones (**122**) with  $P_4S_{10}$  gave thiazolo[5,4-*b*]pyrimido[6,1-*a*]isoquinolin-5-ones (**123**) [89H(29)1929].


Oxidation of 1-aryl-9-methoxy-1,2,3,5,6,7-hexahydro-7*H*-pyrido[3,2,1-*ij*]-quinazolin-3-ones with  $KMnO_4$  in dioxane gave 1,2,3,7-tetrahydro derivatives (73USP3709887).

### 5. Reactivity of Substituents Attached to Ring Carbon Atoms


Methylthio derivatives were prepared from perhydropyrido[1,2-*c*]pyrimidine-1-thiones (62JOC1970; 71JMC878; 72USP3631046; 74USP3772230; 75USP3868372) and from 9,10-dimethoxy-2-thioxo-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-4-ones (84JMC1470) with methylating agents. (In the case of the pyrimido[6,1-*a*]isoquinoline derivative, the starting compounds were earlier described as 4-thioxo-2-oxo derivatives [77SAP77/06706; 78GEP2720085; 79GEP2801289].

1,9-Diazacycl[3,3,3]azines (**125** and **126**) were prepared by the reaction of 1-imino-8-methyl-1*H*-pyrido[1,2-*c*]pyrimidines (**124**) with ethoxymethylenemalononitrile and acetic anhydride, respectively (74CPB2765; 78YZ623). In the latter cases, the hydrolysis of the imino group also occurred to give 4-oxo derivatives of **124** (78YZ623).

Heating pyrido[1,2-*c*]pyrimidin-3-one (**127**) in 1 *N* HCl or in 50% acetic acid afforded the tricyclic derivatives **128** and **129**, respectively (82KGS518).



Treatment of 2-substituted 3-amino-4-cyano-2,4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-ones (**130**) with acyl chlorides afforded tricyclic 3,5-disubstituted 2,5,6,8,9,10,11,11*a*-octahydro-1*H*-pyrido[1,2-*c*]pyrimido[5,4-*e*]pyrimidine-1,6-diones (**131**) (90MI3; 93MI1, 93MI3).



The 3-imino group of 4-cyano-2-ethyl-3-imino-2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidine-1-thione was acylated with phenyl isocyanate (78MI1). The imino group of 1-imino-4-cyano-3-methylthio-1*H*-pyrido[1,2-*c*]pyrimidine was alkylated and acylated with methyl iodide and acetic anhydride (75YZ13). Reaction of 3-amino-4-phenyl-4-[2-(*N,N*-di-*n*-propylamino)ethyl]-4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one with acetic anhydride in pyridine and with sodium nitrite in aqueous acetic acid afforded 3-acetamido and perhydro-1,3-dioxo derivatives, respectively (87USP4680295).


The hydroxy groups of 9-methoxy-10-hydroxy- and 9-hydroxy-10-methoxy-3-methyl-2-(*N*-methylimino)-2,3,6,7-tetrahydro-4*H*-pyrimido[6,1-


*a*]isoquinolin-4-ones were alkylated with epibromohydrin to give 3'-bromo-2'-hydroxypropyl (84INIP153028) or 2',3'-epoxypropoxy derivatives (83EUP75165). The epoxy and bromo derivatives were reacted with amines (83EUP75165; 84INIP153028). The side-chain hydroxy group of 3-(2-hydroxyethyl)-9,10-dimethoxy-1,3,4,5,6,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-one was acylated with acyl chlorides (61JMC505; 62USP3021331). The hydroxy group of 3-hydroxy-3,4,6,7-tetrahydro- and 1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines has been acetylated (81CB61). The side-chain benzylamino group of 2-substituted 2,3,4,4*a*,5,6-hexahydro-1*H*-pyrimido[1,6-*a*]quinolin-1-ones was debenzylated by hydrogenation over Pd/C (70USP3494922).

Diazotization of 4-(*p*-aminophenyl)-9,10-dimethoxy-6,7-dihydro- and -1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines, followed by treatment with 30% H<sub>3</sub>PO<sub>2</sub>, gave deaminated products (55CPB259).

Oxidation of the 4-methyl group on the phenyl ring of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-methyl-2,3,6,7-tetrahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one with DDQ gave a complex, which was treated with ZnCl<sub>2</sub> in boiling methanol to yield the 4-methoxymethyl derivative (84TL2901; 86INIP157279). The 4-methoxymethyl group was cleaved in 2 *N* hydrochloric acid to the hydroxymethyl group, which was oxidized with pyridinium chromate to the 4-aldehyde. The aldehyde was converted to its 4-oxime, which was dehydrated in refluxing Ac<sub>2</sub>O, and the 4-nitrile was hydrolyzed with aqueous NaOH to give the 4-carboxy derivative (86INIP157279).


Heating pyrimido[6,1-*a*]isoquinolin-4-one (**132**) in methanol gave the tetracyclic compound **133** (86CB2553). The reaction of 1-amino-2-[(2,3,4-trimethylphenyl)amino]-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one hydrochloride (**134**) with HNO<sub>2</sub> or with triethyl orthoesters gave the tetracyclic compounds **135** and **136**, respectively [89H(29)1929].





Acylation of 2-[(2,4,6-trimethylphenyl)amino]-9,10-dimethoxy-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one with acetyl chloride gave a 2-acetamido derivative (84JMC1470). (Earlier the starting compound was described as a 4-amino-2-oxo-2*H* derivative, which afforded a mixture of 3-acetyl-4-[substituted imino]-2,3,6,7-tetrahydro-2-oxo-2*H* and 4-acetamido-6,7-dihydro-2-oxo-2*H* derivatives [77SAP77/06706; 78GEP2720085].

The acetamido group of 2-acetamido-1-[nitro(cyano)methylene]perhydropyrido[1,2-*c*]pyrimidine [74JCS(P1)1611], or that of 1-acetamido-2-(substituted amino)-6,7-dihydro- and 1-acetamido-2-oxo-2,3,6,7-tetrahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones [89H(29)1929], was hydrolyzed by treatment with conc. HCl. In the latter case, the amino group was acylated with trifluoroacetyl anhydride.



The hydroxy group in **137** ( $\text{R}' = \text{H}$ ) was acylated with *O-p*-tolyl chlorothionoformate (96JMC1872). The ester group of **138** ( $\text{R}^2 = \text{Me}$ ) was hydrolyzed under basic conditions, and the carboxyl group was esterified with benzyl alcohol to give **138** ( $\text{R}^2 = \text{CH}_2\text{Ph}$ ). The 6-thionoformate group of **137** ( $\text{R}' = \text{C(S)O-p-Tolyl}$ ) was reduced to give 6-unsubstituted bicycles **138** (96JMC1872).


The reaction of 2-cyanomethylperhydropyrimidine with LAH gave the 2-(2-aminoethyl) derivative (69JHC181).

## 6. Ring Transformation


8-Cyano-1,2,3,4-tetrahydro-6*H*,7*H*-1,6-naphthyridin-7-one was obtained from **127** in boiling water (80KGS416, 80KGS1120) or by heating in DMF in the presence of benzylamine (82KGS518). Treatment of 2-benzyl-9-chloro-1,2,3,5,6,7-hexahydropyrido[3,2,1-*ij*]quinazolin-7-one with NaN<sub>3</sub> in chloroform in the presence of concentrated H<sub>2</sub>SO<sub>4</sub> gave 2-benzyl-10-chloro-1,2,3,5,6,7-hexahydro-8*H*-pyrimido[5,6,1-*jk*][1,4]benzodiazepin-8-one (72MI1).

## 7. Miscellaneous

Cyclocondensation of 1-methylthio-4,4*a*,5,6,7,8-hexahydro-3*H*-pyrido[1,2-*c*]pyrimidine (**139**) with anthranilic acids (71JMC878; 72USP3631046; 74USP3772230; 75USP3868372) or with ethyl 5-amino-3-methylisothiazole-4-carboxylate [76IJC(B)391] afforded the tetracyclic derivatives **140** and **141**, respectively.



The reaction of pyrido[1,2-*c*]pyrimidin-1-one (**142**) with 1 or 2 mol of maleic anhydride afforded the cycloadduct **143** and the polycyclic compound **144**, respectively (75IZV2608). The latter was formed from the cycloadduct **143**.



Reaction of 1-(nitromethylene)perhydropyrido[1,2-*c*]pyrimidine with *p*-chlorobenzenesulfonyl azide in dioxane at 80°C gave the tricyclic 1-nitro-6,6*a*,7,8,9,10-hexahydro-5*H*-pyrido[1,2-*c*][1,2,3]thiazolo[1,5-*a*]pyrimidine [79JCS(P1)2361].

## IV. Synthesis

### A. PYRIDO[1,2-*c*][1,3]OXAZINES AND THEIR BENZO DERIVATIVES


#### 1. By Formation of One Bond $\alpha$ to the Bridgehead Nitrogen Atom [6+0( $\alpha$ )]

Treatment of 2-(2-vinyloxyethyl)pyridine with  $\text{Br}_2$  in  $\text{CCl}_4$  at  $0^\circ\text{C}$  gave 1-bromomethyl-2,3-dihydro-1*H*-pyrido[1,2-*c*][1,3]oxazinium bromide (86KGS1396).


#### 2. By Formation of One Bond $\beta$ to the Bridgehead Nitrogen Atom [6+0( $\beta$ )]

Perhydro[1,3]oxazino[3,4-*a*]quinolin-1-one (**146**) was prepared from perhydroquinoline (**145**) by sequential treatment with  $\text{O}_3$ ,  $\text{NaBH}_4$ ,  $\text{LiOH}$ ,  $\text{NaH}$ , and finally diazomethane (80JA1454). Treatment of perhydroquinoline (**147**) with  $\text{NaBH}_4$ , and then with *p*-toluenesulfonic acid in benzene under reflux, gave a 1 : 6 mixture of  $\alpha$ - and  $\beta$ -lactones **148**. The  $\beta$  isomer of **148** was also converted to **146** in 93% yield with  $\text{LiOH}$ ,  $\text{NaH}$ , and diazomethane (86CPB2380). Propionate **98** was obtained from **149** by reaction with  $\text{LiOH}$  and diazomethane [84JCS(CC)597; 86CPB2380].


4-Imino-hexahydro[1,3]oxazino[4,3-*a*]isoquinolines (**151**) were obtained from tetrahydroisoquinolines (**150**) in good yields [83H(20)1325;







85GEP3510526; 90CB803; 93MI2, 93MIP1], or from **152** [83H(20)1325; 85GEP3510526; 92T4937; 93MIP1].



2-Ethoxycarbonyl-1-(2-hydroxyethyl)tetrahydroisoquinolines were cyclized to 1,2,4,6,7,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinolin-4-ones with phosgene in the presence of triethylamine (90T4039), or by mixing with NaOMe at 130°C (90T4039; 92T4937), or by treatment with NaIO<sub>4</sub>-periodate in aqueous methanol in the presence of NaOH at 5°C (86CJC2205). When 2-(2-ethoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-1,3-propanediol was treated with boiling SOCl<sub>2</sub>, a mixture of 1-chloromethyl- and 1-hydroxymethyl-1,2,4,6,7,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinolin-4-ones was obtained (90T4039; 93MI2).

Cyclization of 2-(1-alkoxycarbonyl-2-piperidinyl)ethanols with mesyl chloride in pyridine (91T3805) or in the presence of NEt<sub>3</sub> [88CPB1597; 90H(30)855], with NaH [83H(20)601; 85H(23)831] or with KOH in boiling methanol (91CJC211), led to perhydropyrido[1,2-*c*][1,3]oxazin-1-ones.

### 3. By Formation of One Bond $\gamma$ to the Bridgehead Nitrogen Atom [6+0( $\gamma$ )]

Cyclization of 3-(2-oxo-3,1-benzoxazin-1-yl)propionic acid in PPA at 100–120°C gave 6,7-dihydro-1*H*,3*H*-5*H*-pyrido[3,1-*ij*][3,1]benzoxazine-3,7-dione (87EUP239129; 90CPB1575). Asymmetric bromolactonization of 2-(2,3-dimethylacryloyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in DMF in the presence of NBS afforded a diastereomeric mix-

tures of 3-methyl-3-(2-bromoethyl)-1,3,4,6-tetrahydro-7*H*-[1,4]oxazino[1,3-*b*]isoquinoline-1,4-diones (77CL1109).

#### 4. By Formation of Two Bonds from [5+1] Atom Fragments

Goodson–Christopher cyclization of 2-(2-piperidyl)ethanols with aldehydes yielded perhydropyrido[1,2-*c*][1,3]oxazines [17CB1407; 50JA358; 54JA2431; 56BRP756686, 56CLY1180; 57CLY927; 58CLY2081, 58N516; 60AP74, 60BRP856357, 60CCC2179, 60JOC2028, 60M840; 62USP3031454; 63AP38; 65RTC1367; 66MI2; 67RZC1389, 67TL2471; 68CJC1105, 68T4423; 70LA(737)24, 70T1217, 70T3941; 71T2055; 72JCS(CC)1152; 76IJC(B)777, 76JCS(P2)418, 76OMR(8)258; 78TL4647; 80BRP2071653; 85T2891; 87T935; 88TL1691; 89TL1947; 95TA2149]. When ketones or cyclic ketones were applied, disubstituted and spiro derivatives were obtained [66AP997, 76IJC(B)777; 85GEP3439131; 90EUP373531].

Reaction of racemic and meso-1,3-di(2-piperidyl)-2-propanone with 40% formaldehyde at pH 5 gave dodecahydro-3,3'-bi-1*H*,3*H*-pyrido[1,2-*c*][1,3]oxazines [71LA(753)27].

Similarly, starting from the appropriate 2-substituted ethanols, partly or fully saturated [1,3]oxazino[3,4-*b*]isoquinolines [77JCS(P2)370; 80HCA1158], [1,3]oxazino[4,3-*a*]isoquinolines [66AP997; 76OMR(8)258; 77JCS(P2)370; 85GEP3439131; 90CB803; 92T4937; 94JAP(K)94/41142], and [1,3]oxazino[3,4-*a*]quinolines [77JCS(P2)1592; 93JCR(S)170] were prepared with aldehydes [66AP997; 76BCJ837, 76OMR(8)258; 79JHC21; 92T4937] or with a form of formaldehyde. Pyrido[1,2-*c*][1,3]benzoxazines [70T1217; 76BCJ837, 76IJC(B)975; 77USP4025512; 79JHC21; 91KGS124] and pyrido[3,2,1-*ij*]benzoxazines [80JCS(P2)1778; 84OMR(22)424; 90EUP373531] were prepared from 2-(2-piperidyl)cyclohexenol, 2-(hexahydro- or tetrahydro-2-pyridyl)phenols, and 8-hydroxymethylperhydroquinolines on treatment with aldehydes (76BCJ837; 79JHC21; 90EUP373531) or with a form of formaldehyde.

Instead of formaldehyde, *N,N,N',N'*-tetramethylmethylenediamine (80HCA1158) or dibromomethane [76IJC(B)975] could also be applied.

Perhydropyrido[1,2-*c*][1,3]oxazin-1-ones were prepared in the reaction of the appropriate 2-(2-piperidyl)ethanols and ethyl chloroformate (63AP38) in the presence of sodium ethylate in boiling benzene, or when 2-(2-piperidyl)ethanol was reacted with dimethyl carbonate in the presence of sodium methylate (91T1311). 1-Hydroxymethyl-9,10-dimethoxy-1,2,4,6,7,11*b*-hexahydro-[1,3]oxazino[4,3-*a*]isoquinoline-4-one and 4-thione were prepared from 1-[bis(hydroxymethyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline with ethyl chloroformate in the presence of sodium methylate, and thiophosgene in the presence of  $\text{NEt}_3$ , respectively


(85GEP3510526). Reaction of 2-(2-hydroxy-2-substituted ethyl)-1,2,3,4-tetrahydroquinolines with diethyl carbonate at 100°C in toluene in the presence of sodium methylate gave mixtures of epimers of 3-substituted 1,3,4,4a,5,6-hexahydro[1,3]oxazino[3,4-*a*]quinolin-1-ones (89EUP322263).

Optically active and racemic 1-ethylideneperhydro[1,3]oxazino[3,4-*b*]isoquinolines (**42**) were prepared in good yields from the appropriate 3-(2-hydroxyethyl)perhydroisoquinoline with *N,N*-dimethylpropionamide dimethyl acetal (80HCA1158).

Optically active *cis*-3,4a-H-1,3,4,4a,5,6-hexahydropyrido[1,2-*c*][1,3]oxazine-1,6-diones were obtained from (+)-2-(2-hydroxy-2-phenylethyl)- and (+)-2-(2-hydroxypentyl)-1,2,3,4-tetrahydropyridin-4-one with 1,1'-carbonyldiimidazole in THF in the presence of triethylamine (93JA8851, 93JOC5035).

The 1-imine derivatives of 4-phenylperhydropyrido[1,2-*c*][1,3]oxazines were prepared from *erythro*- and *threo*-2-(2-piperidyl)-2-phenylethanols with cyanogen bromide followed by treatment with hydrogen chloride in boiling ethanol (73AP284).

Treatment of 8-hydroxymethyl-1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoline-8-carboxylic acid, or 1-(2-hydroxyethyl)-1,2,3,4-tetrahydroisoquinolines with COCl<sub>2</sub> in the presence of a base furnished 1,5,6,7-tetrahydro-3*H*-pyrido[3,2,1-*ij*][3,1]benzoxazin-3-one (92JMC1076), the -1,3-dione (**102**) (78JHC645), and 1,2,4,6,7,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinolin-4-ones (92T4937), respectively.



1-Oxopyrido[1,2-*c*][1,3]oxazin-3-ium chloride (**153**) was prepared from 2-(2-pyridyl)-1,3-propanediol by reaction with COCl<sub>2</sub> in the presence of NEt<sub>3</sub> at -30°C (92JOC5764). When 6 mol COCl<sub>2</sub> was used and the reaction mixture was treated with gaseous NH<sub>3</sub> at -70°C, **154** was obtained in excellent yield.


## 5. By Formation of Two Bonds from [4+2] Atom Fragments

7-Substituted 6,7-dihydro-1*H*,3*H*,5*H*-pyrido[3,2,1-*ij*][3,1]benzoxazines (**157–159**) were prepared from 1-(1-benzotriazolyl)-1,2-dihydro-3*H*-


[3,1]benzoxazine (**155**) with 9-vinylcarbazole (**156**) and *N*-methyl-*N*-vinylacetamide (Scheme 15) (95JOC3993).

#### 6. By Formation of Two Bonds from [3+3] Atom Fragments

The palladium-catalyzed arylation of cyclic enamide **160** with 2-iodophenol furnished a ca. 2:1 mixture of **161** and pyrido[1,2-*c*][1,3]benzoxazin-6-one (**162**) (90JOC2464).



SCHEME 15




### 7. By Formation of Three Bonds from [3+2+1] Atom Fragments

The reaction of 1-cyanomethylene-6,7-dimethoxy-1,2,3,4-tetrahydroquinoline with 35% aqueous formaldehyde in the presence of 2 *N* NaOH at 65°C afforded [1,3]oxazino[4,3-*a*]isoquinoline (**100**) (73JHC435).

### 8. By Formation of Three Bonds from [2+2+2] Atom Fragments

[1,3]Oxazino[4,3-*a*]isoquinolin-2-ones (**163**) [10LA(374)1; 67JCS(C)1569; 68AGE826; 71JOC2211; 75JCS(P1)1001] and [1,3]oxazino[3,4-*a*]quinolin-3-ones (**164**) [06CB968; 65JCS(CC)574; 66JCS(CC)262; 67JCS(C)1569; 71JOC2211; 75JCS(P1)1001] were prepared in exothermic cycloaddition reactions of isoquinolines and quinolines, respectively, with dimethylketene [67JCS(C)1569; 71JOC2211] and diphenylketene [68AGE826; 75JCS(P1)1001]. The 6,7-dihydro derivative of **65** was obtained in 17% yield, accompanied by other products, in the reaction of 3,4-dihydroisoquinoline *N*-oxide and dimethylketene in ethyl acetate [87JCS(P1)1635].




### 9. Ring Transformations

Treatment of chloronitro derivative **165** with 2 *N* NaOH at 75–80°C gave pyrido[3,2,1-*ij*][3,1]benzoxazine-1,3-dione (**102**) (64M59).


Ring expansion of 2,2-diphenyl-8-methylperhydroisoxazolo[2,3-*a*]pyridinium salt on the action of NaOH furnished 3,3-diphenylperhydro-pyrido[1,2-*c*][1,3]oxazine in good yield (91G393).

10. *Miscellaneous*

The Lewis acid-promoted intramolecular cyclocondensation of piperidine epimers (**166**, R = H) led to the formation of a 2 : 1 mixture of epimers **167** (R = H) and **168** with a preference for *cis*-fused tricycles (**167**, R = H) (90JOC1447). The 3-methylpiperidine derivative (**166**, R = Me) gave only the *cis*-fused epimer (**167**, R = Me).




Ozonolysis of carbamate **169** and successive workup with dimethyl sulfide, followed by cyclization with formic acid, yielded hexahydro-3*H*-[1,3]oxazino[4,3-*a*]isoquinolin-4-one (**170**) (85SC883).



The intramolecular conjugate addition of either a 1 : 2 mixture of *E* and *Z* isomers or pure *Z* isomer of **171** proceeded smoothly with potassium *tert*-butoxide (0.3 equiv) in THF at low temperature (between -20 and -58°C) and gave an 8 : 11 mixture of pyrido[1,2-*c*][1,3]oxazines (**33** and **34**) in 87% yield (96SL100).

Intramolecular hetero-Diels-Alder cycloaddition of *N*-acylimines **173** and **178**, prepared *in situ* from an isomeric mixture of methylol acetates (**172**) by heating (81JA7573; 84JA3240) or from chloroformate (**177**) and *N*-trimethylsilylimines (**176**) derived from aldehydes **175** (91TL4371), respectively, diastereoselectively afforded only one type of the cycloaddition products **174** and **179**, containing *trans*-fused bicycles.


Treatment of dodecahydro-3,3'-bi-1*H*,3*H*-pyrido[1,2-*c*][1,3]oxazines with 2% sodium amalgam in aqueous acetic acid gave 3-[(2-piperidyl)methyl]perhydropyrido[1,2-*c*][1,3]oxazines [71LA(753)27].



## B. PYRIDO[1,2-*c*][1,3]THIAZINES AND THEIR BENZO DERIVATIVES

### 1. By Formation of One Bond $\beta$ to the Bridgehead Nitrogen Atom [6+0( $\beta$ )]

Cyclization of 3-(3-butenyl)-4-ethoxy-6,6-dimethyl- and 3-(3-alkenyl)-4-ethoxy-6-phenyltetrahydro-1,3-thiazin-2-ones in formic acid at room temperature afforded 3,3-dimethylperhydropyrido[1,2-*c*][1,3]thiazine-1,6-dione and *cis*-3,4*a*,5,6-*H*-5-alkyl-7-formyloxy-3-phenylperhydropyrido[1,2-*c*][1,3]thiazin-1-ones (85T2007). In the latter cases, the reaction proceed via a "double chair" transition state (180) containing a phenyl ring in an equatorial position.



### 2. By Formation of One Bond $\gamma$ to the Bridgehead Nitrogen Atom [6+0( $\gamma$ )]

Heating three *N*-substituted 3-(2-hydroxyethyl)-1,2,3,4-tetrahydroisoquinoline-2-thioamides in boiling 6 *N* hydrochloric acid gave 1-(substituted

imino)-1,3,4,4*a*,5,10-hexahydro[1,3]thiazino[3,4-*b*]isoquinolines (79GEP 2848926; 80GEP3017865; 85MIP1). Similarly, 1-(2-hydroxyethyl)-1,2,3,4-tetrahydroisoquinoline-2-thioamides in boiling ethanol containing hydrogen chloride afforded 4-(substituted imino)-1,2,4,6,7,11*b*-hexahydro[1,3]-thiazino[4,3-*a*]isoquinolines [83H(20)1325], whereas 1-[bis(hydroxymethyl)-methyl]tetrahydroisoquinolines and the mono-*O*-benzoyl derivative yielded 1-hydroxymethyl- and 1-(benzoyloxy)methyl-4-(substituted imino)-1,2,4,6,7,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinolines (85GEP3510526; 90CB803; 93MI2).

Mixtures of 1-(3-chloropropyl)-1,4-dihydro-2*H*-[3,1]benzothiazin-2-ones or their 3,3-dioxides and anhydrous AlCl<sub>3</sub> were stirred at ambient temperature for 30 min, and then at 170–180°C for 1 h, to give 1,5,6,7-tetrahydro-3*H*-pyrido[3,2,1-*ij*][3,1]benzothiazin-3-ones and their 2,2-dioxides [88JAP(K)88/170385].

### 3. By Formation of Two Bonds from [5+1] Atom Fragments

1-Iminoperhydropyrido[1,2-*c*][1,3]thiazine hydrobromides were prepared when 2-(2-hydroxyethyl)piperidines were treated with gaseous HBr followed by PBr<sub>3</sub> in carbon tetrachloride, and the 2-(2-bromoethyl)piperidines were reacted with thiourea in boiling ethanol [70T3941; 82OMR(20)239].

The reactions of 2-(2-mercaptoethyl)piperidines and aldehydes afforded perhydropyrido[1,2-*c*][1,3]thiazines [70T3941; 82OMR(20)239]. In an exothermic reaction, 1-(2-mercaptoethyl)-1,2,3,4-tetrahydroisoquinoline and 40% aqueous formaldehyde yielded 1,2,4,6,7,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinoline [77JCS(P2)370]. The similar reaction with 4-nitrobenzaldehyde in boiling benzene furnished the *cis*-4,11*b*-H-1-(4-nitrophenyl) derivative [76OMR(8)258].

### 4. By Formation of Two Bonds from [4+2] Atom Fragments

1-(Substituted imino)perhydropyrido[1,2-*c*][1,3]thiazines were obtained when 2-(2-hydroxyethyl)piperidine was reacted with aryl and aralkyl isocyanates and then the thioureas were cyclized by heating in aqueous 48% hydrogen bromide [76IJC(B)770]. 1,3,4,4*a*,5,10-Hexahydro[1,3]thiazino[3,4-*b*]isoquinoline-1-thione was prepared when 3-(2-hydroxyethyl)-1,2,3,4-tetrahydroisoquinoline was reacted with CS<sub>2</sub> in pyridine in the presence of NEt<sub>3</sub>, and the reaction mixture was then treated with mesyl chloride (79GEP2848926). Perhydropyrido[1,2-*c*][1,3]thiazine-1-thione was prepared in 91% yield in the reaction of 2-(2-chloroethyl)piperidine hydrochloride and CS<sub>2</sub> in DMF in the presence of K<sub>2</sub>CO<sub>3</sub> at room temperature (63JOC981). When 2-(2-chloro- or 2-bromoethyl)piperidine hydrohalides



were reacted with sodium dimethyldithiocarbamate, only the substitution of the halo atom occurred (63JOC981). 3,5,6,7-Tetrahydro-1*H*-pyrido[3,2,1-*ij*][3,1]benzothiazine-3-thiones and -3-ones were prepared from 8-hydroxymethyl-1,2,3,4-tetrahydroisoquinolines by treatment with CS<sub>2</sub> or COS in boiling ethanol in the presence of NaOH (87EUP239927).

### 5. By Formation of Three Bonds from [2+2+2] Atom Fragments

Tetramethyl 2,3-dimethoxy-6,11*a*-dihydropyrido[1,2-*c*][1,3]benzothiazine-8,9,10,11-tetracarboxylate was prepared in the reaction of 6,7-dimethoxy-2*H*-1,3-benzoxazine and dimethyl acetylenedicarboxylate in diethyl ether at 0°C [82H(19)489].

### 6. Ring Transformations

The reaction of 1-(substituted imino)-9,10-dimethoxy-1,2,4,6,7,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinoline with P<sub>4</sub>S<sub>10</sub> at 150–170°C gave 1-(substituted imino)-9,10-dimethoxy-1,2,4,6,7,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinoline [83H(20)1325; 85GEP3510526; 90CB803].

3,5,6,7-Tetrahydro-1*H*-pyrido[3,2,1-*ij*][3,1]benzothiazine-1,3-dithione was prepared from 3,5,6,7-tetrahydro-1*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine-1,3-dione with P<sub>4</sub>S<sub>10</sub> in boiling pseudocumene (78JHC645).

## C. PYRIDO[1,2-*c*]PYRIMIDINES AND THEIR BENZO DERIVATIVES

### 1. By Formation of One Bond $\alpha$ to the Bridgehead Nitrogen Atom [6+0( $\alpha$ )]

Hydrogenation of ethyl *N*-[2-(2-pyridyl)ethyl]carbamate in ethanol over Raney Ni at 130°C and 120 atm gave perhydropyrido[1,2-*c*]pyrimidin-1-one (67YZ663). Cyclization of ethyl *N*-[2-(1,2,3,4-tetrahydro-2-quinolyl)ethyl]carbamate at 190–200°C afforded 2,3,4,4*a*,5,6-hexahydro-1*H*-pyrimido[1,6-*a*]quinolin-1-one (60YZ1414), whereas that of 1-(2-benzamidoethyl)-6,7-dimethoxy-3,4-dihydroisoquinoline in boiling toluene with phosphoryl chloride led to 4-phenyl-9,10-dimethoxy-6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinoline (63YZ1043).

Hydrogenation of 1-acylamidinomethylene-1,2,3,4-tetrahydroisoquinoline (**48**, R = Me, R<sup>1</sup> = Ph) over Pd/C gave 2-amino-4-phenyl-9,10-dimethoxy-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinoline via **49** (R = Me, R<sup>1</sup> = Ph) (90CB493). When an ethanolic solution of 1-[(benzoylamidino)methylene]tetrahydroisoquinoline (**48**, R = Me, R<sup>1</sup> = Ph) was evaporated


at atmospheric pressure and the residue was heated for another 0.5 h, **51** hydrate ( $R = \text{Me}$ ,  $R^1 = \text{Ph}$ ) was obtained (90CB493). When **48** was heated in boiling 2% hydrochloric acid, hydrochloride salts of monohydrates of **51** were obtained (86MIP1).

## 2. By Formation of One Bond $\beta$ to the Bridgehead Nitrogen Atom [6+0( $\beta$ )]

2-Chloro-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones (**182**) were obtained by the cyclization of barbituric acid derivatives **181** [80GEP2847693; 84EUP124893, 84JMC1470; 86HCA1671; 89H(29)1929]. Cyclization in PPA afforded 2,4-dioxo-2,3,6,7-tetrahydro-4*H* derivatives (80GEP2847693). 1-Substituted 4-phenyl-4-[2-(*N,N*-di(2-propylamino)-4,4*a*,5,6,7,8-hexahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-ones were prepared by the cyclization of  $\alpha$ -(1-acyl-2-piperidyl)- $\alpha$ -phenyl- $\alpha$ -[2-(*N,N*-di(2-propylamino)ethyl]acetamides with powdered potassium hydroxide in boiling acetone or DMSO (87EUP215477).

Cyclization of 1-[*N*-(un)substituted amino(thio)carbonyl]-2-[phenyl (methoxycarbonyl)methyl]piperidines in boiling ethanol containing hydrogen chloride gave 4-phenyl-2-(un)substituted perhydropyrido[1,2-*c*]pyrimidine-1,3-diones (64JMC146).

Cyclization of Reissert compound **183** furnished pyrimido[1,2-*c*]quinazolin-4-one (**184**) (89JHC1357).



Cyclization of 2-aryl-2-(2-piperidynyl)acetamide (**185**) in the presence of KOH afforded 1-substituted 4,4*a*,5,6,7,8-hexahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-ones (**108**) (85JMC1285).


## 3. By Formation of One Bond $\gamma$ to the Bridgehead Nitrogen Atom [6+0( $\gamma$ )]

Cyclization of alkyl 2-[1-amino(thio)carbonyl]-2-piperidyl]acetates under acidic or basic conditions gave 1,3-dioxo- and 1-thioxo-3-

oxoperhydropyrido[1,2-*c*]pyrimidines (56CB1642; 64JMC146). 2,4-Dioxo- and 2-oxo-4-thioxo-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines [69IJC684, 69YZ649; 71JAP71/09467; 75MI1; 76IJC(B)784] were prepared similarly. 2-Substituted 4-phenyl-1,3-dioxo- and 1-thioxo-3-oxoperhydropyrido[1,2-*c*]pyrimidines could be prepared similarly in one-pot reactions, when aryl iso(thio)cyanates were reacted with methyl 2-phenyl-2-(2-piperidinyl)acetate, and the reaction products were subsequently cyclized without isolation (64JMC146). Cyclization of  $\alpha$ -(1-amino-carbonyl-2-piperidyl)- $\alpha$ -phenyl- $\alpha$ -[2-(*N,N*-di(2-propyl)amino)ethyl]acetonitrile and its *N*-[2-(3,4-dimethoxyphenyl)ethyl]-substituted derivatives in the presence of sodium hydride in boiling tetrahydrofuran gave 3-amino-4,4*a*,5,6,7,8-hexahydro-1*H*- and 2-substituted 3-iminoperhydropyrido[1,2-*c*]pyrimidin-1-ones, respectively (87USP4680295).

Cyclization of 6,7-diethoxy-2-propylaminocarbonyl-1,2,3,4-tetrahydroisoquinoline-1-acetonitrile by NaOMe in boiling methanol afforded 9,10-dimethoxy-2-imino-3-propyl-1,2,4,6,7,11*b*-hexahydropyrimido[6,1-*a*]isoquinolin-4-one (95S863).

1-Aryl-3,4,5,6-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinoline-2,4-diones (**187**) were obtained from 1-arylidene-2-ethoxycarbonylamino-3-arylmethyl-1,2,3,4-tetrahydroisoquinolines (**186**) (84T4003).



Heating 3-[(3-benzyl-6-(un)substituted-1,2,3,4-tetrahydroquinazolin-1-yl)]propionic acids in PPA at 100°C resulted in 2-benzyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-*ij*]quinazolin-7-one. When the cyclization was carried out in the presence of acetic acid, the 9-acetyl derivative was produced (72MI1).


Treatment of 1-cyanomethyl-2-[(propylamino)carbonyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline with sodium methoxide in boiling methanol afforded 2-imino-3-propyl-9,10-dimethoxy-1,2,3,6,7,11*b*-hexahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one (95S863).

#### 4. By Formation of Two Bonds from [5+1] Atom Fragments

Perhydropyrido[1,2-*c*]pyrimidines and their -1-ones and -1-thiones were prepared from the appropriate 2-(2-piperidyl)ethylamines or their *N*-substituted derivatives by treatment with aldehydes [59CB637; 62JOC1970; 67YZ663; 69JHC181; 70T701; 71JAP71/16753; 73OMR(5)397; 90TL4543], Et<sub>2</sub>CO<sub>3</sub> (62JOC1970), or CS<sub>2</sub> (62JOC1970; 71JMC878; 72USP3631046; 74USP3772230; 75USP3868372), respectively. When cyclohexanone was used, a 1,1-spiro derivative of perhydropyrido[1,2-*c*]pyrimidine was obtained (67YZ663). Similarly, 2-methyl-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrimido[1,6-*a*]quinoline [79JCS(P2)581], 1,3,4,5,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines (59YZ1008; 78FES237; 90KGS1665; 95MI4), and their -4-ones (77SAP77/06706; 78GEP2720085; 81FRP2470130; 84JMC1470, 84USP4482556; 95MI4) were prepared from the appropriate 2-(1,2,3,4-tetrahydroquinolin-2-yl)- and 2-(1,2,3,4-tetrahydroisoquinolin-1-yl)ethylamines. 1-Substituted 4,4*a*,5,6,7,8-hexahydro-3*H*-pyrido[1,2-*c*]pyrimidines were obtained from the reactions of 2-(2-piperidyl)ethylamine and imino ester hydrochlorides in boiling ethanol (67YZ663). 2-(1,2,3,4-Tetrahydroisoquinolin-1-yl)ethylamine and triethyl orthoacetate reacted in boiling butanol to afford 4-methyl-1,6,7,11*b*-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinoline (90KGS1665).

4-Phenyl-4-{[*N,N*-di(2-propyl)amino]ethyl}perhydropyrido[1,2-*c*]pyrimidine-1,3-dione was obtained in the reaction of  $\alpha$ -phenyl- $\alpha$ -{[*N,N*-di(2-propyl)amino]ethyl}-2-piperidineacetamide and 1,1'-carbonyldiimidazole in the presence of sodium hydride (87USP4680295). 6-Dialkylamino-1,2,3,5,6,7-hexahydropyrido[3,2,1-*ij*]quinazolin-3-ones were prepared via the reaction of 8-aminomethyl-3-(alkylamino)-1,2,3,4-tetrahydroquinoline and 1,1'-carbonyldiimidazole in THF (90MIP2; 92JMC1076).

The reactions of 2-piperidineacetamides with aqueous formaldehyde [68BRP1114397; 72JCS(P2)1920] or with *N,N*-dimethylcarboxamide dialkyl acetals (84EUP104647; 85JMC1285) gave perhydro- or 4,4*a*,5,6,7,8-hexahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-ones, respectively. Reaction of 1-chlorocarbonyl-2-[1-cyano-1-phenyl-3-{[*N,N*-di(2-propyl)amino]propyl}]piperidine with ammonium hydroxide or primary amines at 80°C afforded 4-phenyl-4-{[2,*N,N*-di(2-propyl)amino]ethyl}-3-amino-4,4*a*,5,6,7,8-hexahydro-1*H*- and 3-iminoperhydropyrido[1,2-*c*]pyrimidin-1-ones, respectively (87USP4680295). 1,3-Dioxo- and 3-oxo-1-thioxo-2,3-dihydro-1*H*-pyrido[1,2-*c*]pyrimidines were obtained in the reactions of 2-(2-pyridyl)acetamides with Et<sub>2</sub>CO<sub>3</sub> and CS<sub>2</sub>Cl<sub>2</sub>, respectively (57HCA1319). 1,3,4,6,7,11*b*-Hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-ones were produced when *N*-substituted 2-(1,2,3,4-tetrahydroisoquinolin-1-yl)acetamides were treated with aldehydes [61JMC505; 62USP3021331; 77JCS(P2)370; 90JHC957].



5,6,7,8-Tetrahydro-1*H*-pyrido[1,2-*c*]pyrimidines **189** and -1-one **190** were prepared from cyclic aminoazadienes **188** by reaction with aldehydes and triphosgene, respectively (92SL563). 4-Cyano-5,6,7,8-tetrahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-one and its 1-methyl and 5-dimethylaminomethylene derivatives were prepared in the reactions of 2-[cyano(aminocarbonyl)-methylene]piperidine with triethyl orthoformate in acetic anhydride with *N,N*-dimethylacetamide diethyl acetal, or with *N,N*-dimethylformamide diethyl acetal (80KGS416, 80KGS1120; 82KGS518).


The reactions of 1-aminocarbonylmethylene-3,4-dihydro- and 1,2,3,4-tetrahydroisoquinolines with *N,N*-dimethylcarboxamide diethyl acetals, triethyl orthoformate, and diethyl carbonate yielded 6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-ones [81KFZ(5)44; 82KGS1095; 84JMC1470] and 9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinoline-2,4-dione (84JMC1470), respectively. A mixture of 1-ethoxycarbonyl-9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinoline-2,4-dione and 1-[cyano(ethoxycarbonyl)methylene]-1,2,3,4-tetrahydroisoquinoline was obtained when 6,7-dimethoxy-1-aminocarbonylmethylene-1,2,3,4-tetrahydroisoquinoline was reacted with ethyl chloroformate in methylene chloride in the presence of pyridine (84JMC1470).

1-Aryl-9-methoxy-1,2,3,5,6,7-hexahydropyrido[3,2,1-*ij*]quinazolin-3-ones were prepared from 1-aminocarbonyl-6-methoxy-1,2,3,4-tetrahydroquinoline on treatment with aromatic aldehydes in boiling benzene in the presence of methanesulfonic acid (73USP3709887).

3-Methyl-5-methoxy-2-phenyl-2,4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidine-1-thione was obtained in the reaction of 2-acetonil-3-methoxypiperidine and phenyl isothiocyanate in boiling methylene chloride (55JOC136).

Reductive alkylation of 3-(2-nitro-1-hydroxyethyl)isoquinoline over Pd/C in the presence of hydrogen and acetone afforded a mixture of 1,1-dimethyl-4-hydroxy-2,3,4,4*a*,5,10-hexahydro-1*H*-pyrimido[1,6-*b*]-isoquinoline and 3-[1-hydroxy-3-(*N*-isopropylamino)propyl]-1,2,3,4-tetrahydroisoquinoline (72JMC49).

Heating 2-(2-pyridyl)benzodiazonium tetrafluoroborate in a nitrile at  $80^\circ C$  gave 6-substituted pyrido[1,2-*c*]quinazolinium tetrafluoroborates (72GEP2043665).



The reactions of iminophosphorane (**191**,  $\text{R} = \text{H}$ ,  $\text{R}^1 = \text{COOEt}$ ) with aryl isocyanate,  $\text{CO}_2$ ,  $\text{CS}_2$ , and aroyl chloride gave pyrido[1,2-*c*]pyrimidines **192**, **193**, and **194** ( $\text{R} = \text{H}$ ,  $\text{R}^1 = \text{COOEt}$ ), respectively (92T4601). The similar reactions of iminophosphorane **191** [ $\text{R} = \text{R}^1 - (\text{CH}=\text{CH})_2$ ] afforded tricyclic pyrido[1,2-*c*]quinazolinium derivatives **194**, [ $\text{R} = \text{R}^1 = -(\text{CH}=\text{CH})_2$ ] and **195**.

### 5. By Formation of Two Bonds from [4+2] Atom Fragments

Perhydropyrido[1,2-*c*]pyrimidine-1,3-diones were prepared in the reaction of alkyl 2-piperidineacetate with ethyl urethane in diethyl ether in the presence of sodium (56CB1642), by heating with  $\text{KOCN}$  in hydrochloric acid (59CB637; 64JMC146). 1-Thioxoperhydropyrido[1,2-*c*]pyrimidin-3-one was obtained when ethyl 2-piperidine acetate was reacted with  $\text{KSCN}$  in acidified ethanol (59CB637). Reaction of methyl 2-piperidyl acetate with aryl isocyanates yielded 2-arylperhydropyrido[1,2-*c*]pyrimidine-1,3-diones (94GEP4225629). 2-Phenyl-1-thioxo- and 2,4-diphenyl-1-thioxoperhydropyrido[1,2-*c*]pyrimidin-3-ones were prepared in the reactions of 2-piperidineacetic acid (75CJC41) and its 2-phenyl-substituted methyl ester derivative (64JMC146) with alkyl or aryl iso(thio)cyanates. Reaction of ethyl cyclohexylideneacetate and cyclohexylidenemalononitrile with iso(thio)cyanates afforded 2-substituted 2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidine-1,3-diones [87CR(305)441] and 2-substituted 4-cyano-3-imino-2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-ones (78MI1; 90MI3), respectively. In the latter cases the 3-imino group was acylated when an excess of isocyanates was applied (78MI1). 2,4-Dioxo-

and 2-oxo-4-thioxo-1,3,4,6,7,11*b*-hexahydro-, 2-oxo-4-amino- and 2-oxo-4-substituted 1,6,7,11*b*-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolines were prepared in the reactions of 2-(6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)acetates or -acetic acids with urea, KOCN, and ( $\omega$ -chloroalkyl)isocyanates, with phenyl isothiocyanate, *S*-methylisothioureia, and imino ethers, respectively [59YZ1008; 69IJC684; 76IJC(B)784; 79IJC(B)277; 84JHC149; 95S863].


2-Acyl-2,3-dihydro-1*H*-pyrido[1,2-*c*]pyrimidin-4-ones were obtained when 2-vinylpyridine was reacted with acyl isocyanates (75IZV2608). Cyclocondensation of 3-methoxy-2-(2-oxopropyl)piperidine and phenyl isothiocyanate in boiling ethylene dichloride afforded 3-methyl-5-methoxy-2-phenyl-2,4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidine-1-thione (55JOC136).

The reaction of 2-phenyl-5(4*H*)-oxazolone and 4-[2-(*E*)-dimethylaminoethenyl]-6-methyl-2-methoxypyrimidine in boiling acetic acid afforded 7-benzamido-3-methyl-1-methoxy-8*H*-pyrido[1,2-*c*]pyrimidin-8-one (91BSB533).

The reaction of 1-(2-methyl-3-furyl)-6,7-dimethoxy-3,4-dihydroisoquinoline with phenyl isocyanate gave an *E-Z* mixture of 3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-4-one (**132**) (86CB2553).

## 6. By Formation of Two Bonds from [3+3] Atom Fragments

1-Imino-1*H*-pyrido[1,2-*c*]pyrimidines (**196**) were prepared via the reactions of 2-pyridineacetonitriles and 2-pyridineacetates with dimethyl cyanoamidedithiocarboxylate and *O*-ethyl and *O*-ethyl-*S*-methyl cyanoamidedithiocarboxylate (74CPB2765; 75YZ13; 78YZ623).



Horner-Witting reaction of the succinate (**197**) with 4-formylpyrimidine led to ethyl 8-oxo-8*H*-pyrido[1,2-*c*]pyrimidine-6-carboxylate (80LA542).


Cycloaddition of 2-(dicyanomethylene)piperidine with iso(thio)cyanates afforded 3-imino-4-cyano-2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-ones or -1-thiones (**198**, R<sup>1</sup> = H, X = O or S) (78MI1). When excess iso(thio)cyanate was applied, the 3-imino group also reacted to give **198** (R<sup>1</sup> = CXNHR<sup>2</sup>).

The reaction of ethyl 2-(1,2,3,4-tetrahydroisoquinolin-1-yl)acetate hydrochloride with potassium cyanate in boiling water gave 2,3,4,6,7,11*b*-hexahydro-1*H*-pyrimido[6,1-*a*]isoquinoline-2,4-dione (69IJC684). 3,4,6,7-Tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinoline-2,4-dione and its 2-thioxo derivative were prepared in the reactions of 1-methyl-3,4-dihydroisoquinoline with benzoyl isocyanate and ethoxycarbonyl isothiocyanate, respectively, in the presence of  $\text{NEt}_3$  (75CB1541).

Cyclocondensation of 2-(arylamino)quinolines with bis-(2,4,6-trichlorophenyl) 2-substituted malonates at 200–250°C afforded 2-aryl-4-substituted 2,3-dihydro-1*H*-pyrimido[1,6-*a*]quinoline-1,3-diones (83M227).

### 7. By Formation of Three Bonds from [2+2+2] Atom Fragments

The reaction of 2,4-dimethylquinazoline and dimethyl acetylenedicarboxylate gave the 1:2 and 1:3 adducts **201** and **202** [68JCS(C)926]. It was suggested that pyrimido[1,6-*a*]quinoline (**201**) was produced from the initially formed pyrido[1,2-*c*]quinazoline (**199**) via the 10-membered system **200**.



### 8. By Formation of Three Bonds from [3+2+1] Atom Fragments

The reaction of 2-(2-phenethyl)quinoline with 2 mol phenyl isocyanate at 180°C for 2 h gave 4-benzyl-2-phenyl-2,3-dihydro-1*H*-pyrimido[1,6-*a*]quinoline-1,3-dione (83M227).




### 9. By Formation of Four Bonds from [3+1+1+1] Atom Fragments

1-Cyanomethylene-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline reacted with 2 mol formaldehyde and 1 mol primary amines, hydroxylamine, or acylhydrazide to give 3-substituted 1-cyano-9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolines (73JHC435; 81CB61; 84MI3). *cis*-1,11*b*-*H*-1-Phenyl-3-substituted 2,3,4,6,7,11*b*-hexahydro-1*H*-pyrimido[6,1-*a*]isoquinolines were prepared in the reaction of 1-benzyl-3,4-dihydroisoquinoline, primary amines, and 2 mol formaldehyde followed by treatment with sodium borohydride (93PHA941; 95MIP3).

### 10. By Formation of Four Bonds from [2+2+1+1] Atom Fragments

From the reaction mixtures of pyridines (203) and imidoyl chlorides (204) in the presence of a large excess of isonitriles (205), the pyrido[1,2-*c*]pyrimidium chlorides (206) and the imidazo[1,5-*a*]pyridinium salts (207) could be isolated (93TL2319). The yields of 206 were higher when R<sup>1</sup> and R<sup>2</sup> were isopropyl groups.




### 11. Ring Transformations


Treatment of 4-(2-hydroxyethylpiperido)pyrimidine (208) with PCl<sub>3</sub> and then with H<sub>2</sub>O yielded 2-acetylpyrido[1,2-*c*]pyrimidine (209) [74JCS(P1)1611].



achieved when quinoxalines (**212**) were cyclized to **215** in the presence of a dipolarophile.



The regiospecificity of the rearrangement of benzo[*a*]quinolizidines (**216**) to pyrimido[6,1-*a*]isoquinolin-4-ones (**218**) via tetracyclic intermediates (**217**) on the action of 2,2,2-trifluoroethylamine is governed by stereoelectronic factors (82TL2829; 83JOC5074; 84USP4454319). Although triethylamine gave the same products, no reaction occurred with pyridine and dimethylaniline.



The hydrogenation of 1-[(1,2,4-oxadiazol-3-yl)methyl]-6,7-dialkoxy-3,4-dihydroisoquinolines over Pd/C or Raney Ni in acidified ethanol gave hydrochloride salts of pyrido[6,1-*a*]isoquinoline monohydrates (**51**) (86MI1; 87CB1039).

Ring transformation of mesoionic pyrimido[1,2-*a*]quinoline-1,3-diones (**219**) in 2,4,6-trichlorophenole at 240°C afforded pyrimido[1,6-*a*]quinoline-1,3-diones (**220**) (83M227).


1,3-Dimethyl-6,7,8,9-tetrahydropyrido[1,2-*c*]pyrimidinium-4-carboxylate was obtained by both the photochemical rearrangement of 2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one in acetic acid (83TL5237; 87JOC2455) and the acidic hydrolysis of 7-(aminoethylidene)-6-methoxy-8-oxo-1-azabicycl[4.2.0]octane in a mixture of benzene and acetic acid (87JOC2455).

The reactions of 1-[(6-methyl-5-methylthio-4-oxo-4*H*-1,3-oxazin-2-yl)-methylene]1,2-dihydroisoquinoline with secondary amines or with ethanolic

KOH furnished 2-amino- and 2-hydroxy-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones (80YZ1261).


Photochemical transformation of the cycloalkane-annulated pyridinium-*N*-aminide **221** afforded pyrido[3,2,1-*ij*]quinazolin-3-one **222** (88CB411). Photolysis of thiobarbiturates (**223**) gave 1-thioxo-3-oxo-hexahydropyrido[1,2-*c*]pyrimidines (**224**) [96H(42)117].

The reader is also referred here to Section III,A,5.




## 12. Miscellaneous

From the reaction products of the palladium(II)-catalyzed aminocarbonylation of unsaturated ureas (**225**), perhydropyrido[1,2-*c*]pyrimidine-1,3-diones (**226**) could be isolated, among other substances (88JA3994, 88JOC5731). Treatment of **227** with trifluoroacetic acid in methylene chloride at ambient temperature for 2 h afforded 1-oxoperhydropyrido[1,2-*c*]pyrimidine-8-carboxylates (**137**) (96JMC1872).




Treatment of tricyclic compound (**228**) with phenylmagnesium bromide gave an allylic sulfoxide, which underwent a stereospecific [2,3]-sigmatropic

rearrangement yielding perhydropyrido[1,2-*c*]pyrimidin-1-one (**229**) (93SL551).



Ureas **230** were cyclized to 1,2,3,6,7,11*b*-hexahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones **231** on the action of diisobutylaluminium hydride followed by treatment with formic acid [84S1071; 85H(23)2907]. From **230** ( $R = R^1 = H$ ,  $R^2 = Me$ ,  $R^3 = R^4 = \text{valence bond}$ ), a diastereomeric mixture of **231** ( $R = R^1 = R^4 = H$ ,  $R^2 = H$ ,  $Me$ ,  $R^3 = Me$ ,  $H$ ) was obtained (84S1071). Cyclization of carboxamides (**232**) in boiling  $POCl_3$  resulted in 4-aryl-9,10-dimethoxy-6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinolines (51JPJ1007; 55JPJ709, 55CPB253; 61MI1; 63YZ1043).



From the incubated reaction mixture of benzylamine and butyraldehyde or 2-ethyl-2-hexenal in the presence of dissolved oxygen in a mixture of 90% methanol 0.1 *M* phosphate buffer at 37°C for 48 h, 2-benzyl-1-phenyl-6-propyl-4,5,7-triethyl-2,3,5,6,7,8- and -2,4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidines could be isolated (89MI2).

## V. Applications and Important Compounds

### A. PYRIDO[1,2-*c*][1,3]OXAZINES AND THEIR BENZO DERIVATIVES

Pyrido[1,2-*c*][1,3]oxazines are used as intermediates in the total syntheses of anhydrocannabisativene (84JA3240), (+)-4-hydroxysedamine and (+)-

4-hydroxyallosedamine (85T2891), (–)-3-hydroxyallosedamine (87T935), (±)-lupinine [90H(30)885], (±)-sedridine (91TL4371), (–)-sedamine (93JOC5035), (–)-porantheridine (93JA8851), and (–)-sedacryptine (96SL100)alkaloids. Pyrido[1,2-*c*][1,3]oxazines were often applied to justify the stereochemistry of 2-(2-hydroxyalkyl)piperidines [56CLY1180; 68T4423; 71T2055; 78TL4647; 83H(20)601; 85H(23)831; 88TL1691; 89TL1947; 91T3805; 95TA2149]. [1,3]Oxazino[3,4-*a*]quinolines were used in the stereoselective synthesis of (±)-perhydrogephyrotoxin alkaloid [80JA1454; 84JCS(CC)597; 84TL3247; 86CPB2380].

CNS activities of *trans*-4,4*a*-H-1-imino-4-phenylperhydropyrido[1,2-*c*][1,3]oxazine were investigated (80MI1). Antitumor activity of 11-methoxy-1,2,4,6,7,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinoline was investigated [94JAP(K)94/41142, 94T6259]. 1[4-(Hexadecyloxy)phenyl]perhydropyrido[1,2-*c*][1,3]oxazine was patented as fading prevention compound for colored photographic material [88JAP(K)88/149643]. 1-Isopropylidene-4,4-dimethyl-1,3,4,4*a*-tetrahydro[1,3]oxazino[3,4-*a*]quinolin-3-one was investigated as an antiplasticizer for biphenol polycarbonates and was patented as a stiffening agent (66MI1; 67MI1; 68USP3386935; 71USP3625877).

9-Fluoro-10-(cyclic amino)-7-oxo-1*H*,3*H*,7*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine-6-carboxylic acids exhibit antibacterial activities (90EUP373531). The dopaminergic (D2) and serotonergic (5HT<sub>1A</sub>) activities of 6-(di-*n*-propylamino)-6,7-dihydro-1*H*,3*H*,5*H*-pyrido[3,2,1-*ij*][3,1]benzoxazin-3-one were measured (92JMC1076; 93MI4).

## B. PYRIDO[1,2-*c*][1,3]THIAZINES AND THEIR BENZO DERIVATIVES

Certain types of 1-(substituted imino)-1,3,4,4*a*,5,10-hexahydro[1,3]thiazino[3,4-*b*]isoquinolines, 1-hydroxymethyl-1,2,4,6,7,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinoline-4-(thi)ones, and 1,5,6,7-tetrahydro-3*H*-pyrido[3,2,1-*ij*][3,1]benzothiazine-3-(thi)ones are patented as analgesics, anti-inflammatories, and antipyretics (79GEP2848926; 80GEP3017865; 85GEP3510526) and as agrochemical fungicides [87EUP239927; 88JAP(K)88/170385].

## C. PYRIDO[1,2-*c*]PYRIMIDINE AND THEIR BENZO DERIVATIVES

2-[3-(1,3-Dioxolan-1-yl)propyl]perhydropyrido[1,2-*c*]pyrimidin-3-one was used in the preparation of racemic tetraponerines T4 and T8 alkaloids (90TL4543). Actisomide, an antiarrhythmic agent (**18**), has been introduced into human therapy (85JMC1285; 87MI1; 88MI1). 2-(2-Fluoro-4-chloro-5-

propargyloxy)perhydropyrido[1,2-*c*]pyrimidin-2-one was patented as a protoporphyrinogen oxidase inhibitor (94USP5298502).

1-Aryl-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2,4-diones are useful precursors in the synthesis of the pyrimidoaporphine nucleus (84T4003). 6-(*N,N*-Dipropylamino)-1,2,3,5,6,7-hexahydropyrido[3,2,1-*ij*]-quinazolin-3-one exhibits selective serotonin (5HT<sub>1A</sub>) agonist activity (92JMC1076; 93JMC1301, 93MI4; 95JMC1295). Representatives of broad-spectrum antibacterials, carbapenems contain 5,6,7,8-tetrahydropyrido[1,2-*c*]pyrimidinium moieties (86EUP168707, 86EUP169410).

Trequinsin (**19**) was under clinical investigation as a very potent antihypertensive peripheral vasodilator having platelet aggregation inhibitory properties (82MI1; 84JMC1470; 87MI3). Trequinsin (**19**) was claimed to be useful in the treatment of alopecia (89GEP3816995; 90EUP370379). Its biological properties were intensively investigated [81MI1; 84MI1, 84MI2, 84MI4; 85JMC1285, 85MI1; 86MI1, 86MI2, 86MI3; 87MI1, 87MI2, 87MI4, 87MI5, 87MI6, 87MI8; 88AF240, 88MI2; 89MI1; 90BJ(266)127, 90MI1, 90MI2; 91MI1, 91MI2, 91MI3; 92JBC(267)1798, 92MI1, 92MI2, 92PHA46; 93MI5; 94JBC30676; 95MI1, 95MI2, 95MI3, 95MIP1, 95MIP2; 96GEP4430128].

2-Dodecyl- and 2-ethylperhydropyrido[1,2-*c*]pyrimidines were patented as fading prevention compounds for colored photographic material [88JAP(K)88/149643].

## ACKNOWLEDGMENTS

The author thanks Professor Alan R. Katritzky and Professor Gurnos Jones for their encouragement and helpful comments, and Dr. David Durham for linguistic improvements. The invaluable assistance of Mrs. K. Juhász-Kupás and Mrs. J. Baráth-Csutorás throughout the preparation of this manuscript is gratefully acknowledged.

## REFERENCES

- |            |  |
|------------|--|
| 06CB968    | H. Staudinger and H. W. Klever, <i>Chem. Ber.</i> <b>39</b> , 968 (1906).                          |
| 10LA(374)1 | H. Staudinger, H. W. Klever, and P. Kober, <i>Justus Liebigs Ann. Chem.</i> <b>374</b> , 1 (1910). |
| 17CB1407   | K. Hess and A. Eichel, <i>Chem. Ber.</i> <b>50</b> , 1407 (1917).                                  |
| 50JA358    | L. H. Goodson and H. Christopher, <i>J. Am. Chem. Soc.</i> <b>72</b> , 358 (1950).                 |
| 51JPJ1007  | T. Kametani and S. Kano, <i>J. Pharm. Soc. Jpn.</i> <b>71</b> , 1007 (1951).                       |
| 54JA2431   | C. H. Talford and M. G. Van Campen, Jr., <i>J. Am. Chem. Soc.</i> <b>76</b> , 2431 (1954).         |
| 55CPB1253  | T. Kametani and T. Katagi, <i>Pharm. Bull.</i> <b>3</b> , 253 (1955).                              |

- 55CPB1259 T. Kametani and T. Katagi, *Pharm. Bull.* **3**, 259 (1955).
- 55JOC136 B. B. Baker and F. J. McEvoy, *J. Org. Chem.* **20**, 136 (1955).
- 55JPJ709 T. Kametani and T. Katagi, *J. Pharm. Soc. Jpn.* **75**, 709 (1955).
- 56BRP756686 M. G. van Campen, Jr. and C. H. Tilford, Br. Pat. 756,686 (1956) [CA **52**, 3,869 (1958)].
- 56CB1642 K. Winterfeld and W. Göbel, *Chem. Ber.* **89**, 1642 (1956).
- 56CLY1180 R. Leukes, J. Kovár, and K. Bláha, *Chem. Listy* **50**, 1180 (1956) [CA **50**, 1,169 (1956)].
- 57CLY927 R. Lukes, K. Bláha, and J. Kovár, *Chem. Listy* **51**, 927 (1957) [CA **51**, 14,736 (1957)].
- 57HCA1319 A. Hunger and K. Hoffmann, *Helv. Chim. Acta* **40**, 1319 (1957).
- 58CLY2081 R. Lukes, J. Kloubek, J. Kovár, and K. Bláha, *Chem. Listy* **52**, 2081 (1958) [CA **53**, 5,234 (1959)].
- 58N516 M. Rink and H. W. Eich, *Naturwissenschaften* **45**, 516 (1958).
- 59CB637 K. Winterfeld and W. Göbel, *Chem. Ber.* **92**, 637 (1959).
- 59YZ1008 T. Yamazaki, *Yakugaku Zasshi* **79**, 1008 (1959) [CA **54**, 5,679 (1960)].
- 60AP74 M. Rink and H. W. Eich, *Arch. Pharm. (Weinheim, Ger.)* **293**, 74 (1960).
- 60BRP856357 Wm. S. Merrell Co., Br. Pat. 856,357 (1960) [CA **55**, 13,453 (1961)].
- 60CCC2179 R. Lukes, J. Kovár, and K. Bláha, *Collect. Czech. Chem. Commun.* **25**, 2179 (1960).
- 60JOC2028 R. K. Hill and L. J. Loeffler, *J. Org. Chem.* **25**, 2028 (1960).
- 60M840 I. Weisz and A. Dudás, *Monatsh. Chem.* **91**, 840 (1960).
- 60YZ1414 M. Nagata, *Yakugaku Zasshi* **80**, 1414 (1960) [CA **55**, 5516 (1960)].
- 61HC(15-2)1201 W. L. Mosby, *Chem. Heterocycl. Compd.* **39**, 1201 (1961).
- 61HC(15-2)1203 W. L. Mosby, *Chem. Heterocycl. Compd.* **39**, 1203 (1961).
- 61HC(15-2)1207 W. L. Mosby, *Chem. Heterocycl. Compd.* **39**, 1207 (1961).
- 61JMC505 J. G. Lombardino, J. I. Bodin, C. F. Gerber, W. M. McLamore, and G. D. Laubach, *J. Med. Pharm. Chem.* **3**, 505 (1961).
- 61MI1 T. Kametani, H. Iida, and S. Kano, *Yakugaku Kenkyu* **33**, 223 (1961) [CA **55**, 19,933 (1961)].
- 62JOC1970 R. F. Shuman, H. V. Hansen, and E. D. Amstutz, *J. Org. Chem.* **27**, 1970 (1962).
- 62USP3021331 J. G. Lombardino, W. M. McLamore, and G. D. Laubach, U. S. Pat. 3,021,331 (1962) [CA **57**, 786 (1962)].
- 62USP3031454 C. H. Tilford, U. S. Pat. 3,031,454 (1962) [CA **57**, 9,824 (1962)].
- 63AP38 K. Winterfeld and H. Geschonke, *Arch. Pharm. (Weinheim, Ger.)* **296**, 38 (1963).
- 63JOC981 J. R. Piper and T. P. Johnston, *J. Org. Chem.* **28**, 981 (1963).
- 63YZ1043 T. Kametani and S. Kano, *Yakugaku Zasshi* **83**, 1043 (1963) [CA **60**, 13,241 (1964)].
- 64JMC146 G. DeStevens and M. Bernier, *J. Med. Chem.* **7**, 146 (1964).
- 64M59 E. Ziegler and T. Kappe, *Monatsh. Chem.* **95**, 59 (1964).
- 65JCS(CC)574 R. N. Pratt, S. A. Procter and G. A. Taylor, *J. Chem. Soc., Chem. Commun.*, 574 (1965).
- 65RTC1367 H. C. Beyerman, L. Maat, A. van Veen, and A. Zweistra, *Recl. Trav. Chim. Pays-Bas* **84**, 1367 (1965).
- 66AP997 W. Schneider and K. Schilken, *Arch. Pharm. (Weinheim, Ger.)* **299**, 997 (1966).



- 66JCS(CC)262 R. N. Pratt and G. A. Taylor, *J. Chem. Soc., Chem. Commun.*, 262 (1966).
- 66MI1 W. J. Jackson, Jr. and J. R. Caldwell, *Am. Chem. Soc., Div. Org. Coat. Plast. Chem., Prepr.* **26**, 160 (1966) [*CA* **66**, 29,485 (1967)].
- 66MI2 H. Marciszewski, *Acta Phys. Pol.* **23**, 183, (1966) [*CA* **66**, 8,166 (1967)].
- 67JCS(C)1569 R. N. Pratt, G. A. Taylor, and S. A. Procter, *J. Chem. Soc. C*, 1569 (1967).
- 67MI1 W. J. Jackson, Jr. and J. R. Caldwell, *J. Appl. Polym. Sci.* **11**, 211 (1967) [*CA* **67**, 64,959 (1967)].
- 67RZC1389 J. Kotler-Brajtburg, *Rocz. Chem.* **41**, 1389 (1967).
- 67TL2471 T. Matsunaga, I. Kawasaki, and T. Kaneko, *Tetrahedron Lett.*, 2471 (1967).
- 67YZ663 T. Yamazaki, M. Nagata, H. Sugano, and N. Inoue, *Yakugaku Zasshi* **87**, 663 (1967) [*CA* **67**, 90,769 (1967)].
- 68AGE826 R. Huisgen, B. A. Davis, and M. Morikawa, *Angew. Chem., Int. Ed. Engl.* **7**, 826 (1968).
- 68BRP1114397 F. Hoffmann-La Roche and Co., A.-G., Br. Pat. 1,114,397 (1968) [*CA* **69**, 59,272 (1969)].
- 68CJC1105 G. A. Cooke and G. Fodor, *Can. J. Chem.* **46**, 1105 (1968).
- 68JCS(C)926 R. M. Acheson, M. W. Foxton, and J. K. Stubbs, *J. Chem. Soc. C*, 926 (1968).
- 68T4423 T. A. Crabb and R. F. Newton, *Tetrahedron* **24**, 4423 (1968).
- 68TCA417 V. Galasso, *Theor. Chim. Acta* **11**, 417 (1968).
- 68USP3386935 W. J. Jackson, Jr. and J. R. Caldwell, U. S. Pat. 3,386,935 (1968) [*CA* **69**, 28,318 (1968)].
- 69IJC684 M. D. Nair and S. R. Mehta, *Indian J. Chem.* **7**, 684 (1969).
- 69JHC181 R. L. Peck and A. R. Day, *J. Heterocycl. Chem.* **6**, 181 (1969).
- 69YZ649 H. Kaneko and K. Natsuka, *Yakugaku Zasshi* **89**, 649 (1969) [*CA* **71**, 61,326 (1969)].
- 70LA(737)24 C. Schoepf, E. Gams, H. Hinkel, G. Krueger, and M. Hoehn, *Justus Liebigs Ann. Chem.* **737**, 24 (1970).
- 70T701 T. A. Crabb and R. F. Newton, *Tetrahedron* **26**, 701 (1970).
- 70T1217 T. A. Crabb and E. R. Jones, *Tetrahedron* **26**, 1217 (1970).
- 70T3941 T. A. Crabb and R. F. Newton, *Tetrahedron* **26**, 3941 (1970).
- 70USP3494922 W. B. Wright, Jr., U. S. Pat. 3,494,922 (1970) [*CA* **72**, 100,741 (1970)].
- 71JAP71/09467 H. Kaneko and T. N. Nagatsuka, Jpn. Pat. 71/09,467 (1971) [*CA* **75**, 36,105 (1971)].
- 71JAP71/16753 R. Tachikawa, T. Miyadera, and H. Takagi, Jpn. Pat. 71/16,753 (1971) [*CA* **75**, 49,130 (1971)].
- 71JMC878 G. E. Hardtmann, B. S. Heugi, J. H. Gogerty, L. C. Iorio, and H. W. Barnes, *J. Med. Chem.* **14**, 878 (1971).
- 71JOC2211 J. C. Martin, K. C. Brannock, R. D. Burpitt, P. G. Gott, and V. A. Hoyle, Jr., *J. Org. Chem.* **36**, 2211 (1971).
- 71LA(753)27 C. Schoepf, G. Benz, H. Hinkel, S. Kluessendorf, G. Krueger, R. Rausch, and R. Rokohl, *Justus Liebigs Ann. Chem.* **753**, 27 (1971).
- 71T2055 G. Fodor, D. Butruille, S. C. Huber, and F. Letourneau, *Tetrahedron* **27**, 2055 (1971).

- 71TL3361 T. A. Crabb and R. F. Newton, *Tetrahedron Lett.*, 3361 (1971).
- 71USP3625877 W. J. Jackson, Jr. and J. R. Caldwell, U. S. Pat. 3,625,877 (1971) [CA **76**, 114,251 (1972)].
- 72AX(B)37 C. S. Huber, *Acta Crystallogr., Sect. B* **B28**, 37 (1972).
- 72GEP2043665 R. R. Schmidt, Ger. Pat. 2,043,665 (1972) [CA **77**, 34,478 (1972)].
- 72JCS(CC)1152 C. Fuganti, D. Ghiringhelli, and P. Grasselli, *J. Chem. Soc., Chem. Commun.*, 1152 (1972).
- 72JCS(P2)1920 T. A. Crabb and R. F. Newton, *J. Chem. Soc., Perkin Trans. 2*, 1920 (1972).
- 72JMC49 M. S. Chodnekar, A. F. Crowther, W. Hepworth, R. Howe, B. J. McLoughlin, A. Mitchell, B. S. Rao, R. P. Slatcher, L. H. Smith, and M. A. Stevens, *J. Med. Chem.* **15**, 49 (1972).
- 72MI1 F. Gatta, R. Landi-Vittory, M. Tomassetti, and B. G. Nunez, *Chim. Ther.* **7**, 480 (1972) [CA **78**, 72,086 (1973)].
- 72USP3631046 G. E. Hardtmann, U. S. Pat. 3,631,046 (1972) [CA **76**, 99,704 (1972)].
- 73AP284 H. Wollweber and R. Hiltmann, *Arch. Pharm. (Weinheim, Ger.)* **306**, 284 (1973).
- 73JHC435 K. Harsányi, P. Kiss, and D. Korbonits, *J. Heterocycl. Chem.* **10**, 435 (1973).
- 73MI1 A. Griffiths, *J. Cryst. Mol. Struct.* **3**, 349 (1973).
- 73MI2 A. Griffiths, *J. Cryst. Mol. Struct.* **3**, 357 (1973).
- 73OMR(5)397 T. A. Crabb, P. J. Chivers, and R. F. Newton, *Org. Magn. Reson.* **5**, 397 (1973).
- 73USP3709887 G. A. Cooke and W. J. Houlihan, U. S. Pat. 3,709,887 (1973) [CA **78**, 84,439 (1973)].
- 74CPB2765 M. Matsuo, H. Awaya, C. Maseda, Y. Tominaga, R. Natsuki, Y. Matsuda, and G. Kobayashi, *Chem. Pharm. Bull.* **22**, 2765 (1974).
- 74JCS(P1)1611 J. Clark, M. Curphey, and I. W. Southon, *J. Chem. Soc., Perkin Trans. 1*, 1611 (1974).
- 74USP3772230 G. E. Hardtmann, U. S. Pat. 3,772,230 (1974) [CA **80**, 59,956 (1974)].
- 75CB1541 L. Capuano and K. Müller, *Chem. Ber.* **108**, 1541 (1975).
- 75CJC41 W. D. Marshall, T. T. Nguyen, D. B. MacLean, and I. D. Spenser, *Can. J. Chem.* **53**, 41 (1975).
- 75IZV2608 N. N. Zobova, N. R. Rubinova, and B. A. Arbuzov, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 2608 (1975) [CA **84**, 74,213 (1976)].
- 75JCS(P1)1001 G. A. Taylor, *J. Chem. Soc., Perkin Trans. 1*, 1001 (1975).
- 75MI1 J. Kóbor, *Szegedi Tanárképző Főiskola Tud. Közl.*, 155 (1975) [CA **87**, 84,789 (1977)].
- 75USP3868372 G. E. Hardtmann, U. S. Pat. 3,868,372 (1975) [CA **83**, 28,269 (1975)].
- 75YZ13 H. Awaya, C. Maseda, Y. Tominaga, R. Natsuki, Y. Matsuda, and G. Kobayashi, *Yakugaku Zasshi* **95**, 13 (1975) [CA **83**, 9966 (1975)].
- 76BCJ837 A. Sakurai and H. Midorikawa, *Bull. Chem. Soc. Jpn.* **49**, 837 (1976).
- 76IJC(B)391 S. Rajappa, B. G. Advani, and R. Sreenivasan, *Indian J. Chem., Sect. B* **B14**, 391 (1976).
- 76IJC(B)770 V. P. Arya, V. Honkan, and S. J. Shenoy, *Indian J. Chem., Sect. B* **B14**, 770 (1976).

- 76IJC(B)777 V. P. Arya, S. J. Shenoy, and V. M. Tatil, *Indian J. Chem., Sect. B* **B14**, 777 (1976).
- 76IJC(B)784 V. P. Arya and S. J. Shenoy, *Indian J. Chem., Sect. B* **B14**, 784 (1976).
- 76IJC(B)975 O. P. Malik, R. S. Kapil, and N. Anand, *Indian J. Chem., Sect. B* **B14**, 975 (1976).
- 76JCS(P2)418 I. D. Blackburne, A. R. Katritzky, D. M. Read, P. J. Chivers, and T. A. Crabb, *J. Chem. Soc., Perkin Trans. 2*, 418 (1976).
- 76OMR(8)258 T. A. Crabb and J. S. Mitchell, *Org. Magn. Reson.* **8**, 258 (1976).
- 77CL1109 S. Terashima, S. S. Jew, and K. Koga, *Chem. Lett.*, 1109 (1977).
- 77JCS(P2)370 T. A. Crabb, J. S. Mitchell, and R. F. Newton, *J. Chem. Soc., Perkin Trans. 2*, 370 (1977).
- 77JCS(P2)1592 T. A. Crabb and J. S. Mitchell, *J. Chem. Soc., Perkin Trans. 2*, 1592 (1977).
- 77SAP77/06706 B. Lal, H. Dornauer, B. K. Bhattacharya, A. N. Dohadwalla, and N. J. DeSouza, *S. Afr. Pat.* 77/06,706 (1977) [CA **90**, 54,969 (1979)].
- 77USP4025512 H. E. Zaugg and D. L. Arendsen, *U. S. Pat.* 4,025,512 (1977) [CA **87**, 68,375 (1977)].
- 78FES237 J. Gilbert, C. Gansser, C. Viel, R. Cavier, E. Chenu, and M. Hayat, *Farmaco, Ed. Sci.* **33**, 237 (1978).
- 78GEP2720085 B. Lal, H. Dornauer, B. K. Bhattacharya, A. N. Dohadwalla, and N. J. DeSouza, *Ger. Pat.* 2,720,085 (1978) [CA **90**, 54,972 (1979)].
- 78JHC645 G. M. Coppola, *J. Heterocycl. Chem.* **15**, 645 (1978).
- 78MI1 M. Ebeid and I. Bitter, *Egypt. J. Pharm. Sci.* **19**, 349 (1978) [CA **95**, 97,705 (1981)].
- 78TL4647 J. J. Tufariello and Sk. A. Ali, *Tetrahedron Lett.*, 4647 (1978).
- 78YZ623 K. Kurata, M. Yamada, H. Awaya, Y. Tominaga, Y. Matsuda, and G. Kobayashi, *Yakugaku Zasshi* **98**, 623 (1978) [CA **89**, 197,443 (1978)].
- 79GEP2801289 B. Lal, H. Dornauer, B. K. Bhattacharya, and A. N. Dohadwalla, *Ger. Pat.* 2,801,289 (1979) [CA **91**, 39,527 (1979)].
- 79GEP2848926 D. Farge, A. Jossin, G. Ponsinet, and D. Reisdorf, *Ger. Pat.* 2,848,926 (1979) [CA **91**, 57,042 (1979)].
- 79IJC(B)277 M. D. Nair and J. A. Desai, *Indian J. Chem., Sect. B* **B17**, 277 (1979).
- 79JCS(P1)2361 N. I. Viswanathan and V. Balakrishnan, *J. Chem. Soc., Perkin Trans. 1*, 2361 (1979).
- 79JCS(P2)504 T. A. Crabb and G. C. Jackson, *J. Chem. Soc., Perkin Trans. 2*, 504 (1979).
- 79JCS(P2)581 T. A. Crabb and J. S. Mitchell, *J. Chem. Soc., Perkin Trans. 2*, 581 (1979).
- 79JHC21 H. E. Zaugg, D. L. Arendsen, and R. S. Egan, *J. Heterocycl. Chem.* **16**, 21 (1979).
- 79JHC829 G. M. Coppola and G. E. Hardtmann, *J. Heterocycl. Chem.* **16**, 829 (1979).
- 79JHC897 G. M. Coppola, *J. Heterocycl. Chem.* **16**, 897 (1979).
- 79MI1 J. Fekete and J. Balla, *Magy. Kém. Foly.* **85**, 104 (1979) [CA **91**, 39,285 (1979)].
- 80BRP2071653 T. A. Crabb, G. C. Jackson, and P. A. Jupp, *Br. Pat.* 2,071,653 (1980) [CA **96**, 199,529 (1982)].
- 80GEP2847693 B. Lal, A. D'sa, H. Dornauer, and N. J. DeSouza, *Ger. Pat.* 2,847,693 (1980) [CA **93**, 220,770 (1980)].

- 80GEP3017865 D. Farge, A. Jossin, G. Ponsinet, and D. Reisdorf, *Ger. Pat.* 3,017,865 (1980) [CA **94**, 156,950 (1980)].
- 80HCA1158 A. Kuemin, E. Maverick, P. Seiler, N. Vanier, L. Damm, R. Hobi, J. D. Dunitz, and A. Eschenmoser, *Helv. Chim. Acta* **63**, 1158 (1980).
- 80INIP147624 Hoechst Pharm. Ltd., *Indian Pat.* 147,624 (1980) [CA **94**, 84,152 (1981)].
- 80JA1454 L. E. Overman and C. Fukaya, *J. Am. Chem. Soc.* **102**, 1454 (1980).
- 80JCS(P2)1778 T. A. Crabb and C. H. Turner, *J. Chem. Soc., Perkin Trans. 2*, 1778 (1980).
- 80JHC1785 G. M. Coppola, *J. Heterocycl. Chem.* **17**, 1785 (1980).
- 80KGS416 V. G. Granik, E. O. Sochneva, and N. P. Solov'eva, *Khim. Geterotsikl. Soedin.*, 416 (1980) [CA **93**, 114,353 (1981)].
- 80KGS1120 V. G. Granik, E. O. Sochneva, N. P. Solov'eva, E. F. Kuleshova, and O. S. Anisimova, *Khim. Geterotsikl. Soedin.*, 1120 (1980) [CA **94**, 192,250 (1980)].
- 80LA542 S. Linke, J. Kurz, D. Lipinski, and W. Gau, *Liebigs Ann. Chem.*, 542 (1980).
- 80MI1 H. Wollweber, R. Hiltmann, K. Stoepel, and H. G. Kroneberg, *Eur. J. Med. Chem.* **15**, 111 (1980).
- 80OMR(13)159 T. A. Crabb and P. A. Jupp, *Org. Magn. Reson.* **13**, 159 (1980).
- 80YZ1261 T. Kinoshita, M. Aono, M. Watanabe, and S. Furukawa, *Yakagu Zasshi* **100**, 1261 (1980) [CA **94**, 175,034 (1981)].
- 81CB61 P. Kiss and S. Holly, *Chem. Ber.* **114**, 61 (1981).
- 81FRP2470130 B. Lal, H. Dornauer, B. K. Bhattacharya, A. N. Dohadwalla, and N. J. DeSouza, *Fr. Pat.* 2,470,130 (1981) [CA **96**, 6753 (1982)].
- 81INIP149457 Hoechst Pharm. Ltd., *Indian Pat.* 149,457 (1981) [CA **97**, 144,868 (1982)].
- 81JA7573 B. Nader, T. R. Bailey, R. W. Franck, and S. M. Weinreb, *J. Am. Chem. Soc.* **103**, 7573 (1981).
- 81KFZ(5)44 V. F. Knyazeva, V. G. Granik, R. G. Glushkov, and G. S. Arutyunyan, *Khim.-Farm. Zh.* **15**(5), 44 (1981) [CA **95**, 115,238 (1981)].
- 81MI1 B. Lal, B. K. Bhattacharya, N. K. Dadkar, A. N. Dornauer, N. J. DeSouza, B. A. Schoelkens, D. Ruppert, and U. Weithmann, *IRCS Med. Sci.: Libr. Compend.* **9**, 325 (1981) [CA **95**, 73,469 (1981)].
- 82H(19)489 L. Fodor, J. Szabó, G. Bernáth, and P. Sohár, *Heterocycles* **19**, 489 (1982).
- 82KGS518 V. G. Granik, A. M. Zhidkova, and R. A. Dubinskii, *Khim. Geterotsikl. Soedin.*, 518 (1982) [CA **97**, 55,765 (1982)].
- 82KGS1095 V. G. Granik, V. F. Knyazeva, I. V. Persianova, N. P. Solov'eva, and R. G. Glushkov, *Khim. Geterotsikl. Soedin.*, 1095 (1982) [CA **98**, 4513 (1983)].
- 82MI1 D. Ruppert and K. U. Weithmann, *Life Sci.* **31**, 2037 (1982).
- 82OMR(20)239 T. A. Crabb, P. A. Jupp, and Y. Takeuchi, *Org. Magn. Reson.* **20**, 239 (1982).
- 82TL2829 B. E. Maryanoff, A. J. Molinari, G. P. Wooden, and R. A. Olofson, *Tetrahedron Lett.* **23**, 2829 (1982).
- 83EUP59698 E. Eriksoo, E. B. M. Sandberg, and L. J. T. Stalhandske, *Eur. Pat.* 59,698 (1983) [CA **98**, 34,513 (1983)].

- 83EUP75165 B. Lal, A. N. Dohadwalla, V. A. A. Aroskar, N. K. Dadkar, H. Dornauer, J. Mascarenhas, and N. J. DeSouza, Eur. Pat. 75,165 (1983) [CA **99**, 122,487 (1983)].
- 83H(20)601 M. Natsume and M. Ogawa, *Heterocycles* **20**, 601 (1983).
- 83H(20)1325 F. Fülöp, M. S. El-Gharib, A. Sohajda, G. Bernáth, J. Kóbor, and Gy. Dombi, *Heterocycles* **20**, 1325 (1983).
- 83JOC5074 B. E. Maryanoff, A. J. Molinari, D. F. McComsey, C. A. Maryanoff, G. P. Wooden, and R. A. Olofson, *J. Org. Chem.* **48**, 5074 (1983).
- 83M227 T. Kappe, Y. Ravai, and W. Stadlbauer, *Monatsh. Chem.* **114**, 227 (1983).
- 83OMR(21)203 Y. Takeuchi and T. A. Crabb, *Org. Magn. Reson.* **21**, 203 (1983).
- 83TL5237 S. Hirokami, T. Takahashi, M. Nagata, and T. Yamazaki, *Tetrahedron Lett.* **24**, 5237 (1983).
- 84EUP104647 G. W. Adelstein and R. J. Chorvat, Eur. Pat. Appl. 104,647 (1984) [CA **101**, 90,961 (1984)].
- 84EUP124893 A. Kaiser and F. Kienzle, Eur. Pat. Appl. 124,893 (1984) [CA **102**, 78,909 (1985)].
- 84INIP153028 Hoechst Pharm. Ltd., Indian Pat. 153,028 (1984) [CA **102**, 45,970 (1985)].
- 84JA3240 T. R. Bailey, R. S. Garigipati, J. A. Morton, and S. M. Weinreb, *J. Am. Chem. Soc.* **106**, 3240 (1984).
- 84JCS(CC)597 T. Ibuka, G. N. Chu, and F. Yoneda, *J. Chem. Soc., Chem. Commun.*, 597 (1984).
- 84JHC149 J. Kóbor, F. Fülöp, M. S. El-Gharib, and G. Bernáth, *J. Heterocycl. Chem.* **21**, 149 (1984).
- 84JMC1470 B. Lal, A. N. Dohadwalla, N. K. Dadkar, A. D'sa, and N. J. DeSouza, *J. Med. Chem.* **27**, 1470 (1984).
- 84MI1 K. Sugio and J. W. Daly, *Life Sci.* **34**, 123 (1984).
- 84MI2 P. H. Wu, R. A. Barraco, and J. W. Phillis, *Gen. Pharmacol.* **15**, 251 (1984).
- 84MI3 P. Kiss, S. Holly, and K. Harsányi, *Magy. Kém. Foly.* **90**, 547 (1984) [CA **102**, 185,042 (1985)].
- 84MI4 P. Usinger and W. Rupp, *Verh. Dtsch. Ges. Inn. Med.* **90**(Pt 2), 1904 (1984) [CA **103**, 16,605 (1985)].
- 84MIP1 C. Summers, PCT Int. Appl. 84/3,281 (1984) [CA **102**, 203,957 (1985)].
- 84OMR(22)424 T. A. Crabb, P. A. Jupp, and C. H. Turner, *Org. Magn. Reson.* **22**, 424 (1984).
- 84S1071 S. Kano, Y. Yuasa, and S. Shibuya, *Synthesis*, 1071 (1984).
- 84T4003 G. R. Lenz, *Tetrahedron* **40**, 4003 (1984).
- 84TL2901 B. Lal, R. M. Gidwani, J. Reden, and N. J. DeSouza, *Tetrahedron Lett.* **25**, 2901 (1984).
- 84TL3247 T. Ibuka, G. N. Chu, and F. Yoneda, *Tetrahedron Lett.* **25**, 3247 (1984).
- 84USP4454319 B. E. Maryanoff and A. J. Molinari, U. S. Pat. 4,454,319 (1984) [CA **101**, 90,974 (1984)].
- 84USP4482556 B. Lal, H. Dornauer, B. K. Bhattacharya, A. N. Dohadwalla, and N. J. De Souza, U. S. Pat. 4,482,556 (1984) [CA **102**, 78,910 (1985)].
- 85GEP3340773 U. Lerch and B. Renger, Ger. Pat. 3,340,773 (1985) [CA **103**, 160,531 (1985)].

- 85GEP3439131 G. Bernáth, J. Kóbor, F. Fülöp, P. Sohár, P. Perjési, E. Ezer, Gy. Hajós, E. Pálosi, L. Dénes, and L. Szporny, Ger. Pat. 3,439,131 (1985) [CA **103**, 160,523 (1985)].
- 85GEP3510526 G. Bernáth, J. Kóbor, F. Fülöp, A. Sohajda, A. Kálmán, E. Ezer, Gy. Hajós, E. Pálosi, L. Dénes, and L. Szporny, Ger. Pat. 3,510,526 (1985) [CA **104**, 109,667 (1986)].
- 85H(23)831 M. Ogawa and M. Natsume, *Heterocycles* **23**, 831 (1985).
- 85H(23)2907 S. Kano and Y. Yuasa, *Heterocycles* **23**, 2907 (1985).
- 85JMC1285 R. J. Chorvat, K. A. Prodan, G. W. Adelstein, R. M. Rydzewski, K. T. McLaughlin, M. H. Stamm, L. G. Frederick, H. C. Schniepp, and J. L. Stickney, *J. Med. Chem.* **28**, 1285 (1985).
- 85JOC1666 K. T. Potts, K. G. Bordeaux, W. R. Kuehnlng, and R. L. Salsbury, *J. Org. Chem.* **50**, 1666 (1985).
- 85MI1 W. Linz, G. Wiemer, and B. A. Schoelkens, *Adv. Pharmacol. Res. Pract., Proc. Congr. Hung. Pharmacol. Soc., 4th*, 1985, **1**, 387 (1985) [CA **106**, 188,741 (1987)].
- 85MIP1 Rhone-Poulenc Industries, Isr. Pat. 60,021 (1985) [CA **102**, 132,055 (1985)].
- 85SC883 S. Kano, Y. Yuasa, and S. Shibuya, *Synth. Commun.* **15**, 883 (1985).
- 85T2007 P. N. W. Van der Vliet, J. A. M. Hamersma, and W. N. Speckamp, *Tetrahedron* **41**, 2007 (1985).
- 85T2861 J. A. M. Hamersma and W. N. Speckamp, *Tetrahedron* **41**, 2861 (1985).
- 85T2891 F. Halin, P. Slosse, and C. Hootele, *Tetrahedron* **41**, 2891 (1985).
- 86AHC(39)281 I. Hermecz and L. Vasvári-Debreczy, *Adv. Heterocycl. Chem.* **39**, 281 (1986).
- 86CB2553 W. Lösel and K. H. Pook, *Chem. Ber.* **119**, 2553 (1986).
- 86CJC2205 Z. Czarnocki, D. B. Maclean, and W. A. Szarek, *Can. J. Chem.* **64**, 2205 (1986).
- 86CPB2380 T. Ibuka and G. N. Chu, *Chem. Pharm. Bull.* **34**, 2380 (1986).
- 86EUP168707 B. G. Christensen, D. B. R. Johnston, and S. M. Schmitt, Eur. Pat. Appl. 168,707 (1986) [CA **106**, 66,999 (1987)].
- 86EUP169410 B. G. Christensen, D. B. R. Johnston, and S. M. Schmitt, Eur. Pat. Appl. 169,410 (1986) [CA **106**, 67,000 (1987)].
- 86HCA1671 F. Kienzle, Y. Bounameaux, R. E. Minder, and R. Muggli, *Helv. Chim. Acta* **69**, 1671 (1986).
- 86INIP157279 Hoechst India Ltd., Indian Pat. 157,279 (1986) [CA **107**, 96,731 (1987)].
- 86KGS1396 D. G. Kim and G. G. Skvortsova, *Khim. Geterotsikl. Soedin.*, 1396 (1986) [CA **107**, 39,722 (1987)].
- 86MI1 Gy. Blaskó, E. Major, G. Glaskó, I. Rózsa, and Cs. Szántay, *Eur. J. Med. Chem.* **21**, 91 (1986).
- 86MI2 Gy. Blaskó, K. Tihanyi, G. Blaskó, E. Major, and Cs. Szántay, *Thromb. Res.* **43**, 249 (1986).
- 86MI3 C. Lugnier, P. Schoeffter, A. Le Bec, E. Strouthou, and J. C. Stoclet, *Biochem. Pharmacol.* **35**, 1743 (1986).
- 86MIP1 D. Korbonits, P. Kiss, G. Héja, I. Bata, K. Simon, P. Kolonits, K. Mármárosi, Cs. Gönczi, E. Pálosi, S. Virág, L. Tardos, I. Stadler, and P. Körmöczy, PCT Int. Appl. 86/02,928 (1986) [CA **110**, 173,262 (1989)].

- 87CB1039 D. Korbonits, P. Kiss, I. Bata, G. Héja, K. Simon, and P. Kolonits, *Chem. Ber.* **120**, 1039 (1987).
- 87CR(305)441 E. H. Bahaji, J. Couquelet, and P. Tronche, *C. R. Seances Acad. Sci., Ser. 2* **305**, 441 (1987).
- 87EUP215477 K. T. McLaughlin, R. J. Chorvat, and K. A. Prodan, Eur. Pat. 215,477 (1987) [CA **106**, 213,973 (1987)].
- 87EUP239129 M. Uchida, S. Morita, and M. Chihiro, Eur. Pat. 239,129 (1987) [CA **108**, 186 740 (1988)].
- 87EUP239927 Y. Kurahashi, S. Kagabu, N. Matsumoto, T. Yamada, and K. Wada, Eur. Pat. 239,927 (1987) [CA **108**, 37,849 (1988)].
- 87JCS(P1)1635 A. R. Evans, R. Martin, G. A. Taylor, and C. H. M. Yap, *J. Chem. Soc., Perkin Trans. I*, 1635 (1987).
- 87JOC2455 S. Hirokami, T. Takahashi, M. Nagata, and T. Yamazaki, *J. Org. Chem.* **52**, 2455 (1987).
- 87MI1 L. E. Borowicz, H. C. Schniepp, and M. C. Sanguinetti, *J. Cardiovasc. Pharmacol.* **9**, 57 (1987).
- 87MI2 K. J. Rorig, Z. Ruben, and S. N. Anderson, *Proc. Soc. Exp. Biol. Med.* **184**, 165 (1987) [CA **106**, 148,968 (1987)].
- 87MI3 K. C. Agarwal, R. S. Buckley, and R. E. Parks, Jr., *Thromb. Res.* **47**, 191 (1987).
- 87MI4 E. F. Smith, III and R. W. Olson, *Prog. Clin. Biol. Res.* **242**, 241 (1987).
- 87MI5 F. Lanza, A. Bertz, A. Stierle, G. Corre, and J. P. Cazenave, *Thromb. Res.* **45**, 477 (1987).
- 87MI6 E. F. Smith, III and J. W. Egan, *J. Pharmacol. Exp. Ther.* **241**, 855 (1987).
- 87MI7 D. A. Roston, *J. Liq. Chromatogr.* **10**, 3427 (1987).
- 87MI8 R. F. G. Booth, S. P. Buckham, D. O. Lunt, P. W. Manley, and R. A. Porter, *Biochem. Pharmacol.* **36**, 3517 (1987).
- 87PHA739 A. Pricken, F. Fülöp, P. Pfügel, and G. Bernáth, *Pharmazie* **42**, 739 (1987).
- 87PHA858 H. P. Richter, F. Fülöp, P. Pfügel, and G. Bernáth, *Pharmazie* **42**, 858 (1987).
- 87T935 W. Ibebeke-Bomangwa and C. Hootele, *Tetrahedron* **43**, 935 (1987).
- 87USP4680295 K. W. Fowler and R. J. Chorvat, U. S. Pat. 4,680,295 (1987) [CA **107**, 176,063 (1987)].
- 88AF240 W. Linz, G. Wiener, and B. A. Schölkens, *Arzneim.-Forsch.* **38**, 240 (1988).
- 88CB411 G. Baum, A. Friderichs, A. Kuemmell, W. Massa, and G. Seitz, *Chem. Ber.* **121**, 411 (1988).
- 88CPB1597 Y. Matsubara, R. Yoneda, S. Harusawa, and T. Kurihara, *Chem. Pharm. Bull.* **36**, 1597 (1988).
- 88JA3994 Y. Tamaru, M. Hojo, H. Higashimura, and Z. Yoshida, *J. Am. Chem. Soc.* **110**, 3994 (1988).
- 88JAP(K)88/149643 Y. Kaneko, Jpn. Kokai 88/149,643 (1988) [CA **110**, 182,849 (1989)].
- 88JAP(K)88/170385 T. Shibata, H. Sugiyama, K. Mori, and Y. Kojima, Jpn. Kokai 88/170,385 (1988) [CA **110**, 2892 (1989)].
- 88JOC5731 Y. Tamura, M. Hojo, and Z. Yoshida, *J. Org. Chem.* **53**, 5731 (1988).

- 88MI1 L. G. Frederick, F. R. Hatley, S. J. McDonald, M. H. Stamm, and S. M. Garthwaite, *J. Cardiovasc. Pharmacol.* **11**, 657 (1988).
- 88MI2 A. F. Prigent, S. Fougier, G. Nemoz, G. Anker, H. Pacheco, C. Lugnier, A. Lebec, and J. C. Stoclet, *Biochem. Pharmacol.* **37**, 3671 (1988).
- 88MRC748 T. A. Crabb and A. N. Trethewey, *Magn. Reson. Chem.* **26**, 748 (1988).
- 88TL1691 P. Merlin, J. C. Braekman, and D. Daloz, *Tetrahedron Lett.* **29**, 1691 (1988).
- 89EUP322263 A. Renaud, A. R. Schoofs, J. M. Guiraudie, and D. Brochet, Eur. Pat. Appl. 322,263 (1989) [CA **112**, 216,909 (1990)].
- 89GEP3816995 R. H. Rupp and B. Lal, Ger. Pat. 3,816,995 (1989) [CA **113**, 46,096 (1990)].
- 89H(29)1929 G. A. Howarth, *Heterocycles* **29**, 1929 (1989).
- 89JHC1357 J. T. Hahn and F. D. Popp, *J. Heterocycl. Chem.* **26**, 1357 (1989).
- 89MI1 S. M. Garthwaite, F. R. Hatley, L. G. Frederick, and C. Cook, *J. Cardiovasc. Pharmacol.* **13**, 218 (1989).
- 89MI2 K. Kikugawa, T. Kato, and A. Iwata, *Lipids* **24**, 962 (1989) [CA **112**, 93,348 (1990)].
- 89PHA694 A. Pricken, F. Fülöp, P. Pfügel, and G. Bernáth, *Pharmazie* **44**, 694 (1989).
- 89TL1947 P. J. Tirel, M. Vaultier, and R. Carrie, *Tetrahedron Lett.* **30**, 1947 (1989).
- 90BJ(266)127 J. E. Souness, B. K. Diocee, W. Martin, and S. A. Moodie, *Biochem. J.* **266**, 127 (1990).
- 90CB493 D. Korbonits, G. Horváth, P. Kiss, K. Simon, and P. Kolonits, *Chem. Ber.* **123**, 493 (1990).
- 90CB803 F. Fülöp, G. Bernáth, M. S. El-Gharib, J. Kóbor, P. Sohár, I. Pelczér, Gy. Argay, and A. Kálmán, *Chem. Ber.* **123**, 803 (1990).
- 90CPB1575 M. Uchida, M. Chihara, S. Morita, H. Yamashita, K. Yamasaki, T. Kanbe, Y. Yabuuchi, and K. Nakagawa, *Chem. Pharm. Bull.* **38**, 1575 (1990).
- 90EUP370379 B. Lal, J. Blumbach, A. N. Dohadwalla, and N. J. DeSouza, Eur. Pat. Appl. 370,379 (1990) [CA **114**, 234,867 (1991)].
- 90EUP373531 A. Yazaki, S. Inoue, and H. Amano, Eur. Pat. Appl. 373,531 (1990) [CA **113**, 211,997 (1990)].
- 90H(30)885 T. Kurihara, Y. Matsubara, H. Osaki, S. Harusawa, and R. Yoneda, *Heterocycles* **30**, 885 (1990).
- 90JHC957 F. Fülöp, É. Semeg, G. Bernáth, and P. Sohár, *J. Heterocycl. Chem.* **27**, 957 (1990).
- 90JOC1447 M. J. Fisher and L. E. Overman, *J. Org. Chem.* **55**, 1447 (1990).
- 90JOC2464 K. Nilsson and A. Hallberg, *J. Org. Chem.* **55**, 2464 (1990).
- 90JOC5117 B. Lal, R. M. Gidwani, and N. J. De Souza, *J. Org. Chem.* **55**, 5117 (1990).
- 90KGS1665 O. V. Shekhter, S. A. Chernyak, N. L. Sergovskaya, Yu. S. Tsizin, F. S. Mikhailitsin, S. K. Drusvyatskaya, and N. A. Uvarova, *Khim. Geterotsikl. Soedin.*, 1665 (1990) [CA **115**, 8,749 (1991)].
- 90MI1 R. C. Guy and C. D. Port, *Acute Toxicol. Data* **1**, 55 (1990) [CA **114**, 226,078 (1991)].



- 90MI2 C. Lugnier and V. B. Schini, *Biochem. Pharmacol.* **39**, 75 (1990).
- 90MI3 M. Y. Ebeid, H. H. Hassanein, M. V. Riad, and A. B. Hassan, *Egypt. J. Pharm. Sci.* **31**, 267 (1990) [CA **113**, 90,919 (1990)].
- 90MIP1 E. Hasegawa, A. Kawaguchi, M. Kajitani, M. Yasumoto, N. Kasa-hara, and J. Yamamoto, *PCT Int. Appl.* 90/07,509 (1990) [CA **115**, 29,325 (1991)].
- 90MIP2 M. W. Moon, R. F. Heier, and J. K. Morris, *PCT Int. Appl.* 90/15,058 (1990) [CA **114**, 143,420 (1991)].
- 90SL48 D. S. Brown, T. Hansson, and S. V. Ley, *Synlett*, 48 (1990).
- 90SL749 D. S. Brown, P. Charreau, and S. V. Ley, *Synlett*, 749 (1990).
- 90T4039 L. Lázár, F. Fülöp, Gy. Dombi, G. Bernáth, Gy. Argay, and A. Kálmán, *Tetrahedron* **46**, 4039 (1990).
- 90TL4543 T. H. Jones, *Tetrahedron Lett.* **31**, 4543 (1990).
- 91ACH375 I. Huber, F. Fülöp, J. Kobor, and G. Bernáth, *Acta Chim. Acad. Sci. Hung.* **128**, 375 (1991).
- 91ACS716 K. Nilsson, A. Hallberg, R. Isaksson, and J. Sandstroem, *Acta Chem. Scand.* **45**, 716 (1991).
- 91BSB533 A. Copar, B. Stanovnik, and M. Tisler, *Bull. Soc. Chim. Belg.* **100**, 533 (1991).
- 91CB111 D. Korbonits, K. Simon, and P. Kolonits, *Chem. Ber.* **124**, 111 (1991).
- 91CJC211 F. Driessens and C. Hootele, *Can. J. Chem.* **69**, 211 (1991).
- 91G393 A. Liquori, G. Romeo, S. Giovanni, G. Sindona, and N. Uccella, *Gazz. Chim. Ital.* **121**, 393 (1991).
- 91JST(245)53 B. Fernandez, L. Carballeira, and M. A. Rios, *J. Mol. Struct.* **245**, 53 (1991).
- 91KGS124 G. V. Pshenichnyi, S. Hamo, V. A. Mashenkov, and L. S. Stanishevskii, *Khim. Geterotsikl. Soedin.*, 124 (1991) [CA **115**, 49,560 (1991)].
- 91KGS1556 N. V. Shibaeva, I. I. Nechayuk, S. V. Borodaev, D. S. Yufit, Y. T. Struchkov, A. I. Pyshchev, and S. M. Lukyanov, *Khim. Geterotsikl. Soedin.*, 1556 (1991) [CA **117**, 111,563 (1992)].
- 91MI1 T. T. Kararli, T. Catalano, and R. M. Bittman, *Pharm. Res.* **8**, 123 (1991).
- 91MI2 M. A. Malesker, S. M. Mohiuddin, C. J. Destache, A. Stoysich, R. R. Dean, D. E. Hilleman, and M. H. Sketch, *DICP, Ann. Pharmacother.* **25**, 231 (1991) [CA **115**, 270,269 (1991)].
- 91MI3 J. E. Souness, C. M. Carter, B. K. Diocee, G. A. Hassal, L. J. Wood, and N. C. Turner, *Biochem. Pharmacol.* **42**, 937 (1991).
- 91MRC1040 T. A. Crabb and A. V. Patel, *Magn. Reson. Chem.* **29**, 1040 (1991).
- 91T1311 D. S. Brown, P. Charreau, T. Hansson, and S. V. Ley, *Tetrahedron* **47**, 1311 (1991).
- 91T3805 P. Merlin, J. C. Braekman, and D. Daloze, *Tetrahedron* **47**, 3805 (1991).
- 91TL4371 T. Uyehara, N. Chiba, I. Suzuki, and Y. Yamamoto, *Tetrahedron Lett.* **32**, 4371 (1991).
- 92GEP4104257 W. Loesel, O. Roses, D. Arndts, and G. Schingnitz, *Ger. Pat.* 4,104,257 (1992) [CA **118**, 6,878 (1993)].
- 92JBC(267)1798 T. J. Trophy, J. M. Stadel, M. Burman, L. B. Cieslinski, M. M. McLaughlin, J. R. White, and G. P. Livi, *J. Biol. Chem.* **267**, 1798 (1992).

- 92JMC1076 M. W. Moon, J. K. Morris, R. F. Heier, C. G. Chidester, W. E. Hoffmann, M. F. Piercey, J. S. Althaus, P. F. von Voigtlander, D. L. Evans, L. M. Figur, and R. A. Lahti, *J. Med. Chem.* **35**, 1076 (1992).
- 92JOC5764 Y. M. Choi, V. Rosso, N. Kucharczyk, and R. D. Sofia, *J. Org. Chem.* **57**, 5764 (1992).
- 92JST(274)259 L. Carballeira, B. Fernandez, and A. Miranda, *J. Mol. Struct.* **274**, 259 (1992).
- 92MI1 C. S. Cook, L. F. Rozek, J. Hribar, G. L. Schoenhard, and A. Karim, *Eur. J. Drug Metab. Pharmacokinet.* **17**, 145 (1992).
- 92MI2 N. L. Oquist, S. J. Strada, and M. Artman, *Pediatr. Res.* **31**, 300 (1992) [*CA* **116**, 143,597 (1992)].
- 92MRC129 T. A. Crabb, S. T. Ingate, and T. G. Nevell, *Magn. Reson. Chem.* **30**, 129 (1992).
- 92PHA46 C. Lugnier, J. C. Doré, J. C. Stoclet, and C. Viel, *Pharmazie* **47**, 46 (1992).
- 92SL563 J. Barluenga, M. Tomas, V. Kouznetsov, and E. Rubio, *Synlett*, 563 (1992).
- 92T4601 P. Molina, A. Lorenzo, and E. Aller, *Tetrahedron* **48**, 4601 (1992).
- 92T4937 P. Sohár, L. Lázár, F. Fülöp, G. Bernáth, and J. Kóbor, *Tetrahedron* **48**, 4937 (1992).
- 93JA8851 D. L. Comins and H. Hong, *J. Am. Chem. Soc.* **115**, 8851 (1993).
- 93JCR(S)170 T. A. Crabb, S. T. Ingate, and T. G. Nevell, *J. Chem. Res., Synop.*, 170 (1993).
- 93JMC1301 C. G. Chidester, C. H. Lin, R. A. Lahti, S. R. Haadsma-Svensson, and M. W. Smith, *J. Med. Chem.* **36**, 1301 (1993).
- 93JOC5035 D. L. Comins and H. Hong, *J. Org. Chem.* **58**, 5035 (1993).
- 93MI1 H. H. Hassanein and M. Y. Ebeid, *Bull. Fac. Pharm. (Cairo Univ.)* **31**, 33 (1993) [*CA* **121**, 83,251 (1994)].
- 93MI2 Bernáth, F. Fülöp, and J. Kóbor, *Acta Pharm. Hung.* **63**, 129 (1993) [*CA* **120**, 8,413 (1994)].
- 93MI3 M. Y. Ebeid, H. H. Hassanein, and M. Riad, *Bull. Fac. Pharm. (Cairo Univ.)* **31**, 187 (1993) [*CA* **121**, 83,250 (1994)].
- 93MI4 M. W. Moon, J. K. Morris, R. F. Heier, R. S. P. Hsi, M. O. Manis, M. E. Royer, R. R. Walters, C. F. Lawson, M. W. Smith, R. A. Lahti, M. F. Piercey, and V. H. Sethy, *Drug Des. Discovery* **9**, 313 (1993) [*CA* **120**, 95,412 (1994)].
- 93MI5 C. S. Cook, L. F. Rozek, J. Stolzenbach, S. Anderson, G. L. Schoenhard, and A. Karim, *Pharm. Res.* **10**, 427 (1993).
- 93MIP1 J. Kóbor, L. Lázár, I. Huber, J. Árva, L. Szporny, B. Kiss, E. Kárpáti, É. Pálosi, Zs. Szombathelyi, Á. Sarkadi, A. Gere, M. Bodó, K. Csomor, J. Laszy, Zs. Szentirmai, E. Lapis, S. Szabó, G. Bernáth, and F. Fülöp, *PCT Int. Appl.* 93/12,118 (1993) [*CA* **119**, 225,960 (1993)].
- 93MRC505 T. A. Crabb, S. T. Ingate, T. G. Nevell, and S. Sumner, *Magn. Reson. Chem.* **31**, 505 (1993).
- 93PHA941 Gy. Dormány, A. Gere, M. Paróczai, Cs. Szántay, Jr., and J. Schön, *Pharmazie* **48**, 941 (1993).
- 93SL551 G. R. Heintzelman, M. Parvez, and S. M. Weinreb, *Synlett*, 551 (1993).
- 93TL2319 E. Marchand and G. Morel, *Tetrahedron Lett.* **34**, 2319 (1993).

- 94GEP4225629 M. Schaefer and D. Karlheinz, Ger. Pat. 4,225,629 (1994) [CA 120, 270,444 (1994)].
- 94H(37)2051 D. Korbonits and K. Horváth, *Heterocycles* 37, 2051 (1994).
- 94JAP(K)94/41142 A. Terajima, T. Kato, O. Tamura, F. Ikeuchi, J. Kobayashi, and K. Yamada, Jpn. Kokai 94/41,142 (1994) [CA 121, 179,502 (1994)].
- 94JBC30676 R. Pillai, S. F. Staub, and J. Colicelli, *J. Biol. Chem.* 269, 30676 (1994).
- 94T6259 T. Katoh, M. Kiriara, T. Yoshino, O. Tamura, F. Ikeuchi, K. Nakatani, F. Matsuda, K. Yamada, K. Gomi, T. Ashizawa, and S. Terashima, *Tetrahedron* 50, 6259 (1994).
- 94USP5298502 B. P. Halling and D. A. Witkowski, U. S. Pat. 5,298,502 (1994) [CA 121, 4,153 (1994)].
- 95JMC1295 A. N. Jain, N. L. Harris, and J. Y. Park, *J. Med. Chem.* 38, 1295 (1995).
- 95JOC3993 A. R. Katritzky, B. Rachwal, and S. Rachwal, *J. Org. Chem.* 60, 3993 (1995).
- 95MI1 K. H. Banner, F. Marchini, A. Buschi, E. Moriggi, C. Semeraro, and C. P. Page, *Pulm. Pharmacol.* 8, 37 (1995).
- 95MI2 S. M. Yu, Z. J. Cheng, and S. C. Kuo, *Eur. J. Pharmacol.* 280, 69 (1995).
- 95MI3 N. E. Leclerc, G. Haan-Archipoff, M. Lenoble, and A. Beretz, *J. Cardiovasc. Pharmacol.* 25(Suppl. 2), S88 (1995).
- 95MI4 J. Tari, F. Fülöp, and G. Bernáth, *Gyógyszerészet*, 39, 347 (1995) [CA 123, 339,973 (1995)].
- 95MIP1 M. S. Barnette, T. J. Torphy, and S. B. Christensen, PCT Int. Appl. 95/00,139 (1995) [CA 122, 205,217 (1995)].
- 95MIP2 C. A. Lawson, D. J. Pinsky, A. Smerling, and D. M. Stern, PCT Int. Appl. 95/09,636 (1995) [CA 123, 17,877 (1995)].
- 95MIP3 B. Kiss, A. Gere, M. Bihari, Gy. Domány, M. Pellionisz-Paroczai, I. Schön, B. Hegedüs, L. Szporny, E. Kárpáti, Cs. Szántay, Cs. Szántay, Jr., and É. Zágón, Hung. Teljes 66,858 (1995) [CA 123, 314,000 (1995)].
- 95S863 F. Fülöp, H. Wamhoff, and P. Sohár, *Synthesis*, 863 (1995).
- 95TA2149 C. Louis and C. Hootelé, *Tetrahedron: Asymmetry* 6, 2149 (1995).
- 95ZK899 F. Knoch, H. Wiedenfeld, F. Herold, and B. Gutkowska, *Z. Kristallogr.* 210, 899 (1995).
- 96GEP4424369 W. Hallenbach, T. Himmler, T. Jaetsch, B. Mielke, K.-D. Bremm, R. Endermann, F. Pirro, M. Stegemann, and H.-G. Wetzstein, Ger. Pat. 4,424,369 (1996) [CA 124, 261,012 (1996)].
- 96GEP4430128 M. Schoenharting, S. Mueller, and P. Zabel, Ger. Pat. 4,430,128 (1996) [CA 124, 250,901 (1996)].
- 96H(42)117 H. Takechi and M. Machida, *Heterocycles* 42, 117 (1996).
- 96JMC1872 P. S. Dragovich, J. E. Barker, J. French, M. Imbacuan, V. J. Kalish, C. R. Kissinger, D. R. Knighton, C. T. Lewis, E. W. Moomaw, H. E. Parge, L. A. K. Pelletier, T. J. Prins, R. E. Showalter, J. H. Tatlock, K. D. Tucker, and J. E. Villafranca, *J. Med. Chem.* 39, 1872 (1996).
- 96SL100 E. Akiyama and M. Hirama, *Synlett*, 100 (1996).

# Heterocycle-Fused Acridines

PAUL W. GROUNDWATER

*School of Health Sciences, University of Sunderland, Sunderland  
SR1 3SD, United Kingdom*

MUNAWAR ALI MUNAWAR

*Department of Chemistry, Islamia University, Bahawalpur, Pakistan*

I. Introduction	90
II. Pyridoacridines	90
A. Pyrido[ <i>a</i> ]acridines (Benzo[ <i>j</i> ]phenanthrolines)	90
1. Pyrido[2,3- <i>a</i> ]acridines (Benzo[ <i>j</i> ][1,7]phenanthrolines)	90
2. Pyrido[3,2- <i>a</i> ]acridines (Benzo[ <i>j</i> ][4,7]phenanthrolines)	92
3. Pyrido[3,4- <i>a</i> ]acridines (Benzo[ <i>j</i> ][2,7]phenanthrolines)	94
4. Pyrido[4,3- <i>a</i> ]acridines (Benzo[ <i>j</i> ][3,7]phenanthrolines)	95
B. Pyrido[ <i>b</i> ]acridines	95
1. Pyrido[2,3- <i>b</i> ]acridines	96
2. Pyrido[3,2- <i>b</i> ]acridines	97
3. Pyrido[3,4- <i>b</i> ]acridines	99
4. Pyrido[4,3- <i>b</i> ]acridines	99
C. Pyrido[ <i>c</i> ]acridines (Benzo[ <i>b</i> ]phenanthrolines)	99
1. Pyrido[2,3- <i>c</i> ]acridines (Benzo[ <i>b</i> ][1,7]phenanthrolines)	100
2. Pyrido[3,2- <i>c</i> ]acridines (Benzo[ <i>b</i> ][1,10]phenanthrolines)	104
3. Pyrido[3,4- <i>c</i> ]acridines (Benzo[ <i>b</i> ][1,8]phenanthrolines)	108
4. Pyrido[4,3- <i>c</i> ]acridines (Benzo[ <i>b</i> ][1,9]phenanthrolines)	111
D. Pyrido[ <i>k</i> ]acridines	112
1. Pyrido[2,3,4- <i>kl</i> ]acridines	112
2. Pyrido[3,4,5- <i>kl</i> ]acridines	123
3. Pyrido[4,3,2- <i>kl</i> ]acridines	123
III. Pyranoacridines	124
A. Pyrano[2,3- <i>a</i> ]acridines	124
B. Pyrano[2,3- <i>c</i> ]acridines	127
1. Isolation and Biological Activity	127
2. Syntheses	129
C. Pyrano[3,2- <i>a</i> ]acridines	137
D. Pyrano[3,2- <i>b</i> ]acridines	138
IV. Pyrroloacridines	139
A. Pyrrolo[2,3- <i>b</i> ]acridines	139
B. Pyrrolo[2,3- <i>c</i> ]acridines	139
C. Pyrrolo[2,3,4- <i>kl</i> ]acridines	142
V. Thienoacridines	142
A. Thieno[2,3- <i>c</i> ]acridines	142
B. Thieno[3,2- <i>c</i> ]acridines	144
C. Thieno[3,4- <i>c</i> ]acridines	145

VI. Furoacridines.....	145
A. Furo[2,3- <i>a</i> ]acridines.....	145
B. Furo[2,3- <i>c</i> ]acridines.....	146
1. Isolation.....	146
2. Syntheses.....	148
C. Furo[3,2- <i>b</i> ]acridines.....	152
References.....	152


## I. Introduction

This review covers the following groups of heterocycle-fused acridines: pyridoacridines, pyranoacridines, pyrroloacridines, thienoacridines, and furoacridines.

Heterocycle-fused acridines possess a variety of biological activities, including  $\text{Ca}^{2+}$  releasing, antiviral (e.g., anti-HIV), antimicrobial (e.g., antiamebic and antiplasmodium) and antitumor properties. They are also enzyme inhibitors (e.g., topoisomerase II inhibitors and protein tyrosine kinase inhibitors) and have DNA-intercalation and metal-chelating properties.

## II. Pyridoacridines

Depending on the ring fusion, pyridoacridines can be classified into the following main classes: pyrido[*a*]acridines (benzo[*j*]phenanthrolines), pyrido[*b*]acridines, pyrido[*c*]acridines (benzo[*b*]phenanthrolines), and pyrido[*kl*]acridines (dibenzo[*f,ij*][2,7]naphthyridines).




### A. PYRIDO[*a*]ACRIDINES (BENZO[*j*]PHENANTHROLINES)

The pyridine ring is fused at bond *a* of the acridine. Depending on the position of the nitrogen in the fused pyridine ring, four different types of pyrido[*a*]acridines are possible.

#### 1. Pyrido[2,3-*a*]acridines (Benzo[*j*][1,7]phenanthrolines)


Dobson *et al.* (48JCS123) constructed this ring system by using the Ullmann-amine coupling reaction between 7-aminoquinoline **1** and potassium 2,4-dichlorobenzoate, followed by cyclization of the resultant diaryl-



SCHEME 1. (a) Cu bronze, amyl alcohol,  $150^\circ\text{C}$ , 6 h; (b)  $\text{POCl}_3/\text{PCl}_5$ ,  $150^\circ\text{C}$ , 6 h; (c) diethylaminopropylamine, phenol,  $100^\circ\text{C}$ , 2 h.

amine **2** with a mixture of  $\text{POCl}_3$  and  $\text{PCl}_5$  (Scheme 1). The pyridoacridine **3** was then converted to a potential antimalarial compound **4**, but poor activity was observed.


Gordon *et al.* (90MI1) obtained a triquinobenzene **5** from a two-step reaction between 1,3,5-tribromobenzene and anthranilic acid. The reaction involved three Ullmann-amine couplings followed by intramolecular acylations.



**5**

Reisch *et al.* (93JHC1469) obtained quino[*a*]acridone **6** as the main product from the condensation of phloroglucinol and 6-methylantranilic acid (Scheme 2). The synthesis of similar quino[*a*]acridones from phloroglucinol and anthranilic acids has been reported in patents (35FRP771486).

The condensation product **7** of *m*-phenylenediamine and 2-formylcyclohexanone, on treatment with polyphosphoric acid (PPA), gave the octahydrobenzophenanthroline **8**, which, on dehydrogenation, afforded




SCHEME 2

quino[*a*]acridine **9** (Scheme 3) (74IJC1230). A rearrangement prior to cyclodehydration is involved. The synthesis of similar compounds from 1,3-diiodobenzene and 2-acylanilines, using the Ullmann-amine coupling reaction followed by cyclization, has been reported by Hellwinkel and Itemann (85LA1501).



In an attempted reaction toward a pyrido[2,3,4-*kl*]acridine, Gellerman *et al.* (92TL5577) isolated a pyrido[2,3-*a*]acridine **11** from an acid-catalyzed reaction between 1-amino-4-methylacridin-9(10*H*)one **10** and acetylacetone (Scheme 4).

## 2. Pyrido[3,2-*a*]acridines (Benzo[*j*][4,7]phenanthrolines)

12-Chloropyrido[3,2-*a*]acridines **12** were prepared by the route described in Scheme 1, but with 6-aminoquinolines instead of 7-aminoquinoline (46JCS151; 47JCS678). The chloroderivatives **12** were then converted to potent antimalarial agents with dialkylaminoalkylamines or alkylaminoalkylamines in phenol at 100°C.




SCHEME 3. (a) EtOH, rt, 65%; (b) PPA, 160–170°C, 2 h, 40%; (c) Se, 300°C, 6 h, 58%.

SCHEME 4. (a) AmOH,  $H^+$ ,  $130^\circ C$ , 1.5 h, 40%.

The double Ullmann-amine coupling of *p*-phenylenediamine with 2-chlorobenzoic acid followed by two acid-catalyzed Friedel-Crafts acylations afforded quino[3,2-*a*]acridone **13** (52JCS1874). A similar regioselectivity was observed when 1,4-diiodobenzene was coupled with aminoacetophenone and the resultant diketone was treated with  $H_2SO_4$  to give quino[3,2-*a*]acridine **14** (85LA501). The quino[3,2-*a*]acridine **15** was obtained after dehydrogenation of the minor product from *p*-phenylenediamine and 2-formylcyclohexanone (see Section II,B,1 on pyrido[2,3-*b*]acridines) (74IJC1324).

We have prepared pyrido[3,2-*a*]acridines, **20** and **21** (96TH1), by Lewis acid-catalyzed cyclization of enamines **18**, formed by the condensation of 6-aminoquinoline **16** with 2-cyano-**17a** ( $Z = CN$ ) or 2-ethoxycarbonylcyclohexanone **17b** ( $Z = CO_2Et$ ), to give the tetrahydropyrido[2,3-*a*]acridines **19**. Oxidation of these tetrahydro derivatives, with palladium on charcoal, gave the fully aromatic systems **20** (Scheme 5). Oxidation of the amino derivative **19a** also resulted in the formation of some of the deaminated product **21**.






SCHEME 5. **a** X = NH<sub>2</sub>, **b** X = OH. (a) PhCH<sub>3</sub>, reflux; (b) AlCl<sub>3</sub>, 190°C; (c) Pd-on-C, 270–300°C.



The synthesis of some hexa- and heptacyclic molecules **24** and **25** containing a pyrido[3,2-*a*]acridine nucleus has been reported, the principal step being the ring closure of anthraquinone-derived precursors **22** and **23** (Scheme 6) (84KGS962).

### 3. Pyrido[3,4-*a*]acridines (Benzo[*j*][2,7]phenanthrolines)

No natural or synthetic compounds based on this ring system **26** have been reported.



SCHEME 6. (a) PPA, 170°C, 96%; (b) PPA, 180°C, 79%.



#### 4. Pyrido[4,3-a]acridines (*Benzo[j][3,7]phenanthrolines*)


No natural or synthetic compounds based on this ring system **27** have been reported.

### B. PYRIDO[*b*]ACRIDINES





The auxiliary pyridine ring is fused at bond *b* of the acridine nucleus in this class of pyridoacridines and, depending on the position of nitrogen in the auxiliary pyridine, four different types of pyrido[*b*]acridines are possible.

### 1. *Pyrido[2,3-*b*]acridines*

This ring system can be seen in the pentacyclic alkaloids: ascididemin **28**, 2-bromoleptoclinidone **29**, 11-hydroxyascididemin **30**, 8,9-dihydro-11-hydroxyascididemin **31**, calliactine **32**, the heptacyclic eilatin **33**, and the octacyclic biemnadin **34**. (See Section II,D,1 on pyrido[2,3-*kl*]acridines.)




- 28**  $R^1 = R^2 = H$   
**29**  $R^1 = Br, R^2 = H$   
**30**  $R^1 = H, R^2 = Br$



**31****32****33****34**

The organic pigments, the linear-*trans*-quinacridones, such as **36**, also possess this ring system. These quinacridones can be used in printing ink and as a colorant for plastics (67CRV1). They also exhibit photovoltaic and photoconductive properties (84CL1305; 87CL609). A large number of quinacridones have been synthesized. The synthetic methods have been reviewed by Labana and Labana (67CRV1). The most useful method involves the dehydrogenation of dihydroquinones, such as **35**, prepared from diethyl 2,5-dioxo-1,4-cyclohexanedicarboxylate and anilines (Scheme 7).

Some soluble quinacridones **37** have been prepared by applying this strategy (92JHC167). The introduction of long alkylthio groups into the 4 and 11 positions weakened the intermolecular hydrogen bonding and increased the solubility in different solvents. Diethyl 2,5-dioxo-1,4-cyclohexanedicarboxylate, on acid-catalyzed condensation with 2-aminobenzophenone followed by dehydrogenation with chloranil, afforded quinacridine **38** (88JHC1063).




SCHEME 7. (a) Heat; (b) e.g., chloranil.

**37****38**


The synthesis of isoquino[3,4-*b*]acridine **40** from the interaction of *p*-phenylenediamine with 2-formylcyclohexanone, followed by ring closure (after *in situ* rearrangement) and then dehydrogenation of **39**, has been reported by Berde *et al.* (72IJC332). Further examination of the cyclodehydration reaction also gave octahydroquino[3,2-*a*]acridine **41** as the minor product, which was then dehydrogenated to provide quino[3,2-*a*]acridine **15** (Scheme 8) (74IJC1324).

## 2. Pyrido[3,2-*b*]acridines

Morton *et al.* (93H2757) have described a synthesis of pyrido[3,2-*b*]acridones **43** and **44** starting from 3-amino-4-methylacridin-9(10*H*)one **42** (Scheme 9). Both compounds were found to be inactive against cultured




SCHEME 8. (a) EtOH, rt, 77%; (b) PPA, 180°C, 3 h, 51% (**39**), 14% (**41**); (c) Se, 300–330°C, 5–10 h, 25% (**40**), 38% (**15**).



SCHEME 9. (a) NaBH<sub>4</sub>, AcOH, 10 h, 75%; (b) EtOCH=C(CO<sub>2</sub>Et)<sub>2</sub>, 155–160°C, 1.5 h.; (c) PPE, 120–125°C, 1.5 h, 72% (b,c); (d) NaOH, EtOH, 2 h, 67.5%.

L1210 cells at concentrations up to  $10\ \mu\text{M}$  and showed negligible antibacterial activity.

The acid-catalyzed conversion of *N,N'*-bis(2'-carboxyphenyl)-1,3-diaminobenzene to quino[3,2-*b*]acridone **45** has been described in a patent (64USP3124581). Kumar and Jain [79IJC(B)623] have reported the synthesis of the octahydroquinolino[*b*]quinoline **46** from the base-catalyzed condensation of *N*-benzoyldecahydroquinolin-7-one with 2-aminobenzaldehyde.




### 3. Pyrido[3,4-*b*]acridines

The synthesis of decahydropyrido[3,4-*b*]acridine **47**, by a Friedländer reaction, and its opioid-antagonistic activity ( $\text{IC}_{50} = 54\ \text{nM}$ ) has been claimed [92JAP(K)92/275288].

### 4. Pyrido[4,3-*b*]acridines

Pyridoacridine alkaloids, eudistone A **48** and B **49**, possess this ring as a part of their structures (see pyrido[2,3,4-*kl*]acridines).




## C. PYRIDO[*c*]ACRIDINES (BENZO[*b*]PHENANTHROLINES)

The auxiliary pyridine is fused at bond *c* of the acridine nucleus. Depending upon the position of the nitrogen in the auxiliary pyridine ring, four different types of pyrido[*c*]acridine are possible.

### 1. Pyrido[2,3-*c*]acridines (Benzo[*b*][1,7]phenanthrolines)


Among the pyridoacridine alkaloids, meridine **50** and cystodamine **51** exhibit this ring skeleton (see Section II,D,1 on pyrido[2,3,4-*k*l]acridines). This ring pattern can also be observed in quino[*a*]acridines **6** and **9** and triquinobenzene **5** (see Section II,A,1 on pyrido[2,3-*a*]acridines).




**50** R = OH

**51** R = NH<sub>2</sub>

In search of potential anti-malarial agents, Dobson *et al.* (48JCS123) prepared 7,10-dichlorobenzo[*b*][1,7]phenanthroline **52** by the route described in Scheme 1, but with 5-aminoquinoline **48** as a precursor of 7-diethylaminopropylamino-10-chlorobenzo[*b*][1,7]phenanthroline **53**. No significant activity was observed when compound **53** was tested against *Plasmodium gallinaceum* (*in vivo*).




**52**



**53**


The coupling reaction between 5-aminoquinoline **54** and 2-chlorobenzoic acid gave a very poor yield (5%) of quinolyanthranilic acid **56**. With diphenyliodonium-2-carboxylate **55**, the yield increased to 80%. Quinolyanthranilic acid **56** was then converted to the sulfonamide **57** after cyclization with POCl<sub>3</sub> (Scheme 10) (87MI1). The sulfonamide **57** showed negligible activity against L1210 leukemia cells in culture, against P388 leukemia *in vivo*, and against the Lewis lung solid tumor.

Wardani and Lhomme (93TL6411) reported two routes for the synthesis of 10-aminobenzo[*b*][1,7]phenanthroline **64** from 3,6-diaminoacridine (proflavine) **58**. In first route the proflavine **58** was monoacylated to give **59**. Activation of the free amino group was achieved by tosylation. Alkylation of the monoacetyl monotosyl proflavine **60** with 3-bromopropionaldehyde ethylene acetal gave the intermediate **61**. Acidic treatment afforded 10-aminobenzo[*b*][1,7]phenanthroline **64** in an 18% overall yield starting from



SCHEME 10. (a)  $\text{Cu}^{2+}$  ( $\text{CH}_3\text{COO}^-$ )<sub>2</sub>, *N*-methylpyrrolidone, 95°C, 12 h, 80%; (b)  $\text{POCl}_3$ ,  $\Delta$ ; (c) 4-amino-3-methoxymethanesulfonanilide,  $\text{H}^+$ , MeOH.

proflavine **58** (Scheme 11). The second route involves the Skraup cyclization. The monoacylated proflavine **59** was reacted with acrolein diethyl acetal in refluxing acetic acid. The resultant mixture of **62** and **63** was treated





SCHEME 11. (a)  $\text{Ac}_2\text{O}$ ,  $\text{EtCO}_2\text{H}$ , 20°C, 10 h, 83%; (b)  $\text{TsCl}$ , pyridine,  $\text{Et}_3\text{N}$ , 4°C, 10 h, 65% (**60**); (c) DMF,  $\text{K}_2\text{CO}_3$ ,  $\text{BrCH}_2\text{CH}_2\text{CH}(\text{OCH}_2)_2$ , 80°C, 3 h, 72%; (d)  $\text{H}_2\text{SO}_4$ , 1 h, 40%; (e)  $\text{AcOH}$ ,  $\text{CH}_2=\text{CHCH}_2\text{CH}(\text{OC}_2\text{H}_5)_2$ , reflux, 3 h; (f) DDQ,  $\text{AcOH}$ , 100°C, 15 min.; (g) 4 *M*  $\text{HCl}$ , 80°C, 1 h, 40% (e,f,g).



with DDQ in acetic acid to afford **63** as the sole product. Deprotection with 4 M HCl produced 10-aminobenzo[*b*][1,7]phenanthroline **64** (Scheme 11). The Skraup synthesis of dipyridoacridine **65** from proflavine **58** has also been reported [67JCS(C)1415].


The synthesis of a number of benzo[*b*][1,7]phenanthroline anticancer agents from 10-aminobenzo[*b*][1,7]phenanthroline **64** has been claimed (91MIP1). Thus, 11-formyl-10-hydroxybenzo[*b*][1,7]phenanthroline **66** exhibited cytotoxicity, with an  $IC_{50}$  of 6.5  $\mu M$ , against L1210 leukemia cells.

**65****66**


A large number of 1-hydroxy-2-ethoxycarbonylbenzo[*b*][1,7]phenanthrolines **68** have been synthesized from 3-aminoacridines **67** by using the route shown in Scheme 12, and potent antimicrobial activities and low toxicities have been claimed (78USP4060527).

Reisch *et al.* (93JHC981) described two different methods for the synthesis of 4-azaacronycine **71**. One method involves the fusion of 1,3-dihydroxy-10-methyl-9(10*H*)-acridone **69** with 3-amino-3-methylbut-1-yne in the presence of  $CuCl_2$  in a closed ampule, followed by methylation (Scheme 13). The second method involves the *N*-alkylation of 3-amino-1-methoxy-10-methyl-9(10*H*)-acridone **70** with 3-chloro-3-methylbut-1-yne, followed by *in situ* cyclization (Scheme 13).

We prepared a range of pyrido[2,3-*c*]acridines **74** by the base- or acid-catalyzed cyclization of the corresponding enamines **72**, followed by




SCHEME 12.  $R^1, R^2, R^3 = H, \text{alkyl, aryl, alkylamino, alkylthio, nitro, cyano, alkylsulfonyl, etc.}$  (a)  $EtOCH=C(CO_2Et)_2, \Delta$ ; (b)  $Ph_2O, 260^\circ C$ .




SCHEME 13. (a)  $\text{CuCl}_2$ , heat, closed ampule; (b) methylation, 10% (a,b); (c) DMF,  $\text{K}_2\text{CO}_3$ , KI,  $120^\circ\text{C}$ , 8 h,  $\text{N}_2$ , 20%.

oxidation of the dihydro derivatives **73** (Scheme 14) (96TH1). The aminopyrido[2,3-*c*]acridine **74a** was tested for the inhibition of the spontaneous proliferation of a human gastric carcinoma cell line, MKN 45, and had an  $\text{IC}_{50} < 1 \mu\text{mol dm}^{-3}$ , but was noncytotoxic (95BRP9425409, 95MIP1).

Buu-Hoï [67JCS(C)213] used a quite different method for the construction of the benzo[*b*][1,7]phenanthroline ring system. Condensation of 2-naphthol with 5-aminoquinolines **75** and paraformaldehyde generated naphthaleno[*b*][1,7]-phenanthrolines **76** (Scheme 15).






SCHEME 14.  $\text{R} = \text{H}$  or  $\text{OMe}$ ,  $\text{R}^1 = \text{H}$  or  $\text{OH}$ ,  $\text{R}^2 = \text{H}$  or  $\text{OH}$ . (a)  $\text{NaNH}_2$ , DME, reflux, 3 h; (b)  $\text{H}_3\text{PO}_4$ ,  $150\text{--}160^\circ\text{C}$ ; (c)  $\text{MnO}_2$ , DMF, reflux.



SCHEME 15. (a) Paraformaldehyde, 250°C, 17% (R = H), 43% (R = Me).


## 2. Pyrido[3,2-*c*]acridines (Benzo[*b*][1,10]phenanthrolines)

Eilatin **33** and eudistone A **48** and B **49** are pyridoacridine alkaloids that possess this ring skeleton. This ring system is also found in a synthetic isomer, isoascidemin **77**, of ascididemin **28** (see pyrido[*b*]acridines and pyrido[2,3,4-*kl*]acridines). Three other alkaloids, the plakinidines (A–C) **78–80** from *Plakortis* sponge, also share this ring system (90JA1, 90TL3271).


**77****78** R = H**79** R = Me**80**

The synthesis of a number of 7-(mono and dialkylaminoalkylamino) derivatives **81** (46JCS151; 47JA1543; 62JMC546; 72JMC739), and 7-anilino derivatives **82** (87MI1; 93JPS262) of benzo[*b*][1,10]phenanthrolines by the route described in Scheme 1, but using 8-aminoquinolines instead of 7-aminoquinoline, and their biological evaluation has been reported. Benzo[*b*][1,10]phenanthroline-7-ones **83** were also separated during these syntheses. Some of the alkylamino derivatives **81** were found to be highly effective against ascites tumors at low dosage (72JMC739). The anilino derivatives **82** were found to be active against L1210 murine leukemia (93JPS262), P388 leukemia cells (87MI1), and a Lewis lung solid tumor (87MI1). Using the same strategy, Wilkinson and Finar (48JCS288) have prepared some 7-aminobenzo[*b*][1,10]phenanthrolines **84** and related compounds. None of the amino derivatives showed significant antibacterial or


trypanocidal activity. The same route was used to prepare 7-dimethylamino-propylthiobenzo[*b*][1,10]phenanthroline **85** as a potential platelet aggregation inhibitor (72JMC61). No significant activity was observed.

**81**


$R^1 = \text{H, OMe}; R^2 = \text{H, Cl}$   
 $R^3 = \text{H, alkyl, chloroalkyl, etc.}$   
 $R^4 = \text{alkyl, chloroalkyl, etc.}$

**82**


$R^1 = \text{H, Me}_2\text{N, MeSO}_2\text{NH, PhSO}_2\text{NH}$   
 $R^2 = \text{H, MeO, MeNH, Me}_2\text{N}$

**83**



$R^1 = \text{H, MeO}; R^2 = \text{H, Cl}$

**84**


$R = \text{H, F, MeO}$

**85**

The synthesis and antileishmania activity of 8,9,10,11-tetrahydrobenzo[*b*][1,10]phenanthroline-7(12*H*)-one **86** and 7-chloro-8,9,10,11-tetrahydrobenzo[*b*][1,10]phenanthroline **87** has been described by Satti *et al.* [93-IJC(B)978].


**86****87**

A quite different approach to the construction of the benzo[*b*][1,10]-phenanthroline ring system, for example, **90**, was used by Koft and Case




SCHEME 16. (a)  $\text{HOCH}(\text{CH}_2\text{OH})_2$ ,  $\text{H}_3\text{AsO}_4$ ,  $\text{H}_2\text{SO}_4$ ,  $\text{H}_2\text{O}$ ,  $130\text{--}140^\circ\text{C}$ , 2.5 h, 53%; (b)  $\text{POCl}_3/\text{PCl}_5$ , reflux, 5 h, 81%; (c) 10% Pd on charcoal,  $\text{H}_2$ , EtOH, KOH, 3 h, 36%; (d) Na-Hg, EtOH,  $\text{H}_2\text{O}$ ,  $\text{NaHCO}_3$ , 4–5 h, 47%; (e)  $\text{H}_2\text{C}=\text{CHCHO}$ ,  $\text{H}_3\text{AsO}_4$ ,  $\text{H}_3\text{PO}_4$ ,  $100\text{--}110^\circ\text{C}$ , 1 h, 8.5%.

(62JOC865). They used 4-aminoacridone **88** and 4-aminoacridine **89** as the starting materials (Scheme 16). The Skraup synthesis was also applied to the preparation of quino[8,7-*b*][1,10]phenanthroline **91** and its 7-oxo derivative **92** (62JOC865).




Condensation of 5,6-dihydroquinolin-8(7*H*)-ones, such as **93**, with 2-aminoaromatic aldehydes, such as **94**, afforded dihydrobenzo[*b*][1,10]phenanthrolines, such as **95** (Scheme 17), as precursors of a number of interesting compounds (88JA3673; 90AGE923; 93JOC1666). Condensation of 5,6-dihydroquinolin-8(7*H*)-one **93** with ternary iminium perchlorates, for example, **96**, in the presence of ammonium acetate has been reported to give compounds such as **97** that contain the benzo[*b*][1,10]phenanthroline ring system (Scheme 18) (93TL1775).




SCHEME 17


Cyclocondensation of 2-aminobenzoylformic acid **98** and cyclohexane-1,2-dione dioxime **99**, followed by decarboxylation with concomitant dehydrogenation of the diacid **100**, gave quino[3,2-*c*]acridine **101** (70JPR1105). The same skeleton **102** was obtained from the Ullmann-amine coupling reaction of 2-aminobenzophenone and 1,2-diiodobenzene, followed by ring closure (85LA1501).



In a search for dyestuffs, *o*-phenylenediamine was reacted with 1-nitroanthraquinone and the resulting bisquinone **103** was cyclized with H<sub>2</sub>SO<sub>4</sub> to give **104** (Scheme 20) (74MI1).




SCHEME 18



SCHEME 19. (a)  $\text{H}_2\text{O}$ , reflux, 22%; (b) paraffin oil,  $\text{N}_2$ , 320°C, 93%.


### 3. Pyrido[3,4-c]acridines (Benzo[*b*][1,8]phenanthrolines)

The pentacyclic pyridoacridine alkaloids (amphimedine **105**, neoamphimedine **106**, petrosamine **107**, and debromopetrosamine **108**) also contain this ring skeleton (see pyrido[2,3-*kl*]acridines).




SCHEME 20. (a)  $\text{Na}_2\text{CO}_3$ , Cu-bronze,  $\text{PhNO}_2$ ; (b) 70%  $\text{H}_2\text{SO}_4$ , 160°C, 73% (a,b).

Elslager and Tendick (62JMC546) prepared 7-chloro[*b*][1,8]phenanthrolines **109**, via Ullmann-amine coupling followed by cyclization, a route described in Scheme 1, but with 5-aminoisoquinoline, and converted them to potential amebicidal 7-(mono- and dialkylaminoalkylamino)benzo[*b*][1,8]phenanthrolines **110**.



7-Chlorobenzo[*b*][1,8]phenanthroline **109** ( $X = \text{H}$ ) was later used by Creech *et al.* (72JMC739) to prepare nitrogen mustard derivatives **111** of benzo[*b*][1,8]phenanthroline as antitumor agents, and by Sánchez *et al.* (90H2003) to prepare a series of 7-anilino derivatives of benzo[*b*][1,8]phenanthroline **114**. These anilino derivatives **114** were also prepared to cyclization of 2-(isoquinoline-5'-yl)benzanilides **113** with  $\text{POCl}_3$  (Scheme 21)




SCHEME 21.  $R = \text{F, OMe, NMe}_2, \text{NHCOMe, SO}_2\text{Me, SO}_2\text{NH}_2, \text{NHSO}_2\text{Ph, NHSO}_2\text{-}p\text{-C}_6\text{H}_4\text{Me}$ . (a)  $\text{POCl}_3$ , reflux, 39%; (b)  $\text{H}_2\text{SO}_4$ , heat, 60%; (c)  $\text{PCl}_5$ ; (d)  $\text{ArNH}_2$ , EtOH,  $\text{MeSO}_3\text{H}$ ; (e)  $\text{ArNH}$ ,  $\text{C}_6\text{H}_6$ , moderate; (f)  $\text{POCl}_3$ , reflux, 42–62%, (c,d,f); (g)  $\text{POCl}_3$ ,  $\text{PCl}_5$ ; (h)  $\text{H}_3\text{O}^+$ .




(90H2003). Biological evaluation of these anilino derivatives **114** along with 7-chlorobenzo[*b*][1,8]phenanthroline **109** ( $X = H$ ) and benzo[*b*][1,8]-phenanthroline-7(12*H*)-one **112** showed a tight binding tendency with DNA. Significant inhibition of L1210 murine leukemia cells by benzo[*b*]-[1,8]phenanthroline-7(12*H*)-one **112** demonstrated that the anilino side chain was unnecessary for activity. No change in the activity was observed on substitution of electron-withdrawing or electron-donating substituents onto the aniline ring. 7-Chlorobenzo[*b*][1,8]phenanthroline **109** was found to be inactive (93JPS262).

Denny and Baguley (87MI1) used diphenyl iodonium-2-carboxylate **55** as an *N*-arylation agent in an Ullmann-amine coupling step, as described in Scheme 9, but with 5-aminoisoquinoline, and prepared some 7-anilino-benzo[*b*][1,8]phenanthrolines **115**. None of the anilino derivatives showed significant activity against the P388 leukemia and Lewis lung solid tumor, although they displayed tight binding with DNA. Another derivative **116** of benzo[*b*][1,8]phenanthroline was tested as an antinociceptive agent but was found to be inactive (91MI1).




R = MeO, MeNH, Me<sub>2</sub>N

**115**




**116**

The Ullmann-Fetvadjan reaction has been applied to 5-aminoisoquinoline to prepare naphtho[2,1-*b*][1,8]phenanthrolines, such as **117** (Scheme 22) [67JCS(C)213; 80JCS(P1)1233].



**117**

SCHEME 22




SCHEME 23. (a)  $\text{Na}_2\text{CO}_3$ , Cu,  $\text{PhNO}_2$ , reflux, 59%; (b) MCPBA,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$  to rt, 87%; (c)  $\text{H}_2\text{SO}_4$ , AcOH,  $130^\circ\text{C}$ , 37%.

In the development of pyridone fused acridines, Kennedy *et al.* used a sulfoxide-based route to produce 3,7-dimethyl-5-methoxy-1-phenylthio-1,2,3,4-tetrahydro-2-oxobenzo[*b*][1,8]phenanthroline **118** (Scheme 23) [91-JCS(P1)2499].

#### 4. Pyrido[4,3-*c*]acridines (Benzo[*b*][1,9]phenanthrolines)




Kubo and Nakahara have reported the formation of an isomer **119** of amphimedine **105**, which possesses this novel ring system (Scheme 24) (88H2095).



SCHEME 24. (a) 10% Pd/C,  $\text{Et}_3\text{N}$ , MeOH, rt 20 h, 18%.

D. PYRIDO[*kl*]ACRIDINES

In this class, the extra pyridine ring is fused at bonds *k* and *l* of the acridine. Three types of pyrido[*kl*]acridines **120** are possible, depending on the position of the nitrogen in the fused pyridine ring.








1. *Pyrido[2,3,4-*kl*]acridines*

a. *Isolation and Biological Activity.* The polycyclic aromatic alkaloids based on the pyrido[2,3,4-*kl*]acridine skeleton are members of a fast-growing class of marine sponge and ascidian (tunicate) metabolites. More than 50 alkaloids of this class have been isolated and characterized during the past 12 years.

Norsegoline **121** is the simplest member of this class isolated from *Eudisotoma* sp., a tunicate (88TL3861; 89JOC5331). Other tetracyclic alkaloids include varamines A **122** and B **123**, lissoclins A **124** and B **125**, diplamine **126**, cystodytins A–J **128–137**, and pantherinine **138**. Varamines A **122** and B **123**, isolated from the ascidian *Lissoclinium vareau*, are brilliant red pigments that were found to be cytotoxic toward L1210 murine leukemia, with  $IC_{50}$  values of 0.03 and 0.05  $\mu\text{g/ml}$ , respectively (89JOC4256). Lissoclins A **124** and B **125**, isolated from *Lissoclinium* sp. collected from the Great Barrier Reef, Australia, did not show significant activity against the fungus *Candida albicans* (94JOC6600). Diplamine **126**, another tetracyclic alkaloid isolated from the tunicate *Diplosoma* sp., showed cytotoxicity towards L1210 murine leukemia cells ( $IC_{50} = 0.02 \mu\text{g/ml}$ ) (89TL4201) and human colon cancer cell lines ( $IC_{50} < 1.4 \mu\text{M}$ ) (94JMC3819). DNA intercalation and topoisomerase II inhibition ( $IC_{90} = 9.2 \mu\text{M}$ ) by diplamine **126** was also observed (94JMC3819). The isolation of another homolog of this series, “isobutyramide” **127**, from an unidentified tunicate has been reported (93CRV1825).



The tunicate *Cystodytes dellechiaiei* is a very rich source of pyrido[2,3,4-*kl*]acridine alkaloids. Nine tetracyclic alkaloids, cystodytins A–I **128–136**, have been isolated from this species (88JOC1800; 91JNP1634). Except for cystodytin C **130**, all other cystodytins were isolated as inseparable isomeric pairs (3.5:1) of cystodytins,  $\beta,\beta$ -dimethylacrylate and tiglate amides

[cystodytins A **128** and B **129**, D **131** and E **132**, F **133** and G **134**, and H **135** and I **136**]. Cystodytin J **137**, isolated from a Fijian *Cystodytes* sp., was found to be a good DNA intercalator, a potent inhibitor of topoisomerase II ( $IC_{90} = 8.0 \mu M$ ), and a potent cytotoxin against the human colon tumor cell line HCT 116 ( $IC_{50} = 1.6 \mu M$ ) (94JMC3819). Cystodytins A–C **128–130** showed powerful  $Ca^{2+}$  releasing activity in sarcoplasmic reticulum and cytotoxicity against L1210 murine leukemia cells ( $IC_{50} \sim 0.2 \mu g/ml$ ) (88JOC1800). Cytotoxic activity ( $IC_{50}s = 0.68\text{--}1.4 \mu g/ml$ ) against both



L1210 cells and epidermoid carcinoma KB cells was also observed for other cystodytins (91JNP1634). A bromo-substituted tetracyclic alkaloid pantherinine **138** has been isolated from the ascidian *Aplidium pantherinum*, and a moderate cytotoxic activity ( $ED_{50} = 4.5 \mu\text{g/ml}$ ) against P388 murine leukemia cells has been reported by Kim *et al.* (93JNP1813).

Pentacyclic alkaloids contain an additional fused heterocyclic ring, such as tetrahydropyridine, pyridine (pyridone), thiazine, or thiazole. Calliactine was shown to be a pyridoacridine alkaloid (87T4023) nearly half a century after its isolation from the Mediterranean anemone *Calliactis parasitica* in 1940 (40BSF608). Although the exact structure of the alkaloid is still unclear, the structural analysis shows that it contains an additional tetrahydropyridine ring (87T4023). The structure of neocalliactine acetate **139**, derived from calliactine by heating with water (aromatization) followed by reaction with acetic anhydride, has been established by a total synthesis (92LA1205; 93H943). On the basis of spectral data and the establishment of the neocalliactine acetate **139** structure, structure **32** is the most favorable among the four proposed by Cimino *et al.* for calliactine (87T4023).


**139****32**

Amphimedine **105**, the first pyridoacridine to be fully characterized, was isolated from the Guamanian sponge, *Amphimedon* sp. (83JA4835). Its regioisomer, neoamphimedine **106**, was isolated from the Micronesian sponge *Xestospongia* cf. *carbonaria*, along with amphimedine **105** and debromopetrosamine **108** (93CRV1825). Neoamphimedine **106** was found to be a potent inhibitor of mammalian topoisomerase II ( $IC_{50} = 1.3 \mu\text{M}$ ), but not of topoisomerase I. Intercalation of neoamphimedine **106** into DNA was observed with a  $K_m$  of  $2.8 \times 10^5 \text{ M}^{-1}$  and a binding site size of 1.8 base pairs per molecule. Amphimedine **105**, debromopetrosamine **108**, and petrosamine **107** (from the sponge (*Petrosia* sp.)) have little effect on topoisomerase I or II activity, despite comparable cytotoxicity (40BSF608).

Ascididemin **28**, from *Didenum* sp. (88TL1177), and 2-bromoleptoclinidone **29**, from *Leptoclinides* sp. (87JA6134; 89TL1069), were the first polycyclic aromatic metabolites to be isolated from ascidians. Both compounds show cytotoxicity toward leukemia cell lines with  $IC_{50}$ s of  $0.4 \mu\text{g/ml}$ , whereas ascididemin also inhibits topoisomerase II ( $IC_{50} = 75 \mu\text{M}$ ) and causes release of calcium ions in the sarcoplasmic reticulum (91JOC804). Two


regioisomers, meridine **50** and 11-hydroxyascididemin **30** were isolated from the ascidians *Amphicarpa meridina* and *Leptoclinides* sp., respectively (91JOC804). Both of these isomers, along with 8,9-dihydro-11-hydroxyascididemin **31**, have also been isolated from the Okinawan marine sponge *Biemna* sp. (93T8337). Meridine **50** exhibits cytotoxicity against P388 murine leukemia cells ( $IC_{50} = 0.3\text{--}0.4\text{ }\mu\text{g/ml}$ ) (91JOC804), and 8,9-dihydro-11-hydroxyascididemin **31** exhibits cytotoxicity against human epidermoid carcinoma KB ( $IC_{50} = 0.2\text{ }\mu\text{g/ml}$ ) and murine lymphoma L1210 ( $IC_{50} = 0.7\text{ }\mu\text{g/ml}$ ) cells *in vitro* (93T8337). A new pentacyclic alkaloid, cystodamine **51**, has been isolated from the ascidian *Cystodytes dellechiaiei* (94TL7023). The new alkaloid shows cytotoxicity against CEM human leukemic lymphoblasts ( $IC_{50} = 1.0\text{ }\mu\text{g/ml}$ ).

Shermilamines A **140**, B **141**, and C **142** are thiazinone-containing pentacyclic alkaloids isolated from the purple tunicate *Trididemum* sp. (**140** and **141**) (88JOC4619; 89JOC4231) and a Fijian *Cystodytes* sp. (**141** and **142**) (94JMC3819). Shermilamine B **141** has been reported to exhibit cytotoxicity against KB cells ( $IC_{50} = 5.0\text{ }\mu\text{g/ml}$ ) (91JOC804) and HCT cells ( $IC_{50} = 13.8\text{ }\mu\text{M}$ ) (94JMC3819), and shermilamine C **142** exhibits cytotoxicity against HCT cells ( $IC_{50} = 16.3\text{ }\mu\text{M}$ ). Shermaline B **141** and C **142** also inhibit topoisomerase II ( $IC_{90} = 118\text{ }\mu\text{M}$  and  $138\text{ }\mu\text{M}$ , respectively) (94JMC3819).



A series of pentacyclic aromatic alkaloids that incorporate a thiazole ring were isolated from sponges, ascidians (tunicates), and the lamelliariidae mollusk *Chelynotus semperi*. Dercitin **143** (88JA4356; 92JOC1523), a metabolite of deep-water sponge *Dercitus* sp., exhibits a remarkable biological activity. It inhibits a variety of cultured cell clones at nanomolar concentrations and exhibits antitumor activity (in mice) and antiviral activity (against herpes simplex and A-59 murine corona virus) at micromolar concentrations. Burres *et al.* (89MI2) observed the inhibition of both DNA and RNA syntheses by dercitin **143** by up to 83% at 400 nM and inhibition of protein synthesis to a lesser extent. Inhibition of DNA polymerase and DNase nick translation at 1.0 nM by dercitin **143** was also reported. Dercitin showed a

potent intercalation into nucleic acids and little inhibition of topoisomerases (89MI2). New structural types of anti-HIV drugs based on dercitin have been proposed by Taraporewala *et al.* (92JMC2744).




- 144** R = Me<sub>2</sub>N
- 145** R = MeNH
- 147** R = Me<sub>2</sub>CHCH<sub>2</sub>CONH
- 148** R = EtCONH
- 149** R = MeCONH
- 150** R = Me<sub>2</sub>C=CHCONH


Nordercitin **144**, dercitamine **145**, and dercitamide (kuanoniamine C) **148** were also isolated from *Dercitus* sp. and *Stelletta* sp., along with dercitin **143** (89TL4359; 92JOC1523). Kuanoniamines A–D **146–149** and shermilamine B **141** were found in the mollusc *Chelynotus semperi* and its prey, an unidentified tunicate (90JOC4426). A new kuanoniamine, the dehydrokuanoniamine B **150**, has been isolated along with kuanoniamine D **149** and other alkaloids from a Fijian *Cystodytes* sp. (94JMC3819). Kuanoniamines A **146**, B **147**, and D **149** exhibit cytotoxicities against KB cells, with IC<sub>50</sub> values of 2.0, >10, and 1.0 μg/ml, respectively (90JOC4426). Cytotoxicities against HCT cells (IC<sub>50</sub> 7.8 and 8.3 μM) for dehydrokuanoniamine B **150** and kuanoniamine D **149** were also reported (94JMC3819). Kuanoniamine D **149** can form complexes with Fe(II), Co(II), Cu(II), and Zn(II) ions (92JOC1523).

Two hexacyclic alkaloids, cyclodercitin **151** and stelletamine **152** from *Stelletta* sp. (89TL4359; 92JOC1523), and three optically active hexacyclic alkaloids, segoline A **153**, segoline B **154**, and isosegoline A **155** from the Red Sea tunicate, *Eudistoma* sp., have been isolated along with tetra- and pentacyclic alkaloids (88TL3861; 89JOC5331). Another interesting compound isolated from *Eudistoma* sp. was the symmetrical, heptacyclic eilatin **33** (88TL6655; 94JMC3819). Cytotoxicity (IC<sub>50</sub> = 5.3 μM) of eilatin **33** against HCT cell lines has been reported (94JMC3819). This compound was also found to regulate cell growth and to affect cAMP-mediated cellular processes (93MI1). Because of the presence of the 1,10-phenanthroline skeleton, eilatin **33** is capable of chelating metal ions such as Ni(II) (88TL6655).


Two octacyclic alkaloids, eudistones A **48** and B **49**, along with ascidide-min **28**, have been isolated from another tunicate of the genus *Eudistoma* (from the Seychelles) (91JOC5369). These compounds are optically active, but their absolute configurations are still unknown. Another octacyclic alkaloid, biemnadin **34**, isolated from the Okinawan marine sponge *Biemna*




151




152




33



153



154



155


sp., has been shown to exhibit cytotoxicity against human epidermoid carcinoma KB and murine lymphoma L 1210 cells *in vitro* (93T8337).

b. *Syntheses.* The biological activity and the novel ring systems of these pyridoacridine alkaloids make them appealing targets for synthesis. A number of approaches have been developed for the synthesis of these compounds.

*Imine formation.* An example of this route is Echavarren and Stille's use of a simple intramolecular imine formation between a quinone moiety and an amino group to complete the nucleus (Scheme 25) of amphimedine **105** (88JA4051). The quinone **159** was prepared by a palladium-catalyzed cross-coupling of 5,8-dimethoxyquinolin-4-yl triflate **157** (from 5,8-dimethoxyquinolin-4-one **156**) with 2-*t*-butoxycarbonyl-aminophenyl-trimethyltin **158**, followed by deprotection of the amino group, reprotection by the trifluoroacetyl group, and then oxidation with ceric ammonium nitrate (CAN). The aza-Diels–Alder reaction of the resultant quinone **159** with Ghosez's diene **160** afforded an intermediate **161**. Deprotection of the amino group with aq. HCl and *in situ* formation of the imine gave a precursor **162** of the amphimedine **105**, which was obtained by methylation with dimethyl sulfate.


Similar strategies have been employed by Kubo and Nakahara (88H2095) for the synthesis of amphimedine **105**; by Szczepankiewicz and Heathcock (94JOC3512) for the synthesis of diplamine **126**; by Nakahara *et al.* (93H1139) for the synthesis of eilatin **33**; by Gómez-Bengoia and Echavarren






SCHEME 25. (a)  $(\text{Tf})_2\text{O}$ , 2,6-lutidine,  $\text{CH}_2\text{Cl}_2$ , 92–95%; (b)  $\text{Pd}(\text{PPh}_3)_4$ ,  $\text{LiCl}$ , dioxane, 7 h,  $100^\circ\text{C}$ ; (c) TFA; (d) TFAA,  $(i\text{Pr})_2\text{NEt}$ , 82–87% (b,c,d); (e) CAN,  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ ,  $23^\circ\text{C}$ , 15 min; (f) THF,  $23^\circ\text{C}$ , 16 h; (g) pyridinium–HF, 48% (e,f,g); (h) 6 M HCl, THF aq.,  $70\text{--}80^\circ\text{C}$ , 86%; (i)  $\text{Me}_2\text{SO}_4$ ,  $\text{K}_2\text{CO}_3$ , DME, 96%.

(91JOC3497) for the synthesis of isoascididemin **77**, a regioisomer of the naturally occurring ascididemin **28**; and by Jolivet *et al.* for the synthesis of a series of quino- and pyranoquinoacridines, such as **163** and **164** [95JCS(P1)2333].






SCHEME 26. (a)  $\text{MeO}_2\text{CCH}_2\text{N}_3$ , NaOMe, MeOH,  $-10$  to  $0^\circ\text{C}$ , 48%; (b) xylene,  $140^\circ\text{C}$ , 78% (**167**), 19% (**168**); (c)  $\text{MnO}_2/\text{H}_2\text{SO}_4$ , 75%.

**Nitrene insertion.** A nitrene insertion reaction is central to many syntheses of pyridoacridine alkaloids and their analogues. For example, Labarca *et al.* [87JCS(P1)927] have reported a three-step synthesis of a pyridoacridine **169** starting from 2-methoxyacridine-9-carboxaldehyde **165** (Scheme 26). Cyclization of the vinyl azide **166** by thermolysis is believed to involve a nitrene insertion reaction, to give either **167** or **168**.

Ciufolini and his co-workers have completed the total syntheses of pyridoacridine alkaloids such as cystodytins A **128** (91JA8016), B **129** (91JA8016), and J **137** (92JA10081), diplamine **126** (92JA10081), dercitin **143** (92JA10081; 95JA12460), nordercitin **144** (92JA10081; 95JA12460), kuanoniamine D **149** (92JA10081; 95JA12460), and shermilamine B **141** (92JA10081) by using nitrene insertion methodology. Nitrene insertion is also involved in the Gellerman synthesis of the pyrido[2,3,4-*k*]acridines (92TL5577), and a similar approach was used by McKillop and his co-workers for the synthesis of norsegolone **121** and other analogs [92-JCS(CC)1453; 93JCS(P1)879].

**Cyclodehydration.** This route has been used by Bracher for the synthesis of ascididemin **28** (Scheme 27) (89H2093). Freshly prepared 2-aminoaceto-




SCHEME 27. (a)  $O_2$ ,  $Ce(SO_4)_2$ , 78%; (b)  $AcOH/H_2SO_4$ , 94%; (c)  $Me_2NCH(OEt)_2$ , DMF; (d)  $NH_4Cl$ ,  $AcOH$ , 59% (c,d).

phenone was used for oxidative amination of *p*-quinolinoquinone **170** in the presence of air and cerium ions, to give intermediate **171**, which cyclized to the linear pyridoacridine **172** on heating in a mixture of conc. sulfuric and acetic acids. Condensation of the side-chain methyl group of **172** with dimethylformamide diethyl acetal afforded an enamine **173**, which cyclized to ascididemin **28**.


The same strategy has been applied to the preparation of a number of pyridoacridine alkaloids, which include 2-bromoleptoclidinone **29** (90LA205), 11-hydroxyascididemin **30** (93H943) and kuanoniamine A **146** (93H943), and also for the synthesis of neocalliactine acetate **139** (92LA1205; 93H943) (a derivative of calliactine **32**).

**Biomimetic synthesis.** Kashman and his co-workers have reported novel biomimetic syntheses of pyrido[2,3,4-*kl*]acridines by the reaction of kinuramine **174** or its derivatives, such as **177**, and other analogs, such as **178**, with a variety of diones (e.g., **175**), quinones (e.g., **170**), and hydroquinones (e.g., **179**) (Scheme 28) (93TL1823; 93TL1827; 94S239, 94T12959). Using this strategy they have prepared a number of pyridoacridines, including the marine alkaloids, eilatin **33** (93TL1827), ascididemin **28** (94S239), their derivatives, and other analogs such as **176** and **180** (93TL1823; 94T12959).


**Miscellaneous syntheses.** Moody *et al.* (90TL4375; 92T3589) have described a synthesis of ascididemin **28** that involves the epoxidation of 1,10-phenanthroline **181**, ring opening of the epoxide **182** with 2-iodoaniline to afford the amino alcohol **183**, and oxidation followed by photocyclization of the *o*-iminoquinone **184** (Scheme 29).



SCHEME 28




SCHEME 29. (a) NaClO, aq.; (b) 2-iodoaniline, Et<sub>3</sub>Al, CH<sub>2</sub>Cl<sub>2</sub>, 79%; (c) Ba(MnO<sub>4</sub>)<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 83%; (d) *hν*, quartz, H<sub>2</sub>SO<sub>4</sub>, 32%.



SCHEME 30. (a)  $\text{Me}_3\text{SiCl}$ ,  $\text{Et}_3\text{N}$ , THF,  $60^\circ\text{C}$ ; (b) 4-pyridylithium,  $-40$  to  $20^\circ\text{C}$ , 2 h, 87% (a,b); (c)  $\text{NaN}_3$ , PPA,  $45^\circ\text{C}$ , 20 h, 69%; (d)  $\text{PCl}_5$ , DMF (cat.)  $\text{POCl}_3$ ,  $180^\circ\text{C}$ , 20 h; (e)  $\text{MeOS}_2\text{OF}$ ,  $20^\circ\text{C}$ , 40 min; (f)  $\text{KOH}$ ,  $\text{K}_3[\text{Fe}(\text{CN})_6]$ ,  $20^\circ\text{C}$ , 10 h; (g)  $\text{CuCN}$ , DMSO,  $150^\circ\text{C}$ , 4 h, 38% (d,e,f,g); (h) PPA,  $90^\circ\text{C}$ , 5 h, 35%.


A novel synthesis of amphimedine **105** has been reported by Prager *et al.* (89H847; 91AJC277). It involves an azido ring expansion of a pyridylazafuorenol **185**, by the Schmidt reaction, to 5-(4-pyridyl)benzo[*a*]-[2,7]naphthyridin-4-one **186**, and then refunctionalization to the  $\alpha$ -cyano precursor **187**, followed by cyclization in polyphosphoric acid (Scheme 30). Guillier *et al.* (95JOC292) have described a new synthesis of the intermediate **186**.

Taking advantage of the activity of the 9-position of acridines toward active methylenes, Gellerman *et al.* (92TL5577) have developed a



SCHEME 31. (a)  $\text{AmOH}$ , cat.  $\text{H}_2\text{SO}_4$ ,  $130^\circ\text{C}$ , 1.5 h.

method for the preparation of pyrido[2,3,4-*kl*]acridines starting from 1-aminoacridines. Thus, acid-catalyzed condensation of acetylacetone with 1-amino-4-methylacridine **188** gave a pyridoacridine **189** (Scheme 31).




## 2. Pyrido[3,4,5-*kl*]acridines

No natural or synthetic compounds based on this ring system **190** have been reported.


## 3. Pyrido[4,3,2-*kl*]acridines

Only a few examples of this ring system have been reported. Grout *et al.* [68JCS(C)2689] have cyclized *N*-acyl derivatives **191** of 9-aminobenzo[*a*]acridines to pyrido[4,3,2-*kl*]acridines **192** by heating with  $\text{AlCl}_3/\text{NaCl}$  at 200–220°C (Scheme 32).

The only natural product based on this ring system is necatorone **193**. This alkaloid was isolated from a toadstool, *Lactarius necator* (84TL3575). This fungal metabolite showed a considerable mutagenic activity in the Ames test. A synthesis of necatorone **193** involving oxidative cyclization has been reported (Scheme 33) (85TL5975).



SCHEME 32.  $\text{R}^1 = \text{H, Me}$ ;  $\text{R}^2 = \text{H, Me}$ .




SCHEME 33. (a)  $\text{POCl}_3$ ,  $\text{CH}_3\text{CN}$ , 85–93%; (b)  $\text{MnO}_2$ ,  $\text{C}_6\text{H}_6$ , reflux, 24 h, 90–98%; (c) 48%  $\text{HBr}$ , 64%; (d)  $\text{H}_2/\text{Pd}-\text{C}$ , 82–85%; (e) aq.  $\text{NaOH}$  (5%),  $\text{O}_2$ , 67%.

### III. Pyranoacridines


Only a few pyranoacridine ring systems have been reported in the literature.

#### A. PYRANO[2,3-*a*]ACRIDINES

The pentacyclic alkaloid bicyclo-*N*-methylatalaphylline **194**, isolated from *Atlantia monophylla* Correa, possesses this ring system as a part of its structure (72JOC3035). Formation of this ring system (e.g., **196**) from isoprene-containing acridone alkaloids or their derivatives (3-OH protected, e.g., **195**) has been reported (Scheme 34) [70T2905; 82P1771; 83JCS(P1)1681].



Bhavsar and his co-workers reported the formation of pyrano[2,3-*a*]acridin-2-ones, such as **199**, from 8-aryl-7-hydroxy-benzopyran-2-ones,




SCHEME 34


such as **197**, by using the Chapman–Mumm rearrangement of an imino ester **198** (Scheme 35) (87MI2, 87MI3).

We have described a novel method for the construction of this ring system that involves the condensation of 7-oxo-5,6,7,8-tetrahydroflavone **200** with ethyl anthranilate or anthranilonitrile, followed by base-catalyzed cyclization and then dehydrogenation of the dihydro derivatives, **201** and **203** (Scheme 36) [94JCS(P1)173]. 12-Amino-2-phenylpyrano[2,3-*a*]acridin-4-one APPA **204** was found to be a very potent inhibitor ( $\text{IC}_{50} = 1.9 \mu\text{mol dm}^{-3}$ ) of the EGF-dependent proliferation of DHER cells, and of the spontaneous proliferation of a human gastric carcinoma cell line, MKN 45, with an  $\text{IC}_{50}$  of  $0.1 \mu\text{mol dm}^{-3}$ . In addition, APPA **204** was tested against 60 cancer cell lines as part of the NCI Developmental Therapeutics Program and was shown to have an activity profile similar to that of known topoisomerase II inhibitors.

We have also developed an alternative synthesis [97JCS(P1) 601] of this ring system that utilizes the von Strandtmann flavone annellation procedure.


SCHEME 35. (a) Base, (b) heat, (c)  $\text{H}_3\text{O}^+$ .





SCHEME 36. (a) PTSA, toluene, reflux, 47%; (b) PTSA, toluene, reflux, 65%; (c) NaNH<sub>2</sub>, DME, reflux, 64% (**201**), 29% (**203**); (d) Hg(OAc)<sub>2</sub>, DMSO, 51%; (e) MnO<sub>2</sub>, toluene, reflux, 72%.

Thus, the esters **205** were treated with the dimsyl anion to give the  $\beta$ -ketosulfoxides **206**, which were cyclized to the pyranoacridinones **207** upon treatment with an aromatic aldehyde in the presence of piperidine (Scheme 37).







SCHEME 37. (a) <sup>-</sup>CH<sub>2</sub>SOCH<sub>3</sub>, DMSO; (b) ArCHO, piperidine, DMSO.

B. PYRANO[2,3-*c*]ACRIDINES

## 1. Isolation and Biological Activity

Most of the pyranoacridone alkaloids are based on this ring system. Acronycine (acronine) **208** was the first pyranoacridine alkaloid to be isolated, in 1948 by Hughes and co-workers from the bark of *Baurella simplicifolia* (*Acronychia baueri*, an Australian Rutaceae plant) [48NAT(L)223] and in 1949 by Lahey and Thomas from *Vepris amphody* (49MI1). The correct structure was established in 1966 by degradative studies supported by NMR studies (66AJC275, 66T3245) and finally by X-ray crystallographic studies [70AX(B)853]. Acronycine **208** has broad-spectrum antineoplastic activity (85MI1; 89MI1; 92MI1), although its poor solubility in aqueous media is a major hindrance to its development as a clinical agent. Efforts were continued to isolate more alkaloids based on this skeleton, from other plants of Rutaceae family and also through molecular variation, to improve the cytostatic activity of acronycine **208**. Other alkaloids based on this system include noracronycine **209** [66T3245; 78MI1; 83JCS(P1)1681; 84JNP285], de-*N*-methylacronycine **210** [78MI1; 83JCS(P1)1681], de-*N*-methylnoracronycine **211** [78MI1; 83JCS(P1)1681], citracridone-I **212** [78MI1; 82H273; 83CPB901, 83JCS(P1)1681; 90JCS(P1)1593], citracridone-II **213** [82H273; 83CPB895; 90JCS(P1)1593], citracridone-III **214** (91H1781), 11-hydroxynoracronycine **215** [82H273; 83CPB895, 83JCS(P1)1681; 90JCS(P1)1593], 11-methoxynoracronycine (baiyamine A) **216** (86H1595), 11-hydroxy-20-methoxynoracronycine **217** (84JNP325), acrifoline **218** (95JNP1629), atalaphyllidine **219** (75E1387; 82IJC16), atalaphyllinine **220** [82IJC16, 82P1771; 83JCS(P1)1681], *N*-methylatalaphyllinine (11-hydroxy-*N*-methylseverifoline) **221** [82IJC16, 82P1771; 83JCS(P1)1681; 96P235], severifoline **222** (82P1771), *N*-methylseverifoline **223** [82P1771; 83JCS(P1)1681], acronycine epoxide **224** (88MI3), *trans*-1,2-dihydroxy-1,2-dihydrocitracridone-I **225** (95H187), (+)-1-hydroxy-1,2-dihydro-de-*N*-methylacronycine **226** (87H2057), (–)-*cis*-1,2-dihydroxy-1,2-dihydro-de-*N*-methylacronycine **227** (86JNP1091), 1-oxo-1,2-dihydro-de-*N*-methylacronycine **228** (87H2057), bicyclo-*N*-methylatalaphylline **194** (72JOC3035), acrignine **229** (93CPB406), neoacrimarines C **230** and D **232** (93CPB1757), ataline **231** [73JCS(CC)615], glycobisamines A–C **233**, **234a**, and **234b** [93JCS(P1)471], and buntanbismine **235** (96P221). These alkaloids have been isolated from various species of *Citrus*, *Glycosmis*, *Severinia*, *Sarcomelicope*, and other plants (all Rutaceae family), and some of them have demonstrated significant biological activity. For example, 11-hydroxynoracronycine **215** showed significant effects on Epstein–Barr virus-EA activation (95MI1), whereas glycobisamine A **233** showed *in vitro* antimalarial activity comparable to that of chloroquine diphosphate (91AAC377).


208  $R^1 = \text{OMe}, R^3 = \text{Me}, R^2 = R^4 = R^5 = \text{H}$ 209  $R^1 = \text{OH}, R^3 = \text{Me}, R^2 = R^4 = R^5 = \text{H}$ 210  $R^1 = \text{OMe}, R^2 = R^3 = R^4 = R^5 = \text{H}$ 211  $R^1 = \text{OH}, R^2 = R^3 = R^4 = R^5 = \text{H}$ 212  $R^1 = R^5 = \text{OH}, R^2 = \text{H}, R^3 = \text{Me}, R^4 = \text{OMe}$ 213  $R^1 = \text{OH}, R^2 = \text{H}, R^3 = \text{Me}, R^4 = R^5 = \text{OMe}$ 214  $R^1 = R^4 = R^5 = \text{OH}, R^2 = \text{H}, R^3 = \text{Me}$ 215  $R^1 = R^4 = \text{OH}, R^2 = R^5 = \text{H}, R^3 = \text{Me}$ 216  $R^1 = \text{OH}, R^2 = R^5 = \text{H}, R^3 = \text{Me}, R^4 = \text{OMe}$ 217  $R^1 = R^4 = \text{OH}, R^2 = \text{H}, R^3 = \text{Me}, R^5 = \text{OMe}$ 218  $R^1 = R^5 = \text{OH}, R^2 = R^3 = \text{H}, R^4 = \text{OMe}$ 219  $R^1 = R^4 = \text{OH}, R^2 = R^3 = R^5 = \text{H}$ 220  $R^1 = R^4 = \text{OH}, R^2 = \text{X}, R^3 = R^5 = \text{H}$ 221  $R^1 = R^4 = \text{OH}, R^2 = \text{X}, R^3 = \text{Me}, R^5 = \text{H}$ 222  $R^1 = \text{OH}, R^2 = \text{X}, R^3 = R^4 = R^5 = \text{H}$ 223  $R^1 = \text{OH}, R^2 = \text{X}, R^3 = \text{Me}, R^4 = R^5 = \text{H}$ 224  $R^1 = R^3 = R^7 = R^8 = \text{H}, R^5 = \text{OMe}, R^6 = \text{Me}, R^2R^4 = \text{O}$ 225  $R^1 = R^4 = R^5 = R^8 = \text{OH}, R^2 = R^3 = \text{H}, R^6 = \text{Me}, R^7 = \text{OMe}$ 226  $R^1 = R^3 = R^4 = R^6 = R^7 = R^8 = \text{H}, R^2 = \text{OH}, R^5 = \text{OMe}$ 227  $R^1 = R^3 = R^6 = R^7 = R^8 = \text{H}, R^2 = R^4 = \text{OH}, R^5 = \text{OMe}$ 228  $R^1R^2 = \text{O}, R^3 = R^4 = R^6 = R^7 = R^8 = \text{H}, R^5 = \text{OMe}$




## 2. Syntheses

Various approaches have been used to synthesize acronycine **208** and its derivatives. Lahey and Stick's synthesis (Scheme 38) involves the condensation of 2,3-dimethylchroman-5,7-diol **236** with anthranilic acid, followed by *N*-methylation of the minor product **238** to produce 1,2-dihydronoraacronycine **239** (73AJC2311).


Beck *et al.* (68JA4706) have reported three interrelated syntheses of acronycine. One synthesis (Scheme 39) used 5,7-dimethoxy-1,2,3,4-tetrahydroquinolin-2(1*H*)-one **240**, which was coupled with 2-iodobenzoic acid to give the acid **241**. Ring closure with PPA, followed by refluxing with



SCHEME 38. (a)  $\text{ZnCl}_2$ , BuOH, reflux, 2 h; (b) MeI,  $\text{K}_2\text{CO}_3$ , acetone.




SCHEME 39. (a) 2-Iodobenzoic acid, CuI, nitrobenzene,  $\text{K}_2\text{CO}_3$ , 165–175°C, 6.5 h, 40%; (b) PPA, 90°C, 1.5 h; (c) MeOH, HCl, reflux, 2.5 h, 82% (b,c); (d)  $\text{BCl}_3$ ,  $\text{CH}_2\text{Cl}_2$ ; (e) MeLi, ether/HCl, 64% (d,e); (f) pyridinium chloride, 190–200°C, (g) MeI,  $\text{K}_2\text{CO}_3$ , acetone, 20% (f,g); (h) DDQ, toluene, 40–45%; (i)  $\text{Me}_2\text{SO}_4$ ,  $\text{K}_2\text{CO}_3$ , acetone, 16 h, 60%.



SCHEME 40. (a) 2-Bromobenzoic Acid,  $\text{Cu}(\text{AcO})_2$ ,  $\text{KAcO}$ ,  $\text{Et}_3\text{N}$ ,  $i\text{BuOH}$ , 58%; (b) TFAA,  $\text{CH}_2\text{Cl}_2$ , rt, 3 days, 62%; (c)  $\text{CH}_3\text{I}$ ,  $\text{PhCH}_2\text{NEt}_3\text{Cl}$ ,  $\text{NaOH}$  (aq.), 2-butanone, 96%.


methanolic  $\text{HCl}$ , afforded methyl 1,3-dimethoxy-9-oxacridin-4-propionate **242**. Ether cleavage at C-1, followed by reaction with an excess of  $\text{MeLi}$ , yielded the tertiary alcohol **243**. Fusion with pyridinium chloride at high temperature caused  $O$ -demethylation at C-3 with concomitant ring closure. Treatment of the crude product with  $\text{MeI}$  under basic conditions produced dihydronoracronycine **239**. Dehydrogenation with DDQ afforded noracronycine **209**, which was converted to acronycine **208** by  $O$ -methylation with dimethyl sulfate.

Loughhead (90JOC2445) coupled 5-amino-2,2-dimethyl-7-methoxychromene **244** with 2-bromobenzoic acid, and the resultant product **245** was cyclized with TFAA. The de- $N$ -methylacronycine **210** was then converted to acronycine **208** by methylation under phase-transfer conditions (Scheme 40). The same approach has been used by Elomri *et al.* to prepare 6-demethoxyacronycine **246** which was found to be more potent than acronycine **208** in some biological assays (92H799).




Hlubucek *et al.* annelated dimethylpyran rings onto 3-hydroxyacridones **247** by a Claisen-type rearrangement of their  $\alpha,\alpha$ -dimethyl propargyl ethers **248** (Scheme 41) [69CI(L)1809; 70AJC1881]. Similar strategies, with some modifications, were used by others to prepare acronycine **208** and its derivatives and analogs (72JMC266; 76JNP399; 82BSB33; 84LA31, 84T5181; 89AP31; 91AP67; 92JHC1293, 92M473; 93JHC1469).

Bandaranayaka *et al.* [74JCS(P1)998] devised an efficient synthesis of acronycine **208** that involves the condensation of 1,3-dihydroxyacridin-




SCHEME 41. (a)  $\text{HC}\equiv\text{C}-\text{C}(\text{CH}_3)_2\text{Cl}$ ,  $\text{K}_2\text{CO}_3$ , KI, DMF,  $50-70^\circ\text{C}$ ,  $\text{N}_2$ , 14–18 h; (b) DMF,  $130^\circ\text{C}$ , 5h; (c)  $\text{Me}_2\text{SO}_4$ , DMF, NaH,  $\text{N}_2$ ,  $45^\circ\text{C}$ , 1 h, 85%; (d)  $\text{Me}_2\text{SO}_4$ , DMF,  $\text{K}_2\text{CO}_3$ ,  $\text{N}_2$ ,  $60^\circ\text{C}$ , 18 h, 86%.

9(10*H*)-one **247** ( $\text{R}^1 = \text{R}^2 = \text{H}$ ) with 1,1-dimethoxy-3-hydroxy-3-methylbutane in pyridine at  $150^\circ\text{C}$ , followed by methylation of the angular pyranoacridine **211**, which was isolated by repeated crystallization. Methylation of the unpurified condensation product also gave isoacronycine **249** and noracronycine **209**, in addition to acronycine **208**. Use of citral and farnesal in place of 1,1-dimethoxy-3-hydroxy-3-methylbutane provided mono- or diprenyl-substituted acridones and their cyclized product. The same approach was used by Ramesh and Kapil [86IJC(B)684] to prepare 11-hydroxynoracronycine **215** and atalaphyllidine **219**.



Lewis and his co-workers have reported three interrelated syntheses of acronycine **208** (81T209). In one synthesis, 2,6-dimethoxy-4-hydroxy-2'-nitrobenzophenone **250**, obtained as a minor product from Friedel–Crafts acylation of 3,5-dimethoxyphenol with 2-nitrobenzoylchloride, was treated with 3-chloro-3-methylbut-1-yne under basic conditions. The resultant nitro compound **251** was reduced to the amine **252** with zinc. Upon reaction with sodium hydride in DMSO, this amine provided a mixture of de-*N*-methylisoacronycine **253** and de-*N*-methylacronycine **210**. De-*N*-methylacronycine **210** was converted to acronycine **208** by methylation with methyl iodide (Scheme 42).

Coppola (84JHC913) condensed *N*-methylisatoic anhydride **254** with the lithium enolate of 2,6,7,8-tetrahydro-2,2-dimethylbenzopyran-5-one **255** to




SCHEME 42. (a)  $\text{HC}\equiv\text{C}-\text{C}(\text{CH}_3)_2\text{Cl}$ , DMF,  $\text{K}_2\text{CO}_3$ , KI,  $65^\circ\text{C}$ ,  $\text{N}_2$ , 14 h, 90%; (b) Zn/EtOH, rt 5 days, 98%; (c) NaH, DMSO, rt, 6 days, 29% (**210**), 43% (**253**); (d) MeI,  $\text{K}_2\text{CO}_3$ , acetone, reflux, 11 h, 80%.

obtain 5,6-dihydro-6-demethoxyacronycine **256**. Dehydrogenation with DDQ provided 6-demethoxyacronycine **246** (Scheme 43).


Watanabe *et al.* (84CPB1264) have reported a one-step synthesis of acronycine **208**. Lithium methyl(2-methoxycarbonyl)phenyl amide **258** generated from methyl *N*-methylantranilate **257** *in situ* in the presence of excess lithium cyclohexylamide (LCA), was reacted with 6-bromo-2,2-dimethyl-7-methoxychromene **259** to produce acronycine **208**. A benzyne intermediate **260** is believed to be involved in this reaction (Scheme 44).

A regioselective synthesis of acronycine **208** from 3-acetyl-4-chloro-2-cyanomethylquinoline **261** has been described by Anand and Sinha (Scheme 45) [90H1733; 91JCS(P1)2339]. This synthesis involves alkylation of the cyanomethylene **261** with 1-bromo-3-methylbut-2-ene, methanolysis of the resulting nitrile **262** to give the ester **263**, and finally, ring closure and hydroxy-dechlorination to afford norglycocitrine II **264**. Oxidative cyclization of this acridone **264** with DDQ gave de-*N*-methylnoracronycine **211**,




SCHEME 43. (a) LDA, THF,  $\text{N}_2$ ,  $-65^\circ\text{C}$ , 56%; (b) DDQ, 88%.





SCHEME 44. (a) LCA, THF,  $N_2$ ,  $-78^\circ C$ ; (b) LCA, THF,  $N_2$ ,  $-10^\circ C$ , 41% (a,b).

which was converted to acronycine **208** by methylation with methyl iodide. In another reaction, glycocitrine II **265** was converted to noracronycine **209** by oxidative cyclization with benzeneselenenyl chloride followed by hydrogen peroxide [83JCS(P1)1681].




SCHEME 45. (a)  $(CH_3)_2C=CHCH_2Br$ ,  $K_2CO_3$ , DMF, reflux, 30 h, 48%; (b) MeOH, HCl, 70%; (c) NaH, THF, 3 h; (d) PhOH,  $100^\circ C$ , 3 h; (e) HCl, MeOH, 10 h, 47% (c,d,e); (f) DDQ, toluene, 52%; (g) NaH, DMF, MeI, 85%.

The syntheses of acronycine **208** and its derivatives, such as **266**, **267** reported by Blechert *et al.*, have novelty in that they involve the formation of ring "A" (Scheme 46) (78CB439; 80LA503).



Microbial conversions of acronycine **208** to its hydroxy derivatives have been reported by two research groups (74JMC599, 74JMC653). Among many microbial agents, *Aspergillus alleaceus*, *Cunninghamella echinulata*, and *Streptomyces spectabilis* are found to be effective.

The reaction of organolithium compounds with noracronycine provided 7-substituted derivatives [95JCS(P1)511]. The reaction of acronycine with  $P_4S_{10}$  produced the thio analog **268** (79JPS36; 82S493), and oxidation of acronycine **208** resulted in one or more products that include acronycine epoxide **224**, 1-hydroxy-2-oxo-1,2-dihydroacronycine **269**, *cis*-1,2-dihydroxy-1,2-dihydroacronycine **270**, and 5-hydroxyacronycine **271**, de-




SCHEME 46. (a)  $TiCl_4$ ,  $CH_2Cl_2$ , rt 2 h, 60% (X = Br); (b) heat, 16%; (c)  $Ac_2O$ ; (d)  $tBuOK$ ; (e) DMSO, pyridine, TFA, DCC, rt 20 h; (f) MeI,  $K_2CO_3$ , acetone, 68% (X = Br); (g) BuLi, ether, 0°C, 4 h, 38%.


pending on the nature of the oxidizing agent (86JNP1091; 90M709; 94LA317, 94M731). The synthesis of 1-hydroxy-1,2-dihydroacronycine **272** and 2-hydroxy-1,2-dihydroacronycine **273** from acronycine **208** has also been reported (88MI2).

**268** X = S; R<sup>1</sup> = H**271** X = O; R<sup>1</sup> = OH**269** R<sup>1</sup> = OH; R<sup>2</sup>R<sup>3</sup> = O**270** R<sup>1</sup> = R<sup>2</sup> = OH; R<sup>3</sup> = H**272** R<sup>1</sup> = OH; R<sup>2</sup> = R<sup>3</sup> = H**273** R<sup>1</sup> = R<sup>2</sup> = H; R<sup>3</sup> = OH

Reisch and Gunaherath [89JCS(P1)1047] have reported the synthesis of 2,12-dimethyl-6-hydroxypyrano[2,3-*c*]acridine-3,7(12*H*)-dione **275** by two different routes starting from the alkylation of 1,3-dihydroxy-10-methylacridin-9(10*H*)-one **69** to give the  $\alpha,\beta$ -unsaturated ester **274** (Scheme 47).



SCHEME 47. (a) K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 2 h, 73%; (b) I<sub>2</sub>, HIO<sub>4</sub> (aq.), EtOH, rt, 2 h, 90%; (c) Ac<sub>2</sub>O, pyridine, 100°C, 3 h, 32%; (d) K<sub>2</sub>CO<sub>3</sub>, MeOH, reflux, 15 min, 77%; (e) PEG, 200°C, 30 min, 71%; (f) PEG, 220°C, 15 min, 45%.




SCHEME 48

C. PYRANO[3,2-*a*]ACRIDINES

The coupling of 2,3-dihydroxy-10-methylacridin-9(10H)-one **276** with 3-chloro-3-methylbut-1-yne afforded a pyrano[3,2-*a*]acridine **277** (Scheme 48) (83MI1).


6-Aminobenzopyran-2-ones **279** undergo the Conrad-Limpach reaction with 2-ethoxycarbonylcyclohexanone **278** to give anils **280**, which, on heating in diphenyl ether at reflux, give cyclized products **281** (Scheme 49) (83JHC775).

We have prepared a series of pyrano[3,2-*a*]acridines (e.g., **282**) by the route described in Scheme 34, but using 6-oxo-5,6,7,8-tetrahydroflavone instead of 7-oxo-5,6,7,8-tetrahydroflavone (84TH1).

SCHEME 49. (a) Xylene, reflux, 29–30%; (b) Ph<sub>2</sub>O, heat, 52%.


D. PYRANO[3,2-*b*]ACRIDINES

Linear pyranoacridines are very rare in nature. Only a few acridone alkaloids based on the pyrano[3,2-*b*]acridine ring system have been isolated and characterized. These include pyranofoline **283** and glycofoline **284** from *Glycosmis citrifolia* (Willd.) Lindl. [83JCS(P1)1681], honyumine **285** from *Citrus grandis* (86H41) and *Citrus funadoko* [90JCS(P1)1593], junosidine **286** from *Citrus junos* Tanaka (87H2077), and yukocitrine **287** from *Citrus yuko* Hort plant (92H2123) and, with 4-(2'-hydroxy-3'-methylbut-3'-enyl)-yukocitrine **288**, from *Bosistoa transversa* (96P235). Isoacronycine **249** or its de-*N*-methyl or de-*O*-methyl precursors have been separated as side products in most of the acronycine **208** syntheses (see pyrano[2,3-*c*]acridines).



- 283** R<sup>1</sup> = Me; R<sup>2</sup> = OMe; R<sup>3</sup> = OH; R<sup>4</sup> = H  
**284** R<sup>1</sup> = Me<sub>2</sub>C=CHCH<sub>2</sub>; R<sup>2</sup> = R<sup>4</sup> = H; R<sup>3</sup> = OH  
**285** R<sup>1</sup> = Me; R<sup>2</sup> = H; R<sup>3</sup> = OMe; R<sup>4</sup> = OH  
**286** R<sup>1</sup> = Me; R<sup>2</sup> = R<sup>4</sup> = H; R<sup>3</sup> = OMe  
**287** R<sup>1</sup> = Me; R<sup>2</sup> = R<sup>4</sup> = H; R<sup>3</sup> = OH  
**288** R<sup>1</sup> = Me; R<sup>2</sup> = CH<sub>2</sub>=C(CH<sub>3</sub>)CH(OH)CH<sub>2</sub>;  
 R<sup>3</sup> = OH; R<sup>4</sup> = H

Reisch *et al.* (91LA685) have reported a regioselective synthesis of isoacronycine **249** from 1,3-dihydroxy-10-methylacridin-9(10*H*)-one **69** that involves iodination at C-2, followed by palladium-catalyzed Heck condensation with 3-hydroxy-3-methylbut-1-ene to give isonoracronycine **289**. Methylation of isonoracronycine **289** with MeI gave isoacronycine **249** (Scheme 50).



SCHEME 50. (a) I<sub>2</sub>, H<sub>5</sub>IO<sub>6</sub>, EtOH, rt, 92%; (b) Pd(OAc)<sub>2</sub>, (*n*Bu)<sub>4</sub>N<sup>+</sup>Br, CH<sub>2</sub>=CH-C(OH)Me<sub>2</sub>; NaHCO<sub>3</sub>, DMSO/DMF, N<sub>2</sub>, 80°C, 36 h, 48%; (c) MeI, NaH, THF, 12 h, 80%.

We have prepared a linear pyranoacridine **291** by the condensation of *N*-benzyl anthranilonitrile with 7-oxo-5,6,7,8-tetrahydroflavone **200**, followed by base-catalyzed cyclization of the resultant enamine **290** (Scheme 51) (94TH1).

#### IV. Pyrroloacridines

Pyrroloacridines have been scarcely reported in the literature; only a few ring systems have been described.


##### A. PYRROLO[2,3-*b*]ACRIDINES

Bilgic and Young have reported the formation of the benzo[*j*]pyrrolo[2,3-*b*]acridine **294** in a reaction between 1-(*N,N*-dimethylaminomethyl)naphth-2-ol **292** and 5-aminoindole. A quinone methide **293** is believed to be involved as an intermediate (Scheme 52). The reaction of the naphthol **292** with 5-aminoindazole gave the angular pyrazoloacridine **295** [80JCS(P1) 1233].


##### B. PYRROLO[2,3-*c*]ACRIDINES

Takagi *et al.* have synthesized a number of 4,5-dihydropyrrolo[2,3-*c*]acridines **297** from 4-oxo-4,5,6,7-tetrahydroindoles **296** (Scheme 53) (73BSF2807). Syntheses of condensed heterocyclic compounds based on 4-oxotetrahydroindoles have also been reported in the Russian literature (75MI1).

Another strategy involves the fusion of a pyrrole ring onto the acridine nucleus. The Japp-Klingemann reaction of the diazonium salt **298** of 3-



SCHEME 51. (a) PTSA, toluene, reflux; (b) LDA, THF, N<sub>2</sub>, -78°C.




SCHEME 52. (a)  $\text{Ph}_2\text{O}$ ,  $\text{N}_2$ , reflux, 16 h, 67% **294**, 61% **295**.




aminoacridine with ethyl 2-methylacetoacetate provided a hydrazone **299**, which was cyclized to pyrrolo[2,3-*c*]acridine **300** in the presence of  $\text{ZnCl}_2$  (Scheme 54) (78KGS1277; 79KGS1092).

Wardani and Lhomme (93TL6411) used a different pathway for the construction of the pyrrole ring. Base-catalyzed alkylation of *N*-acetyl-*N'*-tosylproflavine **60** with bromoacetaldehyde diethyl acetal, followed by deprotection of the acetal function with concomitant ring closure and deacylation in acidic media yielded 9-amino-3-tosylpyrrolo[2,3-*c*]acridine **301**. Detosylation was achieved by basic hydrolysis to give 9-aminopyrrolo[2,3-*c*]acridine **302** (Scheme 55).

We have prepared pyrrolo[2,3-*c*]acridines **304** by our standard method, involving the base-catalyzed cyclization of the enamines **303**, followed by oxidation (Scheme 56) (96TH1).



SCHEME 53.  $\text{R}^1 = \text{H, Me, Et, Ph, } p\text{-An, } \beta\text{-Naph}$ ;  $\text{R}^2 = \text{Me, Ph}$ .

SCHEME 54. (a) Ethyl 2-methylacetoacetate/base, 51%; (b)  $\text{ZnCl}_2$ .SCHEME 55. (a)  $\text{DMF}$ ,  $\text{K}_2\text{CO}_3$ ,  $\text{BrCH}_2\text{CH}(\text{OEt})_2$ ,  $80^\circ\text{C}$ , 4 days; (b)  $\text{CH}_3\text{SO}_3\text{H}/\text{CH}_2\text{Cl}_2$  (1:9) reflux, 24 h, 40% (a,b); (c)  $\text{KOH}$ ;  $\text{DMF}-\text{H}_2\text{O}$ ,  $78^\circ\text{C}$ , 5 h, 75%.SCHEME 56. (a)  $\text{NaNH}_2$ , DME; (b)  $\text{MnO}_2$ , DMF, reflux.



C. PYRROLO[2,3,4-*kl*]ACRIDINES

Three polycyclic alkaloids that contain this ring system as part of their structures, plakinidines A **78**, B **79**, and C **80**, were isolated from the marine sponge *Plakortis* sp. (see Section II,C,1 on pyrido[3,2-*c*]acridines).

Gellerman *et al.* (94T12959) have described the biomimetic synthesis of a pyrrolo[2,3,4-*kl*]acridine **305** (Scheme 57).

## V. Thienoacridines


Only a few thienoacridine ring systems are known, and all are synthetic.

A. THIENO[2,3-*c*]ACRIDINES


The Pfitzinger reaction of 6,7-dihydrobenzothiophen-4(5*H*)-ones **306** with isatins **307** produced 4,5-dihydrothieno[2,3-*c*]acridine-6-carboxylic acids **308** (Scheme 58) (50RTC1053; 55BSF1252, 55JCS21; 58JCS2418). Decarboxylation of the acid **308** (R = Me, X = H) upon heating above the melting point has been reported to give the dihydro derivative **309** (50RTC1053; 55BSF1252), and Buu-Hoï has reported the decarboxylation with concomitant dehydrogenation of the acid **308** (R = Et, X = Br) to give 6-bromo-2-ethylthieno[2,3-*c*]acridine **310** (Scheme 58) (58JCS2418).

Remers *et al.* (71JMC1127) have used a quite different approach, which involves the Vilsmeier–Haack formylation of 6,7-dihydrobenzothiophen-4(5*H*)-one **306** (R = H) followed by cyclocondensation with aniline to give 4,5-dihydrothieno[2,3-*c*]acridine **311** (Scheme 59).


Strekowski *et al.* (90JOC4777) condensed the 6,7-dihydrobenzothiophen-4(5*H*)-one **306** (R = H) with 2-trifluoromethylaniline and then cyclized the resultant imine **312** with lithium 4-methylpiperazide to afford this ring system **313** (Scheme 60).




SCHEME 57




SCHEME 58. (a) KOH, EtOH, reflux, 10–24 h; (b) Heat > 300°C.



SCHEME 59. (a) POCl<sub>3</sub>–DMF, 100°C, 1 h, 17%; (b) aniline, AcOH, reflux, 3 h, 67%.



SCHEME 60. (a) Lithium 4-methylpiperazide, Et<sub>2</sub>O, –10°C, 30 min; (b) H<sub>3</sub>O<sup>+</sup>.




SCHEME 61

The Fetvadjan–Ullmann reaction between 4-hydroxy-7-(*p*-tolyl)benzothiophene **314**, aniline, and paraformaldehyde provides another pathway for the construction of thieno[2,3-*c*]acridines, such as **315** (Scheme 61) (81JHC1519).


Suresh *et al.* (93SUL7) have described a novel route for the preparation of thieno[2,3-*c*]acridines **316** that involves photocyclization (Scheme 62).

We have used the strategy developed for the synthesis of pyrido[2,3-*c*]acridines to prepare thieno[2,3-*c*]acridines, such as **317** (96TH1).


**317**

## B. THIENO[3,2-*c*]ACRIDINES

Buu-Hoï and Royer (46CR806) obtained a series of thieno[3,2-*c*]acridines **320** by using the Pfitzinger reaction between 4,5-dihydrobenzothiophene-7(6*H*)-one **318** and isatins **319**, followed by decarboxylation at high temperature (Scheme 63). One of the decarboxylated products **320** ( $\text{R}^1 = \text{Me}$ ,  $\text{R}^2 = \text{H}$ ) was dehydrogenated with  $\text{PbO}$  at  $310^\circ\text{C}$  to give the fully aromatic system **321**.



SCHEME 62



SCHEME 63.  $\text{R}^1 = \text{H, Me, Br; R}^2 = \text{H, Me. (a) KOH, EtOH; (b) heat; (c) PbO, 310}^\circ\text{C.}$

### C. THIENO[3,4-*c*]ACRIDINES


Isatins **307** on reaction with 1,3-dimethyl-6,7-dihydroisothiophene-4(5*H*)-one **322** gave 2,3-dimethyl-4,5-dihydrothieno[3,4-*c*]acridine-6-carboxylic acids **323** (Scheme 64) (50RTC1053).

## VI. Furoacridines


Only three furoacridine ring systems have been reported.

### A. FURO[2,3-*a*]ACRIDINES

The reactions of copper(I) phenylacetylide **325a** and copper(I) isopropenylacetylide **325b** with 1-hydroxy-2-iodo-3-methoxy-10-methylacridin-9(10*H*)-one **324** gave furo[2,3-*a*]acridones **236a** and **236b** (Scheme 65) (84LA31).



SCHEME 64







SCHEME 65


## B. FURO[2,3-*c*]ACRIDINES

### 1. Isolation

This ring system is the basic skeleton of a number of acridone alkaloids isolated from intact plants or cell tissue cultures of various species from the Rutaceae family. Most of the dihydrofuroacridone alkaloids have been isolated from *Ruta graveolens*: rutacridone **327** (67MI1; 81MI1; 87PHA67; 88MI1; 90PHA500; 91MI3), rutacridone epoxide **328** (81MI1, 81ZN200; 82ZN132; 85MI2; 87PHA67; 88MI1; 90PHA500; 91MI2), 20-hydroxyrutacridone epoxide **329** (82ZN132; 85MI2), 1-hydroxyrutacridone epoxide **330** (85MI2), gravacridonol **331** (81MI1; 85MI2), gravacridone chloride **332** (73P2359; 87PHA67; 88MI1), isogravacridone chloride **333** (77P151; 91MI1), gravacridondiol **334** (72P2121; 76MI1, 76P240), gravacridondiol acetate **335** (91MI2), gravacridondiol monomethyl ether **336** (72P2121), gravacridontriol **337** (76MI1, 76P240), gravacridonolchlorine **338** (72P2121, 72P2359), and rutagravin **339** (85MI2). Rutacridone **327** and its epoxide **328** have also been detected in *Boenninghausenia albiflora* (78P169).





- 329  $R^1 = H$ ;  $R^2 =$    
 330  $R^1 = OH$ ;  $R^2 =$    
 331  $R^1 = H$ ;  $R^2 = H_2C=CCH_2OH$   
 332  $R^1 = H$ ;  $R^2 = H_3CC(Cl)CH_2OH$   
 333  $R^1 = H$ ;  $R^2 = H_3CC(OH)CH_2Cl$   
 334  $R^1 = H$ ;  $R^2 = H_3CC(OH)CH_2OH$   
 335  $R^1 = H$ ;  $R^2 = H_3CC(OH)CH_2OAc$   
 336  $R^1 = H$ ;  $R^2 = H_3CC(OH)CH_2OMe$   
 337  $R^1 = H$ ;  $R^2 = HOC(CH_2OH)_2$   
 338  $R^1 = H$ ;  $R^2 = ClC(CH_2OH)_2$




- 341  $R^1 = OH$ ;  $R^2 = R^3 = H$   
 342  $R^1 = OMe$ ;  $R^2 = OH$ ;  $R^3 = H$   
 343  $R^1 = OMe$ ;  $R^2 = OH$ ;  $R^3 = Me$

Some of these dihydrofuroacridones, **327**, **328**, **331**, **333**, **334**, and **337**, have been separated by Baumert *et al.* from the cell culture of *Thamnosma montana* (94MI1). They have also obtained the glucosides of gravacridonol, gravacridondiols, and gravacridontriols. The last two glucosides were also isolated from roots and tissue culture of *Ruta graveolens* (76MI1, 76P240).

Three bisacridone alkaloids, citbisamines A **341**, B **342**, and C **343**, containing a C—C bond linkage between the dihydrofuroacridone and the acridone ring systems, have been isolated by Takemura *et al.* from the roots of Marsh grapefruit (*Citrus paradisi*) and Hirado-buntan (*Citrus grandis*) (95CPB1340). Previously, Fraser and Lewis reported the isolation of two dimeric alkaloids (containing *O*-linkages), atalanine **344** and ataline **231**, from *Atlantia ceylanica* [73JCS(CC)615].




A fully dehydrogenated furoacridine (furacridone = furofoline-I) **345** was detected for the first time in *Ruta graveolens* by Reisch *et al.* (77P151) as a mixture with 1-hydroxy-3-methoxy-10-methylacridin-9(10*H*)-one. Wu *et al.* [83JCS(P1)1681] were able to isolate furofoline-I **345** and furofoline II **346** from *Glycosmis citrifolia* (willd.) Lindl.




**345** R = H

**346** R = C(OH)Me<sub>2</sub>

**347** R = COMe



**348**




**349**

Hallacridone **347** was isolated from *Ruta graveolens* by Baumert *et al.*, along with the dihydrofuroacridones **327**, **328**, and **332** (87PHA67; 88MI1). Its structure was revised by Reisch and Gunaherath [89JCS(P1)1047] on the basis of spectroscopic evidence and total synthesis. It was also isolated from tissue cultures of *Ruta graveolens* (90PHA500) and *Thamnosma montana* (94MI1). Isolation of two new alkaloids, thehaplosine **348** (93MI2) and furoparadine **349** (95H187), has been achieved from the aerial parts of *Halophyllum thesioides* and roots of Marsh grapefruit (Rutaceae), respectively.

## 2. Syntheses


Rutacridone **327** was synthesized for the first time by Mester *et al.* (81H77) by base-catalyzed alkylation, with concomitant cyclization, of 1,3-dihydroxy-10-methylacridin-9(10*H*)-one **69** with 1,4-dibromo-2-methylbut-2-ene. The linear isomer, isorutacridone **350**, was also obtained as a by-product (Scheme 66). A better yield of rutacridone **327** was obtained when Al<sub>2</sub>O<sub>3</sub> was used as the catalyst (90M829). Once again, isorutacridone **350** was obtained as a by-product (Scheme 66).

Maier *et al.* have observed that microsomes (from *Ruta graveolens* cell cultures) catalyze the condensation of 1,3-dihydroxy-10-methylacridin-9(10*H*)-one **69** with isopentenyl pyrophosphate or dimethylallyl pyrophosphate, in the presence of NADPH and O<sub>2</sub>, to produce rutacridone **327**, and also that the reaction involved glycocitrine-II **265** as an intermediate (90MI2; 93P691). A possible precursor **351** of rutacridone **327** has also been isolated from a reaction of glycocitrine-II **265** with *m*-chloroperbenzoic acid (MCPBA) (Scheme 67) (93CPB383).




SCHEME 66. (a) Na, MeOH,  $\text{BrCH}_2\text{CH}=\text{C}(\text{CH}_3)\text{CH}_2\text{Br}$ , 15.5% (**327**), 5.2% (**350**); (b)  $\text{Al}_2\text{O}_3$ ,  $\text{ClCH}_2\text{CH}=\text{C}(\text{CH}_3)\text{CH}_2\text{Br}$ .

Selective hydroxylation of rutacridone **327** with  $\text{SeO}_2$  in the presence of *t*BuOOH provided gravacridonol **331** (91LA299), and oxidation with  $\text{KMnO}_4$  afforded rutagravin **339**, isorutagravin **340**, gravacridondiol **334**, and dihydrohallacridone **353** [69CI(L)1809]. Dehydrogenation of dihydrohallacridone with DDQ produced hallacridone **347** [94JCR(S)157].




To confirm its structure, Reisch *et al.* have synthesized hallacridone **347** (Scheme 68) [89JCS(P1)1047]. Ullmann-amine coupling of 2-chlorobenzoic acid and 3,5-dimethoxyaniline gave an amine **354** that, on treatment with  $\text{DMF-POCl}_3$ , provided 4-formyl-1,3-dimethoxyacridin-9(10*H*)-one **355**. *N*-Methylation, *O*-demethylation, and subsequent condensation with 1-chloropropan-2-one in basic media gave hallacridone **347**.




SCHEME 67






SCHEME 68. (a)  $\text{POCl}_3$ , DMF, rt, 1.5 h, 15%; (b) MeI,  $\text{Ag}_2\text{O}$ , DMF, 16 h, 76%; (c)  $\text{BCl}_3$ ,  $\text{CH}_2\text{Cl}_2$ , rt 72 h, 64%; (d)  $\text{ClCH}_2\text{COCH}_3$ ,  $\text{K}_2\text{CO}_3$ , acetone, reflux, 2 h, 50%.

Takagi and Ueda have prepared a number of 4,5-dihydrofuro[2,3-*c*]acridines **358a–c** from 4,5,6,7-tetrahydrobenzofuran-4-ones **356** by condensing with isatin, anthranilic acid, and 2-aminophenylcarbonyl hydrochlorides **357** using a range of conditions (Scheme 69) (71CPB1218; 72CPB380,



SCHEME 69.  $\text{R}^1 = \text{Me, Ph, } p\text{MeO-Ph, } p\text{Br-Ph}$ ;  $\text{R}^2 = \text{Me, Ph}$ . (a)  $\text{KOH}$ , EtOH, reflux, 50–64 h, 18–31% (**358c**); (b) heat 110–140°C, 1 h, 40–71%, (a,b); (c) 120–200°C, 1 h, 16–38%; (d)  $\text{Pd/C}$ , 260–290°C, 15 min, 40–54%; (e)  $\text{POCl}_3$ , 135°C, 2 h, 71%.




SCHEME 70. (a) LDA,  $-65$  to  $-40^{\circ}\text{C}$ , 2 h, 67%; (b) DDQ, toluene,  $70^{\circ}\text{C}$ , 15 min., 100%.

72CPB2051). Dehydrogenation of 4,5-dihydrofuro[2,3-*c*]acridines **358** has also been reported to give the aromatic systems **359**.

Coppola (84JHC1569) condensed *N*-methylisatoic anhydride **254** with the lithium enolate of 4,5,6,7-tetrahydrobenzofuran-4-one **356** ( $R = \text{H}$ ) and obtained *N*-methylfuro[2,3-*c*]acridin-6-one **361** after dehydrogenation of the resultant 4,5-dihydrofuroacridone **360** (Scheme 70).


The method of Jayabalan and Shanmugan is novel in that it involves the construction of a ring between a quinoline and furan moieties to complete this skeleton (Scheme 71) (91ZN558).

Once again, we have used the strategy developed for the synthesis of pyrido[2,3-*c*]acridines to prepare furo[2,3-*c*]acridines **362** (96TH1).



**362** ( $R = \text{H}$  or  $\text{OMe}$ )

SCHEME 71



SCHEME 72

### C. FURO[3,2-*b*]ACRIDINES

Reisch and co-workers have isolated isorutacridone **350** as a by-product during their base-catalyzed (81H77) and  $\text{Al}_2\text{O}_3$ -catalyzed (90M829) synthesis of rutacridone **327** (Scheme 66). They observed that the use of an ion-exchange resin as the catalyst favored the formation of isorutacridone **350** as the major product (81H77). The same group also reported the formation of another linear furoacridine, 4-hydroxy-3-methylene-2,2,10-trimethyl-2,3-dihydrofuro[3,2-*b*]acridin-5(10*H*)-one **363** (Scheme 72) (89JHC1849).

### ACKNOWLEDGMENTS

We thank the Government of Pakistan for the award of a C. O. T. Studentship (to M. A. M.).

### REFERENCES

- |             |   |
|-------------|---|
| 35FRP771486 | I. G. Farbenindustrie, A.-G., Fr.Pat. 771,486 (1935) [ <i>CA</i> <b>29</b> , 1435 (1935)].              |
| 40BSF608    | E. Lederer, G. Tessier, and C. Hutterer, <i>Bull. Soc. Chim. Fr.</i> <b>7</b> , 608 (1940).             |
| 46CR806     | Ng. Ph. Buu-Hoi, and R. Royer, <i>C. R. Hebd. Seances Acad. Sci.</i> <b>233</b> , 806 (1946).           |
| 46JCS151    | J. Dobson and W. O. Kermack, <i>J. Chem. Soc.</i> , 151 (1946).   |
| 47JA1543    | H. R. Snyder and H. E. Freier, <i>J. Am. Chem. Soc.</i> <b>69</b> , 1543 (1947).                        |
| 47JCS678    | J. Dobson, W. C. Hutchison, and W. O. Kermack, <i>J. Chem. Soc.</i> , 678 (1947).                       |
| 48JCS123    | J. Dobson, W. C. Hutchison, and W. O. Kermack, <i>J. Chem. Soc.</i> , 123 (1948).                       |
| 48JCS288    | J. W. Wilkinson and I. L. Finar, <i>J. Chem. Soc.</i> , 288 (1948).                                     |
| 48NAT(L)223 | G. K. Hughes, F. N. Lahey, J. R. Price, and L. J. Webb, <i>Nature (London)</i> <b>162</b> , 223 (1948). |

- 49MI1 F. N. Lahey and W. C. Thomas, *Aust. J. Sci. Res., Ser. A* **2**, 423 (1949).
- 50RTC1053 Ng. Ph. Buu-Hoï, N. Hoán, and Ng. H. Khôi, *Recl. Trav. Chim. Pays-Bas* **69**, 1053 (1950).
- 52JCS1874 G. M. Badger and R. Pettit, *J. Chem. Soc.*, 1874 (1952).
- 55BSF1252 P. Cagniant and P. Cagniant, *Bull. Soc. Chim. Fr.*, 1252 (1955).
- 55JCS21 M. Sy, Ng. Ph. Buu-Hoï, and Ng. D. Xuong, *J. Chem. Soc.*, 21 (1955).
- 58JCS2418 Ng. Ph. Buu-Hoï, *J. Chem. Soc.*, 2418 (1958).
- 62JMC546 E. F. Elslager and F. H. Tendick, *J. Med. Pharm. Chem.*, 546 (1962).
- 62JOC865 E. Koft and F. H. Case, *J. Org. Chem.* **27**, 865 (1962).
- 64USP3124581 H. Bohler and F. Kehner, U.S. Pat. 3,124,581 (1964) [CA **61**, 13462 (1964)].
- 66AJC275 P. L. Macdonald and A. V. Robertson, *Aust. J. Chem.* **19**, 275 (1966).
- 66T3245 T. R. Govindachari, B. R. Pai, and P. S. Subramanian, *Tetrahedron* **22**, 3245 (1966).
- 67CRV1 S. S. Labana and L. L. Labana, *Chem. Rev.* **67**, 1 (1967).
- 67JCS(C)213 Ng. Ph. Buu-Hoï, *J. Chem. Soc. C*, 213 (1967).
- 67JCS(C)1415 M. Dufour, Ng. Ph. Buu-Hoï, and P. Jacquignon, *J. Chem. Soc. C*, 1415 (1967).
- 67MI1 J. Reisch, K. Szendrei, E. Minker, and I. Novák, *Acta Pharm. Suec.* **4**, 265 (1967) [CA **68**, 39861k (1969)].
- 68JA4706 J. R. Beck, R. Kowk, R. N. Booher, A. C. Brown, L. E. Patterson, P. Pranc, B. Rokey, and A. Pohland, *J. Am. Chem. Soc.* **90**, 4706 (1968).
- 68JCS(C)2689 R. T. Grout, M. W. Partridge, J. M. Sparke, and H. J. Vipond, *J. Chem. Soc. C*, 2689 (1968).
- 69CI(L)1809 J. Hlubucek, E. Ritchie, and W. C. Taylor, *Chem. Ind. (London)*, 1809 (1969).
- 70AJC1881 J. Hlubucek, E. Ritchie, and W. C. Taylor, *Aust. J. Chem.* **23**, 1881 (1970).
- 70AX(B)853 J. Z. Gougoutas and B. A. Kaski, *Acta Crystallogr., Sect. B* **B26**, 853 (1970).
- 70JPR1105 E. Uhlemann and P. Kurze, *J. Prakt. Chem.* **312**, 1105 (1970).
- 70T2905 T. R. Govindachari, N. Viswanathan, B. R. Pai, V. N. Ramachandran, and P. S. Subramaniam, *Tetrahedron* **26**, 2905 (1970).
- 71CPB1218 K. Takagi and T. Ueda, *Chem. Pharm. Bull.* **19**, 1218 (1971).
- 71JMC1127 W. A. Remer, G. J. Gibbs, J. F. Poletto, and M. J. Weiss, *J. Med. Chem.* **14**, 1127 (1971).
- 72CPB380 K. Takagi and T. Ueda, *Chem. Pharm. Bull.* **20**, 380 (1972).
- 72CPB2051 K. Takagi and T. Ueda, *Chem. Pharm. Bull.* **20**, 2051 (1972).
- 72IJC332 H. V. Berde, V. N. Gogte, and B. D. Tilak, *Indian J. Chem.* **10**, 332 (1972).
- 72JMC61 E. F. Elslager, N. F. Haley, J. R. McLean, D. Potoczak, H. Veloso, and R. H. Wheelock, *J. Med. Chem.* **15**, 61 (1972).
- 72JMC266 J. Schneider, E. L. Evans, E. Grunberg, and R. I. Fryer, *J. Med. Chem.* **15**, 266 (1972).
- 72JMC739 H. J. Creech, R. K. Preston, R. M. Peck, and A. P. O'Connell, *J. Med. Chem.* **15**, 739 (1972).

- 72JOC3035 D. Basu and S. C. Basa, *J. Org. Chem.* **37**, 3035 (1972).  
72P2121 J. Reisch, Zs. Rózsa, K. Szendrei, I. Novák, and E. Minker, *Phytochemistry* **11**, 2121 (1972).  
72P2359 J. Reisch, K. Szendrei, Zs. Rózsa, I. Novák, and E. Minker, *Phytochemistry* **11**, 2359 (1972).  
73AJC2311 F. N. Lahey and R. V. Stick, *Aust. J. Chem.* **26**, 2311 (1973).  
73BSF2807 K. Takagi, N. Kobayashi, and T. Ueda, *Bull. Soc. Chim. Fr.* **9-10**, 2807 (1973).  
73JCS(CC)615 A. W. Fraser and J. R. Lewis, *J. Chem. Soc., Chem. Commun.*, 615 (1973).  
74IJC1230 H. M. Dali, V. N. Gogte, G. B. Mullick, and B. D. Tilak, *Indian J. Chem.* **12**, 1230 (1974).  
74IJC1324 V. N. Gogte, G. B. Mullick, and B. D. Tilak, *Indian J. Chem.* **12**, 1324 (1974).  
74JCS(P1)998 W. M. Bandaranayake, M. J. Begley, B. O. Brown, D. G. Clarke, L. Crombie, and D. A. Whiting, *J. Chem. Soc., Perkin Trans. I*, 998 (1974).  
74JMC599 R. E. Betts, D. E. Walters, and J. P. Rosazza, *J. Med. Chem.* **17**, 599 (1974).  
74JMC653 D. R. Brannon, D. H. Horton, and G. H. Svoboda, *J. Med. Chem.* **17**, 653 (1974).  
74MI1 D. W. Ragnekar and S. V. Sunthankar, *Indian J. Technol.* **12**, 548 (1974).  
75E1387 S. C. Basa, *Experientia* **31**, 1387 (1975).  
75MI1 V. I. Shvedov, L. B. Altukhova, A. N. Grinev, A. I. Ermakov, and Yu. N. Sheinker, *V sb. Khim. Farmakol. Indol'n. Soedin.*, 57 (1975); *Zh. Khim. Abstr.* No. 232ZH1213 (1975) [CA **84**, 121749u].  
76JNP399 J. H. Adams, P. J. Bruce, and J. R. Lewis, *J. Nat. Prod.* **39**, 399 (1976).  
76MI1 Zs. Rózsa, I. N. Kuzovkina, J. Reisch, I. Novák, K. Szendrei, and E. Minker, *Fitoterapia* **47**, 147 (1976).  
76P240 J. Reisch, Zs. Rózsa, K. Szendrei, I. Novák, and E. Minker, *Phytochemistry* **15**, 240 (1976).  
77P151 J. Reisch, Zs. Rózsa, K. Szendrei, I. Novák, and E. Minker, *Phytochemistry* **16**, 151 (1977).  
78CB439 S. Blechert, K.-E. Fichter, and E. Winterfeldt, *Chem. Ber.* **111**, 439 (1978).  
78KGS1277 N. N. Suvorov, T. M. Alyab'eva, and T. E. Khoshtariya, *Khim. Geterotsikl. Soedin.*, 1277 (1978).  
78MI1 M. T. Fauvel, J. Gleye, C. Moulis, and I. Fouraste, *Planta Med. Phytother.* **12**, 207 (1978).  
78P169 Zs. Rózsa, K. Szendrei, I. Novák, J. Reisch, and E. Minker, *Phytochemistry* **17**, 169 (1978).  
78USP4060527 H. Nakamoto, S.-I. Nakamoto, H. Amemiya, S. Miyamura, M. Shiba, and N. Nakamura, U.S. Pat. 4,060,527 (1977) [CA **88**, 121145b(1978)].  
79IJC(B)623 Y. Kumar and P. C. Jain, *Indian J. Chem., Sect. B* **B17**, 623 (1979).  
79JPS36 J. R. Dimmock, A. J. Repta, and J. Kaminski, *J. Pharm. Sci.* **68**, 36 (1979).

- 79KGS1092 T. M. Alyab'eva, T. E. Khoshtariya, A. M. Vasil'ev, L. G. Tret'yakova, T. K. Efimova, and N. N. Suvorov, *Khim. Geterotsikl. Soedin.*, 1092 (1979).
- 80JCS(P1)1233 O. Bilgic and D. W. Young, *J. Chem. Soc., Perkin Trans. I*, 1233 (1980).
- 80LA503 S. Blechert, K.-E. Fichter, J. Lindner, and E. Winterfeldt, *Liebigs Ann. Chem.*, 503 (1980).
- 81H77 I. Mester, J. Reisch, Zs. Rózsa, and K. Szendrei, *Heterocycles* **16**, 77 (1981).
- 81JHC1519 H. H. Moussa and S. Abdel-Meguid, *J. Heterocycl. Chem.* **18**, 1519 (1981).
- 81MI1 Zs. Rózsa, J. Reisch, K. Szendrei, and E. Minker, *Fitoterapia* **52**, 93 (1981).
- 81T209 J. H. Adams, P. M. Brown, P. Gupta, M. S. Khan, and J. R. Lewis, *Tetrahedron* **37**, 209 (1981).
- 81ZN200 A. Nahrstedt, U. Eilert, B. Wolters, and V. Wary, *Z. Naturforsch. C* **36**, 200 (1981).
- 82BSB33 R. R. Smolders, A. Waefelaer, R. Coomans, D. Francart, J. Hanuise, and N. Voglet, *Bull. Soc. Chim. Belg.* **91**, 33 (1982).
- 82H273 T.-S. Wu, H. Furukawa, and C.-S. Kuoh, *Heterocycles* **19**, 273 (1982).
- 82IJC16 J. S. Shah and B. K. Sabata, *Indian J. Chem. B* **21**, 16 (1982).
- 82P1771 T.-S. Wu, C.-S. Kuoh, and H. Furukawa, *Phytochemistry* **21**, 1771 (1982).
- 82S493 R. R. Smolders, J. Hanuise, R. Coomans, V. Proietto, N. Voglet, and A. Waefelaer, *Synthesis*, 493 (1982).
- 82ZN132 U. Eilert, B. Wolters, A. Nahrstedt, and V. Wary, *Z. Naturforsch. C* **37**, 132 (1982).
- 83CPB895 T.-S. Wu, C.-S. Kuoh, and H. Furukawa, *Chem. Pharm. Bull.* **31**, 895 (1983).
- 83CPB901 T.-S. Wu and H. Furukawa, *Chem. Pharm. Bull.* **31**, 901 (1983).
- 83JA4835 F. J. Schmitz, S. K. Agarwal, S. P. Gunasekera, P. G. Schmidt, and J. N. Shoolery, *J. Am. Chem. Soc.* **105**, 4835 (1983).
- 83JCS(P1)1681 T. S. Wu, H. Furukawa, C.-S. Kuoh, and K.-S. Hsu, *J. Chem. Soc., Perkin Trans. I*, 1681 (1983).
- 83JHC775 J. R. Merchant, G. Martyres, and N. M. Koshti, *J. Heterocycl. Chem.* **20**, 775 (1983).
- 83MI1 R. R. Smolders, T. Blondiau, J. Hanuise, and N. Voglet, *Ing. Chim. (Brussels)* **64**, 79 (1983).
- 84CL1305 M. Tomita, S. Kusabayashi, and M. Yokoyama, *Chem. Lett.*, 1305 (1984).
- 84CPB1264 M. Watanabe, A. Kurosaki, and S. Furukawa, *Chem. Pharm. Bull.* **32**, 1264 (1984).
- 84JHC913 G. M. Coppola, *J. Heterocycl. Chem.* **21**, 913 (1984).
- 84JHC1569 G. M. Coppola, *J. Heterocycl. Chem.* **21**, 1569 (1984).
- 84JNP285 S. Funayama and G. A. Cordell, *J. Nat. Prod.* **47**, 285 (1984).
- 84JNP325 S. C. Basa and R. N. Tripathy, *J. Nat. Prod.* **47**, 325 (1984).
- 84KGS962 M. V. Kazankov, M. I. Bernadskii, and M. Y. Mustafina, *Khim. Geterotsikl. Soedin.*, 962 (1984).

- 84LA31 J. Reisch, I. Mester, and S. M. El-Moghazy Aly, *Liebigs Ann. Chem.*, 31 (1984).
- 84T5181 R. R. Smolders, J. Hanuise, T. Lepoint, N. Voglet, B. Tinant, J. P. Declercq, and M. Van Meerssche, *Tetrahedron* **40**, 5181 (1984).
- 84TL3575 B. Fugmann, B. Steffan, and W. Steglich, *Tetrahedron Lett.* **25**, 3575 (1984).
- 85LA1501 D. Hellwinkel and P. Itemann, *Liebigs Ann. Chem.*, 1501 (1985).
- 85MI1 M. Suffnes and G. A. Cordell, in "The Alkaloids" (A. Brossi, ed.), Vol. 25, and references therein. Academic Press, New York, 1985.
- 85MI2 A. Nahrstedt, V. Wary, B. Engel, and E. Reinhard, *Planta Med.* **51**, 517 (1985).
- 85TL5975 C. S. Hilger, B. Fugmann, and W. Steglich, *Tetrahedron Lett.* **26**, 5975 (1985).
- 86H41 T.-S. Wu, S.-C. Huang, T.-T. Joung, J.-S. Lai, and H. Furukawa, *Heterocycles* **24**, 41 (1986).
- 86H1595 M. Ju-ichi, M. Inoue, K. Aoki, and H. Furukawa, *Heterocycles* **24**, 1595 (1986).
- 86IJC(B)684 K. Ramesh and R. S. Kapil, *Indian J. Chem., Sect. B* **B25**, 684 (1986).
- 86JNP1091 S. Mitaku, A.-L. Skaltsounis, F. Tillequin, M. Koch, J. Pusset, and G. Chauvière, *J. Nat. Prod.* **49**, 1091 (1986).
- 87CL609 K. Manabe, S. Kusabayashi, and M. Yokoyama, *Chem. Lett.* 609 (1987).
- 87H2057 S. Mitaku, A.-L. Skaltsounis, F. Tillequin, and M. Koch, *Heterocycles* **26**, 2057 (1987).
- 87H2077 M. Ju-ichi, M. Inoue, K. Sakiyama, M. Yoneda, and H. Furukawa, *Heterocycles* **26**, 2077 (1987).
- 87JA6134 S. J. Bloor and F. J. Schmitz, *J. Am. Chem. Soc.* **109**, 6134 (1987).
- 87JCS(P1)927 C. V. Labarca, A. R. MacKenzie, C. J. Moody, C. W. Rees, and J. J. Vaquero, *J. Chem. Soc., Perkin Trans. 1*, 927 (1987).
- 87MI1 W. A. Denny and B. C. Baguley, *Anti-Cancer Drug Des.* **2**, 61 (1987).
- 87MI2 M. D. Bhavsar and J. D. Lakhani, *Man-Made Text., India* **30**, 107, 111, 113, 115, 117, 119, 120 (1987) [*CA* **108**, 96160z (1987)].
- 87MI3 M. D. Bhavsar and U. G. Chavan, *Man-Made Text India* **30**, 224, 225, 230 (1987) [*CA* **109**, 92715g (1987)].
- 87PHA67 A. Baumert, D. Gröger, J. Schmidt, and C. Mügge, *Pharmazie* **42**, 67 (1987).
- 87T4023 G. Cimino, A. Crispino, S. de Rosa, S. de Stefano, M. Gavagnin, and G. Sodano, *Tetrahedron* **43**, 4023 (1987).
- 88H2095 A. Kubo and S. Nakahara, *Heterocycles* **27**, 2095 (1988).
- 88JA3673 T. W. Bell and J. Liu, *J. Am. Chem. Soc.* **110**, 3673 (1988).
- 88JA4051 A. M. Echavarren and J. K. Still, *J. Am. Chem. Soc.* **110**, 4051 (1988).
- 88JA4356 G. P. Gunawardana, S. Kohmoto, S. P. Gunasekera, O. J. McConnell, and F. E. Koehn, *J. Am. Chem. Soc.* **110**, 4356 (1988).
- 88JHC1063 K. Kitahara and H. Nishi, *J. Heterocycl. Chem.* **25**, 1063 (1988).
- 88JOC1800 J. Kobayashi, J. Cheng, M. R. Walchli, H. Nakamura, Y. Hirata, T. Sasaki, and Y. Ohizumi, *J. Org. Chem.* **53**, 1800 (1988).

- 88JOC4619 N. M. Cooray, P. J. Scheuer, L. Parkanyi, and J. Clardy, *J. Org. Chem.* **53**, 4619 (1988).
- 88MI1 A. Baumert, D. Gröger, J. Schmidt, I. N. Kuzovkina, and C. Mügge, *Fitoterapia* **59**, 83 (1988).
- 88MI2 S. Mitaku, A.-L. Skaltsounis, F. Tillequin, and M. Koch, *Planta Med.* **54**, 24 (1988).
- 88MI3 M. Brum-Bousquet, S. Mitaku, A.-L. Skaltsounis, F. Tillequin, and M. Koch, *Planta Med.* **54**, 470 (1988).
- 88TL1177 J. Kobayashi, J. Cheng, H. Nakamura, Y. Ohizumi, Y. Hirata, T. Sasaki, T. Ohta, and S. Nozoe, *Tetrahedron Lett.* **29**, 1177 (1988).
- 88TL3861 A. Rudi, Y. Benayahu, I. Goldberg, and Y. Kashman, *Tetrahedron Lett.* **29**, 3861 (1988).
- 88TL6655 A. Rudi, Y. Benayahu, I. Goldberg, and Y. Kashman, *Tetrahedron Lett.* **29**, 6655 (1988).
- 89AP31 J. Reisch and W. Probst, *Arch. Pharm. (Weinheim, Ger.)* **322**, 31 (1989).
- 89H847 R. H. Prager, C. Tsopelas, and T. Heisler, *Heterocycles* **29**, 847 (1989).
- 89H2093 F. Bracher, *Heterocycles* **29**, 2093 (1989).
- 89JCS(P1)1047 J. Reisch and G. M. K. B. Gunaherath, *J. Chem. Soc., Perkin Trans. 1*, 1047 (1989).
- 89JHC1849 J. Reisch and G. M. K. B. Gunaherath, *J. Heterocycl. Chem.* **26**, 1849 (1989).
- 89JOC4231 A. R. Carroll, N. M. Cooray, A. Poiner, and P. J. Scheuer, *J. Org. Chem.* **54**, 4231 (1989).
- 89JOC4256 T. F. Molinski and C. M. Ireland, *J. Org. Chem.* **54**, 4256 (1989).
- 89JOC5331 A. Rudi and Y. Kashman, *J. Org. Chem.* **54**, 5331 (1989).
- 89MI1 R. T. Dorri, J. D. Liddil, D. D. Van Hoff, M. Soble, and C. K. Osborne, *Cancer Res.* **49**, 340 (1989).
- 89MI2 N. S. Burres, S. Sazesh, G. P. Gunawardana, and J. J. Clement, *Cancer Res.* **49**, 5267 (1989).
- 89TL1069 F. S. de Guzman and F. J. Schmitz, *Tetrahedron Lett.* **30**, 1069 (1989).
- 89TL4201 A. G. Charyulu, T. C. McKee, and C. M. Ireland, *Tetrahedron Lett.* **30**, 4201 (1989).
- 89TL4359 G. P. Gunawardana, S. Kohmoto, and N. P. Burres, *Tetrahedron Lett.* **30**, 4359 (1989).
- 90AGE923 T. W. Bell and J. Liu, *Angew. Chem., Int. Ed. Engl.* **29**, 923 (1990).
- 90H1733 R. C. Anand and A. K. Sinha, *Heterocycles* **31**, 1733 (1990).
- 90H2003 E. Sánchez, C. del Campo, C. Avendaño, and E. Llama, *Heterocycles* **31**, 2003 (1990).
- 90JA1 W. D. Inman, M. O'Neill-Johnson, and P. Crews, *J. Am. Chem. Soc.* **112**, 1 (1990).
- 90JCS(P1)1593 H. Furukawa, C. Ito, T. Mizuno, M. Ju-ichi, M. Inoue, I. Kajiura, and M. Omura, *J. Chem. Soc., Perkin Trans. 1*, 1593 (1990).
- 90JOC2445 D. Loughhead, *J. Org. Chem.* **55**, 2445 (1990).
- 90JOC4426 A. R. Carroll and P. J. Scheuer, *J. Org. Chem.* **55**, 4426 (1990).
- 90JOC4777 L. Strekowski, R. L. Wydra, M. T. Cegla, A. Czarny, D. B. Harden, S. E. Patterson, M. A. Battiste, and J. M. Coxon, *J. Org. Chem.* **55**, 4777 (1990).



- 90LA205 F. Bracher, *Liebigs Ann. Chem.*, 205 (1990).
- 90M709 J. Reisch and A. Wickramasinghe, *Monatsh. Chem.* **121**, 709 (1990).
- 90M829 J. Reisch, A. Wickramasinghe, and W. Probst, *Monatsh. Chem.* **121**, 829 (1990).
- 90MI1 M. D. Gordon, E. E. Jaffe, and A. Foris, *Dyes Pigm.* **12**, 301 (1990).
- 90MI2 W. Maier, B. Schumann, and D. Gröger, *FEBS Lett.* **263**, 289 (1990).
- 90PHA500 W. Probst and D. Gröger, *Pharmazie* **45**, 500 (1990).
- 90TL3271 R. R. West, C. L. Mayne, C. M. Ireland, L. C. Brinen, and J. Clardy, *Tetrahedron Lett.* **31**, 3271 (1990).
- 90TL4375 C. J. Moody, C. W. Rees, and R. Thomas, *Tetrahedron Lett.* **31**, 4375 (1990).
- 91AAC377 S. F. Queener, H. Fujioka, Y. Nishiyama, H. Furukawa, M. S. Bartlett, and J. W. Smith, *Antimicrob. Agents Chemother.* **35**, 377 (1991).
- 91AJC277 R. H. Prager, C. Tsopelas, and T. Heisler, *Aust. J. Chem.* **44**, 277 (1991).
- 91AP67 J. Reisch and P. Dziemba, *Arch. Pharm. (Weinheim, Ger.)* **324**, 67 (1991).
- 91H1781 M. Ju-ichi, Y. Takemura, C. Ito, and H. Furukawa, *Heterocycles* **32**, 1781 (1991).
- 91JA8016 M. A. Ciufolini and N. E. Byrne, *J. Am. Chem. Soc.* **113**, 8016 (1991).
- 91JCS(P1)2339 R. C. Anand and A. K. Sinha, *J. Chem. Soc., Perkin Trans. 1*, 2339 (1991).
- 91JCS(P1)2499 M. J. Kennedy, C. J. Moody, C. W. Rees, and R. Thomas, *J. Chem. Soc., Perkin Trans. 1*, 2499 (1991).
- 91JNP1634 J. Kobayashi, M. Tsuda, A. Tanabe, M. Ishibashi, J. F. Cheng, S. Yamamura, and T. Sasaki, *J. Nat. Prod.* **54**, 1634 (1991).
- 91JOC804 F. J. Schmitz, F. S. de Guzman, M. B. Hussain, and D. van der Helm, *J. Org. Chem.* **56**, 804 (1991).
- 91JOC3497 E. Gómez-Bengoa and A. M. Echavarren, *J. Org. Chem.* **56**, 3497 (1991).
- 91JOC5369 H. Y. He and D. J. Faulkner, *J. Org. Chem.* **56**, 5369 (1991).
- 91LA299 J. Reisch and A. A. Voerste, *Liebigs Ann. Chem.*, 299 (1991).
- 91LA685 J. Reisch, H. M. T. B. Hearth, and N. S. Kumar, *Liebigs Ann. Chem.*, 685 (1991).
- 91MI1 E. Llama, C. del Campo, and M. Capo, *J. Pharm. Pharmacol.* **43**, 68 (1991).
- 91MI2 H. Paulini, R. Popp, O. Schimmer, O. Ratka, and E. Röder, *Planta Med.* **57**, 59 (1991).
- 91MI3 H. Paulini, R. Waibel, J. Kiefer, and O. Schimmer, *Planta Med.* **57**, 82 (1991).
- 91MIP1 D. Bigg, J. Lhomme, H. Salez, and A. Wardani, *PCT Int. Appl. WO 91/07,403* (1991) [*CA* **115**, 207973h(1991)].
- 91ZN558 L. Jayabalan and P. Shanmugan, *Z. Naturforsch. B* **46**, 558 (1991).
- 92H799 A. Elomri, S. Michel, F. Tillequin, and M. Koch, *Heterocycles* **34**, 799 (1992).
- 92H2123 Y. Takemura, H. Uchida, M. Ju-ichi, C. Ito, K. Nakagawa, T. Ono, and H. Furukawa, *Heterocycles* **34**, 2123 (1992).

- 92JA10081 M. J. Bishop and M. A. Ciufolini, *J. Am. Chem. Soc.* **114**, 10081 (1992).
- 92JAP(K)92/275288 H. Nagase, H. Wakita, K. Kawai, T. Endo, and O. Matsumoto, *Jpn. Kokai Tokkyo Koho JP 92/275,288* (1992) [*CA* **119**, 49367a (1993)].
- 92JCS(CC)1453 N. M. Ali, S. K. Chattopadhyay, A. McKillop, R. M. Perret-Gentil, T. Ozturk, and R. A. Rebelo, *J. Chem. Soc., Chem. Commun.*, 1453 (1992).
- 92JHC167 K. Kitahara, H. Yanagimoto, N. Nakajima, and H. Nishi, *J. Heterocycl. Chem.* **29**, 167 (1992).
- 92JHC1293 J. Reisch and P. Dziemba, *J. Heterocycl. Chem.* **29**, 1293 (1992).
- 92JMC2744 I. B. Taraporewala, J. W. Cessac, T. C. Chanh, A. V. Delgado, and R. F. Schinazi, *J. Med. Chem.* **35**, 2744 (1992).
- 92JOC1523 G. P. Gunawardana, F. E. Koehn, A. Y. Lee, J. Clardy, H. Y. He, and J. D. Faulkner, *J. Org. Chem.* **57**, 1523 (1992).
- 92LA1205 F. Bracher, *Liebigs Ann. Chem.*, 1205 (1992).
- 92M473 J. Reisch, A. W. Voerste, M. Top, and P. Dziemba, *Monatsh. Chem.* **123**, 473 (1992).
- 92MI1 H. L. Shieh, J. M. Pezzuto, and G. A. Cordeil, *Chem.-Biol. Interact.* **81**, 35 (1992).
- 92T3589 C. J. Moody, C. W. Rees, and R. Thomas, *Tetrahedron* **48**, 3589 (1992).
- 92TL5577 G. Gellerman, A. Rudi, and Y. Kashman, *Tetrahedron Lett.* **33**, 5577 (1992).
- 93CPB383 C. Ito, T. Ono, K. Hatano, and H. Furukawa, *Chem. Pharm. Bull.* **41**, 383 (1993).
- 93CPB406 Y. Takemura, M. Abe, M. Ju-ichi, C. Ito, K. Hatano, M. Omura, and H. Furukawa, *Chem. Pharm. Bull.* **41**, 406 (1993).
- 93CPB1757 Y. Takemura, T. Kurozumi, M. Ju-ichi, M. Okano, N. Fukamiya, C. Ito, T. Ono, and H. Furukawa, *Chem. Pharm. Bull.* **41**, 1757 (1993).
- 93CRV1825 T. F. Molinski, *Chem. Rev.* **93**, 1825 (1993).
- 93H943 Y. Kitahara, S. Nakahara, T. Yonezawa, M. Nagatsu, and A. Kubo, *Heterocycles* **36**, 943 (1993).
- 93H1139 S. Nakahara, Y. Tanaka, and A. Kubo, *Heterocycles* **36**, 1139 (1993).
- 93H2757 J. Morton, C. Huel, and E. Bisagni, *Heterocycles* **36**, 2757 (1993).
- 93IJC(B)978 N. K. Satti, K. A. Suri, O. P. Suri, and A. Kapil, *Indian J. Chem., Sect. B* **B32**, 978 (1993).
- 93JCS(P1)471 H. Furukawa, C. Ito, T. Ono, T.-S. Wu, and C.-S. Kuoh, *J. Chem. Soc., Perkin Trans. 1*, 471 (1993).
- 93JCS(P1)879 S. H. Dunn and A. McKillop, *J. Chem. Soc., Perkin Trans. 1*, 879 (1993).
- 93JHC981 J. Reisch, P. Dziemba, M. La Mura, and A. R. R. Rao, *J. Heterocycl. Chem.* **30**, 981 (1993).
- 93JHC1469 J. Reisch, P. Dziemba, and T. Adam, *J. Heterocycl. Chem.* **30**, 1469 (1993).
- 93JNP1813 J. Kim, E. O. Pordesimo, S. I. Toth, F. J. Schmitz, and I. van Altena, *J. Nat. Prod.* **56**, 1813 (1993).

- 93JOC1666 R. P. Thummel, S. Chirayil, C. Hery, J.-L. Lim, and T.-L. Wang, *J. Org. Chem.* **58**, 1666 (1993).
- 93JPS262 E. Llana, C. del Campo, M. Capo, and M. Anadon, *J. Pharm. Sci.* **82**, 262 (1993).
- 93MI1 N. R. Shochet, A. Rudi, Y. Kashman, Y. Hod, M. R. El-Maghrabi, and I. Spector, *J. Cell. Physiol.* **157**, 481 (1993).
- 93MI2 A. Ulubelen, A. H. Mericli, F. Mericli, U. Sonmez, and R. Ilarsalan, *Nat. Prod. Lett.* **1**, 269 (1993).
- 93P691 W. Maier, A. Baumert, B. Schumann, H. Furukawa, and D. Gröger, *Pytochemistry* **32**, 691 (1993).
- 93SUL7 J. R. Suresh, L. Jayabalan and P. Shanmugam, *Sulfur Lett.* **17**, 7 (1993).
- 93T8337 C.-M. Zeng, M. Ishibashi, K. Matsumoto, S. Nakaike, and J. Kobayashi, *Tetrahedron* **49**, 8337 (1993).
- 93TL1775 U. Westerwelle and N. Risch, *Tetrahedron Lett.*, **34**, 1775 (1993).
- 93TL1823 G. Gellerman, A. Rudi, and Y. Kashman, *Tetrahedron Lett.* **34**, 1823 (1993).
- 93TL1827 G. Gellerman, M. Barbad, and Y. Kashman, *Tetrahedron Lett.* **34**, 1827 (1993).
- 93TL6411 A. Wardani and J. Lhomme, *Tetrahedron Lett.* **34**, 6411 (1993).
- 94JCR(S)157 J. Reisch, H. R. W. Dharmaratne, K. Schiwiek, and G. Henkel, *J. Chem. Res., Synop.*, 157 (1994).
- 94JCS(P1)173 P. W. Groundwater and K. R. H. Solomons, *J. Chem. Soc., Perkin Trans. I*, 173 (1994).
- 94JMC3819 L. A. McDonald, G. S. Eldredge, L. R. Barrows, and C. M. Ireland, *J. Med. Chem.* **37**, 3819 (1994).
- 94JOC3512 B. G. Szczepankiewicz and C. H. Heathcock, *J. Org. Chem.* **59**, 3512 (1994).
- 94JOC6600 P. A. Searle and T. F. Molinski, *J. Org. Chem.* **59**, 6600 (1994).
- 94LA317 J. Reisch and K. Schiwiek, *Liebigs Ann. Chem.*, 317 (1994).
- 94M731 J. Reisch and K. Schiwiek, *Monatsh. Chem.* **124**, 731 (1994).
- 94MI1 A. Baumert, W. Maier, U. Matern, J. Schmidt, B. Schumann, and D. Gröger, *Planta Med.* **60**, 143 (1994).
- 94S239 G. Gellerman, A. Rudi, and Y. Kashman, *Synthesis*, 239 (1994).
- 94T12959 G. Gellerman, A. Rudi, and Y. Kashman, *Tetrahedron* **50**, 12959 (1994).
- 94TH1 K. R. H. Solomons, Ph.D. Thesis, University of Wales, Cardiff (1994).
- 94TL7023 N. Bontemps, I. Bonnard, B. Banaigs, G. Combaut, and C. Francisco, *Tetrahedron Lett.* **35**, 7023 (1994).
- 95BRP9425409 P. M. Evans, P. W. Groundwater, M. A. Munawar, and K. R. H. Solomons, Br. Pat. Appl. 9,425,409.1 (1995).
- 95CPB1340 Y. Takemura, Y. Matsushita, N. Nagareya, M. Abe, J. Takaya, M. Ju-ichi, T. Hashimoto, Y. Kan, S. Takaoka, Y. Asakawa, M. Omura, C. Ito, and H. Furukawa, *Chem. Pharm. Bull.* **43**, 1340 (1995).
- 95IH187 Y. Takemura, Y. Matsushita, S. Onishi, T. A. Atarashi, Y. Kunitomo, M. Ju-ichi, M. Omura, C. Ito, and H. Furukawa, *Heterocycles* **41**, 187 (1995).
- 95JA12460 M. A. Ciufolini, Y.-C. Shen, and M. J. Bishop, *J. Am. Chem. Soc.* **117**, 12460 (1995).

- 95JCS(P1)511 C. Jolivet, C. Rivalle, and E. Bisagni, *J. Chem. Soc., Perkin Trans. I*, 511 (1995).
- 95JCS(P1)2333 C. Jolivet, C. Rivalle, C. Huel, and E. Bisagni, *J. Chem. Soc., Perkin Trans. I*, 2333 (1995).
- 95JNP1629 T. Ono, C. Ito, H. Furukawa, T.-S. Wu, C. S. Kuoh, and K.-S. Hsu, *J. Nat. Prod.* **58**, 1629 (1995).
- 95JOC292 F. Guillier, F. Nivoliers, A. Godard, F. Marsais, G. Quéguiner, M. A. Siddique, and V. Snieckus, *J. Org. Chem.* **60**, 292 (1995).
- 95MI1 Y. Takemura, M. Ju-ichi, C. Ito, H. Furukawa, and H. Tokuda, *Planta Med.* **61**, 366 (1995).
- 95MIP1 P. M. Evans, P. W. Groundwater, M. A. Munawar, and K. R. H. Solomons, Br. Pat Appl. 9,425,409.1; PCT Int. Appl. GB95/02948 (1995).
- 96P221 T.-S. Wu, S.-C. Huang, and P.-L. Wu, *Phytochemistry* **42**, 221 (1996).
- 96P235 A. A. Auzi, T. G. Hartely, R. D. Waigh, and P. G. Waterman, *Phytochemistry* **42**, 235 (1996).
- 96TH1 M. A. Munawar, Ph.D. Thesis, University of Wales, Cardiff (1996).
- 97JCS(P1)601 J. A. Drewe and P. W. Groundwater, *J. Chem. Soc., Perkin Trans. I*, 601 (1997).

This Page Intentionally Left Blank

# The Chemistry of C-Nucleosides and Their Analogs II: C-Nucleosides of Condensed Heterocyclic Bases

MOHAMMED A. E. SHABAN

*Department of Chemistry, Faculty of Science, Alexandria University,  
Alexandria 21321, Egypt*

I. Introduction.....	166
II. Condensed Azole C-Nucleosides.....	167
A. Furo[3,4- <i>c</i> ]pyrrolyl Acyclo C-Nucleosides.....	167
B. Indole C-Nucleosides.....	167
C. Indole Acyclo C-Nucleosides.....	171
D. Benzo[ <i>c</i> ]pyrrole C-Nucleosides.....	172
E. Carbazole C-Nucleosides.....	173
F. Pyrido[3,4- <i>b</i> ]indole C-Nucleosides.....	174
G. Pyrido[3,4- <i>b</i> ]indole Reverse C-Nucleosides.....	174
H. Pyrido[3,4- <i>b</i> ]indole Acyclo C-Nucleosides.....	175
I. 1,2,4-Triazolo[4',3':2,3]1,2,4-triazino[5,6- <i>b</i> ]indole Acyclo C-Nucleosides.....	177
III. Condensed 1,2-Diazole C-Nucleosides.....	177
A. Pyrazolo[1,2- <i>a</i> ]pyrazole Acyclo C-Nucleosides.....	177
B. Indazole C-Nucleosides.....	178
C. Indazole Homo C-Nucleosides.....	179
D. Indazole Reverse C-Nucleosides.....	179
E. Indazole Acyclo C-Nucleosides.....	180
IV. Condensed 1,3-Diazole C-Nucleosides.....	180
A. Furo[2,3- <i>d</i> ]imidazole Acyclo C-Nucleosides.....	180
B. Benzimidazole C-Nucleosides.....	182
C. Benzimidazole Acyclo C-Nucleosides.....	184
V. Condensed Oxazole C-Nucleosides.....	186
A. Furo[2,3- <i>d</i> ]oxazole Acyclo C-Nucleosides.....	186
B. Furo[3,2- <i>d</i> ]oxazole Acyclo C-Nucleosides.....	187
C. Furo[3,4- <i>d</i> ]oxazole Acyclo C-Nucleosides.....	188
D. Thiazolo[3,4- <i>c</i> ]oxazole Acyclo C-Nucleosides.....	189
E. Benzoxazole C-Nucleosides.....	190
VI. Condensed Thiazole C-Nucleosides.....	190
A. Pyrrolo[1,2- <i>c</i> ]thiazole Acyclo C-Nucleosides.....	190
B. Pyrazolo[5,1- <i>b</i> ]thiazole Acyclo C-Nucleosides.....	191
C. Imidazo[2,1- <i>b</i> ]thiazole Acyclo C-Nucleosides.....	191
D. Furo[2',3':4,5]imidazo[2,1- <i>b</i> ]thiazole Acyclo C-Nucleosides.....	191
E. Benzothiazole C-Nucleosides.....	192
F. Benzothiazole Carbocyclic C-Nucleosides.....	194
G. Benzothiazole Acyclo C-Nucleosides.....	194

VII. Condensed 1,2,3-Triazole C-Nucleosides .....	196
A. Furo[3,4- <i>d</i> ]1,2,3-triazole Acyclo C-Nucleosides .....	196
VIII. Condensed 1,3,4-Thiadiazole C-Nucleosides .....	197
A. 1,2,4-Triazolo[3,4- <i>b</i> ]1,3,4-thiadiazole Acyclo C-Nucleosides .....	197
IX. Condensed Azine C-Nucleosides .....	197
A. Cyclopenta[ <i>c</i> ]pyridine C-Nucleosides .....	197
B. Pyrrolo[2,3- <i>b</i> ]pyridine C-Nucleosides .....	198
C. Pyrrolo[3,2- <i>c</i> ]pyridine C-Nucleosides .....	198
D. Imidazo[1,2- <i>a</i> ]pyridine C-Nucleosides .....	199
E. Imidazo[1,2- <i>a</i> ]pyridine Acyclo C-Nucleosides .....	199
F. Imidazo[1,5- <i>a</i> ]pyridine C-Nucleosides .....	200
G. Imidazo[1,5- <i>a</i> ]pyridine Carbocyclic C-Nucleoside .....	200
H. Imidazo[4,5- <i>b</i> ]pyridine C-Nucleosides .....	201
I. Furo[2',3':4,5]imidazo[1,2- <i>a</i> ]pyridine Acyclo C-Nucleosides .....	202
J. 1,2,4-Triazolo[1,5- <i>a</i> ]pyridine C-Nucleosides .....	202
K. 1,2,4-Triazolo[1,5- <i>a</i> ]pyridine Acyclo C-Nucleosides .....	203
L. 1,2,4-Triazolo[4,3- <i>a</i> ]pyridine C-Nucleosides .....	203
M. 1,2,4-Triazolo[4,3- <i>a</i> ]pyridine Acyclo C-Nucleosides .....	203
N. Quinoline C-Nucleosides .....	204
O. Quinoline Homo C-Nucleosides .....	206
P. Quinoline Carbocyclic C-Nucleosides .....	207
Q. Quinoline Reverse C-Nucleosides .....	207
R. 1,2,4-Triazolo[4,3- <i>a</i> ]quinoline Acyclo C-Nucleosides .....	209
S. Acridine Acyclo C-Nucleosides .....	210
T. Isoquinoline C-Nucleosides .....	210
U. Isoquinoline Acyclo C-Nucleosides .....	211
X. Condensed 1,2-Diazine C-Nucleosides .....	212
A. Pyrazolo[3,4- <i>d</i> ]pyridazine C-Nucleosides .....	212
B. Pyrazolo[1',2':1,2]pyrazolo[4,3- <i>d</i> ]pyridazine C-Nucleosides .....	213
C. Pyrazolo[1',2':1,2]pyrazolo[4,3- <i>d</i> ]tetrazolo[1,5- <i>b</i> ]pyridazine Acyclo C-Nucleosides .....	213
D. Imidazo[1,5- <i>b</i> ]pyridazine C-Nucleosides .....	214
E. 1,2,4-Triazolo[4,3- <i>b</i> ]pyridazine C-Nucleosides .....	214
F. Cinnoline Acyclo C-Nucleosides .....	215
G. Phthalazine C-Nucleosides .....	215
H. Pyrimido[4,5- <i>c</i> ]pyridazine Acyclo C-Nucleosides .....	216
I. 1,2,4-Triazolo[3,4- <i>a</i> ]phthalazine C-Nucleosides .....	217
J. 1,2,4-Triazolo[3,4- <i>a</i> ]phthalazine Acyclo C-Nucleosides .....	217
XI. Condensed 1,3-Diazine C-Nucleosides .....	218
A. Pyrrolo[2,3- <i>d</i> ]pyrimidine C-Nucleosides .....	218
B. Pyrrolo[3,2- <i>d</i> ]pyrimidine C-Nucleosides .....	220
C. Pyrrolo[3,2- <i>d</i> ]pyrimidine Acyclo C-Nucleosides .....	223
D. Furo[3,2- <i>d</i> ]pyrimidine C-Nucleosides .....	224
E. Thieno[3,2- <i>d</i> ]pyrimidine C-Nucleosides .....	226
F. Thieno[3,2- <i>d</i> ]pyrimidine Acyclo C-Nucleosides .....	226
G. Thieno[3,4- <i>d</i> ]pyrimidine C-Nucleosides .....	227
H. Pyrazolo[1,5- <i>a</i> ]pyrimidine C-Nucleosides .....	227
I. Pyrazolo[3,4- <i>d</i> ]pyrimidine C-Nucleosides .....	229
J. Pyrazolo[4,3- <i>d</i> ]pyrimidine C-Nucleosides .....	230
K. Pyrazolo[4,3- <i>d</i> ]pyrimidine Acyclo C-Nucleosides .....	247


L. Imidazo[1,2- <i>a</i> ]pyrimidine Acyclo C-Nucleosides .....	248
M. Imidazo[4,5- <i>d</i> ]pyrimidine C-Nucleosides .....	249
N. Imidazo[4,5- <i>d</i> ]pyrimidine Acyclo C-Nucleosides .....	252
O. Isothiazolo[4,5- <i>d</i> ]pyrimidine C-Nucleosides .....	254
P. Thiazolo- and Selenazolo[5,4- <i>d</i> ]pyrimidine C-Nucleosides .....	255
Q. 1,2,3-Triazolo[1,5- <i>c</i> ]pyrimidine C-Nucleosides .....	256
R. 1,2,4-Triazolo[1,5- <i>a</i> ]pyrimidine C-Nucleosides .....	257
S. 1,2,4-Triazolo[1,5- <i>c</i> ]pyrimidine C-Nucleosides .....	257
T. 1,2,4-Triazolo[1,5- <i>c</i> ]pyrimidine Acyclo C-Nucleosides .....	258
U. 1,2,4-Triazolo[4,3- <i>a</i> ]pyrimidine C-Nucleosides .....	259
V. 1,2,4-Triazolo[4,3- <i>a</i> ]pyrimidine Acyclo C-Nucleosides .....	259
W. Quinazoline C-Nucleosides .....	260
X. Quinazoline Acyclo C-Nucleosides .....	260
Y. Pyrido[1,2- <i>a</i> ]pyrimidine C-Nucleosides .....	261
Z. Pyrido[4,3- <i>d</i> ]pyrimidine C-Nucleosides .....	262
A'. Pyrimido[4,5- <i>d</i> ]pyrimidine Acyclo C-Nucleosides .....	262
B'. Pyrazino[2,3- <i>d</i> ]pyrimidine C-Nucleosides .....	263
C'. Pyrazino[2,3- <i>d</i> ]pyrimidine Acyclo C-Nucleosides .....	264
D'. Pyrrolo[1',2':1,2]pyrazino[5,6- <i>d</i> ]pyrimidine C-Nucleosides .....	275
E'. Thieno[2',3':2,3]pyrazino[6,5- <i>d</i> ]pyrimidine Acyclo C-Nucleosides .....	276
XII. Condensed 1,4-Diazine C-Nucleosides .....	277
A. Pyrrolo[1,2- <i>a</i> ]pyrazine C-Nucleosides .....	277
B. Pyrrolo[1,2- <i>a</i> ]pyrazine Acyclo C-Nucleosides .....	277
C. Imidazo[1,2- <i>a</i> ]pyrazine C-Nucleosides .....	279
D. Imidazo[1,5- <i>a</i> ]pyrazine C-Nucleosides .....	280
E. Oxazolo[3,4- <i>a</i> ]pyrazine Acyclo C-Nucleosides .....	280
F. 1,2,4-Triazolo[4,3- <i>a</i> ]pyrazine C-Nucleosides .....	281
G. Quinoxaline C-Nucleosides .....	282
H. Quinoxaline Acyclo C-Nucleosides .....	282
I. Pyrido[2,3- <i>b</i> ]pyrazine Acyclo C-Nucleosides .....	284
J. Pyrrolo[1,2- <i>a</i> ]quinoxaline C-Nucleosides .....	285
K. Furo[2,3- <i>b</i> ]quinoxaline Acyclo C-Nucleosides .....	286
L. Furo[3,4- <i>b</i> ]quinoxaline Acyclo C-Nucleosides .....	286
M. Pyrazolo[3,4- <i>b</i> ]quinoxaline (Flavazole) C-Nucleosides .....	287
N. Pyrazolo[3,4- <i>b</i> ]quinoxaline (Flavazole) Acyclo C-Nucleosides .....	288
O. Benzo[ <i>f</i> ]quinoxaline Acyclo C-Nucleosides .....	289
P. Benzo[ <i>g</i> ]quinoxaline Acyclo C-Nucleosides .....	290
Q. Pyrido[2,3- <i>c</i> ]pyrazolo[3,4- <i>b</i> ]pyrazine Acyclo C-Nucleosides .....	290
R. Benzo[ <i>g</i> ]pyrazolo[3,4- <i>b</i> ]quinoxaline Acyclo C-Nucleosides .....	291
S. Benzo[ <i>h</i> ]pyrazolo[3,4- <i>b</i> ]quinoxaline Acyclo C-Nucleosides .....	291
T. Benzo[ <i>i</i> ]pyrazolo[3,4- <i>b</i> ]quinoxaline Acyclo C-Nucleosides .....	292
U. Quinoxalino[7',6':2,3]quinoxaline Acyclo C-Nucleosides .....	292
V. Pyrazolo[3,4- <i>b</i> ]quinoxalino[7',6':2,3]quinoxaline Acyclo C-Nucleosides .....	292
XIII. Condensed Oxazine C-Nucleosides .....	293
A. Pyrrolo[3,2- <i>d</i> ]oxazine C-Nucleosides .....	293
B. Pyrazolo[4,3- <i>d</i> ]oxazine C-Nucleosides .....	293
C. Pyrazolo[3,4- <i>e</i> ]oxazine C-Nucleosides .....	294
D. Benzo[ <i>d</i> ]oxazine Acyclo C-Nucleosides .....	295
XIV. Condensed 1,2,3-Triazine C-Nucleoside .....	295
A. Thiazolo[5,4- <i>d</i> ]1,2,3-triazine C-Nucleosides .....	295



XV. Condensed 1,2,4-Triazine C-Nucleosides .....	296
A. Pyrrolo[2,1- <i>f</i> ]1,2,4-triazine C-Nucleosides .....	296
B. Pyrrolo[1,5- <i>d</i> ]1,2,4-triazine C-Nucleosides .....	296
C. Imidazo[5,1- <i>f</i> ]1,2,4-triazine C-Nucleosides .....	297
D. Imidazo[5,1- <i>f</i> ]1,2,4-triazine Acyclo C-Nucleosides .....	298
E. 1,2,4-Triazolo[3,4- <i>f</i> ]1,2,4-triazine C-Nucleosides .....	298
F. 1,2,4-Triazolo[4,3- <i>b</i> ]1,2,4-triazine Acyclo C-Nucleosides .....	299
G. 1,2,4-Triazolo[3,4- <i>c</i> ]1,2,4-triazine Acyclo C-Nucleosides .....	300
H. 1,2,4-Triazolo[3,4- <i>f</i> ]1,2,4-triazine Acyclo C-Nucleosides .....	301
XVI. Condensed 1,3,5-Triazine C-Nucleosides .....	301
A. Pyrazolo[1,5- <i>a</i> ]1,3,5-triazine C-Nucleosides .....	301
B. Pyrazolo[1,5- <i>f</i> ]1,3,5-triazine Acyclo C-Nucleosides .....	303
C. Imidazo[1,5- <i>a</i> ]1,3,5-triazine Acyclo C-Nucleosides .....	303
XVII. Condensed 1,4-Diazepine C-Nucleosides .....	305
A. Benzo[ <i>b</i> ]thiazolo[3,2- <i>d</i> ]1,4-diazepine Acyclo C-Nucleosides .....	305
XVIII. Condensed 1,4-Oxazepine C-Nucleosides .....	305
A. Benzo[ <i>b</i> ]thiazolo[3,2- <i>d</i> ]1,4-oxazepine Acyclo C-Nucleosides .....	305
XIX. Condensed 1,5-Diazepine C-Nucleosides .....	305
A. Benzo[ <i>f</i> ]1,5-diazepine Homo C-Nucleosides .....	305
XX. Condensed 1,5-Thiazepine C-Nucleosides .....	306
A. Benzo[ <i>f</i> ]1,5-thiazepine Homo C-Nucleosides .....	306
XXI. Condensed 1,3,5-Triazepine C-Nucleosides .....	307
A. Benzo[ <i>f</i> ]1,3,5-triazepine Acyclo C-Nucleosides .....	307
B. Pyrimido[4,5- <i>f</i> ]1,3,5-triazepine Acyclo C-Nucleosides .....	307
XXII. Conclusion .....	308
References .....	309

## I. Introduction

The present review complements and concludes the first part [97-AHC(68)223], which was devoted to the chemistry of C-nucleosides of hetero monocyclic bases. C-Nucleosides reviewed in this part were systematized according to the size and complexity of the base component, starting with those of simpler base components followed by more complex ones. Within a class of a particular base component, the arrangement also goes from less to more complex attached components. The C-nucleosides of a certain category are discussed first, followed by their analogs in the sequence homo, carbocyclic, reverse, and acyclo C-nucleosides [for definitions, see Part I, 97AHC(68)223]. To avoid redundancy, whenever the synthesis of a C-nucleoside of a condensed base comprised the elaboration of a C-nucleoside of a monocyclic base, the synthesis of the latter is usually not discussed, since it has already been mentioned in the first part of this review. The literature has been surveyed to Vol. 125, No. 7 (1996), of *Chemical Abstracts* and Vol. 142 No. 10 (1996), of the *Index Chemicus*.



SCHEME 1

## II. Condensed Azole C-Nucleosides

### A. FURO[3,4-*c*]PYRROLYL ACYCLO C-NUCLEOSIDES


#### 1. Furo[4,3-*c*]pyrrol-1-yl Acyclo C-Nucleosides

Base-catalyzed de-*O*-acetylation and deesterification of the 3-(tetra-*O*-acetyl-*D*-arabino-tetritol-1-yl)-4-ethoxycarbonyl-2,5-dimethyl-2-nitropyrrole **1** took place with concomitant  $\gamma$ -lactone ring formation to provide the furo[3,4-*c*]pyrrol-1-yl acyclo C-nucleoside **2** [85AQ(C)49] (Scheme 1).


### B. INDOLE C-NUCLEOSIDES

#### 1. Indol-2-yl C-Nucleosides

Kinetically controlled acid-catalyzed cyclodehydration of the 2-(*D*-gluco- or *D*-manno-pentitol-1-yl)-4,5,6,7-tetrahydroindol-4-one (**3**) (Section II, C,1) furnished the 2-( $\alpha$ -*D*-arabinofuranosyl)-4,5,6,7-tetrahydroindol-4-one (**5**) [74JCS(P1)1237; 80MI5; 83MI9; 85MI10]. The furanose C-nucleoside **5** then was transformed to the thermodynamically more stable pyranose analog **6** (82MI5) (Scheme 2).



SCHEME 2




SCHEME 3

Dehydrative cyclization of the 2-(D-galacto-pentitol-1-yl) indol-4-one **9** directly gave the 2-(β-D-lyxopyranosyl)indol-4-one **10** without passing through the β-D-furanose C-nucleoside **7** because of steric destabilization of the transition state **8**, which contains the bulky CH<sub>2</sub>OH, HO-2', and HO-3' groups residing on the same side of the new furan ring [80MI5; 83MI9] (Scheme 3). C-Nucleoside **10** inhibited growth of Ehrlich ascites tumor cells [81FA(36)733].


Cyclization of indol-2-yl acyclo C-nucleosides that carry acid-sensitive O-protective groups such as **11** has been successfully achieved without affecting these groups by dehydration with triphenylphosphine-diethyl azodicarboxylate-iodine; a mixture of anomeric C-nucleosides (**12**) was usually produced [94CL265; 95JAP(K)95/118268] (Scheme 4).

## 2. Indol-3-yl C-Nucleosides

Cyclization of the 3-(D-manno-pentitol-1-yl)indole derivative **13** (Section II,C,2) with dilute hydrochloric acid gave a mixture of the 3-(α- and β-D-arabinofuranosyl)indoles **14** and **15**; the α-anomer predominated (91JOC5466) (Scheme 5).




SCHEME 4




Glycosylation of indole with glycosyl halides in the presence of silver oxide was studied by Russian groups, who found that a glycosyl halide having a participating group at C2 such as **16** gave a mixture of one anomer of the indol-3-yl *C*-nucleoside **17**, the *N*-nucleoside **19**, and the *ortho* acid amide **18** (80MI7) (Scheme 6). Glycosyl halides without a participating group at C2 (e.g., **20**) gave a mixture of the two anomeric indol-3-yl *C*-nucleosides (**22**) in which the  $\alpha$ -anomer preponderated (60MI1; 80KGS1423; 84MI4) (Scheme 7).

### 3. Indol-4-yl *C*-Nucleosides

Reaction of the *C*- $\beta$ -D-ribofuranosylnitromethane **24** with 2-allyl-1-ethoxycarbonylpyrrole in the presence of phenyl isocyanate formed the isoxazoline **26**. Catalytic reduction of **26** produced the  $\alpha$ -ketol **27**, which






SCHEME 7


cyclized with Lewis acids to the indol-4-yl *C*-nucleoside **28** [87JCS(CC)680] (Scheme 8).

#### 4. Indol-7-yl *C*-Nucleosides

Example **31** was obtained by reacting **24** with 3-allyl-1-(triisopropylsilyl)pyrrole **30** similarly to the preparation of **28** [87JCS(CC)680] (Scheme 9).



SCHEME 8




**SCHEME 9**

### C. INDOLE ACYCLO C-NUCLEOSIDES


### 1. Indol-2-yl Acyclo C-Nucleosides

2-Amino-2-deoxyaldoses [66AQ(B)471; 74JCS(P1)1237; 80MI4; 85MI10] **32**, (R = H) and 2-alkylaminoaldoses (**32**, R = alkyl) (83MI9; 85MI7) cyclocondensed with cyclohexane-1,3-diones to produce 2-(alditol-1-yl)-1,5,6,7-tetrahydroindol-4-ones (**35**) (Scheme 10). Structures of the acyclic *C*-nucleosides **35** were proved by oxidation to the corresponding indol-2-carboxylic acids [66AQ(B)471]. Some 4-hydrazono derivatives of **35** were prepared (91MI1).

*aldehydo*-Sugar derivatives (e.g., **36**) reacted with 2-lithioindole to afford the indol-2-yl acyclo *C*-nucleosides (e.g., **37**) [94CL265; 95JAP(K)95/118268] (Scheme 11).



SCHEME 10



SCHEME 11

## 2. Indol-3-yl Acyclo C-Nucleosides

Trapping the saccharide carbene **40**, formed by copper-catalyzed thermal decomposition of 1-diazo-1-deoxyketose acetates (**39**), by 1-alkylindoles gave the acetylated 3-(2-ulose-1-yl)indoles **41** (67MI3; 68DOK849, 68MI3) (Scheme 12).


Condensation of 1-alkylamino-1-deoxy-D-fructose (**42**) with cyclohexane-1,3-diones is a simple reaction that leads to 3-(D-arabino-tetritol-1-yl)-1,5,6,7-tetrahydroindol-4-ones (**45**) in high yield [74JCS(P1)1237] (Scheme 13).

The 1,2,3,5,6,7-hexahydro-4-oxoindol-3-yl acyclo C-nucleoside **47** was formed upon catalytic reduction of the 2-hydroximinobenzofuranone derivative **46**. Chemical dehydrogenation of **47** gave the tetrahydroindol-3-yl C-nucleoside **48** [87JCS(P1)581] (Scheme 14).


## D. BENZO[c]PYRROLE C-NUCLEOSIDES

### 1. Phthalimid-3-yl C-Nucleosides

Diels-Alder cycloaddition of maleimide onto the furan ring of **49** gave the oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxamide **50**, which was aroma-



SCHEME 12



SCHEME 13

tized and de-*O*-benzoylated to the 3- $\beta$ -D-ribofuranosylphthalamide **51** [84JOC1534; 85MI9] (Scheme 15).


## E. CARBAZOLE C-NUCLEOSIDES

### 1. Carbazol-1-yl C-Nucleosides

The C-nucleoside **53** was obtained by Lewis acid-catalyzed condensation of the 4- $\beta$ -D-ribofuranosyl-4-oxobutanal **52** with 2,3-unsubstituted indoles [89JCS(P1)649] (Scheme 16).


### 2. Carbazol-4-yl C-Nucleosides

2-Allyl-1-phenylsulfonylindole reacted with the C- $\beta$ -D-ribofuranosyl-nitromethane **24** in the presence of phenyl-isocyanate (see Scheme 8) to give the carbazol-4-yl C-nucleoside **54** [87JCS(CC)680] (Scheme 17).



SCHEME 14





SCHEME 15

### F. PYRIDO[3,4-*b*]INDOLE *C*-NUCLEOSIDES


#### 1. *Pyrido[3,4-*b*]indol-1-yl C-Nucleosides* (*β*-Carbolin-1-yl *C*-Nucleosides)

Pictet–Spengler reaction of 2,5-anhydro-D-mannose (**55**) and tryptamine hydrochloride (**56**) at ambient temperature affected the tetrahydropyridine ring formation of the (1*R*) and (1*S*)-1-( $\alpha$ -D-arabinofuranosyl)-1,2,3,4-tetrahydro- $\beta$ -carboline **57** [83CJC2721, 83JCS(CC)601] (Scheme 18).


### G. PYRIDO[3,4-*b*]INDOLE REVERSE *C*-NUCLEOSIDES

#### 1. *Pyrido[3,4-*b*]indol-1-yl Reverse C-Nucleosides* (*β*-Carbolin-1-yl Reverse *C*-Nucleosides)

The reverse *C*-nucleoside **59** was prepared by cyclocondensation of tryptamine (**56**) with the protected C5 aldehyde function of **58** (95SC3027) (Scheme 19).




SCHEME 16



SCHEME 17


H. PYRIDO[3,4-*b*]INDOLE ACYCLO C-NUCLEOSIDES1. *The Naturally Occurring Pyrido[3,4-*b*]indol-1-yl Acyclo C-Nucleoside "Pyridindolol"*

Pyridindolol was isolated (75JAN555) from culture filtrates of *Streptomyces alboverticillatus*, and its structure was established as 1-[(1*R*)-2-dihydroxyethyl]-3-hydroxymethyl-9-*H*-pyrido[3,4-*b*]indole (**60**) (75JAN555,




75JAN876). Pyridindolol is a specific inhibitor of neutral bovine  $\beta$ -galactosidase in acid media (75JAN555; 76JAN696).

(*R*, *S*) Pyridindolol (**64**) was synthesized by Pictet–Spengler reaction of tryptophan methyl ester with 2,3-*O*-isopropylidene-D-glyceraldehyde (**61**) as shown in Scheme 20 [78H(9)175; 79JOC535].




SCHEME 18




SCHEME 19

## 2. Pyridol[4,3-*b*]indol-3-yl Acyclo C-Nucleosides ( $\beta$ -Carbolin-3-yl Acyclo C-Nucleosides)

Treatment of the previously mentioned 3-(2-ulso-1-yl)indoles **41** (Section II,C,2) with acetic anhydride and perchloric acid gave the indole[2,3-*c*]pyrylium perchlorates **65**. Ammonium hydroxide in ether caused oxygen–nitrogen exchange and provided **66** [68DOK849, 68MI3] (Scheme 21).



SCHEME 20



SCHEME 21

### I. 1,2,4-TRIAZOLO[4',3':2,3]1,2,4-TRIAZINO[5,6-*b*]INDOLE ACYCLO C-NUCLEOSIDES

#### 1. 1,2,4-Triazolo[4',3':2,3]1,2,4-triazino[5,6-*b*]indol-3-yl Acyclo C-Nucleosides


Hydrazone **69** (R = H) derived from 3-hydrazino-5*H*-1,2,4-triazino[5,6-*b*]indole (**67**, R = H) and aldose monosaccharides (**68**) produced the acyclo C-nucleoside (**70**, R = H) upon oxidative cyclization with iron(III) chloride (92BCJ546). The poly-*O*-acetyl derivatives of the 10-methyl and 10-ethyl congeners (**70**, R = Me or Et) were obtained in one step from the corresponding hydrazones (**69**, R = Me or Et) by cyclization with a mixture of bromine in acetic acid, anhydrous sodium acetate, and acetic anhydride (97UP1) (Scheme 22).

### III. Condensed 1,2-Diazole C-Nucleosides

#### A. PYRAZOLO[1,2-*a*]PYRAZOLE ACYCLO C-NUCLEOSIDES

##### 1. Pyrazolo[1,2-*a*]pyrazol-3-yl Acyclo C-Nucleosides

The only reported acyclo C-nucleoside of this kind **75** was prepared by Hanisch and Henseke upon heating the 1,5:4,6-dianhydro-2,3-hexodiulose bis(phenylhydrazone) **74** with copper(II) sulfate (68CB4170) (Scheme 23).




SCHEME 22


## B. INDAZOLE C-NUCLEOSIDES

### 1. Indazol-3-yl C-Nucleosides

Dehydrocyclization of the epimeric mixture of the indazol-3-yl acyclo C-nucleoside **77** (Section III,E) by heating with hydrochloric acid afforded mainly the 3- $\beta$ -D-ribofuranosylindazole **78** and its  $\alpha$ -anomer (79JHC81) (Scheme 24).



SCHEME 23



SCHEME 24

## C. INDAZOLE HOMO C-NUCLEOSIDES


## 1. Indazol-3-yl Homo C-Nucleosides

The indazol-3-yl homo C-nucleoside **81** was obtained by 1,3-dipolar cycloaddition of benzyne to the 2,5-anhydro-D-allonoyldiazomethane derivative **80** (79JHC81) (Scheme 25).


## D. INDAZOLE REVERSE C-NUCLEOSIDES

## 1. Indazol-3-yl Reverse C-Nucleosides

Although 1,3-dipolar cycloaddition of benzyne or 4,6-dichlorobenzyne to the D-riboseuronyldiazomethane glycoside **83** afforded a single isomer (**82**) of this category of C-nucleosides, monosubstituted benzyne provided a mixture of the two isomers **84** and **85** in most cases (76JHC1241; 79JHC81) (Scheme 26).



SCHEME 25



SCHEME 26

### E. INDAZOLE ACYCLO C-NUCLEOSIDES

#### 1. Indazol-3-yl Acyclo C-Nucleosides


Aldonoyldiazomethane acetates **39** were used to prepare **86** by cycloaddition to arynes (76JHC1241) (Scheme 27). Acyclo C-nucleosides **86** showed a significant antitumor activity against HeLa cells (79JHC81).

## IV. Condensed 1,3-Diazole C-Nucleosides

### A. FURO[2,3-*d*]IMIDAZOLE ACYCLO C-NUCLEOSIDES

#### 1. Furo[2,3-*d*]imidazol-5-yl Acyclo C-Nucleosides

The reaction product of 2-amino-2-deoxy-D-glucopyranose (**87**) with alkyl or aryl isocyanates or isothiocyanates were previously assigned the structure of 1,2-dideoxy-D-glucopyrano[1,2-*d*]imidazolidin-2-ones (**89**, Z =




SCHEME 27

O) (56CB1246; 61HCA403; 75OPP291; 79JAN436) or the corresponding 2-thiones (**89**,  $Z = S$ ) [61AQ(B)379; 63LA(669)146; 64AQ(B)653; 65NEP6507269, 65NEP6507271, 65NEP6507423]. Results of quantitative oxidation with sodium periodate or lead tetra-acetate [68HCA569; 74AQ(C)57],  $^1\text{H}$  NMR [68HCA569; 84MI8; 86AQ(C)11; 91MI5], and  $^{13}\text{C}$  NMR (91MI5) spectral data, in addition to the X-ray crystallographic analysis [74AX(B)1801; 76AX(B)1363, 76AX(B)2115, 76CSC353, 76CSC369; 78AX(B)184; 79AQ1002; 80AX(B)3048; 83AX(C)1418; 84AX(C)898; 85AX(C)277, 85AX(C)1658; 86AQ(C)11, 86AX(C)454, 86AX(C)1659; 91MI5; 93MI5; 95ZK506], however, indicated that these compounds are in fact the 1,2-dideoxy-D-glucofurano[1,2-*d*]imidazolidin-2-ones (**90**,  $Z = O$ ) and the corresponding 2-thiones (**90**,  $Z = S$ ). Compounds **90** were produced from the initially formed 2-deoxy-2-ureido- or 2-thioureidoglucopyranoses **88**. The structure of compounds **90** conform with their classification as acyclo C-nucleosides, namely: 1a,4a,5,6-tetrahydro-6-hydroxy-5-[(2*R*)-1,2-dihydroxyethyl]-*cis*-furo[2,3-*d*]imidazol-3-one (**90**,  $Z = O$ ) or the corresponding 3-thioxo congeners **90** ( $Z = S$ ) (Scheme 28).


This reaction was applied to other 2-amino- and 2-alkylamino-2-deoxyaldohexoses (**91**;  $n = 0$ ,  $R = \text{H}$ , alkyl) [74AQ(C)57; 79AQ1002; 84MI7, 84MI8; 86AQ(C)11; 87MI3; 88MI6; 90MI4; 91MI5; 93T2655; 94T3273; 95ZK506], as well as 2-amino- and 2-alkylamino-2-deoxyaldohexoses (**91**;  $n = 1$ ,  $R = \text{H}$ , alkyl) (87MI2; 89MI4; 93T2676), to yield **96** or **97**. Some 3-imino (90MI5) and 3-selenoxo derivatives (92MI4) of **96** or **97** were also prepared (Scheme 29).

The broad-spectrum antibiotic streptozotocin **98** is a 2-deoxy-2-ureido-D-glucopyranose derivative and, consequently, afforded the furo[2,3-*d*]imidazol-6-yl acyclo C-nucleoside **99** when treated with sulfamic acid or with hydrogen and palladium (67JA4808; 76JAN1218; 79JOC9) (Scheme 30).



SCHEME 28





$n = 0 \text{ or } 1$ ;  $Z = \text{O, S, Se, NH}$ ;  $R = \text{H, Me, Et, Pr, ArCH}_2$ ;  $R' = \text{H, Ar}$


SCHEME 29

The 3-thioxo-furo[2,3-*d*]imidazol-6-yl acyclo *C*-nucleosides **101** undergo facile acid-catalyzed tetrahydrofuran ring opening to give the imidazol-4-yl acyclo *C*-nucleosides **100** (84MI11; 88MI8) and *S*-benzylation to **102** (84MI6) (Scheme 31).


## B. BENZIMIDAZOLE C-NUCLEOSIDES

### 1. Benzimidazol-2-yl *C*-Nucleosides

Heating 2-(*D*-tetritol-1-yl)benzimidazoles (**103**) (Section IV,C) with an acid in the presence of zinc(II) chloride caused dehydrocyclization of their




SCHEME 30




SCHEME 31

tetritol-1-yl chains to the corresponding 2-( $\alpha$ - or  $\beta$ -D-tetrafuranosyl)benzimidazoles (**104**). The structure of **104** was confirmed by oxidation to benzimidazole-2-carboxylic acid (**105**) [40JBC(133)293; 45JBC(159)503] (Scheme 32).

Benzimidazol-2-yl C-nucleosides (e.g., **107**) were also synthesized by condensation of anhydroaldonic acids such as 2,5-anhydro-D-allonic acid (**106**) with 1,2-diaminobenzene [50JBC(186)387; 69CCC247; 80JCS(P1)2683; 86SC35] (Scheme 33).



SCHEME 32




SCHEME 33

## C. BENZIMIDAZOLE ACYCLO C-NUCLEOSIDES


1. *Benzimidazol-2-yl Acyclo C-Nucleosides*

Condensation of 1,2-diaminobenzene with aldoses (**68**) in the presence of acids led to the formation of three products: 1,2-bis(alditol-1-ylidene-amino)benzenes (**108**), 2-(alditol-1-yl)quinoxalines (**111**) (Section XII,G), and 2-(alditol-1-yl)benzimidazoles (**112**); the yield of the latter was marginal. Formation of **111** and **112** was rationalized in terms of oxidation of the aldoses (**68**) to alduloses (**109**) and aldonic acids (**110**) that cyclocondense with 1,2-diaminobenzene to give **111** and **112**, respectively (1887CB281, 1887CB2205, 1887CB3111; 1893CB3092; 01CB902; 34CB155, 34CB898, 34JA1248). This rationale was verified when the yield of benzimidazoles **112** was made to considerably increase by carrying out the reaction in the presence of copper(II) acetate as an oxidizing agent (40JOC637; 57JCS3961) or by employing aldonic acids or their lactones in place of the parent aldoses [39JA1266; 40JBC(133)293, 40NAT(L)559; 42JA1609; 43JA994, 43JA1854, 43JBC(150)345; 44JA1912, 44JCS339; 45JBC(159)503; 50JA3882; 51JA855, 51JA4907; 52JA4521; 53JA4320; 56JA4491; 65JOC79; 82MI8] (Scheme 34). The benzimidazole structure of **112** was conclusively proved by oxidation to benzimidazole-2-carboxylic acid (01CB902; 34CB898).

The plant-growth-regulating benzimidazol-2-yl acyclo C-nucleoside **116** was prepared (93ZOR1643) by cyclocondensation of the *aldehydo-D*-arabinose derivative **113** and the quinonimine **114** (Scheme 35).



SCHEME 34




SCHEME 35

The double-headed bis(benzimidazol-2-yl) acyclo C-nucleosides **118** were obtained from the reaction of 1,2-diaminobenzene with aldaric acids of various configurations (**117**) [29JA2225; 42JBC(143)551; 48BJ(42)2, 50BJ(47)1; 73MI2] (Scheme 36).

2-(Alditol-1-yl)benzimidazoles are far superior as derivatives for characterization of aldoses to hydrazones and osazones (51MI1; 58UK179; 70CRV389, 70MI1). They have been used to characterize sugars from *Helix pomatia* (41JCS125) and nucleic acids (43JCS625; 47JCS21). With racemic tartaric acid, they form diastereoisomeric salts that are resolvable to afford the two individual enantiomers of the acid [39JA1266; 48USP2456752; 57NAT(L)367]. 5-Methyl-2-(*L*-arabino-tetritol-1-yl)benzimidazole showed antitumor activity against 6C3H-ED lymphosarcoma in mice (56JA4491).

Some empirical rules were devised to correlate the configuration at C1 of the alditolyl chains (C2 of the parent sugar) of 2-(alditol-1-yl)benzimidazoles with their polarimetric (42JA1612) and spectropolarimetric properties (67JA4129). The mass spectra of these compounds have been investigated (82MI8).



SCHEME 36

## V. Condensed Oxazole C-Nucleosides


### A. Furo[2,3-*d*]OXAZOLE ACYCLO C-NUCLEOSIDES

#### 1. Furo[2,3-*d*]oxazol-5-yl Acyclo C-Nucleosides


D-Glucose (**119**) reacted with potassium thiocyanate to give a product that was erroneously called the glucopyrano[3,2-*d*]oxazole (**120**) (36CB748; 45JOC267) or the glucopyrano[2,3-*d*]oxazole (**121**) [38CB590; 52CI(L)-1034] structures. Quantitative oxidation with sodium periodate (54JCS2645), acid strength measurements (59ACSA1129),  $^1\text{H}$  NMR (68BCJ261), and  $^{13}\text{C}$  NMR (91MI6) spectrometry, however, indicated that the product is actually the furo[2,3-*d*]oxazolidin-5-yl acyclo C-nucleoside **123** ( $\text{Z} = \text{S}$ ). This reaction was also applied to other aldohexoses (67CB845; 94MI7). Potassium cyanate (54JCS2645; 91MI6; 94MI7; 95MI1; 96AJC409) and urea (89MI6; 91MI8) also reacted with aldoses to give the corresponding **123** ( $\text{Z} = \text{O}$  or  $\text{NH}$ ) (Scheme 37).

The 3,5,6-tri-*O*-benzoyl derivative **128** of **123** ( $\text{R} = \text{PhCO}$ ) has been prepared by treating the 1,2-*O*-sulfinyl- $\alpha$ -D-glucopyranose derivative **124** with sodium thiocyanate (95TL5347) (Scheme 38).

1-Phenylfuro[2,3-*d*]oxazolidin-5-yl acyclo C-nucleoside **130** was obtained by cyclization of either of the 1-[2-*O*-(1-phenylcarbamoyl)-D-glucopyranosyl]piperidine **129** (69JOC2654) or methyl 2-*O*-(phenylcarbamoyl)- $\alpha$ -D-glucopyranoside (**131**) [74ACSA(B)559] (Scheme 39).



SCHEME 37




SCHEME 38

## B. FURO[3,2-*d*]OXAZOLE ACYCLO C-NUCLEOSIDES


### 1. Furo[3,2-*d*]oxazol-5-yl Acyclo C-Nucleosides

Ketalization (59CB1288; 64ACSA185) or acetalation (68IZV2655) of 2-benzamido-2-deoxy-D-glucose **132** took place with simultaneous sugar ring contraction and oxazoline ring formation; the product is the tetrahydrofuro[3,2-*d*]oxazolin-5-yl acyclo C-nucleoside **133** having the fused rings of the heterocyclic system *cis*-fused. The oxazoline ring of **133** is stable to bases so that its C5 OH can be etherified [61NAT(L)495; 68JCS(C)1903] or esterified (62CB996) in basic media to the corresponding derivatives **134**. However, the oxazoline ring of **134** is even more sensitive to acids than are dioxolane rings; they undergo  $\beta$ -glycosidation with alcohols in the presence of very dilute acids to **135** [63CB2019; 68JCS(C)1903] (Scheme 40).

Treatment with sodium hydroxide caused evolution of diazomethane from the antibiotic streptozotocin (**98**) and formation of the 3a,5,6,6a-tetrahydro-6-hydroxy-5-[(2*R*)-1,2-dihydroxy-ethyl]-*cis*-furo[2,3-*d*]oxazol-2-one **136** (79JOC9) (Scheme 41).



SCHEME 39




SCHEME 40

The 6-deoxy-L-congener **141** of **136** was obtained from 2-amino-2-deoxy-L-glucopyranose **137** as shown in Scheme 42 (76BCJ313).


### C. Furo[3,4-*d*]oxazole Acyclo C-Nucleosides

#### 1. Furo[3,4-*d*]oxazol-6-yl Acyclo C-Nucleosides

Gigg and Warren cyclized the methyl 2-benzamido-2-deoxy-5,6-*O*-isopropylidene-4-*O*-methylsulfonyl- $\beta$ -D-glucopyranoside **135** to the furo[3,4-*d*]oxazin-6-yl acyclo C-nucleoside **142** by treatment with sodium methoxide in methanol [65JCS1351, 65TL1303; 66JCS(C)1872] (Scheme 43).



SCHEME 41




SCHEME 42

D. THIAZOLO[3,4-*c*]OXAZOLE ACYCLO C-NUCLEOSIDES1. *Thiazolo[3,4-*c*]oxazol-7-yl Acyclo C-Nucleosides*

Cylocondensation of tetra-*O*-acetyl-aldehydo-L-arabinose (**143**) with L-cysteine gave the thiazol-2-yl C-nucleoside **144** (76LA450). Acetylation of the latter gave the 7-(tetra-*O*-acetyl-D-arabino-tetritol-1-yl)thiazolo[3,4-*c*]oxazole **145** (94M189) (Scheme 44).


2. *Thiazolo[3,4-*c*]oxazoldi-1,7-yl Acyclo C-Nucleosides*

Treatment of the thiazol-2-yl acyclo C-nucleoside **144** with an additional molecule of **137** affected oxazole ring closure of the thiazolo[3,4-*c*]oxazole acyclo C-nucleoside **146** having two alditolyl chains (76LA450) (Scheme 44).



SCHEME 43





SCHEME 44

## E. BENZOXAZOLE C-NUCLEOSIDES

### 1. Benzoxazol-2-yl C-Nucleosides


The 2-β-D-ribofuranosylbenzoxazole **150** was formed upon reacting β-D-ribofuranosylformimide (**148**) with 2-aminophenol (86MI4) (Scheme 45).

## VI. Condensed Thiazole C-Nucleosides


### A. PYRROLO[1,2-*c*]THIAZOLE ACYCLO C-NUCLEOSIDES

#### 1. Pyrrolo[1,2-*c*]thiazol-7-yl Acyclo C-Nucleosides

Synthesis of the acyclo C-nucleoside **147** was achieved by [3+2] cycloaddition of thiazolo[3,4-*c*]oxazole C-nucleoside **145** onto dimethylacetylene dicarboxylate (94M189) (Scheme 44).



SCHEME 45



SCHEME 46

## B. PYRAZOLO[5,1-*b*]THIAZOLE ACYCLO C-NUCLEOSIDES

### 1. *Pyrazolo*[5,1-*b*]thiazol-3-yl Acyclo C-Nucleosides

Reaction of 1-bromo-1-deoxy-D-*galacto*-heptulose (**151**) with the pyrazole derivative **152** in the presence of sodium methoxide gave the C-nucleoside **155** (86PHA548) (Scheme 46).

## C. IMIDAZO[2,1-*b*]THIAZOLE ACYCLO C-NUCLEOSIDES


### 1. *Imidazo*[2,1-*b*]thiazol-5-yl Acyclo C-Nucleosides

The thiazole ring of the 5-(D-*arabino*-tetritol-1-yl)-imidazo[2,1-*b*]thiazolium olate **160** was assembled onto the imidazole ring of 4-(tetra-*O*-acetyl-D-*arabino*-tetritol-1-yl)imidazoline-2-thione (**156**) by reaction with 2-bromophenylacetic acid (91MI7) (Scheme 47).

## D. FURO[2',3':4,5]IMIDAZO[2,1-*b*]THIAZOLE ACYCLO C-NUCLEOSIDES

### 1. *Furo*[2',3':4,5]imidazo[2,1-*b*]thiazol-6-yl Acyclo C-Nucleosides

2-Thioxo-furo[2,3-*d*]imidazolidin-6-yl acyclo C-nucleoside acetate **161** condensed with 2-bromophenylacetic acid to form **162**, which cyclized by




SCHEME 47

heating and acetic anhydride and subsequent treatment with triethylamine to furo[2',3:4,5]imidazo[2,1-*b*]thiazolium-3-olate acyclo *C*-nucleoside acetate **165** (91MI7) (Scheme 48).

## E. BENZOTHAZOLE *C*-NUCLEOSIDES

### 1. Benzothiazol-2-yl *C*-Nucleosides

*O*-Protected glycofuranosyl cyanides (e.g., **166**) [78KGS893; 81ACH (106)61; 82ACH(109)229] and glycopyranosyl cyanides (77MI6; 94MI5) reacted with 2-aminothiophenol to furnish the corresponding benzothiazol-




SCHEME 48


2-yl C-nucleoside (e.g., **168**). The reaction takes place, most probably, through the intermediate thioimide **167** (Scheme 49).

Benzothiazol-2-yl C-nucleosides were also obtained by a different mode of synthesis that involved the free radical coupling of the sugar subunit with the heterocycle residue. The 2-deoxy-D-ribofuranosyl free radical **170**, formed by photolysis of the 2-thiopyridone-*N*-(2,5-anhydro-3-deoxy)-D-allonoate **169**, reacted with benzothiazolium camphorsulfonate to form a mixture of 2-( $\alpha$  and  $\beta$ -2-deoxy-D-ribofuranosyl) benzothiazoles **171** (92CL1673) (Scheme 50).

Coupling free radical **173**, obtained by decarboxylative photolysis of the acid **172** in the presence of diacetoxiodobenzene (DAIB), with benzothiazolium trifluoroacetate, gave **174**. Unlike the previous synthesis, this coupling ensued diastereoselectively as a result of the nonplanarity of the free radical centered on the carbon at the junction of the two rings (92TL7575) (Scheme 51).




SCHEME 49



AH = Camphorsulfonic acid

R = PhCO

SCHEME 50



SCHEME 51

## F. BENZOTHAIAZOLE CARBOCYCLIC C-NUCLEOSIDES

### 1. *Benzothiazol-2-yl Carbocyclic C-Nucleosides*

The carbocyclic C-nucleoside analog **177** pertaining to this class was prepared by coupling free radical **176** with benzothiazolium trifluoroacetate [94JCS(P1)2407] (Scheme 52) in a similar way to that used for the preparation of **171**.


## G. BENZOTHAIAZOLE ACYCLO C-NUCLEOSIDES

### 1. *Benzothiazol-2-yl Acyclo C-Nucleosides*


Aldose monosaccharides (**68**), when condensed with 2-aminothiophenols, gave the 2-(alditol-1-yl)benzothiazolines (**178**) [51JA5908; 69ACH(62)65; 70MI5; 74MI9; 77MI1]. In one case (77MI5), this reaction was reported to yield a mixture of the benzothiazol-2-yl (**179**) and benzothiazolin-2-yl (**178**) *C*-nucleosides. Acetylation of **178** affected both *N*- and *O*-acetylation to give **182**, which were also obtained by condensation of 2-aminothiophenol with poly-*O*-acetyl-*aldehydo*-sugars (**180**) followed by *N*-acetylation [69ACH(62)65; 70MI5] (Scheme 53).

Poly-*O*-acetyl-benzothiazol-2-yl acyclo *C*-nucleosides **184** were prepared in good yields from the aldnonitrile acetates (**183**) [69ACH(62)179; 82ACH(109)229] or aldonoil chloride acetates **38** [69ACH(62)179] by reaction with 2-aminothiophenols (Scheme 54).

Synthesis by carbon–carbon bond formation between an acyclic sugar derivative and the benzothiazole ring system has also been utilized for the synthesis of these *C*-nucleosides. In one report, 2,3-*O*-isopropylidene-D-glyceraldehyde (**61**) was coupled with 2-trimethylsilylbenzothiazole to afford the *N*-nucleoside **185** as an intermediate, which underwent a 1,2-shift of the alditolyl chain to produce the *C*-nucleoside **186** (85TL5477) (Scheme 55).




**SCHEME 52**




SCHEME 53


According to other reports (73DOK99; 74JOC1374), C—C bond formation was achieved by reacting 2-benzothiazolyl lithium with *O*-protected aldonolactones such as **187** to form the hemiacetal (lactol) type of C-nucleosides **188**, which were reduced with sodium borohydride to **189** (Scheme 56).



SCHEME 54



SCHEME 55



SCHEME 56


The relation between CD spectral characteristics and configuration of the alditolyl chains of benzothiazol-2-yl *C*-nucleosides (**72T4197**) and their *O*-acetyl derivatives (**73MI1**) was studied.

## VII. Condensed 1,2,3-Triazole *C*-Nucleosides

### A. Furo[3,4-*d*]1,2,3-TRIAZOLE ACYCLO *C*-NUCLEOSIDES

#### 1. Furo[3,4-*d*]1,2,3-triazol-4-yl Acyclo *C*-Nucleosides

Oximation of dehydro-D- or L-ascorbic acid 2-arylhydrazones **191** followed by dehydrative cyclization and concomitant *O*-acetylation of the resulting 2-arylhydrazones-3-oximes **192** led to the formation of the 1,2,3-



SCHEME 57

triazole ring of the furo[3,4-*d*]1,2,3-triazol-4-yl acyclo C-nucleosides **193** (77MI7; 79MI8; 82MI7; 83MI10; 88MI1; 93MI1) (Scheme 57).

## VIII. Condensed 1,3,4-Thiadiazole C-Nucleosides

### A. 1,2,4-TRIAZOLO[3,4-*b*]1,3,4-THIADIAZOLE ACYCLO C-NUCLEOSIDES

#### 1. 1,2,4-Triazolo[3,4-*b*]1,3,4-thiadiazol-6-yl Acyclo C-Nucleosides


The only known examples of this sort are **196** and **198**, and they were synthesized by cyclocondensation of 4-amino-3-aryl-1,2,4-triazole-5-thiols (**195**) with poly-*O*-acetyl derivatives of aldonic (**194**) or aldaric acids (**197**), respectively, in the presence of phosphoryl chloride (95PHA534) (Scheme 58).

## IX. Condensed Azine C-Nucleosides

### A. CYCLOPENTA[*c*]PYRIDINE C-NUCLEOSIDES


#### 1. Cyclopenta[*c*]pyridin-3-yl C-Nucleosides

Inverse [4+2]cycloaddition of the activated 1,2,4-triazin-4-yl C-nucleoside **200** with the electron-rich 1-pyrrolidinocyclopentene and subsequent elimination of a nitrogen molecule led to the formation of the cyclopenta[*c*]pyridin-3-yl C-nucleoside **199** (95AP175) (Scheme 59).



SCHEME 58





SCHEME 59

## B. PYRROLO[2,3-*b*]PYRIDINE C-NUCLEOSIDES


### 1. Pyrrolo[2,3-*b*]pyridin-3-yl C-Nucleosides

The reaction medium was found to be crucial in determining whether *N*- or *C*-alkylation of 1-pyrrolo[2,3-*b*]pyridine magnesium bromide with *aldehydo*-sugar derivatives, such as 2,3,5-tri-*O*-benzyl-D-arabinofuranose **202**, will take place. Although predominant *N*-alkylation occurred in THF, *C*-alkylation at C3 of the pyrrolo[2,3-*b*]pyridine system became almost exclusive in dichloromethane to give the 3-(D-*manno*-tetritol-1-yl)pyrrolo[2,3-*b*]pyridine **203** as a single enantiomerically pure isomer as ascertained by  $^1\text{H}$  NMR,  $^{13}\text{C}$  NMR, and reversed-phase HPLC. Acid-catalyzed dehydrocyclization of **203** gave a mixture of the two anomers of **204** (91JOC5466) (Scheme 60).

## C. PYRROLO[3,2-*c*]PYRIDINE C-NUCLEOSIDES

### 1. Pyrrolo[3,2-*c*]pyridin-6-yl C-Nucleosides

Utilization of 1-methyl-2-methylthio-2-pyrroline as a dienophile to react with **200** produced the 1-methyl-6-( $\beta$ -D-ribofuranosyl)pyrrolidino[3,2-*c*]pyridine **201** (95AP175) (Scheme 59).




SCHEME 60

D. IMIDAZO[1,2-*a*]PYRIDINE C-NUCLEOSIDES1. *Imidazo[1,2-*a*]pyridin-5-yl C-Nucleosides*

Ribosylation of lithiated 2,6-dichloroimidazo[1,2-*a*]pyridine with the D-ribo-1,4-lactone derivative **187** occurred, unexpectedly, at C5 instead of C3 to afford the hemiacetal C-nucleoside **205**. Compound **205** was *O*-acetylated and reductively deacetoxyated with triethylsilane in the presence of a Lewis acid to the anomeric mixture of **206**. The  $\alpha:\beta$  ratio of **206** depended on the Lewis acid (96TL2365) (Scheme 61).


E. IMIDAZO[1,2-*a*]PYRIDINE ACYCLO C-NUCLEOSIDES1. *Imidazo[1,2-*a*]pyridin-3-yl Acyclo C-Nucleosides*

Imidazo[2,1-*b*]thiazolium-3-olate **160** (Section VI,C; Scheme 47) underwent rapid cycloaddition with acetylene mono- and dicarboxylic esters to give the imidazo[1,2-*a*]pyridin-3-yl acyclo C-nucleoside **208** through sulfur extrusion from the intermediate **207** (91MI7) (Scheme 62).




LTMP = Lithiated tetramethylpiperidine

SCHEME 61



Ar = 4-EtO-C<sub>6</sub>H<sub>4</sub> ; R = R' = COOMe ; R or R' = H or COOMe

SCHEME 62



The imidazo[1,2-*a*]pyrid-3-yl acyclo *C*-nucleoside **209** having a truncated thiosugar residue was synthesized and found to be markedly active against varicella zoster virus (94MI1).

## F. IMIDAZO[1,5-*a*]PYRIDINE *C*-NUCLEOSIDES



### 1. Imidazo[1,5-*a*]pyridin-3-yl *C*-Nucleosides

The 2,5-anhydro-D-allonic acid imidate **210** ( $R = OR'$ ,  $Z = O$ ) condensed with 2-aminomethylpyridine to form the corresponding amide **211**. Dehydrative cyclization of the latter gave **212** [84JCS(P1)229]. The reaction was also performed by employing the dithioate **210** ( $R = OR'$ ,  $R^3 = H$ ,  $Z = S$ ) [82MI6; 85JCS(P1)621] (Scheme 63).


## G. IMIDAZO[1,5-*a*]PYRIDINE CARBOCYCLIC *C*-NUCLEOSIDE

### 1. Imidazo[1,5-*a*]pyridin-3-yl Carbocyclic *C*-Nucleoside

The *C*-nucleoside **219** was prepared from 8,9,10-trinorborn-5-en-2-ol (**213**) according to the total synthetic approach outlined in Scheme 64 [86JCS(P1)393].



SCHEME 63




PDC = Pyridine dichromate


SCHEME 64

H. IMIDAZO[4,5-*b*]PYRIDINE C-NUCLEOSIDES1. *Imidazo[4,5-*b*]pyridin-2-yl C-Nucleosides*

In the presence of a coupling reagent (POB), the D-arabino-hexulosonic acid derivative **220** condensed with 2,3-diaminopyridines to provide the amides **221**. The 2-(β-D-pentopyranosyl)imidazo[4,5-*b*]pyridines **222** were then obtained by mild base-catalyzed cyclodehydration of **221** [80JCS(P1)2683] (Scheme 65).



SCHEME 65



SCHEME 66

## I. Furo[2',3':4,5]IMIDAZO[1,2-*a*]PYRIDINE ACYCLO *C*-NUCLEOSIDES



### 1. *Furo*[2', 3':4,5]*imidazo*[1,2-*a*]pyridin-6-yl *Acyclo C-Nucleosides*

Similar to the synthesis of **208**, the furo[2',3':4,5]imidazo[2,1-*b*]thiazolium-3-olate **165** (Section VI,D; Scheme 48) added acetylene carboxylic esters to give **223**, which extruded sulfur to furnish **224** (91MI7) (Scheme 66).


## J. 1,2,4-TRIAZOLO[1,5-*a*]PYRIDINE *C*-NUCLEOSIDES

### 1. *1,2,4-Triazolo*[1,5-*a*]pyridin-2-yl *C-Nucleosides*

The initially formed 1,2,4-triazolo[4,3-*a*]pyridin-3-yl *C*-nucleosides **226**, which result from the reaction of the glycosylthioformimidates **225** and 2-hydrazino-3- or 5-nitropyridines, underwent Dimroth rearrangement to the 1,2,4-triazolo[1,5-*a*]pyridin-2-yl *C*-nucleosides **227** (76JOC3124; 78FRP2358154; 79MI1; 81JMC1291), which exhibit antiviral activity against the virus Sindbis (78FRP2358154) (Scheme 67).



SCHEME 67



SCHEME 68

### K. 1,2,4-TRIAZOLO[1,5-*a*]PYRIDINE ACYCLO C-NUCLEOSIDES

#### 1. 1,2,4-Triazolo[1,5-*a*]pyridin-2-yl Acyclo C-Nucleosides

Acyclo C-nucleosides **229** were synthesized by cyclocondensation of the thioimidates **228** with 2-hydrazino-3- or 5-nitropyridines (83JHC1169) (Scheme 68).

### L. 1,2,4-TRIAZOLO[4,3-*a*]PYRIDINE C-NUCLEOSIDES

#### 1. 1,2,4-Triazolo[4,3-*a*]pyridin-3-yl C-Nucleosides


2-Hydrazinopyridines reacted with glycosylthioformimidates (e.g., **230**) (76JOC3124; 79MI1) or 2,5-anhydrohexoaldonic acids (e.g., **79**) (78MI12) to yield, after de-*O*-protection, mixtures of the  $\alpha$ - and  $\beta$ -anomers of **234** (Scheme 69).

An interesting synthesis of these C-nucleosides utilized the easily accessible 5-( $\beta$ -D-ribofuranosyl)tetrazoles **235** as masked C-glycosyl-diazomethane. Reacting **235** with 2-chloro-3-nitropyridine gave a mixture of 1,2,4-triazolo[4,3-*a*]pyridin-3-yl (**236**) and 1,2,4-triazolo[1,5-*a*]pyridin-2-yl (**237**) C-nucleosides. The latter (**237**) resulted from thermally induced Dimroth-like rearrangement of the former (**236**) (86MI9) (Scheme 70). Compounds **236** and **237** possess considerable cytotoxic effect (86MI9).


### M. 1,2,4-Triazolo[4,3-*a*]PYRIDINE ACYCLO C-NUCLEOSIDES

#### 1. 1,2,4-Triazolo[4,3-*a*]pyridin-3-yl Acyclo C-Nucleosides

As in the preparation of the cyclic analog **236**, the 1,2,4-triazolo[4,3-*a*]pyridin-3-yl acyclo C-nucleoside **239** was obtained, together with the 1,2,4-



SCHEME 69




SCHEME 70

triazolo[1,5-a]pyridin-2-yl acyclo C-nucleoside **240**, by reacting the tetrazole acyclo C-nucleoside **238** and 2-chloro-3-nitropyridine (86MI9) (Scheme 71).

## N. QUINOLINE C-NUCLEOSIDES

### 1. Quinolin-2-yl C-Nucleosides

Glycosyl free radicals (**242**), generated by thermolysis (91T6559) or photolysis of 2,5-anhydroaldonic acids (**241**,  $R = H$ ) in the presence of hypervalent iodine compounds (HVICs) [91TL6559; 92TL7575; 93JCS(P1)2417],



SCHEME 71


as well as by photolysis of the 2-(thiopyridine)-*N*-(2,5-anhydro-aldonoate) (**241**, R = 2-C<sub>5</sub>H<sub>4</sub>NS) [91TL3377; 92CL1673; 94JCS(P1)2931], were coupled with lepidinium salts to give mixtures of the  $\alpha$ - and  $\beta$ -lepidin-2-yl *C*-nucleosides (**243**). The stereoselectivity of the reaction ( $\alpha/\beta$  ratio) seems to be dependent on the structure of the sugar moiety [94JCS(P1) 2931] (Scheme 72).

## 2. Quinolin-3-yl *C*-Nucleosides

Carbon-carbon bond formation between the *aldehydo*-2-deoxy-D-ribose derivative **244** and 3-lithio-2-fluoroquinoline produced the two diastereoisomers of the quinolin-3-yl acyclo *C*-nucleoside **245**. Separation of the two diastereoisomers, cyclization of their alditolyl chains, and de-*O*-protection gave the 3-(2-deoxy- $\beta$ -D-ribofuranosyl)quinoline **246** and its  $\alpha$ -anomer (91TL3297) (Scheme 73).


## 3. Quinolin-4-yl *C*-Nucleosides

Elaboration of the 5-hydroxy-5-( $\beta$ -D-ribofuranosyl)furanone **247** to the 2-carboxamidoquinolin-4-yl *C*-nucleoside **251** was achieved by reaction with aniline as shown in Scheme 74 [93H(36)2805].



SCHEME 72






SCHEME 73


## O. QUINOLINE HOMO C-NUCLEOSIDES

1. *Quinolin-2-yl Homo C-Nucleosides*

Togo, Yokoyama, and their co-workers prepared the lepidin-2-yl homo C-nucleoside **254** by C—C bond formation between the D-ribofuranosyl-methyl free radical **253**, generated by photolytic or thermolytic decarboxylation of the D-ribofuranosylacetic acid derivative **252**, in the presence of HVIC, with lepidinium trifluoroacetate (91TL6559) (Scheme 75).



SCHEME 74



SCHEME 75

## P. QUINOLINE CARBOCYCLIC C-NUCLEOSIDES


### 1. Quinolin-2-yl Carbocyclic C-Nucleosides

Coupling the cyclobutane free radical **176** with lepidinium camphor-sulfonate led to the formation of the carbocyclic C-nucleoside **255** [94JCS(P1)2407] (Scheme 76).


## Q. QUINOLINE REVERSE C-NUCLEOSIDES

### 1. Quinoline-2-yl Reverse C-Nucleosides

The first synthesis of these compounds (**258**) was reported in 1968 by Zhdanov *et al.* (68MI4) by applying the Doebner reaction to Schiff bases **257** of the dialdo-D-xylopentofuranose derivative **256** (Scheme 77). Benzo-[f]quinolin-2-yl reverse C-nucleosides were also similarly prepared by the same group (69ZOB1413).



SCHEME 76




SCHEME 77

Later, some of these C-nucleosides (e.g., **261**) were synthesized by free radical C—C bond formation between the free radical **260**, generated from the D-ribose derivative **259**, and lepidinium trifluoroacetate. Stereoselectivity of this coupling was attributed to the dominance of the steric bulk of the 1,3-dioxolane ring in **260** (92TL7575) (Scheme 78).


The D-galactopyranose lepidin-2-yl reverse C-nucleoside **264** was obtained by coupling salts of 4-substituted quinolines with the free radical **263** (93JOC959) (Scheme 79).

## 2. Quinolin-4-yl Reverse C-Nucleosides

Reaction of the free radical **263** with salts of 2-substituted quinolines such as quinaldine trifluoroacetate directed the coupling to position 4 of the quinoline ring system to give **265** (93JOC959) (Scheme 79).



SCHEME 78




SCHEME 79


## R. 1,2,4-TRIAZOLO[4,3-a]QUINOLINE ACYCLO C-NUCLEOSIDES

### 1. 1,2,4-Triazolo[4,3-a]quinolin-2-yl Acyclo C-Nucleosides

The 1,2,4-triazole ring of **267** was formed by oxidative cyclization of aldehydo-sugar lepidin-2-yl-hydrazone (**266**) with iron(III) chloride (94MI6) (Scheme 80).



SCHEME 80



SCHEME 81

### S. ACRIDINE ACYCLO C-NUCLEOSIDES


#### 1. Acridin-9-yl Acyclo C-Nucleosides

Cyclocondensation of D-mannose (**268**) with two molar equivalents of 3-amino-5,5-dimethylcyclohex-2-en-1-one gave the 9-(D-manno-pentitol-1-yl)acridine-1,8-dione **269** (80MI1) (Scheme 81).


### T. ISOQUINOLINE C-NUCLEOSIDES

#### 1. Isoquinolin-1-yl C-Nucleosides

Carrying out a Pictet–Spengler reaction between 2,5-anhydro-D-mannose (**55**) and dopamine hydrochloride (**270**) furnished the diastereoisomers of 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolin-1-yl C-nucleoside **271** [83CJC2721, 83JCS(CC)601] (Scheme 82).



SCHEME 82



SCHEME 83


## 2. Isoquinolin-3-yl C-Nucleosides

Pyrrolidin-1-yl-cyclohexene added to the activated 1,2,4-triazine ring of **200** to form a bicyclic intermediate, which underwent elimination of a nitrogen molecule to give the tetrahydroisoquinolin-3-yl C-nucleoside **272** (95AP175) (Scheme 83).


## U. ISOQUINOLINE ACYCLO C-NUCLEOSIDES

### 1. Isoquinolin-1-yl Acyclo C-Nucleosides

The acyclo C-nucleoside **274** having a branched alditolyl chain was obtained upon treatment of the 3-(isoquinolin-1-yl)-L-*threo*-1,2-dihydroxypropanoate **273** with methyllithium (92CJC1555) (Scheme 84).



SCHEME 84



SCHEME 85

## 2. Isoquinolin-3-yl C-Nucleosides


Lithiated 2-(*N,N*-diethylcarboxamido)toluene (**276**) added diastereoselectively to the L-glyceraldehyde imine **275** to afford **277** as a single product; removal of the protective groups led to the free nucleoside **278** [89JC-S(CC)930] (Scheme 85).

## X. Condensed 1,2-Diazine C-Nucleosides

### A. PYRAZOLO[3,4-*d*]PYRIDAZINE C-NUCLEOSIDES

#### 1. Pyrazolo[4,3-*d*]pyridazin-3-yl C-Nucleosides

Addition of dimethyl acetylene dicarboxylate to the C-glycosyldiazomethanes **279** formed the pyrazol-3-yl C-nucleoside **280**. Annulation of a pyridazine ring to **280** was accomplished by cyclocondensation of their ester groups with hydrazine hydrate to produce **281** [70JCS(CC)313, 70TL4611; 72CCC2798] (Scheme 86).



R = PhCH<sub>2</sub> , R + R = MeCMe ; R' = H, CH<sub>2</sub>OCH<sub>2</sub>Ph


SCHEME 86

B. PYRAZOLO[1',2':1,2]PYRAZOLO[4,3-*d*]PYRIDAZINE C-NUCLEOSIDES1. *Pyrazolo*[1',2':1,2]*pyrazolo*[4,3-*d*]*pyridazin-6-yl C-Nucleosides*

Stereoselective 1,3-dipolar cycloaddition of the azomethine imine **283**, obtained by reacting acetaldehyde and the dihydropyrazolo[4,3-*d*]-pyridazin-4-one **282**, with the acetylenic derivative **284** resulted in the construction of the second fused pyrazole ring of **285**. Condensation of **282** with the dialdoglucopyranose **286** instead of acetaldehyde gave the aldose azomethine imine **287**, which added **284** to give the C-nucleoside **288** carrying two carbohydrate moieties (93FA231) (Scheme 87).


C. PYRAZOLO[1',2':1,2]PYRAZOLO[4,3-*d*]TETRAZOLO[1,5-*b*]PYRIDAZINE ACYCLO C-NUCLEOSIDES1. *Pyrazolo*[1',2':1,2]*pyrazolo*[4,3-*d*]*tetrazolo*[1,5-*b*]*pyridazin-10-yl Acyclo C-Nucleosides*

These acyclo C-nucleosides were prepared by an extension of the just-mentioned approach. The alditol-1-yl azomethine **291** added methyl acrylate to give **292**. The absolute configuration at C8 and C10 of **292** was



SCHEME 87





SCHEME 88

established by single-crystal X-ray analysis, and they were found to be in a *trans* relationship to each other [92T7965; 93FA231, 93JHC(30)1209] (Scheme 88).

#### D. IMIDAZO[1,5-*b*]PYRIDAZINE C-NUCLEOSIDES


##### 1. Imidazo[1,5-*b*]pyridazin-7-yl C-Nucleosides

The amides **293**, prepared from 2,5-anhydrohexoalonic acids (**79**) and 6-aminomethylpyridazin-3-ones, were cyclodehydrated with phosphoryl chloride to the 2-chloroimidazo[1,5-*b*]pyridazin-7-yl C-nucleosides **294** [82MI6; 84JCS(P1)229; 85JCS(P1)621] (Scheme 89).

#### E. 1,2,4-TRIAZOLO[4,3-*b*]PYRIDAZINE C-NUCLEOSIDES

##### 1. 1,2,4-Triazolo[4,3-*b*]pyridazin-3-yl C-Nucleosides

When cyclocondensed with 3-hydrazinopyridazine, D-ribofuranosylthioformimide (**230**) gave an anomeric mixture of **295**, which was then separated and de-*O*-protected to the C-nucleoside **296** (81JHC893). Compounds



SCHEME 89

**296** were better obtained in the pure  $\beta$ -anomeric form by coupling 3-hydrazinopyridazines with the 2,5-anhydro-D-allonic acid derivative **79** and subsequent cyclodehydration of the formed amides **297**. C-Nucleosides **296** were found devoid of antitumor or antiviral activities (89JMC1547) (Scheme 90).

## F. CINNOLINE ACYCLO C-NUCLEOSIDES


### 1. Cinnolin-3-yl Acyclo C-Nucleosides

The 3-(D-*arabino*-tetritol-1-yl)cinnoline **301** was obtained together with the phenyloszone **302** upon heating aqueous acidic solutions of D-glucose or D-mannose (**299**) and phenylhydrazine (63CB2427) (Scheme 91).

## G. PHTHALAZINE C-NUCLEOSIDES


### 1. Phthalazin-5-yl C-Nucleosides

Aromatization of the Diels-Alder adduct **303**, obtained by addition of dimethylacetylene dicarboxylate to the 2- $\beta$ -D-ribofuranosylfuran **49**, gave the 6-hydroxy-3- $\beta$ -D-ribofuranosylphthalate ester **304**, which was *O*-



$R = \text{PhCO}$ ;  $R^1 = \text{PhCH}_2$ ;  $R^2$  or  $R^3 = \text{H}, \text{Cl}, \text{NH}_2$ ,  $R^4 = \text{Cl}, \text{NH}_2, \text{OH}, \text{OMe}$

SCHEME 90




SCHEME 91

methylated to **305**. Cyclization of the two adjacent ester groups of **305** with hydrazine hydrate took place with simultaneous de-*O*-benzoylation of the sugar residue to give the phthalazin-5-yl C-nucleoside **306** (85MI8) (Scheme 92).


## H. PYRIMIDO[4,5-*c*]PYRIDAZINE ACYCLO C-NUCLEOSIDES

### 1. *Pyrimido [4,5-*c*]pyridazin-4-yl Acyclo C-Nucleosides*

Aldose pyrimid-6-ylhydrazones (**307**) underwent acetylation together with cyclodehydration to the 4-(poly-*O*-acetyl-alditol-1-yl)pyrimido[4,5-*c*]pyridazines **308** (81CPB629) (Scheme 93).



SCHEME 92




SCHEME 93

I. 1,2,4-TRIAZOLO[3,4-*a*]PHTHALAZINE C-NUCLEOSIDES1. 1,2,4-Triazolo[3,4-*a*]phthalazin-3-yl C-Nucleosides


Rosenthal and Lee prepared examples of these C-nucleosides (**310**) by cyclocondensation of the 2,5-anhydro-D-allonic acid **79** with 1-hydrazinophthalazine in the presence of a coupling reagent (CR) (78MI12) (Scheme 94).

J. 1,2,4-TRIAZOLO[3,4-*a*]PHTHALAZINE ACYCLO C-NUCLEOSIDES1. 1,2,4-Triazolo[3,4-*a*]phthalazin-3-yl Acyclo C-Nucleosides

A series of these acyclo C-nucleosides (**312**) were prepared from aldose phthalazin-1-ylhydrazones (**311**), which underwent facile thermal dehydrogenative cyclization to **312**. The cyclization was expedited by catalytic dehydrogenation with palladium on charcoal (81MI5; 83MI8; 89BCJ2701; 91MI9) (Scheme 95).



SCHEME 94



R = H, Ph, PhCH<sub>2</sub>

SCHEME 95

Compounds **312** were also prepared by alternative routes that comprised cyclocondensation of aldonolactones (**313**) with 1-hydrazinophthalazines or aldonic acid hydrazides (**315**) with 1-chlorophthalazines. Their acetates **316** were obtained by direct acetylation of **312** or by condensation of aldonyl chloride acetates (**38**) with 1-hydrazinophthalazines (90MI6) (Scheme 96). 1,2,4-Triazolo[3,4-*a*]phthalazin-3-yl acyclo *C*-nucleosides derived from reducing disaccharides were similarly prepared (90MI2).


The configuration-conformation relationship of the *O*-acetyl-alditol-1-yl chains of **316** was studied using <sup>1</sup>H NMR (89BCJ2701; 91MI9). Compounds **312** were tested as agrochemicals against some insects, nematodes, and herbs, but were found inactive (89BCJ2701; 91MI9). They served, however, as good corrosion inhibitors of aluminum in acid media (85MI1).

## XI. Condensed 1,3-Diazine *C*-Nucleosides


### A. PYRROLO[2,3-*d*]PYRIMIDINE *C*-NUCLEOSIDES

#### 1. Pyrrolo[2,3-*d*]pyrimidin-6-yl *C*-Nucleosides

Direct electrophilic, Lewis acid-catalyzed *C*-ribosylation of pyrrolo[2,3-*d*]pyrimidin-4-ones with **317** gave pyrrolo[2,3-*d*]pyrimidin-7-yl *C*-nucleosides **318**. The latter were halogenated at C6 and de-*O*-benzoylated to **319**, which showed good prophylactic activity against the lethal Semliki Forest virus infection in mice (90JMC2750) (Scheme 97).



SCHEME 96



SCHEME 97


## B. PYRROLO[3,2-*d*]PYRIMIDINE C-NUCLEOSIDES

### 1. *Pyrrolo*[3,2-*d*]pyrimidin-5-yl C-Nucleosides


The previously discussed electrophilic C-ribosylation of **317** with 6-methylpyrrolo[3,2-*d*]pyrimidin-4-one took place at C5, giving **320** as a result of blocking C6 (90JMC2750) (Scheme 97).

### 2. *The Naturally Occurring Pyrrolo*[3,2-*d*]pyrimidin-7-yl C-Nucleoside "9-Deazaadenosine"

Rinehart *et al.* (93JA2504) noticed that the aqueous methanolic extract of the lyophilized cells of the cyanobacterium (blue-green alga) *Anabaena affinis* VS-1 exhibited strong cytotoxicity toward L1210 murine leukemic cells. Workup of the extract led to the isolation of two C-nucleosides, which were assigned the structures of 4-amino-7-( $\beta$ -D-arabino-furanosyl)-5*H*-pyrrolo[3,2-*d*]pyrimidine (9-deazaadenosine) (**322**) and 4-amino-7-(5'-*O*- $\alpha$ -D-glucopyranosyl- $\beta$ -D-ribofuranosyl)-5*H*-pyrrolo[3,2-*d*]pyrimidine (**323**) on the basis of MS,  $^1\text{H}$  NMR,  $^{13}\text{C}$  NMR, and UV spectral measurements (93JA2504).




322



323

The structure of the isolated **322** was further corroborated by direct comparison with synthetic **322**, which was prepared in 1981 by Lim and Klein (81TL25), prior to isolation from the natural source, by a multistep plan that comprised construction of the heterocyclic system by starting from 2-formyl-2- $\beta$ -D-ribofuranosylacetonitrile (**324**) as shown in Scheme 98 (81TL25). The 2',3'-dideoxy analog of **322** was similarly prepared (96MI2).

C-Nucleoside **322** inhibited the growth of various types of mouse and human leukemic cells (81TL25; 93JA2504), colon carcinoma (83MI1, 83MI3), and nine different human cell tumors (84MI1). Both **322** and



SCHEME 98

**323** were found lethally toxic to the aquatic invertebrate *Ceriodaphnia dubia* (93JA2504).


### 3. Pyrrolo[3,2-*d*]pyrimidin-7-yl C-Nucleosides

The *O*-protected 9-deazaadenosine derivative **329** was transformed to other pyrrolo[3,2-*d*]pyrimidin-7-yl C-nucleosides (**333** and **334**) by performing alterations in the sugar subunit (86MI11; 93MI7) (Scheme 99). The prepared compounds were active as antileukemic agents, yet were much less active than the parent 9-deazaadenosine (**322**) (86MI11).

7- $\beta$ -D-Ribofuranosyl-3*H*,5*H*-pyrrolo[3,2-*d*]pyrimidin-4-one (9-deazainosine, **339**) is another important C-nucleoside because of the various biological activities it possesses. It was synthesized from **324** as depicted in Scheme 100 (80TL1013; 83JOC780). The 2',3'-dideoxy analog of **339** was prepared by similar reactions (96MI2).


5'-Tritium-labeled 9-deazainosine was obtained by selective de-*O*-tritylation of **338**, oxidation of the resulting C5' primary hydroxyl to an aldehyde function, and then reduction with sodium borotritide (88MI2). 9-Deazainosine (**339**) exhibited antitumor activity against several mouse and human tumor cells (83MI2; 86MI1) and antiprotozoal activity against the pathogenic protozoa *Leishmania donovani*, *T. brucei gambiense*, *Trypanosoma brucei rhodesiense*, *T. cruzi* [84AAC292; 85AAC33, 85JBC(260)9660; 87AAC111, 87AAC1406], and *Giardia lamblia* (86MI2). It also showed





$R = \text{PhCO}$ ,  $R' = \text{Me}_2\text{CH}$ ,  $X = \text{Br}, \text{Cl}, \text{I}, \text{PhCOO}$ .

SCHEME 99



$R = \text{Ph}_3\text{C}$

SCHEME 100


antibacterial properties against *Pneumocystis carinii* pneumonia in immunosuppressed rats (86AAC181; 87MI1) and has been suggested as a promising drug for the treatment of this disease, frequently encountered in immunosuppressed patients and in patients with AIDS (87MI1).

2,4-Dimethoxy-7- $\alpha$ -D-ribofuranosylpyrrolo[3,2-*d*]pyrimidine **343** was synthesized through ionic C—C bond formation by coupling the carbanion of the active methylene group of 6-cyanomethyl-2,4-dimethoxy-5-nitropyrimidine and the D-ribofuranosyl chloride **340**. The resulting **341** was cyclized to **342** by catalytic reduction and then deprotected to **343** (86JOC1058) (Scheme 101).


### C. PYRROLO[3,2-*d*]PYRIMIDINE ACYCLO C-NUCLEOSIDES

#### 1. Pyrrolo[3,2-*d*]pyrimidin-7-yl Acyclo C-Nucleosides

A number of 9-deazaadenosine acyclo C-nucleosides carrying different polyhydroxyalkyl chains (e.g., **351**) were prepared by Buchanan and his group from 3-amino-2-cyanopyrrol-4-yl acyclo C-nucleosides (e.g., **349**) through construction of their fused pyrimidine rings. Unfortunately, none of these compounds was found active against representative RNA and DNA viruses in cell cultures [91JCS(P1)195] (Scheme 102).



SCHEME 101



SCHEME 102

#### D. FURO[3,2-*d*]PYRIMIDINE C-NUCLEOSIDES


##### 1. The Naturally Occurring Furo[3,2-*d*]pyrimidin-7-yl C-Nucleoside "Pyrrolosine"

Searching for RNA inhibitors from natural sources, Ikegami *et al.* isolated a compound from the culture broth of *Streptomyces alba* A282 that halted embryonic development in starfish (*Asterina pectinifera*) as a result of inhibiting RNA synthesis (90JA9668). Studying the MS, UV,  $^1\text{H}$  NMR,  $^{13}\text{C}$  NMR, and X-ray diffraction data of the isolated compound, the same group concluded that the structure of this compound is 7- $\beta$ -D-ribofuranosylpyrrolo[3,2-*d*]pyrimidin-4-one (9-deazainosine, **339**) and named it "pyrrolosine." Physical and biological properties of the isolated compound, however, were found (90JA9668) to be different from those of **339**, which was synthesized by Klein and his group prior to the isolation of pyrrolosine (80TL1013; 83JOC780) (Section XI,B,3). Accordingly, pyrrolosine was reinvestigated and the results were published 2 years later by both the American (92JA668) and the Japanese groups (92MI1), who revised the structure to 4-amino-7- $\beta$ -D-ribofuranosylfuro[3,2-*d*]pyrimidine (7-oxa-7,9-dideazaadenosine, **355**). The erroneous elucidation of structure was attributed (92JA668, 92MI1) to misinterpretation of X-ray data (90JA9668), and a suggestion has been made to rename pyrrolosine in a way that reflects the actual structure


(92JA668). The revised structure was further established (92JA668) by direct comparison with synthetic **355** prepared as shown in Scheme 103 (86TL815; 90MI8).

In addition to inhibition of RNA synthesis, pyrrolosine inhibited growth of transformed human fibroblast KMST-6 cells and mouse mammary carcinoma FM3A cells (90JA9668). However, it was 10-fold less active than 9-deazaadenosine **322** against mouse L1210 (86TL815; 90MI8) and P815 leukemia cells *in vitro* (86TL815).

The inosine **356**, thioinosine **357**, and dithioxanthosine **358** analogs of **355** were also prepared from **324** by synthetic plans comparable to that depicted in Scheme 103 (90MI8). The inosine analog **356** exhibited activity against the pathogenic protozoa *Leishmania donovani* and *Trypanosoma gambiense* (90MI8).



SCHEME 103




E. THIENO[3,2-*d*]PYRIMIDINE C-NUCLEOSIDES1. Thieno[3,2-*d*]pyrimidin-7-yl C-Nucleosides

7-β-D-Ribofuranosyl[3,2-*d*]pyrimidin-4(3*H*)-one (7-thia-7,9-dideazainosine, **363**) was synthesized from **324** by the multistep elaboration of both rings of its heterocyclic system as detailed in Scheme 104 (82JOC4633). C-Nucleoside **363** significantly inhibited growth of L1210 and P815 leukemia cells in mice (82JOC4633), revealed antiprotozoal activity against *Leishmania donovani* [85JBC(260)9660], and very weakly inhibited human erythrocytic nucleoside phosphorylase (86MI1).


3',5'-Di-*O*-protection of **363** and deoxygenation of C2' OH gave its 2'-deoxy analog (86MI11).

F. THIENO[3,2-*d*]PYRIMIDINE ACYCLO C-NUCLEOSIDES1. Thieno[3,2-*d*]pyrimidin-7-yl Acyclo C-Nucleosides

The thieno[3,2-*d*]pyrimidine system of **367** was constructed onto the acyclic sugar derivative **346**. This acyclo C-nucleoside (**367**) did not inhibit a number of DNA and RNA viruses in cell cultures [91JCS(P1)195] (Scheme 105).



SCHEME 104



SCHEME 105

### G. THIENO[3,4-*d*]PYRIMIDINE C-NUCLEOSIDES


#### 1. Thieno[3,4-*d*]pyrimidin-7-yl C-Nucleosides

Under the catalytic effect of tin(IV) chloride, 1-*O*-acetyl-2,3,5-tri-*O*-benzoyl- $\alpha$ -D-ribofuranose (**368**) regioselectively C-glycosylated 4-formamido-3-methoxycarbonylthiophene at C5 to give a mixture of the two anomers of **369**. Annulation of the pyrimidine ring of the 6-thia-7,9-dideazainosine **370** was achieved by reacting **369** with formamidine acetate [88TL3537; 90MI7; 93JHC(30)509]. C-Nucleoside **370** was further elaborated to the adenosine analog **373** (Scheme 106) and the 6'-iodo-6'-deoxyinosine analog **375** (Scheme 107) [93JHC(30)509]. Compounds **370** and **372** proved cytotoxic to L1210-Cl, sarcoma 180, and HL60 tumor cell lines, whereas **375** effectively inhibited purine nucleoside phosphorylase [93JHC(30)509].

### H. PYRAZOLO[1,5-*a*]PYRIMIDINE C-NUCLEOSIDES

#### 1. Pyrazolo[1,5-*a*]pyrimidin-3-yl C-Nucleosides

In basic media, 1,3-dimethyluracil transferred an  $\alpha$ ,  $\beta$ -unsaturated keto moiety to the 3-aminopyrazol-4-yl C-nucleoside **376**, providing the complementary carbon fragment to annulate the pyrimidine ring of **377**. Removal of the *O*-protective groups of **377** with methanolic hydrochloric acid caused




SCHEME 106


sugar ring enlargement to afford the 3- $\beta$ -D-ribosepyranosylpyrazolo[1,5-*a*]pyrimidin-7-one **380** (86JHC349) (Scheme 108).

## 2. Pyrazolo[1,5-*a*]pyrimidin-7-yl C-Nucleosides

Cyclocondensation of the C-glycoside enaminone **381** with 3-aminopyrazole and removal of the protective groups gave the C-nucleoside **382** [95H(41)507] (Scheme 109).




SCHEME 107



SCHEME 108


I. PYRAZOLO[3,4-*d*]PYRIMIDINE C-NUCLEOSIDES1. *Pyrazolo[3,4-*d*]pyrimidin-6-yl C-Nucleosides*

Cyclocondensation of the ribofuranosylthioformimidates **230** with 3-amino-4-cyanopyrazole gave, stereospecifically, the 6- $\beta$ -D-ribofuranosylpyrazolo[3,4-*d*]pyrimidin-4-one **385** [73JCS(CC)680]. However, the reaction with 3-amino-4-ethoxycarbonylpyrazole was stereoselective to give the two anomers of **385**; the  $\beta$ -anomer preponderated (75JOC2825) (Scheme 110).



SCHEME 109





SCHEME 110

## J. PYRAZOLO[4,3-*d*]PYRIMIDINE C-NUCLEOSIDES

### 1. The Naturally Occurring Pyrazolo[4,3-*d*]pyrimidin-3-yl C-Nucleosides "Formycin," "Formycin B," and Their Congeners


The antibiotic formycin was first isolated in 1964 from culture filtrates of the protoactinomycete *Nocardia interforma* [64JAN(A)96; 66JAP66/17629; 83MI11]. Formycin, together with another related C-nucleoside, formycin B (laurusin), was also isolated from the same organism in 1965 [65JAN(A)175] and from *Streptomyces lavendula* at the early stage of culture growth (65ABC375). The amount of formycin B increased while that of formycin decreased until it disappeared with aging of *S. lavendula* cultures, which implied that formycin might be the precursor of formycin B (65ABC375). Other streptomycetes, namely, *Streptomyces* S-685 (67JAN(A)49), *S. gunamaences* (67JAP67/10928), and *S. M406-A-1* (74JAN909; 75JAN965), also produced formycin.

The 7-amino-3-β-D-ribofuranosylpyrazolo[4,3-*d*]pyrimidine structure **386** of formycin (the C-nucleoside isoster of adenosine) and 3-β-D-ribofuranosylpyrazolo[4,3-*d*]pyrimidin-7-one structure **387** of formycin B (the C-nucleoside isoster of inosine) were elucidated on the basis of degradation [66JAN(A)91], UV, <sup>1</sup>H NMR [66JHC110; 77ZN(C)528], and MS results

(69JHC459). Formycin (**386**) can be deaminated to formycin B (**387**) both chemically by treatment with acids (65ABC377) or sodium nitrite [65JAN(A)178] and enzymatically by adenosine deaminase from various sources [65ABC377, 65JAN(A)175, 65JAN(A)178, 65JAN(A)191; 68JAP68/759; 69BBA(174)696, 69JBC(244)3243; 75MI1). However, amination of formycin B (**387**) to formycin (**386**) was made by adenylosuccinic synthetase from *Pseudomonas fluorescens* and *Streptomyces kasugaensis* (68JAN334) (Scheme 111).


Oxoformycin B, 3- $\beta$ -D-ribofuranosylpyrazolo[4,3-*d*]pyrimidine-5,7-dione (**388**) (the C-nucleoside isoster of xanthosine), was isolated from urine of rabbit and mice injected with formycin (**386**) or formycin B (**387**) (68JAN1, 68MI1) as a result of biological oxidation with hepatic aldehyde oxidase (69JAN36; 70MI3). *Nocardia interforma* and *Streptomyces kasugaensis* are able to transform formycin B (**387**) to oxoformycin B (**388**) by oxidation with xanthine oxidase (68JAN334).

X-ray analysis of formycin hydrobromide monohydrate revealed its existence in the classical *syn* conformation **389** in which N6 is protonated, H1 migrated to N2, and an H-bond is formed between O5' and N4 [66TL597; 74AX(B)1511; 75ANY3]. The conformation of formycin monohydrate, however, was found to be intermediate between the classical *anti* and *syn* conformations (68PNA1494; 73B1196; 75ANY3). Conformations of formycin B and oxoformycin B were found to correspond to the *anti* form **390** and the *syn* form **391**, which is stabilized by an intramolecular N4-H  $\cdots$  O5' H-bond, respectively [76AX(B)813].




a, acid or  $\text{NaNO}_2 + \text{H}^+$ ; b, adenosine deaminase; c, adenylosuccinic synthetase; d, xanthine oxidase; e, hepatic aldehyde oxidase


SCHEME 111



389




390



391

$^1\text{H}$  and  $^{13}\text{C}$  NMR measurements (73JA4761, 73JHC431; 76JA4736; 84MI10) indicated the predominance of the N1-H tautomer (**386**) over the N2-H (**392**) tautomer for formycin and the amide form (**387**) over the imidic acid form (**393**) for formycin B.





Fluorescence [69JBC(244)1228; 77JHC135] and luminescence (82MI2) spectra of formycin, as well as fluorescence and ORD spectra of oxoformycin B [75ZN(C)835], were studied.

Biosynthetic studies pinpointed the importance of lysine and glutamate during the biosynthesis of formycin [71JAN(A)253, 71PAC489; 74JAN909; 76JAN638; 79JBC(254)8819; 80JCS(CC)917].

Because of their isosteric relationship, formycin can replace adenosine in many biochemical processes (biological mimicking) [67JBC(242)3868; 68BBA(155)82, 68BBA(174)696, 68JBC(243)3214, 68MI2; 69MI1, 69MI2, 69PNA581; 70PNA539; 72JBC(247)4014; 74MI2; 75JAN965; 79MI2, 79MI3, 79MI4]. Consequently, formycin displays a wide range of biological activities (70MI2; 75MI4; 78MI11; 79MI4; 81MI2; 82MI1; 83MI3). Among these activities are antiviral [66JAN(A)286; 67JAN(A)49, 67JAN(A)129, 67JAN(A)297; 75MI2; 85MI2], antibacterial [64JAN(A)96; 65JAN(A)178, 65JAN(A)259; 66JAP66/17629; 67JAN(A)308, 67JAP67/21755; 68JBC(243)3532; 78B2350], and antiprotozoal against *Schistosoma mansoni* (74MI1), *Trypanosoma cruzi* (the causative agent to Chaga's disease)

(83MI5), *Leishmania donovani* [81BBR(100)1377], and *L. tropica* (83AAC233). Formycin inhibited also the growth of various types of tumors [64JAN(A)96, 64JAN(A)124; 65JAN(A)259; 66JAP66/17629; 67JAN(A)227, 67JAN(A)277, 67MI1, 67MI2; 68JAN5; 69MI1], increased vascular permeability in rat skin [67JAN(A)369], and selectively inhibited low-molecular-weight RNA [73BBA(312)292]. Unfortunately, many of these activities diminish with time because of the ready conversion of formycin to the much less active formycin B by adenosine deaminase (ADA) (76MI1). In the presence of coformycin {6,7,8-trihydro-8-hydroxy-3- $\beta$ -D-ribofuranosylimidazo[4,5-d]1,3-diazepine (**394**, R = OH)}, 2'-deoxycorformycin (**394**, R = H), or isocorformycin (**395**), the deamination of formycin by ADA is strongly inhibited and the biological activities are enhanced [67JAN(A)227, 67JAN(A)308; 75MI3; 76MI1; 77MI1; 78MI1; 80JAN303].




Albeit of less pronounced magnitude, formycin B possesses anti-viral [66JAN(A)286; 67JAN(A)129; 75MI2], antibacterial [65ABC375, 65JAN(A)175, 65JAN(A)178, 65JAN(A)259; 68JAN264], antiprotozoal [81BBR(100)1377; 82BBR(108)349; 83AAC233, 83PNA288; 85JBC(260)9660], and antitumor activities [65JAN(A)259; 68JAN5].

The first synthesis of formycin (**386**) was reported in 1971 using the nucleoside-nucleoside transformation approach [71JCS(C)2443]. Formycin B (**387**) was *O*-acetylated and transformed to the 6-chloropyrazolo[4,3-*d*]pyrimidin-3-yl derivative **396**. Amination of **396** with liquid ammonia gave formycin (**386**) (Scheme 112).

Synthesis of formycin by the stepwise assembly of the pyrazolopyrimidine system onto the sugar moiety was accomplished by Kalvoda in Czechoslovakia (78CCC1431). The starting material utilized in this synthesis was the 3-cyano-3- $\beta$ -D-ribofuranosylacrylate derivative **397**, which was cyclized with aminoacetonitrile to the pyrazol-3-yl C-nucleoside **398** and then elaborated to **386** (Scheme 113).

A carefully designed synthesis of formycin was published by Buchanan and his group in Scotland and involved a *cine*-substitution of the 1,4-dinitro-




SCHEME 112


3-pyrazol-3-yl *C*-nucleoside **403** with cyanide ion to give the 3(5)cyano-4-nitro-5(3)- $\beta$ -D-ribofuranosylpyrazole **405**. Catalytic reduction of **405** to the 4-amino compound **406** followed by cyclization with formamidine acetate gave formycin triacetate, which was de-*O*-acetylated to formycin **386** [80CJC2624, 80JCS(CC)237] (Scheme 114).

Formycin B (**387**) was prepared [71JCS(CC)986] from the 5-carbamoyl-4-hydrazinocarbonyl-3- $\beta$ -D-ribofuranosylpyrazole **407** (70TL4611; 72CCC2798) through transformation to the 4-amino-5(3)methoxycarbonylpyrazol-3(5)-yl *C*-nucleoside **411**. Cyclization of **411** by heating with formamide and de-*O*-protection of the sugar moiety produced formycin B (**387**) (Scheme 115).

Starting with **405**, Buchanan *et al.* synthesized formycin B (**387**) by annulating the pyrimidinone ring. Compound **405** was transformed to the 4-amino-5(3)-carbamoyl-3(5)- $\beta$ -D-ribofuranosylpyrazole **415** and then cyclized with formic acid and de-*O*-acetylated to **387** [84JCS(P1)2367; 84T119; 86JCS(P1)1267] (Scheme 116).




SCHEME 113




SCHEME 114

Oxoformycin B (**388**), the catabolite of formycin and formycin B, was synthesized before the parent nucleosides in 1970 from the 2,5-anhydro-1-ureido-D-allitol derivative **416**. Compound **416** was used to build the 4,5-dimethoxycarbonylpyrazol-3-yl C-nucleoside **419**, followed by construction of the fused pyrimidine ring as shown in Scheme 117. Selective amidation of the ester function at C5, rather than that at C4, is a key step during this



SCHEME 115



SCHEME 116


synthesis (70TL4611; 72CCC2798) (Scheme 117). The 3- $\beta$ -D-arabinouranosyl congener of **388** (*ara*-oxoformycin B) was also synthesized by a similar synthetic scheme (74MI6).

Chemical deamination of formycin (**386**) with nitrosyl chloride as well as oxidation of formycin B (**387**) with bromine in water also led to the formation of oxoformycin B (**388**) (84JHC1865) (Scheme 118).


Cyclization of the 4-amino-5(3)-cyano-3(5)- $\beta$ -D-ribofuranosyl-pyrazole **406** with carbon disulfide in pyridine formed dithioformycin B (**425**), most probably through the intermediate **424** (88MI7) (Scheme 119).

The pyrazolo[4,3-*d*]pyrimidinone C-nucleoside (5-aminoformycin B) **431**, a C-guanosine analog, was obtained by cyclization of the 4-amino-5(3)-carboxamidopyrazol-3(5)-yl C-nucleoside **415** as detailed in Scheme 120. The pyrazole C-nucleoside **427** was formed upon acid-catalyzed pyrimidine ring opening of formycin 6-oxide **426** (82JA1073). Alternatively, the synthesis of **431** was accomplished by transforming oxoformycin B (**388**) to the dichloro compound **432**, selective amination and deamination at C7, and amination at C5 of **433** (91MI10) (Scheme 120).

The thio analog **437** (5-aminothioformycin B) of **431** was synthesized by a similar plan from **434** as depicted in Scheme 121 (81MI1; 84JOC528).




SCHEME 117




SCHEME 118






SCHEME 119




SCHEME 120



SCHEME 121

Formycin 6-oxide (**426**) was the starting substance used for the preparation of 7-amino-3- $\beta$ -D-ribofuranosylpyrazolo[4,3-*d*]pyrimidin-5-one **439** (oxoformycin). Photo-hydrolytic pyrimidine ring opening of **426** gave the 5-cyano-4-ureidopyrazol-3-yl C-nucleoside **438**, which recycled to **439** when treated with ammonium hydroxide [84JCS(P1)2421] (Scheme 122). Another route to obtain **439** was the direct oxidation of formycin (**386**) with bromine in water; the increased double-bond character between N4 and C5 facilitated the formation of intermediate **441**, which then underwent spontaneous elimination of  $\text{HBr}$  to give **439** (84JHC1865) (Scheme 122).

The aptitude of formycin to biomimic adenosine justified the synthesis of many of its derivatives that comprised alterations in the heterocyclic and/or the sugar moieties. Studying the biological activities of the altered formycins provided valuable results concerning the structure–biological and conformation–biological activity relationships. Primarily, a suggestion has been made linking biological activities of formycin and its derivatives to their conformation: bulky groups at proper sites of the heterocyclic system cause conformational preference due to restriction of rotation about the C-glycosidic bond, a situation that affects biological activities. Special attention was directed toward the preparation of various methyl derivatives of formycin that prefer particular conformations in order to validate or refute this hypothesis. Methylation of formycin (**386**) with methyl iodide




SCHEME 122


in a basic medium caused preferential methylation of the pyrazole ring and gave a mixture of 1-methyl- and 2-methylformycins (**442** and **443**) in the ratio of  $\sim 1:6$ , respectively (74JOC2023). Deamination of **442** (84MI12) and **443** (74JOC2023; 80JA2817) with nitrosyl chloride gave 1-methyl- and 2-methylformycin B, respectively (**445** and **446**). 1-Methylformycin (**442**) was obtained as a single product by heating formycin (**386**) with dimethylformamide dimethylacetal; the initially formed 7-(dimethylamino-methylene)amino intermediate **444** underwent intramolecular methylation to afford **442** (75JA5896; 78MI2) (Scheme 123).

Contrary to basic methylation, methylation of formycin with methyl iodide in neutral media gave a mixture of 4-methyl- and 6-methylformycins (**447** and **448**) in the ratio 2:1. Deamination of **447** and **448** afforded 4-methyl- and 6-methylformycin B **449** and **450**, respectively (80JA2817) (Scheme 124).

The  $pK_a$  measurements of the various methylformycins indicated that methylation of the pyrimidine ring nitrogens caused a significant increase in basicity, whereas methylation of the pyrazole ring nitrogens did not noticeably change the basicity as compared to that of formycin (80JA2817). Comparing the results of introducing methyl groups at the different nitrogens of formycin on biological activities such as adenosine deaminase substrate activity (74JMC62; 77MI2; 78JAN456), antiviral activity (75MI2), and antitumor activity (74JOC2023; 79MI5) invalidated the dependence of activities on conformation (*syn* or *anti*). Accordingly, electronic, steric, and/or structural parameters were considered to be the major influences on




SCHEME 123



SCHEME 124

biological activities (79MI5). The methyl group at N1 of 1-methylformycin (442) was found to block binding to the adenosine deaminase active site (79MI5).

Many modifications were performed on the heterocyclic system of formycin and formycin B, which included the preparation of 451–453



$R = H, Br, I, NEt_2, NHMe, NMe_2$      $Z = S, Se$      $Y = SMe, SCH_2CH=CH_2,$

$^+NMe_3Cl^-$ ,  $NHOH, NHNH_2, SeMe, SeCH_2Ph,$


$OMe$

$SeCH_2C_6H_4-NO_2-p$


[66JAN(A)93; 72JCS(P1)2677; 82JMC1334; 85JMC1740; 86NAR1747; 95JA5951], some of which possessed antitumor (68JAN468), antibacterial [66JAN(A)93; 68JAN468] and antiviral activities [79MI2; 82JMC1334].

Formycin and formycin B with modified sugar subunits have also been prepared using, mostly, the nucleoside–nucleoside approach. In one instance, however, 2'-deoxyformycin B (458) was prepared by regio- and stereospecific palladium-mediated C–C bond formation between the furanoid glycal 454 and protected 3-iodopyrazolo[4,3-*d*]pyrimidine. The C-nucleoside 455 having an unsaturated sugar moiety was subsequently elaborated to 458 (92JOC4690) (Scheme 125).


2'-Deoxy- and 3'-deoxyformycins (463 and 464) were obtained as a 2:3 separable mixture by treatment of formycin (386) with  $\alpha$ -acetoxyisobutyryl chloride in the presence of sodium iodide. The 2'-iodo-2'-deoxy- and 3'-iodo-3'-deoxy intermediates (459 and 460) were reductively dehalogenated, de-*O*-blocked, and separated to afford 463 and 464. Enzymatic deamination of the latter with adenosine deaminase gave 2'-deoxy- and 3'-deoxyformycin B (458 and 465) (73CJC1313) (Scheme 126). The same products were also obtained with  $\alpha$ -acetoxyisobutyryl bromide (73JOC3179; 87S879), followed by catalytic (73JOC3179) or chemical (87S879) reductive debromination of the produced 2'-bromo-2'-deoxy and 3'-bromo-3'-deoxy congeners of 459 and 460.



SCHEME 125



SCHEME 126




SCHEME 127

2'-Deoxyformycin (**463**) was prepared as a sole product from formycin (**386**) by protection of O3' and O5' followed by introduction and reductive removal of a 2'-O-phenoxythiocarbonyl group (85JMC1096; 89MI3) (Scheme 127). 2'-Deoxyformycin B was also prepared from formycin B according to the latter route (89MI3).



Neither 2'-deoxy- nor 3'-deoxyformycins inhibited herpes simplex type 1 virus (92JMC4576), yet 2'-deoxyformycin showed potent *in vitro* growth inhibition of S49 lymphoma cells (85JMC1096). 2'-Deoxyformycin was introduced into triplex-forming oligonucleotide sequences (92MIP1; 94MI9; 95JOC7094) useful in the treatment of HIV-1 infection (92MIP1).

2',3'-Dideoxyformycin (**470**) was synthesized by reductive removal of the 2'-O-phenoxythiocarbonyl group from the 3'-deoxyformycin derivative **469** [89BBR(161)910; 90S411]; it was found ineffective in inhibiting HIV replication [89BBR(161)910] (Scheme 128).

5'-Deoxy-5'-halogenoformycins (**471**) (86MI10; 87S879; 92JMC4576), 5'-chloro-3',5'-dideoxyformycin (**472**) (92JMC4576), 5'-chloro-2',5'-dideoxyformycin (**473**) (92JMC4576), 5'-chloro-2',3',5'-trideoxyformycin (**474**) (92JMC4576), and 5'-chloro-5'-deoxyformycin B (**475**) (86MI10) were prepared from the parent C-nucleosides by modifying their sugar residues.



SCHEME 128




471, R=R'=OH; X=Br, Cl, I; 472, R=OH, R'=H, X=Cl 475

473,  $R = H$ ,  $R' = OH$ ,  $X = Cl$ ; 474,  $R = R' = H$ ,  $X = Cl$

Enzymatic condensation of the thiol group of homo-L-cysteine with O5' of formycin (**386**) gave **476**, which was *S*-methylated and subsequently hydrolyzed to 5'-deoxy-5'-methylmercaptoformycin **477**. Compound **477** potently inhibited rat liver 5'-methylthioadenosine phosphorylase (83MI4) (Scheme 129).

Reaction of formycin B (**387**) with diphenylsulfide and tributylphosphine took place regiospecifically with the primary hydroxyl group to yield the 5'-deoxy-5'-phenylmercaptoformycin B **478** (Scheme 130). This modified C-nucleoside (**478**) poorly inhibited purine nucleoside phosphorylase (93JMC1024).

Modified formycins that involved both the sugar and the heterocyclic moieties include the 2,5'-anhydro- and 4,5'-anhydroformycins **481** and **484** (75JA5896, 75JAN492). These two derivatives were of particular interest because of their fixed conformation in the *anti* and *syn* forms, respectively, and their utilization to investigate the effect of conformation on enzymatic deamination by ADA. The 2,5'-anhydroformycin **481** in the *anti*-locked conformation was prepared by dehydrocyclization of 2',3'-*O*-isopropylideneformycin **479** with diethyl azodicarboxylate and triphenylphosphine (75JAN492), or by heating formycin with dimethylformamide dimethylacetal in DMF (75JA5896). The 4,5'-anhydroformycin **484** in the *syn*-locked conformation was obtained by treatment of **479** with 4-tolylsulfonyl chloride



SCHEME 129





## 2. Pyrazolo[4,3-*d*]pyrimidin-5-yl C-Nucleosides


The pyrimidine rings of the pyrazolo[4,3-*d*]pyrimidin-5-yl C-nucleosides **485** and **486** were formed as a result of cyclocondensation of the  $\beta$ -D-ribofuranosylthioformimidate **230** with 4-amino-3-cyanopyrazole and 4-amino-3-carbamoylpyrazole, respectively. The products were obtained as a mixture of the  $\alpha$ - and  $\beta$ -anomers (75JOC2825; 78NJC357) (Scheme 132). Proton spin-lattice relaxation, particularly that of the anomeric proton (H1'), proved very valuable for characterizing the two anomers of each of **485** and **486** (77JA3267).

## K. PYRAZOLO[4,3-*d*]PYRIMIDINE ACYCLO C-NUCLEOSIDES


### 1. Pyrazolo[4,3-*d*]pyrimidin-3-yl Acyclo C-Nucleosides

The acyclo analog of 1-methylformycin **490** was prepared by etherification of 1-methyl-3-bromomethyl-7-methoxypyrazolo[4,3-*d*]pyrimidine (**488**) with ethylene glycol (**487**) and amination of the produced **489** (84JHC505) (Scheme 133). Compound **490** was devoid of antitumor and antiviral activities (84JHC505).


The acyclo analog of formycin B **496**, however, was synthesized by annulation of the pyrimidinone ring onto the pyrazole ring of **494**, as explained in Scheme 134. Acyclo analogs of formycin and 5-aminoformycin B were also prepared according to this approach [85JCS(P1)2087].



SCHEME 132



SCHEME 133




SCHEME 134

(2'*S*)-3-(2',3'-Dihydroxypropyl)pyrazolo[4,3-*d*]pyrimidines **500** and **501**, acyclo analogs of formycin and formycin B, were also synthesized by building the pyrimidine ring onto the pyrazol-3-yl acyclo *C*-nucleoside **499**. Chemical deamination of **500** gave **501** (Scheme 135). These two acyclo *C*-nucleosides did not inhibit the replication of representative DNA and RNA viruses [85JCS(P1)1425; 89JCS(P1)925].


## L. IMIDAZO[1,2-*a*]PYRIMIDINE ACYCLO *C*-NUCLEOSIDES

### 1. Imidazo[1,2-*a*]pyrimidin-3-yl Acyclo *C*-Nucleosides

The analogs of this type with truncated sugar (**505**, Z = O) and thiosugar residues (**505**, Z = S) were obtained by a one-pot etherification or thioetherification reaction of 3-hydroxymethylimidazo[1,2-*a*]pyrimidine (**503**) with the appropriate alcohol or thioalcohol (**502**) (95MI5) (Scheme 136).



SCHEME 135




SCHEME 136

## M. IMIDAZO[4,5-*d*]PYRIMIDINE C-NUCLEOSIDES


### 1. Imidazo[4,5-*d*]pyrimidin-2-yl C-Nucleosides


Amidation of 2,5-anhydro-D-allonic acid (**106**) with 4,5,6-triaminopyrimidine (**506**) gave the corresponding amide **507**, which then thermally cyclodehydrated to 7-amino-2-β-D-ribofuranosylimidazo[4,5-*d*]pyrimidine (8-β-D-ribofuranosyladenine or C-adenine) (**508**) (69CCC247) (Scheme 137).

The 3'-deoxy-β-D-ribofuranosyl- (cordycepin-*C*) (73MI3; 74MI5), β-D-arabinofuranosyl- (74MI4), and 3'-deoxy-α-D-xylofuranosyl- (75JMC438) analogs (**509**, **510**, and **511**) of C-adenine (**508**) were similarly prepared from the corresponding 2,5-anhydro-aldonic acid. The three C-nucleosides **509–511** were tested against blood schizontocidal malaria and found inactive (75JMC438).



SCHEME 137






A variant of the previous reaction was utilized for the synthesis of the 1,3-dimethyl-8( $\beta$ -D-ribofuranosyl)xanthosine **515**; the ethyl 2,5-anhydro-D-allonodithioate derivative **512** was cyclocondensed with 5,6-diamino-1,3-dimethyluracil (**513**) followed by removal of the *O*-protective group of **514** (86MI4) (Scheme 138).


Imidazo[4,5-*d*]pyrimidin-2-yl *C*-nucleosides (**517**) were also obtained by annulation of their pyrimidine rings onto 4-amino-5-cyano-, 4-amino 5-carbamoyl-, and 4-amino-5-alkoxycarbonylimidazol-2-yl *C*-nucleosides (**516**) with formamidine acetate or diethoxymethyl acetate [71JCS (CC)1267; 72MI1; 73TL2971; 75JHC111, 75T2914; 76MI2] (Scheme 139).

The anomeric mixture of *C*-nucleoside **519** was obtained by C—C bond formation between two subunits: the *aldehyde*-sugar derivative **36** and 2-haloimidazo[4,5-*d*]pyrimidine in the presence of butyllithium. The produced acyclo *C*-nucleoside **518** was cyclized with diethyl azodicarboxylate and triphenylphosphine to **519** [95JAP(K)95/118268] (Scheme 140).

Of special interest are the total synthetic approaches devised by Vogel and his group in Switzerland toward imidazo[4,5-*d*]pyrimidine *C*-nucleosides from noncarbohydrate starting materials (89HCA271;



SCHEME 139




SCHEME 140


90JOC2451; 92SL676, 92T10637). Thus, the total synthesis of cordycepin-*C* (**509**) was achieved by multistep transformation of 5,6-*exo*-epoxy-7-oxabicyclo[2.2.1] heptan-2-one (**520**) to 3'-deoxy-2,5-anhydroallonic acid (**525**) and then to **509** (89HCA271). The high regioselective reduction of **520** to **521** was attributed to steric hindrance of the *endo*-methoxyl group at C2 in **520**, which impedes the competitive attack of the hydride agent onto the C5 *endo*-position. This synthesis included also the key step of employing cesium fluoride in DMF to induce smooth cyclodehydration of amide **526** at a moderate temperature without causing anomerization or thermal decomposition (89HCA271) (Scheme 141).

7-Amino-2-(2'-deoxy- $\beta$ -D-xylofuranosyl)imidazo[4,5-*d*]pyrimidine (**534**) was synthesized from the 7-oxabicyclo[2.2.1]hept-5-en-2-yl derivative **527** as outlined in Scheme 142 (90JOC2451).

Fluoro and azido substituents in the sugar moieties of nucleosides are known to amplify biological activities. Consequently, the 2-(2'-fluoro- and




SCHEME 141




R = (1R)-Camphanoyl ; R' = PhCH<sub>2</sub> ; TAP = 4,5,6-triaminopyrimidine

SCHEME 142

2'-azido-2',3'-dideoxy- $\beta$ -D-ribofuranosyl)imidazo[4,5-*d*]pyrimidines **535** and **536** were synthesized by the total synthetic approach in a plan closely similar to that used for the synthesis of **534** (92SL676, 92T10637).



535



536


## 2. Imidazo[4,5-*d*]pyrimidin-5-yl C-Nucleosides

The C-nucleoside **538** pertaining to this class was obtained by condensation of the thioformimide **230** with 5-amino-4-cyanoimidazole (**537**) (75JHC111) (Scheme 143).

### N. IMIDAZO[4,5-*d*]PYRIMIDINE ACYCLO C-NUCLEOSIDES

#### 1. Imidazo[4,5-*d*]pyrimidin-2-yl Acyclo C-Nucleosides

Aldonic acids (**110**) reacted with 4,5-diamino-1,3-dimethyluracil to give the corresponding 2-(alditol-1-yl)-imidazo[4,5-*d*]pyrimidines (**539**, R = H)




SCHEME 143

(56MI1; 74MI7). The acetates of these acyclo C-nucleosides (**539**,  $\text{R} = \text{Ac}$ ) were obtained by oxidative cyclization of the Schiff bases **540**, derived from *aldehydo*-sugar acetates **180** and 4,5-diimino-1,3-dimethyluracil, with mercury(II) chloride in dimethyl sulfoxide [79CPB1094, 79H(12)359] (Scheme 144).


Imidazole ring formation of acyclo C-nucleoside **543** was made by reaction of 6-chloro-1,3-dimethyl-5-nitrouracil with D-glucopyranosylamine (**541**), followed by catalytic hydrogenation and concomitant cyclization of **542** (67CB492). The same C-nucleoside (**543**) was obtained by reacting 1-amino-1-deoxy-D-glucitol (**544**) with 6-chloro-1,3-dimethyluracil and subsequent nitrosation and cyclization (96S459) (Scheme 145).

The C-analog **549** of the potent antiviral agent acyclovir [9-(2-hydroxyethoxymethyl)guanine (ACV)] was prepared by cyclizing the imidazol-2-yl acyclo C-nucleoside **547** with benzoylisothiocyanate as shown in Scheme 146 (83JHC1169).




SCHEME 144





SCHEME 145




SCHEME 146

## O. ISOTHIAZOLO[4,5-*d*]PYRIMIDINE C-NUCLEOSIDES



### 1. Isothiazolo[4,5-*d*]pyrimidin-3-yl C-Nucleosides

C-Nucleosides **552** and **558**, the analogs of oxoformycin B and formycin B, were prepared from the isothiazol-3-yl C-nucleoside **550** as explained in Scheme 147 (93JOC5181; 94MI10). This scheme comprised two key steps: (i) the selective amidation of **550** at the more reactive C5 ester group to afford **553** as a result of proximity to the ring nitrogen, and (ii) transposition of the C5 amide in **553** to C4 in **555** through the cyclic imide intermediate **554** (94MI10).

The isothiazolo[4,5-*d*]pyrimidin-3-yl C-nucleoside analogs of adenine and guanosine, **559** and **560**, respectively, were also synthesized (94JOC1912). C-Nucleosides **552**, **558**, **559**, and **560** were tested for antiviral activity against HIV, HCMV, HSV, and rhinoviruses and found inactive (93JOC5181; 94JOC1912).




SCHEME 147



## P. THIAZOLO- AND SELENAZOLO[5,4-*d*]PYRIMIDINE C-NUCLEOSIDES

### 1. Thiazolo and Selenazolo[5,4-*d*]pyrimidin-2-yl C-Nucleosides

Cyclocondensation of the thiazol-2-yl and selenazol-2-yl C-nucleosides **561** (R = S and Se) with formimidine acetate gave **562** (R = S and Se).




SCHEME 148

These compounds are inferior to pyrazofurin [97AHC(68)223] as antitumor agents against P388 and L1210 leukemia cells or Lewis lung carcinoma (85JOC1741) (Scheme 148).


### Q. 1,2,3-TRIAZOLO[1,5-*c*]PYRIMIDINE *C*-NUCLEOSIDES

#### 1. 1,2,3-Triazolo[1,5-*c*]pyrimidin-3-yl *C*-Nucleosides

The chlorine atom of the pyrimidin-3-yl homo *C*-nucleoside **564** was displaced by azide ions followed by reduction of the introduced azido function to the amino compound **565**. Treatment of the latter with nitrous acid formed the 1,2,3-triazole ring of the two 1,2,3-triazolo[1,5-*c*]pyrimidin-3-yl *C*-nucleosides **566** ( $R = \text{NH}_2$  and  $\text{H}$ ) [89JCS(P1)2401] (Scheme 149).



SCHEME 149



SCHEME 150


R. 1,2,4-TRIAZOLO[1,5-*a*]PYRIMIDINE C-NUCLEOSIDES1. 1,2,4-Triazolo[1,5-*a*]pyrimidin-2-yl C-Nucleosides

2,5-Anhydro-D-allonodithioate (**512**) reacted with 2-hydrazinopyrimidine to form the 1,2,4-triazolo[4,3-*a*]pyrimidin-3-yl C-nucleoside **567** as an intermediate that underwent thermally induced Dimroth-like rearrangement to the 1,2,4-triazolo[1,5-*a*]pyrimidin-2-yl C-nucleoside **568** (89MI5) (Scheme 150).

Based-induced Dimroth rearrangement of the 3-(β-D-galactopyranosyl)-1,2,4-triazolo[4,3-*a*]pyrimidine **569** (Section XI,V) also gave the corresponding 1,2,4-triazolo[1,5-*a*]pyrimidin-2-yl pyranose C-nucleoside **570** (94MI5) (Scheme 151).


S. 1,2,4-TRIAZOLO[1,5-*c*]PYRIMIDINE C-NUCLEOSIDES1. 1,2,4-Triazolo[1,5-*c*]pyrimidin-2-yl C-Nucleosides

β-D-Ribofuranosylthioformimidate (**230**) condensed with 5-benzyloxy-4-hydrazinopyrimidine to give a mixture of the 1,2,4-triazolo[1,5-*c*]pyrimidin-2-yl (**571**) and 1,2,4-triazolo[4,3-*c*]pyrimidin-3-yl (**572**) C-nucleosides in the



DBU = Diazabicyclo [5.4.0] undec-5-ene

SCHEME 151




SCHEME 152

ratio 3:2. De-*O*-benzylation of this mixture with methanolic ammonia followed by de-*O*-benzylation gave only the free 1,2,4-triazolo[1,5-*c*]-pyrimidin-2-yl *C*-nucleoside **573** as a result of direct deprotection of **571** as well as deprotection and base-induced Dimroth rearrangement of **572** (89JHC991) (Scheme 152).


### T. 1,2,4-TRIAZOLO[1,5-*c*]PYRIMIDINE ACYCLO *C*-NUCLEOSIDES

#### 1. 1,2,4-Triazolo[1,5-*c*]pyrimidin-2-yl Acyclo *C*-Nucleosides

Acyclo *C*-nucleoside **575** was prepared in a similar way to the cyclic analog **573** by reacting 2-[2-(benzyloxy)-ethoxy]thioacetimidate **228** with 5-benzyloxy-4-hydrazino-pyrimidine. Evidently, the first-formed 1,2,4-triazolo[4,3-*c*]pyrimidin-3-yl product **574** isomerized to **575** (89JHC991) (Scheme 153).



SCHEME 153



SCHEME 154

### U. 1,2,4-TRIAZOLO[4,3-*a*]PYRIMIDINE C-NUCLEOSIDES

#### 1. 1,2,4-Triazolo[4,3-*a*]pyrimidin-3-yl C-Nucleosides


The condensed 1,2,4-triazole ring of **577** was formed as a result of condensing the  $\beta$ -D-ribofuranosylcarbodithioate **512** with 2-hydrazino-4-hydroxy-6-methylpyrimidine. Unlike the 1,2,4-triazolo[1,5-*c*]pyrimidine analog **568**, the 1,2,4-triazolo[4,3-*a*]pyrimidin-3-yl C-nucleoside **577** did not undergo Dimroth rearrangement (89MI5) (Scheme 154).

Heating 5-(tetra-*O*-acetyl- $\beta$ -D-galactopyranosyl)tetrazole (**578**) with 2-chloropyrimidine resulted in the formation of **579** (94MI5) (Scheme 155).


### V. 1,2,4-TRIAZOLO[4,3-*a*]PYRIMIDINE ACYCLO C-NUCLEOSIDES

#### 1. 1,2,4-Triazolo[4,3-*a*]pyrimidin-3-yl Acyclo C-Nucleosides

*aldehydo*-Sugar pyrimidin-2-ylhydrazones (**580**) were oxidatively cyclized and simultaneously *O*-acetylated in one-pot preparations by treatment with bromine–acetic acid–sodium acetate followed by acetic anhydride to give the poly-*O*-acetylated 8-acetyl-3-(alditol-1-yl)-1,2,4-triazolo[4,3-*a*]pyrimidin-7-ones **582**. De-*O*-acetylation of **582** gave products **584**. Cycliza-



SCHEME 155



SCHEME 156

tion of hydrazones **580** has also been performed with bromine in water to give **583**. The mass spectral fragmentation pattern of **582** indicated that cyclization took place with N1 rather than N3 of the pyrimidine ring (95PHA784) (Scheme 156).

## W. QUINAZOLINE C-NUCLEOSIDES


### 1. *Quinazolin-8-yl C-Nucleosides*

Annulation of a pyrimidine ring onto the  $\beta$ -D-ribofuranosylanthranilic acid nitrile **587** or the  $\beta$ -D-ribofuranosylanthranilamide **588** C-glycosides by heating with triethyl orthoformate and de-O-blocking of the protective groups on the sugar moieties provided the quinazolin-8-yl C-nucleosides **589** and **590**, respectively (95MI4) (Scheme 157).


## X. QUINAZOLINE ACYCLO C-NUCLEOSIDES

### 1. *Quinazolin-8-yl Acyclo C-Nucleosides*

Benzoxazine-quinazoline ring transformation was the approach used to prepare the double-headed quinazolin-2-yl acyclo C-nucleoside **592** from **591** (Section XIII,D; Scheme 207) by heating with aniline in the presence of phosphorus trichloride (87MI4) (Scheme 158).



SCHEME 157




SCHEME 158

## Y. PYRIDO[1,2-a]PYRIMIDINE C-NUCLEOSIDES

### 1. Pyrido[1,2-a]pyrimidin-3-yl C-Nucleosides

2-Alkylideneaminopyrimidines added onto the  $\beta$ -D-ribofuranosyl chloro-ketene **597** to give an adduct that eliminated a hydrogen chloride molecule to furnish, after de-O-protection, the pyrido[1,2-a]pyrimidin-3-yl C-nucleoside **598** (84MI3; 85CPB2671) (Scheme 159).





SCHEME 159

## Z. PYRIDO[4,3-*d*]PYRIMIDINE *C*-NUCLEOSIDES


### 1. *Pyrido*[4,3-*d*]pyrimidin-3-yl *C*-Nucleosides

The two pyrido[4,3-*d*]pyrimidin-8-yl *C*-nucleosides **600** and **602**, the congeners of adenosine and inosine, respectively, were prepared by annulation of the pyrimidine ring onto 4-amino-3-cyanopyridine and 4-amino-3-carbamoylpyridine *C*-nucleoside **599** and **601**, respectively (92MI6) (Scheme 160).

## A'. PYRIMIDO[4,5-*d*]PYRIMIDINE ACYCLO *C*-NUCLEOSIDES

### 1. *Pyrimido*[4,5-*d*]pyrimidin-2-yl *Acyclo C*-Nucleosides


The amino group of 6-amino-1,3-dimethyluracil added onto penta-*O*-acetyl-D-glucuronoyl isothiocyanate (**603**) to form the thiourea derivative **604**, which eliminated a molecule of water to yield the 2-(penta-*O*-acetyl-D-glucopentitol-1-yl)pyrimido[4,5-*d*]pyrimidine **605** (76MI3; 81CPB1832) (Scheme 161).




SCHEME 160

B'. PYRAZINO[2,3-*d*]PYRIMIDINE C-NUCLEOSIDES1. *Pyrazino[2,3-*d*]pyrimidin-7-yl C-Nucleosides and Homo C-Nucleosides*

Reaction of 5,6-diamino-1,3-dimethyluracil with the 6-hydroxy-6- $\beta$ -D-ribofuranosyl-2*H*-pyran-3(6*H*)-one **606** in toluene gave, in addition to another product (Section XI,Y), the lumazin-7-yl C-nucleoside (**609**) in low yield (5%) and the lumazin-7-yl homo C-nucleoside (**614**, 16%) according to the mechanisms shown in Scheme 162. When the reaction was performed in ethylene glycol, the C-nucleoside (**609**) was obtained as the main product (35%) and the homo C-nucleoside (**614**) in 13% yield (89JOC3927).



SCHEME 161




SCHEME 162

### C'. PYRAZINO[2,3-d]PYRIMIDINE ACYCLO C-NUCLEOSIDES

#### 1. The Naturally Occurring Pteridin-6-yl Acyclo C-Nucleosides


6-(Alditol-1-yl)pteridines (pteridin-6-yl C-nucleosides) are omnipresent in both the plant and animal kingdoms. They play an important role as essential cofactors for the diverse enzymes involved in biological hydroxylation processes. Extensive work has been performed toward isolation, struc-

ture elucidation, and synthesis of naturally occurring members of this class, as well as the synthesis of their congeners. Trivial names have usually been given to most of the naturally occurring members of this class, among which are biopterin (**615**), dictyopterin (**616**), orinapterin (**617**), D-neopterin (**618**), L-neopterin (**619**), D-monapterin (**620**), and L-monapterin (umanapterin) (**621**). A few of the isolated naturally occurring members, however, were systematically named.



a. *Biopterin and Related Compounds.* Biopterin [2-amino-6-(L-erythro-1',2'-dihydroxypropyl)-4-oxo(3-*H*)pteridine] (**615**) is widely distributed in eukaryotes and prokaryotes [63LA(662)72; 64AGE114; 72AGE1061; 75MI5; 80MI3; 82MI3; 84MI4]. Thus, it has been isolated from human urine [55JA3167; 56JA5871; 59BP814462; 72JBC(257)4549], human saliva (89MI1), reptile skins (60MI2), royal jelly of the honeybee [58ZPC(311)79], insects (*Drosophila melanogaster*) (55HCA397, 55JA4865; 77MI3), Mexican leaf frog larvae (78MI3), parasitic helminths (*Ascaris lumbricoides*) (70MI4), *Plodia interpunctella* (71MI1, 71MI2), and bacteria (*Escherichia coli*) [61BBR(6)180]. The structure of biopterin was determined by degradation (55HCA1222, 55JA4865) and mass spectral fragmentation (72TL3219). Biopterin (**615**) has frequently been synthesized, together with its 7-alditolyl isomer (primapterin, **625**), by oxidative cyclocondensation of 2,5,6-triaminopteridin-4-one (**624**) with either of the two C2 epimeric 5-deoxyl-1-aldopentoses **622** or their hydrazones [55JA4865; 56JA5868; 58HCA108; 62LA(658)193, 62ZPC(329)291; 63CB1395; 75BCJ3767; 77HCA211; 79BCJ181; 80BCJ2344; 81MI3; 85HCA1639; 89JAP(K)89/221380, 89LA 1267], as well as the 5-deoxyl-L-ribulose **623** or its hydrazones (69HCA1225; 72HCA570, 72HCA574) (Scheme 163).

This method suffers the laborious separation of the two isomeric C-nucleosides **615** and **625** and characterization of the structure of each. To circumvent these difficulties, biopterin **615** was obtained as a sole entity by reacting 1-amino-1-deoxy-L-erythro-pentulose **626** with 2-amino-4-




SCHEME 163


chloro-5-nitropyrimidin-4-one. The nitro group of the produced **627** was catalytically reduced and concomitantly cyclized to the 7,8-dihydrobiopterin **628**. Oxidation of **628** with manganese dioxide gave **615** [68JCS(CC)120; 69JCS(C)928; 77MI4] (Scheme 164).

Taylor and Jacobi contrived the unequivocal synthesis shown in Scheme 165 to obtain only biopterin (**615**); both of the pyrimidine and pyrazine rings were elaborated onto the alditolyl moiety during this synthesis. A key step during this synthesis was the regiospecific transoximation of the aldehyde function of 5-deoxy-L-erythro-pentulose **629** with acetone oxime **630** (74JA6781; 76JA2301). Synthesis of <sup>13</sup>C8a biopterin was also accomplished according to this synthetic plan for utilization in biochemical studies (79MI7).

7,8-Dihydrobiopterin (**628**) and 5,6,7,8-tetrahydrobiopterin (**633**) are two biologically important derivatives of the parent compound (**615**). The dihydro derivative (**628**) was isolated from the skin of five different species of *Crenilarius* fishes [63ZN(B)551]. The tetrahydro derivative (**633**) was iso-



SCHEME 164




SCHEME 165

lated from the same species of fishes [63ZN(B)551] and from the cyanobacterium (blue-green alga). *Anacystis nidulans* (63MI1; 66MI2). Chemical transformation of the three derivatives to each other is explained in Scheme 166 (66MI2; 73LA1091; 78HCA2731; 79HCA2577; 81MI3; 86EP191335, 86MI6). The autooxidation of tetrahydrobiopterin was studied using ESR spectrometry [74CI(L)233].

The absolute configuration at C6 of the natural tetrahydrobiopterin was studied using NMR and CD spectroscopy (82AJC785) and X-ray crystallographic analysis (85MI5) and found to be *R*, with the alditolyl chain occupying a quasi-equatorial position.

Tetrahydrobiopterin (**633**) is an essential enzyme cofactor in a number of hydroxylation and oxygenase reactions (72AGE1061; 83MI6), including hydroxylation of phenylalanine to tyrosine (63PNA1085), tryptophan to 5-hydroxytryptophan (serotonin) [66MI1; 67SCI217; 74MI3; 80BBA(611)241; 91MI2], hydroxylation of dihydroorotic acid [73BBR(53)929], and 17 $\alpha$ -hydroxylation of progesterone (72MI2). It also acts as an essential cofactor in melanin synthesis [68ZN(B)860] and in the conversion of tyrosine to the neurotransmitter L-dopa (3,4-dihydroxy-L-phenylalanine) (71MI3). The



SCHEME 166

biochemical activities of the natural (6*R*)-tetrahydrobiopterin and the synthetic (6*S*)-isomer were studied; both were found active *in vitro*, but only the natural isomer was found active *in vivo* (86MI6; 88MI3). Abnormalities of biopterin and tetrahydrobiopterin metabolism are linked to the incidence of some metabolic diseases such as Parkinson's disease and phenylalaninemia (85MI4, 85MI6; 92MI5; 93MI2). Some *O*- and *N,O*-acylated derivatives of tetrahydrobiopterin were patented as useful preparations for the treatment of these diseases (83EP79574; 85USP4550109; 86EP191335; 89EP318926).

3-Methylbiopterin and 2'-deoxybiopterin are two naturally occurring pterin-6-yl acyclo *C*-nucleosides related to biopterin. The former was isolated from methanol extracts of the marine anthozoan *Asteroides calycularis* Pallas and found to inhibit growth of mouse and chick fibroblasts in culture (87E950), whereas the latter was isolated from urine of patients with malignant lymphoma (95MI2).

b. *Dictyopterins*. 2-Amino-6-(*D*-threo-1',2'-dihydroxypropyl)pteridin-4-one (dictyopterins, **616**) was isolated from the vegetative cells of the amoeba *Dictyostelium discoideum* (90MI3). It was synthesized, prior to its isolation, by the conventional method of oxidative cyclocondensation of 5-deoxy-*D*-xylose with 2,5,6-triaminopyrimidin-4-one (**624**) (58HCA108; 66CB2162) in a similar way to that used for the synthesis of biopterin (Section XI,C',1,a; Scheme 163).

c. *Orinapterin*. It was isolated from human urine and its structure was determined as 2-amino-6-(*L*-threo-1',2'-dihydroxypropyl)pteridin-4-one (**617**) (92ZPC1061). It was synthesized by the classical method of reacting **624** and 5-deoxy-*L*-xylose (66CB2162).

d. *D- and L-Neopterins*. *D*-Neopterin, 2-amino-6-(*D*-erythro-tetritol-1-yl)pteridin-4-one (**618**), and its *L*-enantiomer (**619**) were found in various natural sources, including human saliva (89MI2) and urine [67MI4; 72JBC(247)4549], ovine pineal glands (84MI2), insects [63CB1406, 63LA(662)72; 79MI6; 80MI2], Mexican frog larvae (78MI3), leguminous plants (80E639), and bacteria (69MI3; 80ABC2061).


*D*-Neopterin (**618**) was synthetically obtained by reacting the triaminopyrimidine **624** with *D*-ribose (63CB1406), *aldehyde-D*-ribose phenylhydrazone (70HCA1202), or *aldehyde-D*-arabinose hydrazone (58JA2018) in a way similar to that described in Scheme 163. *D*-Neopterin 3'-phosphate was chemically prepared from **624** and *D*-ribose 5-phosphate (65CB851) and biosynthetically obtained from guanosine triphosphate by treatment with the cell-free extracts of *Pseudomonas* species ATCC11299a

[66JBC(241)2220] or *Serratia indica* IFO3759 (72ABC1685, 72ABC1695). A mixture of D-neopterin 3'-monophosphate (**634**) and 2',3',-diphosphate (**635**) was obtained when D-neopterin (**618**) was phosphorylated with a mixture of phosphoric acid and phosphorus pentoxide (72BCJ3564). Cyclization of the 3'-monophosphate **634** with DCC afforded the 2',3'-cyclic phosphate **636** (72BCJ3564). Catalytic hydrogenation of the diphosphate **635** gave a mixture of the (6*R*)- and (6*S*)-5,6,7,8-tetrahydro-D-neopterin **637** (86HCA210) (Scheme 167).

D-Neopterin labeled at the amino group or N3 with enzyme or fluorescent markers was prepared for utilization in immunoassays of neopterin [93GEP(D)4308739]. Dihydro-D-neopterin 3'-phosphate labeled at C1' and C2' with  $^3\text{H}$  has also been prepared (91MI3).

L-Neopterin (**619**) was synthesized by reactions similar to those used to obtain its D-enantiomer **618** [56CB2904; 58JA2018; 68HCA1495, 68-JCS(CC)120; 69JCS(C)928]. The preparation of 5,6,7,8-tetrahydro-L-neopterin, by catalytic reduction of the parent compound (**618**) (76HCA248) and its 2-*N*-acetyl-1',2',3'-tri-*O*-acetyl-5,6,7,8-tetrahydro-L-neopterin (79HCA2558; 86HCA210) were reported.

L-Neopterin (**619**) serves as a biosynthetic precursor for biopterin, and their ratio in biological fluids is a good criterion to diagnose malignancy, gout, uremia, and liver disease (91MI2). It was found to provide protection against free-radical-induced injuries such as those encountered with adriamycin cardiotoxicity and gastric ischemic injury (94MI3). L-Neopterin and biopterin are significant in the immune system (94MI4), and 5,6-dihydro-neopterin is used as a drug for the treatment of Parkinson's disease [86JAP(K)86/29382].



SCHEME 167




e. *D* and *L*-Monapterins. The first synthesis of 2-amino-6-(*D*-*threo*-tetritol-yl)pteridin-4-one (*D*-monapterin, **620**) was reported as early as 1947 by the reaction of *D*-xylose (**638**,  $Z = O$ ) with 2,5,6-triaminopyrimidin-4-one (**624**) (47HCA1031; 58JA2018; 63CB1406). *D*-Xylosulose (*D*-xylosone) (51USP2541717), 1-benzylamino-1-deoxy-*D*-xylulose (**639**) (68HCA1495), and *D*-xylose phenylhydrazone (**638**,  $Z = NNHPh$ ) (70HCA1202) also reacted with **624** to give **620** (Scheme 168). Compound **620** has been identified in the ciliate protozoan *Tetrahymena pyriformis* (92MI2).

Reaction of **620** with polyphosphoric acid produced a mixture of *D*-monapterin 3'-monophosphate and 2',3'-diphosphate (72BCJ3564).



*L*-Monapterin (**621**) was isolated from bacteria (64HCA1948; 80N610), human urine [72JBC(247)4549], and saliva (89MI1). *L*-Monapterin (**621**) (47HCA1031; 63CB1406; 68HCA1495), its 3'-monophosphate, and its 2',3'-diphosphate (72BCJ3564) were synthesized by reactions similar to those used for the synthesis of *D*-monapterin (**620**) and its phosphates. *L*-Monapterin was biosynthesized from guanosine triphosphate by incubation with cell-free extracts of *Serratia indica* (72ABC1685, 72ABC1695).

f. *Euglenapterin*. This compound was found in the unicellular alga *Euglena gracilis*; its structure was determined as 2-dimethylamino-6-(*L*-*threo*-tetritol-1-yl)pteridin-4-one (**641**) (76MI4). It was synthesized, together with other products, from *L*-xylose phenylhydrazone (**640**,  $Z = NNHPh$ ) and 5,6-diamino-2-dimethylaminopyrimidin-4-one (80AGE473) (Scheme 168).



SCHEME 168




g. *2-Amino-6-(D-ribo-tetritol-1-yl)pteridin-4-one*. This pteridine acyclo C-nucleoside **642** was isolated from the bacterium *Rhodopseudomonas sphaeroides* GM-1. It has not been given a trivial name (93MI3).



h. *2-Amino-6-[2-(β-D-glucouronopyranosyl)-D-glucopentitol-1-yl]pteridin-4-one*. Isolation of this compound **643** from *Mycobacterium smegmatis*, elucidation of structure, and synthesis was reported by Goto *et al.* [65LA (689)221].

i. *Ichthyopterin*. Ichthyopterin has the structure of 2-amino-(L-erythro-1',2'-dihydroxypropyl)pteridin-4,7-dione (**644**) (91MI4) and was isolated from the skin of goldfish [43LA(554)69; 59LA(625)133] and scales of the cyprinid fish *Misgurnus anguillicaudatus* (55MI1; 68MI5).

j. *Leucettidine*. Leucettidine is a naturally occurring pteridin-6-yl acyclo C-nucleoside that was isolated from extracts of the calcareous sponge *Leucetta microraphis*. Its structure, which was found to be 6-[(1'S)-1'-hydroxypropyl]-3-methylpteridine-2,4-dione (**645**), represents a deviation from the usual substitution pattern of these compounds in having a mono-oxygenated propyl group and no amino group at C2 (81JOC4782).



## 2. *The Naturally Occurring Pteridin-7-yl Acyclo C-Nucleosides "Primapterin" and "Anapterin"*

Primapterin [2-amino-7-(*L*-erythro-1',2'-dihydroxypropyl)pteridin-4-one] (**625**) and anapterin [2-amino-7-(*D*-erythro-1',2',3'-trihydroxypropyl)pteridin-4-one] (**646**) are the two naturally occurring pteridin-7-yl acyclo C-nucleosides known thus far.


Both **625** and **646** were isolated from urine of patients with a transient type of hyperphenylalaninemia that is related to a bipterin synthetase deficiency [88BBR(153)715, 88MI4, 88MI5; 90HCA1064]. Anapterin (**646**) was also found in saliva of healthy human adults (89MI1).

When patients with hyperalaninemia were loaded with tetrahydrobiopterin labeled at C3' with  $^2\text{H}$  (90HCA1058),  $^2\text{H}$ -labeled bipterin and  $^2\text{H}$ -labeled primapterin were produced in equal amounts in their urine [90JBC(265)3923; 92HCA1237]. Furthermore, *in vitro* incubation of tetrahydropteridin-6-yl acyclo C-nucleosides, namely tetrahydrobiopterin (**633**) and tetrahydro-*D*-neopterin (**637**), with phenylalanine hydroxylase produced the two pteridin-7-yl acyclo C-nucleosides primapterin **625** and anapterin **646**, respectively [90BBR(172)1060]. These results led to the conclusion that pteridin-7-yl acyclo C-nucleosides are biologically formed from the corresponding pteridin-6-yl precursors by enzymatic intramolecular rearrangement processes [90BBR(172)1060, 90JBC(265)3923; 92HCA1237].

Before isolation from the natural sources, primapterin (**625**) was synthesized, together with bipterin (**615**) as explained in Scheme 163 (Section XI,C',1,a). Primapterin (**625**) was obtained as a single product by cyclocondensation of 2,5,6-triaminopyrimidin-4-one (**624**) with *aldehydo*-5-deoxy-*L*-arabinose semicarbazone (**647**) as a result of the regioselective addition of the most nucleophilic C5 amino function of **624** onto the azomethine of **647** (89MI2, 90HCA337) (Scheme 169). Anapterin (**646**) was also prepared according to this sequence of reactions from *aldehydo*-*D*-ribose semicarbazone and **623** (89MI2; 90HCA337).

## 3. *Pteridin-6-yl and Pteridin-7-yl Acyclo C-Nucleosides*

The first synthesis of these compounds by cyclocondensation of monosaccharides with 5,6-diaminopyrimidines was reported by Karrer and his group in 1947 (47HCA1031). Since then, a great deal of research work has been done on the synthesis of various members of pteridine acyclo C-nucleosides by this method or modifications therefrom. When ketose (**652**) or aldose (**653**) monosaccharides were cyclocondensed with 2,5,6-triamino-pyrimidin-4-one (**624**), 6- or 7-(alditol-1-yl)pteridin-4-ones (**656** or **658**) or mixtures of both were obtained [47HCA1031; 48HCA777, 48HCA782; 49HCA1041,




SCHEME 169


49JA3977, 49JCS79; 50LA(570)127; 52GEP839498, 52USP2603643; 54-USP2667485; 58JA2018; 63CB1406; 64CB1002; 68HCA1029; 71NKZ-1177; 81AQ(C)126; 82AQ(C)399]. According to the mechanism proposed for this reaction (Scheme 170), the most nucleophilic amino group at C5 of **624** attacks C1 of aldoses or C2 of ketoses.

Aldosuloses (sugar osones) also reacted with **624** to afford mixtures of 6- and 7-(alditol-1-yl)pteridin-4-ones (**656** and **658**) (47JA2566; 51USP-2541717).

In the presence of hydrazine hydrate, ketose (**652**) (49HCA1041, 49JA3977) and aldose (**653**) monosaccharides reacted with **624** to give the



SCHEME 170




SCHEME 171


corresponding pteridin-6-yl acyclo C-nucleosides (**656**) only [48NAT(L)-308; 49CB25, 49HCA1041, 49JA3977, 49JCS79, 49JCS2077; 52JPJ1294; 58JA2018]. Aldose phenylhydrazones (**663**,  $R' = \text{NHAr}$ ) (70HCA1202; 79BCJ181; 84LA1815), aldulose 1-arylhydrazones (56CB956), 1-alkyl-amino-1-deoxyketoses (**664**,  $R' = \text{alkyl}$ ) (48E427; 68HCA1495), glycosylamines (49JCS2077), and monosaccharide phenylosazones (50SWP268531) behaved similarly. These results were explained in terms of an Amadori rearrangement of aldose hydrazones (**663**,  $R' = \text{H, NHAr}$ ) to the corresponding 1-hydrazino-1-deoxyketoses (**664**,  $R' = \text{H, NHAr}$ ), which then cyclocondense with **624** to give **656** as explained in Scheme 171.

7,8-Dihydro-6-(*D*-arabino-tetritol-1-yl)pteridine-2,4-dione **668** was unequivocally prepared by condensation of 1-amino-1-deoxy-*D*-fructose (**42**) with 6-chloro-5-nitrouracil followed by concomitant reduction and cyclization of **667** (62JCS44) (Scheme 172).

The 7-(alditol-1-yl)-1,3-dimethylpteridine-2,4-diones **671** were the only products obtained from the reaction of *aldehydo*-sugar acetates (**180**) with 5,6-diamino-1,3-dimethyluracil (**669**) followed by oxidative cyclization of



SCHEME 172



SCHEME 173

the formed Schiff bases **670** with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) [75JAP(K)75/129593] (Scheme 173).


Enzymatic deamination of the naturally occurring pteridin-6-yl acyclo C-nucleosides biopterin (**615**), dictypterin (**616**), D-neopterin (**618**), and D-monapterin (**620**) with pterin deaminase from the slime mold *Dictyostelium discoideum* caused their conversion to the corresponding lumazin-6-yl {2,4-dioxypyrazino[2,3-*d*]pyrimidin-6-yl} acyclo C-nucleosides: biolumazine (**672**), dictyolumazine (**673**), D-neolumazine (**674**), and D-monolumazine (**675**), respectively (94MI2) (Scheme 174).

Some pteridine acyclo C-nucleosides revealed activities against tumors [52JPJ1294; 75JAP(K)75/129593], bacteria [75JAP(K)75/129593], and viruses [54USP2667485; 75JAP(K)75/129593]. 3-*N*-Propylbiopterin (oncopterin) is a useful diagnostic marker for cancer [94GEP(D)4244261].


#### D'. PYRROLO[1',2':1,2]PYRAZINO[5,6-*d*]PYRIMIDINE C-NUCLEOSIDES

##### 1. Pyrrolo[1',2':1,2]pyrazino[5,6-*d*]pyrimidin-1-yl C-Nucleosides

In addition to the pyrazino[2,3-*d*]pyrimidin-7-yl C-nucleoside **609** and its homo analog **614**, which were obtained by the reaction of 5,6-diamino-1,3-dimethyluracil with the 6-hydroxy-6- $\beta$ -D-ribofuranosyl-2*H*-pyran-3(6*H*)-one derivative **606** (Section XI,B'; Scheme 162), the pyrrolo-pyrazino-pyrimidine C-nucleoside **680** was produced in 30% yield according to the mechanism outlined in Scheme 175 (89JOC3927).



SCHEME 174




SCHEME 175

### E'. THIENO[2',3':2,3]PYRAZINO[6,5-*d*]PYRIMIDINE ACYCLO C-NUCLEOSIDES

#### 1. *The Naturally Occurring Thieno[2',3':2,3]pyrazino[6,5-*d*]pyrimidin-7-yl Acyclo C-Nucleosides "Urothione"*

Urothione was isolated from human urine [40ZPC(263)78; 43-ZPC(277)284], and its 2-amino-7-[(2'*S*)-1',2'-dihydroxyethyl]-6-(methylthio)thieno[2',3':2,3]pyrazino[6,5-*d*]pyrimidine} structure (**681**) was established on the basis of degradative and spectral studies (55CB1251; 67NKZ897, 67TL4507; 69MI3; 70MI6). The *S* configuration of C2' of the side chain has recently been established (95TL2631).

A mixture of the two enantiomers **688** of **681** was synthesized by Sakurai and Goto by elaborating the thiophene ring onto the 6-(4,5-dibenzyloxy-



2-oxopent-1-yl)pterin **685** (68TL2941; 69MI4) (Scheme 176). Taylor and Reiter synthesized the same enantiomeric mixture (**688**) by a different approach, which comprised forming the thieno[2,3-*b*]pyrazine acyclo *C*-nucleoside **694** and then constructing the pyrimidine ring (89JA285) (Scheme 177).

## XII. Condensed 1,4-Diazine *C*-Nucleosides

### A. PYRROLO[1,2-*a*]PYRAZINE *C*-NUCLEOSIDES


#### 1. *Pyrrolo*[1,2-*a*]pyrazin-6-yl *C*-Nucleosides

Treatment of the  $\beta$ -ribofuranosylpyranone derivative **606** with 1,2-diaminoethane, and removal of the sugar-blocking groups, gave the 3,4-dihydro-6-( $\beta$ -D-ribofuranosyl)pyrrolo[1,2-*a*]pyrazine **699** (88JOC1401) (Scheme 178).

### B. PYRROLO[1,2-*a*]PYRAZINE ACYCLO *C*-NUCLEOSIDES


#### 1. *Bis*{*pyrrolo*[1,2:1',2'-*d*]}pyrazine-1,6-diyl Acyclo *C*-Nucleosides

Treatment of 2-carboxy-3-methoxycarbonyl-5-(D-*arabino*-tetritol-1-yl)-pyrrole (**700**) with acetic anhydride caused bimolecular cyclocondensation with simultaneous *O*-acetylation to yield **701** (74MI8) (Scheme 179).




SCHEME 176






SCHEME 177




SCHEME 178




SCHEME 179

C. IMIDAZO[1,2-*a*]PYRAZINE C-NUCLEOSIDES1. *Imidazo*[1,2-*a*]pyrazin-3-yl C-Nucleosides

The 2-amino-1-( $\beta$ -D-ribofuranosyl)ethanol derivative **702** was condensed with 2,3-dichloropyrazine to give **703**, which was elaborated to **707** [93JHC(31)1213] (Scheme 180). C-Nucleoside **707** demonstrated weak suppression of mouse splenic NK-cell activity toward YAC lymphoma cells and *in vivo* anti-inflammatory activity in rats [93JHC(31)1213].



SCHEME 180



SCHEME 181

#### D. IMIDAZO[1,5-*a*]PYRAZINE C-NUCLEOSIDES


##### 1. Imidazo[1,5-*a*]pyrazin-3-yl C-Nucleosides

The imidazole ring of the imidazo[1,5-*a*]pyrazin-3-yl C-nucleoside **709** was formed upon reacting the 2,5-anhydro-D-allonic derivative **79** with 2-aminomethylpyrazine, dehydrocyclization of the resulting amide **708**, and de-*O*-benzoylation of the protected C-nucleoside [84JCS(P1)229] (Scheme 181).

#### E. OXAZOLO[3,4-*a*]PYRAZINE ACYCLO C-NUCLEOSIDES

##### 1. Bis{oxazolo[3,4-*a*:3',4'-*d*]}pyrazine-5,10-diyl Acyclo C-Nucleosides

In a saline solution at pH 4.6, the antibiotic streptozotocin **98** decomposed to a mixture of several products. Acetylation of this mixture and separation of the products gave the acetylated 5,10-di-(*D*-erythro-tritol-1-yl)-bisoxazolo[3,4-*a*:3',4'-*d*]pyrazine-3,8-dione **710** (79JOC9) (Scheme 182).





SCHEME 182


F. 1,2,4-Triazolo[4,3-*a*]pyrazine C-NUCLEOSIDES1. 1,2,4-Triazolo[4,3-*a*]pyrazin-3-yl C-Nucleosides

Benzyl D-ribofuranosylthioformimidates (**711**) reacted with 3-chloro-2-hydrazinopyrazine to form the 8-benzylthio-1,2,4-triazolo[4,3-*a*]pyrazin-3-yl C-nucleosides **712** as a result of nucleophilic displacement of the chloro group by the benzyl mercaptan produced from the initial cyclocondensation step. Compounds **713** were transformed to the formycin and formycin analogs **714** and **716** (79JOC1028; 84JMC924) (Scheme 183). Compound **714** inhibited growth of L1210 tumor cells in culture, has weak antiviral activity, and acted as a coronary vasodilator (84JMC924).


The 3-( $\alpha$ -D-arabinofuranosyl)-1,2,4-triazolo[4,3-*a*]pyrazin-8-one **717** (79-



SCHEME 183



717



718

MI1) and the unsubstituted 3-( $\beta$ -D-ribofuranosyl)-1,2,4-triazolo[4,3-*a*]pyrazine **718** (89MI5) were synthesized by similar reactions.

## G. QUINOXALINE C-NUCLEOSIDES


### 1. Quinoxalin-2-yl C-Nucleosides

Heating the 6-hydroxy-6- $\beta$ -D-ribofuranosylpyranone derivative (**606**) with 1,2-diaminobenzenes gave the quinoxalin-2-yl C-nucleosides **720** (Scheme 184) in addition to the pyrrolo[1,2-*a*]quinoxalin-1-yl C-nucleosides **744** (Section XII,J; Scheme 191) [88JOC1401; 90JCS(P1)67].


## H. QUINOXALINE ACYCLO C-NUCLEOSIDES

### 1. Quinoxalin-2-yl Acyclo C-Nucleosides

Reaction of 1,2-diaminobenzene (**721**) with aldoses (**68**) may only involve the C1 of the sugar to afford the corresponding 2-(alditol-1-yl)benzimidazoles (**112**) (Section IV,C; Scheme 34) or C1 and C2 to give the 2-(alditol-1-yl)quinoxaline **111** (1887CB281, 188CB2205; 34CB1980, 44CB507; 53MI1; 58UK179; 63JOC231; 66ZC329; 68JA1318; 79HCA241; 84ABC2753). 2-Amino-2-deoxyaldoses also reacted with 1,2-diaminobenzene (**721**) to give



SCHEME 184




SCHEME 185

**111** [43JBC(150)351]. The mechanism according to which compounds **111** are formed is shown in Scheme 185 (47CB255).


Ketoses (34CB155; 41CB13; 68JA1318), 1-amino-1-deoxyketoses (Amarori compounds) [44CB507; 47CB255; 48E427; 58RTC827; 59ZN(B)217; 65LA(684)146; 88MI9], aldoses [1889CB87; 37BJ(31)1033; 41CB18; 59CB501], aldoses 1-arylhydrazones [54CB1068; 56CB956; 58CB1605; 58CB2273; 59CB501; 65LA(684)146], and reducing disaccharides (58CB2273; 85ABC3279) also reacted with **721** to afford the corresponding quinoxalin-2-yl acyclo C-nucleosides.

Whenever 4-substituted-1,2-diaminobenzenes (**726**) were used, mixtures of 6- and 7-substituted quinoxalin-2-yl C-nucleosides (**727** and **728**) were obtained in which the 6-substituted isomer **727** usually predominated [56CB956; 58CB1605; 63JOC231; 65LA(684)146] (Scheme 186).

Condensation of 2-ketoaldonic acids (ulosonic acids, **729**) or their esters with **721** gave the 2-(alditol-1-yl)quinoxalin-3-ones **730** (34CB155; 37CB2148; 61CB1743; 69HCA300) (Scheme 187).



SCHEME 186



SCHEME 187

2,3-Diketohexono-1,4-lactones (2,3-hexodiulosono-1,4-lactones, **190**) reacted with 1,2-diaminobenzenes in the presence of hydrazines to give the 2-(1-hydrazonotetritol-1-yl)quinoxalin-3-ones **732** through intermediate **731** (34CB555; 57AG479; 59CB1550; 65HCA1860; 78MI5, 78MI7, 78MI9, 78MI10; 80MI6; 86MI3; 88MI10) (Scheme 188).


2-[(3*S*)-3,4-dihydroxybutyl]-3-methylquinoxaline **740** was prepared as shown in Scheme 189 by reacting the 5-hydroxy-5-(β-D-ribofuranosyl)furanone derivative **247** with 1,2-diaminobenzene [93H(36)2591].

Conformations of quinoxalin-2-yl acyclo *C*-nucleosides (65JOC2457) and the relation between the stereochemistry at C1' and the sign of the Cotton effect of their ORD spectra were studied (67JA4129; 68JA1318). Polarographic reduction of some derivatives of these acyclo *C*-nucleosides was also investigated (86MI5).


## I. PYRIDO[2,3-*b*]PYRAZINE ACYCLO *C*-NUCLEOSIDES

### 1. *Pyrido*[2,3-*b*]pyrazin-3-yl *C*-Nucleosides

In the presence of phenylhydrazine, dehydro-L-ascorbic acid (**741**) reacted with 2,3-diamino-5-bromopyridine to produce a product that was assigned the 7-bromo-3-(1-phenylhydrazono-2,3,4-trihydroxybutyl)pyrido[2,3-*b*]pyrazin-2-one structure **742**. No rationale was offered as to why the possible alternative 6-bromo isomer (**743**) was excluded (64AGE802) (Scheme 190).



SCHEME 188




SCHEME 189

## J. PYRROLO[1,2-a]QUINOXALINE C-NUCLEOSIDES


### 1. Pyrrolo[1,2-a]quinoxalin-1-yl C-Nucleosides

In addition to the quinoxalin-2-yl C-nucleosides **720** (Section XII,G; Scheme 184) formed upon reacting **606** and 1,2-diaminobenzenes, the pyrrolo[1,2-a]quinoxalin-1-yl C-nucleoside **744** was formed in 16% yield according to the mechanism shown in Scheme 191 [88JOC1401; 90JCS(P1)67].



SCHEME 190





SCHEME 191

### K. FURO[2,3-*b*]QUINOXALINE ACYCLO C-NUCLEOSIDES


#### 1. Furo[2,3-*b*]quinoxalin-3-yl Acyclo C-Nucleosides

During *O*-isopropylidenation of the alditolyl chain of the 3-(alditol-1-yl)quinoxalin-2-one **745**, the fused furan ring of **746** was formed as a result of acid-catalyzed cyclodehydration of the enolized C2 carbonyl and C2' OH groups. Removal of the ketal group of **746** gave **747** (93MI6) (Scheme 192).


### L. FURO[3,4-*b*]QUINOXALINE ACYCLO C-NUCLEOSIDES

#### 1. Furo[3,4-*b*]quinoxalin-2-yl Acyclo C-Nucleosides

Reaction of dehydro-D-*arabino*-ascorbic acid (**748**) with two molar equivalents of 1,2-diaminobenzene gave the quinoxalin-2-yl derivative **749**. Treatment of the latter with hydrochloric acid hydrolyzed the 2-aminobenzamido



SCHEME 192



SCHEME 193


group with lactonization of the produced acid to yield the 2-(alditol-1-yl)furo[3,4-*b*]quinoxalin-9-one **750** (84MI9) (Scheme 193).

### M. PYRAZOLO[3,4-*b*]QUINOXALINE (FLAVAZOLE) C-NUCLEOSIDES


#### 1. *Pyrazolo[3,4-*b*]quinoxalin-3-yl C Nucleosides* (*Flavazol-3-yl C-Nucleosides*)

The only synthetic pathway used so far to prepare these *C*-nucleosides was the acid-catalyzed cyclodehydration of the alditolyl chains of their acyclo analogs (Section XII.N). Thus, heating 1-aryl-3-(*D*-*arabino*-tetritol-1-yl)flavazoles (**751**) with dilute sulfuric acid gave, stereospecifically, 1-aryl-3-( $\beta$ -*D*-erythrofuransyl)flavazoles (**752**) (78MI7; 80MI8; 82MI4; 84MI5; 96MI1) (Scheme 194).

During this cyclodehydration, inversion of configuration occurred at C1' of **751** to give the  $\beta$ -*D*-*C*-nucleoside **752** rather than its  $\alpha$ -anomer because of (i) preference of the protonated bulky heterocycle to occupy the equatorial  $\beta$  position in the  $^2\text{E}$  (envelope) conformation (**753**) to gain the stabilization of the reverse anomeric effect, and (ii) destabilization of the  $^2\text{E}$  conformation of the alternative  $\alpha$ -anomer (**754**) by the nonbonded *cis*-1,3-diaxial interaction between the C3' hydroxyl and the bulky heterocycle (80MI8) (Scheme 195).



SCHEME 194



B = 1-Arylflavazol-3-yl

SCHEME 195


However, the outcome of the acid-catalyzed cyclodehydration of 1-phenyl-3-(D-*lyxo*-tetritol-1-yl) flavazole (**755**) was stereoselective, since it produced a mixture of 1-phenyl-3-( $\beta$ - and  $\alpha$ -D-threofuranosyl)flavazoles (**756** and **757**) in the ratio 3:1. The  $\alpha$ -anomer **757** is stereochemically more stable because the bulky heterocycle and the C2' hydroxyl occupy less crowded positions than in the  $\beta$ -anomer **756** (94MI8) (Scheme 196).

Flavazole C-nucleosides revealed cytotoxic activity against the human nasopharynx KB epidermoid carcinoma cells (82MI4; 84MI5) and mouse P388 leukemia cells (84MI5).


## N. PYRAZOLO[3,4-*b*]QUINOXALINE (FLAVAZOLE) ACYCLO C-NUCLEOSIDES

### 1. *Pyrazolo[3,4-*b*]quinoxalin-3-yl C-Nucleosides (Flavazol-3-yl Acyclo C-Nucleosides)*

Quinoxalin-2-yl acyclo C-nucleosides (**758**) (Section XII,H) react with three molar equivalents of hydrazine (43CB1; 71MI4) or arylhydrazines (41CB13, 41CB279, 41CB398; 42CB1536; 44CB507; 53MI1;



SCHEME 196



SCHEME 197


58CB1605, 58MI1; 59ZN(B)217; 63JOC999; 66ZC329; 71ZC380; 72JPR877] to give flavazol-3-yl acyclo C-nucleosides (**761**) (Scheme 197). 3-(1-Arylh-drazono-2,3,4-trihydroxybutyl)quinoxalin-2-ones (**762**) (Section XII,H; Scheme 188) undergo base-catalyzed cyclodehydration to give **761** also [57AG479; 59CB1550; 78MI5, 78MI8, 78MI9, 78MI10; 86MI3; 89MI7, 89MI8; 92MI3; 93H(36)961] (Scheme 197).

Flavazol-3-yl derivatives of oligosaccharides were prepared, mainly, as useful derivatives to characterize these oligosaccharides [46MI1, 46MI2; 52JBC(196)265; 53JA3664; 54JA1671; 55JA1015; 58CB2273, 58JA1445, 58MI1; 62MI1; 69CCC1118; 71JPR940, 71MI5, 71ZC380; 72JPR877, 72MI3]. UV (61SCI112), ORD (67JA4129), CD (78MI6; 86MI8), and MS (70OMS1535; 71MI6, 71MI7) spectral properties, as well as the relation between the configuration of the alditolyl chains and their preferred conformation, were studied (86MI7).

## O. BENZO[f]QUINOXALINE ACYCLO C-NUCLEOSIDES

### 1. Benzo[f]quinoxalin-2- and 3-yl Acyclo C-Nucleosides

Reaction of 1-arylmino-1-deoxyketoses (**764**) with 1,2-diaminonaphthalene (**765**) in the presence of hydrazine hydrate gave a mixture of the 2- and 3-(alditol-1-yl)benzo[f]quinoxalines **766** and **767**, respectively, in the ratio of 2.5:1 (58CB101) (Scheme 198).



SCHEME 198

## P. BENZO[g]QUINOXALINE ACYCLO C-NUCLEOSIDES


### 1. Benzo[g]quinoxalin-2-yl Acyclo C-Nucleosides

Acyclo C-nucleosides of this class (**770**) were prepared by cyclocondensation of alduloses (**768**,  $\text{Z} = \text{O}$ ) or their hydrazones [**768**;  $\text{Z} = \text{Me}(\text{Ph})\text{NN}$ ,  $\text{PhCH}_2(\text{Ph})\text{NN}$ ] with 2,3-diaminonaphthalene (**769**) (58CB101) (Scheme 199).


## Q. PYRIDO[2,3-*c*]PYRAZOLO[3,4-*b*]PYRAZINE ACYCLO C-NUCLEOSIDES

### 1. Pyrido[2,3-*c*]pyrazolo[3,4-*b*]pyrazin-3-yl Acyclo C-Nucleosides

The 1-phenylpyrazole ring of the acyclo C-nucleoside **771** was formed as shown in Scheme 200 by the base-catalyzed cyclodehydration of the imidic acid hydroxyl and hydrazono proton of the pyrido[2,3-*b*]pyrazin-3-yl acyclo C-nucleoside **742** (Section XII,I; Scheme 190) (64AGE802).



SCHEME 199



SCHEME 200

### R. BENZO[*g*]PYRAZOLO[3,4-*b*]QUINOXALINE ACYCLO C-NUCLEOSIDES


#### 1. *Benzo[*g*]pyrazolo[3,4-*b*]quinoxalin-3-yl C-Nucleosides* *{benzo[*g*]flavazol-3-yl Acyclo C-Nucleosides}*

Reaction of 2-(*D-arabino*-tetritol-1-yl)benzo[*f*]quinoxaline (**772**) (Section XII,O) with three molar equivalents of phenylhydrazine gave the 3-(*D-erythro*-1,2,3-hydroxypropyl)benzo[*g*]flavazole **773** (58CB113) (Scheme 201).


### S. BENZO[*h*]PYRAZOLO[3,4-*b*]QUINOXALINE ACYCLO C-NUCLEOSIDES

#### 1. *Benzo[*h*]pyrazolo[3,4-*b*]quinoxalin-3-yl C-Nucleosides* *{Benzo[*h*]flavazol-3-yl Acyclo C-Nucleosides}*

Applying the just-mentioned reaction to the benzo[*g*]quinoxalin-2-yl acyclo C-nucleoside **774** (Section II,P) gave **775** (58CB113) (Scheme 202).



SCHEME 201



SCHEME 202

#### T. BENZO[*i*]PYRAZOLO[3,4-*b*]QUINOXALINE ACYCLO C-NUCLEOSIDES

##### 1. *Benzo[*i*]pyrazolo[3,4-*b*]quinoxalin-3-yl C-Nucleosides* *{Benzo[*i*]flavazol-3-yl Acyclo C-Nucleosides}*

Compound **777** of this type of acyclo C-nucleoside was prepared from the benzo[*g*]quinoxalin-3-yl precursor **776** (Section XII,O) by reaction with phenylhydrazine (58CB113) (Scheme 203).

#### U. QUINOXALINO[7',6':2,3]QUINOXALINE ACYCLO C-NUCLEOSIDES


##### 1. *Quinoxalino[7',6':2,3]quinoxalin-2-yl Acyclo C-Nucleosides*

Reaction of 1-(*N*-methyl-*N*-phenylhydrazono)-D-*arabino*-hexulose (**778**) with 2,3-diaminophenazine (**779**) produced **780** (58CB101) (Scheme 204).


#### V. PYRAZOLO[3,4-*b*]QUINOXALINO[7',6':2,3]QUINOXALINE ACYCLO C-NUCLEOSIDES

##### 1. *Pyrazolo[3,4-*b*]quinoxalino[7',6':2,3]quinoxalin-3-yl* *Acyclo C-Nucleosides*

The known example **781** of these compounds was obtained by reacting **780** with phenylhydrazine (58CB113) (Scheme 204).



SCHEME 203



SCHEME 204

### XIII. Condensed Oxazine C-Nucleosides

#### A. PYRROLO[3,2-*d*]OXAZINE C-NUCLEOSIDES


##### 1. Pyrrolo[3,2-*d*]oxazin-3-yl C-Nucleosides

Construction of the oxazine ring of **783** was achieved by cyanation of the 4-amino-4-ethoxycarbonyl-pyrrol-3-yl C-nucleoside **337** with cyanogen bromide, followed by hydrolysis and cyclization of the ester cyanamide **782** with methanolic potassium hydroxide. Removal of the sugar-protective ketal group gave **783**, which possessed immunostimulant properties [85TL5785; 86JAP(K)86/260094] (Scheme 205).

#### B. PYRAZOLO[4,3-*d*]OXAZINE C-NUCLEOSIDES


##### 1. Pyrazolo[4,3-*d*]oxazin-3-yl C-Nucleosides

The synthesis of the 3- $\beta$ -ribofuranosylpyrazolo[4,3-*d*]oxazine-5,7-dione **409** as an intermediate during the synthesis of formamycin B (**387**) is included in Scheme 115 [71JCS(CC)986].



SCHEME 205






SCHEME 206


### C. PYRAZOLO[3,4-*e*]OXAZINE C-NUCLEOSIDES

#### 1. *Pyrazolo[3,4-*e*]oxazin-3-yl C-Nucleosides*

3-β-Ribofuranosylpyrazolo[3,4-*e*]oxazin-5,7-dione (**786**), the isomer of xanthosine and oxoformycin B (**388**), was prepared by carbonylation of the *O*-protected pyrazofurin **784** [97AHC(68)223] with 1,1'-carbonyldiimidazole (CDI) [84JAP(K)84/184176, 84JCS(P1)553; 87MIP1, 87USP 4656260] (Scheme 206). *C*-Nucleoside **786** has cytotoxic and virucidal activities equivalent or superior to those of pyrazofurin (87MIP1, 87USP4656260); **786** appears to act as a prodrug of pyrazofurin (91JMC1951).

Similar synthetic sequences to that shown in Scheme 206 were used for the preparation of the three pyrazol[3,4-*e*]oxazine *C*-nucleosides **787–789** (85MI3; 91JMC1951). The guanosine isomer **787** showed marginal cytotoxicity toward L1210 leukemia cells (91JMC1951).





SCHEME 207

#### D. BENZO[*d*]OXAZINE ACYCLO C-NUCLEOSIDES

##### 1. Benzo[*d*]oxazin-2-yl Acyclo *C*-Nucleosides


Condensation of tetra-*O*-acetylgalactaroyl dichloride (**790**) with anthranilic acid formed the bis-amide **791**, which was cyclodehydrated to the bis[4-oxobenzo[*d*]oxazin-2-yl] acyclo *C*-nucleoside **591** (87MI4) (Scheme 207). Compound **591** was used in the synthesis of the double-headed quinazolin-8-yl acyclo *C*-nucleosides **592** (Section XI,X; Scheme 158).

### XIV. Condensed 1,2,3-Triazine C-Nucleoside

#### A. THIAZOLO[5,4-*d*]1,2,3-TRIAZINE C-NUCLEOSIDES

##### 1. Thiazolo[5,4-*d*]1,2,3-triazin-2-yl *C*-Nucleosides

Treatment of the 5-amino-4-carboxamido-2-β-D-ribofuranosylthiazole **792** with sodium nitrite and hydrochloric acid effected the formation of the 1,2,3-triazinone ring of **793** (85JOC1741) (Scheme 208). This *C*-nucleoside was not superior to tiazofurin (4-carboxamido-2-β-D-ribofuranosylthiazole) [97AHC(68)223] against P388 and L1210 leukemic cells or Lewis lung carcinoma in culture (85JOC1741).



SCHEME 208

## XV. Condensed 1,2,4-triazine C-Nucleosides

### A. PYRROLO[2,1-*f*]1,2,4-TRIAZINE C-NUCLEOSIDES

#### 1. *Pyrrlo*[2,1-*f*]1,2,4-triazin-7-yl C-Nucleosides


Under slightly acidic conditions, the pyran ring of the semicarbazone **794** underwent contraction to the 2-formyl-1-ureidopyrrol-5-yl C-nucleoside **795**. The latter was cyclodehydrated to **796** and de-*O*-protected to **797** [92H(34)569] (Scheme 209).

Klein and his group synthesized the 4-aminopyrrolo[2,1-*f*]1,2,4-triazin-7-yl C-nucleoside **803** that is related to formycin by multistep annulation of the 1,2,4-triazine ring onto the pyrrol-2-yl C-nucleoside **798** (94TL5339) (Scheme 210). C-Nucleoside **803** established pronounced *in vitro* growth-inhibitory activities against L-1210-C2, S180, and HL60-JG neoplastic cell lines (94TL5339).


### B. PYRROLO[1,5-*d*]1,2,4-TRIAZINE C-NUCLEOSIDES

#### 1. *Pyrrlo*[1,5-*d*]1,2,4-triazin-8-yl C-Nucleosides

The 3-formyl-4-β-D-ribofuranosylpyrrole **804** was elaborated to **806** by reaction with methyl hydrazinocarboxylate to give the corresponding hydra-



SCHEME 209




SCHEME 210

zone **805**, which was then cyclized and de-*O*-protected to **806** (83MI7) (Scheme 211).


### C. IMIDAZO[5,1-*f*]1,2,4-TRIAZINE C-NUCLEOSIDES

#### 1. Imidazo[5,1-*f*]1,2,4-triazin-7-yl C-Nucleosides

Coupling the 2,5-anhydro-D-allonic acid derivative **79** with 6-amino-methyl-1,2,4-triazin-5-ones provided the respective amides **807**, which were cyclodehydrated and de-*O*-blocked to **808** [84JCS(P1)229] (Scheme 212). The 2'-deoxy analogs of **808** were similarly prepared [85JCS(P1)621].



SCHEME 211



SCHEME 212

#### D. IMIDAZO[5,1-*f*]1,2,4-TRIAZINE ACYCLO C-NUCLEOSIDES


##### 1. Imidazo[5,1-*f*]1,2,4-triazin-7-yl Acyclo C-Nucleosides

The acyclo C-nucleoside **811** was prepared in a closely similar plan to that used for the synthesis of its cyclic analog **808**. [2-(Benzoyloxy)ethoxy]-acetic acid was condensed with 6-aminomethyl-1,2,4-triazin-5-one to give amide **810**, which was then cyclized and de-*O*-benzoylated to **811**. This truncated sugar acyclo C-nucleoside did not inhibit herpes simplex viruses (HSV-1 and HSV-2) in cell culture (84JHC697) (Scheme 213).

#### E. 1,2,4-TRIAZOLO[3,4-*f*]1,2,4-TRIAZINE C-NUCLEOSIDES

##### 1. 1,2,4-Triazolo[3,4-*f*]1,2,4-triazin-3-yl C-Nucleosides

The 1,2,4-triazolo[3,4-*f*]1,2,4-triazin-3-yl C-nucleoside **814**, related to guanosine, was obtained by cyclocondensation of 3,4,5-tri-*O*-benzoyl-2,5-anhydro-D-allonoyl chloride (**812**) with 3-amino-6-hydrazino-1,2,4-triazin-




SCHEME 213

5-one followed by removal of the protective groups. Compounds **816**, **818**, and **819**, belonging to this class and related to thioguanosine, adenosine and formycin, and inosine and formycin B, respectively, were prepared according to the nucleoside–nucleoside transformation approaches shown in Scheme 214 (86JMC2231). Only C-nucleoside **818** possessed pronounced antitumor activity toward L-1210, WIL2, and CCRF-CEM cell lines in culture (86JMC2231).

## F. 1,2,4-TRIAZOLO[4,3-*b*]1,2,4-TRIAZINE ACYCLO C-NUCLEOSIDES

### 1. 1,2,4-Triazolo[4,3-*b*]1,2,4-triazin-3-yl Acyclo C-Nucleosides

Oxidative cyclization of (5,6-diphenyl-1,2,4-triazin-3-yl)hydrazones of aldose monosaccharides (**820**) and concurrent acetylation of the alditol chain hydroxyls provided the corresponding *O*-acetylated 3-(alditol-1-yl)-6,7-diphenyl-1,2,4-triazolo[4,3-*b*]1,2,4-triazines **822** and not the alternative structure **823**. De-*O*-acetylation of **822** gave **824** (96PHA707) (Scheme 215).



SCHEME 214




H. 1,2,4-TRIAZOLO[3,4-*f*]1,2,4-TRIAZINE ACYCLO C-NUCLEOSIDES1. 1,2,4-Triazolo[3,4-*f*]1,2,4-triazin-3-yl Acyclo C-Nucleosides

Coupling of [2-(benzoyloxy)ethoxy]acetic acid (**809**) or [2-(1,3-dibenzyloxy)propoxy]acetic acid **829** with 3-amino-6-hydrazino-1,2,4-triazin-5-one gave the two amides **827** and **830**, respectively. Thermal cyclodehydration of **827** and **830** and subsequent deprotection gave the two truncated-sugar acyclo C-nucleosides **828** (84JHC697) and **831** (95MI6) (Scheme 217).

## XVI. Condensed 1,3,5-Triazine C-Nucleosides


A. PYRAZOLO[1,5-*a*]1,3,5-TRIAZINE C-NUCLEOSIDES1. *Pyrazolo*[1,5-*a*]1,3,5-triazin-8-yl C-Nucleosides

The most commonly used strategy for the synthesis of this class of C-nucleosides was the annulation of the 1,3,5-triazine ring onto suitably substituted pyrazol-4-yl C-nucleosides. Thus, the C-nucleosides **836**, related to adenosine and formycin, was prepared by reacting the 3-aminopyrazol-4-yl C-nucleoside **832** with ethoxy *N*-cyanoformimidate (76JHC1305; 96MI2) or by reacting the 3-amino-2-carbamimidoylpyrazol-4-yl C-nucleoside **835** with triethyl orthoformate [84H(22)345] (Scheme 218).



SCHEME 217






SCHEME 218

Prepared by similar reactions was the 8-( $\beta$ -D-ribofuranosyl)pyrazolo[1,5-*a*][1,3,5-triazin-4-one (**840**) related to inosine and formycin. In one route **832** reacted with *N*-ethoxycarbonylformimide (76JHC1305), and in the other the 3-amino-2-carbamoylpyrazol-4-yl *C*-nucleoside **839** reacted with triethyl orthoformate (80JHC1435) or 1,3-dimethyl-1,3,5-triazine-2,6-dione in the presence of sodium ethoxide (86JHC349) (Scheme 219).


4-Thioxo- (**841**) (79JOC4547; 84JHC389), 4-oxo-2-thioxo- (**842**) (76-JHC175), and 2-amino-4-oxopyrazolo[1,5-*a*][1,3,5-triazin-3-yl *C*-nucleosides (**843**) (79JOC4547) were also prepared by very similar reactions.

*C*-Nucleosides **836**, **840**, and **841** revealed potent antileukemic properties toward L-1210 and P815 cell lines *in vitro* (76JHC1305; 78MI4; 79JOC4547).

Synthesis of the 2'-deoxy- $\beta$ -D-ribofuranosylpyrazolo[1,5-*a*][1,3,5-triazine **847** has been achieved by C—C bond formation between the sugar and heterocycle subunits. Palladium-mediated coupling of the 3-*O*-silylated furanoid glycal (1,2-unsaturated sugar) **454** with 8-iodo-4-(tetrahydropyran-2-yloxy)pyrazolo[1,5-*a*][1,3,5-triazine in the presence of triphenylarsine gave **844**. De-*O*-silylation of **844** and stereospecific reduction of the keto group of **846** afforded **847** (95MI3) (Scheme 220).



SCHEME 219



## B. PYRAZOLO[1,5-f]1,3,5-TRIAZINE ACYCLO C-NUCLEOSIDES


### 1. Pyrazolo[1,5-f]1,3,5-triazin-8-yl Acyclo C-Nucleosides

The acyclo C-nucleosides **850–852** were synthesized by reactions that involved the annulation of their 1,3,5-triazine rings onto the pyrazol-4-yl acyclo C-nucleosides **848** and **849**, as shown in Scheme 221 (88JOC2413).


## C. IMIDAZO[1,5-a]1,3,5-TRIAZINE ACYCLO C-NUCLEOSIDES

### 1. Imidazo[1,5-a]1,3,5-triazin-8-yl Acyclo C-Nucleosides


*cis*-1,2-Hydroxylation of the allyl double bond of 8-allylimidazo[1,5-a]1,3,5-triazin-4-ones (**853**) with osmium tetroxide gave the corresponding acyclo C-nucleosides of this type **854**, which did not appreciably inhibit viruses or tumor cells (87MI5) (Scheme 222).



SCHEME 220



SCHEME 221



SCHEME 222

**XVII. Condensed 1,4-Diazepine C-Nucleosides****A. BENZO[*b*]THIAZOLO[3,2-*d*]1,4-DIAZEPINE  
ACYCLO C-NUCLEOSIDES****1. Benzo[*b*]thiazolo[3,2-*d*]1,4-diazepin-1-yl Acyclo C-Nucleosides**


Cyclocondensation of 1-bromo-1-deoxy-D-*galacto*-heptulose pentaacetate (**151**) with 2-amino-4-thioxo-4,5-dihydrobenzo[*b*]1,4-diazepine-3-carboxylic acid ester provided **856** ( $Z = N$ ) [85GEP(D)216938; 86PHA548] (Scheme 223).

**XVIII. Condensed 1,4-Oxazepine C-Nucleosides****A. BENZO[*b*]THIAZOLO[3,2-*d*]1,4-OXAZEPINE  
ACYCLO C-NUCLEOSIDES****1. Benzo[*b*]thiazolo[3,2-*d*]1,4-oxazepin-1-yl Acyclo C-Nucleosides**

The acyclo C-nucleosides **856** ( $Z = O$ ) were prepared from **151** and 2-amino-4-thioxo-4,5-dihydro[*b*]1,4-oxazepine-3-carboxylic acid ester [85GEP(D)216938; 86PHA548] (Scheme 223).

**XIX. Condensed 1,5-Diazepine C-Nucleosides****A. BENZO[*f*]1,5-DIAZEPINE HOMO C-NUCLEOSIDES****1. Benzo[*f*]1,5-diazepin-4-yl Homo C-Nucleosides**

Mixtures of 7- and 8-substituted benzo[*f*]-2-oxo-1,5-diazepin-4-yl homo C-nucleosides **857** were obtained by the reaction of 5-hydroxy-5-β-D-ribofuranosylfuran-2-one (**247**) with 4-substituted-1,2-diaminobenzenes



SCHEME 223


in the presence of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). De-*O*-benzylation of **857** gave the unprotected *C*-nucleosides **858** [91H-(32)1955; 92H(34)955] (Scheme 224).

## XX. Condensed 1,5-Thiazepine *C*-Nucleosides


### A. BENZO[*f*]1,5-THIAZEPINE HOMO *C*-NUCLEOSIDES

#### 1. Benzo[*f*]1,5-thiazepin-2-yl Homo *C*-Nucleosides

Reaction of **247** with 2-aminothiophenol under the same conditions that were applied for the preparation of **857** gave **860** [92H(34)2131] (Scheme 225). Attempted de-*O*-benzylation of **860** resulted in the formation of the unsaturated *C*-nucleosides having a C=C between C1' and C2' [92H(34)2131].



SCHEME 224



SCHEME 225

## XXI. Condensed 1,3,5-Triazepine C-Nucleosides

### A. BENZO[*f*]1,3,5-TRIAZEPINE ACYCLO C-NUCLEOSIDES


#### 1. Benzo[*ff*]1,3,5-triazepin-4-yl Acyclo C-Nucleosides

2,3,4,5,6-Tetra-*O*-acetyl-D-gluconoyl isothiocyanate (**603**) cyclocondensed with 1,2-diaminobenzene to give the acyclo C-nucleoside **861** (Scheme 226). It possessed antibacterial, antiviral, and psychotropic activities [75MI6; 76JAP(K)76/39685; 81CPB1832].


### B. PYRIMIDO[4,5-*f*]1,3,5-TRIAZEPINE ACYCLO C-NUCLEOSIDES

#### 1. Pyrimido[4,5-*ff*]1,3,5-triazepin-4-yl Acyclo C-Nucleosides

Utilization of 4,5-diaminopyrimidines in place of 1,2-diaminobenzene in the aforementioned cyclocondensation reaction produced the acyclo C-nucleosides of this class **862** (Scheme 227) [76JAP(K)76/39685; 76MI6, 81CPB1832].



SCHEME 226



## XXII. Conclusion

The term “C-nucleoside” was only coined after isolation and characterization of the first member of this class: pseudouridine, in 1975 [97ACH(ip)]. Before that, alditolyl derivatives of some heterocycles (acyclo C-nucleosides) were known both as natural products (alditolyl pteridines or biopterins) as well as products of syntheses (e.g., alditolyl derivatives of imidazoles, benzimidazoles, thiazoles, benzothiazoles, 1,2,3-triazoles, quinoxalines, and flavazoles) and were classified as “carbohydrate derivatives of heterocyclic compounds.” After isolation of pseudouridine, other naturally occurring members were successively isolated, characterized, and synthesized. It is worth mentioning that synthesis preceded isolation in two cases: 9-deazaadenosine and pyrrolosine. Comparison with the synthetic compounds facilitated structure elucidation in one case (9-deazaadenosine) and structure reassignment in the other (pyrrolosine).

C-Nucleosides are able to biologically mimic N-nucleosides without undergoing the same metabolic fate. As a result, they exhibit a wide spectrum of biological activities. Their promise in potential utilization as medicinal products stimulated extensive efforts to synthesize C-nucleosides as well as their analogs (homo, carbocyclic, reverse, and acyclo). Such efforts undoubtedly have been encouraged by the persistent search for drugs that are able to inhibit human immunodeficiency viruses (HIV), the causative agent of AIDS. A reasonably large number of C-nucleosides carrying various five- and six-membered nitrogen-containing heterocycles were prepared. Less attention, however, was directed toward the synthesis of C-nucleosides of seven-membered nitrogen-containing heterocycles, to which many of the behavior-controlling drugs belong. Research along this line may lead to products with better properties to overcome the blood–brain barrier and/or the blood–cerebrospinal fluid barrier (93MI4). In short, the synthesis of new C-nucleosides and C-nucleoside analogs is highly desirable and awaits accomplishment.

# ACKNOWLEDGMENT

The author is indebted to Professor Zaki M. El Shafei for his invaluable suggestions and proofreading of the manuscript. MAES would like to dedicate the two parts of this review to Professor Roger W. Jeanloz, with whom he started his professional career (1970–1972 and 1974–1976) at Harvard Medical School, on the occasion of his 75th birthday.

# REFERENCES

- 1887CB281 P. Griess and G. Harrow, *Chem. Ber.* **20**, 281 (1887).
- 1887CB2205 P. Griess and G. Harrow, *Chem. Ber.* **20**, 2205 (1887).
- 1887CB3111 P. Griess and G. Harrow, *Chem. Ber.* **20**, 3111 (1887).
- 1889CB87 E. Fisher, *Chem. Ber.* **22**, 87 (1889).
- 1893CB3092 O. Hinsberg and F. Funcke, *Chem. Ber.* **26**, 3092 (1893).
- 01CB902 B. Schilling, *Chem. Ber.* **34**, 902 (1901).
- 29JA2225 C. S. Hudson and H. S. Isbell, *J. Am. Chem. Soc.* **51**, 2225 (1929).
- 34CB155 H. Ohle, *Chem. Ber.* **67**, 155 (1934).
- 34CB555 E. Erlbach and H. Ohle, *Chem. Ber.* **67**, 555 (1934).
- 34CB898 R. Kuhn and F. Bar, *Chem. Ber.* **67**, 898 (1934).
- 34JA1248 C. S. Hudson, O. Hartley, and C. B. Purves, *J. Am. Chem. Soc.* **56**, 1248 (1934).
- 34CB1980 K. Maurer and B. Schiedt, *Chem. Ber.* **67**, 1980 (1934).
- 36CB748 G. Zemplen, A. Gerecs, and M. Rados, *Chem. Ber.* **69**, 748 (1936).
- 37BJ(31)1033 C. R. Bond, E. C. Knight, and T. K. Walker, *Biochem. J.* **31**, 1033 (1937).
- 37CB2148 H. Ohle, W. Gross, and A. Wolter, *Chem. Ber.* **70**, 2148 (1937).
- 38CB590 G. Zemplen, A. Gerecs, and E. Illes, *Chem. Ber.* **71**, 590 (1938).
- 39JA1266 W. T. Haskins and C. S. Hudson, *J. Am. Chem. Soc.* **61**, 1266 (1939).
- 40JBC(133)293 S. Moore and K. P. Link, *J. Biol. Chem.* **133**, 293 (1940).
- 40JOC637 S. Moore and K. P. Link, *J. Org. Chem.* **5**, 637 (1940).
- 40NAT(L)559 D. J. Bell and E. Baldwin, *Nature (London)* **146**, 559 (1940).
- 40ZPC(263)78 W. Koschra, *Hoppe-Seyler's Z. Physiol. Chem.* **263**, 78 (1940).
- 41CB13 H. Ohle and M. Hielscher, *Chem. Ber.* **74**, 13 (1941).
- 41CB18 H. Ohle and M. Hielscher, *Chem. Ber.* **74**, 18 (1941).
- 41CB279 H. Ohle and G. A. Melkonian, *Chem. Ber.* **74**, 279 (1941).
- 41CB398 H. Ohle and G. A. Melkonian, *Chem. Ber.* **74**, 398 (1941).
- 41JCS125 D. J. Bell and Baldwin, *J. Chem. Soc.*, 125 (1941).
- 42CB1536 H. Ohle and R. Liebig, *Chem. Ber.* **75**, 1536 (1942).
- 42JA1609 N. K. Richtmyer and C. S. Hudson, *J. Am. Chem. Soc.* **64**, 1609 (1942).
- 42JA1612 N. K. Richtmyer and C. S. Hudson, *J. Am. Chem. Soc.* **64**, 1612 (1942).
- 42JBC(143)551 R. Lohmar, R. J. Dimler, S. Moore, and K. P. Link, *J. Biol. Chem.* **143**, 551 (1942).
- 43CB1 H. Ohle and A. Iltgen, *Chem. Ber.* **76**, 1 (1943).
- 43JA994 A. T. Merrill, R. M. Hahn, and C. S. Hudson, *J. Am. Chem. Soc.* **65**, 994 (1943).
- 43JA1854 H. Skolnick, J. G. Miller, and A. R. Day, *J. Am. Chem. Soc.* **65**, 1854 (1943).



- 43JBC(150)345 R. J. Dimler and K. P. Link, *J. Biol. Chem.* **150**, 345 (1943).  
43JBC(150)351 R. Lohmar and K. P. Link, *J. Biol. Chem.* **150**, 351 (1943).  
43JCS625 J. M. Gulland and G. R. Barker, *J. Chem. Soc.*, 625 (1943).  
43LA(554)69 R. Huttie and G. Sprengling, *Justus Liebig's Ann. Chem.* **554**, 69 (1943).  
43ZPC(277)284 W. Koschara, *Hoppe-Seyler's Z. Physiol. Chem.* **277**, 284 (1943).  
44CB507 H. Ohle and J. J. Kruffy, *Chem. Ber.* **77**, 507 (1944).  
44JA1912 R. M. Hann, A. T. Merrill, and C. S. Hudson, *J. Am. Chem. Soc.* **66**, 1912 (1944).  
44JCS339 G. R. Barker, K. R. Cooke, and J. M. Gulland, *J. Chem. Soc.*, 339 (1944).  
45JBC(159)503 G. F. Huebner, R. Lohmar, R. J. Dimler, S. Moore, and K. P. Link, *J. Biol. Chem.* **159**, 503 (1945).  
45JOC267 W. H. Bromund and R. Herbst, *J. Org. Chem.* **10**, 267 (1945).  
46MI1 G. Neumuller, *Ark. Kemi, Mineral. Geol.* **21A**, 13 (1946) [*CA* **41**, 1210 (1947)].  
46MI2 U. Rosenqvist, G. Neumuller, and K. Myrback, *Ark. Kemi, Mineral. Geol.* **24A**, 9 (1946) [*CA* **42**, 5425 (1948)].  
47CB255 F. Weygand and A. Bergmann, *Chem. Ber.* **80**, 255 (1947).  
47HCA1031 P. Karrer, R. Schwyzler, B. Erden, and A. Siegwart, *Helv. Chim. Acta* **30**, 1031 (1947).  
47JA2566 H. G. Petering and D. I. Weisblat, *J. Am. Chem. Soc.* **69**, 2566 (1947).  
47JCS21 G. R. Barker, K. R. Farrar, and J. M. Gulland, *J. Chem. Soc.*, 21 (1947).  
48BJ(42)2 G. A. Levvy, *Biochem. J.* **42**, 2 (1948).  
48E427 F. Weygand, A. Wacker, and V. Schmied-Kowarzik, *Experientia* **4**, 427 (1948).  
48HCA777 P. Karrer and R. Schwyzler, *Helv. Chim. Acta* **31**, 777 (1948).  
48HCA782 P. Karrer and R. Schwyzler, *Helv. Chim. Acta* **31**, 782 (1948).  
48NAT(L)308 H. S. Forrest and J. Walker, *Nature (London)* **161**, 308 (1948).  
48USP2456752 J. D. Surmatis, U.S. Pat. 2,456,752 (1948) [*CA* **43**, 3031 (1949)].  
49CB25 F. Weygad, A. Wacker, and V. Schmied-Kowarzik, *Chem. Ber.* **82**, 25 (1949).  
49HCA1041 P. Karrer and R. Schwyzler, *Helv. Chim. Acta* **32**, 1041 (1949).  
49JA3977 H. G. Petering and J. A. Schmitt, *J. Am. Chem. Soc.* **71**, 3977 (1949).  
49JCS79 H. S. Forrest and J. Walker, *J. Chem. Soc.*, 79 (1949).  
49JCS2077 H. S. Forrest and J. Walker, *J. Chem. Soc.*, 2077 (1949).  
50BJ(47)1 J. K. Grant and G. F. Marrian, *Biochem. J.* **47**, 1 (1950).  
50JA3882 E. Zissis, N. K. Richtmyer, and C. S. Hudson, *J. Am. Chem. Soc.* **72**, 3882 (1950).  
50JBC(186)387 C. F. Huebner and K. P. Link, *J. Biol. Chem.* **186**, 387 (1950).  
50LA(570)127 A. Bertho and M. Bentler, *Justus Liebig's Ann. Chem.* **570**, 127 (1950).  
50SWP268531 P. Ballmer, Swiss Pat. 268,531 (1950) [*CA* **45**, 4747 (1951)].  
51JA1855 T. S. Gardner and E. Wenis, *J. Am. Chem. Soc.* **73**, 1855 (1951).  
51JA4907 D. A. Rosenfeld, N. K. Richtmyer, and C. S. Hudson, *J. Am. Chem. Soc.* **73**, 4907 (1951).  
51JA5908 L. Sattler, F. W. Zerban, G. L. Clark, and C.-C. Chu, *J. Am. Chem. Soc.* **73**, 5908 (1951).

- 51MI1 N. K. Richtmyer, *Adv. Carbohydr. Chem.* **6**, 175 (1951).
- 51USP2541717 H. G. Petering, U.S. Pat. 2,541,717 (1951) [CA **45**, 6224 (1951)].
- 52CI(L)1034 J. T. Edward and E. F. Martlew, *Chem. Ind. (London)*, 1034 (1952).
- 52GEP839498 F. Hoffmann La Roche & Co. A.-G., Ger. Pat. 839,498 (1952) [CA **48**, 12185 (1954)].
- 52JA4521 F. W. Holly, C. H. Shunk, E. W. Peel, J. J. Cahill, J. B. Lavigne, and K. Folkers, *J. Am. Chem. Soc.* **74**, 4521 (1952).
- 52JBC(196)265 J. H. Pazur and D. French, *J. Biol. Chem.* **196**, 265 (1952).
- 52JPJ1294 Y. Sakurai and K. Yoshino, *J. Pharm. Soc. Jpn.* **72**, 1294 (1952).
- 52USP2603643 H. Kirchensteiner and H. Lindlar, U.S. Pat. 2,603,643 (1952) [CA **47**, 4379 (1953)].
- 53JA3664 D. French, G. M. Wild, and W. J. James, *J. Am. Chem. Soc.* **75**, 3664 (1953).
- 53JA4320 J. V. Karabinos, R. M. Hahn, and C. S. Hudson, *J. Am. Chem. Soc.* **75**, 4320 (1953).
- 53MI1 J. C. E. Simpson "Condensed Pyridazines and Pyrazines Rings," p. 300. Wiley (Interscience), New York, 1953.
- 54CB1068 G. Henseke and W. Liebenow, *Chem. Ber.* **87**, 1068 (1954).
- 54JA1671 R. L. Whistler and J. L. Hickson, *J. Am. Chem. Soc.* **76**, 1671 (1954).
- 54JCS2645 J. C. P. Schwarz, *J. Chem. Soc.*, 2645 (1954).
- 54USP2667485 H. G. Petering, U.S. Pat. 2,667,485 (1954) [CA **49**, 1825 (1955)].
- 55CB1251 R. Tschesche, F. Korte, and G. Heuschkel, *Chem. Ber.* **88**, 1251 (1955).
- 55HCA397 M. Viscontini, M. Schoeller, E. Loeser, P. Karrer, and E. Hadron, *Helv. Chim. Acta* **38**, 397 (1955).
- 55HCA1222 M. Viscontini, E. Loeser, P. Karrer, and E. Hadron, *Helv. Chim. Acta* **38**, 1222 (1955).
- 55JA1015 J. H. Pazur, *J. Am. Chem. Soc.* **77**, 1015 (1955).
- 55JA3167 E. L. Patterson, H. P. Broquist, A. M. Albrecht, M. H. von Saltza, and E. L. R. Stokstad, *J. Am. Chem. Soc.* **77**, 3167 (1955).
- 55JA4865 H. S. Forrest and K. Mitchell, *J. Am. Chem. Soc.* **77**, 4865 (1955).
- 55MI1 S. Matsuura, S. Nawa, M. Goto, and Y. Hirata, *J. Biochem. (Tokyo)* **42**, 419 (1955).
- 56CB956 G. Henseke and M. Winter, *Chem. Ber.* **89**, 956 (1956).
- 56CB1246 F. Micheel and W. Lengsfeld, *Chem. Ber.* **89**, 1246 (1956).
- 56CB2904 G. Henseke and H. G. Patzwaldt, *Chem. Ber.* **89**, 2904 (1956).
- 56JA4491 D. Heyl, G. Emerson, M. M. Gasser, E. G. Chase, and K. Folkers, *J. Am. Chem. Soc.* **78**, 4491 (1956).
- 56JA5868 E. L. Patterson, R. Milstrey, and E. L. R. Stokstad, *J. Am. Chem. Soc.* **78**, 5868 (1956).
- 56JA5871 E. L. Patterson, M. H. von Saltza, and E. L. R. Stokstad, *J. Am. Chem. Soc.* **78**, 5871 (1956).
- 56MI1 I. Satoda, T. Fukui, Y. Matsuo, and H. O. Kumura, *Yakugaku Kenkyu* **28**, 633 (1956) [CA **51**, 16495 (1957)].
- 57AG479 G. Henseke, W. Dose, and K. Dittrich, *Angew. Chem.* **69**, 479 (1957).
- 57JCS3961 A. J. Cleaver, A. B. Foster, and W. G. Overend, *J. Chem. Soc.*, 3961 (1957).
- 57NAT(L)367 V. O. G. Klingmuller and G. Gedenk, *Nature (London)* **179**, 367 (1957).

- 58CB101 G. Henseke and W. Lemke, *Chem. Ber.* **91**, 101 (1958).  
58CB113 G. Henseke and W. Lemke, *Chem. Ber.* **91**, 113 (1958).  
58CB1605 G. Henseke and W. Lemke, *Chem. Ber.* **91**, 1605 (1958).  
58CB2273 G. Henseke and E. Brose, *Chem. Ber.* **91**, 2273 (1958).  
58HCA108 M. Viscontini and H. Raschig, *Helv. Chim. Acta* **41**, 108 (1958).  
58JA1445 P. Nordin and D. French, *J. Am. Chem. Soc.* **80**, 1445 (1958).  
58JA2018 E. L. Patterson, R. Milstrey, and E. L. R. Stokstad, *J. Am. Chem. Soc.* **80**, 2018 (1958).  
58MI1 J. E. Courtois and U. Ariyoshi, *Ann. Pharm. Fr.* **16**, 385 (1958) [CA **53**, 8003 (1959)].  
58RTC827 H. I. X. Mager and W. Berends, *Recl. Trav. Chim. Pays-Bas* **77**, 827 (1958) [CA **53**, 10240 (1959)].  
58UK179 Yu. A. Zhdanov and G. N. Dorofeenko, *Usp. Khim.* **27**, 179 (1958) [CA **52**, 11077 (1958)].  
58ZPC(311)79 A. Butenandt and H. Rembold, *Hoppe-Seyler's Z. Physiol. Chem.* **311**, 79 (1958).  
59ACSA1129 A. Wickstrom and J. K. Wold, *Acta Chem. Scand.* **13**, 1129 (1959).  
59BP814462 American Cyanamide Co., Br. Pat. 814,462 (1959) [CA **53**, 20100 (1959)].  
59CB501 G. Henseke and H. Bauer, *Chem. Ber.* **92**, 501 (1959).  
59CB1288 S. Konstans, I. Photaki, and I. Zervas, *Chem. Ber.* **92**, 1288 (1959).  
59CB1550 G. Henseke and K. Dittrich, *Chem. Ber.* **92**, 1550 (1959).  
59LA(625)133 T. Kauffmann, *Justus Liebigs Ann. Chem.* **625**, 133 (1959).  
59ZN(B)217 F. Weygand, K. Fehr, and J. Klebe, *Z. Naturforsch. B: Anorg. Chem. Org. Chem., Biochem., Biophys., Biol.* **14B**, 217 (1959).  
60MI1 Yu. A. Zhdanov, G. N. Dorofeenko, and N. V. Ivanchenko, *Izv. Vyssh. Uchebn. Zaved. Khim. Khim. Tekhnol.* **3**, 680 (1960) [CA **55**, 260 (1961)].  
60MI2 S. Odate, Y. Tatebe, M. Obika, and T. Hama, *Proc. Jpn. Acad.* **35**, 567 (1959) [CA **54**, 18801 (1960)].  
61AQ(B)379 F. Garcia Gonzalez, J. Fernandez Bolanos, and A. Paneque Guerro, *An. Quim., Ser. B* **57**, 379 (1961) [CA **56**, 8704 (1962)].  
61BBR(6)180 M. Goto and H. S. Forrest, *Biochem. Biophys. Res. Commun.* **6**, 180 (1961).  
61CB1743 G. Henseke, D. Lehman, and K. Dittrich, *Chem. Ber.* **94**, 1743 (1961).  
61HCA403 C. J. Morel, *Helv. Chim. Acta* **44**, 403 (1961).  
61NAT(L)495 R. Gigg and P. M. Carroll, *Nature (London)* **191**, 495 (1961).  
61SCI112 P. Nordin and M. Doty, *Science* **134**, 112 (1961).  
62CB996 W. Meyer zu Reckendorf and W. A. Bonner, *Chem. Ber.* **95**, 996 (1962).  
62JCS44 T. Neilson and H. C. S. Wood, *J. Chem. Soc.*, 44 (1962).  
62LA(658)193 R. Tschesche, B. Hess, I. Ziegler, and H. Machleidt, *Justus Liebigs Ann. Chem.* **658**, 193 (1962).  
62MI1 T. Kobayashi, T. Haneishi, and M. Saito, *Nippon Nogei Kagaku Kaishi* **36**, 189 (1962) [CA **61**, 10759 (1964)].  
62ZPC(329)291 H. Rembold and H. Metzger, *Hoppe-Seyler's Z. Physiol. Chem.* **329**, 291 (1962).  
63CB1395 H. Rembold and H. Metzger, *Chem. Ber.* **96**, 1395 (1963).  
63CB1406 H. Rembold and L. Buschmann, *Chem. Ber.* **96**, 1406 (1963).

- 63CB2019 W. Meyer zu Reckendorf, *Chem. Ber.* **96**, 2019 (1963).
- 63CB2427 H. J. Haas and A. Seeliger, *Chem. Ber.* **96**, 2427 (1963).
- 63JOC231 S. Kitaoka and K. Onodera, *J. Org. Chem.* **28**, 231 (1963).
- 63JOC999 M. von Saltza, J. D. Dutcher, J. Reid, and O. Wintersteiner, *J. Org. Chem.* **28**, 999 (1963).
- 63LA(662)72 H. Rembold and L. Buschmann, *Justus Liebigs Ann. Chem.* **662**, 72 (1963).
- 63LA(669)146 F. Kruger and H. Rudy, *Justus Liebigs Ann. Chem.* **662**, 146 (1963).
- 63MI1 I. Ziegler, *Biochem. Z.* **337**, 62 (1963) [*CA* **59**, 11798 (1963)].
- 63PNA1085 S. Kaufmann, *Proc. Natl. Acad. Sci. U.S.A.* **50**, 1085 (1963).
- 63ZN(B)551 I. Ziegler, *Z. Naturforsch. B: Anorg. Chem., Org. Chem., Biochem., Phys., Biol.* **18B**, 551 (1963).
- 64ACSA185 B. Lindberg and H. Agback, *Acta Chem. Scand.* **18**, 185 (1964).
- 64AGE114 W. Pfeleiderer, *Angew. Chem., Int. Ed. Engl.* **3**, 114 (1964).
- 64AGE802 G. Henseke and D. Lehmann, *Angew. Chem., Int. Ed. Engl.* **3**, 802 (1964).
- 64AQ(B)653 F. Garcia Gonzalez, J. Fernandez Bolanoz, and M. Menedez Gallego, *An. Quim., Ser. B* **60**, 653 (1964) [*CA* **63**, 4380 (1965)].
- 64CB1002 F. Weygand, H. Simon, K. D. Keil, and H. Millaur, *Chem. Ber.* **97**, 1002 (1964).
- 64HCA1860 H. Dahn and H. Moll, *Helv. Chim. Acta* **47**, 1860 (1964).
- 64HCA1948 M. Viscontini, M. Pouteau Thouvenot, R. Buhler-Moor, and M. Schroeder, *Helv. Chim. Acta* **47**, 1948 (1964).
- 64JAN(A)96 M. Hori, E. Ito, T. Takita, G. Koyama, T. Takeuchi, and H. Umezawa, *J. Antibiot., Ser. A* **17**, 96 (1964) [*CA* **61**, 11285 (1964)].
- 64JAN(A)124 M. Ichizuka, T. Takeuchi, K. Nitta, G. Koyama, M. Hori, and H. Umezawa, *J. Antibiot., Ser. A* **17**, 124 (1964) [*CA* **61**, 13777 (1964)].
- 65ABC375 S. Aizawa, T. Hidaka, N. Otake, H. Yonehara, K. Isono, N. Igara-shi, and S. Suzuki, *Agric. Biol. Chem.* **29**, 375 (1965) [*CA* **63**, 2353 (1965)].
- 65ABC377 N. Otake, S. Aizawa, T. Hidaka, H. Seto, and H. Yonehara, *Agric. Biol. Chem.* **29**, 377 (1965) [*CA* **63**, 2353 (1965)].
- 65CB851 R. Tschesche and G. Sturm, *Chem. Ber.* **98**, 851 (1965).
- 65JAN(A)175 G. Koyama and H. Umezawa, *J. Antibiot., Ser. A* **18**, 175 (1965) [*CA* **63**, 15158 (1963)].
- 65JAN(A)178 H. Umezawa, T. Sawa, Y. Fukagawa, G. Koyama, M. Murase, H. Hamada, and T. Takeuchi, *J. Antibiot., Ser. A* **18**, 178 (1965) [*CA* **63**, 15393 (1965)].
- 65JAN(A)191 Y. Fukagawa, T. Sawa, T. Takeuchi, and H. Umezawa, *J. Antibiot., Ser. A* **18**, 191 (1965) [*CA* **63**, 15385 (1965)].
- 65JAN(A)259 T. Sawa, Y. Fukagawa, Y. Shimauchi, K. Itoh, M. Hamada, T. Takeuchi, and H. Umezawa, *J. Antibiot., Ser. A* **18**, 259 (1965) [*CA* **64**, 13018 (1966)].
- 65JCS1351 R. Gigg and C. D. Warren, *J. Chem. Soc.*, 1351 (1965).
- 65JOC79 E. Zissis, D. R. Strobach, and N. K. Richtmyer, *J. Org. Chem.* **30**, 79 (1965).
- 65JOC2457 D. Horton and M. J. Miller, *J. Org. Chem.* **30**, 2457 (1965).
- 65LA(684)146 G. Henseke and R. Jakobi, *Justus Liebigs Ann. Chem.* **684**, 146 (1965).

- 65LA(689)221 M. Goto, K. Kobayashi, H. Sato, and F. Korte, *Justus Liebigs Ann. Chem.* **689**, 221 (1965).
- 65NEP6507269 J. R. Geigy, *Neth. Pat.* 6,507,269 (1965) [CA **65**, 792 (1966)].
- 65NEP6507271 J. R. Geigy, *Neth. Pat.* 6,507,271 (1965) [CA **65**, 793 (1966)].
- 65NEP6507423 J. R. Geigy, *Neth. Pat.* 6,507,423 (1965) [CA **65**, 793 (1966)].
- 65TL1303 R. Gigg, C. D. Warren, and J. Cunningham, *Tetrahedron Lett.*, 1303 (1965).
- 66AQ(B)471 F. Garcia Gonzalez, A. Gomez Sanchez, and M. Gomez Guillen, *An. Quim., Ser. B* **62**, 471 (1966) [CA **65**, 20200 (1966)].
- 66CB2162 B. Green and H. Rembold, *Chem. Ber.* **99**, 2162 (1966).
- 66JAN(A)91 K. Kawamura, S. Fukatsu, M. Murase, G. Koyama, K. Madea, and H. Umezawa, *J. Antibiot., Ser. A* **19**, 91 (1966) [CA **66**, 156 (1967)].
- 66JAN(A)93 S. Watanabe, G. Matsushashi, S. Fukatsu, G. Koyama, K. Maeda, and H. Umezawa, *J. Antibiot., Ser. A* **19**, 93 (1966) [CA **65**, 15488 (1966)].
- 66JAN(A)286 T. Takeuchi, J. Iwanaga, T. Aoyagi, and H. Umezawa, *J. Antibiot., Ser. A* **19**, 286 (1966) [CA **66**, 17171 (1967)].
- 66JAP66/17629 H. Umezawa, M. Hori, T. Takeuchi, Y. Okamo, and M. Hamada, *Jpn. Pat.* 66/17,629 (1966) [CA **66**, 27710 (1967)].
- 66JBC(241)2220 G. Guroff and C. A. Strenkoski, *J. Biol. Chem.* **241**, 2220 (1966) [CA **64**, 18054 (1966)].
- 66JCS(C)1872 J. Gigg and C. D. Warren, *J. Chem. Soc. C*, 1872 (1966)].
- 66JHC110 R. K. Robins, L. B. Townsend, F. Cassidy, G. F. Gerster, A. F. Lewis, and R. L. Miller, *J. Heterocycl. Chem.* **3**, 110 (1966).
- 66MI1 E. M. Gal, J. C. Armstrong, and B. Ginsberg, *J. Neurochem.* **13**, 643 (1966) [CA **65**, 10863 (1966)].
- 66MI2 F. J. Maclean, H. S. Forrest, and J. Myers, *Arch. Biochem. Biophys.* **114**, 404 (1966) [CA **64**, 20275 (1966)].
- 66TL597 G. Koyama, K. Maeda, H. Umezawa, and Y. Iitaka, *Tetrahedron Lett.*, 597 (1966).
- 66ZC329 G. Henseke, *Z. Chem.* **6**, 329 (1966).
- 67CB492 F. Buhler and W. Pfeleiderer, *Chem. Ber.* **100**, 492 (1967).
- 67CB845 J. C. Jochims, A. Seeliger, and G. Taigel, *Chem. Ber.* **100**, 845 (1967).
- 67JA4129 W. S. Chilton and R. C. Krahn, *J. Am. Chem. Soc.* **89**, 4129 (1967).
- 67JA4808 R. R. Herr, H. K. Jahnke, and A. D. Argoudelis, *J. Am. Chem. Soc.* **89**, 4808 (1967).
- 67JAN(A)49 N. Izhida, M. Homma, K. Kumagai, Y. Shimizu, S. Matsumotu, and A. Izawa, *J. Antibiot., Ser. A* **20**, 49 (1967) [CA **66**, 63956 (1967)].
- 67JAN(A)129 N. Ishida, A. Izawa, M. Homma, K. Kumagai, and S. Shimizu, *J. Antibiot., Ser. A* **20**, 129 (1967) [CA **67**, 41152 (1967)].
- 67JAN(A)227 T. Sawa, Y. Fukagawa, I. Homma, T. Takeuchi, and H. Umezawa, *J. Antibiot., Ser. A* **20**, 227 (1967) [CA **67**, 79161 (1967)].
- 67JAN(A)277 T. Kunimoto, M. Hori, and H. Umezawa, *J. Antibiot., Ser. A* **20**, 277 (1967) [CA **67**, 115458 (1967)].
- 67JAN(A)297 T. Takeuchi, J. Iwanaga, T. Aoyagi, M. Murase, T. Sawa, and H. Umezawa, *J. Antibiot., Ser. A* **20**, 297 (1967) [CA **67**, 115537 (1967)].
- 67JAN(A)308 H. Umezawa, T. Sawa, Y. Fukagawa, I. Homma, M. Ishizuka,

- and T. Takeuchi, *J. Antibiot., Ser. A* **20**, 308 (1967) [CA **68**, 48111 (1968)].
- 67JAN(A)369 M. Harada, M. Takeuchi, and K. Katagiri, *J. Antibiot., Ser. A* **20**, 369 (1967) [CA **68**, 38034 (1968)].
- 67JAP67/10928 Nippon Kayaku Co. Ltd., Jpn. Pat. 67/10928 (1967) [CA **68**, 24552 (1968)].
- 67JAP67/21755 H. Umezawa, Jpn. Pat. 67/21755 (1967) [CA **68**, 28466 (1968)].
- 67JBC(242)3868 A. Nakazawa, M. Tokushige, O. Hayaishi, M. Ikehara, and Y. Mizuno, *J. Biol. Chem.* **242**, 3868 (1967).
- 67MI1 I. C. Caldwell, J. F. Henderson, and A. R. P. Paterson, *Can. J. Biochem.* **45**, 735 (1967) [CA **67**, 1887 (1967)].
- 67MI2 J. F. Henderson, A. R. P. Paterson, I. C. Caldwell, and M. Hori, *Cancer. Res.* **27**, 715 (1967) [CA **67**, 10029 (1967)].
- 67MI3 Yu. A. Zhadnov, V. I. Kornilov, and G. V. Bogdanova, *Carbohydr. Res.* **4**, 492 (1967).
- 67MI4 A. Sakurai and M. Goto, *J. Biochem. (Tokyo)* **61**, 142 (1967).
- 67NKZ897 M. Goto, A. Sakurai, and H. Yamakami, *Nippon Kagaku Zasshi* **88**, 897 (1967) [CA **69**, 52107 (1968)].
- 67SCI217 W. Lovenberg, E. Jequier, and A. Sjoerdsma, *Science* **155**, 217 (1967).
- 67TL4507 M. Goto, A. Sakurai, K. Ohta, and H. Yamamaki, *Tetrahedron Lett.*, 4507 (1967).
- 68BBA(155)82 M. Ikehara, K. Murao, F. Harada, and S. Nishimura, *Biochim. Biophys. Acta* **155**, 82 (1968).
- 68BBA(174)696 M. Ikehara, K. Murao, F. Harada, and S. Nishimura, *Biochim. Biophys. Acta* **174**, 696 (1968).
- 68BCJ261 J. Yoshimura and H. Hashimoto, *Bull. Chem. Soc. Jpn.* **41**, 261 (1968).
- 68CB4170 G. Hanisch and G. Henseke, *Chem. Ber.* **101**, 4170 (1968).
- 68DOK849 Yu. A. Zhdanov, V. I. Kornilov, and G. N. Dorofeenko, *Dok. Akad. Nauk SSSR* **178**, 849 (1968).
- 68HCA569 H. Fritz, C. J. Morel, and O. Wacker, *Helv. Chim. Acta* **51**, 569 (1968).
- 68HCA1029 M. Viscontini and H. Leidner, *Helv. Chim. Acta* **51**, 1029 (1968).
- 68HCA1495 M. Viscontini and R. Provenzale, *Helv. Chim. Acta* **51**, 1495 (1968).
- 68IZV2655 M. L. Shul'man, I. M. Privalova, and A. Ya. Khorlin, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 2655 (1968).
- 68JA1318 W. S. Chilton and R. C. Krahn, *J. Am. Chem. Soc.* **90**, 1318 (1968).
- 68JAN1 M. Ishizuka, T. Sawa, G. Koyama, T. Takeuchi, and H. Umezawa, *J. Antibiot.* **21**, 1 (1968) [CA **68**, 7671 (1968)].
- 68JAN5 M. Ishizuka, T. Sawa, S. Hori, H. Takayama, T. Takeuchi, and H. Umezawa, *J. Antibiot.* **21**, 5 (1968) [CA **68**, 76815 (1968)].
- 68JAN264 M. Hori, T. Wakashiro, E. Ito, T. Sawa, T. Takeuchi, and H. Umezawa, *J. Antibiot.* **21**, 264 (1968) [CA **70**, 17817 (1969)].
- 68JAN334 T. Sawa, Y. Fukagawa, I. Homma, T. Wakashiro, T. Takeuchi, M. Hori, and T. Komai, *J. Antibiot.* **21**, 334 (1968) [CA **70**, 17738 (1969)].
- 68JAN468 T. Kunimoto, T. Wakashiro, I. Okamura, T. Asajima, and M. Hori, *J. Antibiot.* **21**, 468 (1968) [CA **70**, 35335 (1969)].
- 68JAP68/759 H. Umezawa, Jpn. Pat. 68/759 (1968) [CA **68**, 113352 (1968)].

- 68JBC(243)3214 K. W. Rabinowitz, J. D. Shada, and W. A. Wood, *J. Biol. Chem.* **243**, 3214 (1968).
- 68JBC(243)3532 R. J. Suhadolnik, S. I. Finkel, and B. M. Chassy, *J. Biol. Chem.* **243**, 3532 (1968).
- 68JCS(C)1903 R. Gigg and C. D. Warren, *J. Chem. Soc. C*, 1903 (1968).
- 68JCS(CC)120 K. J. M. Andrews, W. E. Barber, and B. P. Tong, *J. Chem. Soc., Chem. Commun.*, 120 (1968).
- 68MI1 M. R. Sheen, B. K. Kim, H. Martin, and R. E. Parks, Jr., *Proc. Am. Assoc. Cancer Res.* **9**, 249 (1968).
- 68MI2 M. R. Sheen, B. K. Kim, and R. E. Parks, Jr., *Mol. Pharmacol.* **4**, 293 (1968) [*CA* **68**, 111752 (1968)].
- 68MI3 Yu. A. Zhdanov, V. I. Kornilov, and G. N. Dorofeenko, *Carbohydr. Res.* **6**, 414 (1968).
- 68MI4 Yu. A. Zhdanov, Yu. E. Alexeev, and G. N. Dorofeenko, *Carbohydr. Res.* **8**, 121 (1968).
- 68MI5 K. Ohta and M. Goto, *J. Biochem. (Tokyo)* **63**, 127 (1968).
- 68PNA1494 D. C. Ward and E. Reich, *Proc. Natl. Acad. Sci. U. S. A.* **61**, 1494 (1968).
- 68TL2941 A. Sakurai and M. Goto, *Tetrahedron Lett.*, 2941 (1968).
- 68ZN(B)860 N. Kokolis and I. Ziegler, *Z. Naturforsch., B: Anorg. Chem., Org. Chem., Biochem., Biophys., Biol.* **B23**, 860 (1968).
- 69ACH(62)65 R. Bognar, Z. Kolodynska, L. Somogyi, Z. Gyorgydeak, L. Szilagyi, and E. Nemes-Nanasi, *Acta Chim. Acad. Sci. Hung.* **62**, 65 (1969) [*CA* **72**, 43554 (1970)].
- 69ACH(62)179 R. Bognar, I. Farkas, L. Szilagyi, M. Menyhart, E. N. Nemes, and I. F. Szabo, *Acta Chim. Acad. Sci. Hung.* **62**, 179 (1969) [*CA* **72**, 90801 (1970)].
- 69BBA(174)696 M. Ikehara, K. Murao, F. Harada, and S. Nishimura, *Biochim. Biophys. Acta* **174**, 696 (1969).
- 69CCC247 M. Bobek and J. Farkas, *Collect. Czech. Chem. Commun.* **34**, 247 (1969) [*CA* **70**, 78306 (1969)].
- 69CCC1118 J. Farkas, K. Sebesta, K. Horska, Z. Samek, M. Dolejs, and F. Sorm, *Collect. Czech. Chem. Commun.* **34**, 1118 (1969) [*CA* **70**, 97091 (1969)].
- 69HCA300 G. Baschang and H. Fritz, *Helv. Chim. Acta* **52**, 300 (1969).
- 69HCA1225 M. Viscontini and R. Provenzale, *Helv. Chim. Acta* **52**, 1225 (1969).
- 69JAN36 I. Tsukada, T. Kunitomo, M. Hori, and T. Komai, *J. Antibiot.* **22**, 36 (1969) [*CA* **70**, 84509 (1969)].
- 69JBC(244)1228 D. C. Ward, E. Reich, and L. Strayer, *J. Biol. Chem.* **244**, 1228 (1969).
- 69JBC(244)3243 D. C. Ward, A. Cerami, E. Reich, G. Acs, and L. Altwerger, *J. Biol. Chem.* **244**, 3243 (1969).
- 69JCS(C)928 K. J. M. Andrews, W. E. Barber, and B. P. Tong, *J. Chem. Soc. C* 928 (1969).
- 69JHC459 L. B. Townsend and R. K. Robins, *J. Heterocycl. Chem.* **6**, 459 (1969).
- 69JOC2654 W. E. Dick, Jr., D. Weisleder, and J. E. Hodge, *J. Org. Chem.* **34**, 2654 (1969).
- 69MI1 I. C. Caldwell, J. F. Henderson, and A. R. P. Paterson, *Can. J. Biochem.* **47**, 901 (1969) [*CA* **71**, 100038 (1969)].

- 69MI2 A. Kapuler, D. C. Ward, N. Mendelsohn, H. Klett, and G. Acs, *Virology* **37**, 701 (1969) [CA **70**, 111844 (1969)].
- 69MI3 M. Goto, A. Sakurai, K. Ohta, and H. Yamakami, *J. Biochem. (Tokyo)* **65**, 611 (1969).
- 69MI4 A. Sakurai and M. Goto, *J. Biochem. (Tokyo)* **65**, 755 (1969).
- 69PNA581 D. C. Ward, W. Fuller, and E. Reich, *Proc. Natl. Acad. Sci. U. S. A.* **68**, 581 (1969).
- 69ZOB1413 Yu. A. Zhdanov, Yu. E. Alekseev, and G. N. Dorofeenko, *Zh. Obshch. Khim.* **39**, 1413 (1969) [CA **71**, 81668 (1969)].
- 70CRV389 L. B. Townsend and G. Revankar, *Chem. Rev.* **70**, 389 (1970).
- 70HCA1202 M. Viscontini, R. Provenzale, S. Ohlgart, and J. Mallevialle, *Helv. Chim. Acta* **53**, 1202 (1970).
- 70JCS(CC)313 E. M. Acton, K. J. Ryan, and L. Goodman, *J. Chem. Soc., Chem. Commun.* 313, (1970).
- 70MI1 H. El Khadem, *Adv. Carbohydr. Chem. Biochem.* **25**, 351 (1970).
- 70MI2 R. J. Suhadolnik, "Nucleoside Antibiotics." Wiley, New York, 1970.
- 70MI3 M. R. Sheen, H. F. Martin, and R. E. Parks, Jr., *Mol. Pharmacol.* **6**, 255 (1970) [CA **73**, 10889 (1970)].
- 70MI4 T. Fukushima, *Exp. Parasitol.* **28**, 473 (1970) [CA **74**, 96022 (1971)].
- 70MI5 L. Szilagyi and R. Bognar, *Carbohydr. Res.* **15**, 371 (1970).
- 70MI6 K. Iwai, M. Kobashi, and H. Fujisawa, *Chem. Biol. Pteridines, Proc. Int. Symp., 4th*, 1969 199 (1970) [CA **74**, 135331 (1971)].
- 70OMS1535 L. Dolejs, Z. Veisova, and J. Farkas, *Org. Mass Spectrom.* **3**, 1535 (1970).
- 70PNA539 A. M. Kapuler and S. Spiegelman, *Proc. Natl. Acad. Sci. U. S. A.* **66**, 539 (1970).
- 70TL4611 M. Bobek, J. Farkas, and F. Sorm, *Tetrahedron Lett.*, 4611 (1970).
- 71JAN(A)253 T. Kunitomo, T. Sawa, T. Wakashiro, M. Hori, and H. Umezawa, *J. Antibiot., Ser. A* **24**, 253 (1971) [CA **76**, 138994 (1972)].
- 71JCS(C)2443 R. A. Long, A. F. Lewis, R. K. Robins, and L. B. Townsend, *J. Chem. Soc. C*, 2443 (1971).
- 71JCS(CC)986 E. M. Acton, K. J. Ryan, D. W. Henry, and L. Goodman, *J. Chem. Soc., Chem. Commun.*, 986 (1971).
- 71JCS(CC)1267 J. Igolen and T. Huynh-Dinh, *J. Chem. Soc., Chem. Commun.*, 1267 (1971).
- 71JPR940 B. Teichmann, K. Himmelsbach, and O. Westphal, *J. Prakt. Chem.* **313**, 940 (1971).
- 71MI1 N. Kokolis and N. Mylonas, *Folia Biochim. Biol. Graeca* **8**, 21 (1971) [CA **81**, 61202 (1974)].
- 71MI2 N. Kokolis and N. Mylonas, *Folia Biochim. Biol. Graeca* **8**, 28 (1971) [CA **81**, 61203 (1974)].
- 71MI3 T. Lloyd and N. Weiner, *Mol. Pharmacol.* **7**, 569 (1971) [CA **76**, 11491 (1972)].
- 71MI4 N. P. Buu-Hoi, J. N. Vallat, G. Saint Ruf, and G. Lambelin, *Chim. Ther.* **6**, 245 (1971) [CA **76**, 3794 (1972)].
- 71MI5 K. Himmelsbach, O. Westphal, and B. Teichmann, *Eur. J. Immunol.* **1**, 106 (1971) [CA **75**, 61385 (1971)].
- 71MI6 R. G. Cooks, G. S. Johnson, and W. S. Ruliffson, *Carbohydr. Res.* **18**, 233 (1971).



- 71MI7 R. G. Cooks, G. S. Johnson, and W. S. Ruliffson, *Carbohydr. Res.* **18**, 243 (1971).
- 71NKZ1177 M. Tsuchiya, *Nippon Kagaku Zasshi* **92**, 117 (1971) [CA **77**, 19935 (1972)].
- 71PAC489 K. Gergon, D. C. Delong, and J. C. Cline, *Pure Appl. Chem.* **28**, 489 (1971).
- 71ZC380 B. Teichmann, K. Himmelspach, and O. Westphal, *Z. Chem.* **11**, 380 (1971).
- 72ABC1685 M. Kobashi and K. Iwai, *Agric. Biol. Chem.* **36**, 1685 (1972) [CA **78**, 12806 (1973)].
- 72ABC1695 M. Kobashi and K. Iwai, *Agric. Biol. Chem.* **36**, 1695 (1972) [CA **78**, 54192 (1973)].
- 72AGE1061 H. Rembold and W. L. Gyure, *Angew. Chem., Int. Ed. Engl.* **11**, 1061 (1972).
- 72BCJ3564 K. Sugiyura, H. Yamashita, and M. Goto, *Bull. Chem. Soc. Jpn.* **45**, 3564 (1972).
- 72CCC2798 J. Farkas and F. Sorm, *Collect. Czech. Chem. Commun.* **37**, 2798 (1972) [CA **77**, 152495 (1972)].
- 72HCA570 M. Viscontini, R. Provenzale, and W. F. Frei, *Helv. Chim. Acta* **55**, 570 (1972).
- 72HCA574 M. Viscontini and W. F. Frei, *Helv. Chim. Acta* **55**, 574 (1972).
- 72JBC(247)4014 D. C. Ward, T. Horn, and E. Reich, *J. Biol. Chem.* **247**, 4014 (1972).
- 72JBC(247)4549 T. Fukushima and T. Shiota, *J. Biol. Chem.* **247**, 4549 (1972).
- 72JCS(P1)2677 G. H. Milne and L. B. Townsend, *J. Chem. Soc., Perkin Trans. I*, 2677 (1972).
- 72JPR877 B. Teichmann, K. Himmelspach, and O. Westphal, *J. Prakt. Chem.* **314**, 877 (1972).
- 72MI1 J. Igolen, T. Huynh Dinh, A. Kolb, and C. Perreux, *Chim. Ther.* **7**, 207 (1972) [CA **77**, 114766 (1972)].
- 72MI2 B. Samuelsson, *Fed. Proc., Fed. Am. Soc. Exp. Biol.* **31**, 1442 (1972).
- 72MI3 V. Harisdangkul and E. A. Kabat, *J. Immunol.* **108**, 1232 (1972) [CA **77**, 3661 (1972)].
- 72T4197 G. Snatzke, F. Werner-Zamojska, L. Szilagy, R. Bognar, and J. Farkas, *Tetrahedron* **28**, 4197 (1972).
- 72TL3219 Y. Iwanami and M. Akino, *Tetrahedron Lett.*, 3219 (1972).
- 73B1196 P. Prusiner, T. Brennan, and M. Sundralingam, *Biochemistry* **12**, 1196 (1973).
- 73BBA(312)292 H. T. Abelson and S. Penman, *Biochim. Biophys. Acta* **312**, 292 (1973).
- 73BBR(53)929 G. W. Kidder and L. L. Nolan, *Biochem. Biophys. Res. Commun.* **53**, 929 (1973).
- 73CJC1313 M. J. Robins, J. R. McCarthy, Jr., R. A. Jones, and R. Mengel, *Can. J. Chem.* **51**, 1313 (1973).
- 73DOK99 A. Yu. Zhdanov, V. G. Alekseeva, and V. N. Fomina, *Dokl. Akad. Nauk SSSR* **212**, 99 (1973) [CA **79**, 146785 (1973)].
- 73JA4761 T. R. Krugh, *J. Am. Chem. Soc.* **95**, 4761 (1973).
- 73JCS(CC)680 T. Huynh-Dinh, A. Kolb, G. Barnathan, and J. Igolen, *J. Chem. Soc., Chem. Commun.*, 680 (1973).
- 73JHC431 M.-T. Chenon, R. J. Pugmire, D. M. Grant, R. P. Panzica, and L. B. Townsend, *J. Heterocycl. Chem.* **10**, 431 (1973).

- 73JOC3179 T. C. Jain, a. F. Russell, and J. G. Moffatt, *J. Org. Chem.* **38**, 3179 (1973).
- 73LA1091 H. Braun and W. Pfeleiderer, *Liebigs Ann. Chem.*, 1091 (1973).
- 73MI1 L. Szilagyi, R. Bogнар, and I. Farkas, *Carbohydr. Res.* **26**, 305 (1973).
- 73MI2 A. Charlson, *Carbohydr. Res.* **28**, 118 (1973).
- 73MI3 H. El Khadem and E. S. El Ashry, *Carbohydr. Res.* **29**, 525 (1973).
- 73TL2971 A. Kolb, C. Gouyette, H. D. Tam, and J. Igolen, *Tetrahedron Lett.*, 2971 (1973).
- 74ACSA(B)559 L. Kenne, B. Lindberg, A. Pilotti, and S. Svensson, *Acta Chem. Scand., Ser. B* **B28**, 559 (1974).
- 74AQ(C)57 F. Garcia Gonzalez, J. Fernandez Bolanos, and M. A. Pradera de Fuentes. *An. Quim. Ser. C* **70**, 57 (1974) [*CA* **84**, 90457 (1976)].
- 74AX(B)1511 G. Koyama and H. Umezawa, *Acta Crystallogr., Sect. B* **B30**, 1511 (1974) [*CA* **81**, 42616 (1974)].
- 74AX(B)1801 R. Jimenez-Garay, A. Lopez-Castro, and R. Marquez, *Acta Crystallogr., Sect. B* **B30**, 1801 (1974) [*CA* **81**, 69637 (1974)].
- 74CI(L)233 A. J. Pearson, *Chem. Ind. (London)*, 233 (1974).
- 74JA6781 E. C. Taylor and P. A. Jacobi, *J. Am. Chem. Soc.* **96**, 6781 (1974).
- 74JAN909 K. Ochi, S. Iwamoto, E. Hayase, S. Yashima, and Y. Okami, *J. Antibiot.* **27**, 909 (1974) [*CA* **82**, 121316 (1975)].
- 74JCS(P1)1237 A. Gomez Sanchez, E. Toledano, and M. Gomez Guillen, *J. Chem. Soc., Perkin Trans. 1*, 1237 (1974).
- 74JMC62 J. E. Abola, M. J. Sims, D. J. Abraham, A. F. Lewis, and L. B. Townsend, *J. Med. Chem.* **17**, 62 (1974).
- 74JOC1374 H. Ogura and H. Takakashi, *J. Org. Chem.* **39**, 1374 (1974).
- 74JOC2023 L. B. Townsend, R. A. Long, J. P. McGraw, D. W. Miles, R. K. Robins, and H. Evring, *J. Org. Chem.* **39**, 2023 (1974).
- 74MI1 G. W. Crabtree and A. W. Senft, *Biochem. Pharmacol.* **23**, 649 (1974) [*CA* **80**, 143247 (1974)].
- 74MI2 A. Maelicke, M. Sprinzel, F. van der Haar, T. A. Khawaja, and F. Cramer, *Eur. J. Biochem.* **43**, 617 (1974) [*CA* **82**, 52828 (1975)].
- 72MI3 S. Kaufman and D. B. Fisher, in "Molecular Mechanism of Oxygen Activation" (O. Hayaishi, ed.), pp. 285-365. Academic Press, New York, 1974.
- 74MI4 H. El Khadem and D. Swartz, *Carbohydr. Res.* **32**, C1 (1974).
- 74MI5 H. El Khadem and E. S. H. El Ashry, *Carbohydr. Res.* **32**, 339 (1974).
- 74MI6 E. M. Acton, A. Fujiwara, L. Goodman, and D. W. Henry, *Carbohydr. Res.* **33**, 135 (1974).
- 74MI7 H. El Khadem and R. Sindric, *Carbohydr. Res.* **34**, 203 (1974).
- 74MI8 A. Gomez Sanchez, M. G. Guillen, E. P. Ramos, and A. C. Ventula, *Carbohydr. Res.* **35**, 39 (1974).
- 74MI9 D. S. Boolieris, R. J. Ferrier, and L. A. Branda, *Carbohydr. Res.* **35**, 131 (1974).
- 75ANY3 M. Sundaralingam, *Ann. N. Y. Acad. Sci.* **55**, 3 (1975).
- 75BCJ3767 T. Sugimoto and S. Matsuura, *Bull. Chem. Soc. Jpn.* **48**, 3767 (1975).
- 75JA5896 J. Zemlicka, *J. Am. Chem. Soc.* **97**, 5896 (1975).
- 75JAN492 O. Makabe, M. Nakamura, and S. Umezawa, *J. Antibiot.* **28**, 492 (1975) [*CA* **83**, 188288 (1975)].

- 75JAN555 T. Aoyagi, M. Kumagai, T. Hazato, H. Hamada, T. Takeuchi, and H. Umezawa, *J. Antibiot.* **28**, 555 (1975) [CA **83**, 144150 (1975)].
- 75JAN876 M. Kumagai, H. Naganawa, T. Aoyagi, H. Umezawa, H. Nakamura, and Y. Iitaka, *J. Antibiot.* **28**, 876 (1975) [CA **84**, 105433 (1976)].
- 75JAN965 K. Ochi, S. Yashima, and Y. Eguchi, *J. Antibiot.* **28**, 965 (1975) [CA **84**, 56362 (1976)].
- 75JAP(K)75/129593 H. Ogura and M. Sakaguchi, Jpn. Kokai 75/129593 (1975) [CA **85**, 47011 (1976)].
- 75JHC111 T. Huynh-Dinh, A. Kolb, C. Gouyette, and J. Igolen, *J. Heterocycl. Chem.* **12**, 111 (1975).
- 75JMC438 H. S. El Khadem and T. D. Audichya, *J. Med. Chem.* **18**, 438 (1975).
- 75JOC2825 T. Huynh-Dinh, A. Kolb, C. Gouyette, J. Igolen, and S. Tran-Dinh, *J. Org. Chem.* **40**, 2825 (1975).
- 75MI1 R. P. Agarwal, S. M. Sagar, and R. E. Parks, Jr., *Biochem. Pharmacol.* **24**, 693 (1975) [CA **83**, 23999 (1975)].
- 75MI2 J. Giziewicz, E. De Clercq, M. Luczak, and D. Shugar, *Biochem. Pharmacol.* **24**, 1813 (1975) [CA **84**, 99169 (1976)].
- 75MI3 S. Cha, R. P. Agarwal, and R. E. Parks, Jr., *Biochem. Pharmacol.* **24**, 2187 (1975) [CA **84**, 86081 (1976)].
- 75MI4 L. B. Townsend, in "Handbook of Biochemistry and Molecular Biology", (D. G. Fashman, ed.), Vol. 1, pp. 271-401. CRC Press, Cleveland, OH, 1975.
- 75MI5 T. Fukushima, *Tampakushitsu Kakusan Koso* **20**, 691 (1975) [CA **83**, 127563 (1975)].
- 75MI6 H. Ogura, H. Takahashi, K. Takeda, M. Sakaguchi, N. Nimura, and H. Sakai, *Hokusokan Kagaku Toronkai Koen Yoshishu* **8**, 154 (1975) [CA **84**, 150881 (1976)].
- 750PP291 H. D. Heindel, H. D. Burns, T. Honda, V. R. Risch, and L. W. Brady, *Org. Prep. Proced. Int.* **7**, 291 (1975) [CA **84**, 150865 (1976)].
- 75T2914 A. Kolb, C. Gouyette, T. Huynh-Dinh, and J. Igolen, *Tetrahedron* **31**, 2914 (1975).
- 75ZN(C)835 R. J. H. Davies, *Z. Naturforsch., C: Biosci.* **30**, 835 (1975).
- 76AX(B)813 G. Koyama, H. Nakamura, H. Umezawa, and Y. Iitaka, *Acta Crystallogr., Sect. B* **B32**, 813 (1976) [CA **84**, 158295 (1976)].
- 76AX(B)1363 R. Vega, V. Hernandez Montis, and A. Lopez-Castro, *Acta Crystallogr. Sect. B* **B32**, 1363 (1976) [CA **85**, 39521 (1976)].
- 76AX(B)2115 R. Jimenez-Garay, A. Lopez-Castro, and R. Marquez, *Acta Crystallogr. Sect. B* **B32**, 2115 (1976) [CA **85**, 115066 (1976)].
- 76BCJ313 H. Sano, T. Tsuchiya, Y. Ban, and S. Umezawa, *Bull. Chem. Soc. Jpn.* **49**, 313 (1976).
- 76CSC353 R. Jimenez-Garay, R. Vega, and A. Castro-Lopez, *Cryst. Struct. Commun.* **5**, 353 (1976) [CA **85**, 39581 (1976)].
- 76CSC369 E. Moreno, M. Garcia Gea, and V. Hernandez Montis, *Cryst. Struct. Commun.* **5**, 369 (1976) [CA **85**, 102743 (1976)].
- 76HCA248 B. Schircks, J. H. Bieri, and M. Viscontini, *Helv. Chim. Acta* **59**, 248 (1976).
- 76JA2301 E. C. Taylor and P. A. Jacobi, *J. Am. Chem. Soc.* **98**, 2301 (1976).
- 76JA4736 M.-T. Chenon, R. P. Panzica, J. C. Smith, R. J. Pugmire, D. M. Grant, and L. B. Townsend, *J. Am. Chem. Soc.* **98**, 4736 (1976).

- 76JAN638 K. Ochi, S. Kikuchi, S. Yashima, and Y. Eguchi, *J. Antibiot.* **29**, 638 (1976) [*CA* **85**, 43577 (1976)].
- 76JAN696 M. Kumagai, T. Aoyagi, and H. Umezawa, *J. Antibiot.* **29**, 696 (1976) [*CA* **85**, 118632 (1976)].
- 76JAN1218 P. F. Wiley, D. L. McMichael, J. M. Koert, and V. H. Wiley, *J. Antibiot.* **29**, 1218 (1976) [*CA* **86**, 53842 (1977)].
- 76JAP(K)76/39685 H. Ogura and H. Takahashi, *Jpn. Kokai* 76/39685 (1977) [*CA* **86**, 5765 (1977)].
- 76JHC175 F. G. De Las Heras, C. K. Chu, S. Y.-K. Tam, R. S. Klein, K. A. Watanabe, and J. J. Fox, *J. Heterocycl. Chem.* **13**, 175 (1976).
- 76JHC1241 E. Garcia-Abbad, M. T. Garcia-Lopez, G. Garcia-Munoz, and M. Stud, *J. Heterocycl. Chem.* **13**, 1241 (1976).
- 76JHC1305 S. Y.-K. Tam, J. S. Hwang, F. D. De Las Heras, R. S. Klein, and J. J. Fox, *J. Heterocycl. Chem.* **13**, 1305 (1976).
- 76JOC3124 T. Huynh-Dinh, J. Igolen, J.-P. Marquet, E. Bisagni, and J. M. Lhoste, *J. Org. Chem.* **41**, 3124 (1976).
- 76LA450 R. Bogнар, Z. Gyorgydeak, L. Szilagyi, G. Horvath, G. Czira, and L. Radics, *Liebigs Ann. Chem.*, 450 (1976).
- 76MI1 R. P. Agarwal, G. W. Crabtree, R. E. Parks, Jr., J. A. Nelson, R. Keightley, R. Parkman, F. S. Rosen, R. C. Stern, and S. H. Polmar, *J. Clin. Invest.* **57**, 1025 (1976).
- 76MI2 G. Barnathan, T. Huynh Dinh, A. Kolb, and J. Igolen, *Eur. J. Med. Chem.—Chim. Ther.* **11**, 67 (1976) [*CA* **85**, 33341 (1976)].
- 76MI3 H. Ogura, H. Takahashi, K. Takeda, and N. Nimura, *Nucleic Acids Res., Spec. Publ.* **2**, 7 (1976) [*CA* **86**, 140380 (1977)].
- 76MI4 E. Elstner and A. Heupel, *Arch. Biochem. Biophys.* **173**, 614 (1976) [*CA* **84**, 132877 (1976)].
- 77HCA211 B. Schircks, J. H. Bieri, and M. Viscontini, *Helv. Chim. Acta* **60**, 211 (1977).
- 77JA3267 S. Tran-Dinh, J.-M. Neumann, J.-M. Thiery, T. Huynh-Dinh, J. Igolen, and W. Guschlbauer, *J. Am. Chem. Soc.* **99**, 3267 (1977).
- 77JHC135 H. L. Chung and J. Zemlicka, *J. Heterocycl. Chem.* **14**, 135 (1977).
- 77MI1 R. P. Agarwal, T. Spector, and R. E. Parks, Jr., *Biochem. Pharmacol.* **26**, 359 (1977) [*CA* **87**, 98035 (1977)].
- 77MI2 G. W. Crabtree, R. P. Agarwal, R. E. Parks, Jr., A. F. Lewis, and L. B. Townsend, *Proc. Am. Assoc. Cancer Res.* **18**, 181 (1977).
- 77MI3 T. G. Wilson and K. B. Jacobson, *Biochem. Genet.* **15**, 307 (1977) [*CA* **87**, 2634 (1977)].
- 77MI4 H. Hiroshi, *Vitamins* **51**, 544 (1977) [*CA* **88**, 89541 (1978)].
- 77MI5 R. Blattner, R. J. Ferrier, and P. C. Tyler, *Carbohydr. Res.* **54**, 199 (1977).
- 77MI6 I. Farkas, I. F. Szabo, and R. Bogнар, *Carbohydr. Res.* **56**, 404 (1977).
- 77MI7 M. El Sekily, I. El Kholy, and E. S. H. El Ashry, *Carbohydr. Res.* **59**, 141 (1977).
- 77ZN(C)528 H. D. Luedemann and E. Westhof, *Z. Naturforsch., C: Biosci.* **32C**, 528 (1977).
- 78AX(B)184 R. Jimenez-Garay, P. Villares, A. Lopez-Castro, and R. Marquez, *Acta Crystallogr., Sect. B* **B34**, 184 (1978) [*CA* **88**, 113669 (1978)].
- 78B2350 S. A. Brinkley, A. F. Lewis, W. J. Critz, L. L. Witt, L. B. Townsend, and R. L. Blakley, *Biochemistry* **17**, 2350 (1978).

- 78CCC1431 L. Kalvoda, *Collect. Czech. Chem. Commun.* **43**, 1431 (1978) [CA **89**, 197857 (1978)].
- 78FRP2358154 J. Igolen, T. Huynh-Dinh, E. Bisagni, M. Gero, and E. De Maeyer, *Fr. Demande* 2,358,154 (1978) [CA **89**, 215724 (1978)].
- 78H(9)175 G. Wu, E. Yamanaka, and J. M. Cook, *Heterocycles* **9**, 175 (1978).
- 78HCA2731 B. Schircks, J. H. Bieri, and M. Viscontini, *Helv. Chim. Acta* **61**, 2731 (1978).
- 78JAN456 O. Makabe, A. Miyadera, M. Kinoshita, S. Umezawa, and T. Takeuchi, *J. Antibiot.* **31**, 456 (1978) [CA **89**, 44084 (1978)].
- 78KGS893 I. Farkas, I. Szabo, R. Bognar, and L. Szilagyi, *Khim. Geoterotsikl. Soedin.*, 893 (1978) [CA **89**, 180286 (1978)].
- 78MI1 R. P. Agarwal, S. Cha, G. W. Crabtree, and R. E. Parks, Jr., in "Chemistry and Biology of Nucleosides and Nucleotides" (R. E. Harmon, R. K. Robins, and L. B. Townsend, eds.), pp. 159–197. Academic Press, New York, 1978.
- 78MI2 J. Zemlicka, *Nucleic Acids Chem.* **2**, 709 (1978) [CA **90**, 6649 (1979)].
- 78MI3 S. Frost and J. T. Bagnara, *J. Chromatogr.* **153**, 279 (1978) [CA **89**, 102938 (1978)].
- 78MI4 J. J. Fox, K. A. Watanabe, R. S. Klein, C. K. Chu, S. Y. K. Tam, U. Reichman, K. Hirota, I. Wempen, C. Lopez, and J. H. Burchenal, *Colloq.—Inst. Natl. Sante Rech. Med.* **89**, 241 (1978) [CA **92**, 14986 (1980)].
- 78MI5 E. S. H. El Ashry, I. E. El Kholy, and Y. El Kilany, *Carbohydr. Res.* **60**, 303 (1978).
- 78MI6 M. A. E. Sallam, *Carbohydr. Res.* **66**, C4 (1978).
- 78MI7 M. A. E. Sallam, *Carbohydr. Res.* **67**, 79 (1978).
- 78MI8 R. Soliman, E. S. H. El Ashry, I. E. El Kholy, and Y. El Kilany, *Carbohydr. Res.* **67**, 179 (1978).
- 78MI9 E. S. H. El Ashry, M. M. Abdel Rahman, M. A. Nassr, and A. Amer, *Carbohydr. Res.* **67**, 403 (1978).
- 78MI10 E. S. H. El Ashry, M. M. Abdel Rahman, N. Rashed, and A. Amer, *Carbohydr. Res.* **67**, 423 (1978).
- 78MI11 E. De Clercq and P. F. Torrence, *J. Carbohydr. Nucleosides, Nucleotides* **5**, 187 (1978).
- 78MI12 A. Rosenthal and H. H. Lee, *J. Carbohydr., Nucleosides, Nucleotides* **5**, 559 (1978).
- 78NJC357 T. Huynh-Dinh, R. S. Safarti, J. Igolen, J. M. Neumann, and S. Tran-Dinh, *Nouv. J. Chim.* **2**, 357 (1978). [CA **90**, 55239 (1979)].
- 79AQ1002 F. Garcia Gonzalez, J. A. Galbis Perez, J. I. Fernandez Garcia-Hierro, and J. F. Fernandez-Bolanos, *An. Quim.* **75**, 1002 (1979) [CA **93**, 47045 (1980)].
- 79BCJ181 T. Sugimoto and S. Matsuura, *Bull. Chem. Soc. Jpn.* **52**, 181 (1979).
- 79CPB1094 M. Sakaguchi, Y. Miyata, H. Ogura, K. Gonda, S. Koga, and T. Okamoto, *Chem. Pharm. Bull.* **27**, 1094 (1979).
- 79H(12)359 H. Ogura, M. Sakaguchi, T. Okamoto, K. Gonda, and S. Koga, *Heterocycles* **12**, 359 (1979).
- 79HC241 G. W. H. Cheesman and R. F. Cookson, in "The Chemistry of Heterocyclic Compounds" (A. Weissberger and E. C. Taylor, eds.), p. 241, Wiley (Interscience), 1979.

- 79HCA2558 H. J. Furrer, J. H. Bieri, and M. Viscontini, *Helv. Chim. Acta* **62**, 2558 (1979).
- 79HCA2577 H. J. Furrer, J. H. Bieri, and M. Viscontini, *Helv. Chim. Acta* **62**, 2577 (1977).
- 79JAN436 S. Omoto, T. Shomura, H. Suzuki, and S. Inouye, *J. Antibiot.* **32**, 436 (1979) [CA **91**, 189399 (1979)].
- 79JBC(254)8819 K. Ochi, S. Yashima, Y. Eguchi, and K. Matsuhita, *J. Biol. Chem.* **254**, 8819 (1979).
- 79JHC81 G. Alonso, E. Garcia-Ebbad, M. T. Garcia-Lopez, and M. Stud. *J. Heterocycl. Chem.* **16**, 81 (1979).
- 79JOC9 P. F. Wiley, R. R. Herr, H. K. Jahnke, G. G. Chidester, S. A. Mizsak, L. B. Spaulding, and A. D. Argoudelis, *J. Org. Chem.* **44**, 9 (1979).
- 79JOC535 D. Soerens, F. Ungemach, P. Mokry, G. S. Wu, E. Yamanaka, L. Hutchins, M. Di Pierro, and J. M. Cook, *J. Org. Chem.* **44**, 535 (1979).
- 79JOC1028 T. Huynh-Dinh, R. S. Sarfati, C. Gouyette, J. Igolen, E. Bisagni, J. H. Lhoste, and A. Civier, *J. Org. Chem.* **44**, 1028 (1979).
- 79JOC4547 S. Y. K. Tam, R. S. Klein, I. Wempen, and J. J. Fox, *J. Org. Chem.* **44**, 4547 (1979).
- 79MI1 G. Doukhan, T. Huynh-Dinh, E. Bisagni, J. C. Chermann, and J. Igolen, *Eur. J. Med. Chem.—Chim. Ther.* **14**, 375 (1979) [CA **92**, 129221 (1980)].
- 79MI2 J. R. Ogden, R. D. Madsen, and J. A. North, *Abstra. Annu. Meet. Am. Soc. Microbiol.*, Los Angeles, Abstr. A47, p. 8 (1979).
- 79MI3 R. J. Suhadolnik, "Nucleosides as Biological Probes." Wiley (Interscience), New York, 1979.
- 79MI4 R. J. Suhadolink, *Prog. Nucleic Acid Res. Mol. Biol.* **22**, 193 (1979) [CA **91**, 168022 (1979)].
- 79MI5 G. W. Crabtree, R. P. Agarwal, R. E. Parks, Jr., A. F. Lewis, L. L. Wotring, and L. B. Townsend, *Biochem. Pharmacol.* **28**, 1491 (1979) [CA **92**, 209 (1980)].
- 79MI6 S. Katoh, T. Sueoka, N. Nakanishi, K. Hirayama, I. Masuda, and S. Yamada, *Josai Shika Daigaku Kiyo* **8**, 9 (1979) [CA **92**, 107664 (1980)].
- 79MI7 J. I. DeGraw, V. H. Brown, and I. Uemura, *J. Labelled Compd. Radiopharm.* **16**, 559 (1979) [CA **92**, 146723 (1980)].
- 79MI8 M. A. El Sekily and S. Mancy, *Carbohydr. Res.* **68**, 87 (1979).
- 80ABC2061 M. Kohashi, K. Tomita, and K. Iwai, *Agric. Biol. Chem.* **44**, 2061 (1980) [CA **93**, 234646 (1980)].
- 80AGE473 M. Bohme, W. Pfeleiderer, E. Elstner, and W. Richter, *Angew. Chem., Int. Ed. Engl.* **19**, 473 (1980).
- 80AX(B)3048 A. Conde, F. Bernier, and A. Marquez, *Acta Crystallogr., Sect. B* **B36**, 3048 (1980) [CA **94**, 75049 (1981)].
- 80BBA(611)241 T. Kato, T. Yamaguchi, T. Nagatsu, T. Sugimoto, and S. Matsuura, *Biochim. Biophys. Acta* **611**, 241 (1980).
- 80BCJ2344 T. Sugimoto, S. Matsuura, and T. Nagatsu, *Bull. Chem. Soc. Jpn.* **53**, 2344 (1980).
- 80CJC2624 J. G. Buchanan, A. Stobie, and R. H. Wightman, *Can J. Chem.* **58**, 2624 (1980).

- 80E639 Y. Yoshida and M. Akino, *Experientia* **36**, 639 (1980).
- 80JA2817 A. F. Lewis and L. B. Townsend, *J. Am. Chem. Soc.* **102**, 2187 (1980).
- 80JAN303 T. Hidaka, K. Katayama, K. Yamashita, T. Yamashita, K. Watanabe, M. Shimasaki, M. Ohno, T. Takeuchi, and H. Umezawa, *J. Antibiot.* **33**, 303 (1980) [*CA* **93**, 19209 (1980)].
- 80JCS(CC)237 J. G. Buchanan, A. P. Edgar, R. J. Hutchison, A. Stobie, and R. H. Wightman, *J. Chem. Soc., Chem. Commun.* 237 (1980).
- 80JCS(CC)917 J. G. Buchanan, M. R. Hamblin, g. R. Sood, and R. H. Wightman, *J. Chem. Soc., Chem. Commun.*, 917 (1980).
- 80JCS(P1)2683 Y. Chapleur and B. Castro, *J. Chem. Soc., Perkin Trans. 1*, 2683 (1980).
- 80JHC1435 C. K. Chu, K. A. Watanabe, and J. J. Fox, *J. Heterocycl. Chem.* **17**, 1435 (1980).
- 80KGS1423 T. N. Sokolova, I. V. Yartseva, and M. N. Preobrazhenskaya, *Khim. Geterotsikl. Soedin.*, 1423 (1980) [*CA* **94**, 84424 (1981)].
- 80MI1 E. Grinsteins, A. Dreimane, E. Liepins, and E. I. Stankevich, *Latv. PSR Zinat. Akad. Vestis, Kim. Ser.*, 722 (1980) [*CA* **95**, 7663 (1981)].
- 80MI2 S. Katoh, T. Sueoka, and S. Yamada, *Insect. Biochem.* **10**, 119 (1980) [*CA* **93**, 66634 (1980)].
- 80MI3 T. Kukushima, in "Methods in Enzymology" (D. B. McCormick and L. D. Wright, eds.), Vol. 66, p. 508. Academic Press, New York, 1980 [*CA* **93**, 65382 (1980)].
- 80MI4 F. Garcia Gonzalez, M. G. Guillen, J. A. G. Perez, and E. R. Galan, *Carbohydr. Res.* **78**, 17 (1980).
- 80MI5 F. Garcia Gonzalez, M. G. Guillen, J. A. G. Perez, and E. R. Galan, *Carbohydr. Res.* **80**, 37 (1980).
- 80MI6 E. H. S. El Ashry, M. A. M. Nassr, and M. Shoukry, *Carbohydr. Res.* **83**, 79 (1980).
- 80MI7 T. N. Sokolova, V. E. Shevchenko, and M. N. Preobrazhenskaya, *Carbohydr. Res.* **83**, 249 (1980).
- 80MI8 M. A. E. Sallam, R. L. Whistler, and J. L. Markley, *Carbohydr. Res.* **87**, 87 (1980).
- 80N610 H. Wachter, A. Hausen, E. Reider, and M. Schweiger, *Naturwissenschaften* **67**, 610 (1980) [*CA* **94**, 61430 (1981)].
- 80TL1013 M. I. Lim, R. S. Klein, and J. J. Fox, *Tetrahedron Lett.* **21**, 1013 (1980).
- 81ACH(106)61 I. F. Szabo, I. Farkas, L. Somsak, and R. Bognar, *Acta Chim. Acad. Sci. Hung.* **106**, 61 (1981) [*CA* **95**, 62576 (1981)].
- 81AQ(C)126 M. Melgarejo Sampedro, C. Rodriguez Melgarejo, and A. Sanchez Rodrigo, *An. Quim, Ser. C* **77**, 126 (1981) [*CA*, **97**, 39285 (1982)].
- 81BBR(100)1377 D. A. Carson and K.-P. Chang, *Biochem. Biophys. Res. Commun.* **100**, 1377 (1981).
- 81CPB629 H. Ogura, M. Sakaguchi, K. Nakata, N. Hida, and H. Takeuchi, *Chem. Pharm. Bull.* **29**, 629 (1981).
- 81CPB1832 H. Ogura, H. Takahashi, and K. Takeda, *Chem. Pharm. Bull.* **29**, 1832 (1981).
- 81FA(36)733 M. De La Fuente, A. Alonso, C. Barriga, and J. Pena, *Farmaco* **36**, 733 (1981).

- 81JHC893 M. Legraverend, E. Bisagni, and J. L. Lhoste, *J. Heterocycl. Chem.* **18**, 893 (1981).
- 81JMC1291 P. Allard, T. Huynh-Dinh, C. Gouyette, J. Igolen, J.-C. Chermann, and F. Barre-Sinoussi, *J. Med. Chem.* **24**, 1291 (1981).
- 81JOC4782 J. H. Cardellina and J. Meinwald, *J. Org. Chem.* **46**, 4782 (1981).
- 81JOC5416 P. A. Jacobi, M. Martinelli, and E. C. Taylor, *J. Org. Chem.* **46**, 5416 (1981).
- 81MI1 E. M. Acton and K. J. Ryan, *Nucleic Acids Symp. Ser.* **9**, 243 (1981) [CA, **96**, 52616 (1982)].
- 81MI2 R. E. Parks, Jr., J. D. Stoekler, C. Cambor, T. M. Savarese, G. W. Crabtree, and S.-H. Chu, in "Molecular Actions and Targets for Cancer Chemotherapeutic Agents" (A. Sartorelli, L. S. Lazo, and J. R. Bertino, eds.), pp. 229-252. Academic Press, New York, 1981.
- 81MI3 S. Matsuura, *Tanpakushitsu Kakusan Koso* **26**, 1394 (1981) [CA **95**, 169019 (1981)].
- 81MI4 T. N. Sokolova, I. V. Yartseva, and M. N. Preobrazhenskaya, *Carbohydr. Res.* **93**, 19 (1981).
- 81MI5 M. A. E. Shaban, R. S. Ali, and S. M. El Badry, *Carbohydr. Res.* **95**, 51 (1981).
- 81TL25 M. Lim and R. Klein, *Tetrahedron Lett.* **22**, 25 (1981).
- 82ACH(109)229 I. F. Szabo, L. Somsak, G. Batta, and I. Karkas, *Acta Chim. Acad. Sci. Hung.* **97**, 229 (1982) [CA **97**, 72697 (1982)].
- 82AJC785 W. L. F. Armarego, P. Waring, and B. Paal, *Aust. J. Chem.* **35**, 785 (1982).
- 82AQ(C)399 M. Melgarejo Sampedro, C. Rodriguez Melgarejo, M. Noguera Montiel, and A. Sanchez Rodrigo, *An. Quim., Ser. C* **78**, 399 (1982) [CA **98**, 161071 (1983)].
- 82BBR(108)349 D. J. Nelson, S. W. Lafon, T. E. Jones, T. Spector, R. L. Berens, and J. J. Marr, *Biochem. Biophys. Res. Commun.* **108**, 349 (1982).
- 82JA1073 A. F. Lewis and L. B. Townsend, *J. Am. Chem. Soc.* **104**, 1073 (1982).
- 82JMC1334 R. J. Goebel, A. D. Adams, P. A. McKernan, B. K. Murray, R. K. Robins, G. R. Revankar, and P. G. Canonico, *J. Med. Chem.* **25**, 1334 (1982).
- 82JOC4633 W.-Y. Ren, M.-I. Lim, B. A. Otter, and R. S. Klein, *J. Org. Chem.* **47**, 4633 (1982).
- 82MI1 J. G. Buchanan and R. H. Wightman, *Top. Antibiot. Chem.* **6**, 229 (1982) [CA **98**, 34845 (1983)].
- 82MI2 J. Wierzchowski and D. Shugar, *Photochem. Photobiol.* **35**, 445 (1982) [CA **97**, 72675 (1982)].
- 82MI3 T. Sugimoto, *Kiyo—Nagoya Daigaku Kyoyobu [Ser.] B* **26**, 53 (1982) [CA **97**, 38698 (1982)].
- 82MI4 M. A. E. Sallam, *Nucleosides Nucleotides* **1**, 297 (1982).
- 82MI5 J. A. Galbis Perez, E. Roman Galan, J. L. Jimenez Requejo, and F. Polo Corales, *Carbohydr. Res.* **102**, 111 (1982).
- 82MI6 L. J. S. Knutsen, R. F. Newton, D. I. C. Scopes, and G. Klinker, *Carbohydr. Res.* **110**, C-5 (1982).
- 82MI7 M. A. El Sekily, S. Mancy, and B. Gross, *Carbohydr. Res.* **110**, 229 (1982).



- 82MI8 M. A. E. Sallam and S. S. Saudi, *J. Carbohydr. Chem.* **1**, 129 (1982).
- 83AAC233 J. D. Berman, L. S. Lee, R. K. Robins, and G. R. Revankar, *Antimicrob. Agents Chemother.* **24**, 233 (1983) [CA **99**, 133327 (1983)].
- 83AX(C)1418 M. D. Estrada, A. Conde, and R. Marquez, *Acta Crystallogr., Sect. C* **C39**, 1418 (1983) [CA **99**, 222764 (1983)].
- 83CJC2721 I. M. Piper, D. B. MacLean, I. Kvarnstrom, and W. A. Szarek, *Can. J. Chem.* **61**, 2721 (1983).
- 83EP79574 M. Viscontini, Eur. Pat. Appl. EP 79574 (1983) [CA **99**, 175478 (1983)].
- 83JCS(CC)601 D. B. MacLean, W. A. Szarek, and I. Kvarnstrom, *J. Chem. Soc., Chem. Commun.*, **601** (1983).
- 83JHC1169 F. Babin, T. Huynh-Dinh, and J. Igolen, *J. Heterocycl. Chem.* **20**, 1169 (1983).
- 83JOC780 M. Lim, W. Ren, B. A. Otter, and R. S. Klein, *J. Org. Chem.* **48**, 780 (1983).
- 83MI1 R. I. Glazer, K. D. Hartman, and M. C. Knode, *Mol. Pharmacol.* **24**, 309 (1983) [CA **99**, 205723 (1983)].
- 83MI2 T. P. Zimmerman, R. D. Deepprose, G. Wolberg, C. R. Stopford, G. S. Duncan, W. H. Miller, R. L. Miller, M.-I. Lim, W.-Y. Ren, and R. S. Klein, *Biochem. Pharmacol.* **32**, 1211 (1983) [CA **99**, 68731 (1983)].
- 83MI3 J. H. Burchenal, B. Leyland-Jones, K. A. Watanabe, R. S. Klein, C. Lopez, and J. J. Fox, in "Nucleosides, Nucleotides and their Biological Applications" (L. L. Rideout, D. W. Henry, and L. M. Beacham, III, eds.), pp. 47-65. Academic Press, New York, 1983.
- 83MI4 G. Cacciapuoti, M. Porcelli, F. Della Ragione, and M. Carteni-Farina, *Bull. Mol. Biol. Med.* **8**, 199 (1983) [CA, **101**, 73043 (1984)].
- 83MI5 P. Rainey, C. E. Garrett, and D. V. Santi, *Biochem. Pharmacol.* **32**, 749 (1983) [CA **98**, 194708 (1983)].
- 83MI6 D. W. Young, *Chem. Biol. Pteridines: Proc. Int. Symp. Pteridines Folic Deriv., Chem., Biol. Clin. Aspects, 7th, 1982*, 321 (1983) [CA **100**, 63797 (1984)].
- 83MI7 D. L. Swartz and H. S. El Khadem, *Carbohydr. Res.* **112**, C-1 (1983).
- 83MI8 M. A. E. Shaban, M. A. M. Nassr, and M. A. M. Taha, *Carbohydr. Res.* **113**, C-16 (1983).
- 83MI9 E. Roman Galan, J. A. Galbis Perez, and M. A. Arevalo Arevalo, *Carbohydr. Res.* **116**, 255 (1983).
- 83MI10 M. A. El Sekily and S. Mancy, *Carbohydr. Res.* **124**, 97 (1983).
- 83MI11 J. G. Buchanan, *Prog. Chem. Org. Nat. Prod.* **44**, 243 (1983) [CA **100**, 51895 (1984)].
- 83PNA288 P. Rainey and D. V. Santi, *Proc. Natl. Acad. Sci. U.S.A.* **80**, 288 (1983) [CA **98**, 122539 (1983)].
- 84AAC292 J. J. Marr, R. L. Berens, N. K. Cohn, D. J. Nelson, and R. S. Klein, *Antimicrob. Agents Chemother.* **25**, 292 (1984) [CA **100**, 150632 (1984)].
- 84ABC2753 N. Morita, Y. Daido, and M. Takagi, *Agric. Biol. Chem.* **48**, 2753 (1984) [CA **102**, 185357 (1985)].

- 84AX(C)898 M. D. Estrada, A. Conde, and R. Marquez, *Acta Crystallogr., Sect. C* **C40**, 898 (1984) [*CA* **101**, 15364 (1984)].
- 84H(22)345 C. K. Chu, *Heterocycles* **22**, 345 (1984).
- 84JAP(K)84/184176 T. Kato, Jpn. Kokai Pat. 84/184176 (1984) [*CA* **102**, 96005 (1985)].
- 84JCS(P1)229 L. J. S. Knutsen, B. D. Judkins, W. L. Mitchell, R. F. Newton, and D. I. C. Scopes, *J. Chem. Soc., Perkin Trans. I*, 229 (1984).
- 84JCS(P1)553 N. Katagiri, K. Takashima, T. Haneda, and T. Kato, *J. Chem. Soc., Perkin Trans. I*, 553 (1984).
- 84JCS(P1)2367 J. G. Buchanan, N. K. Saxena, and R. H. Wightman, *J. Chem. Soc., Perkin Trans. I*, 2367 (1984).
- 84JCS(P1)2421 S. Bose, S. Kumar, R. J. H. Davis, S. K. Sethi, and J. A. McCloskey, *J. Chem. Soc., Perkin Trans. I*, 2421 (1984).
- 84JHC389 C. K. Chu, *J. Heterocycl. Chem.* **21**, 389 (1984).
- 84JHC505 H. Griengl and G. Gunzl, *J. Heterocycl. Chem.* **21**, 505 (1984).
- 84JHC697 W. L. Mitchell, M. L. Hill, R. F. Newton, P. Ravenscroft, and D. I. C. Scopes, *J. Heterocycl. Chem.* **21**, 697 (1984).
- 84JHC1865 B. G. Ugarkar, G. R. Revankar, and R. K. Robins, *J. Heterocycl. Chem.* **21**, 1865 (1984).
- 84JMC924 S. W. Schneller, R. D. Thompson, J. G. Cory, R. A. Olsson, E. D. De Clercq, T.-K. Kim, and P. K. Chiang, *J. Med. Chem.* **27**, 924 (1984).
- 84JOC528 E. M. Acton and K. J. Ryen, *J. Org. Chem.* **49**, 528 (1984).
- 84JOC1534 I. Maeba, F. Usami, and H. Furukawa, *J. Org. Chem.* **49**, 1534 (1984).
- 84LA1815 M. Kappel, R. Mengel, and W. Pfeleiderer, *Liebigs Ann. Chem.*, 1815 (1984).
- 84MI1 M. Y. Chu, L. B. Zuckerman, S. Sato, G. W. Crabtree, M. A. Bogden, M.-I. Lim, and R. S. Klein, *Biochem. Pharmacol.* **33**, 1229 (1984) [*CA* **101**, 347 (1984)].
- 84MI2 I. Ebels, H. P. J. M. Noteborn, A. De Moree, and M. G. M. Balemans, *Biochem. Clin. Aspects Pteridines* **3**, 127 (1984) [*CA* **102**, 218964 (1985)].
- 84MI3 N. Katagiri, T. Haneda, and N. Takahashi, *Nucleic Acids Symp. Ser.* **15**, 37 (1984) [*CA* **104**, 51056 (1986)].
- 84MI4 M. Viscontini, in "Biochemical and Clinical Aspects of Pteridines" (W. Pfeleiderer, H. Wachter, and H. C. Curtius, eds.), Vol. 3, pp. 19-33. de Gruyter, Berlin and New York, 1984 [*CA* **102**, 221106 (1985)].
- 84MI5 M. A. E. Sallam and S. M. E. Abdel Megid, *Carbohydr. Res.* **125**, 85 (1984).
- 84MI6 J. A. Galbis Perez, P. A. Bravo, F. R. Vincente, J. I. F. Garcia-Hierro, and J. Fuentes Mota, *Carbohydr. Res.* **126**, 91 (1984).
- 84MI7 J. A. Galbis Perez, J. C. Palacios Albarran, J. L. Jimenez Requejo, M. Avalos Gonzalez, and J. M. Fernandez-Bolanos, *Carbohydr. Res.* **129**, 131 (1984).
- 84MI8 J. A. Galbis Perez, J. C. Palacios Albarran, J. L. Jimenez Requejo, M. Avalos Gonzalez, and J. M. Fernandez-Bolanos, *Carbohydr. Res.* **131**, 71 (1984).
- 84MI9 M. A. EL Sekily, S. Mancy, and K. Fahmy, *Carbohydr. Res.* **133**, 324 (1984).

- 84MI10 C. K. Chu, F. M. El-Kabbani, and B. B. Thompson, *Nucleosides Nucleotides* **3**, 1 (1984) [CA **102**, 185353 (1985)].
- 84MI11 F. Fuentes Mota, P. Areces Bravo, F. Rebolledo Vincente, J. I. F. Garcia-Hierro, and J. A. Galbis Perez, *Nucleosides Nucleotides* **3**, 115 (1984).
- 84MI12 B. G. Ugarkar, R. K. Robins, and G. R. Revankar, *Nucleosides Nucleotides* **3**, 233 (1984).
- 84T119 J. G. Buchanan, D. Smith, and R. H. Wightman, *Tetrahedron* **40**, 119 (1984).
- 85AAC33 W. R. Fish, J. J. Marr, R. L. Berens, D. L. Looker, D. J. Nelson, S. W. LaFon, and A. E. Balber, *Antimicrob. Agents Chemother.* **27**, 33 (1985) [CA **102**, 105763 (1985)].
- 85ABC3279 N. Morita, K. Inoue, and M. Takagi, *Agric. Biol. Chem.* **49**, 3279 (1985) [CA **105**, 79263 (1986)].
- 85AQ(C)49 J. Fernandez-Bolanos, I. Robina Ramirez, and J. Fuentes Mota, *An. Quim., Ser. C* **81**, 49 (1985) [CA **105**, 24553 (1986)].
- 85AX(C)277 C. F. Conde, M. Millan, A. Conde, and R. Marquez, *Acta Crystallogr., Sect. C* **C41**, 277 (1985) [CA **102**, 123474 (1985)].
- 85AX(C)1658 C. F. Conde, M. Millan, A. Conde, and R. Marquez, *Acta Crystallogr., Sect. C* **C41**, 1658(1985) [CA **104**, 26983 (1986)].
- 85CPB2671 N. Katagiri, T. Haneda, R. Niwa, and T. Kato, *Chem. Pharm. Bull.* **33**, 2671 (1985).
- 85GEP(D)216938 K. Peseke, I. Farkas, and A. Kerber, Ger. (East) DD 216,938 (1985) [CA **104**, 51073 (1985)].
- 85HCA1639 B. Schircks, J. H. Bieri, and M. Viscontini, *Helv. Chim. Acta* **68**, 1639 (1985).
- 85JBC(260)9660 S. W. LaFon, D. J. Nelson, R. L. Berens, and J. J. Marr, *J. Biol. Chem.* **260**, 9660 (1985).
- 85JCS(P1)621 L. J. S. Knutsen, B. D. Judkins, R. F. Newton, D. I. C. Scopes, and G. Klinkert, *J. Chem. Soc., Perkin Trans. 1*, 621 (1985).
- 85JCS(P1)1425 J. G. Buchanan, A. Millar, R. H. Wightman, and M. R. Harnden, *J. Chem. Soc., Perkin Trans. 1*, 1425 (1985).
- 85JCS(P1)2087 G. J. Ellames, I. M. Newington, and A. Stobie, *J. Chem. Soc., Perkin Trans. 1*, 2087 (1985).
- 85JMC1096 A. Rosowsky, C. V. Solan, and L. J. Gudas, *J. Med. Chem.* **28**, 1096 (1985).
- 85MC1740 J. A. Secrist, III, A. T. Shortnacy, and J. A. Montgomery, *J. Med. Chem.* **28**, 1740 (1985).
- 85JOC1741 J. W. Hennen, B. C. Hinshaw, T. A. Riley, S. G. Wood, and R. K. Robins, *J. Org. Chem.* **50**, 1741 (1985).
- 85MI1 B. A. Abd. El-Naby, M. M. Essa, and M. A. E. Shaban, *Surf. Technol.* **26**, 165 (1985).
- 85MI2 L. Sarih, B. Agoutin, O. Lecoq, D. Weill, P. Jullien, and T. Heyman, *Virology* **145**, 171 (1985) [CA **103**, 98414 (1985)].
- 85MI3 L. B. Townsend, V. G. Beylin, and L. L. Wotring, *Nucleosides Nucleotides* **4**, 29 (1985).
- 85MI4 S. Ghisla, H. C. Curtius, D. Heintel, T. Kuster, W. Leimbacher, and A. Niederwieser, *Biochem. Clin. Aspects Pteridines* **4**, 143 (1985) [CA **105**, 74433 (1986)].
- 85MI5 S. Matsuura, T. Sugimoto, S. Murata, Y. Sugawara, and H. I.

- Iwasaki, *J. Biochem. (Tokyo)* **98**, 1341 (1985) [*CA* **104**, 30828 (1986)].
- 85MI6 T. Nagatsu, *Gendai Igaku* **33**, 197 (1985) [*CA* **104**, 127443 (1986)].
- 86MI7 J. A. Galbis Perez, J. L. Jimenez Requejo, J. C. Palacios Albarran, and M. Avalos Gonzalez, *Carbohydr. Res.* **138**, 153 (1985).
- 85MI8 I. Maeba, T. Ishikawa, and H. Furukawa, *Carbohydr. Res.* **140**, 332 (1985).
- 85MI9 I. Maeba, F. Usami, T. Ishikawa, H. Furukawa, T. Ishida, and M. Inoue, *Carbohydr. Res.* **141**, 1 (1985).
- 85MI10 J. A. Galbis Perez, R. B. Caballero, and A. C. Ventula, *Carbohydr. Res.* **143**, 129 (1985).
- 85TL5477 A. Dondoni, M. Fagnolo, A. Medici, and P. Pedrini, *Tetrahedron Lett.* **26**, 5477 (1985).
- 85TL5785 S. Niitsuma, K. Kato, T. Takita, and H. Umezawa, *Tetrahedron Lett.* **26**, 7585 (1985).
- 85USP4550109 K. Folkers and K. P. Laesecke, U.S. Pat. 4,550,109 (1986) [*CA* **104**, 95488 (1986)].
- 86AAC181 J. M. S. Bartlett, J. J. Marr, S. F. Queener, R. S. Klein, and J. W. Smith, *Antimicrob. Agents Chemother.* **30**, 181 (1986).
- 86AQ(C)11 J. A. Galbis Perez, J. L. Jimenez Requejo, J. C. Palacios Albarran, M. Avalos Gonzalez, and J. Fernandez-Bolanos, *An. Quim., Ser. C* **82**, 11 (1986) [*CA* **107**, 7477 (1987)].
- 86AX(C)454 M. D. Estrada, A. Conde, and R. Marquez, *Acta Crystallogr. Sect. C* **C42**, 454 (1986) [*CA* **104**, 178083 (1986)].
- 86AX(C)1659 M. D. Estrada, A. Conde, and R. Marquez, *Acta Crystallogr. Sect. C* **C42**, 1659 (1986) [*CA* **105**, 236253 (1986)].
- 86EP191335 H. Sakai and T. Kanai, Eur. Pat. Appl. EP 191,335 (1986) [*CA* **111**, 114973 (1989)].
- 86HCA210 S. Antoulas, R. Prewo, J. H. Bieri, and M. Viscontinini, *Helv. Chim. Acta* **69**, 210 (1986).
- 86JAP(K)86/260094 H. Umezawa, S. Niitsuma, K. Kato, and T. Takita, Jpn. Kokai Pat. 86/260,094 (1986) [*CA* **106**, 138736 (1987)].
- 86JAP(K)86/293982 Kanegafuchi Chemical Industry Co. Ltd., Jpn Kokai Pat. 86/293,982 [*CA* **107**, 7009 (1987)].
- 86JCS(P1)393 R. C. Cookson, P. J. Dudfield, and D. I. C. Scopes, *J. Chem. Soc., Perkin Trans. 1*, 393 (1986).
- 86JCS(P1)1267 J. G. Buchanan, D. Smith, and R. H. Wightman, *J. Chem. Soc., Perkin Trans. 1*, 1267 (1986).
- 86JHC349 C. K. Chu, J. J. Suh, M. Mesbah, and S. J. Cutler, *J. Heterocycl. Chem.* **23**, 349 (1986).
- 86JMC2231 K. Ramasamy, B. G. Ugarkar, P. A. McKernan, R. K. Robins, and G. R. Revankar, *J. Med. Chem.* **29**, 2231 (1986).
- 86JOC1058 T. L. Cupps, D. S. Wise, Jr., and L. B. Townsend, *J. Org. Chem.* **51**, 1058 (1986).
- 86MI1 J. D. Stoeckler, J. B. Ryden, R. E. Parks, Jr., M.-Y. Chu, M.-I. Lim, W.-Y. Ren, and R. S. Klein, *Cancer Res.* **46**, 1774 (1986) [*CA* **105**, 17922 (1986)].
- 86MI2 R. L. Berens and J. J. Marr, *Biochem. Pharmacol.* **35**, 4191 (1986) [*CA* **106**, 29969 (1987)].

- 86MI3 E. S. H. El Ashry, M. A. Rahman, G. H. Labib, A. M. El-Massry, and A. Mofti, *Carbohydr. Res.* **152**, 339 (1986).
- 86MI4 H. S. El Khadem and J. Kawai, *Carbohydr. Res.* **153**, 271 (1986).
- 86MI5 B. A. Abd-El-Naby, M. A. M. Nassr, and S. Hamdona, *Bull. Electrochem.* **2**, 71 (1986).
- 86MI6 S. Matsuura, S. Murata, T. Sugimoto, M. Sawada, and T. Nagatsu, *Chem. Express* **1**, 403 (1986) [*CA* **107**, 77497 (1987)].
- 86MI7 M. A. E. Sallam, H. M. El Nahas, S. M. E. Abdel Megid, and J. Kozlowski, *J. Carbohydr. Chem.* **5**, 33 (1986).
- 86MI8 M. A. E. Sallam and S. M. E. Abdel Megid, *J. Carbohydr. Chem.* **5**, 49 (1986).
- 86MI9 J. Kobe, B. Brdar, and J. Soric, *Nucleosides Nucleotides* **5**, 135 (1986).
- 86MI10 S. H. Chu, L. Ho, E. Chu, T. Savarese, Z. H. Chen, E. C. Rowe, and M. Y. W. Chu, *Nucleosides Nucleotides* **5**, 185 (1986).
- 86MI11 K. V. B. Rao, W. Y. Ren, J. H. Burchenal, and R. S. Klein, *Nucleosides Nucleotides* **5**, 539 (1986).
- 86NAR1747 K. G. Upadhyaya, Y. S. Sanghvi, R. K. Robins, G. R. Revankar, and B. G. Ugarkar, *Nucleic Acids Res.* **14**, 1747 (1986) [*CA* **105**, 43246 (1986)].
- 86PHA548 K. Peseke, I. Farkas, and A. Kerber, *Pharmazie* **41**, 548 (1986).
- 86SC35 F. Ricciardi and M. M. Joulie, *Synth. Commun.* **16**, 35 (1986).
- 86TL815 Bhattacharya, K. Birendra, M. I. Lim, B. A. Otter, and R. S. Klein, *Tetrahedron Lett.* **27**, 815 (1986).
- 87AAC111 J. D. Berman, W. L. Hanson, J. K. Lovelace, V. B. Waits, J. E. Jackson, W. L. Champan, Jr., and R. S. Klein, *Antimicrob. Agents Chemother.* **31**, 111 (1987) [*CA* **106**, 95635 (1987)].
- 87AAC1406 C. J. Bacchi, R. L. Berens, H. C. Nathan, R. S. Klein, I. A. Elegbe, K. V. B. Rao, P. P. McCann, and J. J. Marr, *Antimicrob. Agents Chemother.* **31**, 1406 (1987) [*CA* **107**, 168325 (1987)].
- 87E950 A. Aiello, E. Fattorusso, S. Magno, G. Misuracea, and E. Novelino, *Experientia* **43**, 950 (1987).
- 87JCS(CC)680 A. P. Kozikowski and X. M. Cheng, *J. Chem. Soc., Chem. Commun.*, 680 (1987).
- 87JCS(P1)581 M. J. Diane, J. Galan, A. Gomez-Sanchez, A. Lopez-Castro, and M. Rico, *J. Chem. Soc., Perkin Trans. 1*, 581 (1987).
- 87MI1 J. W. Smith, S. Bartlett, S. F. Queener, M. M. Durkin, M. A. Jay, M. T. Hull, R. S. Klein, and J. J. Marr, *Diagn. Microbiol. Infect. Dis.* **7**, 113 (1987) [*CA* **107**, 190404 (1987)].
- 87MI2 M. Avalos Gonzalez, J. L. Jimenez Requeio, J. C. Palacios Albaran, M. D. Ramos Montero, and J. A. Galbis Perez, *Carbohydr. Res.* **161**, 49 (1987).
- 87MI3 J. A. Galbis Perez, F. Zamora Mata, and P. Turmo Fernandez, *Carbohydr. Res.* **163**, 132 (1987).
- 87MI4 E. S. H. El Ashry, N. Rashed, and A. Moussad, *J. Carbohydr. Chem.* **6**, 599 (1987).
- 87MI5 B. Golankiewicz, J. Zeidler, and E. De Clercq, *Nucleosides Nucleotides* **6**, 663 (1987).
- 87MIP1 T. Kato and N. Katagiri, *Can. Pat.* 1,228,852 (1987) [*CA* **109**, 38193 (1988)].

- 87S879 P. Serafinowski, *Synthesis*, 879 (1987).
- 87USP4656260 K. Kato and N. Katagiri, U.S. Pat. 4,656,260 (1987) [CA **107**, 218104 (1987)].
- 88BBR(153)715 H. C. Curtius, T. Kuster, A. Matasovic, N. Blau, and J.-L. Dhondt, *Biochem. Biophys. Res. Commun.* **153**, 715 (1988) [CA **109**, 90743 (1988)].
- 88JOC1401 I. Maeba, T. Kakeuchi, T. Iijima, and H. Furukawa, *J. Org. Chem.* **53**, 1401 (1988).
- 88JOC2413 G. V. Ullas, C. K. Chu, M. K. Ahn, and Y. Kosugi, *J. Org. Chem.* **53**, 2413 (1988).
- 88MI1 M. A. El Sekily and S. Mancy, *Pak. J. Sci. Ind. Res.* **31**, 616 (1988) [CA **110**, 193282 (1989)].
- 88MI2 A. K. Singh and R. S. Klein, *J. Labelled Compol. Radiopharm.* **25**, 1219 (1988) [CA **110**, 193300 (1989)].
- 88MI3 T. Nagatsu, S. Matsuura, and T. Sugimoto, *Bitamin* **62**, 385 (1968) [CA **109**, 166088 (1988)].
- 88MI4 J.-L. Dhondt, P. Guibaud, M. O. Rolland, C. Dorche, S. Andre, G. Forzy, and J. M. Hayte, *Eur. J. Pediatr.* **147**, 153 (1988).
- 88MI5 M. Blaskovics and T. A. Guidici, *N. Engl. J. Med.* **319**, 1611 (1988).
- 88MI6 J. Fuentes Mota, F. Garcia-Hierro, P. Areces Bravo, F. Rebolledo Vincente, and J. A. Galbis Perez, *Nucleosides Nucleotides* **7**, 457 (1988).
- 88MI7 A. Rosowski, M. Ghoshal, and V. C. Solan, *Carbohydr. Res.* **176**, 47 (1988).
- 88MI8 J. A. Galbis Perez, P. Areces Bravo, F. Rebolledo Vincente, J. I. F. Garcia-Hierro, and J. Fuentes Mota, *Carbohydr. Res.* **176**, 97 (1988).
- 88MI9 J. Beck, F. Ledl, and T. Severin, *Carbohydr. Res.* **177**, 240 (1988).
- 88MI10 Y. El Kilany, N. Rashed, M. Mansour, M. Abdel Rahman, and E. S. El Ashry, *Carbohydr. Res.* **7**, 199 (1988).
- 88TL3537 S. P. Rao, K. V. B. Rao, B. A. Otter, R. S. Klein, and W. Y. Ren, *Tetrahedron Lett.* **29**, 3537 (1988).
- 89BBR(161)910 S. Neidle, L. Urpi, P. Serafinowski, and D. Whitby, *Biochem. Biophys. Res. Commun.* **161**, 910 (1989).
- 89BCJ2701 M. A. E. Shaban and M. A. M. Taha, *Bull. Chem. Soc. Jpn.* **62**, 2701 (1989).
- 89EP318926 M. Kurono, T. Suzuki, T. Ogasawara, N. Ohishi, and K. Yagi, *Eur. Pat. Appl.* EP 318,926 (1989) [CA **112**, 118545 (1990)].
- 89HCA271 F. Gasparini and P. Vogel, *Helv. Chim. Acta* **72**, 271 (1989).
- 89JA285 E. C. Taylor and L. A. Reiter, *J. Am. Chem. Soc.* **111**, 285 (1989).
- 89JAP(K)89/221380 H. Kikuchi and K. Mori, *Jpn. Kokai Pat.* 89/221,380 (1989) [CA **112**, 197978 (1990)].
- 89JCS(CC)930 R. D. Clark, S. M. Jahangir, and J. R. Kern, *J. Chem. Soc., Chem. Commun.*, 930 (1989).
- 89JCS(P1)649 I. Maeba, T. Takeuchi, T. Iijima, K. Kitaori, and H. Muramatsu, *J. Chem. Soc., Perkin Trans. I*, 649 (1989).
- 89JCS(P1)925 J. G. Buchanan, M. Harrison, and R. H. Wightman, *J. Chem. Soc., Perkin Trans. I*, 925 (1989).
- 89JCS(P1)2401 F. J. Lopez-Herrera, M. S. Pino Gonzalez, and R. Pabon Aguas, *J. Chem. Soc., Perkin Trans. I*, 2401 (1989).

- 89JHC991 F. Dennin, O. Rousseaux, D. Blondeau, and H. Sliwa, *J. Heterocycl. Chem.* **29**, 991 (1989).
- 89JMC1547 Y. Kang, S. B. Larson, R. K. Robins, and G. R. Revankar, *J. Med. Chem.* **32**, 1547 (1989).
- 89JOC3927 I. Maeba, K. Kitaori, and C. Ito, *J. Org. Chem.* **54**, 3927 (1989).
- 89LA1267 K. Mori and H. Kikuchi, *Liebigs Ann. Chem.*, 1267 (1989).
- 89MI1 S. Katoh, T. Sueoka, S. Matsuura, and T. Sugimoto, *Life Sci.* **45**, 2561 (1989) [*CA* **112**, 52768 (1990)].
- 89MI2 M. Viscontini, and M. Bosshard, *Chem. Biol. Pteridines, Proc. Int. Symp. Pteridines Folic Acid Deriv.*, 9th, 1989, 73 (1989) [*CA* **115**, 92806 (1991)].
- 89MI3 V. C. Solan and A. Rosowsky, *Nucleosides Nucleotides* **8**, 1369 (1989).
- 89MI4 M. Avalos Gonzalez, P. Cintas Moreno, I. M. Gomez Monterrey, J. L. Jimenez Requejo, J. C. Palacios Albarran, F. Rebollo Vicente, and J. Fuentes Mota, *Carbohydr. Res.* **187**, 1 (1989).
- 89MI5 H. S. El Khadem, J. Kawai, and D. L. Swartz, *Carbohydr. Res.* **189**, 149 (1989).
- 89MI6 R. F. Helm and J. J. Karchesy, *J. Carbohydr. Chem.* **8**, 687 (1989).
- 89MI7 L. Awad, A. Mousaad, and E. S. H. El Ashry, *J. Carbohydr. Chem.* **8**, 765 (1989).
- 89MI8 A. Mousaad, L. Awad, N. El Shimy, and E. S. H. El Ashry, *J. Carbohydr. Chem.* **8**, 733 (1989).
- 90BBR(172)1060 H.-Ch. Curtius, C. Adler, I. Rebrin, C. W. Heizmann, and S. Ghisla, *Biochem. Biophys. Res. Commun.* **172**, 1060 (1990).
- 90HCA337 M. Viscontini and R. Bosshard, *Helv. Chim. Acta* **73**, 337 (1990).
- 90HCA1058 C. Adler, H.-C. Curtius, S. Datta, and M. Viscontini, *Helv. Chim. Acta* **73**, 1058 (1990).
- 90HCA1064 M. Viscontini, *Helv. Chim. Acta* **73**, 1064 (1990).
- 90JA9668 S. Ikegami, H. Isomura, N. Tsuchimori, Y. T. Osano, T. Hayase, T. Yugami, H. Ohkishi, and T. Matsuzaki, *J. Am. Chem. Soc.* **112**, 9668 (1990).
- 90JBC(265)3923 H.-C. Curtius, A. Matasovic, G. Schoedon, T. Kuster, P. Guibaud, T. A. Giudici, and N. Blau, *J. Biol. Chem.* **265**, 3923 (1990).
- 90JCS(P1)67 I. Maeba, K. Kitaori, Y. Itaya, and C. Ito, *J. Chem. Soc., Perkin Trans. 1*, 67 (1990).
- 90JMC2750 N. S. Girgis, M. A. Michael, D. F. Smee, H. A. Alghamandan, R. K. Robins, and H. B. Cottam, *J. Med. Chem.* **33**, 2750 (1990).
- 90JOC2451 F. Gasparini and P. Vogel, *J. Org. Chem.* **55**, 2451 (1990).
- 90MI1 M. A. E. Shaban and M. A. M. Taha, *Int. J. Chem.* **1**, 59 (1990).
- 90MI2 M. A. E. Shaban and M. A. M. Taha, *Int. J. Chem.* **1**, 77 (1990).
- 90MI3 R. Klein, R. Thiery, and I. Tatischeff, *Eur. J. Biochem.* **187**, 665 (1990).
- 90MI4 J. Kovacs, I. Pinter, A. Messmer, G. Toth, U. Lendering, and P. Koell, *Carbohydr. Res.* **198**, 358 (1990).
- 90MI5 P. Areces Bravo, J. I. Fernandez Garcia Hierro, J. Fuentes Mota, and J. A. Galbis Perez, *Carbohydr. Res.* **198**, 363 (1990).
- 90MI6 M. A. E. Shaban and M. A. M. Taha, *Carbohydr. Res.* **203**, 330 (1990).
- 90MI7 S. A. Patil, B. A. Otter, and R. S. Klein, *Nucleosides Nucleotides* **9**, 937 (1990).

- 90MI8 B. K. Bhattacharya, B. A. Otter, R. L. Berens, and R. S. Klein, *Nucleosides Nucleotides* **9**, 1021 (1990).
- 90S411 P. Serafinowski, *Synthesis*, 411 (1990).
- 91H(32)1955 Y. Ito, C. Ito, and I. Maeba, *Heterocycles* **32**, 1955 (1991).
- 91JCS(P1)195 J. G. Buchanan, D. A. Craven, R. H. Wightman, and M. R. Harn-  
den, *J. Chem. Soc., Perkin Trans. 1*, 195 (1991).
- 91JMC1951 R. Zou, V. G. Beylin, M. P. Groziak, L. L. Wotring, and L. B.  
Townsend, *J. Med. Chem.* **34**, 1951 (1991).
- 91JOC5466 M. Cornia, G. Casiraghi, and L. Zetta, *J. Org. Chem.* **56**, 5466  
(1991).
- 91MI1 M. M. El Sadek, *Alexandria J. Pharm. Sci.* **5**, 234 (1991) [*CA* **116**,  
214824 (1992)].
- 91MI2 G. Sahin, *Biyokim. Derg.* **16**, 77 (1991) [*CA* **118**, 207590 (1993)].
- 91MI3 G. Katzenmeier, B. Schwarzkopf, Le Van Quang, C. Schmid, and  
A. Bacher, *Pteridines* **2**, 169 (1991) [*CA* **116**, 194033 (1992)].
- 91MI4 S. Takikawa and S. Matsuura, *Pteridines* **2**, 151 (1991) [*CA* **118**,  
38660 (1993)].
- 91MI5 G. J. Fernandez-Bolanos Guzman, S. Garcia Rodriquez, J.  
Fernandez-Bolanos, M. J. Diane, and A. Lopez-Castro, *Carbo-  
hydr. Res.* **210**, 125 (1991).
- 91MI6 J. Kovacs, I. Pinter, U. Lendering, and P. Koll, *Carbohydr. Res.*  
**210**, 155 (1991).
- 91MI7 P. Areces M. Avalos, R. Babiano, L. Gonzalez, J. L. Jime-  
nez, J. C. Palacios, and M. D. Pilo, *Carbohydr. Res.* **222**, 99  
(1991).
- 91MI8 R. F. Helm and J. J. Karchesy, *J. Carbohydr. Chem.* **10**, 113 (1991).
- 91MI9 M. A. E. Shaban and M. A. M. Taha, *J. Carbohydr. Chem.* **10**,  
757 (1991).
- 91MI10 Y. S. Sanghvi, S. B. Larson, D. F. Smee, G. R. Revankar, and  
R. K. Robins, *Nucleosides Nucleotides* **10**, 1417 (1991).
- 91TL3297 M. S. Solomon and P. B. Hopkins, *Tetrahedron Lett.* **32**, 3297  
(1991).
- 91TL3377 H. Togo, M. Fujii, T. Ikuma, and M. Yokoyama, *Tetrahedron Lett.*  
**32**, 3377 (1991).
- 91TL6559 H. Togo, M. Aoki, and M. Yokohama, *Tetrahedron Lett.* **32**,  
6559 (1991).
- 92BCJ546 A. Mousaad, H. Abdel Hamid, A. El Nemr and E. S. H. El Ashry,  
*Bull. Chem. Soc. Jpn.* **65**, 546 (1992).
- 92CHC1555 Z. Czarnocki, D. Suh, D. B. MacLean, P. G. Hultin, and  
W. A. Szarek, *Can. J. Chem.* **70**, 1555 (1992).
- 92CL1673 H. Togo, S. Ishigami, and M. Yokoyama, *Chem. Lett.*, 1673 (1992).
- 92H(34)569 M. Hayashi, A. Araki, and I. Maeba, *Heterocycles* **34**, 569 (1992).
- 92H(34)955 Y. Ito, M. Wakimura, C. Ito, and I. Maeba, *Heterocycles* **34**,  
955 (1992).
- 92H(34)2131 Y. Ito, M. Wakimura, C. Ito, and I. Maeba, *Heterocycles* **34**,  
2131 (1992).
- 92HCA1237 C. Alder, H.-C. Curtius, E. Wetzel, M. Viscontini, T. A. Giudici,  
M. Blaskovics, M. O. Rolland, and P. Guibaud, *Helv. Chim.  
Acta* **75**, 1237 (1992).
- 92JA668 B. A. Otter, S. A. Patil, R. S. Klein, and S. E. Ealick, *J. Am. Chem.  
Soc.* **114**, 668 (1992).



- 92JMC4576 Serafinowski, E. Dorland, K. R. Harrap, J. Balzarini, and E. De Clercq, *J. Med. Chem.* **35**, 4576 (1992).
- 92JOC4690 H.-C. Zhang and G. D. Daves, Jr., *J. Org. Chem.* **57**, 4690 (1992).
- 92MI1 S. Ikegami, H. Isomura, N. Tsuchimori, K. Hamada, H. Kobayashi, Y. Kojima, Y. T. Osano, S. Kumazawa, and T. Matsuzaki, *Anal. Sci.* **8**, 897 (1992) [*CA* **118**, 124946 (1993)].
- 92MI2 R. Klein, *Anal. Biochem.* **203**, 134 (1992) [*CA* **117**, 22641 (1992)].
- 92MI3 L. Somogyi, *Carbohydr. Res.* **229**, 89 (1992).
- 92MI4 J. Fernandez Bolanos Guzman, T. Skrydstrup, A. Lopez-Castro, Ma J. Dıanez Millan, and Ma D. E. de Oya, *Carbohydr. Res.* **237**, 303 (1992).
- 92MI5 T. Nagatsu, H. Ichise, K. Chitani, and S. Kato, *Bitamin* **66**, 661 (1992) [*CA* **122**, 126262 (1995)].
- 92MI6 K. V. B. Rao, R. S. Klein, M. S. P. Sarma, and B. A. Otter, *Nucleosides Nucleotides* **11**, 61 (1992).
- 92MIP1 G. R. Revankar, M. E. Hogan, T. S. Rao, and H. N. Shroff, *PCT Int. Appl. WO* 92/21,690 [*CA* **119**, 203763 (1993)].
- 92SL676 P. Pechy, F. Gasparini, and P. Vogel, *Synlett*, 676 (1992).
- 92T7965 M. Zlicar, B. Stanovnick, and M. Tisler, *Tetrahedron* **48**, 7965 (1992).
- 92T10637 V. Jeanneret, F. Gasparini, P. Pechy, and P. Vogel, *Tetrahedron* **48**, 10637 (1992).
- 92TL7575 E. Vismara, G. Torri, N. Pastori, and M. Marchiandi, *Tetrahedron Lett.* **33**, 7575 (1992).
- 92ZPC1601 S. Ogiwara, T. Nagatsu, R. Teradaira, K. Fujita, and T. Sugimoto, *Biol. Chem. Hoppe-Seyler* **373**, 1061 (1992) [*CA* **118**, 77623 (1993)].
- 93FA231 B. Stanovnik, B. Jelen, and M. Zlicar, *Farmaco* **48**, 231 (1993).
- 93GEP(D)4308739 H. Rokos, Ger. DE 4,308,739 (1993) [*CA* **121**, 152790 (1994)].
- 93H(36)961 N. Rashed, H. Abdel Hamid, and M. M. Shoukry, *Heterocycles* **36**, 961 (1993).
- 93H(36)2591 I. Maeba, M. Wakimura, Y. Ito, and C. Ito, *Heterocycles* **36**, 2591 (1993).
- 93H(36)2805 I. Maeba, Y. Ito, M. Wakimura, and C. Ito, *Heterocycles* **36**, 2805 (1993).
- 93JA2504 M. Namikoshi, W. W. Carmichael, R. Sakai, E. A. Jareserijman, A. M. Kaup, and K. L. Rinehart, *J. Am. Chem. Soc.* **1115**, 2504 (1993).
- 93JCS(P1)2417 H. Togo, M. Aoki, T. Kuramochi, and M. Yokoyama, *J. Chem. Soc., Perkin Trans. 1*, 2417 (1993).
- 93JHC(30)509 S. A. Patil, B. A. Otter, and R. S. Klein, *J. Heterocycl. Chem.* **30**, 509 (1993).
- 93JHC(30)1209 M. Zlicar, B. Stanovnik, and M. Tisler, *J. Heterocycl. Chem.* **30**, 1209 (1993).
- 93JHC(31)1213 M. MacCoss, L. C. Meurer, K. Hoogesteen, J. P. Springer, G. Koo, L. B. Peterson, R. L. Tolman, and E. Emini, *J. Heterocycl. Chem.* **31**, 1213 (1993).
- 93JMC1024 J. W. Chern, H. Y. Lee, C. S. Chen, D. S. Shewach, P. E. Daddona, and L. B. Townsend, *J. Med. Chem.* **36**, 1024 (1993).
- 93JOC959 E. Vismara, A. Donna, F. Minisci, A. Naggi, N. Pastori, and G. Torri, *J. Org. Chem.* **58**, 959 (1993).

- 93JOC5181 H. Wamhoff, R. Berressem, and M. Nieger, *J. Org. Chem.* **58**, 5181 (1993).
- 93MI1 M. A. El Sekily and S. Mancy, *Arabian J. Sci. Eng.* **18**, 405 (1993) [CA **120**, 323400 (1994)].
- 93MI2 R. Hashimoto, *Gendai Igaku* **41**, 5 (1993) [CA **120**, 103423 (1994)].
- 93MI3 T. Hariu, E. Okamoto, M. Arai, and M. Goto, *Pteridines* **4**, 63 (1993) [CA **120**, 192096 (1994)].
- 93MI4 J. B. Taylor and P. O. Kennewell, "Modern Medicinal Chemistry." Ellis Horwood, New York, 1993.
- 93MI5 M. J. Diane, M. D. Estrada, and A. Castro-Lopez, *Carbohydr. Res.* **242**, 265 (1993).
- 93MI6 N. Rashed, H. Abdel Hamid, and E. S. H. El Ashey, *Carbohydr. Res.* **243**, 399 (1993).
- 93MI7 L. A. Ciszewski, P. Lipka, W. Y. Ren, and K. A. Watanabe, *Nucleosides Nucleotides* **12**, 487 (1993).
- 93T2655 M. Avalos, R. Babiano, P. Cintas, J. L. Jimenez, J. C. Palacios, and C. Valencia, *Tetrahedron* **49**, 2655 (1993).
- 93T2676 M. Avalos, R. Babiano, P. Cintas, J. L. Jimenez, J. C. Palacios, and C. Valencia, *Tetrahedron* **49**, 2676 (1993).
- 93ZOR1643 V. N. Komissarov and G. E. Levitan, *Zh. Org. Khim.* **29**, 1643 (1993) [CA **121**, 301162 (1994)].
- 94BCJ149 N. Rashed, M. Shoukry, and E. S. H. El Ashry, *Bull. Chem. Soc. Jpn.* **67**, 149 (1994).
- 94CL265 M. Yokoyama, A. Toyoshima, T. Akiba, and H. Togo, *Chem. Lett.*, 265 (1994).
- 94GEP(D)4244561 T. Sugimoto, S. Ogiwara, H. Hidaka, R. Teradaira, K. Fujita, and T. Nagatsu, Ger. Offen. DE 4,244,561 (1994) [CA **121**, 152793 (1994)].
- 94JCS(P1)2407 S. Ishigami, H. Togo, and M. Yokohama, *J. Chem. Soc., Perkin Trans. I*, 2407 (1994).
- 94JCS(P1)2931 H. Togo, S. Ishigami, M. Fujii, T. Ikuma, and M. Yokoyama, *J. Chem. Soc., Perkin Trans. I*, 2931 (1994).
- 94JOC1912 H. Wamhoff, R. Berressem, and M. Nieger, *J. Org. Chem.* **59**, 1912 (1994).
- 94M189 Z. Gyorgydeak, L. Szilagi, J. Kajtar, G. Argay, and A. Kalman, *Monatsh. Chem.* **125**, 189 (1994).
- 94MI1 A. Elhakmaoui, A. Gueffier, J. C. Milhavet, Y. Blache, J. P. Chapat, O. Chavignon, J. C. Teulade, R. Snoeck, G. Andrei, and E. De Clerq, *Bioorg. Med. Chem. Lett.* **4**, 1937 (1994) [CA **122**, 31367 (1995)].
- 94MI2 R. Klein, I. Tatischeff, G. Tam, and N. Mano, *Chirality* **6**, 564 (1994) [CA **122**, 106350 (1995)].
- 94MI3 T. Icho, S. Kojima, M. Hayashi, Y. Kajiura, K. Kitabatake, and K. Kubota, *Int. Congr. Ser.—Excerpta Med.* **1058** (1994) [CA **122**, 150950 (1995)].
- 94MI4 G. Reibnegger and H. Wachter, *Sci. Pharm.* **62**, 90 (1995) [CA **122**, 211389 (1995)].
- 94MI5 S. H. Mahmoud, L. Somsak, and I. Farkas, *Carbohydr. Res.* **254**, 91 (1994).
- 94MI6 N. Rashed, E. I. Ibrahim, and E. S. H. El Ashry, *Carbohydr. Res.* **254**, 295 (1994).

- 94MI7 J. Kovacs, I. Pinter, D. Abeln, J. Kopf, and P. Koll, *Carbohydr. Res.* **257**, 97 (1994).
- 94MI8 M. A. M. Sallam, and H. A. El Shenaway, *Carbohydr. Res.* **261**, 327 (1994).
- 94MI9 T. S. Rao, M. E. Hogan, and G. R. Revankar, *Nucleosides Nucleotides* **13**, 95 (1994).
- 94MI10 D. Buffel, L. Meerpoel, S. M. Toppet, and G. J. Hoornaert, *Nucleosides Nucleotides* **13**, 719 (1994).
- 94T3273 M. Avalos, R. Babiano, P. Cintas, J. L. Jimenez, J. C. Palacios, and C. Valencia, *Tetrahedron* **50**, 3273 (1994).
- 94TL5339 S. A. Patil, B. A. Otter, and R. S. Klein, *Tetrahedron Lett.* **35**, 5339 (1994).
- 95AP175 M. Richter and G. Seitz, *Arch. Pharm. (Weinheim, Ger.)* **328**, 175 (1995).
- 95H(41)507 I. Maeba, Y. Nishiyama, S. Kanazawa, and A. Sato, *Heterocycles* **41**, 507 (1995).
- 95JA5951 R. W. Miles, V. Samano, and M. J. Robins, *J. Am. Chem. Soc.* **117**, 5951 (1995).
- 95JAP(K)95/118268 M. Yokoyama and H. Togo, Jpn. Kokai Pat. 95/118,268 (1995) [*CA* **123**, 144511 (1995)].
- 95JOC7094 H. Kuhn, D. P. Smith, and S. S. David, *J. Org. Chem.* **60**, 7094 (1995).
- 95MI1 J. Kovacs, I. Pinter and P. Koll, *Carbohydr. Res.* **272**, 255 (1995).
- 95MI2 T. Sugimoto, A. Yoshida, R. Teradaira, K. Fujita, and T. Nagatsu, *Biol. Amines* **11**, 1 (1995) [*CA* **122**, 234528 (1995)].
- 95MI3 H.-C. Zhang, M. Brakta, and G. D. Davies, Jr., *Nucleosides Nucleotides* **14**, 105 (1995).
- 95MI4 M. S. P. Sarma, P. Wilson, B. A. Otter, and R. S. Klein, *Nucleosides Nucleotides* **14**, 397 (1995).
- 95MI5 A. Gueiffier, Y. Blache, J. P. Chapat, A. Elhakmaoui, E. M. Essassi, G. Andrei, R. Snoeck, E. De Clercq, O. Chavignon, J. C. Teulade, and F. Fauvelle, *Nucleosides Nucleotides* **11**, 551 (1995).
- 95MI6 T. S. Rao and G. R. Revankar, *Nucleosides Nucleotides* **14**, 1601 (1995).
- 95PHA534 M. A. E. Shaban, A. Z. Nasr, and M. A. M. Taha, *Pharmazie* **50**, 534 (1995).
- 95PHA784 M. A. E. Shaban, M. A. M. Taha, A. Z. Nasr, and A. E. A. Morgan, *Pharmazie* **50**, 784 (1995).
- 95SC3027 R. K. Manna, P. Jaisankar, and V. S. Giri, *Synth. Commun.* **25**, 3027 (1995).
- 95TL2631 A. Sakurai, H. Hori, N. Kuboyama, Y. Hashimoto, and Y. Okumura, *Tetrahedron Lett.* **36**, 2631 (1995).
- 95TL5347 D. Beaupere, A. Elmeslouti, P. Levlievre, and R. Uzan, *Tetrahedron Lett.* **36**, 5347 (1995).
- 95ZK506 M. J. Dianez, M. D. Estrada, A. Lopez-Castro, and S. Perez-Garrido, *Z. Kristallogr.* **209**, 506 (1994) [*CA* **122**, 291393 (1995)].
- 96AJC409 P. Meszaros, I. Pinter, and G. Toth, *Aust. J. Chem.* **49**, 409 (1996).
- 96MI1 M. A. E. Sallam, H. M. El Nahas, S. M. E. Abdel Megid, and T. Anthonsen, *Carbohydr. Res.* **280**, 127 (1996).

- 96MI2 C. S. Lee, J. F. Du, and C. K. Chu, *Nucleosides Nucleotides* **15**, 1223 (1996).
- 96PHA707 M. A. E. Shaban, M. A. M. Taha, and A. Z. Nasr, *Pharmazie* **51**, 707 (1996).
- 96S459 A. Rybar, J. Alfoldi, M. Fedoronko, and J. Kozak, *Synthesis*, 459 (1996).
- 96TL2365 K. S. Gudmundsson, J. C. Drach, and L. B. Townsend, *Tetrahedron Lett.* **37**, 2365 (1996).
- 97AHC(68)223 M. A. E. Shaban and A. Z. Nasr, *Adv. Heterocycl. Chem.* **68**, in press (1997).
- 97UP1 M. A. E. Shaban, M. A. M. Taha, A. Z. Nasr, and A. E. A. Morgan, unpublished results (1997).
- 97UP2 M. A. E. Shaban, A. Z. Nasr, and M. A. M. Taha, unpublished results (1997).

This Page Intentionally Left Blank

## Cumulative Index of Authors, Volumes 1–70

- Abarca-Gonzalez, B., see Sepúlveda-Arques, J., **63**, 339.
- Abboud, J. L. M., see Catalan, J., **41**, 187.
- Abdallah, M. A., see Shawali, A. S., **63**, 277.
- Abramovitch, R. A., Saha, J. G., *Substitution in the Pyridine Series: Effect of Substituents*, **6**, 229.
- Acheson, R. M., Spenser, I. D., *The Carbolines*, **3**, 79.
- Abu-Shanab, F. A., Wakefield, B. J., Elnagdi, M.H., *Methylpyridines and Other Methylazines as Precursors to Bicycles and Polycycles*, **68**, 181.
- Acheson, R. M., *1-Hydroxypyrrroles, 1-Hydroxyindoles, and 9-Hydroxycarbazoles*, **51**, 105; *Reactions of Acetylenecarboxylic Acids and Their Esters with Nitrogen-Containing Heterocyclic Compounds*, **1**, 125.
- Acheson, R. M., Elmore, N. F., *Reactions of Acetylenecarboxylic Esters with Nitrogen-Containing Heterocycles*, **23**, 263.
- Adam, W., *The Chemistry of 1,2-Dioxetanes*, **21**, 437.
- Aiello, E., see Cirrincione, G., **48**, 65.
- Akibe, K-A., see Ohkata, K., **65**, 283.
- Albert, A., *4-Amino-1,2,3-triazoles*, **40**, 129; *The Chemistry of 8-Azapurines (1,2,3-Triazolo[4,5-d]pyrimidines)*, **39**, 117; *Annelation of a Pyrimidine Ring to an Existing Ring*, **32**, 1; *Covalent Hydration in Nitrogen Heterocycles*, **20**, 117.
- Albert, A., Armarego, W. L. F., *Covalent Hydration in Nitrogen-Containing Heteroaromatic Compounds. I. Qualitative Aspects*, **4**, 1.
- Albert, A., Yamamoto, H., *Heterocyclic Oligomers*, **15**, 1.
- Alcalde, E., *Heterocyclic Betaines: Pyridinium (Imidazolium) Azolate Inner Salts with Several Interannular Linkages*, **60**, 197.
- Alexeev, S. G., see Charushin, V. N., **46**, 73.
- Almerico, A. M., see Cirrincione, G., **48**, 65.
- Anastassiou, A. G., Kasmai, H. S., *Medium-Large and Large  $\pi$ -Excessive Heteroannulenes*, **23**, 55.
- Anderson, P. S., see Lyle, R. L., **6**, 45.
- ApSimon, J. W., See Paré, J. R. J., **42**, 335.
- Arai, S., Hida, M., *Polycyclic Aromatic Nitrogen Cations*, **55**, 261.
- Arán, V. J., Goya, P., Ochoa, C., *Heterocycles Containing the Sulfamide Moiety*, **44**, 81.
- Arbuzov, B. A., Nikonov, G. N., *Phosphorus Heterocycles from  $\alpha$ -Hydroxyalkylphosphines and Vinylphosphines*, **61**, 59.
- Armarego, W. L. F., *Quinazolines*, **1**, 253; **24**, 1.
- Armarego, W. L. F., see Albert, A., **4**, 1.
- Ashby, J., Cook, C. C., *Recent Advances in the Chemistry of Dibenzothiophenes*, **16**, 181.
- Avendaño López, C., González Trigo, G., *The Chemistry of Hydantoins*, **38**, 177.
- Badger, G. M., Sasse, W. H. F., *The Action of Metal Catalysts on Pyridines*, **2**, 179.
- Balaban, A. T., see Kuznetsov, E. V., **50**, 157.
- Balaban, A. T., Dinculescu, A., Dorofeenko, G. N., Fischer, G., Koblik, A. V., Mezheritskii, V. V., Schroth, W.,

- Pyrylium Salts: Syntheses, Reactions and Physical Properties*, **52**.
- Balaban, A. T., Schroth, W., Fischer, G., *Pyrylium Salts, Part I. Syntheses*, **10**, 241.
- Banister, A. J., see Rawson, J. M., **62**, 137.
- Bapat, J. B., Black, D. StC., Brown, R. F. C., *Cyclic Hydroxamic Acids*, **10**, 199.
- Baram, S. G., see Mamaev, V. P., **42**, 1.
- Barker, J. M., *gem-Dithienylalkanes and Their Derivatives*, **32**, 83; *The Thienopyridines*, **21**, 65.
- Barluenga, J., Tomas, M., *Synthesis of Heterocycles from Azadienes*, **57**, 1.
- Barton, H. J., see Bojarski, J. T., **38**, 229.
- Barton, J. W., *Benzo[c]cinnolines*, **24**, 151.
- Becher, J., see Bryce, M. R., **55**, 1.
- Beke, D., *Heterocyclic Pseudobases*, **1**, 167.
- Belen'kii, L. I., *The Literature of Heterocyclic Chemistry, Part III*, **44**, 269.
- Belen'kii, L. I., Kruchkovskaya, N. D., *The Literature of Heterocyclic Chemistry, Part IV*, **55**, 31.
- Benassi, R., Folli, U., Schenetti, L., Taddei, F., *The Conformations of Acyl Groups in Heterocyclic Compounds*, **41**, 75.
- Benneche, T., see Undheim, K. **62**, 305.
- Berg, U., see Gallo, R., **43**, 173.
- Bernáth, G., see Fülöp, F., **69**, 349.
- Bhatt, M. V., see Shirwaiker, G. S., **37**, 67.
- Bhushan, V., see Lohray, B. B., **68**, 89.
- Black, D. StC., Doyle, J. E., *1-Azabicyclo[3.1.0]hexanes and Analogs with Further Heteroatom Substitution*, **27**, 1.
- Black, D. StC., see Bapat, J. B., **10**, 199.
- Blackman, A., *Reactions of Coordinated Ligands*, **58**, 123.
- Blaha, K., Červinka, O., *Cyclic Enamines and Imines*, **6**, 147.
- Bobbitt, J. M., *The Chemistry of 4-Oxy- and 4-Keto-1,2,3,4-tetrahydroisoquinolines*, **15**, 99.
- Bodea, C., Silberg, I., *Recent Advances in the Chemistry of Phenothiazines*, **9**, 321.
- Bohle, M., Liebscher, J., *Ring Contraction of Heterocycles by Sulfur Extrusion*, **65**, 39.
- Böhm, S., see Kuthan, J., **59**, 179.
- Böhm, S., see Kuthan, J. **62**, 19.
- Bojarski, J. T., Mokrosz, J. L., Barton, H. J., Paluchowska, M. H., *Recent Progress in Barbituric Acid Chemistry*, **38**, 229.
- Bönnemann, H., Brijoux, W., *Organocobalt-Catalysed Synthesis of Pyridines*, **48**, 177.
- Bonnett, R., North, S. A., *The Chemistry of the Isoindoles*, **29**, 341.
- Bosshard, P., Eugster, C. H., *The Development of the Chemistry of Furans, 1952-1963*, **7**, 377.
- Boulton, A. J., Ghosh, P. B., *Benzofuroxans*, **10**, 1.
- Boulton, A. J., see Gasco, A., **29**, 251; Wünsch, K. H., **8**, 277.
- Bradsher, C. K., *Cationic Polar Cycloaddition*, **16**, 289; **19**, xi.
- Brijoux, W., see Bönnemann, H., **48**, 177.
- Brown, C., Davidson, R. M., *1,4-Benzothiazines, Dihydro-1,4-benzothiazines, and Related Compounds*, **38**, 135.
- Brown, R. F. C., see Bapat, J. B., **10**, 199.
- Broy, W., see Mayer, R., **8**, 219.
- Brunner, E., see Burger, K., **60**, 1.
- Bryce, M. R., Becher, J., Fält-Hansen, B., *Heterocyclic Synthesis using new Heterodienophiles*, **55**, 1.
- Bryce, M. R., Vernon, J. M., *Reactions of Benzyne with Heterocyclic Compounds*, **28**, 183.
- Bulka, E., *The Present State of Selenazole Chemistry*, **2**, 343.
- Bunting, J. W., *Heterocyclic Pseudobases*, **25**, 1.
- Burger, K., Wucherpennig, U., Brunner, E., *Fluoro Heterocycles with Five-membered Rings*, **60**, 1.
- Busby, R. E., *Thiadiazines with Adjacent Sulfur and Nitrogen Ring Atoms*, **50**, 255.
- Buscemi, S., see Vivona, N., **56**, 49.
- Butler, R. N., *Recent Advances in Tetrazole Chemistry*, **21**, 323.
- Cagniant, P., Cagniant, D., *Recent Advances in the Chemistry of Benzo[b]furan and Its Derivatives. Part I. Occurrence and Synthesis*, **18**, 337.
- Calf, G. E., Garnett, J. L., *Isotopic Hydrogen Labeling of Heterocyclic Compounds by One-Step Methods*, **15**, 137.

- Catala Noble, A., see Popp, F. D., **8**, 21.  
Catalan, J., Abboud, J. L. M., Elguero, J.,  
    *Basicity and Acidity of Azoles*, **41**, 187.  
Červinka, O., see Blaha, K., **6**, 147.  
Chambers, R. D., Sargent, C. R.,  
    *Polyfluoroheteroaromatic Compounds*,  
    **28**, 1.  
Charushin, V. N., Alexeev, S. G., Chupakhin,  
    O. N., van der Plas, H. C., *Behavior of*  
    *Monocyclic 1,2,4-Triazines in Reactions*  
    *with C-, N-, O-, and S-Nucleophiles*,  
    **46**, 73.  
Charushin, V. N., Chupakhin, O. N., van der  
    Plas, H. C., *Reactions of Azines with*  
    *Bifunctional Nucleophiles: Cyclizations*  
    *and Ring Transformations*, **43**, 301.  
Cheeseman, G. W. H., *Recent Advances in*  
    *Quinoxaline Chemistry*, **2**, 203.  
Cheeseman, G. W. H., Werstiuk, E. S. G.,  
    *Quinoxaline Chemistry: Developments*  
    *1963-1975*, **22**, 367; *Recent Advances in*  
    *Pyrazine Chemistry*, **14**, 99.  
Chimirri, A., Gitto, R., Grasso, S., Monforte,  
    A.M., Zappalà, M., *Annelated 1, 5-*  
    *Benzothiazepines*, **63**, 61.  
Chupakhin, O. N., see Charushin, V. N., **43**,  
    301; **46**, 73.  
Cirrincione, G., Almerico, A. M., Aiello, E.,  
    Dattolo, G., *Diazoazoles*, **48**, 65.  
Clapp, L. B., *1,2,4-Oxadiazoles*, **20**, 65.  
Claramunt, R. M., see Elguero, J., **22**, 183.  
Cleghorn, H. P., see Lloyd, D., **17**, 27.  
Comins, D. L., O'Connor, S., *Regioselective*  
    *Substitution in Aromatic Six-Membered*  
    *Nitrogen Heterocycles*, **44**, 199.  
Cook, C. C., see Ashby, J., **16**, 181.  
Cook, M. J., Katritzky, A. R., Linda, P.,  
    *Aromaticity of Heterocycles*, **17**, 255.  
Costero, A. M., *The Chemistry of Unsaturated*  
    *Nitrogen Heterocyclic Compounds*  
    *Containing Carbonyl Groups*, **58**, 171.  
Crabb, T. A., Katritzky, A. R.,  
    *Conformational Equilibria in Nitrogen-*  
    *Containing Saturated Six-Membered*  
    *Rings*, **36**, 1.  
Crabb, T. A., Jackson, D., Patel, A. V.,  
    *Saturated Bicyclic 6/5 Ring-Fused*  
    *Systems with Bridgehead Nitrogen and a*  
    *Single Additional Heteroatom*, **49**, 193.  
Cusmano, G., see Vivona, N., **56**, 49.  
Daltrozzi, E., see Scheibe, G., **7**, 153.  
Dattolo, G., see Cirrincione, G., **48**, 65.  
Davidson, J. L., Preston, P. N., *Use of*  
    *Transition Organometallic Compounds*  
    *in Heterocyclic Synthesis*, **30**, 319.  
Davidson, R. M., see Brown, C., **38**, 135.  
Davis, M., *Benzisothiazoles*, **14**, 43; *Recent*  
    *Advances in the Chemistry of*  
    *Benzisothiazoles and Other Polycyclic*  
    *Isothiazoles*, **38**, 105; *Sulfur Transfer*  
    *Reagents in Heterocyclic Synthesis*,  
    **30**, 47.  
Deady, L. W., see Zoltewicz, J. A., **22**, 71.  
Dean, F. M., *Recent Advances in Furan*  
    *Chemistry, Part I*, **30**, 167; *Part II*, **31**, 237.  
den Hertog, H. J., van der Plas, H. C.,  
    *Hetarynes*, **4**, 121.  
Dinculescu, A., see Balaban, A. T., **S2**.  
Doddi, G., Ercolani, G., *Thiopyrylium,*  
    *Selenopyrylium, and Telluropirylium*  
    *Salts*, **60**, 65.  
Donald, D. S., Webster, O. W., *Synthesis of*  
    *Heterocycles from Hydrogen Cyanide*  
    *Derivatives*, **41**, 1.  
Dorofeenko, G. N., see Balaban, A. T., **S2**.  
Dou, H. J. M., see Gallo, R. J., **36**, 175.  
Doyle, J. E., see Black, D. StC., **27**, 1.  
Drum, C., see Katritzky, A. R., **40**, 1.  
Duffin, G. F., *The Quaternization of*  
    *Heterocyclic Compounds*, **3**, 1.  
Dyke, S. F., *1,2-Dihydroisoquinolines*, **14**,  
    279.  
Dzenis, J., see Wamhoff, H., **55**, 129.  
Easton, C. J., Hughes, C. M. M., Savage,  
    G. P., Simpson, G. P., *Cycloaddition*  
    *Reactions of Nitrile Oxides with Alkenes*,  
    **60**, 261.  
Eckstein, Z., Urbański, T., *1,3-Oxazine*  
    *Derivatives*, **2**, 311; **23**, 1.  
Eisch, J. J., *Halogenation of Heterocyclic*  
    *Compounds*, **7**, 1.  
El Ashry, E. S. H., Mousaad, A., Rashed, N.,  
    *2,3,4-Furantriones*, **53**, 233.  
El Ashry, E. S. H., Rashed, N., Taha, M.,  
    Ramadan, E., *Condensed 1,2,4-*  
    *Triazines: I. Fused to Heterocycles with*  
    *Three-, Four-, and Five-membered Rings*,  
    **59**, 39.



- El Ashry, E. S. H., Rashed, N., Mousaad, A., Ramadan, E., *Condensed 1, 2, 4-Triazines: II. Fused to Heterocycles with Six- and Seven-Membered Rings and Fused to Two Heterocyclic Rings*, **61**, 207.
- El Ashry, E. S. H., Kilany, Y. E., *Acyclonucleosides: Part 1. Seco-Nucleosides*, **67**, 391.
- El Ashry, E. S. H., Kilany, Y. E., *Acyclonucleosides: Part 2. diseco-Nucleosides*, **68**, 1.
- El Ashry, E. S. H., Kilany, Y. E., *Acyclonucleosides: Part 3. Tri-, Tetra-, and Penta-Seco-Nucleosides (Two, Three, and Four Bonds Disconnections)*, **69**, 129.
- Elgemeie, G. E. H., see Elnagdi, M. H., **41**, 319.
- Elguero, J., see Catalan, J., **41**, 187.
- Elguero, J., Claramunt, R. M., Summers, A. J. H., *The Chemistry of Aromatic Azapentalenes*, **22**, 183.
- Elguero, J., Marzin, C., Katritzky, A. R., Linda, P., *The Tautomerism of Heterocycles*, **51**.
- Elmoghayar, M. R. H., see Elnagdi, M. H., **41**, 319; **48**, 223.
- Elmore, N. F., see Acheson, R. M., **23**, 263.
- Elnagdi, M. H., Elgemeie, G. E. H., Elmoghayar, M. R. H., *Chemistry of Pyrazolopyrimidines*, **41**, 319.
- Elnagdi, M. H., Elmoghayar, M. R. H., Sadek, K. U., *Chemistry of Pyrazoles Condensed to Heteroaromatic Five- and Six-Membered Rings*, **48**, 223.
- Elnagdi, M. H., see Abu-Shanab, F. A., **68**, 181.
- El'tsov, A. V., see Timpe, H. J., **33**, 185.
- Elwahi, A. H., see Ibrahim, Y. A., **65**, 235.
- Elvidge, J. A., Jones, J. R., O'Brien, C., Evans, E. A., Sheppard, H. C., *Base-Catalyzed Hydrogen Exchange*, **16**, 1.
- Epszajn, J., see Quéguiner, G., **52**, 187.
- Ercolani, G., see Doddi, G., **60**, 65.
- Esker, J. L., Newcomb, M., *The Generation of Nitrogen Radicals and their Cyclizations for the Construction of the Pyrrolidine Nucleus*, **58**, 1.
- Eugster, C. H., see Bosshard, P., **7**, 377.
- Evans, E. A., see Elvidge, J. A., **16**, 1.
- Fält-Hansen, B., see Bryce, M. R., **55**, 1.
- Fedrick, J. L., see Shepherd, R. G., **4**, 145.
- Fetles, M., Pliml, J., *3-Piperideines (1,2,3,6-Tetrahydropyridines)*, **12**, 43.
- Filler, R., *Recent Advances in Oxazolone Chemistry*, **4**, 75.
- Filler, R., Rao, Y. S., *New Developments in the Chemistry of Oxazolones*, **21**, 175.
- Fischer, G., *1,2,4-Triazolo[1,5-a]pyrimidines*, **57**, 81.
- Fischer, G., *Tropones, Tropolones, and Tropylium Salts with Fused Heterocyclic Rings Part 1: Synthesis*, **64**, 81.
- Fischer, G., *Tropones, Tropolones, and Tropylium Salts with Fused Heterocyclic Rings Part 2: Synthesis, Reactivity, and Application*, **66**, 285.
- Fischer, G. W., see Balaban, A. T., **10**, 241; **S2**.
- Fletcher, I. J., Siegrist, A. E., *Olefin Synthesis with Anils*, **23**, 171.
- Flitsch, W., *The Chemistry of 4-Azaazulenes*, **43**, 35; *Hydrogenated Porphyrin Derivatives: Hydporphyrins*, **43**, 73.
- Flitsch, W., Jones, G., *The Chemistry of Pyrrolizines*, **37**, 1.
- Flitsch, W., Kraemer, U., *Cyclazines and Related N-Bridged Annulenes*, **22**, 321.
- Folli, U., see Benassi, R., **41**, 75.
- Fowler, F. W., *Synthesis and Reactions of 1-Azirines*, **13**, 45.
- Freeman, F., *The Chemistry of 1-Pyridines*, **15**, 187.
- Frenna, V., see Vivona, N., **56**, 49.
- Friedrichsen, W., *Benzo[c]furans*, **26**, 135.
- Friedrichsen, W., see Lüpfer, S., **69**, 271.
- Fringuelli, F., Marino, G., Taticchi, A., *Tellurophene and Related Compounds*, **21**, 119.
- Fujita, E., Nagao, Y., *Chiral Induction Using Heterocycles*, **45**, 1.
- Fülöp, F., see Valters, R. E., **64**, 251.
- Fülöp, F., see Valters, R. E., **66**, 1.
- Fülöp, F., Bernáth, G., Pihlaja, K., *Synthesis, Stereochemistry and Transformations of Cyclopentane-, Cyclohexane-, Cycloheptane-, and Cyclooctane-Fused 1,3-Oxazines 1,3-Thiazines, and Pyrimidines*, **69**, 349.
- Furukawa, N., see Oae, S., **48**, 1.
- Furusaki, F., see Takeuchi, Y., **21**, 207.

- Gallo, R. J., Makosza, M., Dou, H. J. M., Hassanaly, P., *Applications of Phase Transfer Catalysts in Heterocyclic Chemistry*, **36**, 175.
- Gallo, R. J., Roussel, C., Berg, U., *The Quantitative Analysis of Steric Effects in Heteroaromatics*, **43**, 173.
- Gardini, G. P., *The Oxidation of Monocyclic Pyrroles*, **15**, 67.
- Garín, J., *The Reactivity of Tetrathia- and Tetraselenafulvalenes*, **62**, 249.
- Garnett, J. L., see Calf, G. E., **15**, 137.
- Gasco, A., Boulton, A. J., *Furoxans and Benzofuroxans*, **29**, 251.
- Gelbin, A., see Henning, H. G., **57**, 139.
- George, M. V., Khetan, S. K., Gupta, R. K., *Synthesis of Heterocycles through Nucleophilic Addition to Acetylenic Esters*, **19**, 279.
- Ghosh, P. B., see Boulton, A. J., **10**, 1.
- Giannopoulos, T., see Varvounis, G., **66**, 193.
- Gilchrist, T. L., *Ring-Opening of Five-Membered Heteroaromatic Anions*, **41**, 41.
- Gilchrist, T. L., Gymer, G. E., *1,2,3-Triazoles*, **16**, 33.
- Gitto, R., see Chimirri, A., **63**, 61.
- Glukhovtsev, M. N., see Simkin, B. Ya., **56**, 303.
- Glushkov, R. G., Granik, V. G., *The Chemistry of Lactim Ethers*, **12**, 185.
- Gol'dfarb, Ya. L., see Litvinov, V. P., **19**, 123.
- Gompper, R., *The Reactions of Diazomethane with Heterocyclic Compounds*, **2**, 245.
- González Trigo, G., see Avendaño Lopez, C., **38**, 177.
- Goya, P., see Arán V. J., **44**, 81.
- Granik, V. G., see Glushkov, R. G., **12**, 185.
- Grandberg, I. I., see Kost, A. N., **6**, 347.
- Grasso, S., see Chimirri, A., **63**, 61.
- Greenhill, J. V., see Lue, P., **67**, 209.
- Griffin, T. S., Woods, T. S., and Klayman, D. L., *Thioureas in the Synthesis of Heterocycles*, **18**, 99.
- Grimmett, M. R., *Advances in Imidazole Chemistry*, **12**, 103; **27**, 241; *Electrophilic Substitution in the Azines*, **47**, 325; *Halogenation of Heterocycles: I. Five-membered Rings*, **57**, 291; *II. Six- and Seven-membered Rings*, **58**, 271; *III. Heterocycles Fused to Other Aromatic and Heteroaromatic Rings*, **59**, 245.
- Grimmett, M. R., Keene, B. R. T., *Reactions of Annular Nitrogens of Azines with Electrophiles*, **43**, 127.
- Gronowitz, S., *Recent Advances in the Chemistry of Thiophenes*, **1**, 1.
- Groundwater, P. W., Munawar, M. A., *Heterocycle-Fused Acridines*, **70**, 89.
- Guilloton, O., see Quiniou, H., **50**, 85.
- Gupta, R. K., see George, M. V., **19**, 279.
- Gut, J., *Aza Analogs of Pyrimidine and Purine Bases of Nucleic Acids*, **1**, 189.
- Gymer, G. E., see Gilchrist, T. L., **16**, 33.
- Hanson, P., *Heteroaromatic Radicals, Part I: General Properties; Radicals with Group V Ring Heteroatoms*, **25**, 205; *Part II: Radicals with Group VI and Groups V and VI Ring Heteroatoms*, **27**, 31.
- Hardy, C. R., *The Chemistry of Pyrazolopyridines*, **36**, 343.
- Hazai, L., *3(2H)-Isoquinolinones and Their Saturated Derivatives*, **52**, 155.
- Heacock, R. A., *The Aminochromes*, **5**, 205.
- Heacock, R. A., Kasperek, S., *The Indole Grignard Reagents*, **10**, 43.
- Heinz, B., see Ried, W., **35**, 199.
- Henning, H. G., Gelbin, A., *Advances in Tetramic Acid Chemistry*, **57**, 139.
- Hermecz, I., *Chemistry of Diazabicycloundecene (DBU) and Other Pyrimidoazepines*, **42**, 83.
- Hermecz, I., Kerestűri, G., Vasvári-Debreczy, L., *Aminomethylenemalonates and Their Use in Heterocyclic Synthesis*, **54**.
- Hermecz, I., Meszaros, Z., *Chemistry of Pyrido[1,2-a]pyrimidines*, **33**, 241.
- Hermecz, I., Vasvári-Debreczy, L., *Tricyclic Compounds with a Central Pyrimidine Ring and One Bridgehead Nitrogen*, **39**, 281.
- Hermecz, I., *Recent Developments in the Chemistry of Pyrido[1,2-a]pyrimidines*, **63**, 103.

- Hermecz, I., *Chemistry of Pyrido[1,2-b][1,2]oxazines, Pyrido[1,2-b][1,2]thiazines, Pyrido[1,2-b]pyridazines and Their Benzologs: Part I*, **69**, 89.
- Hermecz, I., *Chemistry of Pyrido[1,2-c][1,3]oxazines, Pyrido[1,2-c][1,3]thiazines, Pyrido[1,2-c]pyrimidines, and Their Benzologs: Part II*, **70**, 1.
- Hettler, H., *3-Oxo-2,3-dihydrobenz[d]isothiazole-1,1-dioxide (Saccharin) and Derivatives*, **15**, 233.
- Hetzheim, A., Moeckel, K., *Recent Advances in 1,3,4-Oxadiazole Chemistry*, **7**, 183.
- Hewitt, D., *The Chemistry of Azaphosphorines*, **43**, 1.
- Hibino, S., see Kametani, T., **42**, 245.
- Hida, M., see Arai, S., **55**, 261.
- Hiremath, S. P., Hosmane, R. S., *Applications of Nuclear Magnetic Spectroscopy to Heterocyclic Chemistry: Indole and Its Derivatives*, **15**, 277.
- Hiremath, S. P., Hooper, M., *Isatogens and Indolones*, **22**, 123.
- Hirota, K., see Wamhoff, H., **55**, 129.
- Holm, A., *1,2,3,4-Thiatriazoles*, **20**, 145.
- Honda, T., see Kametani, T., **39**, 181.
- Hooper, M., see Hiremath, S. P., **22**, 123.
- Hörnfeldt, A. B., *Selenophenes*, **30**, 127.
- Hosmane, R. S., see Hiremath, S. P., **15**, 277.
- Hughes, C. M. M., see Easton, C. J., **60**, 261.
- Hunt, J. H., see Swinbourne, F. J., **23**, 103.
- Hurst, D. T., *The Nitration of Phenyl-substituted Heterocycles*, **58**, 215.
- Ibrahim, Y. A., Elwahy, A. H., Kadry, A. M., *Thienopyrimidines: Synthesis, Reactions, and Biological Activity*, **65**, 235.
- Iddon, B., *Benzo[c]thiophenes*, **14**, 331.
- Iddon, B., Scowston, R. M., *Recent Advances in the Chemistry of Benzo[b]thiophenes*, **11**, 177.
- Ikeda, M., see Tamura, Y., **29**, 71.
- Illuminati, G., *Nucleophilic Heteroaromatic Substitution*, **3**, 285.
- Illuminati, G., Stegel, F., *The Formation of Anionic  $\sigma$ -Adducts from Heteroaromatic Compounds: Structures, Rates, and Equilibria*, **34**, 305.
- Ishikura, M., see Terashima, M., **46**, 143.
- Ionescu, M., Mantsch, H., *Phenoxazines*, **8**, 83.
- Irwin, W. J., Wibberley, D. G., *Pyridopyrimidines: 1,3,5-, 1,3,6-, 1,3,7-, and 1,3,8-Triazanaphthalenes*, **10**, 149.
- Jackson, D., see Crabb, T. A., **49**, 193.
- Jaffé, H. H., Jones, H. L., *Applications of the Hammett Equation to Heterocyclic Compounds*, **3**, 209.
- Jankowski, K., see Paré, J. R. J., **42**, 335.
- Jankowski, K., Paré, J. R. J., Wightman, R. H., *Mass Spectrometry of Nucleic Acids*, **39**, 79.
- Jensen, K. A., Pedersen, C., *1,2,3,4-Thiatriazoles*, **3**, 263.
- Johnson, C. D., see Tomasik, P., **20**, 1.
- Johnson, F., Madroñero, R., *Heterocyclic Syntheses Involving Nitrilium Salts and Nitriles under Acidic Conditions*, **6**, 95.
- Jones, G., *Aromatic Quinolizines*, **31**, 1.
- Jones, G., Sliskovic, D. R., *The Chemistry of the Triazolopyridines*, **34**, 79.
- Jones, G., see Flitsch, W., **37**, 1.
- Jones, H. L., see Jaffé, H. H., **3**, 209.
- Jones, J. R., see Elvidge, J. A., **16**, 1.
- Jones, P. M., see Katritzky, A. R., **25**, 303.
- Jones, R. A., *Physicochemical Properties of Pyrroles*, **11**, 383.
- Joule, J. A., *Recent Advances in the Chemistry of 9H-Carbazoles*, **35**, 83; *Thianthrenes*, **48**, 301.
- Kadaba, P. K.,  $\Delta^3$ - and  $\Delta^4$ -1,2,3-Triazolines, **37**, 351; *1,2,4-Triazolines*, **46**, 169.
- Kadaba, P. K., Stanovnik, B., Tišler, M.,  $\Delta^2$ -1,2,3-Triazolines, **37**, 217.
- Kadry, A. M., see Ibrahim, Y. A., **65**, 235.
- Kametani, T., Hibino, S., *The Synthesis of Natural Heterocyclic Products by Hetero Diels-Alder Cycloaddition Reactions*, **42**, 245.
- Kametani, T., Honda, T., *The Application of Aziridines to the Synthesis of Natural Products*, **39**, 181.

- Kanemasa, S., see Tsuge, O., **45**, 231.
- Kappe, T., Stadlbauer, W., *Isatoic Anhydrides and Their Uses in Heterocyclic Synthesis*, **28**, 127.
- Kasmai, H. S., see Anastassiou, A. G., **23**, 55.
- Kasperek, S., *1-, 2- and 3-Benzazepines*, **17**, 45.
- Kasperek, S., see Heacock, R. A., **10**, 43.
- Katritzky, A. R., Drum, C., *Advances in Heterocyclic Chemistry: Prospect and Retrospect*, **40**, 1.
- Katritzky, A. R., Jones, P. M., *The Literature of Heterocyclic Chemistry, Part II*, **25**, 303.
- Katritzky, A. R., Lagowski, J. M., *Prototropic Tautomerism of Heteroaromatic Compounds. I. General Discussion and Methods of Study*, **1**, 311; *II. Six-Membered Rings*, **1**, 339; *III. Five-Membered Rings and One Hetero Atom*, **2**, 1; *IV. Five-Membered Rings with Two or More Hetero Atoms*, **2**, 27.
- Katritzky, A. R., Taylor, R., *Electrophilic Substitution of Heterocycles: Quantitative Aspects*, **47**, 1.
- Katritzky, A. R., Weeds, S. M., *The Literature of Heterocyclic Chemistry*, **7**, 225.
- Katritzky, A. R., see Cook, M. J., **17**, 255; Crabb, T. A., **36**, 1; Elguero, J., **51**; Sammes, M. P., **32**, 233; **34**, 1, 53; **35**, 375, 413.
- Katritzky, A. R., see Rewcastle, G. W., **56**, 155.
- Keay, J. G., *The Reduction of Nitrogen Heterocycles with Complex Metal Hydrides*, **39**, 1.
- Keene, B. R. T., see Grimmett, M. R., **43**, 127.
- Keene, B. R. T., Tissington, P., *Recent Developments in Phenanthridine Chemistry*, **13**, 315.
- Kerestüri, G., see Hermecz, I., **54**.
- Khetan, S. K., see George, M. V., **19**, 279.
- Khlebnikov, A. F., Novikov, M. S., Kostikov, R. R., *Carbenes and Carbenoids in Synthesis of Heterocycles*, **65**, 93.
- Kilany, Y. E., see El Ashry, E. S. H., **67**, 391.
- Kilany, Y. E., see El Ashry, E. S. H., **68**, 1.
- Kilany, Y. E., see El Ashry, E. S. H., **69**, 129.
- Kirschke, K., see Schulz M., **8**, 165.
- Kiselyov, A. S., see Strekowski, L. **62**, 1.
- Klayman, D. L., see Griffin, T. S., **18**, 99.
- Kleinpeter, E., *Conformational Analysis of Saturated Six-Membered Oxygen-Containing Heterocyclic Rings*, **69**, 217.
- Klemm, L. H., *Syntheses of Tetracyclic and Pentacyclic Condensed Thiophene Systems*, **32**, 127.
- Klinkert, G., see Swinbourne, F. J., **23**, 103.
- Knabe, J., *1,2-Dihydroisoquinolines and Related Compounds*, **40**, 105.
- Kobayashi, Y., Kumadaki, I., *Dewar Heterocycles and Related Compounds*, **31**, 169.
- Koblik, A. V., see Balaban, A. T., **52**.
- Kobylecki, R. J., McKillop, A., *1,2,3-Triazines*, **19**, 215.
- Kochetkov, N. K., Likhoshesterov, A. M., *Advances in Pyrrolizidine Chemistry*, **5**, 315.
- Kochetkov, N. K., Sokolov, S. D., *Recent Developments in Isoxazole Chemistry*, **2**, 365.
- Kolar, P., see Tišler, M., **64**, 1.
- Korbonits, D., see Valters, R. E., **64**, 251.
- Korbonits, D., see Valters, R. E., **66**, 1.
- Korzhevina, O. B., see Ryabukhin, Y. I., **66**, 131.
- Kost, A. N., Grandberg, I. I., *Progress in Pyrazole Chemistry*, **6**, 347.
- Kostikov, R. R., see Khlebnikov, A. F., **65**, 93.
- Koutecký, J. see Zahradnik, R., **5**, 69.
- Kraemer, U., see Flitsch, W., **22**, 321.
- Kress, T. J., see Paudler, W. W., **11**, 123.
- Kricka, L. J., Vernon, J. M., *Nitrogen-Bridged Six-Membered Ring Systems: 7-Azabicyclo-[2.2.1]hepta-2,5-dienes, Naphthalen-1,4-imines, and Anthracen-9,10-imines*, **16**, 87.
- Kruchkovskaya, N. D., see Belen'kii, L. I., **55**, 31.
- Kuhla, D. E., Lombardino, J. G., *Pyrrolidiazines with a Bridgehead Nitrogen*, **21**, 1.
- Kuhla, D. E., see Lombardino, J. G., **28**, 73.
- Kumadaki, I., see Kobayashi, Y., **31**, 169.
- Kurzer, F., *1,2,4-Thiadiazoles*, **32**, 285.
- Kuthan, J., *Pyrans, Thiopyrans, and Selenopyrans*, **34**, 145.
- Kuthan, J., Šebek, P., Böhm, S., *Developments in the Chemistry of*

- Thiopyrans, Selenopyrans, and Telluropyrans*, **59**, 179.
- Kuthan, J., Šebek, P., Böhm, S., *New Developments in the Chemistry of Pyrans*, **62**, 19.
- Kuzmenko, V. V., Pozharskii, A. F., *N-Aminoazoles*, **53**, 85.
- Kuznetsov, E. V., Shcherbakova, I. V., Balaban, A. T., *Benzo[c]pyrylium Salts: Syntheses, Reactions, and Physical Properties*, **50**, 157.
- Lagowski, J. M., see Katritzky, A. R., **1**, 311, 339; **2**, 1, 27.
- Lakhan, R., Ternai, B., *Advances in Oxazole Chemistry*, **17**, 99.
- Lalezari, I., Shafiee, A., Yalpani, M., *Selenium-Nitrogen Heterocycles*, **24**, 109.
- Lavender, I., see Rawson, J. M., **62**, 137.
- Liebscher, J., see Bohle, M., **65**, 39.
- Likhoshervstov, A. M., see Kochetkov, N. K., **5**, 315.
- Linda, P., see Cook, M. J., **17**, 255; Elguero, J., **S1**.
- Lindner, E., *Metallacyclo-alkanes and -alkenes*, **39**, 237.
- Lister, J. H., *Current Views on Some Physicochemical Aspects of Purines*, **24**, 215; *Physicochemical Aspects of the Chemistry of Purines*, **6**, 1.
- Litvinov, V. P., Gol'dfarb, Ya. L., *The Chemistry of Thienothiophenes and Related Systems*, **19**, 123.
- Lloyd, D., Cleghorn, H. P., *1,5-Benzodiazepines*, **17**, 27.
- Lloyd, D., Cleghorn, H. P., Marshall, D. R., *2,3-Dihydro-1,4-diazepines*, **17**, 1.
- Lloyd, D., McNab, H., *2,3-Dihydro-1,4-diazepines and 2,3-Dihydro-1,4-diazepinium Salts*, **56**, 1.
- Lohray, B. B., Bhushan, V., *1,3,2-Dioxathiolane Oxides: Epoxide Equivalents and Versatile Synthons*, **68**, 89.
- Lombardino, J. G., Kuhla, D. E., *1,2- and 2,1-Benzothiazines and Related Compounds*, **28**, 73.
- Lombardino, J. G., see Kuhla, D. E., **21**, 1.
- Lozac'h, N., *1,6,6a<sup>S</sup><sup>IV</sup>-Trihiapentalenes and Related Structures*, **13**, 161.
- Lozac'h, N., Stavaux, M., *The 1,2- and 1,3-Dithiolium Ions*, **27**, 151.
- Lue, P., Greenhill, J. V., *Enaminones in Heterocyclic Synthesis*, **67**, 209.
- Lukyanov, S. M., *1,3-Oxazinium and 3-Azapyrylium Salts*, **64**, 341.
- Lund, H., *Electrolysis of N-Heterocyclic Compounds*, **12**, 213.
- Lund, H., Tabakovic, I., *Electrolysis of N-Heterocyclic Compounds, Part II*, **36**, 235.
- Lüpfert, S., Friedrichsen, W., *Heteropentalenes with a Fused Imidazole or 1,2,4-Triazole Ring and One Bridgehead Nitrogen Atom*, **69**, 271.
- Lyle, R. E., Anderson, P. S., *The Reduction of Nitrogen Heterocycles with Complex Metal Hydrides*, **6**, 45.
- Lythgoe, D. J., Ramsden, C. A., *4-Unsubstituted, 5-Amino and 5-Unsubstituted, 4-Aminoimidazoles*, **61**, 1.
- Mackay, S. P., Meth-Cohn, O., Waigh, R. D., *Synthesis of Quaternary Benzo[c]phenanthridine Alkaloids and Their Analogues*, **67**, 345.
- Madroñero, R., see Johnson, F., **6**, 95.
- Magdesieva, N. N., *Advances in Selenophene Chemistry*, **12**, 1.
- Mamaev, V. P., Shkurko, O. P., Baram, S. G., *Electron Effects of Heteroaromatic and Substituted Heteroaromatic Groups*, **42**, 1.
- Mann, M. E., see White, J. D., **10**, 113.
- Mantsch, H., see Ionescu, M., **8**, 83.
- Marino, G., *Electrophilic Substitutions of Five-Membered Rings*, **13**, 235.
- Marino, G., see Fringuelli, F., **21**, 119.
- Marsais, F., see Quéguiner, G., **52**, 187.
- Marshall, D. R., see Lloyd, D., **17**, 1.
- Marzin, C., see Elguero, J., **S1**.
- Mayer, R., Broy, W., Zahradnik, R., *Monocyclic Sulfur-Containing Pyrones*, **8**, 219.
- McGill, C. K., Rappa, A., *Advances in the Chichibabin Reaction*, **44**, 1.
- McKillop, A., see Kobylecki, R. J., **19**, 215.

- McNab, H., see Lloyd, D., **56**, 1.
- McNaught, A., *The Nomenclature of Heterocycles*, **20**, 175.
- Medio-Simon, M., see Sepúlveda-Arques, J., **63**, 339.
- Merlini, L., *Advances in the Chemistry of Chrom-3-enes*, **18**, 159.
- Meszaros, Z., see Hermecz, I., **33**, 241.
- Meth-Cohn, O., Suschitzky, H., *Heterocycles by Ring-Closure of Ortho-Substituted t-Anilines—The t-Amino Effect*, **14**, 211.
- Meth-Cohn, O., Tarnowski, B., *Cyclizations under Vilsmeier Conditions*, **31**, 207; *Thiocoumarins*, **26**, 115.
- Meth-Cohn, O., *The t-Amino Effect: Heterocycles Formed by Ring Closure of ortho-Substituted t-Anilines*, **65**, 1.
- Meth-Cohn, O., see Mackay, S. P., **67**, 345.
- Mezheritskii, V. V., Tkachenko, V. V., *Synthesis of Peri-Annulated Heterocyclic Systems*, **51**, 1.
- Mezheritskii, V. V., see Balaban, A. T., **52**.
- Minisci, F., Porta, O., *Advances in Homolytic Substitution of Heteroaromatic Compounds*, **16**, 123.
- Minkin, V. I., see Sadekov, I. D., **58**, 47; see Simkin, B. Ya., **56**, 303; see Sadekov, I. D., **63**, 1.
- Moeckel, K., see Hetzheim, A., **7**, 183.
- Mokrosz, J. L., see Bojarski, J. T., **38**, 229.
- Monforte, A. M., see Chimirri, A., **63**, 61.
- Moody, C. J., *Azodicarbonyl Compounds in Heterocyclic Synthesis*, **30**, 1; *Claisen Rearrangements in Heteroaromatic Systems*, **42**, 203.
- Moreno-Mañas, M., Pleixats, R., *Dehydroacetic Acid, Triacetic acid Lactone, and Related Pyrones*, **53**, 1.
- Moreno-Mañas, M., Pleixats, R., *Palladium (0)-Catalyzed Allylation of Ambident Nucleophilic Aromatic Heterocycles*, **66**, 73.
- Moriarty, R. M., Prakash, O., *Synthesis of Heterocyclic Compounds Using Organohypervalent Iodine Reagents*, **69**, 1.
- Mousaad, A., see El Ashry, E. S. H., **53**, 233.
- Mousaad, A., see El Ashry, E. S. H., **61**, 207.
- Moynehan, E. B., see Popp, F. D., **13**, 1.
- Munawar, M. A., see Groundwater, P. W., **70**, 89.
- Nagao, Y., see Fujita, E., **45**, 1.
- Nair, M. D., see Rajappa, S., **25**, 113.
- Nasr, A. Z., see Shaban, M. A. E., **49**, 277; see Shaban, M. A. E., **68**, 225.
- Natekar, M. V., see Rajappa, S., **57**, 187.
- Nayak, A., see Newkome, G. R., **25**, 83.
- Newcomb, M., see Esker, J. L., **58**, 1.
- Newkome, G. R., Nayak, A., *Thiazolidinones*, **25**, 1.
- Nikonov, G. N., see Arbuzov, B. A., **61**, 59.
- Novikov, M. S., see Khlebnikov, A. F., **65**, 93.
- Norman, R. O. C., Radda, G. K., *Free-Radical Substitution of Heteroaromatic Compounds*, **2**, 131.
- North, S. A., see Bonnett, R., **29**, 341.
- Oae, S., Furukawa, N., *Heteroaromatic Sulfoxides and Sulfones: Ligand Exchange and Coupling in Sulfuranes and Ipso-Substitutions*, **48**, 1.
- O'Brien, C., see Elvidge, J. A., **16**, 1.
- Ochoa, C., see Arán, V. J., **44**, 81.
- O'Connor, S., see Comins, D. L., **44**, 199.
- Ohkata, K., Akiba, K.-A., *Cycloadditions and Reactions of Oxa-Aromatics with Nucleophiles*, **65**, 283.
- Ollis, W. D., Ramsden, C. A., *Meso-ionic Compounds*, **19**, 1.
- Paluchowska, M. H., see Bojarski, J. T., **38**, 229.
- Paré, J. R. J., see Jankowski, K., **39**, 79.
- Paré, J. R. J., Jankowski, K., ApSimon, J. W., *Mass Spectral Techniques in Heterocyclic Chemistry: Applications and Stereochemical Considerations in Carbohydrates and Other Oxygen Heterocycles*, **42**, 335.
- Patel, A. V., see Crabb, T. A., **49**, 193.
- Paudler, W. W., Kress, T. J., *The Naphthyridines*, **11**, 123.
- Paudler, W. W., Sheets, R. M., *Recent Developments in Naphthyridine Chemistry*, **33**, 147.
- Pedersen, C., see Jensen, K. A., **3**, 263.
- Pedersen, C. Th., *1,2-Dithiole-3-thiones and 1,2-Dithiol-3-ones*, **31**, 63.

- Perlmutter, H. D., *1,4-Diazocines*, **45**, 185;  
*1,5-Diazocines*, **46**, 1; *1,2-Diazocines*,  
*1,3-Diazocines*, *Triazocines*, and  
*Tetrazocines*, **50**, 1.
- Perlmutter, H. D., Trattner, R. B.,  
*Azocines*, **31**, 115.
- Perrin, D. D., *Covalent Hydration in Nitrogen  
Heteroaromatic Compounds. II.  
Quantitative Aspects*, **4**, 43.
- Pihlaja, K., see Fülöp, F., **69**, 349.
- Pleixats, R., see Moreno-Mañas, M., **53**, 1;  
see Moreno-Mañas, M., **66**, 73.
- Pliml, J., Prystaš, M., *The Hilbert-Johnson  
Reaction of 2,4-Dialkoxypyrimidines  
with Halogenoses*, **8**, 115.
- Pliml, J., see Ferles, M., **12**, 43.
- Popp, F. D., *Developments in the Chemistry  
of Reissert Compounds, 1968-1978*, **24**,  
187; *Reissert Compounds*, **9**, 1; *The  
Chemistry of Isatin*, **18**, 1.
- Popp, F. D., Catala Noble, A., *The Chemistry  
of Diazepines*, **8**, 21.
- Popp, F. D., Moynahan, E. B., *Heterocyclic  
Ferrocenes*, **13**, 1.
- Porta, O., see Minisci, F., **16**, 123.
- Porter, A. E. A., *The Chemistry of  
Thiophenium Salts and Thiophenium  
Ylids*, **45**, 151.
- Pozharskii, A. F., see Kuzmenko, V. V.,  
**53**, 85.
- Prakash, O., see Moriarty, R. M., **69**, 1.
- Preston, P. N., see Davidson, J. L., **30**, 321.
- Prinzbach, H., Futterer, E., *The 1,2- and  
1,3-Dithiolium Ions*, **7**, 39.
- Prystaš, M., see Pliml, J., **8**, 115.
- Pullman, A., Pullman, B., *Electronic Aspects  
of Purine Tautomerism*, **13**, 77.
- Pullman, B., see Kwiatkowski, J. S., **18**, 199.
- Pujari, H. K., *Condensed 4-Thiazolidinones*,  
**49**, 1.
- Quéguiner, G., Marsais, F., Snieckus, V.,  
Epszajn, J., *Directed Metalation of  
 $\pi$ -Deficient Azaaromatics: Strategies of  
Functionalization of Pyridines,  
Quinolines, and Diazines*, **52**, 187.
- Quiniou, H., Guilloton, O., *1,3-Thiazines*,  
**50**, 85.
- Radda, G. K., see Norman, R. O. C., **2**, 131.
- Rádl, S., *Mono- and Diazaquinones*, **61**, 141.
- Rádl, S., *1,2,4-Triazoline-3,5-Diones*, **66**, 119.
- Rajappa, S., Nair, M. D., *Ring Synthesis of  
Heteroaromatic Nitro Compounds*, **25**,  
113.
- Rajappa, S., Natekar, M. V., *Piperazine-2,5-  
diones and Related Lactim Ethers*, **57**,  
187.
- Ramadan, E., see El Ashry, E. S. H., **59**, 39.
- Ramadan, E., see El Ashry, E. S. H., **61**, 207.
- Ramsden, C. A., *Heterocyclic Betaine  
Derivatives of Alternant Hydrocarbons*,  
**26**, 1.
- Ramsden, C. A., see Ollis, W. D., **19**, 1.
- Ramsden, C. A., see Lythgoe, D. J., **61**, 1.
- Rao, Y. S., see Filler, R., **21**, 175.
- Rappa, A., see McGill, C. K., **44**, 1.
- Rashed, N., see El Ashry, E. S. H., **53**, 233;  
**59**, 39.
- Rashed, N., see El Ashry, E. S. H., **61**, 207.
- Rawson, J. M., Banister, A. J., Lavender, I.,  
*The Chemistry of Dithiadiazolylum and  
Dithiadiazolyl Rings*, **62**, 137.
- Rees, C. W., Smithen, C. E., *The Reactions  
of Heterocyclic Compounds with  
Carbenes*, **3**, 57.
- Reid, S. T., *The Photochemistry of  
Heterocycles*, **11**, 1; *The Photochemistry  
of Oxygen- and Sulfur-Containing  
Heterocycles*, **33**, 1; *Photochemistry of  
Nitrogen-Containing Heterocycles*, **30**,  
239.
- Reinhoudt, D. N., *(2 + 2)-Cycloaddition and  
(2 + 2)-Cycloreversion Reactions of  
Heterocyclic Compounds*, **21**, 253.
- Rewcastle, G. W., Katritzky, A. R.,  
*Generation and Reactions of  $sp^2$ -  
Carbanionic Centers in the Vicinity of  
Heterocyclic Nitrogen Atoms*, **56**, 155.
- Richardt, G., see Wamhoff, H., **64**, 159.
- Ried, W., Heinz, B., *Four-Membered Rings  
Containing One Sulfur Atom*, **35**, 199.
- Robins, D. J., *Advances in Pyrrolizidine  
Chemistry*, **24**, 247.
- Roussel, C., see Gallo, R., **43**, 173.
- Ruccia, M., Vivona, N., Spinelli, D.,  
*Mononuclear Heterocyclic  
Rearrangements*, **29**, 141.
- Ryabukhin, Y. I., Korzhavina, O. B.,  
Suzdalev, K. F., *Chemistry of 1,3-*

- Thiazin-4-ones and Their Derivatives*, **66**, 131.
- Sadek, K. U., see Elnagdi, M. H., **48**, 223.
- Sadekov, I. D., Minkin, V. I., *Tellurium-containing Heterocycles with Two Heteroatoms*, **58**, 47.
- Sadekov, I. D., Minkin, V. I., *Six-Membered Heterocycles with a Tellurium Atom*, **63**, 1.
- Saha, J. G., see Abramovitch, R. A., **6**, 229.
- Sammes, M. P., Katritzky, A. R., *The 2H-Imidazoles*, **35**, 375; *The 4H-Imidazoles*, **35**, 413; *The 3H-Pyrazoles*, **34**, 1; *The 4H-Pyrazoles*, **34**, 53; *The 2H- and 3H-Pyrroles*, **32**, 233.
- Sandström, J., *Recent Advances in the Chemistry of 1,3,4-Thiadiazoles*, **9**, 165.
- Sargent, C. R., see Chambers, R. D., **28**, 1.
- Sargent, M. V., Stransky, P. O., *Dibenzofurans*, **35**, 1.
- Sasaki, T., *Heteroadamantanes*, **30**, 79.
- Sasse, W. H. F., see Badger, G. M., **2**, 179.
- Savage, G. P., see Easton, C. J., **60**, 261.
- Scheibe, G., Daltrozso, E., *Diquinolylmethane and Its Analogs*, **7**, 153.
- Schenetti, L., see Benassi, R., **41**, 75.
- Schmitz, E., *Three-Membered Rings with Two Hetero Atoms*, **2**, 83; **24**, 63.
- Schneller, S. W., *Thiochromanones and Related Compounds*, **18**, 59.
- Schroth, W., see Balaban, A. T., **10**, 241; **S2**.
- Schulz, M., Kirschke, K., *Cyclic Peroxides*, **8**, 165.
- Scrowston, R. M., *Recent Advances in the Chemistry of Benzo[b]thiophenes*, **29**, 171.
- Scrowston, R. M., see Iddon, B., **11**, 177.
- Šebek, P., see Kuthan, J., **59**, 179.
- Šebek, P., see Kuthan, J., **62**, 19.
- Sepúlveda-Arques, J., Abarca-Gonzalez, B., Medio-Simon, M., *Cycloaddition Reactions with Vinyl Heterocycles*, **63**, 339.
- Shaban, M. A. E., Nasr, A. Z., *Synthesis of Condensed 1,2,4-Triazolo[3,4-x] Heterocycles*, **49**, 277.
- Shaban, M. A. E., Taha, M. A. M., Sharshira, E. M., *Synthesis and Biological Activities of Condensed Heterocyclo[n,m-a, b, or c]quinazolines*, **52**, 1.
- Shaban, M. A. E., Nasr, A. Z., *The Chemistry of C-Nucleosides and Their Analogs I: C-Nucleosides of Hetero Monocyclic Bases*, **68**, 225.
- Shaban, M. A. E., *The Chemistry of C-Nucleosides and Their Analogs II: C-Nucleosides of Condensed Heterocyclic Bases*, **70**, 163.
- Shafiee, A., see Lalezari, I., **24**, 109.
- Sharshira, E. M., see Shaban, M. A. E., **52**, 1.
- Shawali, A. S., Abdallah, M. A., *The Chemistry of Heterocyclic Hydrazonoyl Halides*, **63**, 277.
- Shcherbakova, I. V., see Kuznetsov, E. V., **50**, 157.
- Shepherd, R. G., Fedrick, J. L., *Reactivity of Azine, Benzoazine, and Azinoazine Derivatives with Simple Nucleophiles*, **4**, 145.
- Sheppard, H. C., see Elvidge, J. A., **16**, 1.
- Shirwaiker, G. S., Bhatt, M. V., *Chemistry of Arene Oxides*, **37**, 67.
- Shkurko, O. P., see Mamaev, V. P., **42**, 1.
- Siegrist, A. E., see Fletcher, I. J., **23**, 171.
- Silberg, I., see Bodea, C., **9**, 321.
- Silvester, M. J., *Recent Advances in Fluoroheterocyclic Chemistry*, **59**, 1.
- Simkin, B. Ya., Minkin, V. I., Glukhovtsev, M. N., *The Concept of Aromaticity in Heterocyclic Chemistry*, **56**, 303.
- Simpson, G. P., see Easton, C. J., **60**, 261.
- Slack, R., Wooldridge, K. R. H., *Isothiazoles*, **4**, 107.
- Sliskovic, D. R., see Jones, G., **34**, 79.
- Smalley, R. K., *The Chemistry of Indoxazenes and Anthranils, 1966-1979*, **29**, 1.
- Smith, G. F., *The Acid-Catalyzed Polymerization of Pyrroles and Indoles*, **2**, 287.
- Smithen, C. E., see Rees, C. W., **3**, 57.
- Snieckus, V., see Quéguiner, G., **52**, 187.
- Spenser, I. D., see Abramovitch, R. A., **3**, 79.
- Speranza, M., *The Reactivity of Heteroaromatic Compounds in the Gas Phase*, **40**, 25.



- Spinelli, D., see Ruccia, M., **29**, 141.  
Spiteller, G., *Mass Spectrometry of Heterocyclic Compounds*, **7**, 301.  
Stadlbauer, W., see Kappe, T., **28**, 127.  
Stanovnik, B., see Kadaba, P. K., **37**, 217;  
Tišler, M., **9**, 211; **24**, 363; **49**, 385.  
Stavaux, M., see Lozac'h, N., **27**, 151.  
Steel, P. J., *Aromatic Biheterocycles: Syntheses, Structures, and Properties*, **67**, 1.  
Stegel, F., see Illuminati, G., **34**, 305.  
Strekowski L., Kiselyov, A. S., *N-Fluoropyridinium Salts*, **62**, 1.  
Stölben, S., see Wamhoff, H., **64**, 159.  
Stoodley, R. J., *1,4-Thiazines and Their Dihydro Derivatives*, **24**, 293.  
Stransky, P. O., see Sargent, M. V., **35**, 1.  
Summers, A. J. H., see Elguero, J., **22**, 183.  
Summers, L. A., *The Bipyridines*, **35**, 281; *The Phenanthrolines*, **22**, 1.  
Suschitzky, H., see Meth-Cohn, O., **14**, 211.  
Suzdalev, K. F., see Ryabukhin, Y. I., **66**, 131.  
Swinbourne, F. J., Hunt, J. H., Klinkert, G., *Advances in Indolizine Chemistry*, **23**, 103.  
  
Tabakovic, I., see Lund, H., **36**, 235.  
Taddei, F., see Benassi, R., **41**, 75.  
Taha, M., see El Ashry, E. S. H., **59**, 39.  
Taha, M. A. M., see Shaban, M. A. E., **52**, 1.  
Takeuchi, Y., Furusaki, F., *The Chemistry of Isoxazolidines*, **21**, 207.  
Tamura, Y., Ikeda, M., *Advances in the Chemistry of Heteroaromatic N-Imines and N-Aminoazonium Salts*, **29**, 71.  
Tarnowski, B., see Meth-Cohn, O., **26**, 115; **31**, 207.  
Taticchi, A., see Fringuelli, F., **21**, 119.  
Taylor, R., see Katritzky, A. R., **47**, 1.  
Tedder, J. M., *Heterocyclic Diazo Compounds*, **8**, 1.  
Terashima, M., Ishikura, M., *Boron-substituted Heteroaromatic Compounds*, **46**, 143.  
Ternai, B., see Lakhan, R., **17**, 99.  
Thyagarajan, B. S., *Aromatic Quinolizines*, **5**, 291; *Claisen Rearrangements in Nitrogen Heterocyclic Systems*, **8**, 143.  
  
Timpe, H. J., *Heteroaromatic N-Imines*, **17**, 213.  
Timpe, H. J., El'tsov, A. V., *Pseudoazulenes*, **33**, 185.  
Tišler, M., *Heterocyclic Quinones*, **45**, 37.  
Tišler, M., see Kadaba, P. K., **37**, 217.  
Tišler, M., Stanovnik, B., *Pyridazines*, **9**, 211; *Recent Advances in Pyridazine Chemistry*, **24**, 363; *Advances in Pyridazine Chemistry*, **49**, 385.  
Tišler, M., Kolar, P., *Amino Acids as Synthons for Heterocyclic Compounds*, **64**, 1.  
Tissington, P., see Keene, B. R. T., **13**, 315.  
Tkachenko, V. V., see Mezheritskii, V. V., **51**, 1.  
Tomas, M., see Barluenga, J., **57**, 1.  
Tomasik, P., Johnson, C. D., *Applications of the Hammett Equation to Heterocyclic Compounds*, **20**, 1.  
Toomey, J. E., Jr., *Synthesis of Pyridines by Electrochemical Methods*, **37**, 167.  
Trofimov, B. A., *Preparations of Pyrroles from Ketoximes and Acetylenes*, **51**, 177.  
Tsuge, O., Kanemasa, S., *Recent Advances in Azomethine Ylide Chemistry*, **45**, 231.  
Trattner, R. B., see Perlmutter, H. D., **31**, 115.  
  
Ugi, I., *Pentazoles*, **3**, 373.  
Umamoto, T., *S-, Se-, and Te-(Perfluoroalkyl)dibenzothiophenium, -selenophenium, and -tellurophenium Salts*, **64**, 323.  
Undheim, K., Benneche, T., *Organometallics in Coupling Reactions in  $\pi$ -Deficient Azaheterocycles*, **62**, 305.  
Urbański, T., see Eckstein, Z., **2**, 311; **23**, 1.  
  
Valters, R. E., Fülöp, F., Korbonits, D., *Recent Developments in Ring-Chain Tautomerism I. Intramolecular Reversible Addition Reaction of the C=O Group*, **64**, 251.  
Valters, R. E., Fülöp, F., Korbonits, D., *Recent Developments in Ring-Chain Tautomerism II. Intramolecular Reversible Addition Reactions to the C=N, C $\equiv$ N, and C $\equiv$ C Groups*, **66**, 1.

- van der Haak, H. J., see van der Plas, H. C., **33**, 95.
- van der Plas, H. C., Wozniak, M., van den Haak, H. J., *Reactivity of Naphthyridines toward Nitrogen Nucleophiles*, **33**, 95.
- van der Plas, H. C., see Charushin, V. N., **43**, 301; **46**, 73.
- van der Plas, H. C., see den Hertog, H. J., **4**, 121.
- Varvounis, G., Giannopoulos, T., *Synthesis, Chemistry, and Biological Properties of Thienopyrimidines*, **66**, 193.
- Vasvari-Debrecezy, L., see Hermecz, I., **39**, 281; **54**.
- Vernon, J. M., see Bryce, M. R., **28**, 183; Kricka, L. J., **16**, 87.
- Vivona, N., see Ruccia, M., **29**, 141.
- Vivona, N., Buscemi, S., Frenna, V., Cusmano, G., *Ring Transformations of Five-membered Heterocycles*, **56**, 49.
- Vorbrüggen, H., *Advances in Amination of Nitrogen Heterocycles*, **49**, 117.
- Waigh, R. D., see Mackay, S. P., **67**, 345.
- Wakefield, B. J., Wright, D. J., *Isoxazole Chemistry since 1963*, **25**, 147.
- Wakefield, B. J., see Abu-Shanab, F. A., **68**, 181.
- Wamhoff, H., *Heterocyclic  $\beta$ -Enamino Esters, Versatile Synthons in Heterocyclic Synthesis*, **38**, 299.
- Wamhoff, H., Dzenis, J., Hirota, K., *Uracils: Versatile Starting Materials in Heterocyclic Synthesis*, **55**, 129.
- Wamhoff, H., Richardt, G., Stölben, S., *Iminophosphoranes: Versatile Tools in Heterocyclic Synthesis*, **64**, 159.
- Weber, H., *Oxidative Transformations of Heteroaromatic Iminium Salts*, **41**, 275.
- Weeds, S. M., see Katritzky, A. R., **7**, 225.
- Weinstock, L. M., Pollak, P. I., *The 1,2,5-Thiadiazoles*, **9**, 107.
- Weis, A. L., *Recent Advances in the Chemistry of Dihydroazines*, **38**, 1.
- Wentrup, C., *Carbenes and Nitrenes in Heterocyclic Chemistry: Intramolecular Reactions*, **28**, 231.
- Werstiuk, E. S. G., see Cheeseman, G. W. H., **14**, 99; **22**, 367.
- White, J. D., Mann, M. E., *Isoindoles*, **10**, 113.
- Wightman, R. H., see Jankowski, K., **39**, 79.
- Willette, R. E., *Monoazaindoles: The Pyrrolopyridines*, **9**, 27.
- Woods, T. S., see Griffin, T. S., **18**, 99.
- Wooldridge, K. R. H., *Recent Advances in the Chemistry of Mononuclear Isothiazoles*, **14**, 1.
- Wooldridge, K. R. H., see Slack, R., **4**, 107.
- Wozniak, M., see van der Plas, H. C., **33**, 95.
- Wright, D. J., see Wakefield, B. J., **25**, 147.
- Wucherpfennig, U., see Burger, K., **60**, 1.
- Wünsch, K. H., Boulton, A. J., *Indoxazenes and Anthranils*, **8**, 277.
- Yakhontov, L. N., *Quinuclidine Chemistry*, **11**, 473.
- Yalpani, M., see Lalezari, I., **24**, 109.
- Zahradnik, R., *Electronic Structure of Heterocyclic Sulfur Compounds*, **5**, 1.
- Zahradnik, R., Koutecký, J., *Theoretical Studies of Physico-chemical Properties and Reactivity of Azines*, **5**, 69.
- Zahradnik, R., see Mayer, R., **8**, 219.
- Zoltewicz, J. A., Deady, L. W., *Quaternization of Heteroaromatic Compounds: Quantitative Aspects*, **22**, 71.
- Zappalà, M., see Chimirri, A., **63**, 61.

This Page Intentionally Left Blank

## Cumulative Index of Titles, Volumes 1–70

### A

- Acetylenecarboxylic acids and esters, reactions with *N*-heterocyclic compounds, **1**, 125
- Acetylenecarboxylic esters, reactions with nitrogen-containing heterocycles, **23**, 263
- Acetylenic esters, synthesis of heterocycles through nucleophilic additions to, **19**, 297
- Acid-catalyzed polymerization of pyrroles and indoles, **2**, 287
- Acidity of azoles, basicity and, **41**, 187
- Acridines, heterocycle-fused, **70**, 89
- Acyl groups in heterocyclic compounds, conformations of, **41**, 75
- Acyclonucleosides, *seco*-nucleosides, **67**, 391  
*diseco*-nucleosides, **68**, 1  
tri-, tetra-, and penta-*seco*-nucleosides, **69**, 129
- Advances  
  in amination of nitrogen heterocycles, **49**, 117  
  in the Chichibabin reaction, **44**, 1  
  in chrom-3-ene chemistry, **18**, 159  
  in heterocyclic chemistry, prospect and retrospect, **40**, 1  
  in homolytic substitution of heteroaromatic compounds, **16**, 123  
  in imidazole chemistry, **12**, 103; **27**, 241  
  in indolizine chemistry, **23**, 103  
  in oxazole chemistry, **17**, 99  
  in pyridazine chemistry, **49**, 385  
  in pyrrolizidine chemistry, **5**, 315; **24**, 247  
  in selenophene chemistry, **12**, 1  
  in tetramic acid chemistry, **57**, 139
- Amination of nitrogen heterocycles, advances in, **49**, 117
- Amino acids as synthons for heterocyclic compounds, **64**, 1
- t*-Amino effect, **14**, 211, 65, 1
- N*-Aminoazoles, **53**, 85
- N*-Aminoazonium salts, *N*-imines and, **29**, 71
- Aminochromes, **5**, 205
- Aminomethylenemalonates and their use in heterocyclic synthesis, **54**, 1
- Aminoimidazoles, **61**, 1
- 4-Amino-1,2,3-triazoles, **40**, 129
- Anils, olefin synthesis with, **23**, 171
- Anionic  $\sigma$ -adducts of heterocycles, **34**, 305
- Anions, ring-opening of five-membered heteroaromatic, **41**, 41
- Annulated 1,5-benzothiazepines, **63**, 61
- Annulation of a pyrimidine ring to an existing ring, **32**, 1
- Annular nitrogens of azines with electrophiles, reactions of, **43**, 127
- Annulenes, *N*-bridged, cyclazines and, **22**, 321
- Anthracen-1,4-imines, **16**, 87
- Anthranils, **8**, 277; **29**, 1
- Applications  
  of the Hammett equation to heterocyclic compounds, **3**, 209; **20**, 1  
  of mass spectral techniques and stereochemical considerations in carbohydrates and other oxygen heterocycles, **42**, 335  
  of NMR spectroscopy to indole and its derivatives, **15**, 277  
  of phase-transfer catalysis to heterocyclic chemistry, **36**, 175
- Arene oxides, chemistry of, **37**, 67

- Aromatic azapentalenes, **22**, 183  
Aromatic biheterocycles, **67**, 1  
Aromatic nitrogen cations, polycyclic, **55**, 261  
Aromatic quinolizines, **5**, 291; **31**, 1  
Aromatic six-membered nitrogen heterocycles, regioselective substitution in, **44**, 199  
Aromaticity  
  concept of in heterocyclic chemistry, **56**, 303  
  of heterocycles, **17**, 255  
Aza analogs of pyrimidine and purine bases, **1**, 189  
4-Azaazulenes, chemistry of, **43**, 35  
7-Azabicyclo[2.2.1]hepta-2,5-dienes, **16**, 87  
1-Azabicyclo[3.1.0]hexanes and analogs with further heteroatom substitution, **27**, 1  
Azadienes, synthesis of heterocycles from, **57**, 1  
Azapentalenes, aromatic, chemistry of, **22**, 183  
Azaphosphorines, chemistry of, **43**, 1  
8-Azapurines, chemistry of, **39**, 117  
Azines  
  reactions of annular nitrogens of, with electrophiles, **43**, 127  
  reactivity with nucleophiles, **4**, 145  
  theoretical studies of, physicochemical properties and reactivity of, **5**, 69  
Azinoazines, reactivity with nucleophiles, **4**, 145  
Aziridine intermediates, synthesis of natural products via, **39**, 181  
1-Azirines, synthesis and reactions of, **13**, 45  
Azocines, **31**, 115  
Azodicarbonyl compounds in heterocyclic synthesis, **30**, 1  
Azoles, basicity and acidity of, **41**, 187  
Azomethine ylide chemistry, recent advances in, **45**, 231

**B**

- Barbituric acid, recent progress in chemistry of, **38**, 229  
Base-catalyzed hydrogen exchange, **16**, 1  
Basicity and acidity of azoles, **41**, 187  
Behavior of monocyclic 1,2,4-triazines in reactions with C-, N-, O-, and S-nucleophiles, **46**, 73

- 1-, 2-, and 3-Benzazepines, **17**, 45  
Benzisothiazoles, **14**, 43; **38**, 105  
Benzisoxazoles, **8**, 277; **29**, 1  
Benzoazines, reactivity with nucleophiles, **4**, 145  
Benzo[c]cinnolines, **24**, 151  
1,5-Benzodiazepines, **17**, 27  
Benzo[b]furan and derivatives, recent advances in chemistry of, Part I, occurrence and synthesis, **18**, 337  
Benzo[c]furans, **26**, 135  
Benzofuroxans, **10**, 1; **29**, 251  
2*H*-1-Benzopyrans (chrom-3-enes), **18**, 159  
Benzo[c]pyrylium salts: syntheses, reactions, and physical properties, **50**, 157  
1,2- and 2,1-Benzothiazines and related compounds, **28**, 73  
1,4-Benzothiazines and related compounds, **38**, 135  
Benzo[b]thiophene chemistry, recent advances in, **11**, 177; **29**, 171  
Benzo[c]thiophenes, **14**, 331  
1,2,3-Benzotriazines, **19**, 215  
Benzynes, reactions with heterocyclic compounds, **28**, 183  
Betaines, heterocyclic  
  derivatives of alternant hydrocarbons, **26**, 1  
  pyridinium and imidazolium azolate inner salts, **60**, 197  
Bicyclic 6/5 ring-fused systems with bridgehead nitrogen, **49**, 193  
Bifunctional nucleophiles: cyclizations and ring transformations on reaction of azines with, **43**, 301  
Biological pyrimidines, tautomerism and electronic structure of, **18**, 199  
Bipyridines, **35**, 281  
Boron-substituted heteroaromatic compounds, **46**, 143  
Bridgehead nitrogen  
  saturated bicyclic 6/5 ring-fused systems with, **49**, 193  
  Tricyclic compounds with a central pyrimidine ring and, **39**, 281

**C**

- sp<sup>2</sup>-Carbanionic centers in the vicinity of heterocyclic nitrogen atoms, generation and reactions, **56**, 155

- 9*H*-Carbazoles, recent advances in, **35**, 83  
Carbazoles, 9-hydroxy-, **51**, 168  
Carbenes  
    and nitrenes, intramolecular reactions, **28**, 231  
    reactions with heterocyclic compounds, **3**, 57  
Carbohydrates and other oxygen heterocycles, applications of mass spectral techniques and stereochemical considerations in, **42**, 335  
Carbolines, **3**, 79  
Cationic polar cycloaddition, **16**, 289 (**19**, xi)  
Cations, polycyclic aromatic nitrogen, **55**, 261  
Chemistry  
    and rearrangements of 1,2-dihydroisoquinolines, **40**, 105  
    of arene oxides, **37**, 67  
    of aromatic azapentalenes, **22**, 183  
    of 4-azaazulenes, **43**, 35  
    of azaphosphorines, **43**, 1  
    of 8-azapurines, **39**, 117  
    of azomethine ylides, recent advances in, **45**, 231  
    of barbituric acid, recent progress in, **38**, 229  
    of benzo[*b*]furan, Part I, occurrence and synthesis, **18**, 337  
    of benzo[*b*]thiophenes, **11**, 177; **29**, 171  
    of chrom-3-enes, **18**, 159  
    of C-nucleosides of hetero monocyclic bases and their analogs, **68**, 225  
    of C-nucleosides of condensed heterocyclic bases and their analogs, **70**, 163  
    of diazabicycloundecene (DBU) and other pyrimidoazepines, **42**, 83  
    of diazepines, **8**, 21  
    of dibenzothiophenes, **16**, 181  
    of dihydroazines, **38**, 1  
    of 1,2-dioxetanes, **21**, 437  
    of furans, **7**, 377  
    of hydantoins, **38**, 177  
    of isatin, **18**, 1  
    of isoindoles, **29**, 341  
    of isoxazolidines, **21**, 207  
    of lactim ethers, **12**, 185  
    of mononuclear isothiazoles, **14**, 1  
    of 4-oxy- and 4-keto-1,2,3,4-tetrahydroisoquinolines, **15**, 99  
    of phenanthridines, **13**, 315  
    of phenothiazines, **9**, 321  
    of polycyclic isothiazoles, **38**, 1  
    of pyrazoles condensed to heteroaromatic five- and six-membered rings, **48**, 223  
    of pyrazolopyridines, **36**, 343  
    of pyrazolopyrimidines, **41**, 319  
    of pyrido[1,2-*b*][1,2]oxazines, **69**, 89  
    of pyrido[1,2-*c*][1,3]oxazines, **70**, 1  
    of pyrido[1,2-*b*]pyridazines, **69**, 89  
    of pyrido[1,2-*a*]pyrimidines, **33**, 241  
    of pyrido[1,2-*c*]pyrimidines, **70**, 1  
    of pyrido[1,2-*b*][1,2]thiazines, **69**, 89  
    of pyrido[1,2-*c*][1,3]thiazines, **70**, 1  
    of 1-pyridines, **15**, 197  
    of pyrrolizines, **37**, 1  
    of tetrazoles, **21**, 323  
    of 1,3,4-thiadiazoles, **9**, 165  
    of thienothiophenes, **19**, 123  
    of thiophenes, **1**, 1  
    of thiophenium salts and thiophenium ylids, **45**, 151  
    of triazolopyridines, **34**, 79  
    of unsaturated nitrogen heterocyclic compounds containing carbonyl groups, **58**, 171  
Chichibabin reaction, advances in, **44**, 1  
Chiral induction using heterocycles, **45**, 1  
Chrom-3-ene chemistry, advances in, **18**, 159  
Claisen rearrangements  
    in heteroaromatic systems, **42**, 203  
    in nitrogen heterocyclic systems, **8**, 143  
Complex metal hydrides, reduction of nitrogen heterocycles with, **6**, 45; **39**, 1  
Concept of aromaticity in heterocyclic chemistry, **56**, 303  
Condensed heterocyclo[*n,m-a, b*, or *c*]quinazolines, **52**, 1  
Condensed 4-thiazolidinones, **49**, 1  
Condensed thiophene systems, tetra- and pentacyclic, **32**, 127  
Condensed 1,2,4-triazines: I. Fused to heterocycles with three-, four-, and five-membered rings, **59**, 39  
Condensed 1,2,4-triazolo[3,4-*z*] heterocycles, synthesis, **49**, 277  
Conformational equilibria in nitrogen-containing saturated six-membered rings, **36**, 1  
Conformations of acyl groups in heterocyclic compounds, **41**, 75

- Coordinated ligands, reactions of, **58**, 123  
Covalent hydration  
  in heteroaromatic compounds, **4**, 1, 43  
  in nitrogen heterocycles, **20**, 117  
Current views on some physicochemical aspects of purines, **24**, 215  
Cyclazines and related N-bridged annulenes, **22**, 321  
Cyclic enamines and imines, **6**, 147  
Cyclic hydroxamic acids, **10**, 199  
Cyclic peroxides, **8**, 165  
Cyclizations  
  and ring transformations on reaction of azines with bifunctional nucleophiles, **43**, 301  
  of nitrogen radicals in pyrrolidine synthesis, **58**, 1  
  under Vilsmeier conditions, **31**, 207  
Cycloaddition reactions  
  cationic polar, **16**, 289 (**19**, xi)  
  of nitrile oxides with alkenes, **60**, 261  
(2 + 2)-Cycloaddition and (2 + 2)-cycloreversion reactions of heterocyclic compounds, **21**, 253

## D

- Dehydroacetic acid, triacetic acid lactone, and related pyrones, **53**, 1  
Developments in the chemistry of furans (1952-1963), **7**, 377  
  of Reissert compounds (1968-1978), **24**, 187  
  of thiopyrans, selenopyrans, and telluropyrans, **59**, 179  
Dewar heterocycles and related compounds, **31**, 169  
2,4-Dialkoxypyrimidines, Hilbert-Johnson reaction of, **8**, 115  
Diazabicycloundecene (DBU) and other pyrimidoazepines, chemistry of, **42**, 83  
Dizaquinones, **61**, 59  
Diazepines, chemistry of, **8**, 21  
1,4-Diazepines, 2,3-dihydro-, **17**, 1; **56**, 1  
Diazines, functionalization by directed metalation, **52**, 187  
Diazirines, diaziridines, **2**, 83; **24**, 63  
Diazoazoles, **48**, 65

- 1,2-Diazocines, 1,3-diazocines, triazocines, and tetrazocines, **50**, 1  
1,4-Diazocines, **45**, 185  
1,5-Diazocines, **46**, 1  
Diazo compounds, heterocyclic, **8**, 1  
Diazomethane, reactions with heterocyclic compounds, **2**, 245  
Dibenzofurans, **35**, 1  
Dibenzothiophenes, chemistry of, **16**, 181  
Dihydroazines, recent advances in chemistry of, **38**, 1  
Dihydro-1,4-benzothiazines, and related compounds, **38**, 135  
2,3-Dihydro-1,4-diazepines, **17**, 1  
2,3-Dihydro-1,4-diazepines and 2,3-dihydro-1,4-diazepinium salts, **56**, 1  
1,2-Dihydroisoquinolines and related compounds, **14**, 279; **40**, 105  
1,3,2-Dioxathiolane oxides, epoxide equivalents and versatile synthons, **68**, 89  
1,2-Dioxetanes, chemistry of, **21**, 437  
Diquinolylmethane and its analogs, **7**, 153  
Directed metalation of  $\pi$ -deficient azaromatics: strategies of functionalization of pyridines, quinolines, and diazines, **52**, 187  
*gem*-Dithienylalkanes and their derivatives, **32**, 83  
1,2-Dithiole-3-thiones and 1,2-dithiol-3-ones, **31**, 63  
1,2- and 1,3-Dithiolium ions, **7**, 39; **27**, 151  
Dithiadiazolylum, **62**, 139  
Dithiadiazolyl rings, **62**, 139

## E

- Electrochemical synthesis of pyridines, **37**, 167  
Electrolysis of *N*-heterocyclic compounds  
  Part I, **12**, 213  
  Part II, **36**, 235  
Electronic aspects of purine tautomerism, **13**, 77  
Electronic effects of heteroaromatic and substituted heteroaromatic groups, **42**, 1  
Electronic structure  
  of biological pyrimidines, tautomerism and, **18**, 199  
  of heterocyclic sulfur compounds, **5**, 1

Electrophiles, reactions of annular nitrogens of azines with, **43**, 127

Electrophilic substitution of heterocycles: quantitative aspects, **47**

Electrophilic substitutions of five-membered rings, **13**, 235

Enamines and imines, cyclic, **6**, 147

$\beta$ -Enamino esters, heterocyclic, as heterocyclic synthons, **38**, 299

$\pi$ -Excessive heteroannulenes, medium-large and large, **23**, 55

## F

Ferrocenes, heterocyclic, **13**, 1

Five-membered heteroaromatic anions, ring-opening of, **41**, 41

Five-membered heterocycles, ring transformations of, **56**, 49

Five-membered ring fluoro-heterocycles, **60**, 1

Five-membered rings, electrophilic substitutions of, **13**, 235

Fluoro heterocycles with five-membered rings, **60**, 1

Fluoroheterocyclic chemistry, recent advances in, **59**, 1

Formation of anionic  $\sigma$ -adducts from heteroaromatic compounds, **34**, 305

Four-membered rings containing one sulfur atom, **35**, 199

Free radical substitutions of heteroaromatic compounds, **2**, 131

Furan chemistry, recent advances in, Part I, **30**, 167; Part II, **31**, 237

Furans, developments of the chemistry of (1952-1963), **7**, 377

Furans, dibenzo-, **35**, 1

2,3,4-Furantriones, **53**, 233

Furoxans, **29**, 251

## G

Gas phase reactivity of heteroaromatic compounds, **40**, 25

Generation

of nitrogen radicals and their cyclizations for the construction of the pyrrolidine nucleus, **58**, 1

and reactions of  $sp^2$ -carbanionic centers in the vicinity of heterocyclic nitrogen atoms, **56**, 155

Grignard reagents, indole, **10**, 43

## H

Halogenation

of heterocycles

five-membered rings, **57**, 291

fused to other aromatic and

heteroaromatic rings, **59**, 245

six- and seven-membered rings, **58**, 271

of heterocyclic compounds, **7**, 1

Hammett equation, applications to

heterocyclic compounds, **3**, 209; **20**, 1

Hetarynes, **4**, 121

Heteroadamantanes, **30**, 79

Heteroannulenes, medium-large and large  $\pi$ -excessive, **23**, 55

Heteroaromatic *N*-aminoazonium salts, **29**, 71

Heteroaromatic compounds

free-radical substitutions of, **2**, 131

homolytic substitution of, **16**, 123

nitrogen, covalent hydration in, **4**, 1, 43

prototropic tautomerism of, **1**, 311, 339; **2**, 1, 27; **S1**

quaternization of, **22**, 71

reactivity of, in gas phase, **40**, 25

Heteroaromatic *N*-imines, **17**, 213; **29**, 71

Heteroaromatic nitro compounds, ring synthesis of, **25**, 113

Heteroaromatic radicals, Part I, general

properties; radicals with Group V ring

heteroatoms, **25**, 205; Part II, radicals

with Group VI and Groups V and VI

ring heteroatoms, **27**, 31

Heteroaromatic and substituted

heteroaromatic groups, electronic

effects, **42**, 1

Heteroaromatic substitution, nucleophilic, **3**, 283

Heteroaromatic sulfoxides and sulfones:

ligand exchange and coupling in

sulfuranes and *ipso*-substitutions, **49**, 1

Heteroaromatic systems, Claisen

rearrangements in, **42**, 203



- Heteroaromatics, quantitative analysis of  
steric effects in, **43**, 173
- Heterocycles  
aromaticity of, **17**, 255  
chiral induction using, **45**, 1  
containing the sulfamide moiety, **44**, 81  
contraction of, by sulfur extrusion, **65**, 39  
halogenation of, **7**, 1; **57**, 291; **58**, 271;  
**59**, 245  
nomenclature of, **20**, 175  
phosphorus, from  $\alpha$ -  
hydroxyalkylphosphines and  
vinylphosphines, **61**, 59  
photochemistry of, **11**, 1  
quantitative aspects of electrophilic  
substitution of, **47**  
synthesis from azadienes, **57**, 1  
by ring closure of ortho-substituted  
*t*-anilines, **14**, 211, **65**, 1
- Heterocycles, phenyl-substituted, nitration  
of, **58**, 215
- Heterocyclic betaine derivatives of alternant  
hydrocarbons, **26**, 1
- Heterocyclic betaines: pyridinium  
(imidazolium) azolate inner salts with  
several interannular linkages, **60**, 197
- Heterocyclic chemistry  
applications of phase-transfer catalysis in  
**36**, 175  
literature of, **7**, 225; **25**, 303; **44**, 269;  
**55**, 31
- Heterocyclic compounds  
application of Hammett equation to, **3**, 209;  
**20**, 1  
(2 + 2)-cycloaddition and (2 + 2)-  
cycloreversion reactions of, **21**, 253  
halogenation of, **7**, 1  
isotopic hydrogen labeling of, **15**, 137  
mass spectrometry of, **7**, 301  
quaternization of, **3**, 1; **22**, 71  
reactions of, with carbenes, **3**, 57  
reactions of diazomethane with, **2**, 245  
reactions with benzyne, **28**, 183
- N*-Heterocyclic compounds (*see also*  
Nitrogen heterocycles)  
containing carbonyl groups, chemistry of,  
**58**, 171  
electrolysis of, **12**, 213  
photochemistry of, **30**, 239  
reaction of acetylenecarboxylic acids and  
esters with, **1**, 125; **23**, 263
- Heterocyclic diazo compounds, **8**, 1
- Heterocyclic ferrocenes, **13**, 1
- Heterocyclic hydrazoneyl halides, chemistry  
of, **63**, 277
- Heterocyclic iminium salts, oxidative  
transformation, **41**, 275
- Heterocyclic oligomers, **15**, 1
- Heterocyclic products, natural, synthesis of  
by hetero Diels-Alder cycloaddition  
reactions, **42**, 245
- Heterocyclic pseudobases, **1**, 167; **25**, 1
- Heterocyclic quinones, **45**, 37
- Heterocyclic sulphur compounds, electronic  
structure of, **5**, 1
- Heterocyclic synthesis, *see also* Synthesis  
azodicarbonyl compounds and, **30**, 1  
carbenes and carbenoids in, **65**, 93  
enaminones in, **67**, 209  
heterocyclic  $\beta$ -enamino esters and, **38**, 299  
iminophosphoranes, **64**, 159  
involving nitrilium salts and nitriles under  
acidic conditions, **6**, 95  
through nucleophilic additions to  
acetylenic ester, **19**, 279  
sulfur transfer reagents in, **30**, 47  
thioureas in, **18**, 99  
uses of isatoic anhydrides in, **28**, 73  
using aminomethylenemalonates, **54**  
using new heterodienophiles, **55**, 1  
using organohypervalent iodine reagents,  
**69**, 1  
uracils in, **55**, 129
- Hetero Diels-Alder cycloaddition reactions,  
synthesis of natural heterocyclic  
products by, **42**, 245
- Heterodienophiles, new, heterocyclic  
synthesis using, **55**, 1
- Heteropentalenes, **69**, 271
- Hilbert-Johnson reaction of 2,4-  
dialkoxypyrimidines with halogenoses,  
**8**, 115
- Homolytic substitution of heteroaromatic  
compounds, **16**, 123
- Hydantoins, chemistry of, **38**, 177
- Hydrogen cyanide derivatives, synthesis of  
heterocycles from, **41**, 1
- Hydrogen exchange  
base-catalyzed, **16**, 1  
one-step (labeling) methods, **15**, 137
- Hydrogenated porphyrin derivatives:  
hydroporphyrins, **43**, 73
- Hydroxamic acids, cyclic, **10**, 199

1-Hydroxypyrroles, 1-hydroxyindoles, and 9-hydroxycarbazoles, **51**, 105

## I

Imidazole chemistry, advances in, **12**, 103; **27**, 241

2*H*-Imidazoles, **35**, 375

4*H*-Imidazoles, **35**, 413

Imidazolium azolate inner salts, **60**, 197

*N*-Imines, heteroaromatic, **17**, 213; **29**, 71

Iminium salts, oxidative transformation of heterocyclic, **41**, 275

Indole Grignard reagents, **10**, 43

Indole(s)

acid-catalyzed polymerization, **2**, 287 and derivatives, application of NMR spectroscopy to, **15**, 277

1-hydroxy-, **51**, 119

Indolizine chemistry, advances in, **23**, 103

Indolones, isotogens and, **22**, 123

Indoxazenes, **8**, 277; **29**, 1

Isatin, chemistry of, **18**, 1

Isatogens and indolones, **22**, 123

Isatoic anhydrides, uses in heterocyclic synthesis, **28**, 127

Isoindoles, **10**, 113; **29**, 341

Isoquinolines

1,2-dihydro-, **14**, 279

4-oxy- and 4-keto-1,2,3,4-tetrahydro-, **15**, 99

3(2*H*)-Isoquinolinones and their saturated derivatives, **52**, 155

Isothiazoles, **4**, 107

recent advances in the chemistry of monocyclic, **14**, 1

polycyclic, recent advances in chemistry of, **38**, 105

Isotopic hydrogen labeling of heterocyclic compounds, one-step methods, **15**, 137

Isoxazole chemistry, recent developments in, **2**, 365; since 1963; **25**, 147

Isoxazolidines, chemistry of, **21**, 207

## L

Lactim ethers, chemistry of, **12**, 185

Ligand exchange and coupling in sulfuranes and *ipso*-substitutions, **48**, 1

Ligands, coordinated, reactions of, **58**, 123  
Literature of heterocyclic chemistry, **7**, 225; **25**, 303; **44**, 269; **55**, 31

## M

Mass spectral techniques in heterocyclic chemistry: applications and stereochemical considerations in carbohydrates and other oxygen heterocycles, **42**, 335

Mass spectrometry of heterocyclic compounds, **7**, 301 of nucleic acids, **39**, 79

Medium-large and large  $\pi$ -excessive heteroannulenes, **23**, 55

Meso-ionic compounds, **19**, 1

Metal catalysts, action on pyridines, **2**, 179

Metalation, directed, of pyridines, quinolines, and diazines, **52**, 187

Metallacycloalkanes and -alkenes, **39**, 237

Methylazines, **68**, 181

Methylpyridines, **68**, 181

Monoazaindoles, **9**, 27

Monocyclic pyrroles, oxidation of, **15**, 67

Monocyclic sulfur-containing pyrones, **8**, 219

Mononuclear heterocyclic rearrangements, **29**, 141

Mononuclear isothiazoles, recent advances in chemistry of, **14**, 1

Monoquinones, **61**, 59

## N

Naphthalen-1,4-imines, **16**, 87

Naphthyridines, **11**, 124

reactivity of, toward nitrogen nucleophiles, **33**, 95

recent developments in chemistry of, **33**, 147

Natural heterocyclic products by hetero Diels-Alder cycloaddition reactions, synthesis of, **42**, 245

Natural products, synthesis via aziridine intermediates, **39**, 181

New developments in the chemistry of oxazolones, **21**, 175

- N*-Fluoropyridinium salts, **62**, 1  
Nitration of phenyl-substituted heterocycles, **58**, 215  
Nitrenes, carbenes and, intramolecular reactions of, **28**, 231  
Nitrile oxides, cycloadditions with alkenes, **60**, 261  
Nitriles and nitrilium salts, heterocyclic synthesis involving, **6**, 95  
Nitro-compounds, heteroaromatic, ring synthesis of, **25**, 113  
Nitrogen-bridged six-membered ring systems, **16**, 87  
Nitrogen heterocycles (*see also* *N*-Heterocyclic compounds)  
  advances in amination of, **49**, 117  
  aromatic six-membered, regioselective substitution in, **44**, 199  
  conformational equilibria in saturated six-membered rings, **36**, 1  
  covalent hydration in, **20**, 117  
  photochemistry of, **30**, 239  
  reactions of acetylenecarboxylic esters with, **23**, 263  
  reduction of, with complex metal hydrides, **6**, 45; **39**, 1  
Nitrogen heterocyclic systems, Claisen rearrangements in, **8**, 143  
Nitrogen radicals, generation and cyclization, **58**, 1  
Nomenclature of heterocycles, **20**, 175  
Nuclear magnetic resonance spectroscopy, application to indoles, **15**, 277  
Nucleic acids, mass spectrometry of, **39**, 79  
Nucleophiles,  
  bifunctional, cyclisations and ring transformations on reaction of azines with, **43**, 301  
  cycloadditions and reactions of oxa-aromatics with, **65**, 283  
  reactivity of azine derivatives with, **4**, 145  
Nucleophilic additions to acetylenic esters, synthesis of heterocycles through, **19**, 299  
Nucleophilic aromatic heterocycles, ambident  
  palladium(0)-catalyzed allylation, **66**, 73  
Nucleophilic heteroaromatic substitution, **3**, 285

## O

- Olefin synthesis with anils, **23**, 171  
Oligomers, heterocyclic, **15**, 1

- Organocobalt-catalyzed synthesis of pyridines, **48**, 177  
Organometallic compounds, transition metal, use in heterocyclic synthesis, **30**, 321  
  coupling reactions in  $\pi$ -deficient azaheterocycles, **62**, 305  
Oxa-aromatics, cycloadditions and reactions with nucleophiles, **65**, 283  
1,3,4-Oxadiazole chemistry, recent advances in, **7**, 183  
1,2,4-Oxadiazoles, **20**, 65  
1,2,5-Oxadiazoles, **29**, 251  
1,3-Oxazine derivatives, **2**, 311; **23**, 1  
  synthesis and stereochemistry of, **69**, 349  
Oxaziridines, **2**, 83; **24**, 63  
Oxazole chemistry, advances in, **17**, 99  
Oxazolone chemistry  
  new developments in, **21**, 175  
  recent advances in, **4**, 75  
Oxidation of monocyclic pyrroles, **15**, 67  
Oxidative transformations of heteroaromatic iminium salts, **41**, 275  
3-Oxo-2,3-dihydrobenz[*d*]isothiazole 1,1-dioxide (saccharin) and derivatives, **15**, 233  
Oxygen heterocycles, applications of mass spectral techniques and stereochemical considerations in carbohydrates and others, **42**, 335  
4-Oxy- and 4-keto-1,2,3,4-tetrahydroisoquinolines, chemistry of, **15**, 99

## P

- Pentazoles, **3**, 373  
Peri-annellated heterocyclic systems, synthesis, **51**, 1  
Peroxides, cyclic, **8**, 165 (*see also* 1,2-Dioxetanes)  
Phase transfer catalysis, applications in heterocyclic chemistry, **36**, 175  
Phenanthridine chemistry, recent developments in, **13**, 315  
Phenanthrolines, **22**, 1  
Phenothiazines, chemistry of, **9**, 321  
Phenoxazines, **8**, 83  
Photochemistry  
  of heterocycles, **11**, 1

- of nitrogen-containing heterocycles, **30**, 239  
of oxygen- and sulfur-containing heterocycles, **33**, 1  
Physicochemical aspects of purines, **6**, 1; **24**, 215  
Physicochemical properties  
  of azines, **5**, 69  
  of pyrroles, **11**, 383  
Piperazine-2,5-diones and related lactim ethers, **57**, 187  
3-Piperidine, **12**, 43  
Polycyclic aromatic nitrogen cations, **55**, 261  
Polyfluoroheteroaromatic compounds, **28**, 1  
Polymerization of pyrroles and indoles, acid-catalyzed, **2**, 1  
Porphyrin derivatives, hydrogenated: hydrophorphyrins, **43**, 73  
Preparation of pyrroles from ketoximes and acetylenes, **51**, 177  
Present state of selenazole chemistry, **2**, 343  
Progress in pyrazole chemistry, **6**, 347  
Prototropic tautomerism of heteroaromatic compounds, **1**, 311, 339; **2**, 1, 27; **S1**  
Pseudoazulenes, **33**, 185  
Pseudobases, heterocyclic, **1**, 167; **25**, 1  
Purine bases, aza analogs of, **1**, 189  
Purines  
  physicochemical aspects of, **6**, 1; **24**, 215  
  tautomerism, electronic aspects of, **13**, 77  
Pyrans, new developments, **62**, 19  
  thiopyrans, and selenopyrans, **34**, 145  
Pyrazine chemistry, recent advances in, **14**, 99; *see also* Piperazinediones  
Pyrazole chemistry, progress in, **6**, 347  
3*H*-Pyrazoles, **34**, 1  
4*H*-Pyrazoles, **34**, 53  
Pyrazoles condensed to heteroaromatic five- and six-membered rings, **48**, 223  
Pyrazolopyridines, **36**, 343  
Pyrazolopyrimidines, chemistry of, **41**, 319  
Pyridazine chemistry, advances in, **49**, 385  
Pyridazines, **9**, 211; **24**, 363; **49**, 385  
Pyridine(s)  
  action of metal catalysts on, **2**, 179  
  effect of substituents on substitution in, **6**, 229  
  functionalization by directed metalation, **52**, 187  
  organocobalt-catalyzed synthesis, **48**, 177  
  synthesis by electrochemical methods, **37**, 167  
  1,2,3,6-tetrahydro-, **12**, 43  
Pyridinium azolate inner salts, **60**, 197  
Pyridoindoles (the carbolines), **3**, 79  
Pyridopyrimidines, **10**, 149  
Pyrido[1,2-*a*]pyrimidines, chemistry of, **33**, 241  
  recent developments, **63**, 103  
Pyrimidine bases, aza analogs of, **1**, 189  
Pyrimidine ring annelation to an existing ring, **32**, 1  
Pyrimidine ring, tricyclic compounds with a central, **39**, 281  
Pyrimidines  
  2,4-dialkoxy-, Hilbert-Johnson reaction of, **8**, 115  
  fused tricyclic, **39**, 281  
  synthesis and stereochemistry of, **69**, 349  
  tautomerism and electronic structure of biological, **18**, 199  
Pyrimidoazepines, chemistry of diazabicycloundecene (DBU) and other, **42**, 83  
1-Pyridines, chemistry of, **15**, 197  
Pyrones, monocyclic sulfur-containing, **8**, 219  
2-Pyrones, 4-oxy-substituted, dehydroacetic acid and related systems, **53**, 1  
Pyrroles  
  acid-catalyzed polymerization of, **2**, 287  
  1-hydroxy-, **51**, 105  
  from ketoximes and acetylenes, preparations, **51**, 177  
  oxidation of monocyclic, **15**, 67  
  physicochemical properties of, **11**, 383  
2*H*- and 3*H*-Pyrroles, **32**, 233  
Pyrrolidines, generation by radical cyclizations, **58**, 1  
Pyrrolizidine chemistry, **5**, 315; **24**, 247  
Pyrrolizines, chemistry of, **37**, 1  
Pyrrolodiazines with a bridgehead nitrogen, **21**, 1  
Pyrrolopyridines, **9**, 27  
Prylium salts  
  syntheses, **10**, 241  
  syntheses, reactions, and physical properties, **S2**

## Q

- Quantitative analysis of steric effects in heteroaromatics, **43**, 173

## Quaternization

of heteroaromatic compounds, **22**, 71of heterocyclic compounds, **3**, 1Quinazolines, **1**, 253; **24**, 1Quinazolines, fused, **52**, 1Quinolines, functionalization by directed metalation, **52**, 187Quinolizines, aromatic, **5**, 291; **31**, 1Quinones, heterocyclic, **45**, 37

## Quinoxaline chemistry

developments 1963-1975, **22**, 367recent advances in, **2**, 203Quinuclidine chemistry, **11**, 473

## R

Radicals, *see also* Substitution, free-radical and homolyticheteroaromatic, **25**, 205; **27**, 31nitrogen, cyclization of, **58**, 1

## Reactions

of annular nitrogens of azines with electrophiles, **43**, 127of azines with bifunctional nucleophiles: cyclizations and ring transformations, **43**, 301of  $sp^2$ -carbanionic centers in the vicinity of heterocyclic nitrogen atoms, **56**, 155of coordinated ligands, **58**, 123

## Reactivity

of heteroaromatic compounds in the gas phase, **40**, 25of naphthyridines toward nitrogen nucleophiles, **33**, 95Rearrangements, mononuclear heterocyclic, **29**, 141

## Recent advances

azomethine ylide chemistry, **45**, 231in benzo[*b*]thiophene chemistry, **11**, 177in fluoroheterocyclic chemistry, **59**, 1

in furan chemistry

Part I, **30**, 168Part II, **31**, 237in 1,3,4-oxadiazole chemistry, **7**, 183in oxazolone chemistry, **4**, 75in pyrazine chemistry, **14**, 99in pyridazine chemistry, **24**, 363in quinoxaline chemistry, **2**, 203in tetrazole chemistry, **21**, 323

in the chemistry

of benzisothiazoles and other polycyclic isothiazoles, **38**, 105of benzo[*b*]furans, occurrence and synthesis, **18**, 337of benzo[*b*]thiophenes, **29**, 171of 9*H*-carbazoles, **35**, 83of dibenzothiophenes, **16**, 181of dihydroazines, **38**, 1of mononuclear isothiazoles, **14**, 1of phenothiazines, **9**, 321of 1,3,4-thiadiazoles, **9**, 165of thiophenes, **1**, 1

## Recent developments

in naphthyridine chemistry, **33**, 147in isoxazole chemistry, **2**, 365in phenanthridine chemistry, **13**, 315Recent progress in barbituric acid chemistry, **38**, 229Reduction of nitrogen heterocycles with complex metal hydrides, **6**, 45; **39**, 1Regioselective substitution in aromatic six-membered nitrogen heterocycles, **44**, 199Reisert compounds, **9**, 1; **24**, 187Ring closure of *ortho*-substituted *t*-anilines, heterocycles by, **14**, 211, **65**, 1Ring-opening of five-membered heteroaromatic anions, **41**, 41Ring synthesis of heteroaromatic nitro compounds, **25**, 113

## Ring transformations

and cyclizations on reaction of azines with bifunctional nucleophiles, **43**, 301of five-membered heterocycles, **56**, 49

## S

Saccharin and derivatives, **15**, 233

## Salts

1,3-Oxazinium and 3-Azapirylium, **64**, 341*S*-, *Se*-, and*Te*(perfluoroalkyl)dibenzothiophenium, -selenophenium, and -tellurophenium, **64**, 323Saturated bicyclic 6/5 ring-fused systems with bridgehead nitrogen and a single additional heteroatom, **49**, 193

Selenazole chemistry, present state of, **2**, 343  
Selenium-nitrogen heterocycles, **24**, 109  
Selenophene chemistry, advances in, **12**, 1  
Selenophenes, **30**, 127  
Selenopyrans, **34**, 145; **59**, 179  
Selenopyrylium salts, **60**, 65  
Six-membered oxygen-containing rings, saturated, analysis of, **69**, 217  
Six-membered ring systems, nitrogen bridged, **16**, 87  
Steric effects in heteroaromatics, quantitative analysis of, **43**, 173  
Substitution(s)  
  electrophilic, of five-membered rings, **13**, 235  
  free radical, of heteroaromatic compounds, **2**, 131  
  homolytic, of heteroaromatic compounds, **16**, 123  
  nucleophilic heteroaromatic, **3**, 285  
  in pyridines, effect of substituents, **6**, 229  
  regioselective, in aromatic six-membered nitrogen heterocycles, **44**, 199  
Sulfamide moiety, heterocycles containing the, **44**, 81  
Sulfoxides and sulfones: heteroaromatic, **48**, 1  
Sulfur compounds  
  electronic structure of heterocyclic, **5**, 1  
  four-membered rings, **35**, 199  
Sulfur transfer reagents in heterocyclic synthesis, **30**, 47  
Sulfuranes, ligand exchange in, **48**, 1  
Synthesis, *see also* Heterocyclic synthesis and biological activities of condensed heterocyclo[n,m-a, b, or c]quinazolines, **52**, 1  
  of condensed 1,2,4-triazolo[3,4-z]heterocycles, **49**, 277  
  from hydrogen cyanide derivatives, **41**, 1  
  of heterocycles from azadienes, **57**, 1  
  from nitrilium salts and nitriles under acidic conditions, **6**, 95  
  of natural heterocyclic products by hetero Diels-Alder cycloaddition reactions, **42**, 245  
  of peri-annellated heterocyclic systems, **51**, 1

  of pyridines by electrochemical methods, **37**, 167  
  of pyrrolidines by nitrogen radical cyclization, **58**, 1  
  of quaternary benzo[c]phenanthridine alkaloids, **67**, 345  
    and reaction of 1-azirines, **13**, 45  
    by ring-closure of *o*-substituted *t*-anilines, **14**, 211  
  of tetracyclic and pentacyclic condensed thiophene systems, **32**, 127  
  thienopyrimidines, **65**, 235  
  thioureas in, **18**, 99  
  through nucleophilic additions to acetylenic esters, **19**, 279

## T

Tautomeric  
  intramolecular reversible addition reaction to,  
    C=O group, **64**, 251  
    C=N group, **66**, 1  
    C≡N group, **66**, 1  
    C=C group, **66**, 1  
    C≡C group, **66**, 1  
Tautomerism  
  electronic aspects of purine, **13**, 77  
  and electronic structure of biological pyrimidines, **18**, 99  
  prototropic, of heteroaromatic compounds, **1**, 311, 339; **2**, 1, 27; **S1**  
Tellurium atom, 6-membered heterocycles with a, **63**, 1  
Tellurium-containing heterocycles with two heteroatoms, **58**, 47  
Tellurophene and related compounds, **21**, 119  
Telluropyrans, **59**, 179  
Telluropyrylium salts, **60**, 65  
1,2,3,4-Tetrahydroisoquinolines, 4-oxy- and 4-keto-, **15**, 99  
1,2,3,6-Tetrahydropyridines, **12**, 43  
Tetramic acid chemistry, advances in, **57**, 139  
Tetrathia- and Tetraselenafulvalenes, reactivity, **62**, 249  
Tetrazocines, **50**, 1  
Tetrazole chemistry, recent advances in, **21**, 323  
Theoretical studies of physicochemical properties and reactivity of azines, **5**, 69

- Thiadiazines with adjacent sulfur and nitrogen ring atoms, **50**, 255  
1,2,4-Thiadiazoles, **5**, 119; **32**, 285  
1,2,5-Thiadiazoles, chemistry of, **9**, 107  
1,3,4-Thiadiazoles, recent advances in the chemistry of, **9**, 165  
Thianthrenes, **48**, 301  
Thiathiophthenes (1,6,6aS<sup>IV</sup>-trithiapentalenes), **13**, 161  
1,2,3,4-Thiatriazoles, **3**, 263; **20**, 145  
1,3-Thiazin-4-ones, chemistry of, and their derivatives, **66**, 131  
1,3-Thiazines, **50**, 85 synthesis and stereochemistry of, **69**, 349  
1,4-Thiazines and their dihydro derivatives, **24**, 293  
4-Thiazolidinones, **25**, 83  
4-Thiazolidinones, condensed, **49**, 1  
Thienopyridines, **21**, 65  
Thienopyrimidines, synthesis, chemistry, and biological properties, **66**, 193 synthesis, reactions, biological activity, **65**, 235  
Thienothiophenes and related systems, chemistry of, **19**, 123  
Thiochromanones and related compounds, **18**, 59  
Thiocoumarins, **26**, 115  
Thiophenes, recent advances in the chemistry of, **1**, 1  
Thiophenium salts and thiophenium ylids, chemistry of, **45**, 151  
Thiopyrans, **34**, 145; **59**, 179  
Thiopyrones (monocyclic sulfur-containing pyrones), **8**, 219  
Thiopyrylium, selenopyrylium, and telluropirylium salts, **60**, 65  
Thioureas in synthesis of heterocycles, **18**, 99  
Three-membered rings with two heteroatoms, **2**, 83; **24**, 63  
Transition organometallic compounds in heterocyclic synthesis, use of, **30**, 321  
Triacetic acid lactone and related pyrones, **53**, 1  
1,3,5-, 1,3,6-, 1,3,7-, and 1,3,8-Triazanaphthalenes, **10**, 149  
1,2,3-Triazines, **19**, 215  
1,2,4-Triazines, fused to two heterocyclic rings, **61**, 209 fused to heterocycles with 6- and 7-membered rings, **61**, 209 reactions with C-, N-, O-, and S-nucleophiles, **46**, 73  
Triazocines, **50**, 1  
1,2,3-Triazoles, **16**, 33  
1,2,3-Triazoles, 4-amino-, **40**, 129  
 $\Delta^2$ -1,2,3-Triazolines, **37**, 217  
 $\Delta^3$ - and  $\Delta^4$ -1,2,3-Triazolines, **37**, 351  
1,2,4-Triazolines, **46**, 169  
1,2,4-Triazoline-3,5-diones, **67**, 119  
1,2,4-Triazolo[3,4-*z*]heterocycles, synthesis, **49**, 277  
Triazolopyridines, **34**, 79  
1,2,3-Triazolo[4,5-*d*]pyrimidines (8-azapurines), chemistry of, **39**, 117  
1,2,4-Triazolo[1,5-*a*]pyrimidines, **57**, 81  
Tricyclic compounds with a central pyrimidine ring and one bridgehead nitrogen, **39**, 281  
1,6,6aS<sup>IV</sup>-Trithiapentalenes, **13**, 161  
Tropones with fused heterocyclic rings, synthesis, **64**, 81 structure, reactivity, and application, **66**, 285  
Tropolones with fused heterocyclic rings synthesis, **64**, 81 structure, reactivity, and application, **66**, 285  
Tropylium salts with fused heterocyclic rings synthesis, **64**, 81 structure, reactivity, and application, **66**, 285
- U**
- Unsaturated nitrogen heterocyclic compounds containing carbonyl groups, chemistry of, **58**, 171  
Uracils: versatile starting materials in heterocyclic synthesis, **55**, 129  
Use of transition organometallic compounds in heterocyclic synthesis, **30**, 321
- V**
- Vinyl heterocycles, cycloaddition reactions with, **63**, 339  
Vilsmeier conditions, cyclization under, **31**, 207

## Cumulative Subject Index, Volumes 61–70

- 4-Acetamido-1-acetyl-2-methylimidazole, **61**, 8
- 3-Acetamido-2-cyanothiophene, reaction with sodium hydrogen sulfide, **65**, 257
- 2-Acetamido-2-deoxy- $\beta$ -D-glycopyranosylamines, acetolysis, **68**, 288
- 2-Acetamido-1,2-dideoxy-D-galactonojirimycin, synthesis, **68**, 149
- 2-Acetamido-3,4-dihydro-2*H*-pyridopyrimidin-4-ones, **63**, 188
- 2-Acetamido-4,5-dihydrothiophene-3-carbonitrile, reaction with ethyl cyanoacetate, **66**, 211
- 4(5)-Acetamidoimidazole, hydrolytic decomposition, **61**, 10
- 2-Acetamido-1,4-naphthoquinone, from  $\beta$ -naphthylamine, **69**, 57
- 3-Acetamido-2-picoline, *N*-nitrosation and cyclisation to pyrazolopyridine, **68**, 202
- 2-Acetamido-1,3,4-thiadiazole acyclo *C*-nucleoside, **68**, 337
- Acetamidrazonium iodides, ring chain tautomerisation, **66**, 29
- N*-Acetoacetylcarboxamides, acid catalysed reaction with hydrogen sulfide to give 1,3-thiazin-4-ones, **66**, 137
- Acetone *S*-alkylisothiosemicarbazonium halides, ring chain tautomerisation, **66**, 27
- Acetone 2,4-dimethylthiosemicarbazone, ring chain tautomerisation, **66**, 51
- Acetone 4-phenylsemicarbazone, oxidative cyclisation, **69**, 42
- 3-Acetonyltropolone, from furotropones, **66**, 368
- precursor to fused tropones, **64**, 105
- Acetophenone *N*-(*o*-aminobenzoyl)-*N*-methylhydrazone, ring chain tautomerisation **66**, 35
- Acetophenone 4-methylthiosemicarbazones, ring chain tautomerisation, **66**, 52
- Acetophenone silyl enol ether, oxidation with iodosobenzene to give iodonium salt, **69**, 18
- Acetophenone thiosemicarbazone, ring chain tautomerisation, **66**, 51
- 9-[Acetoxy-3-(acetoxymethyl)butyl]-2-aminopurine, **68**, 28, **68**, 36
- crystal and molecular structure, **68**, 38
- 3-Acetoxy-2-acetoxymethyl-2*H*-pyran, **62**, 63
- 1-Acetoxy-1-(4-aryl-2-thiazolyl)-2-arylhylhydrazines, **69**, 46
- 1-Acetoxy-2-benzopyran-4-one, conversion to oxidopyryliumylide and trapping with dipolarophiles, **65**, 360
- 5-Acetoxybenzo[*b*]thiepin, extrusion of sulfur, **65**, 47
- 4-Acetoxybenzylthiotetrathiafulvalenes, **62**, 267
- 3-Acetoxy-2,3'-bibenzofuran, **67**, 18
- 3-Acetoxy-1-cyano-9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinoline, loss of acetate on heating, **70**, 46
- 4-Acetoxy-*cis*-cyclopent-2-ene-*O*-phosphate, Pd(0) catalysed allylation, **66**, 123
- (2-Acetoxyethoxy)methyl chloride, **69**, 130
- (2-Acetoxyethoxymethyl)imidazothiazine nucleosides, **69**, 140
- 2-Acetoxyethyl acetoxymethyl ether, reaction with silylated quinolines, **69**, 133



- 2-(Acetoxymethoxy)-1,3-dibenzyloxypropane, reaction with nucleosides to give acylonucleosides, **68**, 6
- 2-(Acetoxymethoxy)ethyl acetate, coupling with purines, **69**, 135
- 11-Acetoxy-6-methylbenzo[c]phenanthridine, synthesis, **67**, 379; **67**, 381
- 2-*O*-(Acetoxymethyl)-1,3-di-*O*-benzylglycerol, as a precursor of acylnucleosides, **68**, 2
- 2-Acetoxyethyl-4-iodobutylacetate, reaction with purines to acylonucleosides, **68**, 28
- 3-Acetoxy-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylate, hydrolysis, **63**, 192
- 5-Acetoxy-1,3,4-oxadiazoles, synthesis, **69**, 42
- 2-Acetoxy-2*H*-pyran, **62**, 61
- 6-Acetoxy-3(6*H*)-one, source of 3-oxidopyrylium salts, **65**, 355
- reaction with norbornadiene and norbornene, **65**, 355
- reaction with ethyl vinyl ether and styrene, **65**, 356
- reaction with isoprene, **65**, 356
- dimerisation, **65**, 365
- 2-Acetoxy-2-pyridazine, **62**, 15
- 2-Acetoxy-2-pyridines, **62**, 10
- 2-(1-Acetoxyvinyl)furan, reaction with dimethyl acetylene dicarboxylate, **63**, 341
- 2-Acetoxyvinyl- $\alpha$ -D-lyxopyranosylketone, cyclisation with hydroxylamine, **68**, 291
- 1-Acetyl-4-acetamidoimidazole, **61**, 8
- 8-Acetyl-3-(alditol-1-yl)-1,2,4-triazolo[4,3-*a*]pyrimidin-7-one, **70**, 259
- 5-Acetyl-5-alkyl-1,3-dioxanes, conformational preferences of 5-substituents, **69**, 238
- N*-Acetyl-amino-2-mercaptoimidazole, reaction with phosphoryl chloride, **69**, 308
- 4-(Acetyl-amino)oxanes, NMR spectra and conformations, **69**, 225
- 2-Acetyl-3-amino-1-phenylpyrazolidines, ring chain tautomerisation, **66**, 36
- 6-Acetyl-4-amino-5-phenyl-2-trichloromethylthieno[2,3-*d*]pyrimidine, **66**, 205
- Acetyl anhydrocolchicine, X-ray diffraction, **66**, 287
- 2-Acetyl-4-aryl-3-cyano-6-methylpyridine-2-thione, reaction with aldehydes, **68**, 191
- C*-Acetyl-*N*-(2-benzimidazolyl)methanhydrazonoyl halides, reaction with phenylhydrazine, **63**, 319
- 3-Acetylbenzofuran-2(3*H*)-ones, **65**, 141
- 2-Acetyl-1,2-benzisothiazol-3-one, **66**, 159
- 2-Acetylbenzo[*b*]tellurophenes, **63**, 27
- 2-Acetyl-3-benzyl-4,4,7-trimethyl-octahydro-1,3-benzoxazine, **69**, 358
- 4-Acetyl-7-bromo-2-(5-bromo-2-thienyl)-4*H*-1,3,4-benzodiazine, **63**, 325
- 5-*O*-Acetyl-1-bromo-2-pentene, condensation with persilylated heterocyclic bases, **68**, 73
- 3-Acetyl-4-chloro-2-cyanomethylquinoline, in preparation of acronycine, **70**, 133
- 1-Acetyl-1-chloro-2-glycosylethene, reaction with hydrazines, **68**, 267
- 3-Acetyl-2-chlorotropone, reaction with methylhydrazine, **64**, 104
- 3-Acetylchromone, reaction with diazomethane, **65**, 321
- base catalysed rearrangement, **65**, 353
- 3-Acetylcoumarin, reaction with phenacyl bromide, **65**, 318
- reaction with 2-diazopropane, **65**, 320
- reaction with diazoalkanes, **65**, 320
- 5-Acetyl-3-cyano-6-methylpyridin-2-one, reaction with dimethylformamide dimethylacetal, **68**, 190
- 2-Acetyl-1-[cyano(nitro)methylene]perhydro[1,2-*c*]pyrimidine, hydrolysis, **70**, 44
- $\alpha$ -Acetyl- $\alpha$ -diazoacetamides, decomposition, **65**, 120
- 4-Acetyl-1,3-diazoazulenes, **64**, 105
- 1-Acetyl-2,3-dihydroxyindolines, ring chain tautomerism, **64**, 286
- N*-Acetyl enaminones, photolysis, **67**, 218
- Acetylenic bis-alcohols, oxidation, **69**, 26
- Acetylenic ketones, reaction with secondary amines, **67**, 217
- 3-Acetylfurotropylium salts, reduction, **66**, 383
- 2-*N*-Acetylguanine, preparation of acylnucleoside analogs, **68**, 60

- o*-Acetylhomoveratrylic acid, reaction with *o*-iodobenzamides, **67**, 379
- 3-(*N*-Acetyl-*N*-*R*-hydrazino)propanals, ring chain tautomerisation, **66**, 37
- 3-Acetyl-2-hydroxycyclohepta[*b*]pyrrol-5-one, **64**, 123
- 1-Acetyl-2-hydroxy-4-ethyl-3,4,5,6-tetrahydropyrrolo[3,2,1-*i,j*]quinoline, **65**, 122
- 3-Acetyl-2-hydroxy-2-methyl-2,3-dihydrobenzo-1,4-dioxan, ring chain tautomerism, **64**, 281
- 2-Acetyl-3-hydroxy-6-methylpyrone, synthesis, **69**, 49
- 17- $\beta$ -Acetyl-17-hydroxysteroids, oxidation, **69**, 14
- 6-Acetylimidazo[2,1-*b*]thiazoles, **69**, 286
- 3-Acetylimidole, as precursor of 2,3'-biindole, **67**, 14
- 3-Acetyl-2-methoxytropone, reaction with hydroxylamine, **64**, 104  
reaction with benzamides and guanidines, **64**, 104  
reaction with *o*-phenylenediamine, **64**, 105
- 3-Acetylmethyl-7-bromo-6-chlorothieno[3,2-*d*]pyrimidin-4-one, **66**, 250
- 2-Acetyl-6-methylchromone, reaction with 2-diazopropane, **65**, 321
- 5-Acetyl-6-methyl-2-phenylpyrimidine-4(3*H*)-thione, reaction with phenacyl bromide, **66**, 214
- 10-Acetyl-1-methyl-10*H*-[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-*b*]indole, **61**, 291
- N*-Acetyl-*D*-neuraminy-(2-2)-(s)-[2-azido-1-(hydroxymethyl)ethoxy]-methylthymine, **68**, 18
- 3-Acetyl-4-oxo-6,7-dihydro-12*H*-indolo[2,3-*a*]quinolizine, **68**, 214
- 1-Acetylperhydropyrido[1,2-*b*]pyridazines, reduction, **69**, 100
- 2-Acetylperhydropyrido[1,2-*c*]pyrimidine, <sup>1</sup>H NMR spectra and conformations, **70**, 27
- C*-Acetyl-*N*-(3-phenyl-4-*R*-5-pyrazolyl)methanehydrazonoyl halides, cyclisation, **63**, 301
- C*-Acetyl-*N*-5-pyrazolylhydrazonoyl chlorides, reaction with 2-aminopyridine, **63**, 320
- 2-Acetylpyridine, starting material for pyrido[1,2-*d*][1,2,4]triazines, **61**, 213
- 2-Acetylpyridine-3-carboxamide-*N*-oxides, ring chain tautomerism, **64**, 267
- 2-Acetylpyrido[1,2-*c*]pyrimidine, **70**, 70
- 3-Acetyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 152
- N*-Acetyl pyrroles, from enamines, **67**, 228
- 3-Acetylthieno[2,3-*d*]pyrimidine-4(3*H*)-ones, **66**, 206
- N*-Acetyl-*N'*-tosylproflavine, in preparation of pyrrolo[2,3-*c*]acridines, **70**, 140
- C*-Acetyl-*N*-(5-triazolyl)hydrazonoyl chloride, **63**, 305
- 1-*O*-Acetyl-2,3,5-tri-*O*-benzoyl- $\alpha$ -*D*-ribofuranose, **70**, 227
- 3-Acetyltropolone, precursor for heterofused tropolones, **64**, 103  
reaction with hydrazines, thiosemicarbazides and semicarbazides, **64**, 103  
with azides, **64**, 104  
reaction with benzaldehyde, **64**, 101
- 4-Acetyltropolone tosylhydrazone, cyclisation to pyrrolotropolones, **64**, 102
- 1-Acetyl-3-vinylindole, reaction with tetracyanoethylene, **63**, 374
- L*-Acosamine, **67**, 251
- Acridinediones, synthesis via enamines, **67**, 290
- Acrifoline, **70**, 127
- Acgrinine, **70**, 127
- Acronycine, **70**, 127  
oxidation **70**, 133  
reaction with P<sub>4</sub>S<sub>10</sub>, **70**, 133
- Acronycine epoxide, **70**, 127
- Acryloyl halides, reaction with thiocarbamates, **66**, 149
- Actisomide, as antiarrhythmic, **70**, 3
- Acyclo-AZT, preparation, **68**, 18
- Acyclobenzimidazole nucleoside analogues, conformations, **67**, 392
- Acyclonucleosides, therapeutic activity, **67**, 392  
differentiation of anomeric forms by FAB tandem mass spectrometry, **67**, 392  
as cytotoxic agents, **68**, 13  
as antiviral agents, **68**, 14
- Acyclopseudoisocytidine, **69**, 147
- Acyclopseudouridine, **69**, 147

- Acyclovir *see* 9-[(2-hydroxyethoxy)methyl]guanine
- 1-Acyl-5-acylhydrazino-2-pyrazolines, ring chain tautomerisation, **66**, 39
- 2-(Acylalkylthio)-imidazoles, **69**, 281  
cyclisation to imidazo[2,1-*b*]thiazoles, **69**, 280
- 1-[(Acylamidino)methylene]6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolines, formation, **70**, 42
- 2-Acylamido-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, formylation, **63**, 203
- 1-Acylamido-2,3,6,7-tetrahydro-4*H*-pyrimido[1,6-*a*]quinoline-2,4-diones, reaction with P<sub>4</sub>S<sub>10</sub>, **70**, 48
- N*-Acylaminoacids, conversion to azlactones, **64**, 9
- 2-Acylamino-3-acylthiophenes, condensation with ammonia, **65**, 239
- 6-Acylamino-2-acylthiophenes, reaction with ammonium formate, **65**, 255
- 5-Acylamino-5-allyl-6-amino-4,5-dihydropyrimidin-4-ones, in synthesis of acyclonucleosides, **69**, 181
- 2-Acylamino-3-aminothiazolium salts, cyclisation on heating, **69**, 325
- 2-Acylamino-3-benzoylthiophenes, reaction with potassium thiocyanate, **65**, 248
- $\beta$ -Acylaminocarbonyl derivatives, by hydrolysis of benzo-4*H*-3,1-oxazinium salts, **64**, 349
- 2-Acylamino-3-cyanothiophene, cyclisation to thienopyrimidines, **65**, 244  
reaction with amines, **65**, 244
- 3-Acylamino-2-cyanothiophenes, precursor to thieno[3,2-*d*]pyrimidines, **66**, 245
- 1-Acylaminoimidazolones, **69**, 277
- 4-Acylaminoisothiazolone, ring expansion to 2,3-dichloro-1,3-thiazine-4-ones, **66**, 148
- $\beta$ -Acylaminoketones, conversion to oxazonium salts, **64**, 346
- N*-Acyl-*cis* and *trans*-2-aminomethyl-1-cyclohexanol, *N* to *O* acyl migration, **69**, 398
- N*-Acylaminophosphonium salts, **64**, 179
- 1-Acylamino-4-substituted imidazol-2-ones, **69**, 276
- 2-Acylamino-1,3-thiazine-4-ones, **66**, 177
- 2-Acylaminothiophene-3-carboxylates, reaction with *N,N*-dimethylphosphoramidate, **65**, 244  
reaction with hydrazine, **65**, 245
- $\beta$ -Acylaminovinyl ketones, by ring opening of 3-azapyrylium salts, **64**, 353
- N*-Acylated 2-aminothiadiazoles, in preparation of 1,2,4-triazolo [5,1-*b*] [1,3,4]thiadiazoles, **69**, 334
- 2-Acylanilines, reaction with 1,3-diiodobenzenes, **70**, 92
- N*-Acylbenzoisothiazol-3-ones, reduction and cyclisation, **66**, 159
- 2-Acyl-2,3-dihydro-1*H*-pyrido [1,2-*c*]pyrimidin-4-ones, **70**, 68
- N*-Acyl-3-(3,4-dihydroxyphenyl)-L-alanines, conversion to 3,4-dihydrocoumarins, **69**, 51
- 3-Acylhydrazino-2-aminopyridines, precursor to pyrido[2,3-*e*] [1,2,4]triazines, **61**, 214
- N*-Acylhydrazones of 1,3-dicarbonyls, tautomerism, **64**, 295
- Acyliminophosphoranes, **64**, 166
- 4-Acylmethyl-3-azapyrylium salts, recyclisation to 4-acylaminopyrylium salts, **64**, 357
- 2-Acyl-*N*-methylpyrroles, from nitrones by 6 $\pi$ -cyclisation, **65**, 117
- 1-Acyloxymethyl-9,10-dimethoxy-1,2,4,6,7,11*b*-hexahydro[1,3]thiazino[4,3-*a*] isoquinolin-4-imines, <sup>13</sup>C NMR spectroscopy, **70**, 20
- 2-Acyloxyvinyl azides, reaction with triethyl phosphite, **64**, 191
- o*-Acylphenylacetic acid, reaction with dicyclohexylcarbodiimide and 2-hydroxypyridine, **65**, 346
- 6-Acylsubstituted imidazo[2,1-*b*]thiazoles, UV data, **69**, 300
- Acyltetrathiafulvalene, crossed aldol condensations, **62**, 261
- 3-Acylthienotropones, **64**, 100
- N*-Acyltyramines, oxidation to spiro-oxazines, **69**, 58
- C*-Adenine, *see* 7-amino-2- $\beta$ -D-ribofuranosylimidazo[4,5-*d*]pyrimidine, Adenine, Pd(0) catalysed allylation, **66**, 100, **66**, 121

- Adenosine deaminase, in synthesis of acyclovir, **69**, 135
- AIR, *see* 5-amino-1-( $\beta$ -D-ribofuranosyl)-imidazole-5'-monophosphate
- Ajmalicinoid alkaloids, synthesis, **67**, 287
- L-Alanine, reaction with 1,4-naphthoquinone, **64**, 57
- Aldaric acids, reaction with 1,2-diaminobenzene, **70**, 185
- Aldehyde *N*-acylhydrazones, oxidative cyclisation, **69**, 42
- Aldehyde *N*-(2-aminoethyl)hydrazones, ring chain tautomerisation, **66**, 31
- Aldehyde 2-substituted thiosemicarbazones, ring chain tautomerisation, **66**, 50
- Aldehyde thioacylhydrazones, ring chain tautomerisation, **66**, 44
- Aldehyde thiobenzoylhydrazones, ring chain tautomerisation, **66**, 44
- Aldehyde thiosemicarbazone, ring chain tautomerisation, **66**, 51
- 1-(Alditol-1-yl)acenaphtho[1,2-*e*]1,2,4-triazolo[3,4-*c*]1,2,4-triazines, **70**, 300
- 2-(Alditol-1-yl)-5-alkylthio-1,3,4-thiadiazoles, preparation, **68**, 337
- 4-(Alditol-1-yl)-2-aminoimidazoles, synthesis, **68**, 287
- 4-(Alditol-1-yl)-2-(4-aminophenyl)-1,2,3-triazoles, action as azo dyes, **68**, 323
- 4-Alditolyl-2-aminopyrazole, preparation, **68**, 276
- 5-(Alditol-1-yl)-3-amino-1,2,4-triazines, **68**, 393
- 6-(Alditol-1-yl)-3-amino-1,2,4-triazines, **68**, 393
- 4-(Alditol-1-yl)-2-aryl-5-carboxamido-1,2,3-triazoles, preparation from dehydro-L-ascorbic acid 2-arylhydrazone-3-oximes, **68**, 322
- 2-(Alditol-1-yl)benzimidazoles, **70**, 184, 282 in characterisation of sugars, **70**, 185
- 2-(Alditol-1-yl)benzo[*f*]quinoxalines, **70**, 289
- 3-(Alditol-1-yl)benzo[*f*]quinoxalines, **70**, 289
- 2-(Alditol-1-yl)benzothiazolines, preparation, **70**, 194
- 7-(Alditol-1-yl)-1,3-dimethylpteridine-2,4-diones, **70**, 274
- 5-(Alditol-1-yl)-2,5-diphenyltetrazolium salts, **68**, 340
- 3-(Alditol-1-yl)-6,7-diphenyl-1,2,4-triazolo[4,3-*b*]1,2,4-triazines, **70**, 299
- 2-(Alditol-1-yl)furan derivatives, **68**, 354
- 2-(Alditol-1-yl)furo[3,4-*b*]quinoxalin-9-one, **70**, 287
- 4-(Alditol-1-yl)-5-hydroxy-imidazolin-2-thiones, preparation, **68**, 285
- 4-(Alditol-1-yl)-2-hydroxy-2-mercaptoimidazoles, preparation, **68**, 285
- 5-(Alditol-1-yl)-5-hydroxythiazolidines, **68**, 317
- 3-(Alditol-1-ylidene)pyrroles, preparation, **68**, 257
- 4-(Alditol-1-yl)imidazoles, synthesis, **68**, 286
- 4-(Alditol-1-yl)imidazolidine-2,5-dione, preparation, **68**, 288
- 4-(Alditol-1-yl)imidazolin-2-ones, preparation, **68**, 285
- 4-(Alditol-1-yl)imidazolin-2-thiones, preparation, **68**, 285
- 2-(Alditol-1-yl)-imidazo[4,5-*d*]pyrimidines, **70**, 252
- 3-(Alditol-1-yl)isoxazoles, preparations, **68**, 295
- 5-(Alditol-1-yl)isoxazolines, preparations, **68**, 297
- 3-(Alditol-1-yl)-5-methylthio-1,2,4-triazoles, preparation, **68**, 327
- 4-(Alditol-1-yl)-3-nitropyrroles, preparation, **68**, 259
- 5-(Alditol-1-yl)oxazolidin-2-one, synthesis, **68**, 302
- 6-(Alditol-1-yl)-5-oxo-3-thioxo-1,2,4-triazines, **68**, 393
- 4-(Alditol-1-yl)-2-phenyl-5-phenylazo-1,2,3-triazoles, **68**, 322
- 6-(Alditol-1-yl)pteridines, **70**, 264
- 6-(Alditol-1-yl)pteridones, **70**, 272
- 3-(Alditol-1-yl)pyrazoles, preparation, **68**, 275, 276
- 3-(Alditol-1-yl)pyridazines, **68**, 354
- 4-(Alditol-1-yl)pyridazines, **68**, 354
- 4-(Alditol-1-yl)pyrimidines, **68**, 377
- 2-(Alditol-1-yl)pyrroles, **68**, 254 preparation, **68**, 255
- 3-(Alditol-1-yl)pyrroles, synthesis, **68**, 259
- 2-(Alditol-1-yl)quinoxaline, **70**, 184, 282
- 2-(Alditol-1-yl)quinoxalin-3-ones, **70**, 283
- 4-(Alditol-1-yl)-3-substituted-thiazoles, **68**, 316
- 2-(Alditol-1-yl)-1,5,6,7-tetrahydroindol-4-ones, preparation, **70**, 171

- 4-(Alditol-1-yl)tetrahydropyrimidines, **68**, 377
- 2-(Alditol-1-yl)tetrahydro-1,3-thiazines, **68**, 389
- 2-(Alditol-1-yl)thiazoles, **68**, 315
- 5-(Alditol-1-yl)thiazolin-2-ones, **68**, 317
- (4(5)-Alditol-1-yl)-1,2,3-triazoles, **68**, 320
- Aldonolactones, condensation with 1-hydrazinophthalazines, **70**, 218
- Aldonoyldiazomethane acetates, cycloaddition reactions, **70**, 180
- 1-Aldonoylsemicarbazides, dehydrative cyclisation, **68**, 331
- Aldose {acenaphtho[1,2-*e*]1,2,4-triazin-3-yl}hydrazones, cyclisation, **70**, 300
- Aldose phthalazin-1-ylhydrazones, cyclisation, **70**, 217
- Aldose pyrimid-6-ylhydrazones, acetylation, **70**, 216
- Aliphatic aldehyde 4-methylthiosemicarbazones, ring chain tautomerisation, **66**, 52
- Stema* Alkaloids, synthesis, **69**, 30
- N*-Alkanoylhydrazones of benzoylacetaldehyde, ring chain tautomerism, **64**, 300
- N*-Alkanoylhydrazones of formylpinacoline, ring chain tautomerism, **64**, 301
- N*-Alkanoylhydrazones of methyl 5,5-dimethyl-2,4-dioxohexanoate, ring chain tautomerism, **64**, 302
- 3-Alkenylindoles, Diels-Alder reactions, **63**, 362
- 2-Alkenylpurines, **62**, 345
- 3-Alkenylpyridines, **65**, 132
- 3-Alkenylquinolines, **65**, 132
- S*-Alkenyl-substituted diazoketones, intramolecular cyclisation, **65**, 181
- N*-(2-Alkenylthiophenyl)-*C*-azidohydrazones, thermal cyclisation to triazinobenzothiazines, **61**, 274
- S*-Alkenyl-1,2,4-triazoles, cyclisation, **69**, 323
- 1-Alkoxy-2-benzopyrylium-4-olates, cycloadditions to alkenes, **65**, 207
- o*-Alkoxybenzylidene chlorides, flash vacuum pyrolysis, **65**, 140
- 5-Alkoxycarbonyl imidazo[2,1-*b*]thiazoles, **69**, 285
- 2-Alkoxycarbonyl-3-oxoazetidines, **65**, 105
- 2-Alkoxycyclopent[*b*]pyridines, **64**, 202
- 2-Alkoxy-5,6-dihydro-1,3-thiazin-4-ones, **66**, 149
- 9-Alkoxyguanines, preparation, **69**, 162
- 4-Alkoxy-5-halocyclohepta[*b*]thiophene, resistance to hydrolysis, **64**, 89
- 2-Alkoxy-2-hydroxymethyloxane, conformational equilibria, **69**, 225
- cis*-2-Alkoxy-4-methyl-1,3-dioxane, conformations, **69**, 233
- trans*-2-Alkoxy-4-methyl-1,3-dioxane, conformations, **69**, 233
- 1-(Alkoxy-methyl)-5-fluorouracils, **69**, 173
- 2-Alkoxy-4-methyloxane, conformational equilibria, **69**, 225
- 2-Alkoxy-6-methyloxane, conformational equilibria, **69**, 225
- 2-Alkoxy- $\Delta^3$ -1,3,4-oxadiazolines, by oxidation of ketone *N*-acylhydrazones, **69**, 42
- 2-Alkoxy-2*H*-pyrans, **62**, 62
- tautomerism, **62**, 81
- 4-Alkoxy-4*H*-pyrans, equilibration with 2-alkoxy-2*H*-pyrans, **62**, 81
- 2-Alkoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 184
- 2-Alkoxyprolines, from  $\gamma$ -azidoesters, **64**, 187
- 2-Alkoxyquinolines, **64**, 204
- 2-Alkoxy-2,4,5,5-tetramethyl-1,3-dioxanes, conformations, **69**, 236
- Alkoxytropones, cleavage to tropolones, **64**, 91
- Alkyl 2-acylaminothiophene-3-carboxylates, cyclisation, **66**, 198
- N*-Alkyladenine, condensation with 2-deoxyribose, **68**, 61
- N*-Alkyl- $\alpha$ -alkoxycarbonyl- $\alpha$ -diazacetamide, Rh(II) catalysed conversion to lactones, **65**, 104
- N*-(2-Alkylaminoacyl)hydrazones, ring chain tautomerisation, **66**, 31
- 2-Alkylaminoaldoses, reaction with cyclohexane-1,3-diones, **70**, 171
- 3(5)-Alkylamino-4-aminopyrazoles, **67**, 253
- 2-Alkylamino-4*H*-3,1-benzoxazine, **64**, 211
- 3-(Alkylamino)crotonic esters, reaction with nitroethenes, **68**, 258
- 1-Alkylamino-1-deoxy-D-fructose, condensation with cyclohexane-1,3-diones, **70**, 172

- 2-Alkylamino-2-deoxyaldoheptoses, **70**, 181  
2-Alkylamino-2-deoxyaldohexoses, **70**, 181  
1-Alkylamino-1-deoxy pentuloses, **69**, 166  
*N*-Alkylaminofumarates, oxidation to pyrroles, **67**, 228  
9-Alkylaminoguanines, **68**, 43  
2-Alkyl-4(5)-aminoimidazoles, reaction with diethyl ethoxymethylenemalonates, **61**, 15  
2-Alkylamino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 186  
acylation, **63**, 186  
2-Alkylaminopyrrolo[1,2-*a*]quinoxaline, **64**, 219  
Alkyl 3-aminothiophene-2-carboxylates, precursors to thieno[2,3-*d*]pyrimidines, **66**, 236  
Alkyl 3-aminothiophene-4-carboxylates, reaction with amines to thieno[3,4-*d*]pyrimidines, **66**, 255  
5-Alkylamino-1*H*-1,2,4-triazole, **64**, 198  
2-Alkylamino-1*H*-1,2,4-triazolo[2,3-*b*]indazole, **64**, 199  
2-Alkyl-6-aryl-imidazo[2,1-*b*]  
[1,3,4]thiadiazoles, mass spectra, **69**, 313  
5-Alkylated 3-mercapto-1,2,4-triazoles, ring closure, **69**, 317  
*N*-Alkyl-*N*-benzoyltyramines, oxidation, **69**, 30  
Alkylbis(oxymethyl)phosphines, route to 1,3,2,5-dioxasilaphosphorinanes, **61**, 62  
1-Alkyl- $\beta$ -carboline, reaction with dialkyl oxalates, **61**, 179  
3-Alkylcathin-5,6-diones, base hydrolysis, **61**, 180  
*N*-Alkylcathin-5,6-diones, **61**, 179  
4-Alkylcoumarins, **65**, 298  
9-Alkyl-3-cyano-4-imino-4*H*-pyrido  
[1,2-*a*]pyrimidines, reaction with sodium azide, **63**, 204  
1-Alkyl 4,5-diarylimidazoles, from  $\alpha$ -diarylketones and (1-triphenylphosphoranylideneamino)benzotriazole, **64**, 192  
6-Alkyl-3,4-diaryl-1-methyl-1,2,3,4-tetrahydro-*s*-tetrazines, **66**, 34  
4-Alkyl-3,4-dihydrocoumarins, **65**, 296, **65**, 299  
3-Alkyl-5,6-dihydro-1,3-thiazin-4-ones, **66**, 152  
6-Alkyl-5,6-dihydro-1,3-thiazin-4-ones, **66**, 152  
*N*-Alkyl-*N*-2,2-dimethylvinyliminophosphate, **64**, 174  
*cis*-3,4*a*, 5,6-*H*-5-Alkyl-7-formyloxy-3-phenylperhydropyrido[1,2-*a*]  
[1,3]thiazin-1-ones, **70**, 60  
4-Alkyl-3-halogeno-3,4-dihydrocoumarins, **65**, 298  
*C*-Alkyl-*N*-(2-hydroxyalkyl)aldonitrones, ring chain tautomerisation, **66**, 17  
3-Alkylidene-4-(alditol-1-yl)-3-arylthiazoles, **68**, 316  
Alkylideneazomethine ylides, 1,3-dipolar cycloaddition, **65**, 11  
Alkylidene carbenes, conversion to pyrrol-2-ones, **65**, 121  
Alkylidene hydrazides of cyanoacetic acid, ring chain tautomerisation, **66**, 53  
1-Alkylidene-2-methylaminoguanidinium iodides, ring chain tautomerisation, **66**, 30  
2-*N*-Alkyliminoctahydro-2*H*-3,1-benzoxazines, conformations, **69**, 408  
2-*N*-Alkyliminoctahydro-2*H*-3,1-benzthiazines, conformations, **69**, 408  
2-Alkylimino-3-phenyl-1,3-benzothiazin-4-one, Dimroth rearrangement, **66**, 184  
Alkyl 2-isocyanatothiophene-3-carboxylates, reaction with amines and cyclisation to thieno[2,3-*d*]pyrimidines, **66**, 197  
3-Alkyl-4-iminothieno[2,3-*d*]pyrimidine-2-thiones, **66**, 210  
1-Alkylisatin, reaction product with thiobenzhydrazide ring chain tautomerisation, **66**, 45  
*N*-Alkyl-*N*-methoxy-2-benzimidazolinones, preparation, **69**, 36  
2-Alkyl-*N*-methylpiperidin-3-ones, **65**, 127  
Alkyl nitriles, reaction with  $\alpha$ -carboxylates and zinc dust, **67**, 214  
3-Alkyl-4-oxo-benz[*c*]thiane, **65**, 168  
*N*-Alkylloxybenzimidazoles, **65**, 15  
1-Alkylperhydropyrido[1,2-*c*]pyrimidines, <sup>1</sup>H NMR spectra and conformations, **70**, 25  
Alkyl 2-pyridylsulfoxides, reaction with phenyl Grignards to give 2,2'-bipyridyl, **62**, 404  
5-Alkylpyrimidine-4(3*H*)-thione, bromination to thieno[2,3-*d*]pyrimidines, **66**, 218

- Alkyl  $\alpha$ -(2-quinolyl)glycinate, conversion to imidazo[1,5-*a*]quinoline, **64**, 57
- Alkylsubstituted 4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, octanol-water partition coefficients, **63**, 107
- N-Alkylsubstituted-3-(3-trifluoromethylbenzoyl)propionamides, ring chain tautomerism, **64**, 264
- 2-(*N*-Alkyl-1,2,3,4-tetrahydroisoquinolin-1yl)ethanols, from reductive ring opening of oxazinoisoquinolines, **70**, 32
- Alkyl 2,3,4,9-tetrahydro-6-oxo-6*H*-pyrido[1,2-*a*]pyrimidine-9-carboxylate, **63**, 161
- Alkyl tetrathiafulvalenes, **62**, 276
- 9-Alkyl-3-(1*H*-tetrazol-5-yl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 203
- 3-Alkylthiazolo[3,2-*b*]-s-triazole, **69**, 324
- 3-Alkyl(or 3-aryl)-thieno[2,3-*d*]pyrimidin-2,4-diones, **66**, 195
- (Alkylthio)alkylidenciminium salts, reaction with active methylene groups, **67**, 212
- 2-Alkylthio-5-amino-4-phenyl-6-substituted-thieno[2,3-*d*]pyrimidines, **66**, 218
- 2-Alkylthio-4-aminothieno[2,3-*d*]pyrimidines, **66**, 211
- 6-Alkylthio-1,5,2-azaphosphonioboratacyclohexa-3,6-diene, **61**, 123
- 1'-Alkyl-2-thiopseudouridine, **68**, 367
- 2'-Alkyl-2-thiopseudouridine, **68**, 367
- 4'-Alkyl-2-thiopseudouridine, **68**, 367
- 5'-Alkyl-2-thiopseudouridine, **68**, 367
- 5,5'-Alkyl-2-thiopseudouridine, **68**, 367
- 2-Alkylthio-2*H*-pyrans, **62**, 27
- Alkylthio(seleno)tetrathiofulvalenes, **62**, 266
- 2-Alkylthio-1,3-thiazin-4-ones, **66**, 135, **66**, 137
- 2-Alkylthiothieno[3,2-*d*]pyrimidin-2-one, **66**, 252
- 2-Alkylthiothieno[3,4-*d*]pyrimidine-4(3*H*)-one, **66**, 195
- reaction with amines, **66**, 269
- 2-Alkyl-2,4,4-trimethyl-1,3-dioxanes, conformations, **69**, 233
- 1-Alkyl-3,4,4-trimethyl-5-methylene-2-pyrazolines, reaction product with hydroxylamine ring chain tautomerisation, **66**, 40
- 1-Alkyl-2(and 3-)vinylpyrroles, addition to acrylonitriles, **63**, 372
- N*-Alkynyl diazoacetamides, Rh(II) catalysed decomposition, **65**, 117
- Alkynyliodonium salts in heterocyclic synthesis, **69**, 5
- Alkynyl (*p*-phenylene)bis-iodonium ditriflates, reaction with phenoxides, **69**, 16
- N*-Alkynyl substituted 2-diazoacetamides, Rh(II) catalysed decomposition, **65**, 118
- 5-Allenyl-1,2,4-triazoles, cyclisation, **69**, 323
- Allonitidine, synthesis, **67**, 352; **67**, 365
- 2-Allyl-3-aminocyclohexenones, formation of dihydrobenzofurans, **67**, 220
- 7-(*N*-Allylamino)-6,7-dihydro-1*H*, 3-*H*, 5*H*-pyrido[3,2,1-*ij*][1,3]benzoxazine-3-one, *N*-methylation, **70**, 37
- 2-Allylaminotropone, **64**, 100
- N*-Allylbenzoxazolethione, **66**, 96
- 2-Allyl-1-ethoxycarbonylpyrrole, in preparation of indol-4-yl *C*-nucleosides, **70**, 169
- 8-Allylimidazo[1,5-*a*]-1,3,5-triazin-4(3*H*)-ones, in synthesis of acyclonucleosides, **69**, 181
- hydroxylation, **70**, 303
- N*-Allylindole, **66**, 91
- 3-Allylindole, **66**, 91
- 2-Allylinsine, **62**, 345
- 1-Allyl-3(2-nitrovinyl)indoles, cycloaddition, **63**, 349
- 2-Allyl-3-oxo-L-gulonolactone 3,6-hemiketals, **66**, 83
- 6-Allyloxy- $\alpha$ -diazocarbonyl compounds, decomposition, **65**, 159
- (*o*-Allyloxy)phenyldiazomethanes, photolysis, **65**, 146
- 2-Allyloxypyridine, Pt(0)-catalysed isomerisation to *N*-allyl-2-pyridone, **66**, 100
- 2-Allyl-1-phenylsulfonylindole, in preparation of carbazol-4-yl *C*-nucleoside, **70**, 173
- N*-Allyl-2-pyridone, **66**, 100
- 2-Allylquinoline, from methyl 2-quinolinesulfoxide and allyl Grignard reagent, **62**, 403
- 3-(2-Allyltetrahydrothiophen-2-yl)-2-methylinden-1-one, **65**, 164

- 3-Allylthieno[2,3-*d*]pyrimidin-4-one-2(1*H*)-thione, **66**, 196
- 3-Allylthieno[3,2-*d*]pyrimidin-4(3*H*)-one-2(1*H*)-thiones, **66**, 242
- N*-Allyl-*N*-thiophenylaminone, hetero-Cope rearrangement, **67**, 293
- 3-Allyl-1-(triisopropylsilyl)pyrrole, in preparation of indol-7-yl *C*-nucleosides, **70**, 170
- Alpinigenine, synthesis, **67**, 322
- Alpinine, synthesis, **67**, 322
- AM1 study of tautomerism in aminoimidazoles, **61**, 51
- 6- $\beta$ -Amidocyclonocardicins, **65**, 108
- Amines, reaction with diones to give enamines, **67**, 210
- Aminoacetonitrile, precursor of 4-amino-2-substituted imidazoles, **61**, 11
- o*-Aminoacetophenone, oxidative cyclisation, **69**, 40
- in synthesis of ascididemin, **70**, 119
- 5-Amino-6-acetylthieno[2,3-*d*]pyrimidine, **65**, 249
- L*-Aminoacids, reaction with *N*-sulfonylaniline and *N*-methylmaleimide, **64**, 47
- 3-Aminoacridine, reaction with ethyl 2-methylacetoacetate, **70**, 140
- 4-Aminoacridine, **70**, 106
- 4-Aminoacridone, **70**, 106
- 2-Amino-3-acylthiophenes, condensation with formamide, **65**, 239
- reaction with urethane, **65**, 243
- 1,3-Aminoalcohols, from 1,3-oxazinium salts, **64**, 346
- 4-Amino-5-alkoxycarbonylimidazol-2-yl *C*-nucleosides, **70**, 250
- $\alpha$ -Aminoalkylidene- $\beta$ -alkoxy- $\alpha$ -lactams, rearrangement to enamines, **67**, 217
- 2-Amino-5-alkyl-1,3,4-oxadiazole, in synthesis of imidazo[2,1-*b*][1,3,4]oxadiazoles, **69**, 276
- alkylation, **69**, 277
- 2-( $\theta$ -Aminoalkyl)-2-phenylindane-1,3-diones, ring chain tautomerism, **64**, 286
- 3-Amino-4-(1-amino-2,2-diazinomethylene)thiophene, reaction with aldehydes, **65**, 261
- 4-Amino-7-( $\beta$ -D-arabino-furanosyl)-5*H*-pyrrolo[3,2-*d*]pyrimidine, **70**, 220
- 2-Amino-1-aryl-3-alkylpyrazole, synthesis, **69**, 37
- 6-Amino-5-(aryloxy)-1,3-dimethyluracils, reaction with urea, **61**, 243
- 2-Amino-3-aryl-4-iminothieno[2,3-*d*]pyrimidines, **66**, 208, **66**, 221
- 4-Amino-3-aryl-1,2,4-triazole-5-thiols, cyclocondensations with aldaric acids, **70**, 197
- 5-Amino-6-azido-1,3-dimethylxanthine, thermolysis to 3-aminoiso-ferrenulin, **61**, 244
- 7-Amino-6-azido-1,3-dimethylxanthine, thermolysis to 3-aminoferrulenin, **61**, 256
- 2-Aminobenzaldehyde, **70**, 99
- 9-Aminobenzo[*a*]acridines, in preparation of pyrido[4,3,2-*k*]acridines, **70**, 123
- 7-Aminobenzo[*b*][1,10]phenanthrolines, **70**, 104
- 10-Aminobenzo[*b*][1,7]phenanthroline, preparation, **70**, 100
- 2-Aminobenzophenone, condensation with diethyl 2,5-dioxo-1,4-cyclohexanedicarboxylate, **70**, 96
- 6-Aminobenzopyran-2-ones, reaction with 2-ethoxycarbonylcyclohexanone, **70**, 137
- 2-Amino-1,3-benzothiazin-4-ones, **66**, 163
- from 2-mercaptobenzoic acid and carbodiimide, **66**, 141
- 1-Aminobenzotriazole, oxidation to bistriazolo derivatives, **69**, 62
- 2-Aminobenzotriazole, conversion to 1,2'-bibenzotriazole, **67**, 44
- 2-Aminobenzoylformic acid, reaction with cyclohexane-1,2-dione dioxime, **70**, 107
- N*-(2-Aminobenzoyl)-*N*-methylhydrazones, tautomerism, **64**, 256
- 2-Amino-4-benzylamino-3-cyanopyridine, precursor to pyrido[1,2-*a*]pyrimidines, **63**, 142
- 5-(*o*-Aminobenzyl)-6-azauracil, cyclisation to [1,2,4]triazino[4,3-*a*]quinolines, **61**, 226
- 5-Amino-1-(2-benzyloxyethoxymethyl)-4-methylcarbamoylimidazole, reaction with benzoyl isothiocyanate, **69**, 136
- 2-Amino-6-benzyloxyuracil, alkylation to acyclonucleosides, **68**, 33,47
- 2-Amino-3-benzyloxyuracil, reaction with 1,1,3,3-tetramethoxypropane, **63**, 125



- 2-(2-Aminobenzyl)pyridine, **69**, 99  
2-Amino-5-bromo-3-cyanopyrazine, precursor to pteridines, **62**, 322  
4-Amino-6-bromo-5-cyanopyrrolo[2,3-*d*]pyrimidines, alkylation to give acylonucleosides, **68**, 10  
4-Amino-2-bromimidazole, **61**, 19  
5-Amino-6-*p*-bromophenylimidazo[2,1-*b*]thiazole, **69**, 295  
2-Amino-3-bromotropone, reaction with active methylene compounds, **64**, 109  
conversion to thiazolotropones, **64**, 125  
4-(4-Aminobutyl)-2,6-dimethylpyrimidine-5-carboxylate, formation, **70**, 42  
4-Amino-5-carbamoylimidazol-2-yl *C*-nucleosides, **70**, 250  
4-Amino-5(3)-carbamoyl-3(5)- $\beta$ -D-ribofuranosylpyrazole, **70**, 234  
3-Amino-4-carboalkoxy-6-hydroxycoumarin, **64**, 51  
5-Amino-6-carboalkoxythieno[2,3-*d*]pyrimidine, **65**, 239  
3-Amino-4-carbonitriles, precursor to thieno[3,4-*d*]pyrimidines, **66**, 264  
1-Aminocarbonylmethylene-1,2,3,4-tetrahydroquinoline, formation, **70**, 42  
4-Aminocarbonyl-3-methylthio-1*H*-pyrido[1,2-*c*]pyrimidin-1-one, **70**, 45  
2-(1-Aminocarbonyl-2-piperidyl)acetic acid, formation from perhydropyridopyrimidines, **70**, 41  
5-Amino-4-carboxamido-2- $\beta$ -D-ribofuranosylthiazole, nitrosation, **70**, 295  
5-Amino-6-carboxythieno[2,3-*d*]pyrimidines, **65**, 238  
*o*-Aminochalcones, oxidative cyclisation, **69**, 40  
2-Amino-6-chloromethyl-3-cyano-5-ethoxycarbonyl-4(2-furyl)-4*H*-pyran, **62**, 115  
4-Amino-6-chloro-5-nitropyrimidine, in preparation of acylonucleosides, **68**, 74  
2-Amino-6-chloropurine, Pd(0) catalysed allylation, **66**, 121  
in nucleoside synthesis, **67**, 397  
in *seco*-nucleoside synthesis, **67**, 414  
condensation to acylonucleosides, **68**, 10  
reaction with substituted cyclopropanes, **68**, 30  
conversion to methoxyaminonucleosides, **68**, 3  
alkylation, **69**, 155  
alkylation with bromoalkenylbenzoate, **69**, 158  
4-Amino-2-chlorothieno[2,3-*d*]pyrimidines, **66**, 221  
Aminocinnamates, reaction with sufuryl chloride, **65**, 57  
5'-Aminocordycepin, preparation of ring opened analogue, **68**, 59  
3-Aminocrotonamide, reaction with 2,5-anhydro-D-allonic acid derivatives, **68**, 363  
2-Amino-2-cyanoacetamide hydrochloride, precursor to carboacyclic *C*-nucleosides, **68**, 41  
2-Amino-3-cyano-4,5-dihydrothiophenes, benzylation and condensation with amines, **66**, 207  
2-Amino-5-cyano-3-ethoxycarbonyl-4,6-diphenyl-4*H*-pyran, **62**, 115  
5-Amino-4-cyanoimidazole, in synthesis of imidazo[4,5-*d*]pyrimidin-5-yl *C*-nucleosides, **70**, 252  
4-Amino-5-cyanoimidazol-2-yl *C*-nucleosides, **70**, 250  
2-Amino-3-cyano-4-phenyl-6-(2-thiazolyl)-4*H*-pyran, **62**, 37  
2-Amino-3-cyano-4*H*-pyrans, conversion to pyridines, **62**, 72  
isomerisation to 3-cyano-3,4-dihydro-2*H*-pyridines, **62**, 82  
hydrolytic cleavage, **62**, 87  
conversion to pyranocyanopyridines, **62**, 106  
3-Amino-4-cyanopyrazole, cyclocondensation with ribofuranosylthio-formimidates, **70**, 229  
4-Amino-3-cyanopyrazole, **70**, 247  
4-Amino-3-cyanopyridine, in formation of pyrido[4,3-*d*]pyrimidin-3-yl *C*-nucleosides, **70**, 261  
3-Amino-2-cyanopyrrol-4-yl acyclo *C*-nucleosides, **70**, 223  
2-Amino-3-cyanothiophene, reaction with enamines, **67**, 292  
reaction with carbonyl sulfide, **65**, 247  
reaction with formamide, **65**, 248

- reaction with carbon disulfide, **65**, 248  
condensation with formamide, **65**, 240
- 3-Amino-2-cyanothiophene, reaction with guanidine, **65**, 255
- 2-Amino-3-cyanothiophene-4(5*H*)-one, reaction with phosphorous oxychloride, **65**, 248
- 2-Amino-1-cyclohexacarboxamides, reaction with dicyclohexyl carbodiimide, **69**, 393
- 3-Aminocyclohex-2-enones, reaction with diacylethylenes, **67**, 238
- 5-Amino-1-cyclohexylimidazole-4-carboxylate, as a model compound for C-AIR, **61**, 27
- trans*-2-Amino-1-cyclopentanecarboxamide, failure to cyclise, **69**, 398
- 3'-Amino-3'-deoxy-2',3'-*seco*-adenosine, in synthesis of *seco*-puromycin analogues, **67**, 406
- 2-Amino-2-deoxyaldoheptoses, condensation with 1,3-dicarbonyl compounds, **68**, 255; **70**, 181
- 2-Amino-2-deoxyaldohexoses, **70**, 181
- 1-Amino-1-deoxyaldoses, cyclocondensation with cyanamide, **68**, 287
- 2-Amino-2-deoxyaldose, precursor to 4-imidazolyl acyclo C-nucleosides, **68**, 285  
cyclocondensation with cyanamide, **68**, 287  
in preparation of  
polyhydroxyalkylpyrroles, **67**, 422  
reaction with cyclohexane-1,3-diones, **70**, 171
- 1-Amino-1-deoxy-D-arabino hexulose, reaction with cyanamide, **68**, 69
- 4-Amino-4-deoxy-D-erythronic acid, in preparation of acyclonucleosides, **68**, 74
- 1-Amino-1-deoxy-D-fructose, **68**, 382  
reaction with malondialdehyde, **68**, 349  
reaction with 6-chloro-5-nitrouracil, **70**, 274
- 6-Amino-6-deoxy-D-galactopyranose, reaction with thiophosgene, **68**, 301
- 2-Amino-2-deoxy-D-galactose, reaction with ammonia **68**, 382
- 1-Amino-1-deoxy-D-glucitol, **70**, 253
- 1-Amino-1-deoxy-D-glucopyranose, synthesis, **67**, 422
- 2-Amino-2-deoxy-D-glucopyranose, reaction with isothiocyanates, **70**, 180
- 2-Amino-2-deoxy-L-glucopyranose, **70**, 188
- 1-Amino-1-deoxy-D-glucose, reaction with ammonia **68**, 382
- 2-Amino-2-deoxy-D-glucose, reaction with ammonia **68**, 382  
reaction with 1-ethoxy-2-nitroethene, **68**, 255  
reaction with dimethyl  
acetylenedicarboxylate, **68**, 255  
mechanism of formation of 2-(D-arabino-tetritol-1-yl)-5-(2-deoxy-D-arabino-tetritol-1-yl)pyrazine, **68**, 383
- 1-Amino-1-deoxyketohexoses, in synthesis of 4-(alditol-1-yl)-3-nitropyrroles, **68**, 259
- 1-Amino-1-deoxy-2-ketoses, reaction with carbon disulfide, **68**, 317
- 1-Amino-1-deoxyketose, precursor to 4-imidazolyl acyclo, C-nucleosides, **68**, 285  
reaction with cyanates, **68**, 286
- 2-Amino-2-deoxy-D-mannose, reaction with ammonia **68**, 382
- 1-Amino-1-deoxy-L-erythro-pentulose, reaction with 2-amino-4-chloro-5-nitropyrimidin-4-one, **70**, 266
- 5'-Amino-5'-deoxytiazofurin, **68**, 309
- 4-Amino-3-dialkylaminopyridines, nitration to pyridoimidazoles, **65**, 12
- 2-Amino-4,5-dialkylthiazoles, from  $\alpha$ -tosyloxyketones and thioureas, **69**, 44
- 2-Amino-4,6-diaryl-3-cyano-4*H*-pyrans, conversion to 2-alkoxypyridines, **62**, 72
- 2-Amino-4,6-dichloropyrimidine, reaction with 4-amino-1-butanol, **69**, 153  
preparation of acyclonucleosides, **69**, 181
- 5-Amino-4,6-dichloropyrimidine, in preparation of acyclonucleosides, **68**, 38,64  
preparation of acyclonucleosides, **69**, 177
- 2-Amino-4,6-dichloro-5-(substituted)pyrimidine, in preparation of acyclonucleosides, **68**, 72
- 2-Amino-3,5-dicyano-4-isopropyl-4-methyl-4*H*-pyran, **62**, 115
- 2-Amino-3,5-dicyano-4*H*-pyrans, isomerisation, **62**, 94  
conversion to 6-amino-5-cyanopyrimidines, **62**, 98
- 4-Amino-2,3-dihydro-1,5-benzothiazepine, precursor to imidazo[2,1-*d*][1,5]benzothiazepines, **63**, 78  
reaction with triethyl orthoacetate, **63**, 81
- 4-Amino-4,5-dihydro-5-hydroxy-1,2,4-triazine, ring chain tautomerism, **64**, 307

- 1-Amino-1,2-dihydroimidazo[4,5-*b*]quinolin-2-one, **61**, 226
- 2-Aminodihydropyridines, **67**, 274
- 9-Amino-6,7-dihydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 226
- 5-Amino-4,6-dihydropyrimidines, precursor to pyrimidotriazines, **61**, 251
- 6-Amino-1,4-dihydro-8*H*-pyrimido[6,1-*c*][1,2,4]triazin-8-ones, **61**, 241
- N*-Amino-2,3-dihydro-1,3-thiazin-4-ones, **66**, 159
- 3-Amino-2,3-dihydrothiazole, reaction with formic acid, **69**, 324
- 2-Amino-7-[(2'*S*)-1',2'-dihydroxyethyl]-6-(methylthio)thieno[2',3':2,3]pyrazino[6,5-*d*]pyrimidine], **70**, 276
- 2-Amino-6-(1-*erythro*-1',2'-dihydroxypropyl)-4-oxo(3*H*)pteridine, **69**, 170, **70**, 265
- 2-Amino-(1-*erythro*-1',2'-dihydroxypropyl)pteridin-4,7-dione, **70**, 271
- 2-Amino-6-(*D*-*threo*-1',2'-dihydroxypropyl)pteridin-4-one, **70**, 268
- 2-Amino-6-(1-*threo*-1',2'-dihydroxypropyl)pteridin-4-one, **70**, 268
- 2-Amino-7-(1-*erythro*-1',2'-dihydroxypropyl)pteridin-4-one, **70**, 272
- 2-Amino-9,10-dimethoxy-4-phenyl-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolines, preparation, **70**, 43
- 3-Amino-5,5-dimethylcyclohexen-1-one, reaction with *D*-mannose, **70**, 210
- 5-Amino-2,2-dimethyl-7-methoxychromene, coupling with 2-bromobenzoic acid, **70**, 131
- 6-Amino-1,3-dimethyl-5-nitrosouracil, precursor to pyrimido[4,5-*e*][1,2,4]triazines, **61**, 242  
reaction with aldehydes and hydrazines, **61**, 252
- 4-Amino-1,5-dimethyl-2-phenylpyrazol-3(2*H*)-one, diazotisation and coupling with 3-chloro-2,4-pentanedione, **63**, 291
- 5-Amino-1,3-dimethylthieno[3,4-*d*]pyrimidine-2,4-diones, **66**, 266  
phosphodiesterase inhibition, **66**, 273
- 2-Amino-1,3-dioxane, conformational energies, **69**, 236
- 1-Amino-4,6-diphenylpyridine-2(1*H*)-thione, reaction with dimethylformamide dimethyl acetal, **69**, 117
- 1-Amino-2,5-diphenyltriazole, in synthesis of aziridines, **69**, 13
- 4-Amino-1-(and 2-)-disubstituted imidazoles, **61**, 23
- 4(5)-Amino-5(4)-ethoxycarbonylimidazole, reaction with 2-oxa-1,4-butanediol diacetate, **69**, 137
- 3-Amino-4-ethoxycarbonylpyrazole, **70**, 229
- 4-Amino-4-ethoxycarbonyl-pyrrol-3-yl *C*-nucleoside, reaction with cyanogen bromide, **70**, 293
- 3-Amino-2-formamido thiazolium mesitylene sulfonate, cyclisation, **69**, 326
- 2-Amino-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, acylation, **63**, 184
- 4-Aminofuranones, **67**, 221
- 3-Aminofurans, from Grignard reactions on enamines, **67**, 219
- 2-Aminofurotropolones, **64**, 105
- 2-Amino-6-[2-(β-*D*-glucouronopyranosyl)-*D*-glucopentitol-1-yl)]pteridin-4-one, **70**, 271
- 7-Amino-5'-α-*D*-glucopyranosylpyrrolo[3,2-*d*]pyrimidine, isolation from *Anabaena affinis*, **68**, 227
- 4-Amino-7-(5'-*O*-α-*D*-glucopyranosyl-β-*D*-ribofuranosyl)-5*H*-pyrrolo[3,2-*d*]pyrimidine, **70**, 220
- Aminoguanidine, reaction with 3-deoxyglucosulose, **68**, 78
- 2-Amino-6-halopyrazinicarboxylic esters, arylation, **62**, 363
- 3-Amino-4,4*a*, 5,6,7,8-hexahydro-1*H*-3-iminoperhydropyrido[1,2-*c*]pyrimidin-1-ones, **70**, 64
- 2-Amino-3-hydrazinopyridine, precursor to 3-methylthiopyrido[2,3-*e*][1,2,4]triazines, **61**, 214
- 3-Amino-4-hydrazinopyridine, precursor to pyrido[3,4-*e*][1,2,4]triazines, **61**, 217
- 3-Amino-2-hydrazino-4(3*H*)pyrimidinones, precursor to pyrido[1,2-*b*][1,2,4]triazines, **61**, 238
- 3-Amino-6-hydrazino-1,2,4-triazin-5-one, in synthesis of 1,2,4-triazolo[3,4-*f*]1,2,4-triazin-3-yl acyclo *C*-nucleosides, **70**, 301
- 1-Amino-8-(2-hydroxyalkyl)-4-oxoquinoline-3-carboxylates, cyclisation with diethyl azidocarboxylate, **69**, 115

- 2-Amino-3-(2'-hydroxybenzaldiminomethyl)-4-methoxy-6-methylpyridine, ring chain tautomerisation, **66**, 22
- 4-Amino-3-hydroxycyclohexa-1,5-diene-1-carboxylic acid, **64**, 171
- 5-Amino-1-(2'-hydroxyethyl)-2-methylimidazole, **61**, 24
- 2-Amino-3-hydroxypyridine, reaction with 1,1,3,3-tetramethoxypropane, **63**, 125
- 3-Amino-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 177
- 2-Amino-3-hydroxytropolones, reaction with carboxylic anhydrides, **64**, 109
- 2-Aminoimidazole acyclo-*C*-nucleosides, **69**, 202
- 5-Aminoimidazole-4-carboxamide, alkylations, **69**, 136
- 4-Amino-5-imidazolecarboxylic acid, enzymatic decarboxylation, **61**, 10 synthesis, **61**, 10 enzymatic decarboxylation, **61**, 10 synthesis, **61**, 10
- 2-Aminoimidazo[2,1-*b*][1,3,4]thiadiazoles, alkylation, **69**, 310 cycloaddition with diethyl succinate, **69**, 312
- 3-Amino-2-imino-1,3-benzothiazin-4-one, **66**, 145
- 3-Amino-2-imino-4-methylthiazole, reaction with *N*-(dichloromethylene)-*N*,*N*-dimethylammonium chloride, **69**, 324
- 2-Amino-4-iminothieno[2,3-*d*]pyrimidines, **66**, 219
- 3-Amino-4-iminothieno[2,3-*d*]pyrimidines, **65**, 241
- 4-Amino-5-iodo-6-methyl-2-phenylpyrimidine, coupling to ethylacrylate, **62**, 309
- 5-Aminoisoquinoline, in preparation of 7-chlorobenzo[*b*][1,8]phenanthroline, **70**, 109
- $\alpha$ -Aminoketones, preparation from enol silanes, **69**, 11
- $\beta$ -Aminoketones, dehydration to enaminones, **67**, 215
- N*-Amino-2-mercaptoimidazole, reaction with thiocyanates, **69**, 309
- 5-Amino-2-mercapto-1-methylimidazole, hydrolysis to 3-methyl-2-thiohydantoin, **61**, 32
- from 5-amino-2-methylamino-thiazole, **61**, 28
- 4-Amino-3-mercapto-6-methyl[1,2,4]triazin-5(4*H*)-one, reaction with phenacyl bromide, **61**, 280
- 5-Amino-3-mercaptotriazole, reaction with chloroacetone, **69**, 320
- 1-Amino-2-(*o*-methoxycarbonylphenyl)pyridinium salt, cyclisation, **69**, 113
- 4-Amino-5(3)-methoxycarbonylpyrazol-3(5)-yl *C*-nucleoside, **70**, 234
- 3-Amino-2-methoxycarbonylthiophene, reaction with dimethyl acetylene dicarboxylate, **67**, 293
- 3-Amino-1-methoxy-10-methyl-9(10*H*)-acridone, **70**, 102
- 5-Amino-6-methoxy-4-methylquinoline, intramolecular cyclisation, **68**, 200
- 1-Amino-4-methylacridine, reaction with acetylacetone, **70**, 123
- 1-Amino-4-methylacridin-9(10*H*)one, reaction with acetylacetone, **70**, 92
- 3-Amino-4-methylacridin-9(10*H*)one, **70**, 97
- 5-Amino-2-methylaminothiazole, rearrangement to imidazoles, **61**, 28
- 3-Amino-3-methylbut-1-yne, **70**, 102
- cis* and *trans*-2-Aminomethyl-1-cycloheptanol, reaction with ethyl 4-chlorobenzimidate, **69**, 374
- cis*-2-Aminomethyl-1-cyclohexanol, ring closure with aromatic aldehydes, **69**, 355 reaction with ethyl 4-chlorobenzimidate, **69**, 374
- condensation with *p*-nitrobenzaldehyde ring chain tautomerisation, **66**, 12
- trans*-2-Aminomethyl-1-cyclohexanol, ring closure with aromatic aldehydes, **69**, 355
- cis* and *trans*-2-Aminomethyl-1-cyclohexanols, reaction with formaldehyde, **69**, 354
- trans*-2-Aminomethyl-1-cyclopentanol, conversion to 1,3-oxazine-2-thiones, **69**, 364
- failure to cyclise with aldehydes, **69**, 398
- 2-Aminomethyl-1-cyclopentylamine, cyclocondensation reactions, **69**, 396
- 9-Aminomethylene-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, tautomerism, **63**, 115

- 2-Amino-6-methylene-1,3-thiazin-4-ones, **66**, 152
- 2-Amino-4-(1-methylhydrazino)-6(1*H*)-pyrimidone, precursor to pyrimido [5,4-*e*][1,2,4]triazines, **61**, 254
- 2-Amino-1-methylimidazoline, precursor to imidazolquinazolinones, **67**, 317
- 5-Aminomethyl-6-methylimidazo[2,1-*b*]thiazole, **69**, 297
- 2-Aminomethylpyrazine, in preparation of imidazo[1,2-*a*]pyrazin-3-yl *C*-nucleosides, **70**, 280
- 2-Aminomethylpyridine, in formation of imidazo[1,5-*a*]pyridin-3-yl *C*-nucleosides, **70**, 200
- 2-Amino-4-methylpyridine-reaction with 1,3-acetonedicarboxylate **63**, 133
- 3-Amino-2-methylpyridine, reaction with triethyl orthoformate, **68**, 198
- 3-Amino-5-methyl-2-pyridinol, oxidation, **61**, 144
- 3-Amino-2-methylquinoline, reaction with triethyl orthoformate, **68**, 198
- 4-Amino-2-methylthieno[2,3-*d*]pyrimidines, **66**, 204, **66**, 205
- 6-Amino-5(methylthio)-1,2,4-triazines, precursor to [1,3,5]triazino[2,1-*f*][1,2,4]triazines, **61**, 278
- 6-Aminomethyl-1,2,4-triazin-5-ones, reaction with 2,5-anhydro-D-allonic acids, **70**, 297
- 5-Amino-6-methyluracil, reaction with nitrous acid, **68**, 197
- reaction with *tert*-butoxybis(dimethylamino)methane, **68**, 199
- 2-Amino-1,8-naphthyridines, **67**, 306
- 2-Amino-6-nitro-1,3-benzothiazin-4-ones, from isothiocyanates and ammonia, **66**, 145
- 3-Amino-2-nitropyridine, oxidative cyclisation, **69**, 43
- 2-Amino-3-nitroso-4*H*-pyrido[1,2-*a*]pyrimidine, **63**, 188
- 2-Amino-3-nitroso-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, reduction, **63**, 177
- Aminonojirimycin, synthesis, **68**, 149
- erythro*-3-Amino-2-nonanol, in preparation of 1,3-dideaza analogs of EHNA, **68**, 64
- condensation with ethyl-2-amino-2-cyanoacetate, **68**, 64
- cis*-2-Aminooctahydroquinazolinium cations, conformations, **69**, 407
- 2-Amino-1,3,4-oxadiazoles, reaction with bromoketones, **69**, 277
- reaction with nitriles, **69**, 279
- 2-Amino-1,3,4-oxadiazol-5-yl *C*-nucleoside, **68**, 331
- 2-Amino-1,3-oxazoles, **64**, 190
- 2-Amino-4-oxopyrazolo[1,5-*a*]1,3,5-triazin-3-yl *C*-nucleosides, **70**, 302
- 2-Amino-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidines, **63**, 130
- 2-Aminophenol, imines with benzaldehydes ring chain tautomerisation, **66**, 8
- preparation of 2-β-D-ribofuranosylbenzoxazole, **70**, 190
- 4-Amino-2-*N*-phenylaminoquinazoline, **64**, 213
- 2-Aminophenyl-*t*-anilines, reaction with sulfonyl chloride, **65**, 15
- 2-Aminophenylcarbinols, conversion to benzo-4*H*-3,1-oxazonium salts, **64**, 349
- o*-Aminophenyldialkylamines, cyclisation, **65**, 32
- 2-Amino-4-phenyl-9,10-dimethoxy-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinoline, **70**, 62
- 2-Amino-5-phenyloxazole, in synthesis of imidazo[2,1-*b*]oxazoles, **69**, 273
- N*-(2-Aminophenyl)piperidine benzaldehyde imine, reaction with chlorosulfonyl isocyanate, **65**, 32
- 2-Amino-1-phenyl-1,3-propanediol, imines with aromatic aldehydes ring chain tautomerisation, **66**, 13
- 3-Amino-4-phenyl-4-[2-(*N,N*-di-*n*-propylamino)ethyl-4,4*a*, 5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one, reaction with acetic anhydride, **70**, 49
- 12-Amino-2-phenylpyrano[2,3-*a*]acridin-4-one, inhibitor of cell proliferation, **70**, 125
- 3-Amino-6-phenylthieno[2,3-*d*]pyrimidin-4-one-2(1*H*)-thione, **66**, 198
- 5-Amino-2-phenylthieno[3,4-*d*]pyrimidin-4-thiones, **66**, 266
- 3-Amino-2-piperidone, **64**, 29
- 3-(1-Amino-2-piperidyl)propionaldehyde dimethyl acetal, cyclisation, **69**, 114

- 3-(*N*-Amino-2-piperidyl)propionic acid, preparation and cyclisation, **69**, 114
- 3-Amino-1,2-propanediol, imines with aromatic aldehydes ring chain tautomerisation, **66**, 13
- 3-Aminopropanethiol, reaction with aldopentoses, **68**, 389
- N*-(3-Aminopropyl)-*N*-methylhydrazones, ring chain tautomerisation, **66**, 32
- 1-(3-Aminopropyl)pyrroline, ring chain tautomerisation, **66**, 42
- 5-Amino-6-*iso*-propyltropolone, oxidative dimerisation, **64**, 117
- 2-Aminopurines, synthesis, **69**, 163
- 2-Amino-2*H*-pyrans, formation and ring opening, **62**, 59
- Amino-4*H*-pyrans, 4-enantiomeric substituted, **62**, 36
- 2-Amino-4*H*-pyrans, **62**, 23
- reactions, **62**, 66
- attempted aromatisation, **62**, 70
- N*-substitution, **62**, 100
- heterocyclic reactions, **62**, 103
- 2-(6)-Amino-4*H*-pyrans, **62, 29**, **62**, 33
- 6-Amino-2*H*-pyrans, **62**, 24
- 4-Amino-4*H*-pyran-3-thioamides, cleavage, **62**, 88
- 2-Amino-5*H*-pyrazino[5,6-*e*]pyrido[1,2-*a*]pyrimidin-5-one, **63**, 250
- 3-Aminopyrazol-4-yl *C*-nucleoside, reaction with triethyl orthoformate, **70**, 301
- 3-Aminopyridazine, reaction with hippuric acid, **64**, 54
- 2-Aminopyridine, reaction with 2,6-diphenylpyrylium perchlorate, **63**, 125
- reaction with ethyl cyanoacetate, **63**, 127
- reaction with allenic nitriles, **63**, 128
- reaction with ethyl acetoacetate, **63**, 133
- reaction with *N,N*-disubstituted malonates, **63**, 130
- reaction with  $\beta$ -oxoesters, **63**, 130
- reaction with dimethyl diacetoxyfumarate, **63**, 156
- reaction with oxazolinones to give pyrido[1,2-*a*]pyrimidine, **64**, 52
- 2-Aminopyridinium perchlorate, reaction with haloacetylacetones, **63**, 124
- reaction with ethyl acetoacetate, **63**, 125
- 3(and 5-)-Amino-2-pyridinol, oxidation to hydroxyazabenzquinone, **61**, 143
- Aminopyrido[2,3-*c*]acridine, **70**, 103
- 6-Aminopyrido[1,2-*a*]pyrimidine, **63**, 138
- 2-Amino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, spectra, **63**, 112
- 3-Amino-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 177
- 4-Amino-2*H*-pyrido[1,2-*a*]pyrimidin-2-ones, **63**, 128, **63**, 130
- spectra, **63**, 112
- 2-Amino-1,3-pyridothiazine-4-ones, **66**, 162
- 3-Aminopyrido[4,3-*e*][1,2,4]triazine, photolysis, **61**, 219
- 5-Aminopyrimidino[5,4-*e*][1,2,4]triazine, by amination of 5-methoxy analogue, **61**, 252
- 2-Amino-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones, **70**, 73
- 4-Aminopyrones, by displacement of alkylthio groups, **65**, 309
- 3-Aminopyrrole-2,5-dione, **64**, 6
- 9-Aminopyrrolo[2,3-*c*]acridine, **70**, 140
- 4-Aminopyrrolo[2,1-*f*]1,2,4-triazin-7-yl *C* nucleoside, **70**, 296
- 5-Aminoquinoline, **70**, 100
- 6-Aminoquinolines, reaction with potassium 2,4-dichlorobenzoate, **70**, 92
- 7-Aminoquinoline, reaction with potassium 2,4-dichlorobenzoate, **70**, 90
- 8-Aminoquinolines, in synthesis of pyrido[3,2-*c*]acridines, **70**, 104
- 4-Amino-7- $\beta$ -D-ribofuranosylfuro[3,2-*d*]pyrimidine, isolation and structure, **70**, 224
- 5-Amino-1-( $\beta$ -D-ribofuranosyl)-imidazole-5'-monophosphate, as intermediate in *de novo* biosynthesis of purine nucleotides, **61**, 2
- as biosynthetic precursor of thiamine, **61**, 2
- biosynthesis, **61**, 42
- X-ray crystallography of derivatives, **61**, 48
- 5-Amino-1-( $\beta$ -ribofuranosyl)imidazole-tris-acetyl derivative, rearrangement, **61**, 42
- 7-Amino-2- $\beta$ -D-ribofuranosylimidazo[4,5-*d*]pyrimidine, **70**, 249
- 7-Amino-3-( $\beta$ -D-ribofuranosyl)pyrazolo[4,3-*b*]pyrimidine, **68**, 226

- 7-Amino-3-( $\beta$ -D-ribofuranosyl)pyrazolo [4,3-*d*]pyrimidine, **70**, 230  
biological activities, **70**, 239  
methylation, **70**, 240  
reaction with dimethylformamide dimethylacetal, **70**, 240
- 7-Amino-3- $\beta$ -D-ribofuranosylpyrazolo [4,3-*d*]pyrimidin-5-one, **70**, 239
- 7-Amino-3- $\beta$ -D-ribofuranosylpyrrolo [3,2-*d*]pyrimidine, isolation from *Anabaena affinis*, **68**, 227
- 4-Amino-7- $\beta$ -D-ribofuranosylthieno [3,4-*d*]pyrimidine, **66**, 172  
cytotoxicity, **66**, 273
- 3-Amino-5-( $\beta$ -D-ribofuranosyl)-1,2,4-triazole, **68**, 324
- 2-Aminoselenazoles, synthesis, **69**, 44
- 3-Amino-4-substituted-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-ones,  $^{13}\text{C}$  NMR spectra and conformations, **70**, 30
- 4-Amino-1-substituted imidazoles, acetylation, **61**, 19  
reaction with formates, **61**, 19  
reaction with anhydrides, **61**, 19  
reaction with acylhalides, **61**, 19  
reaction with dimethyl acetylene dicarboxylates, **61**, 21  
reaction with imidates, **61**, 22  
reaction with sulfur monochloride, **61**, 22
- 4-Amino-2-substituted imidazoles, **61**, 11
- 4-Amino-2-substituted methyl 5,6-dihydrothieno[2,3-*d*]pyrimidines, **66**, 204
- 4-Amino-2-substituted thieno[2,3-*d*]pyrimidines, **66**, 205
- 3-Amino-3-tetrahydrofuranecarboxylic acid, **64**, 14
- 9-Amino-6,7,8,9-tetrahydro-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidines, **62**, 225  
oxidation, **63**, 181
- 2-Amino-3,4,5,6-tetrahydropyridine, reaction with  $\beta$ -oxoesters, **63**, 132, **63**, 136  
reaction with diethyl [4-(2-cyanophenyl)phenyl]methylmalonate, **63**, 137  
reaction with 2-alkoxymethylenemalonate, **63**, 141
- 9-Aminotetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, tautomerism, **63**, 113
- 2-Amino-6-(*D*-erythro-tetritol-1-yl)pteridin-4-one, **70**, 268
- 2-Amino-6-(*L*-erythro-tetritol-1-yl)pteridin-4-one, **70**, 268
- 2-Amino-6-(*D*-ribo-tetritol-1-yl)pteridin-4-one, **70**, 271
- 2-Amino-6-(*D*-threo-tetritol-1-yl)pteridin-4-one, **70**, 270
- 2-Amino-6-(*L*-threo-tetritol-1-yl)pteridin-4-one, **70**, 270
- 7-Aminothephylline, oxidation, **61**, 243
- 2-Aminothiadiazoles, oxidative reaction with acetophenones, **69**, 47  
amination, **69**, 334  
reaction with nitriles, **69**, 335
- 2-Amino-1,3,4-thiadiazoles, reaction with phenacyl bromides, **69**, 302  
reaction with acetophenones and halogenating agents, **69**, 305  
reaction with bromoacetaldehyde, **69**, 306
- 4-Amino-1,3-thiazines, conversion to pyrroles, **65**, 56
- 2-Amino-1,3-thiazin-4-ones, from thiourea and acetylenic esters, **66**, 137
- 2-Aminothiazoles, reaction with  $\alpha$ -haloketones, **69**, 284  
reaction with  $\alpha$ -halo- $\beta$ -ketoesters, **69**, 285  
reaction with 2,3-dichloro-1,4-naphthoquinone, **69**, 287  
reaction with chloranil, **69**, 287  
reaction with prop-2-ynyl bromide, **69**, 288  
reaction with 2,2-diethoxy-1-methylpyrrolidine, **69**, 289
- 4-Amino-1,3-thiazolium salts, loss of sulfur, **65**, 73
- 2-Aminothiazolo[3,2-*b*][1,2,4]triazoles, **69**, 320  
acylation, **69**, 329
- 4-Aminothienopyrimidines, Vilsmeier-Haack formylations, **66**, 223
- 3-Aminothieno[2,3-*d*]pyrimidines, **66**, 203
- 4-Aminothieno[2,3-*d*]pyrimidines, **65**, 240, **66**, 206
- 4-Aminothieno[3,2-*d*]pyrimidines, **65**, 255, **66**, 244
- 5-Aminothieno[2,3-*d*]pyrimidines, **66**, 212, **66**, 217  
acylation, **66**, 223
- 5-Aminothieno[3,4-*d*]pyrimidine-2,4(1*H*, 3*H*)diones, **65**, 264
- 2-Aminothienopyrimidin-4(3*H*)-ones, **65**, 242

- 2-Aminothieno[2,3-*d*]pyrimidin-4-ones, **66**, 199
- 3-Aminothieno[2,3-*d*]pyrimidin-4-ones, analgesic activity, **66**, 232
- 4-Aminothieno[2,3-*d*]pyrimidin-2-one, *N*-alkylation with 1,2,3,5-tetra-*O*-acetyl- $\beta$ -D-ribofuranose, **66**, 223
- 2-Aminothieno[3,4-*d*]pyrimidine-4(3*H*)-ones, **66**, 269
- 4-Aminothieno[2,3-*d*]pyrimidine-2(1*H*)-thiones, **66**, 210
- 2-[1-Amino(thio)carbonyl]-2-piperidyl]acetates, cyclisation, **70**, 63
- Aminothiophenes, reaction with 3,3-bismethylthio-2-(cyano)acrylonitrile and methyl 3,3-bismethylthio-2-(cyano)acrylate, **66**, 200
- 2-Aminothiophene-3-carbonitriles, reaction with formamides and ureas, **66**, 204
- 3-Aminothiophene-2-carbonitriles, precursor to thieno[3,2-*d*]pyrimidines, **66**, 244
- 2-Aminothiophene-3-carboxamides, precursor to thieno[2,3-*d*]pyrimidines, **66**, 200, **66**, 202  
reaction with trichloroacetonitrile, **65**, 242  
reaction with thiourea, **65**, 247
- 3-Aminothiophene-2-carboxamides, precursor to thieno[3,2-*d*]pyrimidines, **66**, 243
- 3-Aminothiophene-4-carboxamides, condensation with 3-chloroethyl chloroformate, **66**, 262
- 2-Aminothiophene-3-carboxyhydrazide, reaction with formic acid, **65**, 245
- 2-Aminothiophene-3-carboxylates, reaction with *N*-cyanoamides, **65**, 242  
precursors to thieno[2,3-*d*]pyrimidines, **66**, 195  
reaction with formamide, **65**, 244  
reaction with cyclic ketones, **65**, 245  
reaction with potassium cyanate, **65**, 246  
reaction with ammonium thiocyanate, **65**, 247
- 3-Aminothiophene-2-carboxylate, reaction with formamide, **65**, 256
- 3-Aminothiophene-2-thiocarboxamide, reaction with orthoesters, **65**, 257
- 2-Amino-4-thioxo-4,5-dihydro-1*H*-benzo[*b*][1,4]-diazepin-3-carboxylic acid ethyl ester, **70**, 305  
in synthesis of acyclonucleosides, **69**, 195
- 2-Amino-4-thioxo-4,5-dihydrobenzo[*b*]1,4-oxazepine-3-carboxylic acid ester, **70**, 305
- 6-Amino-3-(*p*-tolyl)[1,2,4]triazin-5(2*H*)thione, reaction with 2*H*-1,3-oxazine-2,6(3*H*)dione, **61**, 284
- 9-Amino-3-tosylpyrrolo[2,3-*c*]acridine, **70**, 140
- 1-Amino-1,2,4-triazole, reaction with dimethylformamide azine, **67**, 42
- 3-Amino-1,2,4-triazole, reaction with *N,N'*-diformylhydrazine, **67**, 42
- 4-Amino-1,2,4-triazole, reaction with dimethylformamide azine, **67**, 43
- 4-Amino-2-trichloromethylthieno[2,3-*d*]pyrimidines, **66**, 205
- 2-Amino-3,4,5-tricyano-6-picoline, reaction with sulfur in presence of base, **68**, 186  
reaction with methylidenemalononitrile, **68**, 189
- 2-Amino-7-(*D*-erythro-1',2',3'-trihydroxypropyl)pteridin-4-one, **70**, 272
- 1-Amino-2-[(2,3,4-trimethylphenyl)amino]-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones, **70**, 50
- N*-Aminotriphenyliminophosphoranes, reaction with aldehydes and ketones, **64**, 178
- 3-Aminotropolones, from oxazotropones, **66**, 368
- 4-(and 5)-Aminotropolone, conversion to pyridotropolones, **64**, 127
- 5-Amino-4-unsubstituted imidazoles, **61**, 24  
diazotisation, **61**, 31  
carboxylation, **61**, 33  
reaction with isocyanates and isothiocyanates, **61**, 34  
reaction with diketene, **61**, 34  
reaction with dialkyl acetylene dicarboxylates, **61**, 36  
reaction with diethyl azodicarboxylate, **61**, 36  
reaction with  
ethoxymethylenemalononitrile, **61**, 36
- C* vs *N*-reactions in addition-eliminations, **61**, 36  
calculations by AM1, **61**, 53
- 7-Amino-2-(2'-deoxy- $\beta$ -D-xylofuranosyl)imidazo[4,5-*d*]pyrimidine, **70**, 251



- Ammonia, reaction with diones to give enamines, **67**, 210
- Ammonium 1,3,2,5-dioxaborataphosphorinanes, from borylation of hydroxyallylphosphines and tertiary amines, **61**, 87
- tautomerism, **61**, 99
- reactions, **61**, 103
- reactions with electrophiles, **61**, 105
- ion exchange, **61**, 114
- thermal decomposition, **61**, 119
- Amphimedine, **70**, 108
- Anapterin, *see* 2-amino-7-(*D*-erythro-1',2',3'-trihydroxypropyl)pteridin-4-one
- Angustycin A analogues, **69**, 145
- 2,5-Anhydroallonamidine, reaction with ethyl acetoacetate, **68**, 364
- 2,5-Anhydro-D-allonic acid, **70**, 217
- reaction with 1,2-diaminobenzene, **70**, 183
- 2,5-Anhydro-D-allonic acid amide, reaction with chlorocarbonylsulfonyl chloride, **68**, 338
- 2,5-Anhydro-D-allonic acid imidates, in synthesis of imidazo[1,5-*a*]pyridin-3-yl C-nucleosides, **70**, 200
- 2,5-Anhydro-D-allonodithioate, reaction with 2-hydrazinopyrimidine, **70**, 257
- 2,5-Anhydro-D-allononitrile, precursor of showdomycin, **68**, 238
- 2,5-Anhydro-D-allononitrile *N*-sulfide, 1,3-dipolar cycloaddition reactions, **68**, 305
- reaction with ethyl cyanoformate, **68**, 334
- 2,5-Anhydro-D-allonoylnitromethane, reaction with ethyl chloroacetate, **68**, 290
- 1-(2,5-Anhydro-D-allonoyloxy)pyridine-2-thione, photoirradiation, **68**, 342
- 1-(2,5-Anhydro-allonoyl)thiosemicarbazide derivatives, **68**, 335
- 2,5-Anhydro-D-allonyldiazomethanes, reaction with benzyne, **70**, 179
- Anhydrocannabisativene, **70**, 74
- 4,3'-Anhydro-2'-deoxypseudouridine, **68**, 370
- 2,5'-Anhydroformycin, **70**, 245
- 4,5'-Anhydroformycin, **70**, 245
- 2,5-Anhydrohexoaldonic acids, reaction with glycosylthioformimides, **70**, 203
- photolysis, **70**, 204
- Anhydro-3-hydroxy-7-methyl-2-phenylimidazo[2,1-*b*]thiazolium hydroxide, reaction with dibenzoylacetylene, **69**, 295
- 2,3-Anhydro-D-mannose, reaction with dopamine hydrochloride, **70**, 210
- 4,5'-Anhydro-1-methylpseudouridine, **68**, 370
- 4,2'-Anhydropseudoisocytidine, **68**, 370
- 4,5'-Anhydropseudouridine, **68**, 369, 370
- methylation, **68**, 360
- 4,2'-Anhydropseudouridine, **68**, 370
- 2,3-Anhydropyranoside 4-triflate, rearrangement to cyclic sulfate, **68**, 114
- Anhydropseudonin, mass spectra, **66**, 307
- isomers, **66**, 310
- catalytic hydrogenation, **66**, 337
- basicity, **66**, 331
- dimethyl ethers, amidation by liquid ammonia, **66**, 345
- 2,5-Anhydro-1-ureido-D-allitols, **70**, 235
- Anilines, Pd catalysed reaction with methyl vinyl ketone, **67**, 214
- 7-Anilinobenzo[*b*][1,8]phenanthroline, **70**, 109
- $\beta$ -Anilinoacetonates, use in quinolone synthesis, **67**, 281
- 3-Anilino-1,4-dihydro-1,4-isoquinolinediene, reaction with thiosemicarbazide, **61**, 232
- 2-Anilinothieno[2,3-*d*]pyrimidines, **66**, 210
- 2-Anilinothiophene-3-carboxylates, reaction with methylisocyanates, **65**, 246
- 4-Anisyl-2-chloropyrimidine, from anisylzinc bromide and 2,4-dichloro-pyrimidine, **62**, 377
- $\beta$ -Anisyltelluro-D-ribofuranoside, in synthesis of showdomycin, **68**, 241
- [*e*]-Annellated 1,3,4-thiadiazines, ring contraction, **65**, 67
- Annotinine, synthesis, **67**, 288
- Annuloline, *see* 2-(2'-(3'',4''-dimethoxyphenyl)-5-(4'-methoxyphenyl)-oxazole, **64**, 188
- Antarafacial[1,6] *H*-shifts, **65**, 4
- Anthranilic acid, in nucleoside synthesis, **67**, 431
- Antipyrine, fluorination, **62**, 6
- Aphyllocladin, **67**, 10
- 2- $\beta$ -D-Arabinofuranosyl-4-carboxamidothiazole, **68**, 309
- 3-( $\alpha$ -D-Arabinofuranosyl)indoles, **70**, 168
- 2-( $\beta$ -D-Arabinofuranosyl)maleimide, synthesis, **68**, 246

- 2-( $\alpha$ -D-Arabinofuranosyl)pyrroles, synthesis, **68**, 247
- (1R) and (1S)-1-( $\alpha$ -D-Arabinofuranosyl)-1,2,3,4-tetrahydro- $\beta$ -carboline, preparation, **70**, 174
- 2-( $\alpha$ -D-Arabinofuranosyl)-4,5,6,7-tetrahydroindol-4-one, preparation, **70**, 167
- 2- $\beta$ -D-Arabinofuranosylthiazolidine, **68**, 307
- C- $\beta$ -D-Arabinofuranosylthioformimidates, in synthesis of 2-imidazolyl C-nucleosides, **68**, 277
- 3-( $\alpha$ -D-Arabinofuranosyl)-1,2,4-triazolo [4,3-*a*]pyrazin-8-one, **70**, 281
- 1-( $\alpha$ -D-Arabinofuranosyl)uracil, use in preparation of nucleosides, **67**, 407
- 2-( $\alpha$ -D-Arabinopyranosyl)pyrroles, synthesis, **68**, 247
- $\beta$ -D-Arabinofuranosylimidazo[4,5-*d*]pyrimidine, **70**, 249
- D-(and L)-Arabinose, in preparation of acyclonucleosides, **68**, 74
- L-Arabinose, use in synthesis of nucleosides, **67**, 411
- D-Arabinose thiosemicarbazone, ring chain tautomerisation, **66**, 20
- 1,2-di-(D-Arabinotetritol-1-yl)pyridin-4-one C-nucleoside, **68**, 349
- Aranorosin, synthesis, **69**, 23
- Arenecarbaldehyde 4-methylthiosemicarbazones, ring chain tautomerisation, **66**, 52
- 4-Arenesulfonyl-5-phenylpyrazole, **63**, 312
- Aristeromycin, **66**, 120
- Aroylactaldehyde *N*-aroylhydrazones, ring chain tautomerism, **64**, 299
- Aroylactaldehyde thiobenzoylhydrazones, ring chain tautomerisation, **66**, 46
- Aroylacetone *N*-benzoylhydrazone, ring chain tautomerism, **64**, 297
- N*-Aroylalcohols, *N*-*O* migration, **64**, 308
- Aroylaminoimidazole-4-carboxylates, **64**, 209
- 2-Aroylaziridines, ring expansion, **69**, 65
- N*-Aroylchloroformamides, dechlorination to benzo-1,3-thiazin-4-ones, **66**, 146
- 2-Aroylcoumaran-3-ones, synthesis, **69**, 20
- N*-Aroylhydrazones of acetylpinacoline, ring chain tautomerism, **64**, 301
- Aroylhydrazones of  $\beta$ -ketoesters, tautomerism, **64**, 296
- N*-Aroylhydrazones of pentane 2,4-diones, ring chain tautomerism, **64**, 297
- 8-Aroyl-7-hydroxy-benzopyran-2-ones, **70**, 124
- N*Aroylmethyl-*N*-(2-hydroxyethyl)-*N,N*-dimethylammonium salts, ring chain tautomerism, **64**, 270
- $\alpha$ -Aroyloxyacetophenones, cyclisation to benzofurans, **69**, 19
- 3-(*o*-Aroylphenyl)pentan-3-ol, thiosemicarbazones ring chain tautomerisation **66**, 20
- 2-(*o*-Aroylphenyl)propan-2-ol, 2,4-dinitrophenylhydrazones, ring chain tautomerisation, **66**, 19
- 2-(*o*-Aroylphenyl)propan-2-ol, thiosemicarbazones, ring chain tautomerisation, **66**, 20
- 5-Aroyl-2-pyrazolines, **63**, 310
- 1-Aroylpyrrole, as precursor of 2,2'-bipyrrrole, **67**, 5
- 9-Arylalkylthio-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, -oxidation, **63**, 181
- 3-Arylamino-2-benzofuroyl-4(3*H*)-quinazolinones, **63**, 316
- 3-Arylamino-2-cyano-3-mercaptoacrylates, reaction with ketose acetates, **68**, 316
- 1-Arylamino-1-deoxyketoses, reaction with 1,2-diaminonaphthalenes, **70**, 289
- 1-Arylaminoisoquinolines, **64**, 206
- 2[(Arylamino)methylene]cyclohexanones, **67**, 220
- cyclodehydration to acridines, **67**, 289
- 9-Arylaminomethylene-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidinones, spectra, **63**, 108
- 9-Arylaminomethylene-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 222
- 3(5)-Arylamino-4-nitrosopyrazoles, **67**, 253
- 2-Arylamino-1,3-quinoxalinothiazine-4-ones, **66**, 165
- 4-(Arylamino)sydn[3,4-*a*]quinoxalines, **64**, 220
- 2-Arylamino-1,3,4-thiadiazoles, **68**, 328
- 2-Arylamino-1,3,4-thiadiazole acyclo C-nucleosides, **68**, 337
- 4-Arylaminothieno[2,3-*d*]pyrimidines, **65**, 241

- 2-Arylaminothiophene-3-carboxamides, reaction with triethyl orthoformate, **66**, 202  
reaction with triethylorthoformate, **65**, 245
- 5-Arylazo-6-arylidenehydrazino-1,3-dimethyluracils, precursor to pyrimido[5,4-*e*][1,2,4]triazines, **61**, 254
- 2-Arylazo-3-benzofuryl-4(*H*)-1,4-benzopyrazine, **63**, 316
- 2-Arylazo-3-benzofuryl-4(*H*)-1,4-benzothiazine, **63**, 328
- 5-Arylazo-6-(dimethylaminomethyleneimino)-1,3-dimethyluracils, photochemical cyclisations to 6-aryl-1,3-dimethyl-6,7-dihydro-6-azalumazine-7-ones, **61**, 243
- 5-Arylazotropolones, reaction with bifunctional synthons, **64**, 90
- 2-Arylbenzo-1,3-benzothiazin-4-ones, by oxidation of 2-aryl-1,3-benzthiazines, **66**, 144
- N*-Aryl-2-benzoselenazolylmethanehydrazonoyl chloride, **63**, 293
- 2-Aryl-1,3-benzothiazine-4-one-1-oxide, ring contraction to benzisothiazoles, **66**, 172
- 2-Arylbenzotriazolin-4-one-1-oxide, synthesis, **69**, 63
- 5-Aryl-2,5'-bitetrazole, **67**, 48
- 4-Aryl-3-bromo-4,6-dimethyl-3,4-dihydro-2-pyrones, debromination, **65**, 289
- C*-Aryl-*N*-(2-carboxyalkyl)nitrones, ring chain tautomerisation, **66**, 17
- 3-Aryl-2-chloro-4-iminothieno[2,3-*d*]pyrimidines, **66**, 207
- N*-Aryl-2-chloro-2-oxoethenehydrazonoyl chloride, reaction with *o*-aminothiophenol, **63**, 293
- 3-Aryl-3-chloropropeniminium salts, reaction with glycine esters, **64**, 11
- 4-Arylcoumarins, **65**, 302
- 6-Aryl-3-cyano-4-methylthio-2*H*-pyran-2-one, **65**, 312  
displacement of thiomethyl group by active methylenes, **65**, 309  
reaction with amines, **65**, 309  
reaction with methoxide, **65**, 312
- 5-Aryldeoxyuracils, via organomercurials, **62**, 400
- 4-Aryl-9,10-dialkoxy-1,6,7,11*b*-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-ones, electrochemical reduction, **70**, 43
- 2-Aryl-2,6-diamino-3,5-dicyano-4*H*-thiopyrans, **62**, 66
- N*-Aryldiazoacetamides, conversion to 2(3*H*)-indolinones, **65**, 122
- N*-Aryldiazoacetacetamides, thermolysis, **65**, 122
- 9-Aryldiazo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 223
- 1-Aryl-1,4-dichloro-4-morpholinoamidrazones, reaction with aniline, **63**, 317
- 1-Aryl-(1,2-dideoxyglycofuran)[2,1-*d*]imidazolidine-2-thiones, acid catalysed isomerisation and dehydration to *C*-nucleosides, **68**, 281
- 1-Aryl-1,4-dihydropyridines, hydrolysis to 4*H*-pyrans, **62**, 67
- 4-Aryl-dihydro-2-quinolinones, synthesis using enaminones, **67**, 280
- 6-Aryl-2,4-dihydro[1,2,4]triazino[4,3-*c*]quinazolin-3-ones, **61**, 267
- 3-Aryl-5,8-dihydro-6,6,8-trimethyl-5,8-ethano-6*H*-pyrano[4,3-*e*][1,2,4]triazine-4-oxide, **61**, 233
- 4-Aryl-9,10-dimethoxy-6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinolines, **70**, 74
- 2-Aryl-4,5-dimethyl-6-substituted-7,7-dioxothieno[2,3-*d*]pyrimidines, **66**, 215
- 2-Aryl-4,5-dimethyl-6-substitutedthieno[2,3-*d*]pyrimidines, **66**, 215
- 4-Aryl-2,4-dioxobutanoic acids, oxidation to furans, **69**, 22
- 3-Aryl-2,4-dioxooctahydro-1*H*-cyclopentapyrimidine, conformations, **69**, 415
- N*-Aryl enaminones, photocyclisation, **67**, 239
- 1-Aryl-3-ethoxycarbonylpyrrolidin-4-one, **64**, 7
- Arylfervenuins, cleavage of triazole ring, **61**, 257
- 3-Arylfervenuins, **61**, 253
- 1-Aryl-3-(2-furoyl)hydrazines, reaction with triphenylphosphine-carbon tetrachloride, **63**, 293
- 1-Aryl-4-(*D*-galacto-pentitol-1-yl)imidazoline-2-thiones, failure to undergo acid-catalysed cyclisation, **68**, 281
- diendo*-2-Aryl-4*a*,5,6,7,8,8*a*-hexahydro-5,8-methano-4*H*-3,1-benzoxazines, conformations, **69**, 419

- 2-Aryl-1,6,7,8,9,9a-hexahydro-4H-quinolizines, **70**, 38
- 9-Arylhiazino-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-ones, **63**, 223
- Arylhydrazonooxomalnonitrile, precursor to pyrimido[4,5-e][1,2,4]-triazines, **61**, 244
- 9-Arylhiazono-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidinones, spectra, **63**, 108
- 3-(1-Arylhiazono-2,3,4-trihydroxybutyl)quinoxalin-2-ones, cyclodehydration, **70**, 289
- C-Aryl-N-(2-hydroxyalkyl)aldonitrines, ring chain tautomerisation, **66**, 17
- 3-Aryl-4-hydroxycoumarins, **65**, 301
- anhydro 2-Aryl-3-hydroxythiazolo[2,3-a]phthalizinium hydroxides, reaction with methyl propiolate, **69**, 121
- 2-Arylideneaminophenyl malonic esters, ring chain tautomerisation, **66**, 54
- 3-Arylideneaminopropionamide oximes, ring chain tautomerisation, **66**, 25
- 2-Arylidene-cyclohepta[b]furan-3,8-diones, **64**, 101
- 2-Arylidene-1-cyclohexanones, reaction with dithiocarbamic acid, **69**, 381
- 2-Arylidene-1-cyclopentanones, reaction with dithiocarbamic acid, **69**, 381
- 9-Arylidene-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidines, addition of bromine, **63**, 216
- 6-Arylimidazo[2,1-b]thiazole-5-carboxylic acid, **69**, 296
- 3-Aryl-4-imino-2-methylthieno[2,3-d]pyrimidines, **66**, 207
- 3-Aryl-4-iminothieno[2,3-d]pyrimidine-2-thiones, **66**, 210
- 2-Aryliodonobenzoates, thermolysis, **69**, 54
- 1-Aryl-9-methoxy-1,2,3,5,6,7-hexahydro-7H-pyrido[3,2,1-ij]quinazolin-3-ones, **70**, 66
- oxidation, **70**, 48
- N-(Arylmethylene)dehydroalanine methyl ester, dimerisation, **64**, 30
- 5-Arylmethylene-1,3-dioxan-4,6-dione, conformations, **69**, 247
- 9-Arylmethylenehydrazono-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-ones, tautomerisation, **63**, 116
- 2-(N-Aryl-N-methylimino)-6,7-dihydro-4H-pyrimido[6,1-a]isoquinolin-4-ones, UV and infrared spectra, **70**, 24
- 3-Aryl-4-methyl-1,2,3-oxathiazolidine 2-oxides, nmr spectra and conformations, **68**, 97, <sup>13</sup>C nmr spectra, **68**, 100
- cis- and trans-3,4a-H-1-Aryl-3-methylperhydropyrido[1,2-c][1,3]oxazine, conformations, **70**, 11
- 3-Aryl-methylperhydropyrido[1,2-c][1,3]oxazine hydrochlorides, hydrolysis, **70**, 38
- 3-Aryl-2-methyl-4-quinazolones, reaction with malonate esters, **68**, 214
- 3-Aryl-2-methylthieno[2,3-d]pyrimidine-4(3H)-ones, **66**, 208
- 2-Aryloctahydroquinazolinones, synthesis, **69**, 390
- 2-Aryl-6H-1,3-oxazin-6-ones, via retro-Diels-Alder reactions from norbornene-fused dihydrooxazinones, **69**, 459
- 2-Aryl-1,3-oxazolidines, tautomerism, **64**, 257
- Aryloxoflavins, cleavage of triazole ring, **61**, 257
- N-Aryl-2-oxo-2-heteroarylethane hydrazonoyl bromides, **63**, 293
- 3-Aryl-4-oxo-4H-pyrido[2,1-a]phthalazine-1-carboxamides, reduction, **69**, 100
- 2-Aryloxy-5,6-dihydro-1,3-thiazin-4-ones, **66**, 149
- 2-Aryloxy-1,3-thiazin-4-ones, **66**, 133
- 2-Arylperhydropyrido[1,2-c]pyrimidin-1,3-diones, **70**, 67
- 3-Arylpiperazinylethylthieno[3,2-d]pyrimidinediones, **66**, 238
- 2-Aryl-2-(2-piperidinyl)acetamide, cyclisation, **70**, 63
- N-Arylprolines, reaction with trifluoroacetic acid anhydride, **64**, 22
- 2-Arylpyrazino[2,3-d][3,1]oxazin-4-one, **64**, 210
- 2-Aryl-4-substituted-2,3-dihydro-1H-pyrimido[6,1-a]quinolin-1,3-diones, **70**, 69
- 2-Aryl-substituted tetrahydro-1,3-oxazines, tautomerism, **69**, 447
- 3-Arylsulfinylchromone, reaction with dienes, **65**, 353
- 4-Arylsulfonyl-2-methyl-5-phenyl-1,3-oxazoles, **65**, 180

- 2-Aryltetrahydro-2*H*-1,3-oxazines, ring chain tautomerisation by NMR, **66**, 9  
ring-chain tautomerism, **69**, 356, 450
- 1-Aryl-3,4,5,6-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2,4-diones, **70**, 64
- 1-Aryl-3,4,6,7-tetrahydro-2*H*-pyrimido[1,6-*a*]quinoline-2,4-diones, **70**, 47
- 2-Aryl-1,2,3,4-tetrahydro-4-quinolones, dehydrogenation, **69**, 74
- 2-Aryl-1-tetralone, as intermediate in synthesis of benzo[*c*]phenanthridines, **67**, 349
- 4-Aryl-2,2,6,6-tetra(trifluoromethyl)-6*H*-1,3,5-oxathiazine, thermolysis, **69**, 383
- 1-Aryl-3-( $\beta$ -D-*arabino*-tetritol-1-yl)flavazoles, **70**, 287
- 2-Arylthiazole-5-carboxylic acids, reaction with base and bromine, **69**, 328
- 7-Arylthienopyrimidin-2(1*H*),4(3*H*)diones **66**, 236
- 1-Arylthieno[2,3-*d*]pyrimidin-4-ones, **66**, 202
- 2-Arylthieno[2,3-*d*]pyrimidin-4-ones, **66**, 199
- 4-Arylthieno[2,3-*d*]pyrimidin-2(1*H*)-thiones, **66**, 210
- 1-Aryl-1,2,3-triazoles, from azidobenzenes and enamines, **67**, 260
- 2-Aryl-1,2,4-triazolo[2',3'-3,2]triazolo[4,5-*d*]pyridazinone, **69**, 329
- 1-Aryl-4,6,6-trimethyl-3-phenyl-1,6-dihydropyrano[2,3-*c*]pyrazoles, reaction with dimethyl acetylene dicarboxylate, **63**, 355
- Arylvinyl-4,5-dimethyl-6-substitutedthieno[2,3-*d*]pyrimidines, **66**, 215
- 2-(2-Arylvinyl)thieno[2,3-*d*]pyrimidin-4-ones, **66**, 228
- Ascididemin, **70**, 96
- Ascorbic acid, Pd(0) catalysed allylation, **66**, 81  
in preparation of EHNA analogs, **68**, 64
- L-Ascorbic acid, in synthesis of acyclonucleosides, **69**, 168
- Aspidosperma alkaloids, **67**, 244
- Asporenomicin A, B & C, **65**, 108
- Atalanine, **70**, 147
- Atalaphyllidine, **70**, 127, 132
- Atalaphyllinine, **70**, 127
- Ataline, **70**, 147
- 1,3,2-Axoazaphosphorinanes, from aminopropyl(alloxycarbonyl)-phosphines, **61**, 75
- 8-Azaadenine acyclonucleosides, **68**, 10
- 1-Aza[14]annulenes, **64**, 188
- Azaanthraquinone-spirodienones, preparation, **69**, 54
- (2-Azaarylamino)methylenemalononitriles, ring chain tautomerisation, **66**, 55
- Azabicyclo[5,3,0]decatrienones, **65**, 118
- 7-Azabicyclo[2,2,1]heptanes, via carbene reactions, **65**, 202
- 1-Azabicyclo[3,2,0]heptanes, **65**, 108
- 7-Azabicyclo[4,2,0]octadienes, **65**, 106
- 8-Azabicyclo[3,2,1]octanes, via carbene reactions, **65**, 200
- Azabicyclo[3,3,0]octanes, **64**, 44
- 1-Azabicyclo[3,3,0]octanes, **65**, 109
- 1-Azabicyclo[4,2,0]octane, **65**, 104, **65**, 126
- Aza-1-bicyclo[2,1,0]pentane, **64**, 5
- 9-Azabicyclo[5,4,0]undecanes, **65**, 131
- 4-Azacronycine, **70**, 102
- 2-Aza-3-cyano-1,4-quinones, **61**, 145
- Azacyclo[3,2,2]azines, from 6-azaindolizine, **68**, 208
- Azacyclo[3,3,3]azines, synthesis, **68**, 185
- Azadienaminones, from azaenaminones and Meldrum's acid, **67**, 310
- 1, 3,4-Azadiphosphacyclopentanes, from 1,5,3,7-diazadiphosphacyclo-octanes, **61**, 78
- 6-Azaindolizine, formation of azacyl[3,2,2]azines, **68**, 208
- 1,3,5-Azaoxaphosphorinanes, from phosphine addition to aldehydes followed by reaction with azomethines, **61**, 63  
nmr and conformations, **61**, 82  
nmr and stereochemistry, **61**, 71
- 1-Aza-7-oxa-4-thiabicyclo[6.2.0]dec-5-en-10-ones, preparation by ring expansion of penams, **69**, 78
- 1,2-Azaphosphetidines, **65**, 172
- 7-Azapteridine, *see* pyrimido[5,4-*e*][1,2,4]triazine
- 3-Azapryylium salts, **64**, 350
- Azaquinones, **61**, 145  
cycloaddition reactions, **61**, 147  
spectra, **61**, 148
- Azaspiroundecane, synthesis, **67**, 275; **67**, 276
- 3-Azathiopyrylium salts, **64**, 353
- Azatropylium salts with tetracyanoquinodimethane, **66**, 380

- 2-Azazulenes, **65**, 118  
 Azazulenones, tautomerism, **66**, 323  
 Azepino[1,2-*a*]quinazolines, **68**, 215  
 Azepinotropones, **64**, 115  
   nmr spectra, **66**, 293  
 Azetidine-2-carboxylic acid, **64**, 5  
 (1.)-3-Azetidinone, **65**, 105  
 Azetidinones, **65**, 74  
 Azetidinothiazolines, **65**, 71  
 Azeto[2,1-*d*][1,5]benzothiazepines, **63**, 64  
 Azeto[2,1-*b*][1,3]oxazines, by ketene addition to dihydrooxazines, **69**, 454  
 Azeto[2,1-*b*][1,3]thiazines, synthesis, **69**, 456  
 Azido-acyclic nucleosides, **68**, 18  
 Azidoalkylbenzotriazole, **64**, 166  
 5-Azido-3-aryl-1,2,4-triazoles, **63**, 297  
*o*-Azidobenzaldehyde azine, thermal decomposition, **67**, 26  
*o*-Azidocinnamates, conversion to quinolines, **64**, 204  
   conversion to isoquinolines, **64**, 207  
 4-Azido-3-coumarinocarboxaldehydes, **65**, 309  
 2'-Azido-2'-deoxypyrimidin-5-yl *C*-nucleosides, **68**, 373  
 6-Azido-6-deoxy-5-*O*-sulfonylfuranose derivatives, reduction **68**, 231  
 5'-Azido-5'-deoxytiazofurin, **68**, 309  
 6-Azido-6-deoxy-5-*O*-(4-tolylsulfonyl)-D-glucitol derivatives, reduction, **68**, 232  
 2-(2-Azido-3,5-dibromobenzoyl)pyridine, pyrolysis, **69**, 113  
 3'-Azido-2',3'-dideoxy-1-methylpseudourine, lack of activity against HIV-1, **68**, 373  
 3-Azido-2,3-dideoxynucleoside, reduction via iminophosphoranes, **64**, 173  
 2-(2'-Azido-2',3'-dideoxy- $\beta$ -D-xylofuranosyl)imidazo[4,5-*d*]pyrimidine, **70**, 252  
 6-Azido-1,3-dimethyluracil, photolysis in presence of acylhydrazines to give fervenulins, **61**, 255  
*N*-(2-Azidoethyl)phthalimide, conversion to condensed imidazolines, **64**, 192  
 5-Azido-2(5*H*)-furanone, preparation, **69**, 65  
 2-Azidomethylbenzimidazoles, conversion to imidazo[1,5-*a*]benzimidazoles, **64**, 193  
 4-Azido-4-methyl-2,3,5,6-tetraphenyl-4*H*-pyran, **62**, 60  
 1-(3-Azido-2-oxopropyl)pyridazin-6-one, in synthesis of acyclonucleosides, **69**, 181  
 2-Azido-2-phenyl-1,3-indanedione, thermolysis to monoazaquinones, **61**, 150  
 3-(*o*-Azidophenyl)isoxazoles, precursor to isoxazolo[4,3-*c*]quinolines, **64**, 205  
 5-Azido-4-phenyltropolone, thermal decomposition, **64**, 122  
 3-Azidopropylloxirane, **64**, 183  
 2-Azido-2*H*-pyrans, **62**, 60  
   decomposition to 1,3-oxazepines, **62**, 97  
 4-Azido-4*H*-pyrans, conversion to oxepines, **62**, 97  
 3-Azidopyrimido[4,5-*e*][1,2,4]triazine, **61**, 307  
*o*-Azidosulfonyl-*t*-anilines, thermolysis, **65**, 27  
 Aziridines, by carbene addition to imines, **65**, 98  
   from iminophosphoranes, **64**, 182  
   synthesis from aminoacids, **64**, 3  
    $\gamma$ -hydroxy- $\alpha$ -aminoacids, **64**, 4  
 Aziridine-*N*-oxides, photolysis, **64**, 97  
 Aziridinoindoles, synthesis, **67**, 217  
 Aziridino[1,2-*a*]pyrrolidine, **64**, 183  
 Azirine acyclo *C*-nucleosides, preparation, **68**, 232  
 Azirino[2,1-*d*][1,5]benzothiazepines, synthesis and structure, **63**, 63  
 Azoalkenyl chlorides, reaction with pyrrolidine and cyclisation, **65**, 25  
 Azobenzene, reaction with isopropylidene carbene, **65**, 173  
*N,N'*-Azocarbazole, thermolysis to 9,9'-bicarbazole, **67**, 17  
 Azolotropylium salts, **64**, 129  
 Azomethine ylides, 1,3-dipolar cycloadditions, **67**, 229  
 Azomycin acyclonucleosides, **69**, 144  
 10*c*-Azoniafluoranthene salts, preparation from azoniafluorene salts, **68**, 213  
 Azoniafluorene salts, reaction with glyoxal, **68**, 213  
 12-Azonianaphth[1,2-*b*]azulene, **67**, 355  
 1',2'-*seco*-AZT, synthesis, **67**, 400  
 Baikaine *see* 1,2,3,6-tetrahydropyridine-2-carboxylic acid  
 Baldwin's rules and ring chain tautomerism, **64**, 272, **66**, 3

- Barbituric acid, Pd(0) catalysed allylation, **66**, 116
- 4-Benzalmino-1,2,4-triazoline-3,5-dione, **67**, 121
- Benzamido-6-bromotropone, reaction with dimethyl sulfide, **66**, 384
- 2-Benzamidocyclohexanecarboxylic acid, cyclodehydration, **69**, 380
- Benzamidohydrazone of 2-(2'-methylaminoethyl)4,5-methylenedioxy-benzaldehyde-ring chain tautomerism, **66**, 36
- 7-Benzamido-3-methyl-1-methoxy-8*H*-pyrido[1,2-*c*]pyrimidin-8-one, **70**, 68
- 2-Benzamido-3-methylsulfonyloxy-L-itol, heating in pyridine, **68**, 305
- 7-Benzamido-8*H*-pyrido[1,2-*b*]pyridazin-8-one, **69**, 117
- 3-Benzamido-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 151
- 7-Benzamido-6*H*-pyrido[1,2-*a*]pyrimidin-6-one, **63**, 159
- 2-Benzamidotropones, cyclisation, **64**, 137
- Benzamidrazonium iodides, ring chain tautomerism, **66**, 29
- Benzazaphosphhepanes, **61**, 76
- Benzazaphospholenes, **61**, 76
- Benzazaphosphorinanes, **61**, 76
- Benzazepine **64**, 226
- Benzazepinones, from phenylalanine **64**, 53
- Benzazinotropones **66**, 108
- UV spectra **66**, 299
- Benzazinotropylium salts, **64**, 130
- conductive salts with
- tetracyanoquinodimethane, **66**, 380
- Benzil dioximes, oxidative cyclisation, **69**, 43
- Benzil monothiobenzoylehydrazones, ring chain tautomerism, **66**, 45
- Benzil phenylacetylhydrazones, ring chain tautomerism, **66**, 45
- Benzimidazole, photolysis, **67**, 38
- Benzimidazole-*N*-oxides, **65**, 14
- Benzimidazolethione, Pd(0) catalysed allylation, **66**, 96
- N*-(2-Benzimidazolyl)-C-ethoxycarbonylformohydrazonoyl chloride, **63**, 315
- N*-(2-Benzimidazolyl)hydrazonoyl chloride, cyclisation, **63**, 305
- 3-(Benzimidazolylthiomethyl)-1-methylpyrazolotropones, **66**, 394
- Benzimidazothiadiazonium salts, ring contraction, **65**, 67
- Benzimidazo[2,1-*c*]-1,2,4-triazole, **63**, 305
- Benz[*g*]indoles, **65**, 123
- Benzoannulated 1,3-oxazine-4-onium salts, **64**, 361
- Benzo[*d*]-3-azapyrylium salts, **64**, 357
- 3,4-Benzocoumarin, synthesis from 2-aryliodonibenzoates, **69**, 54
- Benzocyclobutenedione, **61**, 173
- Benzocyclooctene, **65**, 343
- Benzodiazepinediones, from anthranilamides and dimethyl acetylenedicarboxylate, **67**, 324
- 1,3-Benzodiazepines **64**, 227
- 1,4-Benzodiazepines-from 2-aminobenzophenones **64**, 53
- Benzodiazepinotropones **64**, 129
- Benzodihydropyrans, formation by carbene insertions **65**, 156
- 1,3-Benzodioxin-4-one, conformations, **69**, 245
- 5,6-Benzo-4-diphenylphosphino-2-phenyl-1,3-dioxo-2-boracyclohexane-reactions, **61**, 118
- Benzofurans, **65**, 140; **67**, 219
- palladium coupled homocoupling to 2,2'-bibenzofuran, **67**, 18
- Benzofuro[3,2-*b*][1,5]benzothiazepines, **63**, 90
- Benzofuro[3':5,6]pyrazino[2,3-*d*]pyrimidin-2,4-dione, **61**, 245
- Benzofuro[2,3-*c*]pyridazine, **63**, 383
- Benzofurotropone, **64**, 105
- Benzofurotropylium ions, <sup>1</sup>Hnmr spectra, **66**, 314
- catalytic hydrogenation, **66**, 383
- Benzofurotropylium salts, **64**, 137
- 2-Benzofuryl-3-arylazoimidazo[1,2-*a*]pyridine, **63**, 320
- Benzo[*f*]indoles, **67**, 238
- Benzoindolizine, **65**, 129
- Benzoisothiazoles, from base catalysed ring contraction of 2-aryl-1,3-benzothiazin-4-one-*S*-oxides, **66**, 172
- Benzoisothiazole-*S*-oxide, **66**, 172
- 3-Benzo[*d*]isoxazolyl-4-cyano-5-hydroxy-1-phenylpyrazole, **63**, 314
- Benzo[*c*][1,8]naphthyridine, **62**, 362
- Benzo[*i,j*]-2,7-naphthyridine, preparation, **68**, 200

- Benzonitrile-*N*-phenylimine, 1,3-dipolar cycloaddition to 1,5-benzothiazepines, **63**, 80
- Benzo-oxadiazoles, synthesis, **69**, 43
- Benzo-4*H*-1,3-oxazinium salts, **64**, 349
- Benzo-4*H*-3,1-oxazonium salts, **64**, 349
- 7-and 8-Benzo[*f*]-2-oxo-1,5-diazepin-4-yl homo *C*, -nucleosides, **70**, 305
- Benzo[*c*]phenanthridine alkaloids, **67**, 345  
biological activity and mechanism of action, **67**, 347
- Benzo[*c*]phenanthrid-6(5*H*)-ones, synthesis, **67**, 359; **67**, 360
- Benzo[*b*][1,7]phenanthroline anticancer agents, **70**, 102
- [1]-Benzopyrano[2,3-*b*]  
[1,5]benzothiazepines, **63**, 93
- 7*H*-[1]-Benzopyrano[3,4-*c*]  
[1,5]benzothiazepines, **63**, 94
- 6*H*-[1]-Benzopyrano[4,3-*b*]  
[1,5]benzothiazepi*N*6-one, **63**, 94
- 2*H*-1-Benzopyran-*N*-2-one, reaction with silyloxydienes, **65**, 350
- 2-Benzopyran-3-one-reaction as diene in Diels-Alder reaction, **65**, 345  
preparation, **65**, 346  
reaction with 2-isobutoxy-*N*-isobutoxycarbonyl-1,2-dihydroisoquinoline and ethyl 2,2-dimethyl-1-cyanoethene-1-carboxylate, **65**, 346
- Benzopyranopyridines, **67**, 300
- Benzopyrano[4,3-*b*]pyridines, **67**, 303
- Benzopyrano[3,4-*d*]pyrimidines-from enaminones and amidines, **67**, 315
- Benzopyrano[3,4-*e*]pyrimido[1,2-*b*]  
[1,2,4]triazine, **61**, 305
- Benzopyrano[4,3-*e*]pyrimido[1,2-*b*]  
[1,2,4]triazine, **61**, 305
- Benzopyrano[4,3-*b*]quinoline, **67**, 303
- 2*H*-Benzopyrans, **65**, 298
- Benzopyridotroponeimine, tosylation, sulfonylation, methylation, **66**, 378
- Benzopyridotropones, **64**, 87  
formation of imino-bridged derivatives with hydrazine, **66**, 339  
reduction by Wolff-Kishner reaction, **66**, 340  
reaction with Grignard reagents, **66**, 340  
nitration on benzene ring, **66**, 347  
formation of troponeimines, **66**, 373  
reductive amination, **66**, 378  
NMR spectra, **66**, 288  
IR spectra, **66**, 302
- Benzo[*j*]pyrrolo[2,3-*b*]acridine, **70**, 139
- trans*-Benzopyrroloindole, **65**, 4
- 1-Benzopyrilium triflates, preparation and reaction with 3-(trimethylsilyl)-1-butenes, **65**, 330
- Benzopyrylium ylides, preparation via Cu catalysed decomposition of *o*-(2-azidoacetyl)benzoates, **65**, 363  
preparation via enolisation of epoxyindanones, **65**, 364
- Benzo[*h*]quinoline-5,6-dione, conversion to triazinobenzquinones, **61**, 228
- Benzo[*f*]quinolin-2-yl reverse *C*-nucleoside, **70**, 207
- Benzoquinolizidines, synthesis, **67**, 288
- Benzo[*d*]quinolizinium salts, preparation from 1-methylisoquinoline, **68**, 213
- Benzoquinolizines, isomerisation to acridinones, **67**, 290
- 3-(*p*-Benzoquinonyl)tropolone, **64**, 105
- Benzo[*b*]-1,4-thiazepines, loss of sulfur, **65**, 50
- Benzo[*b*]-1,4-thiazepin-4-ones, loss of sulfur, **65**, 51
- Benzo[*b*]-1,4-thiazepin-4-thiones, loss of sulfur, **65**, 51
- 1,5-Benzothiazepine-4(5*H*)-thiones, reaction with acyl hydrazides, **63**, 79  
precursor to [1,2,4]triazolo[3,4-*d*]  
[1,5]benzothiazepines, **63**, 80
- 1,5-Benzothiazepines, 1,3 dipolar cycloaddition reactions with benzonitrile-*N*-phenylimines, **63**, 80  
1,3 dipolar cycloaddition reactions with benzonitrile oxides, **63**, 82
- Benzo[*f*]1,5-thiazepin-2-yl homo *C*-nucleosides, **70**, 306
- 1,4-Benzothiazine-3-carboxylic acid, derivatives for L-cystine, **64**, 51
- Benzothiazines, from *o*-thioaniline and 1,3-dicarbonyl compounds, **67**, 308  
from vinyl thioethers, **67**, 309
- 1,4-Benzothiazines, from diazo compounds, **65**, 191
- Benzothiazine ylides, from enaminones and 2-methylsufinylaniline, **67**, 310
- 1,3-Benzothiazin-4-ones, **66**, 139



- Benzothiazinonium perchlorates, reaction with guanidines and isothioureas, **66**, 179
- Benzothiazinotropones UV spectra, **66**, 300, **66**, 301
- tautomerism, **66**, 310
- nitration, bromination, **66**, 333
- chlorination, **66**, 342
- S-oxidation, **66**, 351
- Benzothiazinotropone-S-oxides, bromination, **66**, 352
- reduction, **66**, 352
- nitration, **66**, 352
- 9-(Benzothiazin-2-yl) tetrahydropyridopyrimidin-4-one, **63**, 217
- Benzothiazolethione, Pd(0) catalysed allylation, **66**, 96
- Benzothiazolines, from vinyl thioethers, **67**, 309
- Benzo[b]thiazolo[3,2-d]1,4-diazepin-1-yl acyclo C-nucleosides, **70**, 305
- Benzo[b]thiazolo[3,2-d]1,4-oxazepin-1-yl acyclo C-nucleosides, **70**, 305
- Benzothiazolopyrimidines, via thermal cyclization of enamines, **67**, 315
- Benzothiazolo[2,3-c]-1,2,4-triazole, **63**, 299
- 7-(Benzothiazol-1-yl)-6,7-dihydro-1*H*, 3-*H*, 5*H*-pyrido[3,2,1-*i,j*][3,1]benzoxazine, reaction with Grignard reagents, **70**, 32
- 2-Benzothiazolyl lithium, reaction with phosphorus halides to 2,2'-bibenzothiazoles, **67**, 40
- Benzothiazol-2-yl C-nucleosides, conformations and CD spectra, **70**, 194
- Benzothienopyrimidine-2(1*H*),4(3*H*)dithione, **66**, 218
- Benzothienotropones, Wittig reaction, **66**, 340
- chloromethylation, **66**, 356
- Benzo[b]thiepanes, **65**, 168
- Benzo[d]thiepin-2,4-dicarboxylic acid, loss of sulfur, **65**, 46
- Benzothietanes, **65**, 161
- Benzo[c]thiophenes, preparation from iodonium methylides, **69**, 35
- 1-(3-Benzo[b]thiophene)cyclohex-1-ene, Diels-Alder reaction, **63**, 367
- [1]-Benzothiopyrano[2,3-*b*][1,5]benzothiazepines, **63**, 95
- 13*H*-[1]-Benzothiopyrano[2,3-*b*][1,5]benzothiazepin-*N*-13-ones, **63**, 95
- Benzothiopyrano[4,3-*b*]pyrans, **67**, 262
- Benzothiopyranopyridines, **67**, 300
- Benzotriazepines, from enamines, **67**, 324
- 1*H*-1,2,4-Benzotriazepines, **64**, 228
- Benzotriazepinones, from enamines, **67**, 324
- Benzo[*f*]1,3,5-triazepin-4-yl acyclo C-nucleosides, **70**, 307
- 1,2,4-Benzotriazine, from flash vacuum pyrolysis of phosphorenes, **65**, 195
- 4*H*-Benzo[*b*][1,2,4]triazino[6,5-*b*][1,4]thiazin-3(2*H*)-ones, **61**, 274
- Benzotriazoles, Pd(0) catalysed allylation, **66**, 95
- photolysis, **65**, 119
- 1-(1-Benzotriazolyl)-1,2-dihydro-3*H*-[3,1]benzoxazine, **70**, 57
- Benzo[*e*]-1,2,3-trithiepane, loss of sulfur on oxidation, **65**, 52
- Benzotropolones, p*K*<sub>a</sub> values, **66**, 330
- oxidative cleavage to *o*-carboxycinnamic acids, **66**, 367
- Benzotropone, aromaticity, **66**, 307
- Benzotroponopyridinium salts, reaction with azulene aldehyde, **66**, 361
- Benzotropylium salts, oxidation to benzotropones, **66**, 380
- reaction with nucleophiles, **66**, 380
- 1,3,2-Benzoxaphosphole, **64**, 169
- Benzoxathiino[4,3-*b*]pyridines, **64**, 60
- Benzoxazepines, from chromylium salts, **65**, 307
- 1,3-Benzoxazepines, **64**, 226
- Benzoxazepinones, from leucine, **64**, 53
- 3,1-Benzoxazines, **69**, 354
- 1,3-Benzoxazines, **69**, 354
- [3,1]Benzoxazino[1,2-*c*][1,3]benzoxazines, synthesis, **69**, 458
- [3,1]Benzoxazino[4,3-*b*][1,3]benzoxazines, synthesis, **69**, 458
- Benzoxazinone, **64**, 209
- [1,3]Benzoxazino[2,3-*b*][1,3]oxazines, synthesis, **69**, 455
- Benzoxazinotropone, **64**, 128
- solid state structure, **66**, 286
- aromaticity, **66**, 308
- tautomerism, **66**, 308
- alkylation, **66**, 342
- Benzoxaziny[thieno[2,3-*d*]pyrimidines, **66**, 216

- Benzoxazolethione, Pd(0) catalysed allylation, **66**, 95
- Benzoxazol-2(3*H*)-ones, **67**, 249
- Benzoxepinopyrazolones, **65**, 320
- Benzoxetanes, **65**, 138
- Benzoylacetone-*N*-benzoylhydrazone, ring chain tautomerism **64**, 297
- Benzoylacetone dioximes, ring chain tautomerism, **66**, 21
- N*-Benzoyladenine, Pd(0) catalysed reaction with the monoacetate of *cis*-cyclopent-2-en-1,4-diol, **66**, 122
- pertrimethylsilyl derivatives in synthesis of acyclonucleosides, **68**, 60
- 6-Benzoyladenine, reaction with alkylating agents, **69**, 144
- 2-Benzoylamino-5-bromotropone, reaction with methyl sulfate, **64**, 110
- 2-Benzoylamino-3-dimethylaminopropenoate, reaction with 2-cyanomethylpyridine, **64**, 51
- 2-Benzoylamino-5-hydroxytropone, from oxazolotropones, **66**, 368
- N*-Benzoyl-*cis*- and *trans*-aminomethyl-1-cyclohexanols, cyclisations with phosphorus pentasulfide, **69**, 382
- N*-Benzoylaminopropyne, conversion to 2-oxazolines, **64**, 348
- 3-Benzoylaminotropolone, from oxazolotropones, **66**, 368
- 2-Benzoylbenzoyl azide, ring chain tautomerism, **64**, 263
- N*-Benzoyl-*N*-*t*-butyl diazoacetamides, Rh(II) catalysed decomposition **65**, 102
- 3-Benzoylcoumarin, reaction with diazoalkanes, **65**, 320
- N*-Benzoyldecahydroquinolin-7-one, condensation with 2-aminobenzaldehyde, **70**, 99
- 1,3,4-tri-*O*-Benzoyl-2-deoxy-D-ribofuranose, in preparation of acylconucleosides, **68**, 62
- 6-Benzoyl-2,5-diamino-4-thiomethylthieno[2,3-*d*]pyrimidine, **66**, 218
- N*-Benzoyl-2,2-difluoro-3,3-difluoromethylaziridine, **65**, 100
- 2-Benzoyl-2,3-dihydro-1,3-benzothiazin-4-ones, **66**, 159
- 6-Benzoyl-2,3-dihydro-2-phenyl-1,3-thiazin-4-ones, from ring expansion of isothiazolones, **66**, 146
- 2-Benzoyl-5,7-dimethylbenzo[*b*]thiophene-1,1-dioxide, **65**, 165
- N*-Benzoylhydrazones of acylpinacolines, ring chain tautomerism **64**, 300
- N*-Benzoylhydrazones of 1,3-diketones, ring chain tautomerism **64**, 301
- N*-Benzoylhydrazones of methyl 4-aryl-2,4-dioxobutanoates, ring chain tautomerism, **64**, 303
- 2-[4-*O*-Benzoyl-(3*s*)-3-hydroxybutyl]-3-methylquinoxaline, synthesis and debenzoylation, **68**, 79
- 3-Benzoyl-4-iminothienopyrimidin-2-thione, **65**, 242
- 5-Benzoyl-2-methylimidazo[2,1-*b*][1,3,4]thiadiazole, **69**, 308
- 1-Benzoyloxy-2-chloromethoxypropane, coupling with silylated thymine, **69**, 196
- 2,3-Benzoyloxy-cyclobutane free radicals, **68**, 348
- [2-(Benzoyloxy)ethoxy]acetic acid, **70**, 301
- 2-(2-Benzoyloxyethoxymethyl)-8-benzoyloxy-1,2,4-triazolo[1,5-*c*]pyrimidine, **69**, 148
- 2-[2-(Benzoyloxy)-ethoxy]thioacetimidate, reaction with 5-benzoyloxy-6-hydrazinopyrimidine, **70**, 258
- Benzoyloxyethylchloromethyl ether, **69**, 130
- 5-Benzoyloxy-4-hydrazinopyrimidine, cyclisation, **69**, 148
- trans*-1,11*b*-*H*-1-Benzoyloxymethyl-9,10-dimethoxy-4-phenylimino-1,2,3,6,7,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinoline, **70**, 41
- 4-Benzoyloxymethyl-2-oxo-1,3-dioxalane, in synthesis of acyclonucleosides, **69**, 175
- 4-Benzoyl-5-phenyl-1,3-oxathiazol-2-thione, synthesis, **69**, 43
- 1-Benzoyl-2-*N*-propylcycloprop-2-ene, **65**, 160
- 5-Benzoylpyridazine-4-carboxamide, ring chain tautomerism, **64**, 267
- 3-Benzoylpyridine-2-carboxamides, ring chain tautomerism, **64**, 267
- 3-Benzoylpyridine 2 (and 4-)-carboxylic acid, ring chain tautomerism **64**, 260
- 3-Benzoyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 150
- tri-*O*-Benzoyl-β-D-ribofuranosylamidoxime, reaction with acid anhydrides, **68**, 329
- 9-Benzoyl-1,2,3,4-tetrahydropyrido[1,2-*a*]pyrimidin-6-one, **63**, 161

- 2-Benzoyl-3-trifluoromethyl-5-methylpyrrole, synthesis, **67**, 224
- 3-Benzoylthieno[2,3-*d*]pyrimidine-2-thione, **66**, 211
- Benzthiazinotropones, **64**, 109, **64**, 128
- 8-Benzylamino-9-cyano-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, **63**, 142
- 1-Benzyl-4-aminoimidazole, by catalytic reduction of 1-benzyl-4-nitroimidazole, **61**, 17
- (±)-*N*-Benzyl aspidospermidine, **67**, 240
- O*-Benzylated 2-pyridyl acyclo *C*-nucleoside, cyclisation with diethyl azodicarboxylate, **68**, 341
- Benzylbis(α-hydroxybenzyl)phosphine oxide, precursor to 1,3,5-dioxaphosphorinane oxides, **61**, 64
- Benzyl-(*o*-carbamoyl)phenyl sulfoxides, cyclisation to 2,3-dihydro-1,3-benzothiazin-4-ones, **66**, 159
- 2-Benzyl-10-chloro-1,2,3,5,6,7-hexahydro-8*H*-pyrimido[5,6,1-*jk*] [1,4]benzodiazepin-8-one, formation, **70**, 52
- 2-Benzyl-9-chloro-1,2,3,5,6,7-hexahydropyrido[3,2,1-*ij*]quinazolin-7-one, reaction with sodium azide, **70**, 52
- N*-Benzyldeethylaspidospermidine, **67**, 241
- N*-Benzyl diazoacetamides, **65**, 118
- 4-(6-Benzyl-6,7-dihydro-3-aryl-4-oxo-4*H*-pyrido[2,1-*a*]phthalazine-1-carbonyl)morpholine, **69**, 101
- O*-Benzylfagaronine, **67**, 383
- 1,3-di-*O*-Benzylglycerol, as a precursor of acyclonucleosides, **68**, 2
- 2-Benzyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-*ij*]quinazolin-7-one, **70**, 64
- reduction, **70**, 42
- acylation, **70**, 45
- N*-(Benzylidene)alkylamines, reaction with dichlorocarbenes, **65**, 111
- 2,4:3,5-di-*O*-Benzylidene-*anhydro*-*D*-ribose, reaction with 3-chloro-4-lithiopyridine, **68**, 352
- N*-Benzylideneaniline, reaction with dichlorocarbene, **65**, 99
- Benzylidene 1,1'-bisnaphthols, oxidation, **69**, 25
- 9-Benzylidene-6-methyl-6,7,8,9-tetrahydro-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylic acid, conversion to acid chloride, **63**, 195
- 1-Benzyl-5-iodopyrimidin-2-one, coupling with stannanes, **62**, 332
- 3-Benzyl-4-lithio-1,2,3-oxadiazol-5-one, reaction with L-gulonolactones, **68**, 328
- erythro*-β-3-Benzylmalate, synthesis via cyclic sulfites, **68**, 135
- 5-Benzylmercaptopyropionic acid amides, oxidative cyclisation to 2,3,5,6-tetrahydro-1,3-thiazin-4-ones, **66**, 155
- 1-Benzyl-4-nitroimidazole, reduction to 1-benzyl-4-aminoimidazole **61**, 17
- 2-Benzylloxirane, **65**, 136
- Benzylloxolan-3-ones, **65**, 142
- Benzyl *trans*-4*a*, 8-*H*-1-oxo-2-propylperhydropyrido[1,2-*c*]pyrimidine-9-carboxylate, X-ray structure of complex with FKBI2, **70**, 30
- (*R*)- and (*S*)-1-Benzyl-3-azido-2-propanol, precursor for acyclonucleosides, **68**, 18
- N*Benzyl-oxycarbonylamino-*D*-glucose dithioacetal, intramolecular cyclisation, **68**, 302
- 2,3-Benzyl-oxycyclobutane free radicals, coupling with pyridinium trifluoroacetate, **68**, 374
- 2-(Benzyl-oxo)ethanol, precursor in preparation of acyclonucleosides, **68**, 57
- O*-Benzyl-oxylfagaronine, **67**, 382
- 3-(Benzyl-oxo-1-fluoromethylpropyl)chloromethylether, reaction with purines to give acyclonucleosides, **68**, 16
- N*-Benzyl-oxo-β-lactams, **65**, 109
- 2-Benzyl-oxymethyl-1,3-dibenzyl-oxo-2-propanol, as a precursor of acyclonucleosides, **68**, 24
- 1-(Benzyl-oxo)methyl-4-(substituted imino)-1,2,4,6,7,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinolines, **70**, 61
- 3-(*o*-Benzyl-oxo-phenyl)-1-diazoacetone, Rh(II)-catalysed decomposition, **65**, 155
- (1-Benzyl-oxo-3-phthalimido-2-propoxy)methyl chloride, alkylation of purines, **68**, 23
- R*-2-(Benzyl-oxo)propanal, preparation of acyclonucleosides, **68**, 63
- 1,3-bis(Benzyl-oxo)-2-propanone, reaction with lithiated pyrimidines to give carboacyclic *C*-nucleosides, **68**, 40

- 3-Benzoyloxy-2-pyridone, by oxidation of 2-pyridone, **61**, 145
- 9-Benzoyloxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, hydrogenation, **63**, 179
- 4-Benzyl-2-phenyl-2,3-dihydro-1*H*-pyrimido[1,6-*a*]quinoline, heating, **70**, 47
- 4-Benzyl-2-phenyl-2,3-dihydro-1*H*-pyrimido[1,6-*a*]quinolin-1,3-diones, **70**, 69
- 4-Benzyl-2-phenyl-2,3-dihydro-1*H*-pyrimido[6,1-*a*]quinoline-1,3-dione, catalytic reduction, **70**, 43
- 2-Benzyl-1-phenyl-6-propyl-4,5,7-triethyl-2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidines, **70**, 74
- 2-Benzylphenyltellurium trichloride, cyclisation, **63**, 35
- 2-Benzylpyridine, **62**, 403
- Benzyl-2-pyridylsulfoxide, reaction with phenyl Grignard, **62**, 403
- 5-*O*-Benzyl-D-rhamnitol, preparation of acyclonucleosides, **68**, 63
- N*-Benzyl-2-(β-D-ribofuranosyl)ethanolamine, reaction with diethylacetylene dicarboxylate, **68**, 248
- Benzyl D-ribofuranosylthioformimidate, reaction with 3-chloro-2-hydrazinopyrazine, **70**, 281
- 3-Benzylthieno[2,3-*d*]pyrimidine-4-one-2-thione, **66**, 195
- 3-(1'-Benzylthioethylen-1-yl)indole, reaction with methyl maleate, **63**, 376
- 8-Benzylthio-1,2,4-triazolo[4,2-*a*]pyrazin-3-yl C-nucleosides, **70**, 281
- 3,5-Di-*O*-Benzyl-1-*O*-trityl-2-deoxy-D-ribose, precursor in *seco*-nucleoside synthesis, **67**, 417
- 1-Benzyl-2-vinylindole, cycloaddition, **63**, 351
- BETMIP *see* 1-(triphenylphosphoranylideneamine) benzotriazole
- 9,9'-Biacidine, **67**, 58
- spectra, **67**, 58
- reduction, **67**, 58
- Biazetidinine disulfide, **65**, 74
- 1,2'-Bibenzimidazole, **67**, 37
- 2,2'-Bibenzimidazole, **67**, 38
- from photolysis of 2-(2'-furyl)benzimidazole, **67**, 38
- X-ray structure, **67**, 38
- spectra, **67**, 39
- alkylation, **67**, 39
- oxidation, **67**, 39
- reaction with boron trifluoride, **67**, 39
- complexes, **67**, 39
- 2,2'-Bibenzofuran, **67**, 17
- by base catalysed cyclisation of salicylaldehyde ether, **67**, 17
- by palladium catalysed homocoupling of benzofuran with 2-(chloromercury)benzofuran, **67**, 18
- by copper induced homocoupling of 2-trimethylstannylbenzofuran, **67**, 18
- by nickel mediated homocoupling of 2-bromobenzofuran, **67**, 18
- 2,2'-Bibenzothiazole, **67**, 40
- from photolysis of benzothiazole, **67**, 40
- spectra and electrochemical studies, **67**, 40
- dimethylation, **67**, 40
- 2,2'-Bibenzothiophene, from oxidative coupling of 2-lithiobenzothiophene, **67**, 18
- by acid catalyzed dimerization of benzothiophene, **67**, 19
- from 2-bromobenzothiophene, **67**, 19
- theoretical and photoelectron studies on conformation, **67**, 20
- desulfurization, **67**, 20
- reaction with sulfur, **67**, 20
- conversion to a cyclic tetramer, **67**, 20
- 2,3'-Bibenzo[*b*]thiophene, **67**, 19
- theoretical and photoelectron studies, **67**, 20
- reaction with sulfur, **67**, 20
- Diels-Alder reactions, **67**, 20
- 3,3'-Bibenzo[*b*]thiophene, **67**, 19
- from 3-iodobenzothiophene, **67**, 19
- from 3-bromobenzothiophene, **67**, 19
- reaction with sulfur, **67**, 20
- Diels-Alder reactions, **67**, 20
- dilithiation, **67**, 20
- 1,1'-Bibenzotriazoles, from *o,o*-azobenzene bisdiazonium salts with sulfur dioxide, **67**, 44
- 1,2'-Bibenzotriazole, **67**, 44
- 2,2'-Bibenzoxazole, **67**, 39
- reaction of *o*-aminophenol with imidates, **67**, 40

- reaction with lithium aluminium hydride, **67**, 40  
fluorescence and redox properties, **67**, 40  
9,9'-Bicarbazole from oxidation of carbazole, **67**, 17  
by thermolysis of *N,N'*-azocarbazole, **67**, 17  
X-ray structure, **67**, 17  
spectroscopic studies, **67**, 17  
halogenation, **67**, 17  
photolysis, **67**, 17  
thermolysis, **67**, 17  
electropolymerisation, **67**, 17  
2,2'-Bicinchonic acid, decarboxylation to 2,2'-biquinoline, **67**, 53  
3,3'-Bicinnoline, **67**, 64  
4,4'-Bicinnoline, **67**, 65  
spectra, **67**, 65  
Bicyclic ethers, formation, **69**, 61  
Bicyclic oligosulfides of 2,5-diketopiperazines, loss of sulfur, **65**, 80  
Bicyclo[1,1,0]butanes, via intramolecular cyclopropanation reactions, **65**, 213  
Bicyclo-*N*-methylatalaphylline, **70**, 124  
2,2'-Bi(1,3-dithiolyldene), *see* tetrathiafulvalenes  
Biemnadin, **70**, 96, 116  
Bifonazole, **67**, 5  
Bifurans, theoretical studies, **67**, 9  
2,2'-Bifuran, **67**, 8  
preparation by decarboxylation of 3-carboxy analog, **67**, 8  
preparation from furan by coupling with palladium acetate, **67**, 8  
preparation via 2-lithio or 2-chloromercury derivatives, **67**, 8  
preparation via coupling of 2-halofurans, **67**, 8  
from furfural using benzotriazole chemistry, **67**, 8  
spectroscopic studies, **67**, 9  
reactions, **67**, 9  
Vilsmeier formylation, **67**, 10  
2,3'-Bifuran, **67**, 9  
3,3'-Bifuran, **67**, 9  
preparation from 3-bromofuran and low-valent nickel compounds, **67**, 9  
from furanylboroxines, **67**, 9  
Biheterocycles as chelating agents, **67**, 2  
as binucleating ligands, **67**, 2  
in molecular hosts, **67**, 3  
in construction of catenanes, rotaxanes and dendrimers, **67**, 3  
synthesis by low valent transition metal-catalysed homocoupling reactions, **67**, 3  
synthesis of unsymmetrical isomers by palladium catalysed cross-coupling reactions, **67**, 3  
2,2'-Biimidazole, from ammonia on glyoxal, **67**, 28  
by oxidation of *N*-protected biimidazolines, **67**, 29  
X-ray structure, **67**, 29  
reactions, **67**, 30  
halogenations, **67**, 30  
sulfonations, **67**, 30  
as a chelating agent, **67**, 31  
double deprotonation to dianion, **67**, 31  
 $\Delta^{3,3}$ -Bi-3*H*-indazole, **67**, 27  
2,2'-Biindazole, **67**, 26  
3,3'-Biindazole, **67**, 27  
lead tetraacetate oxidation, **67**, 27  
Biindoles-preparation by permanganate oxidation of indoles, **67**, 13  
preparation by reduction of 1-hydroxyindoles, **67**, 13  
2,2'-Biindole, **67**, 13  
preparation by double intramolecular Wittig reaction, **67**, 14  
preparation by Stille coupling, **67**, 14  
naturally occurring, **67**, 14  
reaction with dienophiles, **67**, 16  
Michael reactions, **67**, 16  
2,3'-Biindole, **67**, 14  
by reduction of 3-hydroxy-2,3'-biindole, **67**, 14  
catalytic hydrogenation of 2,3-dihydro-2,3'-biindole, **67**, 14  
by Stille coupling, **67**, 14  
by Fischer cyclisation of 3-acetylindole, **67**, 14  
by dehalogenation of 2'-chloro-2,3'-biindole, **67**, 14  
by reaction of indole and 3-bromoindole, **67**, 15  
nitrosation reactions, **67**, 16  
formylation, **67**, 16  
methylation, **67**, 16

- reaction with hydroxyindole, **67**, 16  
 electropolymerisation, **67**, 16  
**3,3'-Biindole**, **67**, 15  
   preparation from indole and indoxyl, **67**, 15  
   by sulfuration of oxindole, **67**, 15  
   by deselenation of 3,3'-diindolyl selenide, **67**, 15  
   from dinitrostyrene, **67**, 15  
   by coupling of a radical anion, **67**, 15  
   by reduction of reaction product of indole and isatin, **67**, 15  
   acid catalysed rearrangement, **67**, 16  
   oxidation, **67**, 16  
   electropolymerisation, **67**, 16  
**1,1'-Biisoquinoline**, **67**, 56  
   nitration, **67**, 57  
   atropisomerism, **67**, 57  
   *N,N'*-diquaternisation, **67**, 57  
   metal complexes and chirality, **67**, 57  
**3,3'-Biisoquinoline**, **67**, 56  
   metal complexes, **67**, 57  
   molecular orbital calculations and luminescence studies, **67**, 57  
**4,4'-Biisoquinoline**, **67**, 56  
   X-ray structure of 1,1',3,3'-tetrakis(dimethylamino) derivative, **67**, 57  
   atropisomerism, **67**, 57  
**3,3'-Biisoxazole**, from dichloroglyoxime and acetylenic Grignard reagents, **67**, 23  
   X-ray structure, **67**, 25  
   bromination and nitration, **67**, 25  
**3,4'-Biisoxazole**, by reaction of ethynyl magnesium bromide with isoxazole hydroxamic chloride, **67**, 24  
**3,5'-Biisoxazole**, by reaction of ethynyl magnesium bromide with isoxazole hydroxamic chloride, **67**, 24  
   X-ray structure, **67**, 25  
**5,5'-Biisoxazole**, **67**, 24  
   X-ray structure, **67**, 25  
   base catalysed ring opening, **67**, 25  
**Biolumazine**, **70**, 275  
**Biopterin**, *see* 2-amino-6-(*L*-erythro-1',2'-dihydroxypropyl)-4-oxo(3*H*)pteridine  
**3,3'-Bi-1,2,4-oxadiazole**, **67**, 45  
   molecular orbital calculations, **67**, 46  
**4,5'-Bioxazole**, synthesis via Schollkopf procedure, **67**, 32  
**5,5'-Bioxazole**, synthesis via Schollkopf procedure, **67**, 32  
**2,2'-Bioxazoline**, **67**, 31  
**6,6'-Biphenanthridine**, **67**, 58  
**Biphenylene**, **65**, 74  
**Biphenyl** ditelluride, **64**, 326  
**Biphosphines**, via reaction of 1,2-bis(phosphino)ethane with seven membered cyclic sulfates, **68**, 163  
 $\Delta^{4,4'}$ -Bi-4*H*-pyrans, **65**, 314  
**2,2'-Bipyrazine**-from pyrolysis of Cu(II) salt of 2-pyrazine carboxylate, **62**, 397  
**Bipyrazine**, **67**, 63  
   spectra, **67**, 64  
   chelating activity, **67**, 64  
   physical properties, **67**, 64  
**1,1'-Bipyrzole**, **67**, 21  
   MNDO calculations, **67**, 22  
**1,3'(5')-Bipyrzole**, **67**, 21  
   Nalkylations, **67**, 23  
**3,3'-Bipyrzole**-from diacetylene with diazomethane, **67**, 21  
   bromination, **67**, 23  
   formylation, **67**, 23  
**4,4'-Bipyrzole**, from hydrazine and tetraaldehydes, **67**, 22  
**3,3'-Bipyridazine**, **67**, 59  
   chelating agent, **67**, 59  
   X-ray structure of nickel and iron complexes, **67**, 60  
   spectra and physical properties, **67**, 60  
   *N*-oxidation, **67**, 60  
**4,4'-Bipyridazines**, as precursors to 3,3'-bipyrroles, **67**, 6  
**2,2'-Bipyridine**, **67**, 2; **67**, 50  
   low temperature X-ray crystal structure, **67**, 51  
   complexes with metals, **67**, 51  
   incorporation into homochiral structures for use in chiral auxiliaries, **67**, 51  
**2,3'-Bipyridine**, **67**, 50  
**2,2'-Bipyridyl**, preparation via Ullman reaction, **62**, 393  
**2,3'-Bipyridyl**-from 2-chloropyridine and 3-iodopyridine, **62**, 394  
**2,2'-Bipyrimidine**, **67**, 60  
   from 2-bromopyrimidine and copper (I), **62**, 397  
   structure and conformation, **67**, 62  
   spectra and physical properties, **67**, 62  
   metal complexes, **67**, 63  
   oxidation and quaternisation, **67**, 63

- 4,4'-Bipyrimidine, **67**, 61  
from pyrolysis of Cu(II) salt of 4-pyrimidine carboxylate, **62**, 397  
from homocoupling of 4-iodopyrimidines, **62**, 311  
X-ray structure, **67**, 62
- 4,5'-Bipyrimidine, **67**, 61
- 5,5'-Bipyrimidine, **67**, 61
- Bipyrroles, **67**, 2; **67**, 4
- 1,1'-Bipyrrole, preparation by reduction of 2,5-dichloro-analogue, **67**, 4  
by condensation of 1,4-diketones with hydrazine, **67**, 5  
by reaction of *N*-aminopyrroles with 1,4-dicarbonyl compounds, **67**, 5  
by reaction of *N*-pyrrolylsuccinimides with Wittig reagents, **67**, 5  
conformations, **67**, 6  
formylation, **67**, 7
- 2,2'-Bipyrrole, by catalytic reduction of 2-(2'-pyrrolidinyl)pyrrole, **67**, 5  
by condensation of  $\Delta^3$ -pyrrolin-3-one with pyrrole, **67**, 5  
by oxidation of 1-arylpyrroles by palladium acetate, **67**, 5  
conformations by theory and spectroscopic measurements, **67**, 7  
reaction with pyrrolyl aldehydes, **67**, 7  
reaction with triethyl orthoformate, **67**, 7  
alkylation of dianion, **67**, 7  
formylation, **67**, 7
- 2,3'-Bipyrroles, **67**, 6  
theoretical studies of conformations, **67**, 7
- 3,3'-Bipyrroles, **67**, 6  
theoretical studies of conformations, **67**, 7
- 2,2'-Biquinazoline, **67**, 66  
X-ray structure, **67**, 67  
spectra, **67**, 67
- 4,4'-Biquinazoline, **67**, 67  
spectra, **67**, 67  
oxidation, **67**, 67
- 2,2'-Biquinoline, **67**, 52  
preparation by homocoupling reactions of haloquinolines, **67**, 52  
preparation by oxidative coupling of quinolines, **67**, 52  
X-ray structure, **67**, 54  
spectra and theoretical studies, **67**, 54  
physical measurements, **67**, 54  
reactions as a chelating agent, **67**, 54  
oxidations, **67**, 55
- 2,3'-Biquinoline, **67**, 53  
by reaction of quinoline and sodium metal, **67**, 53  
X-ray structure, **67**, 54  
theoretical studies, **67**, 54  
oxidations, **67**, 55
- 2,4'-Biquinoline, **67**, 53  
spectra, **67**, 54
- 3,3'-Biquinoline, **67**, 53  
spectra, **67**, 54
- 3,4'-Biquinoline, **67**, 53
- 4,4'-Biquinoline, **67**, 54
- 2,2'-Biquinoxaline, **67**, 67  
spectra and physical properties, **67**, 68  
reactions, **67**, 68
- 1,2-Bis(alditol-1-ylidene-amino)benzenes, **70**, 184
- Bis(alkylseleno)tetrathiafulvalenes, **62**, 269
- Bis(alkylthio)diselenadithiafulvalenes, **62**, 269, **62**, 280
- Bis(aminothiazoles), **69**, 286
- Bis(benzimidazol-2-yl) acyclo C-nucleosides, **70**, 185
- Bis-(1,3-benzothiazin-4-ones), **66**, 140
- N,N*-Bis(2'-carboxyphenyl)-1,3-diaminobenzene, conversion to quino[3,2-*b*]acridone, **70**, 99
- 2,4-Bis(dialkylamino)pyrylium salts, from enaminones, **67**, 267
- Bis-2,6-diaryl-4-bipyranylidene, **65**, 314
- 1,8-Bis(diazoacetyl)octane, reaction with dodecane-1,12-diol, **65**, 198
- 1,3-Bis(dimethylamino)vinylcarbene, addition to benzaldehyde, **65**, 151
- Bis-2,6-dimethyl-4-bipyranylidene, **65**, 317
- 4,4'-Bis(ethoxycarbonyl)-5,5'-bithiazole, **67**, 35
- 2,2-Bis-ethoxycarbonyl-2*H*-pyran, **62**, 49
- Bis(ethylenediseleno)tetrathiafulvalenes, **62**, 282
- Bisglucosylcarbodiimides, **64**, 181
- Bisglucosylureas, **64**, 181
- Bis( $\alpha$ -hydroxyalkyl)phosphines, conversion to cyclic compounds, **61**, 85  
conversion to 1,3,2,5-dioxaboraphosphorinanes, **61**, 93
- 2,2-Bisimidazole, synthesis via glyoxal sulfate, **68**, 156

- 1,1-Bis(3-indolyl)ethenes, Diels-Alder reaction, **63**, 358  
reaction with maleic anhydride, **63**, 362
- 5,5'-Bis(6-methylimidazo[2,1-*b*]thiazolyl)selenide, **69**, 296
- Bisoxazoles, **65**, 180  
by oxidation of dipeptides, **69**, 38
- Bis[4-oxobenzo[*d*]oxazin-2-yl] acyclo *C*-nucleoside, **70**, 295
- 1,1-Bisphenols, oxidation, **69**, 25
- 5-(Bisphenoxyphosphoryl)oxy-4-pentanolactone, **69**, 27
- Bis[2-(3'-propen-2'-al-1')phenyl]ditelluride, **63**, 26
- Bis[2-(3'-propen-2'-methyl-1'-al)phenyl]ditelluride, **63**, 27
- Bis-4*H*-pyrans, **62**, 53 **62**, 58
- Bis(2-pyridyl)acetylene, **62**, 314
- 1,9-Bis(2-pyrrolyl)pyrromethene, **67**, 7
- Bis(quinoxalotropone), spectra, **66**, 319
- 4,4-Bis(tellurachromanylidene), **63**, 22
- 9,9'-Bis(telluraxanthenyl), **63**, 41,45
- Bis(1,3-thiazin-4-one), **66**, 133
- Bisthienotropylium ions, <sup>1</sup>H NMR spectra, **66**, 314  
aromaticity, **66**, 320  
reduction and transannular cyclisation, **66**, 378  
electron density and molecular orbital calculations, **66**, 379
- 1,1-Bis(2-thienyl)ethanol, reaction with tetracyanoethylene, **63**, 379  
reaction as 4*π*-electron system, **63**, 386
- Bis-1,2,4-triazole, **64**, 200
- Bis(2,4,6-trichlorophenyl)malonates, in synthesis of pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 138
- 5,5'-Bis(trifluoromethyl)-2,2'-bi-1,3,4-oxadiazole, Diels-Alder reactions **67**, 47
- 3,5-Bis(trifluoromethyl)-2-chloropyridine, homocoupling with Zn-Ni, **62**, 409
- Bis(trifluoromethyl)mercury, adds trifluoromethyl groups to heterocycles, **62**, 395
- Bis(trimethylsilyl)-5-benzyluracil, reaction with 2-acetoxyethyl acetoxymethyl ether, **69**, 134
- 2,4-Bis(trimethylsilyloxo)thieno[3,2-*d*]pyrimidine-2,4-diones, alkylation, **66**, 250
- 2,6-Bis(trimethylsilyloxy)-4*H*-pyran, **62**, 67  
conversion to pyran-2,6-diones, **62**, 95
- 2,4-Bis(trimethylsilyloxy)thymine-Pd(0) catalysed allylation, **66**, 127
- 2,4-Bis(trimethylsilyl)pseudouridine, methylation, **68**, 360
- Bis(trimethylsilyl)thymine, condensation with dioxolanes, **69**, 147
- Bistropolofurans, *O,O'*-bismethyl or *O,O'*-bisacetyl derivatives, **66**, 344
- Bistropenyls, from furo and pyrrolotropones, **66**, 368
- Bis(vinylthio)tetrathiafulvalenes, **62**, 270
- 1,5'-Bitetrazole, **67**, 48
- 5,5'-Bitetrazole, synthesis, **67**, 48  
X-ray structure, **67**, 48  
p*K*<sub>a</sub> and p*K*<sub>b</sub> values, **67**, 49  
heat of formation, **67**, 49  
spectra, **67**, 49  
reactions, **67**, 49  
coordination chemistry, **67**, 49
- 4,4'-Bi-1,2,5-thiadiazole-3,3'-dicarboxylate, **67**, 47
- 2,2'-Bi-1,3,4-thiadiazoles, **67**, 47  
ruthenium complex of dimethyl derivative-X-ray structure, **67**, 47
- 2,2'-Bithiazole, formation by Ullmann cross coupling, **67**, 33  
solid state structure, **67**, 36  
spectra, **67**, 36  
dimethylation, **67**, 36  
halogenation of derivatives, **67**, 36  
metal complexes, **67**, 36  
spectra of ruthenium complexes, **67**, 37
- 2,4'-Bithiazole, from Hantzsch reaction, **67**, 34  
as analogs of bleomycin, **67**, 35
- 2,5'-Bithiazole, **67**, 35  
by the Stille reaction, **67**, 35  
solid state structure, **67**, 36
- 4,4'-Bithiazole, **67**, 35  
by reaction of mercuric oxide with the 2,2'-dihydrazino derivative, **67**, 35  
solid state structure, **67**, 36  
metal complexes, **67**, 36
- 4,5'-Bithiazole, **67**, 35
- 5,5'-Bithiazole, **67**, 35  
solid state structure, **67**, 36
- 2,2'-Bithiazole-4,4'-dicarboxylic acid, alkaline decomposition product of cystine, **67**, 34



- Bithiazoline, oxidation to bithiazoles, **67**, 34  
Bithiophenes, **67**, 2  
2,2'-Bithiophene, **67**, 10  
    by nickel mediated homo-coupling reactions, **67**, 10  
    X-ray structure, **67**, 11  
    theoretical studies of conformations, **67**, 12  
    spectroscopy, **67**, 12  
    reactions, **67**, 12  
    halogenation, **67**, 12  
    formylation, **67**, 12  
    Friedel-Crafts acylations, **67**, 12  
    alkylation, **67**, 12  
    dimerisation, **67**, 12  
    Birch reduction, **67**, 12  
    conversion to S-C-ylids, **67**, 12  
3,3'-Bi-1,2,4-triazine, **67**, 69  
5,5'-Bi-1,2,4-triazine, **67**, 69  
1,4'-Bi-1,2,4-triazole, **67**, 42  
3,4'-Bi-1,2,4-triazole, **67**, 42  
    X-ray structure and tautomerism, **67**, 43  
4,4'-Bi-1,2,4-triazole, **67**, 43  
    methyl substituted derivatives, **67**, 43  
    conformation, **67**, 43  
    metal complexes and structure determination, **67**, 43  
    quaternisation, **67**, 44  
4,4'-Bi-1,2,3-triazole, **67**, 41  
5,5'-Bi-1,2,4-triazole, **67**, 42  
    molybdenum carbonyl complexes, **67**, 43  
    methylation, **67**, 44  
3,3'-Bitropolonyls-dehydrative cyclisation, **64**, 118  
Bleomycin A<sub>2</sub>-syntheses, **67**, 34  
N-Boc-L-allylglycine, conversion to detoxinine, **64**, 11  
Bohlmann bands in spectra of *cis* and *trans*-perhydropyrido[1,2-*c*][1,3]oxazines, **70**, 8  
1,4-Boraphosphacyclohexa-2,5-dienes, **61**, 120  
1-Borata-2,6,7-trioxo-4-phosphabicyclo[2,2,2]octane, **61**, 88  
Boroxazolidones, **64**, 27  
Boryloxyalkyl(imido)phosphines, from  $\alpha$ -hydroxyalkylphosphines, **61**, 90  
Boryloxyalkylphosphines, reaction with S and Se, **61**, 104  
    reaction with electrophiles, **61**, 104  
    reaction with bipolar reagents, **61**, 107  
    reaction with nucleophiles, **61**, 110  
Boryloxyphenylenephosphines, **61**, 124  
1,2-Borylphosphinoethenes-synthesis, **61**, 120  
    reactions, **61**, 121  
    spectral properties, **61**, 121  
    4+2 cycloadditions, **61**, 122  
(3-Borylpropenyl)oxazolidin-2-ones, Diels-Alder reactions, **69**, 372  
4-Bromoacetoacetic acid, reaction with pyridazinones, **69**, 154  
3-(Bromoacetyl)tropolone, reaction with thiophenol, **64**, 105  
2-Bromoadenosine, coupling with trialkylaluminiums, **62**, 372  
2-Bromo-2-(alditol-1-yl)pyridine, displacement of bromine, **68**, 351  
4-Bromo-3-(2-aminophenyl)thiomethyl-3-pyrazolin-5-ones, **63**, 76  
5-Bromo-6-arylimidazo[2,1-*b*]thiazoles, **69**, 291  
2-Bromobenzofuran, nickel mediated homocoupling, **67**, 18  
2-Bromobenzothiophene, homocoupling to 2,2'-bibenzothiophene, **67**, 19  
3-Bromobenzothiophene, metal halogen exchange and coupling to 3,3'-bibenzo[*b*]thiophene, **67**, 19  
10-Bromobenzo[*b*]tropoxazine, **64**, 89  
5-(4-Bromobenzoyl)-6-[3-(methylamino)propyl]imidazo[2,1-*b*]thiazole, synthesis, **69**, 289  
S-(*p*-Bromobenzyl)thiotropocin, X-ray diffraction, **66**, 287  
5-Bromo-2-chloropyrimidine, coupling with stannanes, **62**, 332, **62**, 352  
7-Bromo-6-chlorothieno[3,2-*d*]pyrimidin-4(3*H*)one, **66**, 252  
6-Bromo-2*H*-chromene, synthesis, **69**, 50  
3-Bromochromone-reaction with active methylenes, **65**, 303  
5-Bromo-2-(cinnamyloxy)pyrimidine, Pd(0) catalysed rearrangement, **66**, 103  
3-Bromocinnoline, coupling with alkynes, **62**, 318  
3-Bromocoumarin, reaction with Grignard reagents, **65**, 298  
4-Bromocoumarin, cross coupling with organoboranes, **65**, 305  
4-Bromo-1'-cyano-1,4'-biisouquinoline, **67**, 56  
6-Bromo-6-cyclohex-5-enofuranoses, condensation with hydroxylamine, **68**, 292

- 1-Bromo-1-deoxy-D-*galacto*-heptulose, **70**, 191
- 1-Bromo-1-deoxy-D-*galacto*-heptulose pentaacetate, **70**, 305
- 2-*exo*-Bromo-7,7-dichloro-3-endo-hydroxybicyclo[3,2,0]hepta-*N*6-one, ring chain tautomerism, **64**, 269
- 5-Bromo-2,4-dichloropyrimidines, coupling with stannanes, **62**, 333
- trans*-Bromodihydropyrans, **65**, 289
- 1-Bromo-3,4-dimethoxybenzene, in synthesis of nitidine, **67**, 350
- 6-Bromo-2,2-dimethyl-7-methoxychromene, in preparation of acronycine, **70**, 133
- 2-Bromo-5,6-dimethylthieno[2,3-*d*]pyrimidin-4(2*H*)-one, **66**, 225
- 5-Bromo-1,3-dimethyluracil, reaction with dibenzylketones, **69**, 395
- 6-Bromo-2-ethylthieno[2,3-*c*]acridine, **70**, 142
- 3-(4-Bromo-2-fluorobenzyl)benzothieno[3,2-*d*]pyrimidine-2(1*H*),4(3*H*)-diones, **66**, 236
- 3-(4-Bromo-2-fluorobenzyl)thieno[3,4-*d*]pyrimidine-2(1*H*)-4(3*H*)-dione, **66**, 256
- 9-Bromofurobenzotropone, displacement by trifluoromethyl group, **66**, 347
- 5-Bromofurotropone, reaction with isopropylamine, **66**, 346
- 5-Bromo-6-hydroxycyclohepta[*b*]pyrid-7-one, **66**, 334
- 2-Bromo-3-hydroxy-1,4-naphthoquinone, reaction with 2-mercaptotriazoles, **69**, 320
- 2-(5-Bromo-2-hydroxyphenyl)benzothiazoline, ring chain tautomerism, **66**, 43
- 2-Bromo-3-hydroxypyridine, conversion to furo[3,2-*b*]pyridines, **62**, 319
- 2-Bromomidazoles, Ullmann couplings, **67**, 29
- 4(5)-Bromomidazole, Pd(0) catalysed allylation, **66**, 91
- 5-Bromomidazo[2,1-*b*][1,3,4]thiadiazoles, **69**, 309
- 3-Bromoindole, reaction with indole, **67**, 15
- 1-Bromoisoquinoline, coupling with alkynes, **62**, 315
- 3-Bromoisoquinoline, Ullmann coupling reactions, **67**, 56
- 4-Bromoisoquinoline, homocoupling to 4,4'-biisoquinoline, **67**, 56
- coupling with 4-diethylborylisoquinoline, **67**, 56
- Ni catalysed coupling with Grignard reagents, **62**, 390
- 3-Bromoisoquinolin-4-ol, coupling with Ni catalyst, **62**, 407
- 2-Bromoleptoclidone, **70**, 96
- synthesis, **70**, 120
- 5-Bromo-6-methoxy-5,6-dihydro-2*H*-pyran, **62**, 63
- 2-Bromo-3-methoxypyridine, coupling reactions with Zn-Ni or Pd-C, **62**, 407
- 3-Bromomethylbenzo[*d*]isoxazole-reaction with benzene diazonium chloride, **63**, 292
- 6-Bromomethyl-5,6-dihydro-2,4-dimethylthieno[2,3-*d*]pyrimidine, **66**, 218
- 1-Bromomethyl-2,3-dihydro-1*H*-pyrido[1,2-*c*][1,3]oxazinium bromide, **70**, 53
- 6-Bromomethyl-5-methylthieno[2,3-*d*]pyrimidin-2,4-dione, **66**, 225
- 4-Bromomethyl-2-methylthieno[2,3-*d*]pyrimidine, **66**, 228
- 2-Bromo-2-methylpropanamides, reaction with enamines, **67**, 249
- 2-Bromo-3-methylpyrrolo[*b*]tropolone, **66**, 332
- 6-Bromo-8-oxobenzo[*b*]tropoxazine, **64**, 89
- 8-Bromo-6-oxobenzo[*b*]tropoxazine, **64**, 89
- 1-(3-Bromo-2-oxopropyl)pyridazin-6-one, in synthesis of acyclonucleosides, **69**, 181
- 1-Bromo-1-phenylaziridine, reaction with *N,N'*-dimethylethylenediamine, **65**, 176
- 7-Bromo-3-(1-phenylhydrazono-2,3,4-trihydroxybutyl)pyrido[2,3-*b*]pyrazin-2-one, **70**, 284
- cis*-1,4*a*-*H*-1-(*p*-Bromophenyl)perhydropyrido[1,2-*c*][1,3]oxazine, absolute configuration, **70**, 18
- 1-(4-Bromophenyl)perhydropyrido[1,2-*b*][1,3]thiazine, X-ray structure, **70**, 21
- 8-Bromopurine, coupling with trialkylaluminiums, **62**, 372
- Bromopyridines, coupling to styrene in presence of Pd(II), **62**, 307
- 2-Bromopyridine coupling to alkynes, **62**, 314
- coupling with alkenylaluminiums, **62**, 371
- dimerisation, **62**, 393

- coupling with Zn/Ni(II)-phosphine complexes, **62**, 406
- 2-Bromopyridin-3-ols, coupling with Ni catalysts, **62**, 407
- 7-Bromopyrido[1,2-*b*]cinnolinium-11-olate, X-ray crystallography, **69**, 96
- 3-Bromo-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 189
- 3-Bromopyrimidine, coupling with alkynes, **62**, 315
- 5-Bromopyrimidine, boronylation reactions, **62**, 368
- coupling to styrene, ethyl acrylate and acetonitrile, **62**, 308
- coupling to stannanes, **62**, 332
- 5-Bromopyrimidin-2-one, Pd(0) catalysed allylation, **66**, 103
- 3-Bromo-2-pyrone, Diels-Alder reactions, **65**, 340
- 2-Bromoquinoline, coupling with alkynes, **62**, 315
- 3-Bromoquinoline, **65**, 131
- coupling with alkynes, **62**, 318
- coupling to styrene and ethyl acrylate, **62**, 307
- 4-Bromoquinoline, coupling to styrene and ethyl acrylate, **62**, 307
- Bromospirofuraneoxabicyclooctenone, **65**, 340
- 3-Bromo-substituted aliphatic acids, reaction with thiourea to 1,3-thiazin-4-ones, **66**, 151
- 2-Bromotellurenylacetophenone, reaction with dimethylformamide dialkylacetals, **63**, 21
- 9-Bromo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, conformational analysis, **63**, 113
- reaction with thiols, **63**, 224
- reaction with nucleophiles, **63**, 223
- reaction with sodium azide, **63**, 225
- reaction with amines, **63**, 225
- reaction with *N* methylaniline, **63**, 226
- reaction with potassium thiocyanate, **63**, 228
- Bromotetrathiafulvalene, **62**, 285
- 5-Bromouridine, boronylation reactions, **62**, 345
- 3-Bromo-2-vinylthiophene, reaction with 4-phenyl-1,2,4-triazolin-3,5-dione, **63**, 388
- (*E*)-5-(2-Bromovinyl)uracil, **69**, 165
- Buckmasterfullerene C<sub>60</sub>, reaction with carbenes, **65**, 206
- $\beta$ -Bulnesene, **65**, 356
- Buntanbisamine, **70**, 127
- Butane-2,3-dione
- monothiobenzoylhydrazones, ring chain tautomerism, **66**, 45
- Butane-2,3-dione phenylacetylhydrazones, ring chain tautomerism, **66**, 45
- 2-Butanoyl-3,6-dioxo- $\delta$ -lactone, preparation, **69**, 53
- 3-Buten-1-ol, iodocyclization, **69**, 13
- N*-(But-3-enoyl)thiourea, bromination to 2-amino-6-methylene-1,3-thiazin-4-ones, **66**, 152
- 2-*t*-Butoxycarbonyl-aminophenyltiphenyltin, in synthesis of amphimedine, **70**, 117
- 5-*t*-Butoxycarbonyl-3-hydroxy-4,5,6,7-tetrahydroisoxazolo[4,3-*c*]pyridine, **66**, 84
- 1-(*tert*-Butoxycarbonyl)-2-methoxy-3-(4-phenyl-3-butynyl)piperidines, cyclisation, **70**, 8
- 6-*t*-Butoxycarbonyl-3-oxo-2,3,4,5,6,7-hexahydropyrazolo[3,4-*c*]pyridine, **66**, 87
- 2-Butoxy-2,3-dihydropyran-4-one, from diazomalonaldehyde, **65**, 157
- 4-*tert*-Butyl-2-aminomethyl-1-cyclohexanols, cyclisation with ethyl benzimidate, **69**, 374
- 2-Butylbenzofuran, **65**, 141
- 2-*t*-Butylbenzofuran, synthesis, **69**, 16
- (2*R*,3*R*)-*t*-Butyl-3-(*N*-benzoylamino)-2-methylbutanoate, in azetidinone synthesis, **64**, 5
- N*-*t*-Butyl-2-benzoylbenzamides, ring chain tautomerism, **64**, 264
- 1-Butyl-1-dibutylboryl-2-diethylphosphine-2-phenylethene, **61**, 122
- N*-*t*-Butyl-2,2-dichloro-3-arylaziridine, **65**, 99
- 4-*t*-Butyldimethylsilyloxy-1-benzoisopyrylium triflates, reaction with dienes and enolethers, **65**, 351
- 4-*t*-Butyldimethylsilyloxy-1-benzopyrylium salts, reactions with 3-trimethylsilyl-1-butene, **65**, 290
- 6-*t*-Butyldimethylsilyloxy derivatives of tetrahydro-5*H*-chromen, **62**, 49

- N*-*t*-Butyl-4-ethoxypyrrolidin-2-one, **65**, 121
- 2-*t*-Butylfuran, reaction with dichlorocarbene, **62**, 67
- 3-Butyl-2-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 137
- t*-Butyl-4-imidazolecarbamate, HCl hydrolysis to 4(5)-aminoimidazole, **61**, 9
- 6-*t*-Butylimidazo[2,1-*f*]thiazole, thiocyanation **69**, 292
- 2-*tert*-Butyl-8-methylperhydropyrido[1,2-*c*]pyrimidines, <sup>1</sup>H NMR spectra and conformations, **70**, 26
- 6-*t*-Butyl-5-nitrosoimidazo[2,1-*b*]thiazole, **69**, 292
- 1-[*N*{2,2-bis(*tert*)-Butyloxycarbonyl}ethyl]-*N*-methylamino]-5,6,7,8-tetrafluoro-4-oxoquinoline-3-carboxylates, cyclisation, **69**, 117
- 2-*tert*-Butylperhydropyrido[1,2-*c*]pyrimidine, dipole moments, **70**, 22
- <sup>1</sup>H NMR spectra and conformations, **70**, 25
- N*-*t*-Butyl-4-phenylpyrrolidin-2-one, **65**, 120
- cis*-2,4-*a*, 8-*H*-2-Butyl-8-propylperhydropyrido[1,2-*b*][1,2]oxazine, conformation by NMR, **69**, 91
- 2*N*-Butyl-4-*N*-propyl-7-phenyloxepin, **65**, 160
- t*-Butylpyridines from *t*-butyl Grignard and copper(I), **62**, 396
- 2-tri*N*-Butylstannyloxy-5-chloropyrimidine, Pd(0) catalysed allylation, **66**, 104
- 2-*t*-Butyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, photorearrangement, **63**, 234
- 1-*t*-Butyl-4-vinylpyrazole, reaction with diethyl azodicarboxylate, **63**, 389
- reaction with dimethyl acetylene dicarboxylate, **63**, 357
- 1-*t*-Butyl-3-vinylpyrrole, cycloaddition, **63**, 346
- Diels-Alder reactions, **63**, 360
- 3-(3-Butynyl)-4-ethoxy-6,6-dimethyltetrahydro-1,3-thiazin-2-ones, cyclisation in formic acid, **70**, 60
- 3-(3-Butynyl)-4-ethoxy-6-phenyltetrahydro-1,3-thiazin-2-ones, cyclisation in formic acid, **70**, 60
- 5-(3-Butynylthio)-1,2,3-triazines, thermal cyclisation to thieno[2,3-*d*]pyrimidines, **66**, 219
- 3-(3-Butynylthio)[1,2,4]triazin-5-ones, precursor to [1,2,4]triazino[3,2-*b*][1,3]-thiazines, **61**, 273
- Butyrolactones, **64**, 15
- γ-Butyrolactones, **65**, 138
- C-AIR *see* 5-aminoimidazole-4-carboxylic acid ribonucleotide
- Calliactine, **70**, 96, 114
- 1-(1α-Campholenyl)-2,2-dichloro-3-arylaziridines, **65**, 99
- Canthin-4,5-diones, **61**, 178
- 5-Carbamoyl-4-hydrazinocarbonyl-3-β-D-ribofuranosylpyrazole, **70**, 234
- 2-Carbamoyl-6-(β-D-ribofuranosyl)pyridine, biological activity, **68**, 343
- 3-Carbamoyl-5-(β-D-ribofuranosyl)pyridine, biological activity, **68**, 345
- 4-Carbamoyl-6-(β-D-ribofuranosyl)pyridine, biological activity, **68**, 343
- 5'-*O*-Carbamoyltiazofurin, **68**, 309
- Carbanucleotides, via Tsuji-Trost reaction, **66**, 74
- Carbapenamams, **65**, 57
- Carbapenams, synthesis and biological activity **68**, 251
- Carbenes, production of nitrile ylides from nitriles, **65**, 114
- 2-(β-Carboethoxyvinyl)furan, Diels-Alder reaction with methyl acrylate, **63**, 371
- 3-Carboalkoxy-2-pyrones, reaction with vinyl ethers under pressure, **65**, 333
- Carbo-*t*-butoxyhydrazones, in synthesis of 5-substituted-1,3,4-oxadiazolin-2-ones, **69**, 42
- Carbocyclic pyrazofurins, preparation and biological activity, **68**, 270
- 2-Carboethoxy 1,3-thiazin-4-one, **66**, 140
- 1-Carboethoxy-2-(1'-trimethylsilyloxyethen-1-yl)pyrrole-cycloaddition, **63**, 347
- reaction with *N*-phenylmaleimide, **63**, 360
- N*-Carbomethoxy-tyrosine, spirolactone formation, **64**, 16
- 2',3'-*O*-Carbonyloxazinomycin, antileukemic activity, **68**, 386
- (-)-Carbovir, **66**, 120
- 4-Carboxamido-2-α-L-arabinopyranosylthiazole, **68**, 309

- 5-Carboxamido-4-hydroxy-3( $\beta$ -D-ribofuranosyl)pyrazole, **68**, 260  
isolation from culture filtrates of *Streptomyces candidus*, **68**, 259  
X-ray analysis, **68**, 260  
antifungal activity, **68**, 261  
synthesis, **68**, 262
- 5-Carboxamido-4-hydroxy-3( $\alpha$ -D-ribofuranosyl)pyrazole, **68**, 226  
isolation from culture filtrates of *Streptomyces candidus*, **68**, 260
- 4-Carboxamido- $N^3$ -oxide-thiazol-2-yl C-nucleosides, **68**, 310
- 6-Carboxamido-2-oxocaproic acid, ring chain tautomerism, **64**, 291
- 5-Carboxamido-2-oxovaleric acid, ring chain tautomerism, **64**, 290
- 2-Carboxamidoquinolin-4-yl C-nucleoside, **70**, 205
- 4-Carboxamido-3-( $\beta$ -D-ribofuranosyl)isothiazole, synthesis, **68**, 306
- 5-Carboxamido-3-( $\beta$ -D-ribofuranosyl)isothiazole, synthesis, **68**, 306
- 4-Carboxamido-2- $\beta$ -ribofuranosyloxazole, synthesis, **68**, 298  
biological activity, **68**, 299
- 4-Carboxamido-2- $\beta$ -D-ribofuranosylthiazole, **68**, 298  
synthesis and biological activity, **68**, 307  
X-ray structure and computational analysis, **68**, 311  
antiviral activity, **68**, 311
- 3-Carboxamido-1-( $\beta$ -D-ribofuranosyl)-1,2,4-triazole, **68**, 324
- 3-Carboxamido-5-( $\beta$ -D-ribofuranosyl)-1,2,4-triazole, **68**, 324
- 4-Carboxamidothiazol-2-yl-C-nucleosides, **68**, 310  
antitumour activity, **68**, 311
- 5-Carboxamidothiazol-2-yl-C-nucleosides, **68**, 310
- 4-(4-Carboxamidothiazol-2-yl)thiazol-2-yl-C-nucleosides, **68**, 310
- 4-Carboxamido-2- $\beta$ -D-xylofuranosylthiazole, **68**, 309
- 4-Carboxamido-2- $\beta$ -D-xylopyranosylthiazole, **68**, 309
- o*-Carboxyalkyltetrahydrofurfuralenones, amide formation, **62**, 259
- 4-Carboxyglycinamidothiazol-2-yl-C-nucleosides, **68**, 310
- 2-Carboxy-3-methoxycarbonyl-5-(D-arabino-tetritol-1-yl)pyrrole, **70**, 277
- 2-[(Carboxy)methoxy]-3-formylpyrido[1,2-*a*]pyrimidin-4-one cyclisation, **63**, 200
- 1-Carboxymethyl-1-formylcyclobutane, ring chain tautomerism, **64**, 258
- 4-Carboxy-1,3-oxazoles, **65**, 179
- o*-Carboxyphenyldialkylamines, oxidative cyclisation, **65**, 32
- 3-Carboxy-2-(2'-phenylethyl)pyridine-*N*-oxide, cyclisation, **64**, 127
- (*Z*)-3-(*o*-Carboxystyryl)thiophene, cyclisation, **64**, 97
- 3-Carboxypropenones, condensation with hydrazides, **64**, 105
- Carpetimycins, **65**, 108
- Castanospermine, synthesis via reduction of cyclic sulfates with sodium borohydride, **68**, 165
- Cephalosporin V, oxidation of esters, **69**, 76
- Chelerythrine, synthesis, **67**, 358; **67**, 364; **67**, 345  
biological activity, **67**, 347
- Chelilutine, **67**, 353  
synthesis, **67**, 365
- Chelirubine, **67**, 353
- Chinoïn-150 *see* 3-ethyl-2,6-dimethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one
- Chiral Mn(III)salen, *see* [bis(salicylidene)ethylenediamine]manganese(III) complex
- N*-Chloroacetyl-D,L-*m*-tyrosine, cyclisation, **64**, 53
- 9-Chloroacridine, reductive coupling to 9,9'-biacridine, **67**, 58
- 4-Chloro-5-acylpyrimidines, reaction with thioglycolic acid, **65**, 238
- N*-(*o*-Chloroalkyl)indoles, **65**, 32
- 2-(Chloroalkylsulfinyl)tropone, thermolysis, **64**, 100
- 2-Chloroalkylthiotropone, rearrangement to thienotropone, **64**, 99
- N*-(2-Chloroallyl)-enaminones, electrophilic cyclisation, **67**, 246
- 2-Chloro-4-arylthieno[2,3-*d*]pyrimidines, chloride displacement by nucleophiles, **66**, 221
- 7-Chloroazepin-2-ones, **64**, 225

- 3-Chloro-1,2-benzisothiazole, zinc reduction, **67**, 28
- 2-Chlorobenzoic acid, reaction with phenylenediamine, **70**, 93  
in preparation of hallacidone, **70**, 149
- 2-Chlorobenzonitrile, reaction with 2-lithiomethylquinoline, **68**, 213
- 6-Chlorobenzo[c]phenanthridines, synthesis, **67**, 359  
synthesis of analogs, **67**, 360
- 7-Chlorobenzo[b][1,8]phenanthroline, **70**, 109
- 7-Chlorobenzo[b][1,8]phenanthroline-7(12*H*)-one, DNA binding, **70**, 110
- 2-Chlorobenzo-1,3-thiazin-4-one, **66**, 144  
reaction with active methylenes, **66**, 180
- 2-Chlorobenzo[b]thiepin, loss of sulfur, **65**, 48
- 2-Chloro-2,4'-bithiazole, reduction, **67**, 34  
by-product of diazotisation of 2-aminothiazole, **67**, 34
- 1-Chlorobut-1-en-3-one, enaminone formation, **67**, 232
- (E)-5-(4-Chlorobut-2-en-1-yloxy)tropolone, rearrangement to furotropolones, **64**, 99
- (E)-2-(4-Chlorobut-2-en-1-yloxy)tropolone, rearrangement to furotropolones, **64**, 99
- 4-Chlorocinnoline, Busch coupling, **67**, 65
- 3-Chlorocoumarin, reaction with Grignard reagents, **65**, 298  
reaction with lithium dimethylcuprate, **65**, 298
- Chlorocoumarin, reaction with methyl magnesium iodide, **65**, 296
- 4-Chloro-3-coumarincarbaldehydes, **65**, 309
- 3-Chloro-4-cyanopyridazine, coupling with alkynes, **62**, 320
- 2'-Chloro-2'-deoxypseudouridine, **68**, 369
- 5'-Chloro-5'-deoxyformycin B, **70**, 244
- 1-Chloro-1*H*-2,3-dialkylphirenes, **65**, 170
- 4-Chloro-2-dichloromethylthieno[2,3-*d*]pyrimidines, **66**, 205
- 5'-Chloro-2',5'-dideoxyformycin, **70**, 244
- 5'-Chloro-3',5'-dideoxyformycin, **70**, 244
- Chlorodifluoropyridines, synthesis, **67**, 271
- 3-Chloro-3,4-dihydro-2,4-diphenyl-2*H*-1-benzopyran-2-ol, **65**, 298
- 2-Chloro-4,5-dihydro-1,3-oxazin-6-yl acyclic nucleosides, **68**, 387
- 4-Chloro-6,7-dihydro-5*H*-pyrimido[5,4-*d*][1]benzazepine, **64**, 61
- 2-Chloro-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinoline-4-ones, **70**, 62  
substitution of chloro atom, **70**, 44
- 2-Chloro-2,3-dihydro-5,6-thiazin-4-ones, **66**, 149
- 2-Chloro-3,4-dihydrothieno[2,3-*d*]pyrimidines, **65**, 260, **66**, 220  
alkylation, **66**, 222
- 2-Chloro-3,4-dihydrothieno[3,2-*d*]pyrimidines, **66**, 248
- 2-Chloro-3,4-dihydrothieno[3,4-*d*]pyrimidines, **65**, 265, **66**, 267  
reactions with nucleophiles, **65**, 265  
*N*-alkylation, **66**, 268
- 4-Chloro-2,6-dimethyl-5-iodopyrimidine, coupling with stannanes, **62**, 335
- 4-Chloro-2,6-dimethyl-5-phenylethynylpyrimidine, reaction with sodium hydrosulfide, **66**, 213
- 2-Chloro-3,6-dimethylpyrazin-4-oxide, coupling with alkenes, **62**, 313
- 6-Chloro-1,3-dimethylpyrrolo[c]tropylium ion, reaction with *N*-silylamines and *S*-silylmercaptans, **66**, 384
- 3-Chloro-2,4-dimethylquinoline, **65**, 132
- 6-Chloro-3-ethoxycarbonylcoumarin, reaction with active methylenes, **65**, 300
- 4-Chloro-6-ethoxy-5-nitropyrimidines, preparation of acyclonucleosides, **69**, 179
- 2-Chloro-2-ethoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 153
- 2-Chloroethylchloromethylether, reaction with 6-benzoyladenine, **69**, 144
- 2-Chloroethyl chlorosulfite, synthesis from ethylene sulfite, **68**, 145
- 1-(2-Chloroethyl)-3-(2,4-dimethoxyphenylmethyl)thieno[3,4-*d*]pyrimidin-2,4-dione, **66**, 268
- 3-(2-Chloroethyl)-2-methyl-9-benzoyloxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-hydrogenation, **63**, 208
- 3-(2-Chloroethyl)-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 136, **63**, 184
- 3-(2-Chloroethyl)thieno[3,2-*d*]pyrimidin-2,4-dione, **66**, 253
- gem*-Chlorofluoroaziridines, **65**, 99
- 3-Chloro-3-formyl-6-methoxybenzofuran, reaction with 2-aminothiophenol, **63**, 90
- 2-Chloro-3-formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 190

- 2-Chloro-3-formylquinoline, **63**, 92  
4-Chloro-3-formylquinoline, **63**, 92  
*threo*- and *erythro*-Chlorohydrin, synthesis via ring opening of cyclic sulfites, **68**, 145  
6-Chloro-9(*cis*-4'-hydroxybut-2-enyl)purine, preparation, **69**, 158  
2-Chloro-3-hydroxy-4-methoxypyridine, homocoupling with Zn-Ni, **62**, 408  
3-Chloroimidazoanthroquinone, **65**, 16  
2-Chloroimidazo[1,5-*b*]pyridazin-7-yl C-nucleosides, **70**, 214  
7-Chloroimidazo[4,5-*b*]pyridine, by cyclisation of adduct of diethyl ethoxymethylenemalonate and 5-aminoimidazole with phosphoryl chloride, **61**, 40  
6-Chloroimidazo[2,1-*b*]thiazole-5-carboxylic acid, esterification, **69**, 298  
3-Chloroindolizines, **65**, 113  
5-Chloro-4-iodo-2-methylpyrimidine, benzylation by stannanes, **62**, 332  
5-Chloro-4-iodopyrimidine, coupling with alkenes, **62**, 311  
5-Chloro-4-iodo-2-*O*-silyloxy pyrimidine, coupling with alkynes, **62**, 320  
6-Chloroisocytosine, in synthesis of acyclonucleosides, **69**, 159  
1-Chloroisquinoline, Ni catalysed coupling with Grignard reagents, **62**, 390  
5-Chloromercury derivatives of 2-deoxycytidines, **62**, 401  
2-Chloromercuryfuran, as precursor to 2,2'-bifuran, **67**, 8  
2-Chloro-5-methoxytropone, condensation with 2-aminothiophenol, **64**, 110  
2-Chloro-3-methyl-9,10-dimethoxy-4-oxo-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolinium chloride, reaction with mesitylene, **70**, 44  
4-Chloromethyl-1,3,2-dioxathiolane 2-oxide, synthesis, **68**, 106  
synthesis from glycerol, **68**, 107  
reaction with sodium methoxide and phenoxide, **68**, 141  
2-Chloromethyldioxolane, use in alkylation of purines, **68**, 54  
4-Chloromethyl-1-phenyl-2-oxo-pyrido[1,2-*a*]pyrimidin-5-ium-3-olate-reduction, **63**, 171  
reaction with 1-methylpiperazine, **63**, 172  
4-Chloro-3-methyl-6-phenyl-2*H*-pyran, photochemical oxidative ring contraction, **62**, 73  
4-Chloro-2-methyl-6-phenylpyrimidine, homocoupling with Zn-Ni, **62**, 409  
3-Chloro-6-methylpyridazine, Ni catalysed coupling with Grignard reagents, **62**, 392  
2-Chloromethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction with amines, **63**, 187  
reaction with *O*,*O*-dialkylphosphorothioates, **63**, 186  
4-Chloro-2-methylsulfonylpyrimidine, coupling with stannanes, **62**, 334  
2-Chloromethyl-5,6,7,8-tetrahydrobenzo[*b*]thieno[2,3-*d*]pyrimidin-4(3*H*)-ones, blood lipid reducing activity, **66**, 233  
4-Chloro-2-methylthieno[2,3-*d*]pyrimidines, reaction with iodide, **66**, 229  
4-Chloro-6-methylthieno[2,3-*d*]pyrimidines, loss of chlorine, **66**, 229  
2-Chloromethylthieno[2,3-*d*]pyrimidin-4(3*H*)-ones, acetylation, hydrolysis, conversion to Wittig reagent, **66**, 226  
4-Chloro-2-methylthiopyrrolo[2,3-*d*]pyrimidine, conversion to tubercidin analogue, **68**, 10  
5-(Chloromethyl)uracil, reaction with ethylene glycol, **69**, 147  
7-Chloro-1,8-naphthyridine, coupling with stannanes, **62**, 342  
2-Chloronicotinamide, reaction with thioesters to give 1,3-pyridothiazines, **66**, 162  
2-Chloro-6-nitrobenzaldehyde thiosemicarbazone, ring chain tautomerism, **66**, 51  
(2-Chloro-4-nitrobenzoyl)isothiocyanate, reaction with amines to give 2-amino-1,3-benzothiazin-4-ones, **66**, 145  
4-Chloro-3-nitrocoumarin, reaction with nucleophiles on both chlorine and nitro groups, **65**, 312  
6-*p*-Chloro-5-nitroimidazo[2,1-*b*]thiazole, nucleophilic substitution, **69**, 293  
4-Chloro-3-nitropyridines, precursor to 3-substituted 1,2-dihydropyrido[3,4-*c*][1,2,4]triazines, **61**, 217  
reactions with guanidine to give pyrido[4,3-*e*][1,2,4]triazines, **61**, 219

- 4-Chloro-3-nitroquinoline, precursor to [1,2,4]triazino[5,6-*c*]quinolines, **61**, 226  
precursor to [1,2,4]triazino[6,5-*c*]quinolines, **61**, 227
- 2-Chlorooxane, conformations, **69**, 220  
calculated conformational equilibria, **69**, 225
- 2-Chlorooxirane, precursor to bithiazoles, **67**, 34
- 8-Chloro-3-phenylazaazulene, reaction with sodium sulfide, **66**, 374
- (2 $\alpha$ ,4 $\alpha$ ,8 $\alpha$ )*β*-2-(4-Chlorophenyl)-1,4,4a,5,8,8a-hexahydro-2*H*-3,1-benzoxazine, X-ray structure, **69**, 422
- cis*-2-(4-Chlorophenyl)-4a,5,6,7,8,8a-hexahydro-4*H*-1,3-benzoxazine, X-ray structure, **69**, 432
- cis*-2-(4-Chlorophenyl)-4a,5,6,7,8,8a-hexahydro-4*H*-3,1-benzoxazine, X-ray structure, **69**, 433
- (2 $\alpha$ ,4 $\alpha$ ,7 $\alpha$ )*β*-2-(4-Chlorophenyl)hexahydrocyclopent[*e*][1,3]oxazin-4(4*H*)-one, X-ray structure, **69**, 429
- 5-Chloro-6-phenylimidazo[2,1-*b*]thiazole, **69**, 293
- 2-Chloro-4-phenylimino-4*H*-pyrido[1,2-*a*]pyrimidine, hydrolysis, **63**, 174
- 6-*p*-Chlorophenyl-3-methyl-5-nitrosoimidazo[2,1-*b*]thiazole, **69**, 293
- cis*-2-(4-Chlorophenyl)-4,4a,5,6,7,8,8,9a-octahydrocyclohept[*e*][1,3]oxazine, X-ray structure, **69**, 433
- (2 $\alpha$ ,4 $\alpha$ ,9 $\alpha$ )*β*-2-(4-Chlorophenyl)octahydrocyclohept[*e*][1,3]oxazin-4(4*H*)-one, X-ray structure, **69**, 431
- 2-(4-Chlorophenyl)-6-phenylpyrimidine, reaction with methyl chloroacetate, **66**, 217
- 6-Chloro-9-phenylpurine, coupling with alkynes, **62**, 325
- 3-Chloro-2-phenyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 155
- cis*-2-(4-Chlorophenyl)-4a,5,8,8a-tetrahydro-4*H*-3,1-benzoxazine, X-ray structure, **69**, 434
- cis*- and *trans*-2-*p*-Chlorophenyl-4a,5,6,7,8,8a-tetrahydro-4*H*-3,1-benzoxazines, conformations, **69**, 418
- 1-Chlorophthalazines, reaction with aldonic acid hydrazides, **70**, 218
- 3-Chloro-2-piperidone, **64**, 29
- 2-Chloropropargylpyridinium bromide, reaction with methylhydrazine, **61**, 212
- N*-(2-Chloropropionyl)-*N'*-phenylthiourea, reaction with thiocyanate, **66**, 154
- 3-(3-Chloropropyl)thieno[2,3-*d*]pyrimidinediones, **66**, 244
- 6-Chloropteridine, coupling with alkenes, **62**, 313
- 6-Chloropterin coupling, with alkynes, **62**, 324
- 6-Chloropurine, coupling, with alkynes, **62**, 325  
Pd(0) catalysed reaction with (–) monoacetate of *cis*-cyclopenten-2-ene-1,4-diol, **66**, 122  
conversion to methoxy and hydroxy acylonucleosides, **68**, 3  
reaction with 4-methylthiobutan-1-ol, **69**, 156
- 6-Chloropurine nucleosides, Ni catalysed coupling with Grignard reagents, **62**, 393
- 2-Chloro-2*H*-pyran, **62**, 65
- 2-Chloropyrazines, coupling with alkenes, **62**, 311  
coupling with aklenylstannanes, **62**, 330  
arylation, **62**, 364  
reaction with trimethylaluminium, **62**, 371
- 2-Chloropyrazine-1-oxide, phenylation, **62**, 342
- 2-Chloropyrazin-4-oxide, coupling with alkynes, **62**, 322  
phenylation, **62**, 342
- 6-Chloropyrazolo[4,3-*d*]pyrimidin-3-yl derivatives, **70**, 233
- 3-Chloropyridazine, palladium catalyzed coupling to 3,3'-bipyridazine, **67**, 59
- 3-Chloropyridines, **65**, 131
- 2-(and 4-)-Chloropyridine-3-carbonitriles, coupling with alkynes, **62**, 316
- 12-Chloropyrido[3,2-*a*]acridines, **70**, 92
- 2-Chloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 139  
reaction with sodium methoxide, **63**, 184  
reaction with amines, **63**, 185
- 3-Chloro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, ring contraction, **63**, 230
- 7-Chloropyrido[1,2-*a*]pyrimidin-4-one, **63**, 151



- 2-Chloropyrimidines, coupling with alkynes, **62**, 315, **62**, 320  
from pyrazoles and dichlorocarbenes, **65**, 181
- 4-Chloropyrimidine-5-carbaldehydes,  
reaction with alkyl 2-mercaptoacetate, **66**, 212
- 5-Chloropyrimidin-2-one, Pd(0) catalysed  
reaction with *cis*-2-protected  
hydroxymethylcyclopentenyl acetate, **66**, 104  
Pd(0) catalysed reaction with 1-  
tributylstannylbut-2-en-3-*O*-acetate, **66**, 105
- 2-Chloropyrroles, **65**, 111
- 2-Chloropyrrolines, **65**, 111, **65**, 132
- 2-Chloroquinazoline, from indazole and  
dichlorocarbenes, **65**, 187
- 4-Chloroquinazoline, coupling with alkynes, **62**, 324  
reaction with Grignard reagents, **67**, 67
- 2-Chloroquinoline-cross coupling with  
Grignard reagents, **62**, 386  
reaction with lithium to give 2,3'-  
biquinoline, **67**, 53
- 3-Chloroquinolines, **65**, 131
- 3-Chloroquinoxalin-2-carboxaldehyde,  
reaction with 2-aminothiophenol, **63**, 97
- 6-Chloro-9( $\beta$ -ribofuranosyl)purine, coupling  
with alkynes, **62**, 329
- 3-Chloro-4-( $D$ -ribofuranosyl)pyridine,  
preparation, **68**, 346
- 5-Chloro-4-stannylpyrimidines, coupling  
reactions, **62**, 355
- 4-Chloro-2-substituted thieno[2,3-*d*]  
pyrimidines, **66**, 206
- $\omega$ -(3-Chlorosulfonylpropyl)piperidine  
hydrochloride, cyclisation, **69**, 111
- 7-Chloro-8,9,10,11-  
tetrahydrobenzo[*b*][1,10]phenanthroline, **70**, 105
- 9-Chloro-6,7,8,9-tetrahydro-4*H*-pyrido  
[1,2-*a*]pyrimidin-4-ones, conformational  
analysis, **63**, 113
- Chlorotetrathiafulvalenes, **62**, 285
- 2-Chloro-1,3-thiazin-4-ones, **66**, 135  
hydrolysis, **66**, 175  
reaction with ammonia, **66**, 178
- 4-Chlorothieno[2,3-*d*]pyrimidines, reduction  
by zinc, **65**, 252
- 4-Chlorothieno[3,2-*d*]pyrimidines, **66**, 248  
reaction with nucleophiles, **65**, 259
- 6-Chlorothieno[3,2-*d*]pyrimidin-4(3*H*)-one,  
bromination of, **66**, 252
- 6-*t*-Chloro-5-thiocyanatoimidazo[2,1-*b*]  
thiazole, **69**, 292
- 5'-Chloro-2', 3',5'-trideoxyformycin, **70**, 244
- 5-Chloro-2,4,6-trimethylpyrimidine, **65**, 187
- 4-Chloro-  
5(trimethylsilylethynyl)pyrimidines,  
reaction with sodium hydrosulfide, **66**, 213
- $\Delta^{2,2}$ -*trans*-Cholesta-5,7,22-triene-3 $\beta$ -ol,  
preparation from ergosterol acetate, **61**, 169
- Chromones *see* 4-oxo-4*H*-1-benzopyrans
- Chromonol, preparation, **69**, 72
- Chrysin, synthesis, **69**, 52
- 3-Cinnamoyltropolones, oxidation, **64**, 101
- N-Cinnamyl-2-pyridone, **66**, 100
- Cinnoline-4-carboxylic acid, preparation of  
4,4'-bicinnoline, **67**, 65
- Citabisamines A-C, **70**, 147
- Citracidone-I,II and III **70**, 127
- Citropone-X-ray diffraction, **66**, 287  
<sup>13</sup>C NMR, **66**, 293
- Cobalt metal complexes of pyrans, **62**, 109
- Coformycin, *see* {6,7,8-trihydro-8-hydroxy-3-  
 $\beta$ -D-ribofuranosyl}imidazo[4,5-*d*]1,3-  
diazepine,
- bis*(*sym*-Collidine)iodine (I) perchlorate, in  
oxirane formation, **69**, 10
- Coptisine, **67**, 383
- Cordycepin-C, *see* 3'-deoxy-2- $\beta$ -D-  
ribofuranosylimidazo[4,5-*d*]pyrimidine,
- Corrins, **65**, 76; **67**, 6
- Corynantheoid alkaloids, synthesis, **67**, 287
- Coumaran-3-one, synthesis by oxidation of  
silyl enol ethers with iodosobenzene, **69**, 21
- Coumaran-3-one dimethylacetals, **69**, 19
- Coumarin, photosensitised reaction with  
cyclopentene and tetrachloroethylene, **65**, 337  
reaction with trimethylenemethane Pd  
complex, **65**, 330
- Crown ethers, by radical reactions with  
oxetane, **65**, 198
- ( $\pm$ )-Cryptofauronol, **65**, 356
- Cumaranones, condensative dimerisation to  
substituted 2,3'-benzofurans, **67**, 18

- Cuproine *see* 2,2'-biquinoline
- 3-Cupro-2-pyrone, coupling with alkenyl bromides, **65**, 305
- CV-1, *see* 5-hydroxy-4-(D-*arabino*-tetritol-1-yl)imidazolidin-2-one
- 1-Cyano-3-acetoxy-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines, catalytic reduction, **70**, 43
- 2-(1-Cyanoallyl)thiophene, Diels-Alder reactions, **63**, 366  
reaction with *N*-phenylmaleimide, **63**, 366
- 2-Cyanoaminothienopyrimidin-4(3*H*)-ones, **65**, 242
- 11*H*-5-Cyanobenzo[*a*]carbazole, **63**, 358
- 3-Cyano-1-(*o*-chlorobutyl)indoles, **65**, 30
- 2-Cyanochromone, irradiation, **65**, 328  
photochemical reaction with olefins, **65**, 331
- N*-(1-Cyanocyclohexyl)piperidine, oxidation, **69**, 74
- N*-(1-Cyanocyclohexyl)piperidone, preparation, **69**, 74
- 3-Cyano-3-deazaguanine analogue of acyclovir, **69**, 141
- 1-Cyano-6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinolines, catalytic reduction, **70**, 42
- 1-Cyano-9,10-dimethoxy-2,4,6,7-tetrahydro[1,3]oxazino[4,3-*a*]isoquinoline, catalytic hydrogenation, **70**, 34  
reactions with amines and formaldehyde, **70**, 39
- 2-Cyano-3,6-dimethyl-4*H*-pyran, **62**, 50
- 1-Cyanoenamines, reaction with dimethyl acetylenedicarboxylate, **65**, 5
- 1-[Cyano(ethoxycarbonyl)methylene]-1,2,3,4-tetrahydroisoquinoline, **70**, 66
- 3-Cyano-5-ethoxycarbonyl-4*H*-pyran, reaction with guanidine, **62**, 98
- 3-Cyano-2-(ethoxymethylene)aminothiophene, reaction with amines, **65**, 241
- 4-Cyano-3-ethoxymethylenethiophenes, reaction with ammonium acetate, **65**, 261
- N*-Cyanoethyl- $\alpha$ -aminoacids, cyclisation to pyrroles, **64**, 7
- 7-Cyano-3-ethyl-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 133
- 3-Cyano-9-hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 149
- 3-Cyano-2-hydroxy-2-( $\beta$ -D-ribofuranosyl)propionic acid, as precursor of showdomycin, **68**, 240
- Cyanoisochromenes, **65**, 293  
alkylation, **65**, 293
- 3-Cyano-2-mercapto-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 140
- 4-Cyano-5-methoxy-2-phenyl-1,3-oxazoles, **65**, 180
- 2-Cyanomethyl-1,3-benzothiazin-4-one, protonation, **66**, 169
- 6-Cyanomethyl-2,4-dimethoxy-5-nitropyrimidine, condensation with D-ribofuranosyl chlorides, **70**, 223
- 1-Cyanomethylene-6,7-dimethoxy-1,2,3,4-tetrahydroquinoline, reaction with formaldehyde, **70**, 58
- 4-Cyanomethyl-5-fluoro-2,3-dihydro-1-methyl-7-oxo-1*H*, 7*H*-pyrido[3,2,1-*ij*]cinnoline-8-carboxylate, **69**, 107
- 1-(Cyanomethyl)perhydropyrido[1,2-*b*]pyridazine, reduction of cyano group, **69**, 104
- 2-Cyanomethylperhydropyrimidine, reduction, **70**, 51
- 3-Cyano-4-methyl-2-phenylfuran, preparation from enolates and alkynyliodonium salts, **69**, 15
- 1-Cyano-5-methyl-4-phenyl-1,2,3-triazole, thermolysis and reaction with acetonitrile, **65**, 177
- 5-Cyano-6-methylpyrimidine-2,4(1*H*, 3*H*)diones, cyclisation with sulfur, **65**, 264, **66**, 266
- 3-Cyano-4-methyl-2-quinolinone, reaction with sulfur in presence of base, **68**, 186
- 2-Cyano-2(3-methylthieno[2,3-*d*]pyrimidin-2-ylidene)acetonitriles, **66**, 200
- 4-Cyano-3-methylthio-1*H*-pyrido[1,2-*c*]pyrimidin-1-one, **70**, 45
- 3(5)-Cyano-4-nitro-5(3)- $\beta$ -D-ribofuranosylpyrazole, **70**, 234
- 3-Cyano-2-oxofuro[*b*]tropone, **66**, 357
- 3-Cyano-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-2-carboxylate, **63**, 156
- trans*-2-(4'-Cyanophenyl)-5-ethoxy-1,3-dioxane, conformations, **69**, 236
- 3-Cyano-2-picoline, reaction with dimethylformamide dimethylacetal, **68**, 186
- 3-Cyano-4-picoline, reaction with dimethylformamide dimethylacetal, **68**, 186

- 2-(1-Cyanopropen-1-yl)thiophene, cycloaddition, **63**, 354
- Cyanopyridines-cobalt catalysed trimerisation with acetylene, **67**, 51
- 3-Cyano-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction with sodium azide, **63**, 196
- 1-Cyano-2-substituted-9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolines, formation, **70**, 39
- 5-Cyano-5-*O*-sulfonyluronylfuranose derivatives, reduction **68**, 231
- 8-Cyano-1,2,3,4-tetrahydro-6*H*, 7*H*-1,6-naphthyridin-7-one, preparation, **70**, 52
- 11*b*-Cyano-1,2,3,11*b*-tetrahydro-4*H*-pyrido[2,1-*a*]phthalazin-4-one, **69**, 115
- 4-Cyano-5,6,7,8-tetrahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-one, hydrolysis, **70**, 42, **66**
- 1-Cyano-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolines, catalytic reduction, **70**, 42
- 7-Cyanothieno[3,2-*d*]oxazin-4-ones, reaction with primary amines, **65**, 261
- 2-Cyano-2(thieno[2,3-*d*]pyrimidin-2-ylidene)acetates, **66**, 201, **66**, 203
- 2-Cyano-2(thieno[2,3-*d*]pyrimidin-2-ylidene)acetonitriles, **66**, 201, **66**, 203
- Cyanothioacetamide, reaction with cyclic ketones and sulfur, **66**, 203
- 2-Cyanovinylphenylpyrrolidines, acylation and cyclisation, **65**, 30
- Cyclic O<sub>6</sub>, conformations, **69**, 257
- Cycloalkane-fused tetrahydro-1,3-oxazin-4-ones, biological activities, **69**, 463
- Cyclobutatropylium ion, ir spectrum, **66**, 320
- Cyclodercitin, **70**, 116
- Cyclodimerisation of cycloalkanones to 2*H*-pyrans, **62**, 42
- Cycloheptabenzazines, protonation and alkylation, **64**, 131
- Cycloheptabis[1,2,5]thiadiazol-7-one, formation of tetracycles, **66**, 333
- Cyclohepta[*c*]furan-6-ones, **66**, 299
- IR spectra, **66**, 302
- mass spectra, **66**, 306
- aromaticity, **66**, 307
- Cycloheptanol from hydrogenation of dithienotropones, **66**, 368
- Cyclohepta[*b*]pyran-4,9-diones, **64**, 101
- Cycloheptapyrazin-5-ones, ir spectra, **66**, 304
- Cyclohepta[*b*]pyrrol-4-ones, **64**, 124
- Cyclohepta[*b*]pyrrol-8-ones, **64**, 123
- Cycloheptapyrrolotropones, **66**, 392
- Cyclohepta[*c*]thien-6-one, reaction with organometallic agents, **64**, 133
- Cycloheptatrienone-1-carboxylic acid, **65**, 365
- Cycloheptazol-8-ones, UV spectra, **66**, 302
- Cyclohexane-1,2-dione dioxime, reaction with 2-aminobenzoylformic acid, **70**, 107
- 1,3-Cyclohexanedione, reaction with hydrazides, **67**, 218
- 1,3-Cyclohexadione-derived enamines, cycloadditions with nitrile oxides, **67**, 252
- Cyclohexane-fused oxazines, ring chain tautomerism, **66**, 9
- Cyclohexanone, conformations, **69**, 402
- Cyclohexene, conformations, **69**, 401
- 2-Cyclohexenylacetate, as allylating agent in Tsuji-Trost reaction, **66**, 80
- 3-(1-Cyclohexenyl)indole, Diels-Alder reactions, **63**, 385
- C*-Cyclohexyl-*N*-(3-hydroxypropyl)nitron, ring chain tautomerism, **66**, 18
- 2,3-*O*-Cyclohexylidene-*D*-erythrulactone, reaction with 3-deaza-adenine, **69**, 203
- 1-Cyclohexyl-2-methylpyrrol[*b*]trop-8-ones, rotamers shown by nmr, **66**, 292
- Cycloocta[*def*]carbazoles, **65**, 119
- 1,3-Cyclooctadiene, reaction with acyliminium derivatives, **69**, 362
- cis*-Cyclopenta[*d*][1,3]dioxanes, conformations, **69**, 244
- Cyclopenta[1,2-*a*]furanones, **65**, 362
- Cyclopentane-*cis*-1,2-dicarboxylic anhydride, conversion to cyclic urethanes, **69**, 363
- Cyclopenta[*c*]pyridin-3-yl *C*-nucleosides, preparation, **70**, 197
- Cyclopenta[*c*]pyrido[2,1-*f*][1,2,4]triazines, **61**, 223
- 5,6-Cyclopenteno-5-deazapterin, **61**, 247
- 2-Cyclopentenones, synthesis via iodonium salts, **69**, 30
- trans*-fused Cyclopent[*d*][1,3]oxazines, synthesis, **69**, 377
- Cyclopent[*e*][1,3]oxazines, **69**, 367
- Cyclopent[*e*][1,3]oxazin-2-ones, **69**, 363
- Cyclopropabenzopyran, **65**, 321
- Cyclopropa[*c*]isoquinolines, **65**, 130
- Cyclopropanes, **65**, 76
- Cyclopropa[*b*]/[*c*]pyridine, **65**, 129
- Cyclopropyl lactones, **65**, 146

- N*-Cyclopropyl-2-prop-1-en-3-yl)pyrrolidin-3-one, **65**, 127
- N*-9-(and *N*-7-Cyclopropyl)purines, as acylonucleosides, **68**, 36
- D,L-Cycloserine, **64**, 19
- Cyclothiazomycin, **67**, 35
- 4-Cysteine alkyl esters, nitrosation to (s)-thiirane carboxylates, **64**, 4
- Cystodamine, **70**, 100
- Cytallene, preparation, **69**, 197
- Cytodytins A-J, **70**, 112
- Cytosine, Pd(0) catalysed allylation, **66**, 111
- L-Daunosamine, **67**, 251
- 3-Deaza-adenine, reaction with cyclohexylidene-D-erythronolactone, **69**, 203
- 7-Deaza analog of EHNA, **68**, 64
- 3-Deaza(±)EHNA, antineoplastic activity, **68**, 69
- 7-Deazaadenosine acylonucleosides, **68**, 10
- 7-Deazaguanosine acylonucleosides, **68**, 10
- 9-Deazanosine, *see* 7β-D-ribofuranosyl-3*H*, 5*H*-pyrrolo[3,2-*d*]pyrimidin-4-one
- Debromopetrosamine, **70**, 108
- cis*-Decahydro-2,3-dimethylquinazoline, conformations, **69**, 407
- dixeo*-Decahydro-5,8-methano-3,1-benzoxazines, conformations, **69**, 407
- diendo*-1,4,4a,5,8,8a-Decahydro-5,8-methano-2*H*-3,1-quinazolin-4-ones, EI fragmentation, **69**, 445
- cis*-Decahydro-3-methylquinazoline, conformations, **69**, 407
- Decahydrophenanthridines, via Claisen rearrangements of enamines, **67**, 292
- Decahydropyrido[3,4-*b*]acridine, **70**, 99
- trans*-Decalins, conformations, **69**, 403
- Dehydro-L-ascorbic acid, reaction with guanidine, **68**, 288, **69**, 202  
reaction with 2,3-diamino-5-bromopyridine, **70**, 284
- Dehydro-L-ascorbic acid 2-arylhydrazone-3-oximes, precursor of 4-(alditol-1-yl)-2-aryl-5-carboxamido-1,2,3-triazoles, **68**, 322
- Dehydrokuanomiamine, **70**, 116
- 6-Demethoxyacronycine, **70**, 133
- Dercitamine, **70**, 116
- Dercitin, **70**, 115
- 6-Deoxyacyclovir, oxidation, **69**, 135
- 4-(2-Deoxyalditol-1-yl)imidazoles, preparation, **68**, 288
- 3-Deoxyalduloses, reaction with aminoguanidine, **68**, 393
- 3'-Deoxy-2,5-anhydroallonic acid, in synthesis of cordycepin C, **70**, 251
- 5-Deoxy-L-arabinose phenylhydrazones, use in synthesis of acylonucleosides, **69**, 170
- aldehyde*-5-Deoxy-L-arabinose semicarbazone, in synthesis of primapterin, **70**, 272
- 2'-Deoxybiopterin, **70**, 268
- Deoxychlorobavarins, synthesis, **67**, 414
- 2'-Deoxycoformycin, **70**, 233
- 2'-Deoxy-2'-fluoropseudouridine, antiviral activity, **68**, 373
- 2'-Deoxyformycin, **70**, 242, 244
- 2'-Deoxyformycin B, **70**, 242, 244
- 3'-Deoxyformycin, **70**, 242
- 3'-Deoxyformycin B, **70**, 242
- 3-Deoxyglucosulose, reaction with aminoguanidine, **68**, 78
- 5'-Deoxy-5'-halogenoformycins, **70**, 244
- 6'-Deoxy-6'-haloshowdomycins, preparation, **68**, 247
- 3'-Deoxy-2'-,3'-*seco*-inosine, in synthesis of *seco*-puromycin analogues, **67**, 406
- 5'-Deoxy-5'-iodotiazofurin, **68**, 309
- 1-Deoxy-1-isothiocyanate-D-fructose, reaction with carbon disulfide, **69**, 197
- 2'-Deoxy-3'-ketopseudouridine, **68**, 366
- 5'-Deoxy-5'-mercaptotiazofurin, **68**, 309
- 1-Deoxy-1-methylaminoalditols, cyclisation with benzaldehyde, **68**, 305
- 5'-Deoxy-5'-methylmercaptoformycins, **70**, 245
- 6,5'-*cyclo*-5'-Deoxy-5-methyl-2'-,3'-*seco*-uridine, synthesis, **67**, 410
- 5-(2-Deoxy-D-*allo*-pentitol-1-yl)uracils, **68**, 368
- 5-(2-Deoxy-D-*altro*-pentitol-1-yl)uracils, **68**, 368
- 5'-Deoxy-5'-phenylmercaptoformycin B, **70**, 245
- 2'-Deoxypseudoisocytidine, **68**, 371
- 3'-Deoxypseudoisocytidine, **68**, 371

- 2'-Deoxypseudouridine, **68**, 357, 367, 370  
preparation, **68**, 358  
2'-Deoxypseudouridine-5'-phosphate, **68**,  
371  
4-Deoxypyrazofurin, preparation, **68**, 267  
2'-Deoxypyrimidin-5-yl C-nucleosides, **68**,  
366  
2-( $\alpha$ - and  $\beta$ -2-Deoxy-D-ribofuranosyl)  
benzothiazoles, **70**, 193  
3'-Deoxy-2- $\beta$ -D-ribofuranosylimidazo  
[4,5-*d*]pyrimidine, **70**, 249  
2'-Deoxy- $\beta$ -D-ribofuranosylpyrazolo  
[1,5-*a*]1,3,5-triazine, **70**, 303  
3-(2-Deoxy- $\beta$ -D-ribofuranosyl)quinoline,  
preparation, **70**, 205  
5-(2-Deoxy- $\beta$ -D-ribofuranosyl)thiazole, **68**,  
312  
2-Deoxy-D-ribose, reaction with *N*-  
triphenylmethylmaleimide to give 2'-  
deoxyshowdomycin, **68**, 240  
condensation with *N*-alkyladenine, **68**, 61  
2'-Deoxyshowdomycin, **68**, 240  
synthesis, **68**, 237  
3',4'-2'-Deoxythymidine, synthesis, **67**, 413  
2'-Deoxytiazofurin, **68**, 309  
3'-Deoxytiazofurin, **68**, 309  
antitumour activity, **68**, 311  
5'-Deoxytiazofurin, **68**, 309  
2-Deoxy-2-ureidoglucopyranoses, **70**, 181  
2'-Deoxyuridine, mercuration, **62**, 400  
3-Deuterio-3-*p*-  
methoxyphenylperhydropyrido  
[1,2-*c*][1,3]oxazine, reduction, **70**, 32  
Diacetamide purine, preparation of  
acyclonucleoside analogs, **68**, 60  
2,6-Diacetamidopurine, condensation with  
chloromethyl ethers to give  
acylonucleosides, **68**, 9  
2,3-Diacetoxy-1,1-dimethoxypropane,  
reaction with bis-*O*-trimethylsilyluracils,  
**68**, 60  
4,4'-Diacetoxy-5,5'-dimethyl-2,2'-bithiazole,  
solid state structure, **67**, 36  
1,3-Diacetoxy-1-methoxypropane, reaction  
with bis-*O*-trimethylsilyluracils, **68**, 60  
reaction with pertrimethylsilyl derivatives  
of *N*-benzoyladenine, **68**, 60  
1,1-Diacetoxy-1-telluracyclohexa-2,5-dien-4-  
one, reaction with dicyanomethane,  
**63**, 17  
1,1-Diacetoxytellurapyrones, **63**, 33  
*N,N*-Diacetylated-2-arylnaphthylamine  
derivatives, synthesis, **67**, 360  
Diacetylguanine, in preparation of analogues  
of acyclovir, **69**, 144  
*N*-2,9-Diacetylguanine, condensation with  
2,3-dichlorotetrahydrofuran to give  
acyclonucleosides, **68**, 53  
3',5'-Di-*O*-acetylthymidine, ring opening,  
**69**, 195  
Diacylethylenes, reaction with 3-  
aminocyclohex-2-enones, **67**, 238  
2,2-Diacyl-*N*-(1-pyridino)vinylamidines,  
thermolysis, **67**, 252  
Dialdo-D-xylopentofuranose derivatives, in  
synthesis of quinolin-2-yl reverse C-  
nucleoside, **70**, 207  
10-Dialkoxy-4-aryl-2-imino-6,7-  
dihydropyrimido[6,1-*a*]isoquinolinium  
chloride, ring chain tautomerism, **64**, 290  
*trans*-2,3-Dialkoxy-1,4-dioxanes,  
conformations, **69**, 251  
*trans*-2,5-Dialkoxy-1,4-dioxanes,  
conformations, **69**, 251  
22,6-Dialkoxy-2*H*-pyrans, **62**, 28  
7-(Dialkylaminoalkylamino)  
benzo[*b*][1,8]phenanthroline,  
preparation and amebicidal activity, **70**,  
109  
1-Dialkylaminoanthraquinones, conversion  
of oxazinoanthraquinone **65**, 11  
cyclisation, **65**, 23  
2-(or 3-)Dialkylaminobenzothiophenes,  
cyclisation with  
methoxymethylenemalononitrile, **65**, 19  
2-Dialkylaminobenzoyl azides, thermolysis,  
**65**, 29  
2-Dialkylamino-4-chlorothieno[3,4-*d*]  
pyrimidine, **66**, 268  
2-(*N,N*-Dialkylamino)ethyl diazoacetates,  
conversion to morpholinones, **65**, 189  
6-Dialkylamino-1,2,3,5,6,7-  
hexahydropyrido[3,2,1-*ij*]quinazolin-3-  
ones, **70**, 65  
3-Dialkylamino-2-iminopyrido[3,2-*e*]1,3-  
thiazine-4-one, **66**, 171  
*N,N*-Dialkylaminomethyltetrahydrofulvalenes,  
**62**, 277  
2-*N*-Dialkylamino-4-methyloxanes,  
conformational equilibria, **69**, 225

- 2-Dialkylamino-4-morpholinothieno[2,3-*d*]pyrimidines, **65**, 241
- 2-Dialkylaminothieno[3,4-*d*]pyrimidin-4-one, reaction with phosphoryl chloride, **66**, 268
- 3-Dialkylaminothiophenes, cyclisation with methoxymethylenemalononitrile, **65**, 19
- 3,3'-Dialkyl-5,5'-bi-1,2,4-oxadiazoles, **67**, 45
- Dialkyl  $\alpha$ -bromo- $\beta$ -hydroxysuccinate, synthesis by ring opening of cyclic sulfites, **68**, 145
- 2,2-Dialkylchromanones, oxidation, **69**, 72
- N,N*-Dialkyl- $\alpha$ -diazoacetamide, Rh(II) catalysed decomposition, **65**, 118
- trans*-4,6-Dialkyl-2,2-dimethyl-1,3-dioxanes, X-ray structure and NMR determination of structure, **69**, 231
- 3,4-Dialkylisoxazolo[4,3-*c*]quinolines, **64**, 205
- 4,5-Dialkylxyaurones, synthesis, **69**, 22
- 2,3-Dialkyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, bronchorespiratory activity, **63**, 245
- cis* and *trans*-2,5-Dialkyl tetrahydrofuran-3-ones, **65**, 142
- 2,6-Dialkyl-1,3-thiazin-4-one, rearrangement with ammonia to pyrimidinones, **66**, 177
- reduction, **66**, 180
- dimerisation, **66**, 184
- 4,6-Diallyl-*p*-tropoquinone, **64**, 126
- 3,6-Diaminoacridine, **70**, 100
- 1,2-Diaminobenzene, reaction with furanone glycoside, **68**, 79
- reaction with oxidised L-ascorbic acid, **68**, 80
- condensation with aldoses, **70**, 184
- 4,4'-Diamino-3,3'-bi-1,2,5-oxadiazole, **67**, 46
- 2,2'-Diamino-4,4'-bithiazole, nitration, **67**, 36
- 1,2-Diamino-1,2-dideoxy sugars, condensation with benzil, **68**, 383
- 5,6-Diamino-2-dimethylaminopyrimidin-4-one, reaction with L-xylose phenylhydrazone, **70**, 270
- 5,6-Diamino-1,3-dimethyluracil, reaction with 6-hydroxy-6- $\beta$ -D-ribofuranosyl-2*H*-pyran-3(6*H*)-one, **70**, 263
- 1,5-Diaminoimidazole, reaction with acetylacetate to give imidazo[1,5-*b*]-1,2,4-triazepines, **61**, 41
- 2,3-Diaminoisocarbostyrls, reaction with  $\alpha$ -diketones to give 6*H*[1,2,4]triazino[2,3-*b*]isoquinolin-6-ones, **61**, 231
- 4,5-Diamino-6-methoxythieno[2,3-*d*]pyrimidines, **65**, 238
- 5,6-Diamino-3-methylthio[1,2,4]triazine, precursor to pyrazino[2,3-*e*][1,2,4]triazines, **61**, 269
- 1,2-Diaminonaphthalenes, reaction with 1-arylamino-1-deoxyketoses, **70**, 289
- 1,5-Diamino-2-phenylimidazole, from ethyl *N*-(cyanomethyl)benzimidate and hydrazine, **61**, 29
- reaction with diacetyl to give imidazo[1,5-*b*]-1,2,4-triazines, **61**, 42
- 2,3-Diaminopyridine, reaction with oxidised L-ascorbic acid, **68**, 80
- reaction with D-arabinohexulosonic acid derivatives, **70**, 201
- 2,3-Diamino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 177
- 2,3-Diamino-4(3*H*)pyrimidones, reaction with  $\alpha$ -diketones to give pyrido[1,2-*b*][1,2,4]triazines, **61**, 239
- 3,5-Diaminopyrimido[5,4-*e*][1,2,4]triazine, **61**, 251
- 2,3-Diaminothiazoles, in synthesis of thiazolo[3,2-*b*][1,2,4]triazoles, **69**, 325
- 2,4-Diaminothienopyrimidines, **65**, 242
- 2,4-Diaminothieno[2,3-*d*]pyrimidine, **66**, 221
- 2,4-Diaminothieno[3,2-*d*]pyrimidine, **65**, 255
- 2,4-Diamino-6-(3-trifluoromethylphenylthio)thieno[2,3-*d*]pyrimidine, **66**, 227
- 4,5-Diaminotropolone, reaction with formic acid, **64**, 110
- 4,5-Diaminotroponeimine, cyclisation to imidazo- and triazolotroponeimines, **66**, 376
- 1,5:4,6-Dianhydro-2,3-hexodiulose bis(phenylhydrazone), heating with copper (II) sulfate, **70**, 177
- 3,3'-Diaryl-5,5'-bi-1,2,4-oxadiazoles, **67**, 45
- 2,5-Diaryl-1,4-dithiins, sulfur extrusion to thiophenes, **65**, 60
- 2,6-Diarylimidazo[2,1-*b*][1,3,4]oxadiazoles, synthesis, **69**, 277
- 2,6-Diarylimidazo[2,1-*b*][1,3,4]thiadiazoles, Vilsmeier-Haack reaction, **69**, 310
- 2,5-Diaryloxazoles, **69**, 65
- 1,3-Diaryloxazoles, synthesis from acetophenone, **69**, 38
- 3,5-Diarylpyrrole-2-carboxylate, **64**, 10

- 1,5-Diaryl-1,2,3,4-tetrazole, **64**, 201  
2,6-Diaryl[2,1-*b*]-1,3,4-thiadiazoles, from 2-aminothiadiazoles, **69**, 47  
2,5-Diarylthiazolo[3,2-*b*][1,2,4]triazoles, **69**, 325  
1,3-Diazaazulene, conversion to imidazotropones, **64**, 124  
alkylation, **64**, 131  
Diazabenzquinones, **61**, 158  
reactions, **61**, 159  
Diels-Alder reactions, **61**, 160, **61**, 163  
2,5-Diazabicyclo[2.2.1]heptane, **64**, 41  
1,9-Diazacycl[3,3,3]azines, **70**, 48  
1,5,3,7-Diazadiphosphacyclooctane, from *m*-aminobenzoic acid and 1,3,2,5-dioxaborataphosphoniarinanes, **61**, 111  
complexes with molybdenum, **61**, 127  
from phosphorous containing diols and amines, **61**, 73  
alkylation, **61**, 77  
ring contraction, **61**, 78  
reaction with borane, **61**, 80  
Diazadiphosphacyclooctanes, from phosphorous-boron heterocycles and aminomethylphosphines, **61**, 113  
Diazaphospholanes from bis(hydroxymethyl)phosphine and hydrazines, **61**, 75  
4*H*-1,2,4-Diazaphospholes, from bis(diazomethyl)phosphoranes, **65**, 195  
1,3,5-Diazaphosphorinanes, by reaction of amines with tris(oxyethyl)phosphine, **61**, 72  
alkylation, **61**, 77  
conformations, **61**, 81  
reaction with boranes, **61**, 125  
Diazquinones, addition to ergosterol derivatives, **61**, 168  
spectrum, **61**, 176  
chemiluminescence, **61**, 176  
Diazasnoutane, synthesis, **67**, 182  
Diazepines, from pyrylium salts and diazoalkanes, **65**, 292  
Diazepinotropane, **64**, 105  
Diazetidines, **65**, 171  
Diazirine *acyclo* C-nucleosides, synthesis, **68**, 233  
 $\alpha$ -Diazoacetamides, decomposition, **65**, 101  
Diazoacetoacetamides, Rh(II) catalysed decomposition, **65**, 102  
 $\alpha$ -Diazoacetophenone, reaction with 2-methoxypropene, **65**, 150  
2-(Diazoacetyl)cyclobutanones, photolysis, **65**, 153  
Diazoanilides, conversion to  $\beta$ -lactams, **65**, 104  
Diazocines, **65**, 26  
2-Diazocyclohexan-1,3-dione, reaction with 2,3-dihydrofuran, **65**, 150  
1-Diazo-1-deoxyketose, copper catalysed thermal decomposition, **70**, 171  
1-Diazo-2,5-dicarbonyl compounds, cyclisation, **65**, 156  
2-Diazo-4,5-dicyano-2*H*-imidazole, thermolysis, **65**, 196  
2-(2-Diazo-1,3-diketobut-1-yl)-iodobenzene, Rh(II) catalysed decomposition, **65**, 171  
Diazodimedone, reaction with furan, **65**, 150  
9-Diazafluorene, reaction with quinones, **65**, 134  
Diazo ketones, carbene reactions with enamines, **65**, 124  
 $\alpha$ -Diazo- $\beta$ -ketophosphonatoanulates, **65**, 171  
1,3-Diazolidines, ring chain tautomerism, **66**, 23  
thermodynamics, **64**, 256  
2-Diazomethyl-2*H*-1-benzopyrans, decomposition, **65**, 159  
4-Diazomethyl-4*H*-pyrans, decomposition with Pd(II), **65**, 159  
3-Diazopentane-2,4-dione, decomposition in presence of aldehydes and ketones, **65**, 183  
1-Diazo-2,5-pentanedione, precursor to reaction of carbenes with dipolarophiles, **65**, 207  
 $\beta$ -Diazo- $\beta$ -phenylethanol, photolysis, **65**, 135  
2-Diazo-*N*-phenylmalonic acid ethyl ester, decomposition, **65**, 122  
 $\alpha$ -Diazo- $\alpha$ -phenylsulfonylacetopiperidide, photolysis, **65**, 104  
 $\alpha$ -Diazophosphonates, decomposition, **65**, 145  
4-Diazopyrrolidine-2,3-diones, photolysis, **65**, 105  
4-Diazotetraalkyl-3-furanidones, rearrangement, **65**, 137  
3-Diazothiochroman-4-one, Wolff-like rearrangement, **65**, 165  
5-Diazouracils, decomposition, **65**, 123

- Dibenzo[*a,d*]cyclohepten-5,10-imines, via azomethine ylides, **65**, 201
- Dibenzofuro[4,5-*c*]tropones, **64**, 115
- Dibenzofutropone, **64**, 95
- cycloaddition product with dimethyl acetylene dicarboxylate and 1,4-epoxy-1,4-dihydronaphthalene, **66**, 366
- Dibenzophenazine, from  $\beta$ -naphthylamine, **69**, 57
- Dibenzo[*c,f*]quinolizinium chloride, **68**, 213
- Dibenzoselenophene-*Se*-oxide, **64**, 328
- Dibenzotellurophene, **63**, 36
- Dibenzotetraazapentalenes, formation from bibenzotriazoles, **67**, 44
- Dibenzo[*b,f*]thiophins, desulfurisation, **65**, 48
- Dibenzothiophenes, **65**, 60
- Dibenzothiophene-*S*-oxide, **64**, 328
- Dibenzo- $\beta$ -tropolone, reaction with benzoin and ammonia, **64**, 107
- Dibenzotropones, aromaticity, **66**, 307
- 2,5-Dibenzoyl-3,4-dioxypyridazine, bis-*N*-oxide, **61**, 156
- Dibenzoylmethane iodonium ylide, photochemical reaction, **69**, 43
- Dibenzoylmethane 2-methyl (and 2,4-dimethyl)thiosemicarbazones ring chain tautomerism, **66**, 53
- N,N*-Dibenzylglycinate- precursors to pyrroles, **64**, 8
- 6-(4,5-Dibenzyl-2-oxopent-1-yl)pterin, in synthesis of urothione, **70**, 277
- 1,3-Dibenzyl-5-phenyl-1,3,5-diazaphosphorinanes, conformation, **61**, 125
- gem*-Dibromoaziridines, **65**, 99
- 6,8-Dibromobenz[*b*]tropoxazine, hydrolysis, **64**, 89
- Dibromocarbenes, reaction with pyridine, **65**, 177
- 4,5-Dibromocycloheptadienones, reaction with methanol or potassium hydroxide, **64**, 86
- 2,2-Dibromo-1,3-diketones, reaction with copper and double and triple bonds, **65**, 150
- 2,3-Dibromo-1,4-diketones, conversion to 5,5'-bithiazoles, **67**, 35
- 5,5'-Dibromo-2,2'-dipyrrole, **67**, 7
- 5,8-Dibromo-6-hydroxycyclohepta[*b*]pyrid-7-one, **66**, 334
- 3,8-Dibromo-9-hydroxy-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 189
- 6,6'-Dibromindigo, **67**, 14
- 6,8-Dibromo-10-oxobenz[*b*]tropoxazine, **64**, 90
- 7,9-Dibromo-10-oxobenz[*b*]tropoxazine, **64**, 90
- 2,4-Dibromo-11-oxopyrido[1,2-*b*]cinnolin-6-ium hydroxide, **69**, 113
- 1,5-Dibromopentane, reaction with sodium telluride, **63**, 3
- 2,5-Dibromopyridine, coupling with alkynes, **62**, 317
- 2,6-Dibromopyridine, coupling with alkenes, **62**, 314
- 5,7-Dibromo-3-(2-pyridyl)-2,1-benzisoxazole, **69**, 113
- Dibromoquinoxalotropone, replacement of the C-9Br by 2-aminophenylthio group, **66**, 346
- 1,1-Dibromotellurachromanone, **63**, 23
- 1,1-Dibromo-1-telluracyclohexane, **63**, 5
- 9,9-Dibromo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, conformational analysis, **63**, 113
- 1,3-Dibromothienotropone, reaction with organometallic agents, **66**, 357
- 1,3-Dibromothieno[*c*]tropylum salts, reduction, **66**, 382
- Dibromotriphenylphosphoranes, **64**, 165
- trans*-2,5-Di-*t*-butoxy-1,4-dioxane, X-ray structure and *ab initio* calculations on conformations, **69**, 251
- 2,6-Di-*t*-butyl-4-alkylpyrylium cations, reaction with methoxide, **65**, 311
- 2,2-Di-*t*-butyl-6-methyl-2*H*-pyran, **62**, 45
- 1,3-Di(*t*-butyl)-4-methylpyrrole, **65**, 124
- 2,6-Di-*t*-butyl-4*H*-pyran, **62**, 51
- 2,6-Di-*t*-butylpyrylium perchlorate, reaction with Grignard reagents, **65**, 289
- 2,6-Di-*t*-butyl-1-telluracyclohexa-2,5-dien-4-one, reduction, **63**, 15
- Di-*t*-butyl-1,3-thiazepines, desulfurised, **65**, 49
- 2,7-Di-*t*-butyl-1,4-thiazepine, loss of sulfur, **65**, 50
- Di-*t*-butylthio ketene, reaction with dialkyldiazomalonate, **65**, 185
- 5-(1,2-Dicarboethoxyhydrazino)-6-(2-formylhydrazino)-1,3-dimethyluracil,-



- preparation of pyrimido[5,4-*e*]  
[1,2,4]triazines, **61**, 254
- 2,2-Dicarbomethoxy-3-ethyl-2,3-dihydro-1,3-thiazin-4-ones, from *N*-ethylisothiazoline and diazomalonoester, **66**, 148
- 2,6-Dicarbomethoxy-4-iodopyridine, coupling with Cu(II)phenylacetylide, **62**, 397
- 1,3-Dicarbonyl compound *N*-acylhydrazones, **64**, 304
- 4,5-Dicarboxamidothiazol-2-yl *C*-nucleosides, **68**, 310
- 3,3-Dichloroazetidinones, **65**, 107
- gem*-Dichloroaziridines, **65**, 99
- 7,10-Dichlorobenzo[*b*][1,7]phenanthroline, **70**, 100
- Dichloro-*p*-benzoquinones, **67**, 219
- 2,6-Dichloro-9-[2-benzyloxyethoxymethyl]purine, in nucleoside synthesis, **69**, 130
- 4,4'-Dichloro-1,3(5)-bipyrazole, from chlorination of silver pyrazolate, **67**, 21
- 3,3'-Dichloro-4,4'-bi-1,2,5-thiadiazole, **67**, 47
- 1,4-Dichloro-2-butyne, in preparation of allenols, **69**, 171
- 2,3-Dichloro-5,6-dicyanobenzoquinone, reaction with 9-diazofluorene, **65**, 134
- 4,6-Dichloro-2,5-diiformamidopyrimidine, alkylation to acyclonucleosides, **68**, 50
- 4,5-Dichloro-1-(2,3-dihydroxypropyl)pyridazin-6-one, in synthesis of acyclonucleosides, **69**, 181
- 2,2-Dichloro-1,4-dioxane, conformations, **69**, 254
- trans*2,3-Dichloro-1,4-dioxane, conformations, **69**, 254
- Dichloroglyoxime, precursor to 3,3'-biisoxazoles, **67**, 23
- by reaction of acetylene with nitric oxide and nitrogen dioxide, **67**, 24
- by reaction of acetylene with cyanogen *N,N'*-dioxide, **67**, 24
- 4,7-Dichloroisoquinoline, nickel catalysed reaction with methylmagnesium bromide, **62**, 387
- Dichloroketene, 1,4-cycloaddition to enamines, **67**, 262
- 4,5-Dichloro-2-methylthiopyrimidine, coupling with  $\alpha$ -stannylated enol ethers, **62**, 235
- 1,5-Dichloropentane, reaction with sodium telluride, **63**, 3
- 2,6-Dichloropurine, methoxy substitution on 6-position, **68**, 3
- 2,5-Dichloropyrazine, dimethylation by trimethylaluminium, **62**, 371
- 2,6-Dichloropyrazines, double coupling with alkynes, **62**, 322
- 2,4-Dichloropyrimidine, coupling with stannanes, **62**, 332
- reaction with stannanes/  
tetrakis(triphenylphosphino)palladium, **62**, 334
- 2,5-Dichloropyrimidine, coupling with stannanes, **62**, 332
- 4,5-Dichloropyrimidine, coupling with stannanes, **62**, 334
- 4,6-Dichloropyrimidine-5-acetaldehyde, in preparation of EHNA analogs, **68**, 64
- 2,3-Dichloroquinoxaline, production of annelated imidazo[2,1-*b*]thiazoles, **69**, 283
- 10,10-Dichlorotelluraxanthene, **63**, 35
- 2,3-Dichlorotetrahydrofuran, use in alkylation of purines, **68**, 53
- 9,9-Dichloro-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, conformational analysis, **63**, 113
- 2,4-Dichlorothiemo[2,3-*d*]pyrimidine, amine displacement reactions, **66**, 219
- reaction with organolithium reagents, **65**, 250
- 4,5-Dichlorothiemo[2,3-*d*]pyrimidine, **65**, 248
- 2,4-Dichlorothiemo[3,2-*d*]pyrimidine, reaction with nucleophiles, **65**, 259
- 2,4-Dichlorothiemo[3,4-*d*]pyrimidine, reduction with sodium borohydride, **66**, 267
- reaction with nucleophiles, **65**, 265
- reduction, **65**, 265
- 2,5-Dichlorothiophenes, reaction with carbenes, **65**, 194
- Dichlorotriphenylphosphoranes, **64**, 165
- S,N*-Dicinnamylbenzothiazolethione, **66**, 96
- Dictyolumazine, **70**, 275
- Dictyopterin, *see* 2-amino-6-(*D*-threo-1',2'-dihydroxypropyl)pteridin-4-one
- 3,3'-Dicyano-4,4'-bicinnoline, **67**, 65
- 4,4'-Dicyano-1,1'-biisoquinoline, **67**, 56
- 1,2-Dicyanocyclobutene, as a dipolarophile, **64**, 35

- 3,5-Dicyano-2,6-dimethyl-4-phenyl-4*H*-pyran, X-ray crystal structure, **62**, 115
- $\beta,\beta$ -Dicyanoethylene-*t*-anilines, ring closure, **65**, 19
- 8,8-Dicyanoheptafulvenes, hydrolytic ring closure to furotropones, **64**, 121
- 4,5-Dicyanoimidazole, reaction with 2-diazo-4,5-dicyanoimidazole, **67**, 29
- 4,5-Dicyanopyridazine, reaction with 2,3-dimethylbuta-1,3-diene, **69**, 118
- 4,5-Dicyclohexyl-1,3,2-dioxathiolane 2-oxide, X-ray analysis, **68**, 104
- 1,3-Dideaza analog of EHNA, **68**, 64
- 7,8-Didemethyl-8-hydroxy-5-deazariboflavin, synthesis, **67**, 418
- 2',3'-Dideoxyformycin, **70**, 244
- 1,2-Dideoxy-D-glucufurano[1,2-*d*]imidazolidin-2-ones, *see* 1a,4a,5,6-tetrahydro-6-hydroxy-5-[(2*R*)-1,2-dihydroxyethyl]-*cis*-furo[2,3-*d*]imidazol-3-one
- 1,2-Dideoxy-D-glucufurano[1,2-*d*]imidazolidin-2-thiones, *see* 1a,4a,5,6-tetrahydro-6-hydroxy-5-[(2*R*)-1,2-dihydroxyethyl]-*cis*-furo[2,3-*d*]imidazol-3-thione
- 9-[2',3'-Dideoxy-3'-C-(hydroxymethyl)]- $\beta$ -*erythro*-pentafulranosyladenine, synthesis, **68**, 152
- Dideoxyribavarin, synthesis, **67**, 414
- Dienones, oxidation with iodosobenzene, **69**, 8
- 1,2-Diethoxycarbonyl pyrido[1,2,4]triazine, from diethyl azidodicarboxylate and Schiff bases from 3-aminopyridine, **61**, 216
- 2,5-Diethoxy, 2,5-dihydroxymethyl-1,4-dioxane, conformations, **69**, 254
- 2,5-Diethoxytetrahydrofuran, precursor to pyrroles, **64**, 6
- Diethyl aluminium chloride, catalysis of the Beckmann rearrangement of oxime sulfonates, **67**, 213
- 2-Diethylalumino-1-methylpyrrole, coupling with  $\alpha$ -D-glycofuranosyl fluorides, **68**, 247
- Diethyl aminomalonate, reaction with 1,3-diketones, **64**, 12
- 6-Diethylaminophthalazinedione, **61**, 158
- 7-Diethylaminopropylamino-10-chlorobenzo[*b*][1,7]phenanthroline, synthesis and possible antimalarial activity, **70**, 100
- Diethyl 2-aryl-5-ethoxy-5-methyldihydrofuran-3,4-dicarboxylate, **65**, 147
- 1,3-Diethyl 2,7-di-*t*-butylthiophene-4,5-dicarboxylate, **65**, 168
- N,N'*-Diethyl  $\alpha$ -diazoacetamides, decomposition, **65**, 102
- 3,5-Diethyl-1,4-dihydro-2,6-dimethylpyridinedicarboxylate, reaction with 1,3,5-triazine, **68**, 195
- 3,5-Diethyl-2,6-dimethylpyridinedicarboxylate, reaction with dimethylformamide dimethylacetal, **68**, 194
- Diethyl 2,6-dimethyl-3,5-pyridinedicarboxylate, synthesis from ethyl 3-aminocrotonate, **67**, 269
- Diethyl 2,5-dioxo-1,4-cyclohexanedicarboxylate, reaction with anilines, **70**, 96
- 2,2-Diethyl-4,6-diphenyl-2*H*-pyran, reaction with organometallics, **62**, 85
- Diethyl(diphenyl)pyranyl phosphonate, **65**, 316
- Diethyl (4-isoquinoliny)borane, arylation, **62**, 368
- Diethyl(3-pyridyl)borane, **62**, 365
- coupling with alkenyl bromides, **62**, 368
- coupling with bromobenzenes, **62**, 368
- coupling with 1-bromo-2-phenylethyne, **62**, 368
- trans*-2,3-Difluoro-1,4-dioxane, conformations, **69**, 254
- 2-(2,2-Difluoroethenyl)pyridine from 2-iodopyridine and 2,2-difluoroethenyl zinc, **62**, 376
- Difluoromethyl acyclonucleosides, **68**, 56
- 4,5-Difluoro-7-oxo-2,3-dihydro-7*H*-pyrido[3,2,1-*ij*][2,1]benzoxazine-8-carboxylate, displacement of 4-fluorine, **69**, 98
- hydrolysis, **69**, 98
- 9,10-Difluoro-7-oxo-1*H*, 3-*H*, 7*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine-6-carboxylic acids, replacement of 10-fluoro atom, **70**, 37
- 2,2'-Difluoro-4-penten-1-ol, in preparation of fluorinated acyclonucleosides, **67**, 419

- 3,4-Diformylferrocene, reaction with acetone, **64**, 91  
3,4-Diformylfuran, reaction with acetone, **64**, 91  
3,4-Diformylpyrrole, reaction with acetone, **64**, 91  
4,5-Diformyltetraselenafulvalenes, **62**, 293  
4,5-Diformyltetrathiafulvalene, Wittig reaction, **62**, 261  
3,4-Diformylthiophene, reaction with acetone, **64**, 91  
3,4-Diglycosyl-1,2,5-oxadiazoles, **68**, 330  
3,6-Diglycosyl-1,2,4,5-tetrazine *C*-nucleoside, **68**, 394  
Dihalogenophosphoranes, reaction with primary amines, **64**, 165  
1,1-Dihalogenotellurachromanones, **63**, 23  
10,10-Dihalogenotelluraxanthenes, **63**, 40  
4,5-Dihalotetrathiafulvalenes, **62**, 286  
1,3-Diheterocyclohexanes, conformations, **69**, 401  
1,3-Diheterocyclohexenes, conformations, **69**, 401  
6,7-Dihydro-3-aryl-5*H*-imidazo[2,1-*e*]s-triazoles, **63**, 301  
4,5-Dihydroazepines, **64**, 35  
Dihydroazepinoquinolines, **68**, 215  
Dihydroazepinoquinoxalines, **68**, 215  
Dihydrobenzamido-1,3-thiazine-4-ones, **66**, 166  
2,3-Dihydrobenzofurans, **65**, 139  
Dihydrobenzofurans, **67**, 219  
from dichloro-*p*-benzoquinones and 2-[(arylamino)methylene]cyclohexanones, **67**, 219  
5,6-Dihydrobenzo[*b*]furan-7(4*H*)-one, **63**, 370  
2,3-Dihydrobenzofurans, synthesis, **69**, 17  
Dihydrobenzo[*c*]phenanthridin-6(5*H*)-one-precursor to nitidine, **67**, 368  
synthesis, **67**, 368; **67**, 370  
Dihydrobenzo[*b*][1,10]phenanthrolines, **70**, 106  
7,13-Dihydro-6*H*[1]benzopyrano[3,4-*c*][1,5]benzothiazepines, **63**, 94  
6a,7-Dihydro-6*H*[1]benzopyrano[3,4-*c*][1,5]benzothiazepine, **63**, 95  
5a,11-Dihydro-13*H*-[1]benzopyrano[2,3-*b*][1,5]benzothiazepin-13-ones, **63**, 93  
2,3-Dihydro-1,3-benzothiazin-4-thiones, **66**, 156  
oxidation to 2,3 dihydro-1,3-benzothiazin-4-ones, **66**, 159  
4,5-Dihydrobenzothiophene-7(6*H*)-one, reaction with isatins, **70**, 144  
6,7-Dihydrobenzothiophen-4(5*H*)-one, Vilsmeier-Haack formylation, **70**, 142  
reaction with isatins, **70**, 142  
6a,7-Dihydro-6*H*[1]benzothiopyrano[3,4-*c*][1,5]benzothiazepine, **63**, 96  
1,2-Dihydro-4*H*-3,1-benzoxazines, mass spectra, **69**, 439  
4',5'-Dihydro-1,2'-biimidazole, **67**, 28  
7,8-Dihydrobipterin, **70**, 266  
Dihydrocarbazol-4(5*H*)-ones, **67**, 239  
3,4-Dihydrocoumarins, synthesis, **69**, 51  
5,6-Dihydro-6-demethoxyacronycine, **70**, 133  
3,4-Dihydro-2-(3,4-dimethoxyphenyl)-6,7-methylenedioxy-(2*H*)-naphthalone, in synthesis of nitidine, **67**, 350  
2,3-Dihydro-3-dimethylaminomethyl-4*H*-1-benzopyran-4-one, reaction with 2-aminothiophenol, **63**, 94  
2,3-Dihydro-2,2-dimethyl-1,3-benzothiazine-4-one, **66**, 172  
2,3-Dihydro-2,2-diphenylthieno[2,3-*b*]pyridine, **68**, 206  
 $\alpha$ - and  $\beta$ -Dihydro-*N*-ethyl showdomycins, preparation, **68**, 240  
4,5-Dihydrofuro[2,3-*c*]acridines, **70**, 150  
dehydrogenation, **70**, 151  
3a,9-Dihydro-1*H*, 3*H*-furo[3,4-*b*][1,5]benzothiazepin-1-one, **63**, 68  
4,10-Dihydro-1*H*, 3*H*-furo[3,4-*c*][1,5]benzothiazepin-1-one, **63**, 69  
2,3-Dihydrofurotropone, **64**, 100  
8,9-Dihydro-11-hydroxyascididemin, **70**, 96  
2,3-Dihydro-7-hydroxy-1,4-benzothiazine-3-carboxylic acid, **64**, 52  
3,4-Dihydro-3-(2-hydroxyethyl)thieno[3,2-*d*]pyrimidin-2(1*H*)-one, **66**, 240  
3,4-Dihydro-3-(2-hydroxyethyl)thieno[3,4-*d*]pyrimidin-2(1*H*)-one, **66**, 262  
2,3-Dihydro-4-(2-hydroxyphenyl)1,5-benzothiazepines, **63**, 95  
*cis*-6,7-Dihydro-7-hydroxypyrrolo[2,1-*b*][1,5]benzothiazepines, **63**, 67  
activity on the benzodiazepine receptor, **63**, 67

- 2,3-Dihydro-1*H*-imidazo[1,5-*a*]  
benzimidazole, **64**, 193  
Dihydro-6*H*-imidazo[2,1-*b*]  
[1,3,4]thiadiazolo[3,2-*a*]  
pyrimidinones, **69**, 312  
Dihydroimidazo[2,1-*b*]thiazolium ylides,  
reaction with dimethyl acetylene  
dicarboxylate, **69**, 328  
5,6-Dihydro-2-imino-3-phenyl-1,3-thiazin-4-  
one, **66**, 154  
Dihydroindolones, **67**, 238  
4,5-Dihydroisoxazoles, ring opening, **67**, 221  
1,9-Dihydroisoxazolo[4,3-*c*]quinolines, **64**,  
207  
1,2-Dihydro-2-methyl-3-phenyl-4(3*H*)-  
oxothieno[3,2-*d*]pyrimidine, **65**, 260  
5,7-Dihydro-2-methylthieno[3,4-*d*]  
pyrimidin-4(3*H*)-one, **66**, 267  
6,7-Dihydro-2-methylthiothieno[3,2-*d*]  
pyrimidin-4(3*H*)-one, **66**, 245  
reaction with *o*-toluidine, **66**, 248  
Dihydronaphthalenopyrrolinediones, [4+2]-  
cycloadditions, **67**, 367  
1,4-Dihydro-1,6-naphthridones, **67**, 300  
Dihydronitidine, synthesis, **67**, 367  
7,8-Dihydro-1,4-oxathiocins, by carbene  
reactions, **65**, 194  
Dihydrooxazines, reaction with nitrile oxides,  
**69**, 454  
Dihydro-1,3-oxazines, **69**, 363  
synthesis, **69**, 374  
hydrolysis, **69**, 451  
5,6-Dihydro-4*H*-1,3-oxazines, mass spectra,  
**69**, 439  
5,6-Dihydro-4*H*-1,3-oxazinium salts, **64**, 358  
spectra, **64**, 362  
2,3-Dihydro-6*H*-1,4-oxazin-2-ones, **64**, 33  
1,2-Dihydrooxazolo[2,3-*b*]thieno[3,4-*d*]  
pyrimidin-5-one, **66**, 267  
2,3-Dihydrooxazolo[3,2-*a*]thieno[3,2-*d*]  
pyrimidin-5-one, ring opening, **66**, 252  
2,3-Dihydrooxazolo[3,2-*a*]thieno[3,4-*d*]  
pyrimidin-5-one, **66**, 268  
3,4-Dihydro-3-oxo-2-phenyl-2*H*-1-pyran, **65**,  
156  
5,6-Dihydro-2-phenyl-4-substituted-  
aminothieno[2,3-*d*]pyrimidine, **66**, 206  
(±)-Dihydropinidine, **69**, 122  
Dihydropyran, ring contraction, **69**, 68  
3,4-Dihydro-2*H*-pyran-2-ones, **67**, 262  
Dihydro-4-pyranones, **67**, 263  
Dihydropyrans, from ethyl vinyl ethers, **67**,  
261  
4,5-Dihydro-1*H*-pyrazolo[3,4-*b*]  
[1,5]benzothiazepines, **63**, 76  
1,11*b*-Dihydropyridazino[6,1-*a*]isoquinoline,  
thermal dehydrogenation, **69**, 100  
Dihydropyridines, from alkyl 3-  
aminocrotonates, **64**, 31  
Dihydropyridine nucleosides, formation, **67**,  
275  
3,4-Dihydropyrido[1,2-*a*]benzimidazoles,  
from cyclodehydration of enamines, **67**, 259  
7,9-Dihydro-6*H*-pyrido[2,1-*d*]  
[1,5]benzothiazepines, **63**, 86  
5,6-Dihydropyrido[2,3-*b*]  
[1,5]benzothiazepin-5(6*H*)-one, **63**, 83  
structure, **63**, 84  
6,7-Dihydro-1*H*, 3*H*, 5*H*-pyrido[3,2,1-*ij*]  
[3,1]benzothiazine-1,3-thione, reaction  
with 1,3-diaminopropane, **70**, 41  
6,7-Dihydro-1*H*, 3-*H*, 5*H*-pyrido[3,2,1-*ij*]  
[3,1]benzoxazine-3,7-dione, reduction,  
**70**, 35, 54  
11,11-*a*-Dihydro-6*H*, 10*H*-pyrido[1,2-*c*]  
[1,3]benzoxazin-6-one, separation of  
enantiomers, **70**, 6  
UV and CD spectra, **70**, 8  
Dihydro-4-pyridones, from isoxazoline-5-  
spirocyclopropanes, **67**, 276  
2,3-Dihydro-4*H*-pyrido[1,2-*b*][1,2]oxazinium  
bromide, **69**, 110  
hydrogenation, **69**, 96  
3,4-Dihydro-2*H*-pyrido[1,2-*a*]pyrimidines,  
basicity, **63**, 106  
Dihydropyrido[3,4-*a*]pyrimidinediones,  
preparation, **68**, 189  
2,3-Dihydro-1*H*-pyrido[1,2-*c*]pyrimidine-1,3-  
diones, alkylation of nonbridgehead  
nitrogens, **70**, 43  
3,4-Dihydro-2*H*-pyrido[1,2-*a*]pyrimidin-2-  
one, reaction with phosphorus  
trichloride, **63**, 240  
as a base, **63**, 241  
use in detection of bilirubin in body fluids,  
**63**, 242  
6,10-Dihydro-6*H*-pyrido[3'-,2'-  
,5,6]pyrimido[2,1-*c*][1,2,4]triazin-5-one,  
**61**, 241

- Dihydropyrido-1,4-thiazines, loss of sulfur, **65**, 59
- Dihydropyridotriazines, preparation and reduction, **61**, 217
- 5,6-Dihydropyrimido[4,5-*b*]  
[1,5]benzothiazepine-2,4(1*H*, 3*H*)-  
diones, **63**, 86
- 5,11-Dihydropyrimido[5,4-*c*]  
[1,5]benzothiazepine-2,4(1*H*, 3*H*)-  
diones, **63**, 87
- 6,7-Dihydro-2*H*-pyrimido[6,1-*a*]  
isoquinolines, catalytic reduction, **70**, 43
- 6,7-Dihydro-2*H*-pyrimido[6,1-*a*]isoquinolin-  
2-one, **70**, 66
- Dihydropyrroles, preparation, **69**, 28
- 4,5-Dihydropyrrolo[2,3-*c*]acridines, **70**, 139
- 2,3-Dihydro-1*H*-pyrrolo[1,2-*a*]benzimidol-1-  
one, **64**, 192
- 4,10-Dihydro-1*H*-pyrrolo[3,4-*c*]  
[1,5]benzothiazepin-1,3-diones, **63**, 65
- 8,9-Dihydropyrrolo[2,1-*d*]  
[1,5]benzothiazepine-7,10[6*a*,7*aH*]-  
dione *S,S'*-dioxides, **63**, 66
- 6,7-Dihydro-13*H*-quinazolino[2,3-*d*]  
[1,5]benzothiazepin-13-ones, **63**, 96
- 5,6-Dihydroquinolin-8(7*H*)-ones, **70**, 106
- Dihydro-2-quinolones, synthesis from acrylic  
esters and enamines, **67**, 279
- 3,4-Dihydro-6-( $\beta$ -D-  
ribofuranosyl)pyrrolo[1,2-*a*]pyrazine,  
**70**, 277
- (*r*)- and (*s*)-Dihydroshowdomycin, synthesis,  
**68**, 239
- 1,2-Dihydro-2-spirothieno[2,3-*d*]pyrimidine-  
4(3*H*)-thiones, **65**, 249
- 7,8-Dihydro-6-(D-*arabino*-tetritol-1-  
yl)pteridin-2,4-dione, **70**, 274
- 4,5-Dihydropyrazolo[5,1-*d*]  
[1,5]benzothiazepines, **63**, 83  
binding to the benzodiazepine receptor,  
**63**, 83
- 2,7-Dihydro-1,4,5-thiadiazepines, conversion  
to pyridazines, **65**, 51
- Dihydro-1,3-thiazin-4-ones, preparation, **69**,  
384
- 1,2-Dihydro-5*H*-thiazolo[2,3-*d*]  
[1,5]benzothiazepin-5-one, **63**, 79
- Dihydrothiazolo[3,2-*b*][1,2,4]triazole, **69**, 323
- 4,5-Dihydrothieno[2,3-*c*]acridine-6-  
carboxylic acids, **70**, 142
- 4,5-Dihydrothieno[2,3-*b*]  
[1,5]benzothiazepines, **63**, 71
- Dihydrothieno[3,2-*c*]pyridazine, **63**, 388
- 3,4-Dihydrothieno[2,3-*d*]pyrimidine, **65**, 252
- 5,6-Dihydrothieno[2,3-*d*]pyrimidine, **66**, 219
- 5,6-Dihydrothienopyrimidine-2(1*H*),4(3*H*)-  
dione, **66**, 197
- 3,4-Dihydrothieno[3,4-*d*]pyrimidin-2(1*H*)-  
one, **66**, 261
- 2,3-Dihydrothieno[3,2-*e*]-1,3-thiazin-4-ones,  
**66**, 165
- 4,5-Dihydro-3-(2-thienyl)-oxazol-2-ones,  
cyclisation, **66**, 202
- 1,4-Dihydro-1,2,4-triazino[4,3-*b*]  
[1,2,4,5]tetrazine, **64**, 224
- 4,5-Dihydro[1,2,4]triazolo[3,4-*d*]  
[1,5]benzothiazepine, **63**, 79
- 4,5-Dihydro[1,2,4]triazolo[5,1-*d*]  
[1,5]benzothiazepine-6,6-dioxide, **63**, 81
- 2*H*-4,5-Dihydro[1,2,4]triazolo[3,4-*d*]  
[1,5]benzothiazepin-1-one, **63**, 79
- 4,5-Dihydro[1,2,4]triazolo[3,4-*d*]  
[1,5]benzothiazepin-1(2*H*)-thione,  
**63**, 81
- 5,10-Dihydro[1,2,4]triazolo[5,1-*b*]  
quinazolines, **64**, 219
- Dihydrotrapolones- trapping by azides, **64**,  
114
- 1,3-Dihydroxyacridin-9(10*H*)-one, **70**, 132
- 4,4'-Dihydroxy-1,1'-bipthalazine, **67**, 66
- 4,4'-Dihydroxy-2,2'-biquinazoline, **67**, 66
- 9-(1,4-Dihydroxybut-2-oxy)purines, **69**, 164
- 9-(2',4'-Dihydroxybutyl)adenosine, **69**, 154
- (*r*,)-9-[3,4-Dihydroxybutyl]guanine, antiviral  
activity, **67**, 393
- 2-[(3*S*)-3,4-Dihydroxybutyl]-3-  
methylquinoxaline, **70**, 284
- 2(*r*),3(*r*)-*O*-protected-  
Dihydroxybutyrolactone, in preparation  
of acyclonucleosides, **68**, 74
- cis*-1,2-Dihydroxy-1,2-dihydroacronycine,  
**70**, 135
- trans*-1,2-Dihydroxy-1,2-dihydrocitracridone  
I, **70**, 127
- (-)-*cis*-1,2-Dihydroxy-1,2-dihydro-de-*N*-  
methylacronycine, **70**, 127
- trans*-2,5-Dihydroxy-1,4-dioxane,  
conformations, **69**, 252
- 1-[(1*R*)-2-Dihydroxyethyl]-3-  
hydroxymethyl-9-*H*-pyrido[4,3-*b*]indole,  
**69**, 173, **70**, 175

- 6,6'-Dihydroxyindigo, oxidation to indigo, **67**, 14
- 2,4-Dihydroxy-7-methoxy-1,4-benzoxazin-3-one, tautomerism, **64**, 258, **64**, 281
- 1,3-Dihydroxy-10-methyl-9(10*H*)-acridone, **70**, 136
- fusion with 3-amino-3-methylbut-1-yne, **70**, 102
- in synthesis of isoacronycine, **70**, 138
- in preparation of rutacridone, **70**, 148
- 2,3-Dihydroxy-10-methylacridin-9(10*H*)-one, reaction with 3-chloro-3-methylbut-1-yne, **70**, 137
- anhydro*-3,4-Dihydroxy-2-methyl-5,6,7,8-tetrahydropyrido[1,2-*b*]pyridazinium hydroxide, *O*-acylation, **69**, 105
- 1,2-Dihydroxynoracronycine, synthesis, **70**, 129
- 3,4-Dihydroxyproline, **64**, 16
- 2,3-Dihydroxypropoxy acyclonucleosides, preparation, **69**, 162
- 1-[1,3-Dihydroxy-2-propoxy)methyl]-6-azaisocytosine, synthesis, **69**, 197
- 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine, antiviral activity, **67**, 393
- (*s*)-9-[2,3-Dihydroxypropoxy)methyl]guanine, antiviral activity, **67**, 393
- (*S*)-9-(2,3-Dihydroxypropyl)adenine, synthesis and biological activity, **69**, 175
- (*R*)-9-(2,3-Dihydroxypropyl)adenine, synthesis and biological activity, **69**, 175
- 1-(2,3-Dihydroxypropyl)benzamidazole, **69**, 175
- 8-[(*R*)-2,3-Dihydroxypropyl]imidazo[1,5-*a*]-1,3,5-triazin-(3*H*)-ones, synthesis, **69**, 181
- (2'*S*)-3'-(2',3'-Dihydroxypropyl)pyrazolo[4,3-*d*]pyrimidines, **70**, 248
- 2,3-Dihydroxypropyluracil, antiviral activity, **67**, 393
- 7,8-Dihydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 178
- 1,1-Dihydroxy-1-telluracyclohexane, **63**, 5
- Dihydroxytelluranes, **63**, 49
- 6,7-Dihydroxy-1,2,3,4-tetrahydroisoquinolin-1-yl *C*-nucleosides, **70**, 210
- C*-nucleosides, **70**, 209
- 6,7-Dihydroxy-5,6,7,8-tetrahydropyrazino[2,3-*e*][1,2,4]triazines, **61**, 268
- Dihydroxytropylium ions, **66**, 329
- Diimidazo[1,5-*a*:1'-,5'-*d*]pyrazine-5,10-diones from imidazole carboxylic acid, **61**, 193
- reaction with hydrazides, **61**, 193
- 2,4-Diimino-1,3-diazetidene, **64**, 184
- 3,3'-Diindolyl selenide, as precursor of 3,3'-biindole, **67**, 15
- 1,3-Diiodobenzene, reaction with 2-acylanilines, **70**, 92
- 1,4-Diiodobenzene, reaction with aminoacetophenone, **70**, 93
- 1,1-Diiodo-3,5-naphtho-1-telluracyclohexane, **63**, 4
- 3,5-Diiodo-4(1*H*)pyridone, coupling with phenylethynyl copper, **62**, 396
- 2,4-Diiodopyrimidine, coupling with alkynes, **62**, 320
- 4,5-Diiodopyrimidines, coupling with alkenes, **62**, 311
- 1,1-Diiodo-1-telluracyclohexane, **63**, 4
- by oxidation of 1-telluracyclohexane, **63**, 5
- reduction, **63**, 5
- hydrolysis, **63**, 5
- Diisobutylaluminium hydride, in reduction of ribofuranosyl moiety of nucleosides, **69**, 193
- 4,4'-(5'-)-Diisocyanatotetrathiafulvalene, formation of polymers with diols, **62**, 266
- 2,3:5,6-Diisopropylidene-*D*-mannitol, conversion to sulfite, **68**, 115
- 2,2-Diisopropyl-5-(2'-uracilyl)-1,3-dioxane, conformations, **69**, 238
- Diketene, reaction with *N*-(2'-pyridyl)formamides, **63**, 153
- 1,3-Diketone dioximes, ring chain tautomerism, **66**, 21
- 1,3-Diketone hydrazides ring chain tautomerism, **66**, 63
- 1,3-Diketone monoacylhydrazones ring chain tautomerism, **66**, 46
- 1,3-Diketone monobenz or monoacetamidrazonium salts ring chain tautomerism, **66**, 30
- 1,3-Diketone thiobenzoylhydrazones ring chain tautomerism, **66**, 48
- 2,2'-Dilithiodiphenylmethane, reaction with tellurium, **63**, 36
- 4,4'-(5'-)-Dilithiotetrathiafulvalenes, **62**, 280

- Dimedone- precursor to 4*H*-pyrans, **62**, 39  
reaction with arylhydroxylamines, **67**, 211  
Dimethoxybenzocyclobutenedione, **61**, 173  
6,7-Dimethoxy-2*H*-1,3-benzoxazine, reaction  
with dimethyl acetylenedicarboxylate,  
**70**, 62  
7,7'-Dimethoxy-1,1'-biisoquinoline, rhodium  
complexes, **67**, 57  
3,3'-Dimethoxy-4,4'-bipyridazine, **67**, 59  
3,3'-Dimethoxy-5,5'-bi-1,2,4-triazine, Diels-  
Alder reactions, **67**, 69  
7,7'-Dimethoxy-2,2'-bitroponyls, **64**, 118  
Dimethoxycarbene, reaction with acylimines,  
**65**, 181  
4,5-Dimethoxycarbonylpyrazol-3-yl *C*-  
nucleosides, **70**, 235  
9,10-Dimethoxy-6,7-dihydro-2*H*-  
pyrimido[6,1-*a*]isoquinolin-2-one,  
hydrolysis, **70**, 42  
reaction with POCl<sub>3</sub>, **70**, 44  
2,4-Dimethoxy-5,6-dimethylpyrimidine,  
lithiated derivatives in synthesis of  
acyclonucleosides, **69**, 201  
2,2-Dimethoxyoxane, ring inversion, **69**, 258  
1,2-(Di-*p*-methoxyphenyl)imidazo[2,1-*b*]  
oxazoles, **69**, 273  
2,2-Dimethoxy-3,4-di-(tri-  
isopropylsilyl)furan-2-one, **65**, 153  
9,10-Dimethoxy-1,2,4,5,6,11*b*-  
hexahydro[1,3]oxazino[4,3-*a*]  
isoquinoline, ring opening, **70**, 32  
9,10-Dimethoxy-1,3,4,6,7,11*b*-hexahydro-  
2*H*-pyrimido[6,1-*a*]isoquinoline,  
hydrolysis, **70**, 42  
9,10-Dimethoxy-1,3,4,6,7,11*b*-hexahydro-  
2*H*-pyrimido[6,1-*a*]isoquinoline-2,4-  
dione, reduction, **70**, 42  
9,10-Dimethoxy-1,2,3,6,7,11*b*-hexahydro-  
4*H*-pyrimido[6,1-*a*]isoquinolin-4-one,  
preparation, **70**, 43  
2,3-Dimethoxy-3-hydroxyflavanones, by  
oxidation of flavonols, **69**, 73  
9,10-Dimethoxy-1-hydroxymethyl-4-  
(substituted imino)-1,2,4,6,7,11*b*-  
hexahydro[1,3]thiazino[4,3-*b*]  
isoquinolines, reaction with amines,  
**70**, 41  
2,6-Dimethoxy-4-hydroxy-2'-  
nitrobenzophenone, reaction with 3-  
chloro-3-methylbut-1-yne, **70**, 132  
9,10-Dimethoxy-2-imino-3-propyl-  
1,2,4,6,7,11*b*-hexahydropyrimido[6,1-*a*]  
isoquinolin-4-one, **70**, 64  
2,4-Dimethoxy-5-iodopyrimidine, coupling  
with alkynes, **62**, 320  
4,4-Dimethoxyisopyrazoles, **65**, 174  
2,4-Dimethoxy-5-lithiopyrimidine, reaction  
with tri-*O*-benzoyl-*D*-ribofuranosyl  
chloride, **68**, 358  
2,4-Dimethoxy-6-methylpyrimidine, reaction  
with aldehydes, **68**, 375  
3,3-Dimethoxy-2-pentanol, oxidative  
cyclisation, **69**, 57  
2-[2'-(3'-',4'-'-Dimethoxyphenyl)ethen-1'-  
yl]-5-(4'-methoxyphenyl)oxazole, **64**,  
189  
9,10-Dimethoxy-4-phenyl-1,3,4,6,7,11*b*-  
hexahydro-2*H*-pyrido[6,1-*a*]  
isoquinolines, <sup>1</sup>H NMR spectra and  
conformations, **70**, 28  
5,5-Dimethoxy-3-phenylperhydropyrido  
[1,2-*c*][1,3]oxazine, NMR spectra, **70**, 11  
7,7-Dimethoxy-3-phenylperhydropyrido  
[1,2-*c*][1,3]oxazine, NMR spectra, **70**, 11  
3,3-Dimethoxy-1-phenylpropanone,  
preparation, **69**, 7  
2-(3,4-Dimethoxyphenyl)-4*H*-pyrido[1,2-*a*]  
pyrimidin-4-one, **63**, 206  
9,10-Dimethoxy-4-phenyl-1,6,7,11*b*-  
tetrahydro-2*H*-pyrido[6,1-*a*]  
isoquinolines, <sup>1</sup>H NMR spectra and  
conformations, **70**, 28  
hydrolysis, **70**, 42  
2,2-Dimethoxy-2*H*-pyrans, preparation by  
flash vacuum pyrolysis, **62**, 66  
2,4-Dimethoxypyrimidin-5-yl *C*-nucleoside,  
synthesis and anti-leukemic activity, **68**,  
369  
2,6-Dimethoxy-2-pyrone, reaction with  
lithium enolates, **65**, 301  
photosensitised reaction with acrylonitrile,  
**65**, 324  
5,8-Dimethoxyquinolin-4-yl triflate, in  
synthesis of amphimedine, **70**, 117  
2,4-Dimethoxy-7- $\alpha$ -*D*-  
ribofuranosylpyrrolo[3,2-*d*]pyrimidine,  
**70**, 223  
9,10-Dimethoxy-3-substituted-1,3,4,6,7,11*b*-  
hexahydro-2*H*-pyrimido[6,1-*a*]  
isoquinolinones, reduction, **70**, 42

- 9,10-Dimethoxy-2,3,6,7-tetrahydro-4*H*-pyrimido[6,1-*a*]isoquinoline-2,4-dione, reduction with Mg in methanol, **70**, 43  
reaction with POCl<sub>3</sub>, **70**, 44
- 9,10-Dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2,4-dione, reaction with P<sub>4</sub>S<sub>10</sub>, **70**, 46  
**70**, 66
- 5,7-Dimethoxy-1,2,3,4-tetrahydroquinolin-2(1*H*)-one, **70**, 129
- 3,6-Dimethoxy-1,2,4,5-tetroxane, conformations, **69**, 257
- Dimethyl 2-acetyl-5-ethylfuran-3,4-dicarboxylate, **65**, 149
- Dimethylaminoazaazulenes, **66**, 376
- 2-Dimethylaminobenzenesulfonyl azide, thermolysis, **65**, 29
- 9(*N,N*-Dimethylaminocarbonyl)-6-methyl-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, tautomerism, **63**, 114
- 9-Dimethylaminocarbonylthio)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 143
- 4-Dimethylamino-5,6-dihydro(4*H*)-1,3-thiazines, **65**, 55
- 6-(Dimethylaminoethyl)benzo[*c*]phenanthridines, synthesis, **67**, 360
- 1,2-Dimethyl-5-aminoimidazole, from ethyl *N*-(cyanomethyl)acetamidate and methylamine, **61**, 29
- 1-Dimethylamino-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline, formation, **70**, 42
- 1-(*N,N*-Dimethylaminomethyl)naphth-2-ol, reaction with 5-aminoindole, **70**, 139
- 2-Dimethylamino-3-methyl-2,4,6-triphenyl-4*H*-pyran, conversion to pyridine, **62**, 70  
reaction with methanol, **62**, 89
- 2-Dimethylaminoxane, <sup>15</sup>N NMR and conformations, **69**, 227
- 6-Dimethylamino-2-phenyloxazo[*d*]tropyliene, spontaneous rearrangement, **66**, 383
- 4(4'-Dimethylaminophenyl)tellurapyrylium borotetrafluoride coupling with bromine, **63**, 47
- 1,3-Dimethyl-6-(2-aminophenylthio)uracil, precursor to 5,6-dihydropyrimido[4,5-*b*][1,5]benzothiazepin-2,4(1*H*, 3*H*)diones, **63**, 86
- 7-Dimethylaminopropylthiobenzo[*b*][1,10]phe nanthrolines, **70**, 105
- 2-Dimethylamino-2*H*-pyrans, from 1,3-dicarbonyls and β-dimethylamino-α,β-unsaturated aldehydes, **62**, 26  
tautomerism, **62**, 76  
conversion to benzenes, **62**, 93
- 2-Dimethylamino-4*H*-pyrans, aromatisation, **62**, 68
- 2-Dimethylamino-6-(1-*threo*-tetritol-1-yl)pteridin-4-one, **70**, 270
- 4-Dimethylaminotoluene, reaction with *N*-methylformanilide and phosphoryl trichloride, **65**, 26
- 1,3-Dimethyl-6-aminouracil, Nenitzescu reaction, **67**, 238
- 3,5-Dimethyl-4-aryl-1,4-dihydro-2,6-dimethylpyridinedicarboxylate, bromination and cyclisation, **68**, 196
- 2,5-Dimethyl-3,6-arylimidazo[2,1-*b*]thiazoles, **69**, 283
- 1,3-Dimethyl-6-azalumazines, **61**, 242
- N,N'*-Dimethylbarbituric acid, Pd(0) catalysed alkylation as a means of removing diallyl groups from protected amines, **66**, 116
- 6,8-Dimethylbenzotropylium ion, uv spectrum, **66**, 319
- 10,10'-Dimethyl-9,9'-biacridine dinitrate salt, chemiluminescence, **67**, 58
- 1,1'-Dimethyl-2,2'-bibenzimidazole, coupling of 1-methylbenzimidazole with metallating agents and dichlorocarbene, **67**, 38
- 2,2'-Dimethyl-1,1'-bibenzimidazole, from *o,o'*-azoaniline, **67**, 37  
spectra, **67**, 38  
X-ray structure, **67**, 38
- 2,1'-Dimethyl-1,2'-bibenzimidazole, from 2-methylbenzimidazole and 1-methylbenzimidazole-2-sulfonic acid, **67**, 37
- 1,1'-Dimethyl-2,2'-biindole, X-ray structure, **67**, 16  
reaction with dienophiles, **67**, 16
- N,N'*-Dimethyl-1,1'-biisoquinoline- X-ray structure, **67**, 57
- 3,3'-Dimethyl-5,5'-biisoxazole, **67**, 25
- 6,6'-Dimethyl-2,2'-bipyrazine, X-ray structure, **67**, 64



- 1,1'-Dimethylbipyrazoles, **67**, 22  
4,4'-Dimethyl-1,3(5)-bipyrazole, from bromination of 4-methylpyrazole, **67**, 21  
*N,N'*-Dimethyl-3(5),4'-bipyrazoles, **67**, 22  
2,2'-Dimethyl-4,4'-biquinoline, **67**, 54  
4,4'-Dimethyl-2,2'-biquinoline, from *o*-(2-propenyl)aniline, **67**, 53  
by catalytic oxidation of 4-methylquinoline, **67**, 53  
4,4'-Dimethyl-2,2'-bithiazole, solid state structure, **67**, 36  
3,5'-Dimethyl-1,3'-bi-1,2,4-triazoles, **67**, 42  
*N,N*-Dimethylcarbamoylethio-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 210  
reaction with 2-nitrophenyl sulfonyl chloride, **63**, 212  
2,3-Dimethylchroman-5,7-diol, condensation with anthranilic acid, **70**, 129  
2,2-Dimethylchromenes, enantioselective epoxidation, **69**, 8  
2,3-Dimethylchromones, preparation, **69**, 72  
3,6-Dimethyl-2-cyano-4*H*-pyran-decomposition, **62**, 87  
1,3-Dimethyl-2'-deoxypseudouridine, **68**, 371  
5,5-Dimethyl-1,3,5-diazaphosphorinane iodide, from 1,3,5-diazaphosphorinane and methyl iodide, **61**, 77  
Dimethyl dibenzofuran-1,2-dicarboxylate, **63**, 343  
2-Dimethyl-3,5-dicarboethoxy-1,4-dihydropyridine-4-carboxylic acids-rearrangement to pyrroles, **67**, 228  
2,2-Dimethyl-5,5-dicarboethoxy-1,3-dioxan-4,6-dione, conformations, **69**, 247  
Dimethyl dihydrogen 5,6,7,8-tetrahydro-4*aH*-pyrido[1,2-*b*]pyridazine-5,6,7,8-tetracarboxylate, reaction with diazomethane, **69**, 107  
1,3-Dimethyl-6,7-dihydroisothiophene-4(5*H*)-one, **70**, 145  
Dimethyl 1,3-1*H*-dihydro-2-phenyl-pyrazole-3,4-dicarboxylate, **65**, 174  
2,3-Dimethyl-4,5-dihydrothiopheno[3,4-*c*]acridine-6-carboxylic acids, **70**, 145  
1,1'-Dimethyl-4,5'-dinitro-2,2'-biimidazole, structure, **67**, 30  
5,5-Dimethyl-1,3-dioxan-4,6-dione, conformations, **69**, 247  
4,6-Dimethyl-1,3-dioxane, existence as 2,5-twist-boat conformation, **69**, 231  
4,5-Dimethyl-1,3,2-dioxathiolane 2,2-dioxide, mass spectra, **68**, 102  
electrochemical reduction, **68**, 166  
4,5-Dimethyl-1,3,2-dioxathiolane 2-oxide, thermal rearrangement, **68**, 124  
2,2-Dimethyl-1,3-dioxin-4-ones, [2+4]cycloaddition to picolinoyl azide, **63**, 140  
1,1'-Dimethyl-*N,N'*-dioxo-3,3'-biisoquinoline, X-ray structure, **67**, 57  
1,2-Dimethyl-4,5-diphenylpyrrole-3-carboxylate, **65**, 124  
Dimethyl 1,4-diphenyl-1-(*N*-pyrrolidino)1,3-butadiene-2,3-dicarboxylate, cyclisation, **65**, 4  
2,6-Dimethyl-3-ethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, electrochemistry, **63**, 237  
2,4-Dimethyl-3-fluoroquinoline, **65**, 132  
5,7-Dimethylfuro[*b*]tropylium ions, uv spectra, **66**, 319  
1,1-Dimethyl-4-hydroxy-2,3,4,4*a*, 5,10-hexahydro-1*H*-pyrimido[6,1-*a*]isoquinoline, **70**, 66  
Dimethyl *cis*-1-hydroxy-4-hydroxymethylcyclopropen-2-ene dicarboxylate, **66**, 120  
2,2-Dimethyl-5-hydroxymethyl-5-nitro-1,3-dioxane, conformational equilibria, **69**, 238  
2,12-Dimethyl-6-hydroxypyrido[2,3-*c*]acridine-3,7(12*H*)-dione, **70**, 136  
2,4-Dimethyl-9-hydroxypyrido[1,2-*a*]pyrimidinium perchlorate, spectra, **63**, 108  
1,3-Dimethylimidazolidine, ring chain tautomerism, **66**, 23  
2,4-Dimethyl-imidazo[2,1-*b*][1,3,4]thiadiazoles, **69**, 318  
Dimethyl indole-6,7-dicarboxylate, **63**, 346  
Dimethyl indol-3-ylfumarate, reaction with tetracyanoethylene, **63**, 374  
2,6-Dimethyl-5-iodopyrimidine, coupling with alkynes, **62**, 320  
3,5-Dimethylisoxazole, precursor to 3'-methyl-4,5'-biisoxazole, **67**, 24  
*N*-(3,5-Dimethylisoxazol-4-yl)thiourea, reaction with  $\alpha$ -chloroketones, **69**, 286  
Dimethylketene methyl trimethylsilyl acetal, in  $\beta$ -lactam synthesis, **64**, 5

- 1,3-Dimethyl-6-mercaptouracil, reaction with chloroacetaldehyde, **66**, 214
- 2,2-Dimethyl-5-methoxycarbonyl-2*H*-pyran, **62**, 29
- Dimethyl 3-methoxy-2,3-dihydrobenzofuran-1,2-dicarboxylate, **63**, 343
- 1,5-Dimethyl-7-methoxy-1,2,3,4,5,10-hexahydro-4*aH*-pyridazino[1,6-*b*]isoquinoline, **69**, 117  
conformation by IR spectroscopy, **69**, 94  
mass spectroscopy, **69**, 95
- 3,7-Dimethyl-5-methoxy-1-phenylthio-1,2,3,4-tetrahydro-2-oxobenzo[*b*][1,8]phenanthroline, **70**, 111
- 1,3-Dimethyl-6-methylmercapto-*N*-phenylpyrrolo[d]tropylum salt, reaction with malononitrile, **66**, 384
- 6,6-Dimethyl-3-methylthio-6,7-dihydro[1,2,4]triazino[1,6-*c*]quinazolin-5-ium-1-olate, preparation and crystal structure, **61**, 266
- 3,10-Dimethyl-7-methylthio-6,8,9-triazaisoalloxazine, **61**, 270
- 2,7-Dimethyl-1,8-naphthyridin-4-one, **63**, 231
- Dimethyl 2(4-nitrophenyl)benzofuran-4,5-dicarboxylate, **63**, 341
- 1,2-Dimethyl-3-(*o*-nitrophenylthio)indole, precursor to indolo[2,3-*c*][1,5]benzothiazepines, **63**, 90
- 2,3-Dimethyloctahydro-2*H*-1,3-benzoxazines, mass spectra, **69**, 439
- 1,2-Dimethyloctahydro-2*H*-3,1-benzoxazine, conformations, **69**, 405
- cis*-2,3-Dimethyloctahydro-2*H*-3,1-benzoxazines, mass spectra of epimers, **69**, 439
- 1,3-Dimethyloctahydroquinazolinones, **69**, 389
- trans*-3,5-Dimethyloxane, simulated <sup>13</sup>C NMR spectra, **69**, 229
- 3,3-Dimethyl-1,4-oxazin-2-ones, **64**, 34
- Dimethyl [1,2]oxazino[2,3-*a*]quinoline-2,3-dicarboxylate, **69**, 110
- 1,6-Dimethyl-4-oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidinium salts, transformation, **63**, 175
- 3,3-Dimethylpentane-2,4-dione, bis adduct with phenylhydrazines ring chain tautomerism, **66**, 39  
bis adduct with 2,4-dinitrophenylhydrazines ring chain tautomerism, **66**, 39
- r*-4*a*, *t*-1, *c*-8-*H*-1,8-Dimethylperhydropyrido[1,2-*c*][1,3]oxazine, conformations, **70**, 11
- cis*-3,4*a*-*H*-2,3-Dimethylperhydropyrido[1,2-*c*]pyrimidines, <sup>1</sup>H NMR spectra and conformations, **70**, 26
- cis*-4,4*a*-*H*-2,4-Dimethylperhydropyrido[1,2-*c*]pyrimidines, <sup>1</sup>H NMR spectra and conformations, **70**, 26
- trans*-4,4*a*-*H*-2,4-Dimethylperhydropyrido[1,2-*c*]pyrimidines, <sup>1</sup>H NMR spectra and conformations, **70**, 26
- cis*-4*a*-*H*-2,8-Dimethylperhydropyrido[1,2-*c*]pyrimidines, <sup>1</sup>H NMR spectra and conformations, **70**, 26
- trans*4*a*-*H*-2,8-Dimethylperhydropyrido[1,2-*c*]pyrimidines, <sup>1</sup>H NMR spectra and conformations, **70**, 26
- cis*-7,4*a*-*H*-2,7-Dimethylperhydropyrido[1,2-*a*]pyrimidin-3-ones, Bohlmann bands in infrared spectra, **70**, 24
- trans*-7,4*a*-*H*-2,7-Dimethylperhydropyrido[1,2-*a*]pyrimidin-3-ones, Bohlmann bands in infrared spectra, **70**, 24
- cis*-5,4*a*-*H*-2,5-Dimethylperhydropyrido[1,2-*a*]pyrimidin-3-ones, Bohlmann bands in infrared spectra, **70**, 24
- trans*-5,4*a*-*H*-2,5-Dimethylperhydropyrido[1,2-*a*]pyrimidin-3-ones, Bohlmann bands in infrared spectra, **70**, 24
- cis*-4*a*, 5-*H*-2,5-Dimethylperhydropyrido[1,2-*c*]pyrimidin-3-one, <sup>1</sup>H NMR spectra and conformations, **70**, 26
- cis*-4*a*, 7-*H*-2,7-Dimethylperhydropyrido[1,2-*c*]pyrimidin-3-one, <sup>1</sup>H NMR spectra and conformations, **70**, 26
- cis*-4*a*, 8-*H*-2-*X*-Dimethylperhydropyrido[1,2-*c*]pyrimidin-3-one, <sup>1</sup>H NMR spectra and conformations, **70**, 26
- trans*-4*a*, 7-*H*-2-*X*-Dimethylperhydropyrido[1,2-*c*]pyrimidin-3-one, <sup>1</sup>H NMR spectra and conformations, **70**, 26
- trans*-4*a*, 5-*H*-2-*X*-Dimethylperhydropyrido[1,2-*c*]pyrimidin-3-one, <sup>1</sup>H NMR spectra and conformations, **70**, 26

- cis*-8,4*a*-*H*-2,8-Dimethylperhydropyrido  
[1,2-*a*]pyrimidin-3-ones, Bohlmann  
bands in infrared spectra, **70**, 24
- 3,3-Dimethylperhydropyrido[1,2-*c*]  
[1,3]thiazine-1,6-dione, **70**, 60
- 1,3-Dimethylperhydropyrimidine ring chain  
tautomerism, **66**, 23
- 2,4-Dimethyl-3-phenylimidazole, **65**,  
177
- 1,3-Dimethyl-2-phenylimidazolidine, **65**,  
176
- 3,4-Dimethyl-5-phenyl-1,2,3-oxathiazolidine  
2-oxide, **68**, 121
- 2,2-Dimethyl-4(1-phenylpyrazol-4-yl)-8-  
phenyl-1,6,8-triaza-3-  
oxabicyclo[4,3,0]nona-7,9-dione, **63**,  
389
- 1,2-Dimethyl-3-phenyl-2*H*-pyrrolidin-2-one,  
**65**, 125
- 4,6-Dimethyl-2-phenylthieno[2,3-*d*]  
pyrimidine, **66**, 213
- 1,3-Dimethylpseudouridine, conversion to  
pseudoisocytidine, **68**, 369
- acyclo* 1,3-Dimethylpseudouridines, **68**,  
378
- Dimethyl 4*H*-pyran-2,6-dicarboxylate,  
catalytic reduction, **62**, 75
- 2,6-Dimethyl-4*H*-pyran-4-thione,  
methylation, **65**, 316
- 2,6-Dimethylpyridine, reaction with ethyl  
chloroacetate, **68**, 211
- 2,4-Dimethylpyrido[1,2-*a*]pyrimidine-9-  
carboxylate, mass spectrum, **63**, 122
- 2,4-Dimethylpyrido[1,2-*a*]pyrimidinium  
perchlorate, **63**, 125
- 2,8-Dimethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-  
one, **63**, 133
- Dimethyl 3-(2-pyridyl)-4-oxo-3,4-  
dihydroquinoline-2,3-dicarboxylate, **69**,  
109
- 1,3-Dimethylpyrimidin-5-yl triflate, coupling  
with alkenes, **62**, 311
- (-)-or(+)-*trans*-2,5-Dimethylpyrrolidine,  
**64**, 7
- 2,3-Dimethylpyrrolo[*b*]tropone, **66**, 361
- 4,6-Dimethyl-2-pyrone, reaction with methyl  
magnesium iodide, **65**, 295
- 2,3-Dimethylquinoxaline, reaction with  
maleic anhydride and benzoquinone,  
**68**, 183
- 1,3-Dimethyl-8( $\beta$ -*D*-  
ribofuranosyl)xanthosine, **70**, 250
- 6,12-Dimethyl-substituted  
dihydrobenzo[*c*]phenanthridine, **67**,  
379
- 1,3-Dimethyl-5,6,7,8-tetrahydropyrido[1,2-*c*]  
pyridinium-4-carboxylate, reaction with  
ammonia, **70**, 42
- 1,3-Dimethyl-6,7,8,9-tetrahydropyrido[1,2-*c*]  
pyrimidinium-4-carboxylate, **70**, 72
- 1,6-Dimethyl-1,6,7,8-tetrahydro-4*H*-  
pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 175
- 3,3-Dimethyl-2,3,4,10-tetrahydro-1*H*-  
pyrrolo[3,4-*c*][1,5]benzothiazepin-1-one,  
**63**, 65
- 1,3-Dimethylthieno[2,3-*d*]pyrimidin-2,4-  
dione, **66**, 214
- electrophilic reactions, **65**, 250
- 2,4-Dimethylthieno[2,3-*d*]pyrimidine,  
reaction with benzaldehyde, **65**,  
251
- 5,6-Dimethylthieno[2,3-*d*]pyrimidinedione,  
nitration, **66**, 224
- 5,6-Dimethylthieno[2,3-*d*]pyrimidin-4(3*H*)-  
one, **66**, 229
- 5,6-Dimethylthieno[2,3-*d*]pyrimidin-4(3*H*)-  
2(1*H*)-thione, nitration to 5,6-dinitro  
compound, **66**, 225
- 2,6-Dimethylthieno[*b*]tropolone,  
intramolecular electrocyclic reaction,  
**66**, 330
- N*-(Dimethylthio)methylene aldonic acid  
amides, reaction with thiosemicarbazide,  
**68**, 327
- 1,3-Dimethyl-5-  
thiomethylpyrrolo[*c*]tropolone,  
methylation on sulfur, **66**, 347
- 1,3-Dimethyl *cis,trans*-2,3,5-  
triphenylimidazolidine, **65**, 178
- 1,2-Dimethyl-3-vinylindole, reaction with  
tetracyanoethylene, **63**, 375
- 1,5-Dimethyl-2-vinylpyrrole, 1:2 adduct with  
diethyl azidodicarboxylate, **63**, 383
- 7,7'-Dinitro-2,2'-biindazole, **67**, 26
- 4,4'-Dinitro-3,3'-bi-1,2,5-oxadiazole,  
**67**, 46
- 3,8-Dinitrodibenzoselenophene-*Se*-oxide,  
**64**, 329
- 2,4-Dinitro-5-iodo-1,1'-biimidazole, **67**, 28
- 2-(2,4-Dinitrophenyl)isoquinolinium ion,  
pseudo-base and ring chain tautomerism,  
**64**, 290

- 3,8-Dinitro-S-trifluoromethyldibenzothiophenium triflate- trifluoromethylation of aromatics, **64**, 332  
trifluoromethylation of triphenylphosphines, **64**, 334
- 1,3,2,5-Dioxaboraphosphorinanes, **61**, 84  
conformations, **61**, 95  
metal complexes, **61**, 129
- 1,3,2,5-Dioxaborataphosphoniariinanes, **61**, 86
- 1,14-Dioxacyclohexacoranes, by carbene insertion reactions, **65**, 195
- 1,4-Dioxacylooctanes, via carbene reactions, **65**, 191
- Dioxalanes, **65**, 184  
decomposition in the presence of aldehydes and ketones, **65**, 185
- 1,2-Dioxanes, NMR, X-ray structure analysis and conformations, **69**, 229
- 1,3-Dioxane, ring contraction, **65**, 185  
preferred conformation, **69**, 230
- Dioxanes, by carbene reactions, **65**, 191
- 1,4-Dioxane-2-radical, ring inversion, **69**, 259
- 1,3-Dioxan-2-one, conformations **69**, 245
- 1,3-Dioxan-4-one, conformations, **69**, 245
- 1,3-Dioxan-2-ylum ions, conformation, **69**, 244
- 1,3,5-Dioxaphosphorinanes, **61**, 60  
reaction with sulfur, selenium and oxygen, **61**, 65  
reaction with methyl iodide, **61**, 66  
reaction with phenyl azide, **61**, 66  
stereoisomerism, **61**, 66  
complexes with metals, **61**, 128
- 1,3,5-Dioxaphosphorinane oxide, by condensation of benzaldehyde with benzylbis( $\alpha$ -hydroxybenzyl)phosphine oxide, **61**, 64
- 1,3,2,5-Dioxasilaphosphorinanes from reaction of dimethyldichlorosilane and alkylbis(oxyethyl)phosphines, **61**, 62  
stereochemistry, **61**, 71
- 1,3,2-Dioxathiolane 2,2-dioxides, **68**, 91  
dipole moment **68**, 93  
kinetics of hydrolysis, **68**, 94  
mass spectroscopy, **68**, 102  
X-ray analysis, **68**, 103  
comparison of reaction with nucleophiles with ethylene oxide, **68**, 123  
reaction with phenyllithium, **68**, 136  
reaction with hydroxy radicals, **68**, 165  
photochemical chlorination, **68**, 166  
toxicity, **68**, 168
- 1,3,2-Dioxathiolane 2-oxides, **68**, 90  
dipole moment, **68**, 94  
kinetics of hydrolysis, **68**, 94  
infrared spectroscopy, **68**, 95  
NMR spectroscopy, **68**, 95  
pseudo-rotation detected by nmr, **68**, 95  
ESR spectra, **68**, 101  
structural analysis, **68**, 104  
synthesis, **68**, 106  
synthesis from ethylene glycol and dimethyl sulfate, **68**, 107  
complex with metals, **68**, 129  
reaction with phenylmagnesium bromide, **68**, 134  
reaction with sodium methoxide and phenoxide, **68**, 141  
reaction with chlorine gas, **68**, 145  
reaction with thiophenolate ions, **68**, 161  
patented use as alkylating agent and solvent, **68**, 167  
in preparation of polymers, **68**, 168
- Dioxoanthra[*b*]thiophenes, **63**, 366
- 1,1'-Dioxo(benzo[*b*]pyranilidene) tellurapyrans, **63**, 46
- 2,4-Dioxo-3,1-benzoxazines, polymerisations, **69**, 461
- N,N'*-Dioxo-1,1'-biisoquinoline, resolution, **67**, 57
- trans*-fused-2,4-Dioxodecahydroquinazolines, conformations, **69**, 415
- Dioxodecahydroquinazolines, herbicidal activity, **69**, 464
- 2,4-Dioxo-1,3-diphenyl-6,7,8,9-tetrahydropyrido[1,2-*a*]pyrimidinium betaine- photolysis, **63**, 236
- 2,4-Dioxo-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines, **70**, 64  
reduction, **70**, 42
- 2-[*o*-(1,3-Dioxolan-1-yl)phenyl]pyridine, *N*-amination, **69**, 113
- Dioxoles, **65**, 183
- 2,4-Dioxo-3-methyl-1-phenyl-6,7,8,9-tetrahydropyrido[1,2-*a*]pyrimidinium betaine, 1,4-dipolar cycloaddition, **63**, 238

- 4,6-Dioxooctanoic acid, oxidative cyclisation, **69**, 53
- 2,4-Dioxopyrazino[2,3-*d*]pyrimidin-6-yl acyclo *C*-nucleosides, **70**, 275
- 2,7-Dioxopyrido[3,2,1-*ij*]cinnoline-3,8-dicarboxylate, **69**, 117
- 4,6-Dioxopyrido[1,2-*a*]pyrimidine-9-carboxylate, mass spectrum, **63**, 122
- 1,1-Dioxo(tellurapyranylidene) tellurapyrans, **63**, 46
- cis*fused-2,4-Dioxo-5,6,7,7a-tetrahydrocyclopent[*e*][1,3]oxazin-4-ones, conformations, **69**, 415
- 3,4-Dioxotetrahydrofurans, from acetylenic bis-alcohols, **69**, 26
- 4,9-Dioxo-6,7,8,9-tetrahydro-4*H*-pyrido [1,2-*a*]pyrimidines, tautomerism, **63**, 116
- 2,3-Dioxo-1,2,3,4-tetrahydroquinoxaline, **63**, 170
- Dioxothiazines, **66**, 175
- 2,4-Dioxothieno[3,2-*d*]pyrimidine, **65**, 248
- 3,4-Dioxo[1,2,4]triazino[3,4-*a*]phthalazines, **61**, 237
- 2,2'-Diphenyl-1,1'-bibenzimidazole, from *N*-benzylidene-*O*-phenylenediamine with cuprous chloride, **67**, 37
- 5,5'-Diphenyl-2,2'-bi-1,3,4-oxadiazoles, **67**, 49
- from oxidation of bis(benzoylhydrazones) of glyoxal, **67**, 46
- 5,5'-Diphenyl-2,2'-bioxazoline, **67**, 31
- 4,4'-Diphenyl-1,1'-biphtalazine, **67**, 65
- Diphenylbipyrazoles, **67**, 22
- 1,1'-Diphenyl-4,4'-bipyrazole, **67**, 22
- 3,3'-Diphenyl-4,4'-bipyrazole, **67**, 22
- X-ray structure, **67**, 22
- 4,4'-Diphenyl-2,2'-biquinazoline, **67**, 66
- 6,6'-Diphenyl-3,3'-bitetrazine, **67**, 70
- 5,5'-Diphenyl-1,1'-bitetrazole, synthesis and thermolysis, **67**, 48
- 2,2'-Diphenyl-4,4'-bithiazole, **67**, 35
- Diphenylboryloxyalkyl(imido)phosphines, **61**, 90
- Diphenylboryloxymethyl(methyl) phenylphosphine, disproportionation, **61**, 86
- o*-Diphenylboryloxyphenylenephosphine, **61**, 124
- 2,3-Diphenylcyclopropanone, reaction with thioamides, **66**, 150
- Diphenylcyclopropanone, reaction with enamines, **67**, 229
- 2,6-Diphenyl-4-dialkylamino-oxanes, NMR spectra and conformations, **69**, 225
- 1,3-Diphenyl-2,2'-dichloroaziridine, **65**, 98
- 5,6-Diphenyl-5,6-dihydro-1,3-thiazin-4-one, **66**, 150
- 2,5-Diphenyl 1,3,2,5-dioxaboraphosphorinanes from tris(hydroxymethyl)phenyl phosphonium chloride with phenyl dichloroborane, **61**, 84
- reactions, **61**, 103
- reactions with aldehydes, **61**, 109
- 4,5-Diphenyl-1,3,2-dioxathiolane 2-oxide, thermal rearrangement, **68**, 125
- 4,5-Diphenyl-1,3,2-dioxathiole 2,2-dioxide, thermal rearrangement, **68**, 125
- rearrangement to *trans*-stilbene, **68**, 129
- 4,5-Diphenyl-1,3,2-dioxathiole 2-oxide, thermal rearrangement, **68**, 125
- photolysis, **68**, 126
- 1,4-Diphenyl-3,6-(di-2-thienyl)-1,4-dihydro-1,2,4,5-tetrazines, **63**, 334
- 2,2-Diphenyl-1,3-dithiepane, **65**, 194
- 2,5-Diphenyl-1,4-dithiin, reaction with dimethyl diacetylenedicarboxylate, **65**, 62
- 2,6-Diphenyl-3-ethyl-4-methylene-1,3-oxazinium hexachloroantimonate, **64**, 348
- 3,3-Diphenyl-1,2,3,7,8,9-hexahydropyrido[3,2,1-*ij*]cinnoline, **69**, 118
- 2,4-Diphenyl-7-*o*-hydroxyphenyl-5,6-dihydropyrido[2,1-*a*]phthalazinium perchlorate, X-ray crystallography, **69**, 96
- Diphenylimine of ethylglycinate, aziridine synthesis, **64**, 3
- Diphenyl iodonium-2-carboxylate, reaction with 5-aminoquinolines, **70**, 100
- as an *N*-aryllating agent, **70**, 110
- 4-(Diphenylmethylene)pyran, **65**, 293
- 2-Diphenylmethyl-1,3,4-oxadiazole, **64**, 194
- 2,2-Diphenyl-8-methylperhydroisoxazolo[2,3-*a*]pyridinium salts, ring expansion, **70**, 58
- 2,6-Diphenyl-3-methylpyrylium perchlorate, reaction with phenyl magnesium bromide, **65**, 287

- N,N*-Diphenyl-2-methylthioethanamide, Pummerer-type rearrangement, **69**, 33
- 2,6-Diphenyl-oxan-4-ones, NMR spectra, **69**, 227
- 2,3-Diphenyloxirane, **65**, 135
- 2,5-Diphenyl-5-oxo-1,3,2,5-dioxaboraphosphirinan, from oxides of diols and the anhydride of phenylboric acid, **61**, 86
- 3,3-Diphenylperhydropyrido[1,2-*c*][1,3]oxazine, **70**, 58
- cis*-2-Diphenylphosphoryl-5-alkyl-1,3-dioxane, conformations, **69**, 236
- $\Delta^4$ -2,6-Diphenyl-4*H*-pyrans, **62**, 52, **65**, 316
- 1,3-Diphenylpyrazolo[*d*]tropone, **64**, 113
- 4,6-Diphenyl-2-pyrone, reaction with phenyl magnesium bromide, **65**, 295
- 2,6-Diphenylpyrylium perchlorate, reaction with lithiophenylacetylide, **65**, 289  
reaction with triphenylphosphine, **65**, 314
- 2,4-Diphenyl-7-substituted 5,6-dihydropyrido[2,1-*a*]phthalazinium salts, **69**, 116
- cis,trans* 3,5-Diphenyl-5,6,7,8-tetrahydro-3*H*-[1,2,4]oxadiazolo[4,3-*c*]pyrimidine ring chain tautomerism, **66**, 26
- 7,11*b*-Diphenyl-2,3,4,11*b*-tetrahydro-1*H*-pyrido[2,1-*a*]phthalazine, **69**, 117
- 3,6-Diphenyl-1,2,4,5-tetrazine, **64**, 224
- 3,5-Diphenylthiazolo[3,2-*b*][1,2,4]triazoles, **69**, 318
- 5,7-Diphenylthieno[*c*]tropone, reaction with dihalocarbenes, **66**, 364
- Diphenyl(trimethyltetrafulvalenyl)phosphine, **62**, 288
- $\lambda^5$ -1,3-Diphosphetes, **65**, 173
- Diphosphiranes, **65**, 171
- Diplamine, **70**, 112
- 1,3-Dipolar ketocarbenes, **69**, 5
- Dipole cascade reactions, **65**, 202, **65**, 114
- 6-(*N,N*-Dipropylamino)-1,2,3,5,6,7-hexahydropyrido[3,2,1-*ij*]quinazolin-3-one, bioactive conformation, **70**, 22  
serotonin agonist activity, **70**, 76
- N,N'*-(Di-*N*-propyl)-2,6-dinitro-4-trifluoromethylaniline, photocyclisation, **65**, 14
- Dipyrzolo[*b,f*]azepines, **67**, 323
- Dipyrzolo[1,5-*a*:1'-,5'-*d*]pyrazine-4,9-diones from pyrazole-3-carboxylic acid, **61**, 191  
reaction with nucleophiles, **61**, 195
- 2*H*-Dipyrdo[1,2-*a*:2'-,3'-*d*]pyrimidine-2,5(1*H*)-diones, **63**, 203
- 7,7-Dipyrrolidinonorcaradiene, flash vacuum pyrolysis, **65**, 132
- Dipyrrolo[1,2-*a*:1'-,2'-*a*]pyrazine-5,10-diones by dehydration of pyrrole-2-carboxylic acid, **61**, 191  
hydrolysis, **61**, 194
- 1,1-Di(pyrrol-2-yl)alditol, **68**, 254
- 5'-,5'-Di(pyrrol-2-yl)reverse *C*-nucleosides, preparation, **68**, 251
- Di-4-quinolinyll sulfide, desulfurization to 4,4'-biquinoline, **67**, 54
- Discorhabdin C, synthesis, **69**, 55
- Diselenadiazolium salts, **62**, 151
- Disilanyl  $\alpha$ -diazaketones, photolysis, **65**, 173
- ( $\pm$ )-Disparlure, synthesis, **68**, 144
- 2-(*N,N*-Disubstituted)amino-3-phenylthieno[2,3-*d*]pyrimidin-4-ones, **66**, 232
- 4,6-Disubstituted ammonium 1,3,2,5-dioxaborataphosphorinanes, alkylation to stable betaine systems, **61**, 117
- 5,6-Disubstituted-2-benzylmercaptoimidazo[2,1-*b*][1,3,4]thiadiazoles, ring opening of thiazole ring, **69**, 310
- 5,5'-Disubstituted-2,2'-bi-1,3,4-oxadiazoles, **67**, 46
- 2,6-Disubstituted-5-bromoimidazo[2,1-*b*][1,3,4]thiazoles, nucleophilic reactions, **69**, 311
- 2,6-Disubstituted-5-carbalkoxyimidazo[2,1-*b*][1,3,4]thiadiazoles, **69**, 305
- 9-(Disubstitutedcarbamoylthio)pyrido[1,2-*a*]pyrimidine-3-carboxylate, **63**, 212
- 2,6-Disubstituted 1,3-diazaazulenes, nucleophilic reactions, **64**, 89
- 4,4-Disubstituted dihydropyridines, from enamines, **67**, 271
- 2,5-Disubstituted 5,6-dihydro-1*H*-pyrido[1,2-*a*]quinazoline-1,6-diones, **68**, 214
- 2,4-Di-substituted 1,3-dioxadecalins, conformations, **69**, 250
- 2,5-Disubstituted 1,3-dioxane-4,6-diones, conformations, **69**, 245

- N,N*-Disubstituted enamines, 1,4-cycloaddition to ketenes, **67**, 262
- 2,6-Disubstituted-3(2*H*)furanones, **65**, 138
- 2,2-Disubstituted 2-*H* imidazoles, **67**, 258
- 2,6-Disubstituted imidazo[2,1-*b*]  
[1,3,4]oxadiazoles, **69**, 276
- 2,6-Disubstituted imidazo[2,1-*b*]  
[1,3,4]thiadiazoles, **69**, 310  
thiocyanation, **69**, 310
- 5,6-Disubstituted imidazo[2,1-*b*]  
[1,3,4]thiadiazoles, X-ray structures, **69**, 313  
biological activity, **69**, 316
- 2,5-Disubstituted imidazo[2,1-*b*]thiazoles, **69**, 283, 286
- 2,3-Disubstituted indoles, synthesis, **67**, 244
- 3,5-Disubstituted isoxazoles, ring opening, **67**, 221
- 1,5-Disubstituted 2-mercaptoimidazoles, cyclisation, **69**, 283
- 4,5-Disubstituted 2-mercaptoimidazoles, reaction with  $\alpha$ -halo ketones, **69**, 282
- 2,6-Disubstituted-4-methylpyrylium tetrafluoroborate, reaction with diazo compounds, **62**, 56
- 3,5-Disubstituted 2,5,6,8,9,10,11,11*a*-octahydro-1*H*-pyrido[1,2-*c*]pyrimido[5,4-*e*]pyrimidine-1,6-diones, **70**, 49
- 2,5-Disubstituted 1,3,4-oxadiazoles, synthesis, **69**, 42
- 3,5-Disubstituted oxazoles, from oxidation of dioximes of  $\beta$ -diketones, **69**, 40
- 2,7-Disubstituted oxepanes, from diazo alcohols, **65**, 158
- 2-Disubstituted-4-oxothieno[2,3-*d*]pyrimidines, **65**, 242
- 5,6-Disubstituted-pyrimidin-2,4-diones, **69**, 58
- 2,6-Disubstituted pyrylium perchlorates, conversion to 4*H*-pyrans, **62**, 53
- 2,6-Disubstituted pyrylium salts, reaction with organometallics, **65**, 285
- 5,6-Disubstituted quinazoline-2,4-diones, **68**, 209
- 2,2-Disubstituted-tetrahydro-1,3-oxazin-4-ones, synthesis, **69**, 370
- 3,6-Disubstituted 1,2,4,5-tetrazines, reaction with  $\beta$ -D-ribofuranosylacetylenes, **68**, 354
- 2,2-Disubstituted 4(*R*)-thiazolidinecarboxylic acid, **64**, 25
- 2,5-Di-(D-*arabino*-tetritol-1-yl)pyrazine, formation from glucose, **68**, 381  
from browning of D-glucose in the presence of ammonia, **68**, 380
- 1,4-Dithiacines, ring contraction, **65**, 82
- 1,5-Dithiacyclononenes, from carbenes on 1,3-dithianes, **65**, 195
- Dithiacyclophanes, loss of sulfur, **65**, 77
- 1,3,2,4-Dithiadiazoles- by reduction of 1,3,2,4-dithiadiazolylum salts, **62**, 209  
by reaction of chlorosulfonyl chlorides with sulfur diimides, **62**, 209  
from tricyanomethane and dithianitronium ions, **62**, 210  
ESR spectra, **62**, 210  
magnetic studies, **62**, 213  
theoretical studies, **62**, 213  
X-ray diffraction, **62**, 214  
radical formation and rearrangement, **62**, 216  
radical formation and polymerisation, **62**, 217  
adducts of non-radicals with metal ions, **62**, 218  
alkylation of non-radicals, **62**, 218
- 1,2,3,5-Dithiadiazolyl chloride, preparation from nitrile and sulfur dichloride, **62**, 149  
preparation from amidines and sulfur dichloride, **62**, 150  
preparation from tetrachloroethylene and thionyl chloride, **62**, 152  
preparation from aldazines, **62**, 153  
preparation from trichloroacetic anhydride, **62**, 153  
preparation from bis(trimethylsilyl)carbodiimide and sulfur dichloride, **62**, 153  
spectra and calculated structure, **62**, 154  
structure of nickel complexes, **62**, 158  
nmr spectral shifts, **62**, 158  
UV/visible spectra, **62**, 159  
electrochemistry, **62**, 161  
ESR spectrum, **62**, 162  
X-ray diffraction, **62**, 162  
structure of salts with hard anions, **62**, 163  
structure of salts with soft anions, **62**, 165  
structure of mixed salts, **62**, 168  
structure of partially reduced salts, **62**, 168

- metathesis, **62**, 170  
hydrolysis, **62**, 171  
reaction with nitrogen plasma, **62**, 174  
1,2,3,5-Dithiadiazolyl radicals, theoretical studies, **62**, 175  
ESR spectrum, **62**, 177  
photoelectron spectrum, **62**, 177  
conductivity, **62**, 179  
magnetism, **62**, 182  
electron diffraction, **62**, 183  
X-ray diffraction, **62**, 183  
oxidation, **62**, 189  
radical coupling, **62**, 190  
reaction in nitrogen plasma, **62**, 192  
reaction with metal complexes, **62**, 192  
1,2,3,5-Dithiadiazolylium cation, **62**, 146, **62**, 148  
1,3,2,4-Dithiadiazolylium-1,2,3,5-dithiadiazoyl radicals, **62**, 238  
ESR spectrum, **62**, 239  
magnetism, **62**, 239  
1,3,2,4-Dithiadiazolylium salts, from nitriles and dithianitronium salts, **62**, 198  
from thioamides and  $\text{NSCl}_3$ , **62**, 200  
from bromine and  $\text{S}_4\text{N}_4$ , **62**, 201  
theoretical studies, **62**, 201  
NMR, **62**, 202  
electrochemistry, **62**, 204  
X-ray diffraction, **62**, 205  
reduction, **62**, 207  
metathesis, **62**, 208  
hydrolysis, **62**, 208  
1,2,3,5-Dithiadiazolyls, preparation from 1,2,3,5-dithiadiazolylium salts, **62**, 174  
by rearrangement of 1,3,2,4-dithiadiazolyl radicals, **62**, 175  
Dithiadiazolyls, X-ray crystal structure, **62**, 142  
1,3-Dithianes- from carbene reactions, **65**, 193  
Dithianitronium cation, **62**, 195  
hexafluoroarsenate, **62**, 195  
preparation, **62**, 195  
reaction with alkynes, **62**, 196  
reaction with alkenes, **62**, 197  
reaction with phosphalkynes, **62**, 197  
reaction with unsaturated inorganics, e.g.,  $\text{S}_4\text{N}_4$ , **62**, 197  
reaction with nitriles, **62**, 198  
reaction with tricyanomethane anion, **62**, 210  
Dithiatetrazocines, **62**, 150  
1,4,2-Dithiazines, loss of sulfur, **65**, 70  
Dithiazolobenzobisimidazolediones, **69**, 287  
Dithieno[*b,f*]azepines, from enaminones and ethyl 2-mercaptoacetate, **67**, 323  
Dithieno[2,3-*d*]pyrimidine-7-thiones, **66**, 209  
Dithieno[*b,b'*]-tropone, **64**, 96  
Dithienotropones, **64**, 100  
X-ray diffraction, **66**, 286  
UV spectrum, **66**, 301  
IR spectrum, **66**, 302  
Dithienotropylium ions, X-ray diffraction, **66**, 311  
Dithienotropylium salts, **64**, 129  
(*z*)-1,2-Dithienylethylenecarboxylic acids, cyclisation, **64**, 96  
1,2-Dithiins, desulfurisation by reaction with carbenes, **65**, 59  
1,3-Dithiins, from carbene reactions with trithiapentalene, **65**, 192  
1,4-Dithiins, sulfur extrusion to thiophenes, **65**, 60  
1,4-Dithiocins, from carbenes on 1,3-dithiolanes, **65**, 194  
Dithiolanes, loss of sulfur, **65**, 81  
1,2-Dithiolanes, ring contraction, **65**, 75  
1,3-Dithiolanes, reaction with carbenes, **65**, 194  
Dithiolanethiones, **65**, 185  
Dithiolanones, **65**, 185  
[1,2]Dithiolo[3,4-*c*]quinolin-1-ones, **68**, 208  
Dithiooxamide, reaction with trichlorophenylmalonates, **66**, 133  
double cyclisation to 2,2'-bithiazole, **67**, 33  
reaction with oxalbisphenylimidoyl chloride, **67**, 34  
Dithiourethanes, cyclisation to 1,3-thiazin-4-ones, **66**, 137  
Dithioformycin B, **70**, 236  
Ditiazem, synthesis via reaction of cyclic sulfite with *o*-aminothiophenol, **68**, 163  
4,5-Di-*p*-tolylimidazo-2-thioacetic acid, ring closure, **69**, 283  
5,6-Di-*p*-tolylimidazo[2,1-*b*]thiazole-3(2*H*)-one, **69**, 283  
3,4-Di-(trifluoromethyl)-1,2-dithiete, reaction with acetylenes, **65**, 61  
3,5-Di-(trifluoromethyl)-4-phenylpyrazole, **65**, 174  
3,6-Ditrifluoro-1,2,4-triazine *C*-nucleoside, inverse [4+2] cycloaddition reactions, **68**, 343



- Ditropolonofuran, aromaticity, **66**, 308  
Ditropopyrrole, reaction with nitric acid, **66**, 350  
2,3-Divaleryloxy-1,1-dimethoxypropane, as a precursor in the synthesis of acyclonucleosides, **68**, 60  
Divinyl adipate, polymeric structures with 1,2,4-triazoline-3,5-diones, **67**, 187  
Divinytellurides, **63**, 15  
Dodecahydro-3,3'-bi-1*H*, 3*H*-pyrido[1,2-*c*][1,3]oxazines, **70**, 55  
reduction with sodium amalgam, **70**, 59
- EHNA see *erythro*-9(2-hydroxy-3-nonyl)adenine  
Eilatin, **70**, 96, 116  
Elaeocarpus alkaloids, synthesis, **67**, 247  
Ellipticine, synthesis from indolo[1,2-*b*][2,7]naphthyridine-5,12-quinone, **61**, 190  
Enamine from iminophosphoranes, **64**, 178  
Endosulfan, use as an insecticide, **68**, 168  
Enecarbamates, Friedel-Crafts reaction with acid chlorides, **67**, 216  
Enol silanes, conversion to  $\alpha$ -aminoketones, **69**, 11  
(+)-Epichlorohydrin, alkylation of purines, **68**, 21  
(-)-Epilupinine, **65**, 127  
Epimyrine, synthesis, **67**, 286  
(+)-3-Epinupharamine, synthesis, **69**, 122  
Epipodophyllotoxin, **65**, 348  
6-Epithienamycin, **65**, 108  
5,6-*exo*-Epoxy-7-oxabicyclo[2,2,1]heptan-2-one, in synthesis of cordycepin C, **70**, 251  
1,4-Epoxytribenzotroponone, reaction with 3,6-diphenyltetrazine, **64**, 115  
Eritadenine, biological properties, **68**, 74  
2-( $\alpha,\beta$ -D-Erythrofuranosyl)imidazole, preparation, **68**, 278  
Erythromycin cyclic sulfite derivative as antimicrobial agent, **68**, 168  
5-Ethenyl-2-pyrones, **65**, 325  
6-Ethoxy-2-azaazulene, **66**, 343  
2-Ethoxy-1,4-benzodiazepine-5-ones, **64**, 227  
3-Ethoxy-1-benzopyrylium salts, reaction with phenylmagnesium bromide, **65**, 290  
2-Ethoxy-1,3-benzoxazin-4-one, **64**, 210  
2-Ethoxycarbamoylthiophene-3-carboxamides, cyclisation, **65**, 246  
2-Ethoxycarbamoylthiophene-3-carboxylates, reaction with primary amines, **65**, 246  
C-Ethoxycarbonyl-*N*-(benzimidazolyl)hydrazonoyl chlorides, reaction with phenylhydrazine, **63**, 319  
3-Ethoxycarbonylcoumarin, reaction with Grignard reagents, **65**, 299  
cycloaddition with diazoalkanes, **65**, 320  
reaction with lithium diallylcuprate **65**, 299  
2-Ethoxycarbonylcyclohexanone, formation of pyrido[3,2-*a*]acridines, **70**, 93  
9-Ethoxycarbonyl-5*H*, 13*H*-2',3'-dihydrospiro[benzimidazole-6,2'-pyrazolo][1',5':3,4][1,2,4]triazino[5,6-*b*][1,5]benzodiazepine hydrochloride, **61**, 301  
4-Ethoxycarbonyl-2,7-diisopropyl-5-methylthiepin, sulfur extrusion, **65**, 46  
1-Ethoxycarbonyl-9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2,4-dione, **70**, 66  
*N*-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, as coupling agent, **69**, 149  
*N*-[ $\beta$ -(Ethoxycarbonyl)ethyl]-*N*-[4-methoxyphenyl]glycinate, precursor to pyrroles, **64**, 7  
C-Ethoxycarbonyl-*N*-heteroarylhydrazonoyl chlorides, cyclisation, **63**, 302  
Ethoxycarbonyl hydrazones, oxidation, **69**, 42  
2-Ethoxycarbonyl-1-(2-hydroxyethyl)tetrahydroisoquinolines, cyclisation, **70**, 54  
2-[(Ethoxycarbonyl)methoxy]-3-formylpyrido[1,2-*a*]pyrimidin-4-one, **63**, 184  
*anhydro*-3-Ethoxycarbonyl-2-methyl-4-hydroxy-5,6,7,8-tetrahydropyrido[1,2-*b*]pyridazinium hydroxide, **69**, 100  
3-Ethoxycarbonyl-2-methyl-2-(*D*-arabino-tetritol-1-yl) pyrrole, **68**, 254  
9-Ethoxycarbonyl-6-oxo-5,6-dihydropyrazolo[[1',5':3,4][1,2,4]-triazino[5,6-*b*][1,5]benzoxazepine, **61**, 301  
3-Ethoxycarbonyl-4*H*-pyran, reactions of, **62**, 102  
3-Ethoxycarbonyl-2-pyrones, reaction with 2-(trialkylsilyl)oxydienes, **65**, 350

- 2-Ethoxy-1,3-diazaazulenes, nucleophilic reactions on, **64**, 89
- 2-Ethoxy-2,3-dihydro-1,3-benzothiazin-4-one, loss of ethanol and Diels-Alder reaction with dienes, **66**, 183
- 2-Ethoxymethyleneaminothiophene-3-carbonitriles, reaction with amines and heating, **66**, 206
- 2-Ethoxymethyleneimino-3-carbonitriles, precursor to pyrano[2,3-*d*]pyrimidin-3-yl ureas, **64**, 212
- 2-Ethoxymethylenethiophene-3-carboxylates, reaction with arylamines, **65**, 245
- 2-Ethoxy-2-methyl-3(2*H*)furanone, **65**, 149
- 5-Ethoxy-2-methyl-4-trifluoromethyl-1,3-oxazole, **65**, 180
- 2-Ethoxy-2-methyl-5-(2'-uracilyl)-1,3-dioxanes, conformations, **69**, 238
- 2-Ethoxy-1,3,4-oxadiazoles, synthesis, **69**, 42
- 2-Ethoxy-5-(2'-uracilyl)-1,3-dioxane, conformations, **69**, 238
- Ethyl 3-(7-(4-acetyl-3-hydroxy-2-propylphenoxy)methyl)-4-oxo-pyrido[1,2-*a*]pyrimidin-3-yl]propionate, **63**, 206
- Ethyl 3-adenin-9-yl-2-hydroxypropanoate, as antiviral agents, **69**, 181
- Ethyl 3-aminocarbonyl-6-methyl-1,6,7,8-tetrahydro-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-9-carboxylate, structure, **63**, 194
- Ethyl 4-(2-amino-6-chloropurin-9-yl)-2-hydroxybutyrate, **68**, 76
- Ethyl 3-aminocrotonate, condensation with *D*-gluconoyl isothiocyanate pentaacetate, **68**, 376
- Ethyl *cis*-or *trans*-2-amino-1-cyclohexanecarboxylate, reaction with isothiocyanates, **69**, 457
- Ethyl *trans*-2-amino-1-cyclohexanecarboxylates, reaction with potassium cyanate, **69**, 392
- Ethyl 6-amino-4,5-difluoro-1-methyl-7-oxo-1*H*, 7*H*-pyrido[3,2,1-*ij*]cinnoline-8-carboxylate, preparation, **69**, 107
- Ethyl 2-amino-4,5-dihydrothiophene-3-carboxylate, reaction with chlorosulfonylisocyanate, **66**, 197
- Ethyl 2-amino-4,5-dimethylthiophen-6-carboxylate, reaction with triethyl orthoformate and hydrazine, **66**, 199
- Ethyl 2-aminofuro[*b*]tropone-3-carboxylate, base hydrolysis, **66**, 357
- Ethyl 5-amino-2-(1-*N'*-methylhydrazino)thieno[2,3-*d*]pyrimidine-6-carboxylate, **66**, 228
- Ethyl 5-amino-2-methylthio-4-phenylthieno[2,3-*d*]pyrimidine-6-carboxylate, **66**, 218
- Ethyl 2-amino-4*H*-pyrano-3-carboxylate, precursor to pyrano[2,3-*d*]pyrimidines, **64**, 212
- Ethyl 2-aminothiophene-3-carboxylate, heat with phenylisothiocyanate to give thieno[2,3-*d*]pyrimidin-4(3*H*)one-2(1*H*)-thiones, **66**, 195
- Ethyl *N*-aryl-3-cyano-4-ethyl-2-oxopyridazin-5-carboxylate, reaction with benzylidenemalononitriles, **68**, 188
- Ethyl *N*-aryl-3-cyano-4-methyl-5-carboxylate, reaction with dimethylformamide dimethylacetal, **68**, 194
- reaction with carbon disulfide, **68**, 195
- Ethyl-1-aryl-4-hydroxypyrazole-3-carboxylate, synthesis, **69**, 37
- Ethyl  $\alpha$ -azido- $\beta$ -hydroxy-4-methylpentanoate, via reaction of azide ion and cyclic sulfate, **68**, 158
- Ethyl 5,6-benzochromone-2-carboxylate, ring chain tautomerism, **64**, 282
- Ethyl benzooxepan-3-one-2-carboxylate, **65**, 159
- Ethyl-[(2-benzoxazolyl)amino]thiophene-3-carboxylates, hydrolysis and cyclisation, **66**, 196
- Ethyl 9-benzyloxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate-saponification, **63**, 174
- r*-2,*c*-4*a*, *t*-5,*c*-8-*H*-2-Ethyl-5-benzyloxy-8-propylperhydropyrido[1,2-*b*] [1,2]oxazine, conformational equilibrium, **69**, 91
- Ethyl 4-bromo-2-hydroxybutyrate, reaction with purines, **69**, 155
- Ethyl 2-bromomethylthiazol-4-carboxylate, in synthesis of acyclonucleosides, **69**, 202
- Ethyl 4-(4-*tert*-butoxycarbonyl-1-piperazinyl)-5-fluoro-2,3-dihydro-1-methyl-2,7-dioxo-1*H*, 7*H*-pyrido[3,2,1-*ij*]cinnoline-8-carboxylate, crystal structure, **69**, 123

- Ethyl 2-butoxy-2,3-dihydrofuran-3-carboxylate, **65**, 151
- Ethyl 2-*N*-butyl-3,5-dimethylpyrrole-3-carboxylate, **64**, 14
- Ethyl carboethoxyformamdate, precursor for 4(5)aminoimidazoles, **61**, 11
- Ethyl 2(5-carboxy-2-pyridyl)-5-oxo-2,5-dihydroisoxazole-4-carboxylate, **63**, 140
- Ethyl 7-chloro-3-(2'-fluoro-4'-bromobenzyl)thieno[3,4-*d*]pyrimidin-2,4-dione-1-acetate, **66**, 270
- Ethyl 2-chloro-6-methyl-4*H*-pyrido[1,2-*a*]pyrimidine-3-acrylate-reaction with amines, **63**, 185
- Ethyl chroman-2-carboxylate, ring chain tautomerism, **64**, 282
- Ethyl 3-cyanoacrylate, Michael reaction to enamines, **67**, 229
- Ethyl *N*-(3-cyano-4,5-dihydro-2-thienyl)oxamates, reaction with methyl cyanoacetate, **66**, 205
- Ethyl 3-cyano-3-methyl butyrate, reaction with hydrazine en route to pyridazin [6,1-*c*][1,2,4]triazines, **61**, 235
- Ethyl  $\alpha$ -cyano-4-[2-methylthienopyrimidine]acetates, **66**, 211
- Ethyl 2-diazo-6-hydroxy-3-oxoheptanoate, cyclisation, **65**, 155
- Ethyl diazomalonate, reaction with *N*-phenylmaleimide and *N*-methylbenzylidene imine, **65**, 113
- Ethyl 4-diazo-2-*R*-3-oxobutyrate, decomposition, **65**, 149
- Ethyl 2-diazo-3-oxo-5-mercaptopentanoate, decomposition, **65**, 163
- Ethyl diazopyruvate, copper catalysed decomposition with benzonitrile, **65**, 179  
decomposition in presence of butadiene, **65**, 159
- Ethyl 6,7-difluoro-4-hydroxy-8-(2-hydroxyethyl)quinoline-3-carboxylate, oxidation, **69**, 109, **69**
- Ethyl *N*-(difluoromethyl)-2,2-diphenylaziridine-3-carboxylate, **65**, 100
- Ethyl 4,5-difluoro-7-oxo-2,3-dihydro-7*H*-pyrido[3,2,1-*ij*][2,1]benzoxazinone-6-carboxylate, **69**, 109
- 4-(6-Ethyl-6,7-dihydro-3-aryl-4-oxo-4*H*-pyrido[2,1-*a*]phthalazine-1-carbonyl)morpholine, **69**, 101
- Ethyl 1,2-dihydroisoquinoline-3-carboxylate, **65**, 127
- Ethyl 7,8-dihydrorutecarpine-7-carboxylate, **64**, 218
- Ethyl 9-(dimethylaminomethylene)-4-oxo-6,7,8,9-tetrahydropyrido[1,2-*a*]pyrimidine-3-carboxylate, reaction with clayfen, **63**, 215
- 2-Ethyl-5,5-dimethyl-1,3-dioxan-4,6-dione, conformation, **69**, 246
- Ethyl 2,7-dimethylimidazo[2,1-*a*]isoquinoline-3-carboxylates, **65**, 176
- Ethyl 3,5-dimethylimidazole, **69**, 281
- Ethyl 5,7-dimethyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate, **63**, 231
- 3-Ethyl-2,6-dimethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one hydrochloride-thermal stability, **63**, 174
- Ethyl 2,4-dioxy-7-nitro-pyrido[1,2-*a*]pyrimidine-3-carboxylate-, **63**, 140
- 4,5-Ethylenedithio-4'-methyltetraathiafulvalene, lithiation, **62**, 256
- Ethylene glycol monobenzoate, precursor in preparation of acyclonucleosides, **68**, 57
- 1-Ethyleneperhydro[1,3]oxazino[3,4-*a*]isoquinolines, **70**, 56
- Ethylene sulfite, calculation of torsional angle, **68**, 91  
coupling constants, **68**, 91
- Ethyl *N*-ethoxycarbonyl-*N*-(2-ethoxycarbonyl)glycinate, use in the synthesis of pyrroles, **64**, 7
- Ethyl 2-ethoxymethyleneamino-3-thiophenecarboxylate, reaction with hydrazine, **65**, 245
- Ethyl 2-ethoxymethyleneimino-4,5-dimethylthiophene-3-carboxylate, **66**, 199
- Ethyl 3-ethyl-2-methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylate, reaction with amines, **63**, 205
- Ethyl 9-(*N*-ethyl-*N*-phenylcarbamoylthio)-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, **63**, 211
- O*-Ethylfagaronine, synthesis, **67**, 374
- Ethyl 3-(2'-fluoro-4'-bromobenzyl)thieno[3,4-*d*]pyrimidin-2,4-dione-1-acetate, chlorination in 7,8 positions, **66**, 270

- Ethyl 5-fluoro-4-[cyano(ethoxycarbonyl)methyl]-2,3-dihydro-1-methyl-7-oxo-1*H*, 7*H*-pyrido[3,2,1-*ij*]cinnoline-8-carboxylate, hydrolysis, **69**, 107
- Ethyl formyldiazoacetate, reaction with *n*-butylvinyl ether, **65**, 151
- Ethyl formylhippurate, conversion to 4-hydroxyquinoline, **64**, 48
- Ethyl 4,5,6,7,8,8*a*-hexahydro-3*H*-quinolizine-1-carboxylate, **70**, 38
- Ethyl 7-hydroxyindole 1,4-dicarboxylate, **63**, 347
- $\alpha$ -Ethylidene(*Z*)-1*H*-indole-2-acetonitrile, reaction with 2-ethylprop-2-enal, **63**, 378
- r*-4*a*, *c*-5*a*, *t*-9*a*-*H*-1-Ethylideneperhydro[1,3]oxazino[3,4-*b*]isoquinoline, hydrolysis, **70**, 31
- Ethyl imidazo[2,1-*b*]thiazole-6-carboxylate, reaction with hydrazine hydrate, **69**, 298
- Ethyl 5-iminoimidazo[2,1-*b*]thiazole-6-carboxylate, **69**, 288
- trans*-2-Ethyl-3-iodotetrahydrofuran, synthesis, **69**, 26
- N*-Ethylisothiazolone, reaction with diazomalonoester, **66**, 148
- Ethyl 2-isothiocyanato-1-carboxylates, **69**, 395
- Ethyl 2-mercapto-5-methyl-imidazole-4-carboxylate, **69**, 280
- Ethyl 9-mercapto-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, **63**, 211
- Ethyl 2-methyl-4-hydroxy-5,6-dihydro-4*aH*-pyridazino[1,6-*a*]quinoline-3-carboxylate, **69**, 116
- Ethyl 2-methyl-4-hydroxy-5,6,7,8-tetrahydro-4*aH*-pyrido[1,2-*b*]pyridazine-3-carboxylate, dehydrogenation, **69**, 100
- Ethyl -2-(1-methyl-2-indolyl)acrylate, reaction with dihydropyridine, **63**, 378
- Ethyl 7-methyl-9-nitro-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, **63**, 143
- Ethyl 4-(6-methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidin-2-yl)butanoate, **63**, 133
- Ethyl 2-methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-7-carboxamide-, **63**, 134
- Ethyl 6-methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate- structure, **63**, 117
- Ethyl 2-methyl-4-oxo-3,4,5,6-tetrahydro-4*aH*-pyridazino[1,6-*a*]quinoline-3-carboxylate, thermolysis, **69**, 104
- Ethyl 3-methyl-6-phenylimidazo[2,1-*b*]thiazole-2-carboxylate, reaction with dimethyl acetylene dicarboxylate, **69**, 294
- 3-Ethyl-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-thione, **63**, 204
- 4-Ethyl-5-methyl-2-pyrone, annulation with trimethylenemethane Pd(0) complex, **65**, 364
- Ethyl-6-methyltetrahydropyran-3-one-2-carboxylate, **65**, 155
- Ethyl 2-methylthio-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, **63**, 152
- reaction with ethyl mercaptoacetate, **63**, 200
- 2-Ethylloxane, simulated <sup>13</sup>C NMR spectra, **69**, 229
- Ethyl 3-oxo-4-phenyl-1,4-oxazine-3-carboxylate, **65**, 188
- Ethyl 7-oxo-1*H*, 3-*H*, 7*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine-6-carboxylates, hydrolysis, **70**, 37
- Ethyl 4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, **63**, 142
- Ethyl 8-oxo-8*H*-pyrido[1,2-*c*]pyrimidine-6-carboxylate, **70**, 68
- Ethyl 2-oxo-6,7,8,9-tetrahydro-2*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylate, Vilsmeier-Haack formylation, **63**, 172
- cis*-4*a*, 7-*H*-7-Ethyl-perhydropyrido[1,2-*c*][1,3]oxazine, conformations, **70**, 11
- NMR spectra and conformations, **70**, 12
- 4-(Ethyl-*N*-phenyl)amino-2*H*-pyrido[1,2-*a*]pyrimidin-2-one, catalytic reduction, **63**, 171
- Ethyl 3-phenyl-6-*p*-chlorophenylimidazo[2,1-*b*]thiazole-2-carboxylate, X-ray structure, **69**, 300
- Ethyl-2-phenyl-1,3-oxazole-5-carboxylate, **65**, 180
- trans*-4*a*-*H*-7-Ethylphenylperhydro[1,2-*c*][1,3]thiazine, infrared spectroscopy, **70**, 18
- <sup>1</sup>H NMR spectroscopy, **70**, 18
- <sup>13</sup>C NMR spectroscopy, **70**, 20
- Ethyl  $\alpha$ -phenylsulfodiazooacetate, reaction with nitriles, **65**, 180
- Ethyl *N*-(phenylthiomethyl)amino acids-reaction with unsaturated esters, **64**, 10

- Ethyl 3-pyrrolidinocrotonate, reaction with ketenes, **67**, 262
- Ethyl 3-( $\beta$ -D-ribofuranosyl)propynoate, reaction with ammonium dithiocarbamate, **68**, 389
- 3-[3-Ethyl(4-substituted-piperidine)thieno[3,2-*d*]pyrimidine-2(1*H*),4(3*H*)-diones, **66**, 238
- Ethyl DL-tartrate, in preparation of acyclonucleosides, **68**, 74
- Ethyl tetrahydrothiophen-3-one-2-carboxylate, **65**, 163
- Ethyl thieno[2,3-*d*]pyrimidine-6-carboxylate, hydrolysis, **66**, 225
- 4-Ethyl-5-(*p*-tolylazo)tropolone, cyclisation to pyrazolotropolone, **64**, 102
- 10-Ethyl-10*H*[1,2,4]triazolo[3',4':3,4][1,2,4]triazino[5,6-*b*]indole, preparation, **61**, 291
- Ethyl 4,5,6-trifluoro-1-methyl-7-oxo-2,3-dihydro-1*H*, 7*H*-pyrido[3,2,1-*ij*]cinnoline-8-carboxylate, regiospecific displacement of 6-fluoro atom, **69**, 103
- Ethyl 4,5,6-trifluoro-1-methyl-7-oxo-1,2,3,7-tetrahydro-1*H*, 7*H*-pyrido[3,2,1-*ij*]cinnoline-8-carboxylate, reaction with malonate salts, **69**, 104
- 3-Ethyl 1,2,6-trimethyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidinium iodide, **63**, 182
- Ethyl vinyl ether, polymerisation with 4-phenyl-1,2,4-triazoline-3,5-dione, **67**, 187
- 2-Ethynyl-7*a*-hydroxy-3*a*, 7-dimethyl-4,6-diphenylperhydropyrrolo[3,2-*c*]pyridines, ring chain tautomerism, **64**, 286
- 5-Ethynyl-2-pyrones, **65**, 325
- Eudistone A and B, **70**, 99, 116
- Euglenapterin, *see* 2-dimethylamino-6-(1-*threo*-tritol-1-yl)pteridin-4-one
- Exomethylenetetrahydropyridines, from enamines, **67**, 273
- Ezomycins B<sub>1</sub>, B<sub>2</sub>, C<sub>1</sub>, C<sub>2</sub>, D<sub>1</sub>, D<sub>2</sub>, isolation and structures, **68**, 362
- Ezomycins, **68**, 226
- Fagaronine, **67**, 345  
activity against P388 and L1210 cell lines, **67**, 347  
synthesis, **67**, 362; **67**, 374; **67**, 383
- Famciclovir, *see* 9-[4-acetoxy-3-(acetoxymethyl)butyl]-2-aminopurine
- Fauronylacetate, **65**, 356
- Ferrocenotropolone, NMR spectra, **66**, 288
- Ferrocenotropone, NMR spectra, **66**, 288
- Fervenuin, preparation, **61**, 252  
pyrimidine ring cleavage, **61**, 259
- Fervenuin-4-oxide, ring cleavage, **61**, 259  
1,3-dipolar cycloaddition, **61**, 259
- FGAR *see* (*N*-formyl)-glycinamide ribotide
- Flavanols, preparation, **69**, 72
- Flavanones, conversion to isoflavones, **69**, 69
- Flavazol-3-yl acyclo C-nucleosides, **70**, 289
- iso*-Flavones, from flavanones, **69**, 69
- N*-Fluorenylmethyloxycarbonylamino acids, reaction with aldehydes, **64**, 22
- N*-Fluoroalkyltetrachloroaziridines, **65**, 99
- 9-Fluoro-10-(cyclic amino)-7-oxo-1*H*-3*H*-7*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine-6-carboxylic acids, antibacterial activity, **70**, 75
- 5-Fluorocytallene, preparation, **69**, 197
- 1-Fluoro-1-deoxyephedrine, synthesis by reaction of a cyclic sulfamate with fluoride ion, **68**, 147
- 2-(2'-Fluoro-2',3'-dideoxy- $\beta$ -D-xylofuranosyl)imidazo[4,5-*d*]pyrimidine, **70**, 252
- Fluorofurans, **65**, 152
- 5-Fluoro-4-hydroxy-2,3-dihydro-1-methyl-7-oxo-1*H*, 7*H*-pyrido[3,2,1-*ij*]cinnoline-8-carboxylic acid, preparation, **69**, 103
- 4-Fluoroimidazole, from 4(5)-nitroimidazole by reduction and diazotisation in tetrafluoroboric acid solution, **61**, 7
- $\alpha$ -Fluoroketones, **62**, 7
- (2*s*)-1-Fluoro-3-(*R*)-[(4-methylphenyl)sulfinyl]-2-propanol, as a precursor of acyclonucleosides, **68**, 16
- 2-Fluorooxane, calculated conformational equilibria, **69**, 225
- 4-Fluoro-7-oxopyrido[3,2,1-*ij*]cinnoline-8-carboxylic acid, displacement of fluorine atom, **69**, 103
- 2-Fluoropyridine, **62**, 1
- N*-Fluoropyridinium salts, preparation, **62**, 2  
properties, **62**, 3  
reactivity, **62**, 4  
fluorinating agents, **62**, 5  
nucleophilic reactions, **62**, 9

- 3-Fluoroquinoline, **65**, 131  
*N*-Fluoroquinuclidinium fluoride, **62**, 5  
 2-Formamidothiazole, in synthesis of thiazolotriazoles, **69**, 326  
 2-Formamidothiophene-3-carboxamide, cyclisation to thienopyrimidinones, **65**, 243  
 Formycin *see* 7-amino-3-( $\beta$ -D-ribofuranosyl)pyrazolo[4,3-*b*]pyrimidine  
 Formycin B *see* 3-( $\beta$ -D-ribofuranosyl)-pyrazolo[4,3-*b*]pyrimidin-7-one  
 Formycin 6-oxide, in preparation of oxoformycin, **70**, 239  
 3-Formylaminothiophene-2-carboxylate, reaction with ammonia, **65**, 256  
 4-Formyl-2-azacycl[3,2,2]azine, synthesis from 5-methylimidazo[1,5-*a*]pyridine, **68**, 207  
 3-Formyl-4*H*-1-benzopyran-4-ones, **63**, 93  
 2-Formylbenzo[*b*]tellurophene, **63**, 26  
 5-Formyl-2,2'-bithiophene, X-ray structure, **67**, 11  
 5-Formyl-6-*p*-chlorophenylimidazo[2,1-*b*]thiazole, reaction with aminoguanidine, **69**, 298  
 3-Formylchromone, addition reactions, **65**, 293  
 2-Formylcyclohexanone, in synthesis of octahydrobenzophenanthroline, **70**, 91  
 reaction with phenylenediamine, **70**, 93  
*N*-Formyl-2-(2-deuterio-2-*p*-methoxyphenylethyl)piperidine, **70**, 32  
 4-Formyl-1,3-dimethoxyacridin-9(10*H*)-one, in preparation of hallacidone, **70**, 149  
 3-Formyl-4,6-dioxo-1,3,6-trimethylpyrimidine, condensation with Schiff bases, **68**, 189  
 reaction of 2 moles with amines, **68**, 190  
*N*-Formyl enamines, photolysis, **67**, 218  
 (*N*-Formyl)-glycinamidine, precursor of 5-aminoimidazole ribotide, **61**, 28  
 11-Formyl-10-hydroxybenzo[*b*][1,7]phenanthroline, cytotoxicity, **70**, 102  
 6-Formylimidazo[2,1-*b*]thiazole, conversion to thiosemicarbazone, **69**, 298  
 3-Formyl-2-methoxychromone, **65**, 353  
 4-Formyl-7-methoxy-2-methylbenzo[*b*]furan, in the synthesis of benzo[*c*]phenanthridine alkaloids, **67**, 358  
 3-Formyl-4-methoxy-2*H*-pyrido[1,2-*a*]pyrimidin-2-one, **63**, 126  
 5-Formyl-6-methylimidazo[2,1-*b*]thiazole, reduction, **69**, 295  
 3-Formyl-5-methyl-2,4,6-triphenyl-4*H*-pyran, **65**, 287  
 3-Formyl-2-phenylamino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 202  
*cis*-2,3,4-*H*-1-Formyl-2-(2-phenethyl)-3-substituted piperidin-4-ols, preparation, **70**, 39  
 4-Formyl-2-phenyl-1,2,3-triazole, **68**, 320  
*N*-Formylproline, 1,3-dipolar cycloaddition with propargylic aldehyde, **64**, 39  
 3-Formyl-4*H*-pyrans, **65**, 287  
 aldehyde type reactions, **62**, 100  
 1-Formylpyrazoline, ring chain tautomerism, **64**, 299  
 3-Formyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, Wittig reaction, **63**, 191  
 2-Formyl-2- $\beta$ -D-ribofuranosylacetato-nitrile, **70**, 220  
 2-Formyl-3-( $\beta$ -D-ribofuranosyl)propanoate enol ether, reaction with urea, **68**, 374  
 3-Formyl-4- $\beta$ -D-ribofuranosylpyrrole, expansion to pyrrolo[1,5-*d*]1,2,4-triazin-8-yl *C*-nucleosides, **70**, 296  
 9-Formyltetrahydro-2*H*-pyrido[1,2-*a*]pyrimidin-2-ones, tautomerism, **63**, 115  
 3-Formyltetrahydropyrido[1,2-*a*]pyrimidin-4-ones, protonation, **63**, 106  
 structure, **63**, 114  
 9-Formyl-1,6,7,8-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, reduction, **63**, 179  
 reaction with clayfen, **63**, 215  
 reaction with diazomethane, **63**, 218  
 tautomers, **63**, 220  
 Formyltetrahydrothiafulvalene, reduction, **62**, 260  
 reductive amination, **62**, 260  
 Wittig reaction, **62**, 260  
 preparation, **62**, 277  
 4-Formylthieno[2,3-*d*]pyrimidines, **66**, 220  
 3-Formyltropolone, condensation with hydrazines, **64**, 105  
 2-Formyl-1-ureidopyrrol-5-yl *C*-nucleoside, **70**, 296

- Fructosazine, *see* 2,5-di-(D-*arabino*-tetritol-1-yl)pyrazine,  
Fulminic acid, precursor of 5,5'-biisoxazole, **67**, 24  
Furan-3,4-dicarboxaldehyde, precursor to 4,4'-bipyrazole, **67**, 22  
2-Furanoyl chloride, palladium catalysed coupling with silanes to 2,2'-bifurans, **67**, 8  
Furanylboroxines, precursors to 3,3'-bifurans, **67**, 9  
Furazono[3,4-*d*]pyrimidine, in preparation of acyclovir, **69**, 135  
Furo[2,3-*a*]acridones, **70**, 145  
Furobenzofuranones, **65**, 303  
Furo-*p*-benzoquinonetropides, **66**, 386  
Furo[3,4-*c*][1,5]benzothiazepines, **63**, 69  
Furo[3,4-*b*][1,5]benzothiazepin-1-one, **63**, 69  
Furoditropolone, **64**, 117  
Furoditropones, **64**, 118  
Furoditropylium salts, reduction, **66**, 382  
Furofoline-1, **70**, 148  
Furo[2',3':4,5]imidazo[2,1-*b*]thiazolium-3-olate, reaction with acetylene carboxylates, **70**, 202  
Furo[2',3:4,5]imidazo[2,1-*b*]thiazolium-3-olate acyclo *C*-nucleoside acetate, formation, **70**, 192  
Furo[2,3-*d*]oxazolidin-5-yl acyclo *C*-nucleosides, **70**, 186  
Europaradine, **70**, 148  
Furo[3,2-*c*]pyridine, **62**, 396  
Europyridotriazinium salt, precursor to pyrido[1,2-*b*]pyridin[3,4-*c*][1,2,4]triazines, **61**, 309  
Furo[2,3-*d*]pyrimidin-6-one nucleosides, **62**, 327  
Furo[3,4-*c*]pyrroles, **65**, 117  
Furo[2',3':4,5]pyrrolo[1,2-*d*][1,2,4]triazolo[3,4-*f*][1,2,4]triazines, **61**, 295  
Furo[3,4-*c*]pyrrol-1-yl acyclo *C*-nucleoside, **70**, 167  
Furo[3,1-*e*]quinazolines, **64**, 219  
Furothienotropones, UV spectra, **66**, 301  
IR spectra, **66**, 304  
Furothienotropylium ions, electron densities by molecular orbital calculations, **66**, 379  
Furo[3,4-*d*]1,2,3-triazol-4-yl acyclo *C*-nucleosides, preparation, **70**, 197  
Furotropolones, UV spectra, **66**, 300  
molecular orbital calculations, **66**, 329  
pKa values, **66**, 330  
Furotropone, <sup>13</sup>C NMR spectra, **66**, 293  
mass spectra, **66**, 305, **66**, 306  
aromaticity, **66**, 307  
Furo[*a*]tropone, basicity, **66**, 331  
lithium aluminium hydride reduction, **66**, 337  
cycloaddition with dimethyl acetylene dicarboxylate, **66**, 364  
Furo[*b*]tropones, **64**, 99, **64**, 101  
chromium tricarbonyl complexes, **66**, 331  
Furotropylium ions, NMR spectra, **66**, 312  
IR spectra, **66**, 320  
electron densities, **66**, 379  
2-(2-Furyl)alcohols, conversion to pyranones, **69**, 66  
*C*-(2-Furyl)-*N*-(2-hydroxyalkyl)aldonitrines, ring chain tautomerism, **66**, 17  
6-(2'-Furyl)imidazo[2,1-*b*]thiazoles, bromination, **69**, 291  
*N*-Furyl-*N*-methyl diazoacetamide, **65**, 120  
2-(2-Furyl)-2-oxo-*N*-arylethanehydrazonoyl chloride, **63**, 290  
1-(2'-Furyl)-1,3-pentadiene, reaction with maleic anhydride, **63**, 359  
2-Furylpyridines, **62**, 12  
3-(2-Furyl)pyridine, from triflate of pyridin-3-ol and 2-furylzinc chloride, **62**, 377  
Galactaroyl 1,4-bis(4-arylthiosemicarbazide)acetates, cyclisation, **68**, 327  
D-Galactopyranose lepidin-2-yl reverse *C*-nucleoside, **70**, 208  
3-(β-D-Galactopyranosyl)-1,2,4-triazolo[4,3-*a*]pyrimidine, base induced Dimroth rearrangement, **70**, 256  
Galactoryl 1,4-bis(dithiocarbohydrazides)tetraacetates, dehydrocyclization, **68**, 337  
D-Galactose monothiocarbohydrazones, ring chain tautomerism, **66**, 34  
D-Galactose thiosemicarbazones, ring chain tautomerism, **66**, 20  
Gerparvarin, synthesis, **67**, 221

- Girolline, as anticancer agent from marine sponge, **61**, 5  
  enantiomeric synthesis, **61**, 5  
  racemic synthesis, **61**, 5  
Glucofurano[2,1-*d*]imidazolidines, preparation, **68**, 286  
3-( $\beta$ -D-Glucofuranosyl)pyridazines, **68**, 354  
D-Gluconoyl isothiocyanate pentaacetate, condensation with ethyl 3-aminocrotonate, **68**, 376  
  reaction with diazomethane, **68**, 301  
1-D-Gluconoylthiosemicarbazide, dehydrocyclization, **68**, 337  
D-Glucosamine, reaction with 1,3-dicarbonyl compounds, **68**, 69  
D-Glucose monothiocarbonohydrates, ring chain tautomerism, **66**, 34  
D-Glucose thiobenzoylhydrazone, ring chain tautomerism, **66**, 45  
D-Glucose thiosemicarbazone, ring chain tautomerism, **66**, 20  
L-Glyceraldehyde imine, reaction with lithiated 2-(*N,N*-diethylcarboxamido)toluene, **70**, 212  
2-(D-*erythro*-Glycerol-1-yl)pyrrole derivatives, **68**, 253  
Glycobisamines A-C, **70**, 127  
Glycitrine II, conversion to noracronycine, **70**, 134  
Glycofoline, **70**, 138  
2-( $\beta$ -D-Glycofuranosyl)furan, photooxygenation, **68**, 354  
2-(Glycofuranosyl)-2-isocyano-2-(4-tolylsulfonyloxy)ethene, reaction with amines, **68**, 280  
4-( $\beta$ -D-Glycofuranosyl)-4-oxobutyric acid derivatives, **68**, 354  
2-( $\beta$ -D-Glycofuranosyl)pyranones, **68**, 354  
Glycopyrano[2,1-*d*]imidazolidin-2-ones, **68**, 285  
Glycopyrano[2,1-*d*]imidazolidin-2-thiones, **68**, 285  
5-( $\alpha$ -Glycopyranosyl)uracil, **68**, 365  
5-( $\beta$ -Glycopyranosyl)uracil, **68**, 365  
Glycosylalkynyl ketones, reaction with hydrazines, **68**, 267  
C-Glycosylation of protonated pyridines, **68**, 343  
1,2-*trans*-Glycosyl azides, synthesis via azide attack on cyclic sulfates, **68**, 149  
Glycosyl cyanides, reaction with ammonium azide, **68**, 339  
2-Glycosylcyanoacetaldehyde, cyclocondensation with hydrazines, **68**, 269  
C-Glycosyldiazomethanes, reaction with dimethyl acetylene dicarboxylates, **70**, 211  
2-Glycosyl-1,3-diphenylimidazolidines, preparation, **68**, 278  
Glycosylethoxycarbonylmethyl ketone, reaction with hydrazines, **68**, 267  
5-Glycosylisoxazoles, preparation, **68**, 291,294  
3-Glycosylpropargaldehyde, reaction with hydrazines, **68**, 267  
3-Glycosylpropyn-1-ylaldehyde, reaction with hydrazines, **68**, 267  
3-Glycosylpyrazoles, preparation, **68**, 266, 267  
4-Glycosylpyrazoles, preparation, **68**, 269  
Glycosylthioformimides, reaction with 2-hydrazinopyridines, **70**, 202  
Glycosylvinyl ketone, reaction with hydrazines, **68**, 267  
*cis*-Glyoxal sulfate, dipole moment, **68**, 93  
Glyoxal sulfate, precursor to bisimidazoles, **68**, 156  
Gonibutenolides, synthesis, **68**, 144  
Gracridontriol, **70**, 146  
Gravacridondiol, **70**, 146  
Gravacridondiol acetate, **70**, 146  
Gravacridondiol monomethyl ether, **70**, 146  
Gravacridone chloride, **70**, 146  
Gravacridonol, **70**, 146  
Gravacridonolchloride, **70**, 146  
Griseofulvin, **65**, 143  
4-Guanidine-3-nitroquinolines, cyclisation to [1,2,4]triazino[6,5-*c*]quinoline-*N*-oxides, **61**, 227  
6-Guanidino-2-oxocaproic acid, ring chain tautomerism, **64**, 291  
5-Guanidino-2-oxovaleric acid, ring chain tautomerism, **64**, 290  
Hallacridone, **70**, 148  
*N*-Haloarylalkyl-substituted enamines, photocyclisation, **67**, 321



- N*-2-Haloaryl enamines, cyclisation to indoles, **67**, 241  
 cyclisation to carbazoles, **67**, 244
- 4-Halocoumarins- reaction with triethylphosphite, **65**, 317
- 1-Halo-1-deoxy-2-ketose acetates, reaction with thioamides, **68**, 316
- 2'-Halo-2'-deoxypyrimidin-5-yl C-nucleosides, **68**, 373
- 3-Halo-2,4-dimethylpyrido[1,2-*a*]pyrimidinium perchlorate, **63**, 124
- 2-Halogeno-5-arylfuran-3,4-dicarboxylates, **65**, 147
- 6-Halogenoimidazo[2,1-*b*][1,3,4]thiadiazoles, **69**, 306
- 3-Halogenopropionic acids, reaction with thioureas, **66**, 150
- 2-Halogenopyridine, **62**, 11, **62**, 12
- 3-Halogenopyridines, **65**, 131
- 3-Halogenoquinolines, **65**, 131
- 2-Haloimidazo[4,3-*a*]pyrimidines, **70**, 250
- 1-Haloisoquinoline, coupling to 1,1'-biisoquinoline, **67**, 56
- 3-Halomethylpyridines, reaction with derivatives of ethylene glycol, **68**, 352
- 2-Haloquinolines, homocoupling in presence of nickel catalysts, **67**, 52
- 3-Haloquinolines, homocoupling reactions, **67**, 53
- 4-Haloquinoline, homocoupling reactions, **67**, 54
- Halotetrathiafulvalenes, metal-halogen exchange, **62**, 274
- 2-Halotropones, ring contractions, **66**, 369
- Harringtonine alkaloids, synthesis, **67**, 231
- Hennoxazole, **67**, 32
- HEPT, *see* 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine
- C-(and *N*-)-Heteroarylhydrazonoyl halides, 1,3-dipolar cycloaddition reactions, **63**, 306
- 1,3-dipolar cycloadditions to *N*-arylmaleimides, **63**, 309  
 reaction with ethyl cyanoacetate, **63**, 314  
 reaction with benzoylacetonitriles, **63**, 314  
 reaction with malononitriles, **63**, 315  
 reaction with aniline, **63**, 316  
 reaction with thiourea and selenourea, **63**, 321  
 reaction with thiocyanates and selenocyanates, **63**, 322  
 reaction with potassium cyanide, **63**, 329  
 reaction with sodium benzenesulfinate, **63**, 331  
 reaction with triphenylphosphine, **63**, 333
- 2-Heteroarylpyridines, **62**, 10
- 1-Hetero-2-aza-1,3-dienes, **64**, 179
- Heterocyclic troponoids, uv spectra, **66**, 295
- Hexacyclo[6,5,1,0<sup>2,7</sup>, 0<sup>3,11</sup>, 0<sup>4,9</sup>10,14]tetradecane, **65**, 343
- O*-Hexadecylthiocarboxytetrathiafulvalenes, **62**, 279
- (*z*)-4-Hexafuranose-1-ylidene-5-oxazolone, preparation, **68**, 299
- Hexahydrobenzo[*c*]phenanthridine, in synthesis of benzo[*c*]phenanthridine alkaloids, **67**, 351
- Hexahydro-1,3-benzoxazines, synthesis, **69**, 374
- cis*-Hexahydro-1,3-benzoxazines, synthesis, **69**, 376
- trans*-Hexahydro-3,1-benzoxazines, synthesis, **69**, 376
- Hexahydro-2*H*-3,1-benzoxazines, synthesis, **69**, 378, 379  
 reaction with phosphorus pentasulfide, **69**, 383
- 4*a*,5,6,7,8,8*a*-Hexahydro-4*H*-3,1-benzoxazine, conformations, **69**, 417
- cis*-1,4,4*a*,5,8,8*a*-Hexahydro-2-*H*-3,1-benzoxazin-2-one, X-ray structure, **69**, 424
- Hexahydro-2*H*-3,1-benzoxazin-4-one, **69**, 380
- cis*-1,4,4*a*,5,8,8*a*-Hexahydro-2-*H*-3,1-benzoxazin-2-thione, X-ray structure, **69**, 424
- trans*-4*a*,5,6,7,8,8*a*-Hexahydro-2-(4-bromophenyl)-4(3*H*)-quinazolinone, X-ray structure, **69**, 438
- cis*-Hexahydrocyclopent[*e*][1,3]oxazin-2(3*H*)-one, X-ray structure, **69**, 423
- cis*-Hexahydrocyclopent[*e*][1,3]oxazin-2(3*H*)-thione, X-ray structure, **69**, 423
- trans*-Hexahydrocyclopent[*e*][1,3]oxazin-2(3*H*)-thione, X-ray structure, **69**, 423
- 2,3,4,5,6,7-Hexahydro-1*H*-1,4-diazepines, **64**, 227
- (4*α*,4*αβ*,7*αβ*)-Hexahydro-7*a*-hydroxy-4-phenylcyclopenta[*d*][1,3]thiazine-2(1*H*)-thione, X-ray structure, **69**, 434
- Hexahydroimidazonaphthyridines, **67**, 300
- Hexahydroimidazo[1,2,3-*i,jj*][1,8]naphthyridines, **67**, 300

- Hexahydroimidazo[1,2-*a*]pyridone, **67**, 295
- Hexahydroindolizidines, formation, **67**, 247
- Hexahydroindol-6-ones, preparation by oxidation of tyramines, **69**, 30
- (4 $\alpha$ ,5 $\beta$ ,8 $\beta$ ,8 $\alpha$ )-1,4,4a,5,8,8a-Hexahydro-5,8-methano-2*H*-3,1-benzoxazine-2-thione, X-ray structure, **69**, 428
- diendo*-4a, 5,6,7,8,8a-Hexahydro-3*H*-5,8-methano-quinazolin-4-ones, conformations, **69**, 419
- (2 $\alpha$ ,4 $\alpha$ ,7 $\alpha$ )-Hexahydro-2-methyl-2-phenylcyclopent[*e*][1,3]oxazin-4(4*H*)-one, X-ray structure, **69**, 430
- 1,2,3,3a,9,9a-Hexahydro-1-methyl-2-(trimethylsilyl)cyclopenta[*b*][1]benzopyran-9-one, **65**, 290
- 1,2,3,4,4a,5-Hexahydro-8-nitro-1*H*-pyridino[2,1-*c*][1,2,4]benzothiazine-6,6-dioxide, **65**, 28
- Hexahydro[1,3]oxazino[3,4-*b*]isoquinoline, NMR spectra and conformations, **70**, 13
- Hexahydro[1,3]oxazino[4,3-*a*]isoquinoline, conformations, **70**, 9
- 1,2,4,5,6,11*b*-Hexahydro[1,3-*a*]oxazino[4,3-*a*]isoquinoline, conformations by infrared spectroscopy, **70**, 19
- Hexahydro-3*H*-[1,3]oxazino[4,3-*a*]isoquinolin-1-one, **70**, 59
- 1,2,4,6,7,11*b*-Hexahydro[1,3]oxazino[4,3-*a*]isoquinolin-4-ones, **70**, 54
- Hexahydro[1,3]oxazino[3,4-*a*]quinoline, conformations and Bohlmann bands in the spectra, **70**, 9
- 1,2,3,5,6,7-Hexahydro-4-oxoindol-3-yl acyclic C-nucleosides, **70**, 172
- 1,6,7,8,9,9a-Hexahydro-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamide-*N*-alkylation, **63**, 183
- cis*-4a, 5,6,7,8,8a-Hexahydro-*N*-phenyl-4*H*-3,1-benzoxazine-2-amine, X-ray structure, **69**, 426
- trans*-4a, 5,6,7,8,8a-Hexahydro-2-phenyl-4*H*-1,3-benzothiazine, X-ray structure, **69**, 435
- cis*-4a, 5,6,7,8,8a-Hexahydro-*N*-phenyl-4*N*-3,1-benzothiazine-2-amine, X-ray structure, **69**, 434
- trans*-4,4a, 5,6,7,7a-Hexahydro-2-phenylcyclopenta[*e*][1,3]thiazine, X-ray structure, **69**, 435
- cis*-4a, 5,6,7,8,8a-Hexahydro-2-phenyl-4(3*H*)-quinazolinone, X-ray structure, **69**, 438
- trans*-4a, 5,6,7,8,8a-Hexahydro-2-phenyl-4(3*H*)-quinazolinone, X-ray structure, **69**, 438
- 2,3,4,6,7,11*b*-Hexahydro-1*H*-pyridazino[6,1-*a*]isoquinoline, **69**, 115
- 2,3,4a, 4,5,6-Hexahydro-1*H*-pyridazino[1,6-*a*]quinoline, **69**, 100
- catalytic reduction, **69**, 99
- benzoylation, **69**, 101
- 2,4a, 5,6,7,8-Hexahydropyrido[1,2-*a*][1,2]oxazines, reduction, **69**, 96
- cis*-4a, 8-*H*-1,3,4,4a, 7,8-Hexahydropyrido[1,2-*c*][1,3]oxazine-8-carboxylic acid, X-ray crystallography, **70**, 17
- cis*-3,4a-*H*1,3,4,4a, 5,6-Hexahydropyrido[1,2-*a*][1,3]oxazine-1,6-diones, **70**, 56
- Hexahydropyrido[1,2-*c*][1,3]oxazine-1,6-dione, reaction with Grignard reagents, **70**, 35
- 2,4a, 5,6,7,8-Hexahydropyrido[1,2-*b*][1,2]oxazin-8-one, hydrogenation, **69**, 97
- reaction with Grignard reagents, **69**, 97
- 3-(Hexahydro-1*H*-pyrido[2,1-*a*]phthalazin-3-yl)propionate, thermolysis to diazasteroid, **69**, 101
- 4,4a, 5,6,7,8-Hexahydro-3*H*-pyrido[1,2-*b*]pyridazine, **69**, 114
- catalytic reduction, **69**, 99
- Hexahydro-8*H*-pyrido[1,2-*b*]pyridazin-8-ones, NMR and conformations, **69**, 95
- preparation, **69**, 122
- 3,4,6,7,8,9-Hexahydro-2*H*-pyrido[1,2-*a*]pyrimidine, basicity, **62**, 106
- Hexahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-ones chloride, X-ray structure, **70**, 30
- protonation constant, **70**, 21
- 4,4a, 5,6,7,8-Hexahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-one, methylation, **70**, 45
- 1,6,7,8,9,9a-Hexahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 180
- theoretical and spectral studies, **63**, 112
- Hexahydro-6*H*-pyrido[1,2-*a*]pyrimidin-6-one, **63**, 164
- 2,3,4,4a, 5,6-Hexahydro-1*H*-pyrido[1,6-*a*]quinoline, **70**, 24
- Hexahydro-4*H*-pyrido[2,1-*b*][1,3]thiazin-4-one, **63**, 236

- Hexahydropyrimidines, conformational isomerisation, **69**, 401
- 2,3,4,6,7,11*b*-Hexahydro-2*H*-pyrimido [6,1-*a*]isoquinolin-2,4-dione, **70**, 69
- 1,2,3,6,7,11*b*-Hexahydro-4*H*-pyrimido [6,1-*a*]isoquinolin-2,4-dione, reaction with sodium hydride, **70**, 47
- 1,3,4,6,7,11*b*-Hexahydro-2*H*-pyrimido [6,1-*a*]isoquinolin-2-one, **70**, 65
- Bohlmann bands in infrared spectra, **70**, 24
- 1,3,4,5,6,7,11*b*-Hexahydro-2*H*-pyrimido [6,1-*a*]isoquinolin-4-ones, X-ray structure, **70**, 30
- 1,2,3,6,7,11*b*-Hexahydro-4*H*-pyrimido [6,1-*a*]isoquinolin-4-ones, **70**, 73
- 2,3,4,4*a*, 5,6-Hexahydro-1*H*-pyrimido [1,6-*a*]quinolin-1-one, **70**, 62
- 3,4,5,6,7,8-Hexahydroquinazolin-2(1*H*)-one, reaction with nitroacetic acid, **69**, 387
- cis*-Hexahydrospiro[2*H*-1,3-benzoxazine-2,1'-cyclopentan]-4(3*H*)-one, X-ray structure, **69**, 431
- cis*-Hexahydrospiro[cyclohept[*e*] [1,3]oxazine-2(3*H*),1'-cyclopentan]-4(4*a*-*H*)-one, X-ray structure, **69**, 431
- trans*-Hexahydrospiro[cyclohept[*e*] [1,3]oxazine-2(3*H*),1'-cyclopentan]-4(4*a*-*H*)-one, X-ray structure, **69**, 432
- cis*-Hexahydrospiro[cyclohexane-1,2'(1'*H*)-quinazolin]-4'(3'*H*)-one, X-ray structure, **69**, 437
- trans*-Hexahydrospiro[cyclohexane-1,2'(1'*H*)-quinazolin]-4'(3'*H*)-one, X-ray structure, **69**, 437
- 1,2,4,6,7,11*b*-Hexahydro[1,3]thiazino [4,3-*a*]isoquinoline, **70**, 61
- conformations by infrared spectroscopy, **70**, 19
- <sup>1</sup>H NMR spectroscopy, **70**, 18
- 1,3,4,4*a*, 5,10-Hexahydro[1,3]thiazino [3,4-*b*]isoquinoline-1-thione, **70**, 61
- reaction with methyl iodide, **70**, 40
- cis* and *trans*-1,1,2,3,3,4-Hexamethyl-1,3-disilacyclobutanes, **65**, 172
- dl*- and *meso*-2,5-Hexanediols, reaction with thionyl chloride, **68**, 108
- Hexapyrrins, **67**, 6
- 4-*n*-Hexyl-1,3,2-dioxathiolane 2,2-dioxide, reaction with lithium naphthalide, **68**, 138
- 2-Hexylpyridine, from 2-bromopyridine and *n*-hexylzinc, **62**, 375
- Hippuric acid, transformation into oxazolidin-5-one, **64**, 22
- reaction with 1,3-dicarbonyl compounds, **64**, 33
- Homopterocarpin, synthesis, **69**, 52
- Homopyrazofurin, synthesis, **68**, 270
- Homoserine- conversion to lactone, **64**, 16
- Homoshowdomycin, **68**, 250
- Honvumine, **70**, 138
- Hydrazinobis(iminophosphoranes), reaction with 1,3-diketones, **64**, 191
- 6-Hydrazino-1,3-dimethyluracil, precursor to pyrimido[5,4-*e*][1,2,4]triazin-4-oxide, **61**, 253
- 3-Hydrazino-5,6-diphenyl[1,2,4]triazine, reaction with phenacyl halides to triazinotriazines, **61**, 276
- 2-Hydrazino-4-hydroxy-6-methylpyrimidine, in preparation of 1,2,4-triazolo[4,3-*a*]pyrimidin-2-yl *C*-nucleosides, **70**, 259
- 1-Hydrazinoisoquinoline, precursor to [1,2,4]triazino[3,4-*a*]isoquinolines, **61**, 229
- 5-Hydrazinoisoxazolidin-3-ones ring chain tautomerism, **66**, 20
- 5-Hydrazino-2-isoxazolines tautomerism with 5-hydroxylamino-2-pyrazolines, **66**, 40
- 2-Hydrazino-7-methoxytropone, conversion to pyrrolotropolones, **64**, 123
- 2-Hydrazino-3 (or 5)-nitropyridines, formation of 1,2,4-triazolo[4,3-*a*]pyridin-3-yl *C*-nucleosides, **70**, 202
- 4-Hydrazino-7-phenylpyrazolo[1,5-*a*][1,3,5]triazine, reaction with ethyl pyruvate, **61**, 278
- 1-Hydrazinophthalazine, coupling with 2,5-anhydro-D-allonic acid, **70**, 217
- 3(5)-Hydrazinopyrazole condensation with malondialdehyde, **67**, 21
- 5-Hydrazino-2-pyrazolines ring chain tautomerism, **66**, 38
- 3-Hydrazinopyridazines, reaction with 2,5-anhydro-D-allonic acid derivatives, **70**, 215
- 2-Hydrazinopyrimidine, reaction with dimethyl acetylene dicarboxylate to give pyridotriazinones, **61**, 240
- reaction with 2,5-anhydro-D-allonodithioate, **70**, 257

- 4-Hydrazinothieno[2,3-*d*]pyrimidine, cyclocondensation reactions, **65**, 254
- 3-Hydrazino[1,2,4]triazine, reaction with arylidenepyruvic acid, **61**, 276
- 3-Hydrazino-5*H*-[1,2,4]triazino[5,6-*b*]indoles, reaction with ethyl acetoacetate, **61**, 294
- reaction with aldose monosaccharides, **70**, 177
- 3-Hydrazino[1,2,4]triazin-5-one, reaction with 3-iminobutyronitrile to give 3-[3-methyl-5-aminopyrazolyl]-2,5-dihydro[1,2,4]triazin-5-one, **61**, 278
- 3-Hydrazino-1,2,4-triazole reaction with diacetamide, **67**, 42
- 2-Hydrazono-5,6-dihydro-4*H*-1,3-thiazine, reaction with glyoxalic acid to triazinothiazines, **61**, 273
- 9-Hydrazonopyrido[1,2-*a*]pyrimidine-3-carboxylate, reaction with benzoylchloride, **63**, 223
- reaction with aldehydes, **63**, 223
- 9-Hydrazono-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 115
- 2-(1-Hydrazonotetritol-1-yl)quinoxalin-3-ones, **70**, 284
- Hydrazonoyl chlorides, by coupling of diazonium salts with activated chloromethylenes, **63**, 290
- 5-Hydroperoxy-5-alkoxyaldehydes ring chain tautomerism, **66**, 63
- 11-Hydroxyacididemin, synthesis, **70**, 120
- $\alpha$ -Hydroxyacids, synthesis from oxazines, **69**, 462
- 3-Hydroxyacridones, Claisen-type rearrangement, **70**, 131
- 5-Hydroxyacronycine, **70**, 135
- 5-Hydroxy-4-(alditol-1-yl)imidazolidines, preparation, **68**, 286
- N*-Hydroxyalkyl hydrazones ring chain tautomerism, **66**, 16
- N*-(Hydroxyalkyl)imidazoles, synthesis from ring opening of cyclic sulfites with imidazole, **68**, 156
- N*-Hydroxyalkyl imines ring chain tautomerism, **66**, 3
- spectra, **66**, 3
- thermodynamics, **66**, 4
- N*-Hydroxyalkyl nitrones ring chain tautomerism, **66**, 18
- $\alpha$ -Hydroxyalkylphenylphosphine, disproportionation to 1,3,5-dioxaphosphorinanes, **61**, 61
- (-)-3-Hydroxyallosedamine, **70**, 75
- (+)-4-Hydroxyallosedamine, **70**, 75
- 2-(Hydroxyamino)hexahdropyrido[1,2-*a*]pyrimidine, reaction with boron compounds, **63**, 240
- 2-Hydroxy-3-(2-aminophenylthio)-3-(4-methoxyphenyl)propionate, via ring opening of a cyclic sulfite with *o*-aminothiophenol, **68**, 163
- 11-Hydroxyascididemin, **70**, 96
- 1-[3-(Hydroxyazetidin-1-yl)carbonyl]-3-phenyl-4-oxo-4*H*-pyrido[2,1-*a*]phthalazine, *O*-methylation, **69**, 107
- 1-Hydroxy-2-azido-3-propoxymethylpyrimidines, **68**, 47
- 12-Hydroxybenzo[*c*]phenanthridines, synthesis, **67**, 374
- 3-Hydroxy-1-benzopyran-2-one, photoaddition with 2,3-dimethylbut-2-ene, **65**, 328
- 5-Hydroxybenzo[*b*]thiepin, rearrangement, **65**, 47
- 4-Hydroxy-2,4'-biquinazoline, **67**, 67
- [Hydroxy(bisphenoxyphosphoryloxy)iodo]benzene, reaction with 4-pentenoic acid, **69**, 27
- 4-Hydroxy-2-butenolide, reaction with enamionones, **67**, 246
- 6-(4-Hydroxybutylamino)pyrimidines, **69**, 201
- 9-(4-Hydroxybutyl)guanine, carbocyclic analogue of acyclovir, **69**, 153
- 5-Hydroxycanthin-6-one, isolation and methylation to Picrasidine L, **61**, 179
- 5-Hydroxy-6-carboxythieno[2,3-*d*]pyrimidines, **65**, 238
- o*-Hydroxychalcones, oxidation, **69**, 51
- o*-Hydroxycinnamic aldehydes, ring chain tautomerism, **64**, 276
- 3-Hydroxycoumarins, triflation, **65**, 302
- 4-Hydroxycoumarins, arylation, **65**, 301
- reaction with triarylismuth(V) reagents, **65**, 301
- reaction with phosphoryl chloride and dimethyl formamide, **65**, 309
- 2- $\alpha$ -(4-Hydroxycoumarin-3-yl)benzylindane-1,3-dione, ring chain tautomerism, **64**, 283

- cis* and *trans*-2-Hydroxy-1-cycloalkanecarboxamides, reaction with aldehydes and ketones, **69**, 369  
conversion to oxazine-2,4-diones, **69**, 372
- 6-Hydroxycyclohepta[*b*]pyrid-7-one, bromination and nitration, **66**, 334
- 5-Hydroxycyclohepta[*b*]pyrrol-6-ones, **64**, 123  
bromination and nitration, **66**, 333
- 7-Hydroxycyclohepta[*b*]thiophen-6-one, bromination, **66**, 334
- trans*-2-Hydroxy-1-cyclopentanecarboxamide, failure to cyclise with aldehydes, **69**, 398
- cis*-2-Hydroxy-1-cyclopentanecarboxamides, ring closure with ketones, **69**, 370  
conversion to oxazinediones, **69**, 372
- 2-Hydroxy-1,3,2,5-diazaboraphosphorinanes, **61**, 126
- 1-Hydroxy-1,2-dihydroacronycine, **70**, 136
- 2-Hydroxy-1,2-dihydroacronycine, **70**, 136
- N*-Hydroxy-2,3-dihydro-1,3-benzothiazin-4-ones, **66**, 159
- 4-Hydroxy-3,4-dihydro-1,2,3-benzotriazines, ring chain tautomerism, **64**, 306
- (+)-1-Hydroxy-1,2-dihydro-de-*N*-methylacronycine, **70**, 127
- 3-Hydroxy-3,4-dihydro-8-methyl-2*H*-pyrido[1,2-*a*]pyrimidine hydrobromide, **63**, 165
- 4-Hydroxydihydropyran, dehydration, **62**, 62
- 7-Hydroxy-6,7-dihydro-1*H*, 3-*H*, 5*H*-pyrido[3,2,1-*ij*][3,1]benzoxazine-3-one, alkylation of 7-hydroxy group, **70**, 38
- 3-Hydroxy-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrimidine hydrobromide, **63**, 165
- $\alpha$ -Hydroxydimethylacetals, preparation, **69**, 4,11
- 7-Hydroxy-1,5-dimethyl-1,2,3,4,5,10-hexahydro-4*a*-*H*-pyridazino[1,6-*b*]isoquinoline, preparation, **69**, 105
- 8*a*-(2-Hydroxy-3,5-dimethylphenyl)-quinazolinone, **69**, 387
- 8*a*-(4-Hydroxy-3,5-dimethylphenyl)-quinazolinone, **69**, 387
- 5-Hydroxy-2,4-dimethyl-1-thiophenylacetyl-2-pyrazoline, **66**, 49
- 2-Hydroxy-1,3-dioxane, conformational energies, **69**, 236
- 5-Hydroxy-1,3-dioxane, conformation, **69**, 242
- 2-(2-Hydroxyethoxy)benzaldehydes, ring chain tautomerism, **64**, 274
- 1-Hydroxy-2-ethoxycarbonylbenzo[*b*][1,7]phenanthrolines, synthesis and antimicrobial activities, **70**, 102
- 9-[2-(Hydroxyethoxy)methyl]guanine, antiviral activity, **67**, 392  
crystal structure, **69**, 130  
synthesis and biological activity of ring variants, **69**, 131  
synthesis, **69**, 134  
*N*-substituted (aminomethyl)benzoate ester prodrugs, **69**, 135  
*N*-3-methylation, **69**, 136
- 9-(2-Hydroxyethoxymethyl)-1-methylguanine, **69**, 136
- 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine, biological activity, **69**, 142
- 2-*N*-(2-Hydroxyethyl)amino-5-methyl-1,4-benzoquinones, ring chain tautomerism, **64**, 272
- 2- $\beta$ -Hydroxyethylcyclobutanones, photolysis, **65**, 153
- 6 $\alpha$ -(1-Hydroxyethyl)cyclonocardicins, **65**, 108
- 3-(Hydroxyethyl)furotropyliene, **66**, 383
- 7-(2-Hydroxyethyl)guanine, synthesis, **69**, 186
- N*-(2-Hydroxyethyl)hydrazones ring chain tautomerism, **66**, 31
- N*-(2-Hydroxyethyl)imines of benzaldehyde ring chain tautomerism by nmr, **66**, 4
- 1-(2'-Hydroxyethyl)-2-methyl-5-nitroimidazole, metabolism, **61**, 24
- 2-(2-Hydroxyethyl)piperidines, from hydrolysis of perhydropyrido[1,2-*c*][1,3]oxazines, **70**, 31
- 3-(2-Hydroxyethyl)pyrido[1,2-*a*]pyrimidin-4-one, **63**, 136
- 1-(2-Hydroxyethyl)-1,2,3,4-tetrahydroquinoline, **70**, 56
- 3-(2-Hydroxyethyl)thieno[3,2-*d*]pyrimidine-2(1*H*),4(3*H*)-diones, **66**, 238, **66**, 244
- 3-(2-Hydroxyethyl)thieno[3,4-*d*]pyrimidine-2(1*H*),4(3*H*)-dione, **66**, 258,
- 1-(2-Hydroxyethyl)thieno[3,4-*d*]pyrimidine-2,4(3*H*)-dione, **66**, 264,
- 1-Hydroxyethylthieno[2,3-*d*]pyrimidine-2,4(3*H*)-diones, **66**, 202

- 3-(2-Hydroxyethyl)thieno[3,4-*d*]pyrimidine-2(1*H*)-thione,4(3*H*)-one, **66**, 262,  
*cis*-3-Hydroxyflavanone dimethylacetals,  
 synthesis, **69**, 51  
*trans*-3-Hydroxyflavanone dimethylacetals,  
 synthesis, **69**, 51  
 6-Hydroxyfuro[*c*]tropylium ions, UV spectra,  
**66**, 318  
 aromaticity, **66**, 322  
 3-Hydroxy-1,3,4,6,7,11*b*-hexahydro-2*H*-  
 pyrimido[6,1-*a*]isoquinolines,  
 acetylation, **70**, 50  
 9-[4-Hydroxy-2-  
 (hydroxymethyl)butyl]guanine, antiviral  
 activity, **67**, 393  
 9-[4-Hydroxy-3-(hydroxymethyl)-  
 butyl]guanine, **68**, 28  
 crystal and molecular structure, **68**, 38  
 as antiviral agent, **68**, 36  
 4-Hydroxy-3-hydroxymethyl-4*H*-pyran,  
 unstable component of antibiotics in  
*Rhizoctania solani*, **62**, 120  
 C-Hydroxyiminoalkyl nitrones ring chain  
 tautomerism, **66**, 18  
 7-Hydroxyimino-6,7-dihydro-1*H*, 3-*H*, 5*H*-  
 pyrido[3,2,1-*ij*][1,3]benzoxazine-3-one,  
*N*-methylation, **70**, 37  
 2-(Hydroxyimino)pyrido[1,2-*a*]pyrimidine,  
**63**, 169  
 6-Hydroxy-4-imino-4*H*-pyrido[1,2-*a*]  
 pyrimidine, **63**, 148  
 9-Hydroxyiminotetrahydropyrido-  
 pyrimidine-3-carboxylates- reaction with  
 clayfen, **63**, 214  
 9-Hydroxyimino-6,7,8,9-tetrahydro-4*H*-  
 pyrido[1,2-*a*]pyrimidin-4-one, **63**, 213  
 5-Hydroxyindole, syntheses via Nenitzescu  
 reactions, **67**, 236  
 1-Hydroxy-2-iodo-3-methoxy-10-  
 methylacridin-9(10*H*)-one, reaction  
 with copper acetylides, **70**, 145  
 3-[1-Hydroxy-3-(*N*-  
 isopropylamino)propyl]1,2,3,4-  
 tetrahydroisoquinoline, **70**, 66  
 2-Hydroxy-3-isopropyl-4-trifluoromethyl-6-  
 phenyl-2*H*-pyran, **62**, 51  
 5-Hydroxylamino-2-pyrazolines ring chain  
 tautomerism with 5-hydrazino-2-  
 isoxazolines, **66**, 40  
 C(3)-Hydroxylated chromones, preparation,  
**69**, 72  
 11-Hydroxy-20-methoxynoracronycine, **70**,  
 127  
 Hydroxymethyl-L-allylglycine, conversion to  
 (–)-bulgenicine, **64**, 11  
 11-Hydroxy-6-  
 methylbenzo[*c*]phenanthridine,  
 synthesis, **67**, 381  
 4-(2'-Hydroxy-3'-methylbut-3'-enyl)-  
 yukocitrine, **70**, 138  
 4-Hydroxy-3-methylene-2,2,10-trimethyl-2,3-  
 dihydrofuro[3,2-*b*]acridin-5(10*H*)-one,  
**70**, 152  
*cis* and *trans*-2-Hydroxymethyl-1-  
 cyclohexylamine, reaction with  
 formaldehyde, **69**, 353  
 ring closure with aromatic aldehydes, **69**,  
 355  
 reaction with 4-nitrobenzaldehyde, **69**, 357  
 reaction with ureas and thioureas, **69**, 366  
 reaction with 4-chlorobenzimidate, **69**, 374  
*trans*-2-Hydroxymethyl-1-cyclohexylamine,  
 ring closure with aromatic aldehydes,  
**69**, 355  
 reaction with salicylaldehyde, **69**, 458  
*cis*-1-Hydroxy-7*a*-  
 methylcyclopenta[*d*]tetrahydro-1,3-  
 oxazine ring chain tautomerism, **66**, 18  
*trans*-2-Hydroxymethyl-1-cyclopentylamine,  
 failure to cyclise with aldehydes, **69**, 398  
 9-Hydroxy-6-methyl-6,7-dichloro-4*H*(*H*)-  
 pyrido[1,2-*a*]pyrimidin-4-one, **63**, 226  
 4-Hydroxymethyl-3,4-dihydro-1-oxo-1*H*-  
 pyrido[2,1-*c*][1,3]oxazinium chloride,  
 reaction with amines, **70**, 32  
 4-Hydroxymethyl-1,3-dihydropyrido[2,1-*c*]  
 [1,3]oxazin-1-one, from ring opening of  
 pyrido[2,1-*c*][1,3]oxazinium chloride,  
**70**, 32  
 1-Hydroxymethyl-9,10-dimethoxy-4-  
 cyclohexylimino-1,2,4,5,6,11*b*-  
 hexahydro[1,3]oxazino[4,3-*a*]isoquinoline,  
 electrochemical  
 reduction, **70**, 39  
 1-Hydroxymethyl-9,10-dimethoxy-  
 1,2,4,6,7,11*b*-hexahydro-  
 [1,3]oxazino[4,3-*a*]isoquinoline-4-one,  
**70**, 55  
 1-Hydroxymethyl-9,10-dimethoxy-  
 1,2,4,6,7,11*b*-hexahydro-  
 [1,3]oxazino[4,3-*a*]isoquinoline-4-  
 thione, **70**, 38, 55

- 5-Hydroxymethyl-3,5-dimethyl-5,6-dihydro-2*H*-1,4-oxazin-2-one ring chain tautomerism, **66**, 15
- 2-Hydroxy-2-methyl-1,4-dioxane, ring chain tautomerism, **64**, 270
- 4-Hydroxymethyl-1,3,2-dioxathiolane 2-oxide, synthesis, **68**, 106
- 3-Hydroxymethylimidazo[1,2-*a*]pyrimidine, **70**, 248
- 3-Hydroxy-5-methylisoxazole, Pd(0) catalysed reaction with cinnamyl ethyl carbonate, **66**, 84
- 5-Hydroxymethyl-6-methylimidazo[2,1-*b*]thiazole, **69**, 295
- 6-Hydroxymethyl-3-methylimidazo[2,1-*b*]thiazole, **69**, 295
- 6-Hydroxy-3-methyl-2-methylthio-4(3*H*)-pyrimidinone, precursor to 1,6-dimethylpyrimido[5,4-*e*][1,2,4]triazine-5,7(1*H*, 6*H*)dione, **61**, 250
- 9-Hydroxy-2-methyl-8-nitro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reduction, **63**, 177
- 3-Hydroxymethyloxazines, **69**, 371
- 1-Hydroxymethyl-7-oxo-1*H*, 7*H*-pyrido[3,2,1-*ij*]cinnoline-8-carboxylate, *O*-alkylation, **69**, 106
- 5-Hydroxy-5-methyl-2-phenylisoxazolidines, ring chain tautomerism, **64**, 285
- 3-(and 4)-Hydroxy-5-methylproline, **64**, 9
- 3-(5'-Hydroxy-3'-methyl-1*H*-pyrazol-1-yl)-5*H*][1,2,4]triazino[5,6-*b*]indole, **61**, 294
- 9-Hydroxy-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, chlorination, **63**, 188
- nitration, **63**, 206
- reaction with dimethylthiocarbamoyl chloride, **63**, 209
- 6-(Hydroxymethyl)pyrimidine-2,4(1*H*, 3*H*)dione-5-carboxaldehyde, cyclisation, **65**, 263
- 4-Hydroxy-6-methyl-2-pyrone, Pd(0) catalysed allylation, **66**, 96
- Pd(0) catalysed reaction with 5-methylcyclohex-2-enyl-*O*-acetate, **66**, 99
- Pd(0) catalysed reaction with cinnamyl chloride, **66**, 99
- regiospecificity of reactions, **66**, 99
- 5-(Hydroxymethyl)-2-pyrrolidinone, condensation with benzaldehyde, **64**, 44
- anhydro*-4-Hydroxy-2-methyl-5,6,7,8-tetrahydropyrido[1,2-*b*]pyridazinium hydroxide, p*K*<sub>a</sub> values, **69**, 93, 105
- 8-Hydroxymethyl-1,2,3,4-tetrahydroquinoline, **70**, 56
- from hydrolysis of pyridobenzoxazinones, **70**, 31
- 6-Hydroxy-6-methyltetrahydro-1,3-thiazine-2-thiones- ring chain tautomerism, **64**, 308
- 1-Hydroxymethyl-1-thio-4-aryl-1-phospha-3-oxacyclopentenes, formation from 1-phospha-3,5-dioxo-4-aryl-bicyclo[2,2,2]heptanes, **61**, 67
- 5-(Hydroxymethyl)uracil, in synthesis of acyclonucleosides, **69**, 147
- 2-Hydroxy-1,4-naphthoquinone, conversion to iodonium ylide and reaction with phenylacetylene, **69**, 18
- erythro*-9-(2-Hydroxy-3-nonyl)adenine, biological activity, **67**, 393
- synthesis, **68**, 63
- as ADA inhibitor, **68**, 67
- metabolism, **68**, 69
- 11-Hydroxynoracronycine, **70**, 127
- antiviral activity, **70**, 127
- 3-Hydroxyoxacephem, via carbene reactions, **65**, 188
- 6-Hydroxy-4-oxahexanal, ring chain tautomerism, **64**, 275
- 2-Hydroxyoxane, conformations, **69**, 220
- calculated conformational equilibria, **69**, 225
- 1-Hydroxy-2-oxo-1-cyclohexanecarboxamide, reaction with cyanamide, **69**, 392
- 1-Hydroxy-2-oxo-1,2-dihydroacronycine, **70**, 135
- 4-Hydroxy-7-oxo-1*H*, 7*H*-pyrido[3,2,1-*ij*]cinnoline-8-carboxylate, 4-hydroxy acylation, **69**, 107
- 2-Hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxamide, **63**, 139
- 5-Hydroxypentanal, ring chain tautomerism, **64**, 268
- (+)-2-(2-Hydroxypentyl)-1,2,3,4-tetrahydropyridin-4-one, cyclisation, **70**, 56
- o*-Hydroxyphenoxymethyl ketones, ring chain tautomerism, **64**, 277
- (+)-2-(2-Hydroxy-2-phenylethyl)-1,2,3,4-tetrahydropyridin-4-one, cyclisation, **70**, 56

- 5-Hydroxy-5-phenylpentane-2,4-dione, ring chain tautomerism, **64**, 269
- 3-Hydroxy-1-phenylpyrido[2,1-*f*][1,2,4]triazinium perchlorate, **61**, 220
- 3-(2-Hydroxyphenyl)thienopyrimidin-2(1*H*),4-diones, **66**, 196
- o*-Hydroxyphenyltropilidenes, cyclisation to tricyclic tropylum salts, **64**, 137
- 3-Hydroxy-2(2-phenylvinyl)-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylic acid, reduction, **63**, 192
- cis*-5-Hydroxy-L-pipecolic acid, **64**, 28
- 4-Hydroxypipecolic acid, **64**, 29
- 4-Hydroxyproline, from *N*-acylated diethyl aminomalonate, **64**, 12
- conversion to crotanecine, **64**, 39
- 2-[(*z*)-3-Hydroxy-1-propenyl]piperidines, preparation, **69**, 96
- 3-Hydroxypropyladenine, antiviral activity, **67**, 393
- 6-[(1'*S*)-1'-Hydroxypropyl]-3-methylpteridine-2,4-dione, **70**, 271
- (-)-2-(2-Hydroxypropyl)piperidine, reaction with *p*-nitrobenzaldehyde, **70**, 8
- 2-(3-Hydroxypropyl)piperidine hydrobromide, preparation, **69**, 96
- 2-(3-Hydroxypropyl)piperidines, by reduction of perhydropyridooxazines, **69**, 96
- 2-(3-Hydroxypropyl)pyridine-*N*-oxide, cyclisation, **69**, 110
- 9-Hydroxypurines, Mitsunobu reactions with protected alcohols, **69**, 164
- Hydroxyputrescine, condensation with aromatic aldehydes and ring chain tautomerism, **66**, 13
- 2-Hydroxy-2*H*-pyrans (pseudobases), function and stability, **62**, 60
- 4-Hydroxypyrazolo[3,4-*b*]pyridines, **67**, 296
- 3-Hydroxy-2-pyridones, from enaminones, **67**, 271
- 4-Hydroxypyrido[1,2-*b*]pyridazinium salts, **69**, 115
- 7-Hydroxypyrido[2,1-*a*]phthalazinium perchlorate, deprotonation, **69**, 105
- 9-Hydroxypyrido[1,2-*a*]pyrimidinium perchlorate, **63**, 125
- 2-Hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 137
- O*-alkylation, **63**, 185
- 9-Hydroxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, metal complexes, **63**, 124
- 3-Hydroxy-2-pyrone, high pressure reaction with methyl crotonate, **65**, 332
- 3-Hydroxypyrroles, synthesis via enaminones, **67**, 225
- 2-Hydroxypyrrolo[*b*]tropone, benzylation, **66**, 349
- N*-Hydroxyquinoxaline-2,3-dione, **65**, 26
- 5-Hydroxy-5-( $\beta$ -D-ribofuranosyl)furanone, **70**, 205
- 5-Hydroxy-5- $\beta$ -D-ribofuranosylfuran-2-one, **70**, 305
- 6-Hydroxy-3- $\beta$ -D-ribofuranosylphthalate ester, **70**, 215
- 6-Hydroxy-6- $\beta$ -D-ribofuranosylpyranone, reaction with 1,2-diaminobenzene, **70**, 282
- 6-Hydroxy-6- $\beta$ -D-ribofuranosyl-2*H*-pyran-3(6*H*)-one, reaction with diamino-1,3-dimethyluracil 5,6, **70**, 263
- 5-Hydroxy-2-( $\beta$ -D-ribofuranosyl)pyridine, **68**, 341
- 1-Hydroxyrutacridone epoxide, **70**, 146
- 20-Hydroxyrutacridone epoxide, **70**, 146
- (+)-4-Hydroxysedamine, **70**, 75
- 6-Hydroxy-5-substituted-2-thionamido-1,3-thiazin-4-one, **66**, 134
- 2-Hydroxy-1,2,3,4-tetrahydropyridines, **67**, 274; **67**, 275
- 9-Hydroxy-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 179
- 3-Hydroxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolines, acetylation, **70**, 50
- 5-Hydroxy-4-(D-*arabino*-tetritol-1-yl)imidazolidine-2,5-dione, isolation and structure determination, **68**, 227
- 5-Hydroxy-4-(D-*arabino*-tetritol-1-yl)imidazolidin-2-one, synthesis, **68**, 283
- 2-Hydroxythiazoles, synthesis, **69**, 44
- 2-Hydroxythiazolo[3,2-*b*][1,2,4]triazoles, **69**, 327
- O*-acylation, **69**, 329
- 3-Hydroxythieno[2,3-*d*]pyrimidines, acylation, **66**, 223
- 5-Hydroxythieno[2,3-*d*]pyrimidines, **66**, 217
- 4-Hydroxy-7-(*p*-tolyl)benzothiophene, in preparation of thieno[2,3-*c*]acridines, **70**, 144



- 5-Hydroxytropolone, oxidative dimerisation, **64**, 117
- Hydroxytropolones, **64**, 88
- Hydroxytropylium salts, **64**, 134
- (2R, 3R)- $\beta$ -Hydroxyvaline, synthesis via cyclic sulfite, **68**, 158
- 2-Hydroxyxanthone, **65**, 353
- Hypoxanthine, synthesis, **67**, 420
- preparation of acyclonucleoside analogs, **68**, 60
- Ichthyopterin *see* 2-amino-(L-erythro-1',2'-dihydroxypropyl)pteridin-4,7-dione
- 4*H*-Imidazo[1,5-*a*]benzimidazoles, **64**, 193
- Imidazo[2,1-*d*][1,5]benzothiazepine, **63**, 78
- Imidazo[4,5-*d*]-1,2,3-dithiazole, from 1-methyl-4-aminoimidazole and sulfur monochloride, **61**, 22
- Imidazo[1,5-*a*]isoquinoline, **65**, 177
- Imidazo[1,2-*b*]isoquinoline-5,10-diones, from phthaloyl dichloride and imidazoles, **61**, 184
- reactions, **61**, 187
- Imidazole, Pd(0) catalysed allylation, **66**, 87
- glycosylation, **66**, 89
- via cyclisation of nitrosoenaminones, **67**, 258
- Imidazole-4,5-dicarboxaldehydes, aldol condensation to tropones, **64**, 95
- Imidazolidines, from diazouracils, **65**, 176
- Imidazolidin-2-one-4-carboxylic acid, **64**, 18
- N*-(Imidazolyl)benzenecarbohyrazonoyl chloride, **63**, 294
- Imidazolin-2-ylideneammonium picrate, **68**, 69
- Imidazolodiazepines, Pd(0) catalysed allylation, **66**, 126
- Imidazol-5-ones, **64**, 19
- Imidazolopyridones, **67**, 295
- Imidazoquinazolinones, via enaminones, **67**, 317
- Imidazol-1-yloxyalcohols, **68**, 41
- 2-Imidazolyl *C*-nucleosides, preparation, **68**, 277
- 4-Imidazolyl *C*-nucleosides, preparation, **68**, 278
- 2-Imidazolyl reverse *C*-nucleosides, **68**, 282
- Imidazo[2,1-*b*][1,3,4]oxadiazole salts, **69**, 276
- Imidazo[4,5-*d*][1,3]oxazin-7-ones, **64**, 209
- Imidazo[1,2-*a*]pyrazin-3-yl *C*-nucleosides, **70**, 280
- Imidazopyridine Pd(0) catalysed reaction with (–)monoacetate of *cis* cyclopent-2-ene-1,4-diol, **66**, 123
- Imidazo[1,2-*a*]pyridines, via carbene reactions, **65**, 177
- Imidazo[1,5-*a*]pyridine, **65**, 177
- Imidazo[4,5-*b*]pyridines, from 4-aminoimidazole and dimethyl acetylene dicarboxylate, **61**, 21
- from 5-aminoimidazole and acetylacetone, **61**, 39
- from 5-aminoimidazole and ethyl acetoacetate, **61**, 39
- 1(3)-*H*-Imidazo[4,5-*b*]pyridine, reaction with alkylating agents to give *diseconucleosides*, **68**, 45
- Imidazo[1,2-*a*]pyridin-3-yl acyclo *C*-nucleosides, **70**, 199
- 4*H*-Imidazo[5,4-*d*]pyrido[1,2-*a*]pyrimidin-4-one, **63**, 250
- Imidazopyrimidines, **65**, 175
- Imidazo[1,5-*a*]pyrimidines, by trapping 4(5)aminoimidazoles with ethoxymethylenemalonate, **61**, 14;
- with 1,1,3,3-tetramethoxypropane, **61**, 8, **61**, 14
- Imidazo[4,5-*c*]pyrimidines, from 5-aminoimidazoles and ethoxymethylene urethane, **61**, 41
- Imidazo[1,2-*a*]quinolines, via carbene reactions, **65**, 177
- Imidazo[1,5-*a*]quinolines, **64**, 57
- 1*H*-Imidazo[4,5-*c*]quinolin-4(5*H*)-ones, from dimidazo[1,5:1',5'-*d*]pyridazine-5,10-diones, **61**, 199
- Imidazotetrazoles, **65**, 177
- Imidazo[2,1-*b*][1,3,4]thiadiazoles, **64**, 195
- NMR spectra, **69**, 313
- Imidazo[2,1-*b*]-1,3-thiazin-4-one, **66**, 165
- Imidazo[2,1-*b*]thiazole, NMR spectrum, **69**, 298
- mass spectrum, **69**, 300
- Imidazo[2,1-*b*]thiazole-5-carbonitriles, reaction with hydroxylamines, **69**, 298
- Imidazo[2,1-*b*]thiazolium-3-olate, cycloaddition with acetylene dicarboxylates, **70**, 199

- Imidazo[1,5-*b*]-1,2,4-triazepines from 1,5-diaminoimidazole and acetylacetone, **61**, 41  
from 1,5-diaminoimidazole and ethyl acetoacetate, **61**, 41  
Imidazo[1,2,4]triazine, **64**, 223  
Imidazo[1,5-*a*][1,3,5-triazines, by reaction of 4(5)-aminoimidazole with imidates, **61**, 14  
Imidazo[4,5-*e*][1,2,4]triazines, reaction with bromacetic acid and aldehydes, **61**, 306  
Imidazo[5,1-*f*][1,2,4]triazine, **64**, 235  
Imidazo[1,2-*b*][1,2,4]triazino[5,6-*b*]indoles, **61**, 287  
Imidazo[5,1-*f*][1,2,4-triazin-7-yl acyclo *C*-nucleosides, **70**, 298  
Imidazotropone, **64**, 110  
chlorination to mono and dichloroderivatives, **66**, 342  
UV spectra, **66**, 300  
tautomerism, **66**, 310  
hydrogenation, **66**, 336  
Imidazotroponeimines, **66**, 376  
2-Imidazolazirines, transformation to imidazoles, **65**, 175  
5-Imidazolylzinc chloride, coupling to haloheterocycles, **62**, 377  
Imidoyl halides, **64**, 179  
1-Imidoyliminopyridinium-*N*-ylides, thermolysis, **61**, 223  
2-Imino-3-alkyl-1,3-benzothiazin-4-ones, from chlorobenzoic esters and thiourea, **66**, 145  
2-Imino-4-alkyl-2*H*-pyrido[1,2-*a*]pyrimidine hydrochloride, hydrolysis, **63**, 170  
2-Imino-3-amino-1,3-benzothiazin-4-ones, condensation with nitriles, **66**, 167  
2-Imino-3-amino-6-carbomethoxy-1,3-thiazin-4-one, **66**, 138  
2-Imino-3-arylthiazolotropylium salts, **66**, 394  
2-Imino-1,3-benzothiazin-4-one, nitrosation, **66**, 174  
ring opening in base, **66**, 176  
reduction, **66**, 182  
reaction with  $P_2S_5$ , **66**, 183  
3-Imino-4-cyano-2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-ones, **70**, 68  
3-Imino-4-cyano-2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-thiones, **70**, 68  
1-Imino-4-cyano-3-methylthio-1*H*-pyrido[1,2-*c*]pyrimidine, reaction with morpholine, **70**, 45  
reaction with dimethyl acetylenedicarboxylate, **70**, 45  
alkylation and acylation, **70**, 49  
6-Iminocycloheptatriazoles, hydrolysis, **64**, 91  
2-Imino-6,7-dihydro-2*H*-pyrido[6,1-*a*]isoquinolines, heating, **70**, 47  
2-Imino-5,6-dihydro-1,3-thiazin-4-ones, **66**, 150  
2-Imino-9,10-dimethoxy-4-phenyl-6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinoline, X-ray structure of protonated form, **70**, 30  
2-Imino-9,10-dimethoxy-4-phenyl-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolines, reduction, **70**, 43  
4-Iminohexahydro[1,3]oxazino[4,3-*a*]isoquinolines, **70**, 53  
4-Imino-3-methyl-1,3-benzothiazin-4-one, Dimroth rearrangement, **66**, 184  
4-Imino-9-methyl-3(1*H*-tetrazol-5-yl)-4*H*-pyrido[1,2-*a*]pyrimidine, **63**, 197  
6-Imino-4-oxo-6*H*-pyrido[2,1-*a*]isoindole-1-carboxylic acid, **69**, 108  
1-Iminoperhydropyrido[1,2-*c*][1,3]thiazine hydrobromides, **70**, 61  
reaction with tetraethylenepentamine, **70**, 39  
4-Imino-3-phenylbenzothieno[2,3-*d*]pyrimidine-2(1*H*)-thione, **66**, 219  
*trans*-4,4*a*-*H*-1-Imino-4-phenylperhydo[1,2-*c*][1,3]oxazine, CNS activity, **70**, 75  
Iminophosphorane, synthesis, **64**, 160  
spectra, **64**, 168  
stability, **64**, 169  
hydrolysis, **64**, 170  
as a protecting group for amines, **64**, 170  
as intermediates in phosphane oxide catalysed carbodiimide synthesis from isocyanates, **64**, 175  
reaction with phenylisocyanate, **64**, 176  
reaction with  $\beta$ -diketones, **64**, 178  
reaction with acid chlorides, **64**, 179  
reaction with phenoxymethyloxirane, **64**, 182  
2-Imino-3-propyl-9,10-dimethoxy-1,2,3,6,7,11*b*-hexahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one, **70**, 64

- 3-Iminopyrido[1,2-*b*]pyridazines, **69**, 119  
1-Imino-1*H*-pyrido[1,2-*c*]pyrimidines, **70**, 68  
4-Imino-4*H*-pyrido[1,2-*a*]pyrimidine-cycloaddition to methyl propiolate, **63**, 204  
2-Imino-2*H*-pyrido[1,2-*a*]pyrimidine hydrochloride, **63**, 128  
4-Imino-4*H*-pyrido[1,2-*a*]pyrimidin-3-nitrile, **63**, 149  
2-Iminopyrido[3,2-*e*]1,3-thiazin-4-one, Mannich reactions, **66**, 171  
2-Iminopyrimidines, **67**, 311  
4-Imino[3,4-*d*]pyrimidines, **66**, 264  
4-Iminopyrimido[6,1-*a*]isoquinolines, pH dependence of tautomerism, **70**, 23  
5-Iminoselenadiazolines, **63**, 322  
2-Imino-substituted tetrahydro-1,3-oxazines, **69**, 366  
1-Imino-1,2,3,4-tetrahydroquinolinium ion, reaction with 1,1-diphenylethene, **69**, 118  
2-Imino-1,3-thiazine-4-one, methylation, **66**, 170  
4-Iminothieno[2,3-*d*]pyrimidines, **66**, 206  
4-Iminothieno[2,3-*d*]pyrimidine-2(1*H*)thiones, **65**, 242  
4-Iminothieno[2,3-*d*]thiazine-2(1*H*)thiones, **65**, 243  
Indenopyridine, synthesis via enamionones, **67**, 289  
Indigo, **67**, 14  
Indole fluorination, **62**, 6  
Pd(0) catalysed allylation, **66**, 91  
Pd(0) catalysed reaction with acrolein dimethylacetal, **66**, 92  
Indole-3-carboxylic esters, **65**, 124  
2(3*H*)-Indolinones, **65**, 122  
4-(Indolin-2-on-3-yl)hydrazino-5,6,7,8-tetrahydrobenzo[*b*]thieno[2,3-*d*]pyrimidine, herbicide, **66**, 235  
(±)-Indolizidine 223AB, synthesis, **69**, 122  
(-)-Indolizidines 205A, 207A, 209A, 235A, synthesis, **69**, 122  
Indolizidines, **65**, 109  
Indolizidinones, **65**, 128  
Indolizines, reaction with strong base and *N,N*-dimethylamides, **68**, 207  
synthesis, **68**, 185  
Indolizinobenzotropones, nmr spectra, **66**, 293  
UV spectra, **66**, 299  
Indolizinotropones, **64**, 97  
Indolo[2,3-*b*][1,5]benzothiazepine, **63**, 88  
Indolo[2,3-*c*][1,5]benzothiazepine, **63**, 90  
Indolo[2,3-*a*]carbazole alkaloids, **67**, 14  
Indolo[3,2-*c*]coumarin, **65**, 310  
Indolo[1,2-*b*][2,7]naphthyridine-5,12-quinone, precursor to ellipticines, **61**, 190  
Indolo[2,3-*d*]pyridines, **65**, 123  
Indolo[2'',3'':5',6']1,2,4-triazino[3',2':2,3]thiazolo[4,5-*b*]quinoxaline, **61**, 290  
Indolotropolone, **64**, 122, **64**, 88  
tautomerism, **66**, 310  
pK<sub>a</sub> values, **66**, 330  
*O*, and *O,N*-alkylation, **66**, 344  
*N*-acylation, **66**, 349  
Indolotropones, **64**, 95  
IR spectra, **66**, 304  
catalytic hydrogenation, **66**, 336  
chlorination to 6-chlorobenzazaazulene, **66**, 342  
(*E*)-3-(Indol-3-yl)propenenitrile, **63**, 358  
Inosinic acid, synthesis from AIR, **61**, 33  
Intramolecular transacylation reactions, **64**, 310  
2-Iodoadenosine, coupling with alkynes, **62**, 330  
2-(Iodoalkyl)oxetanes, preparation, **69**, 13  
4-(1-Iodoalkyl)oxetan-2-ones, synthesis, **69**, 14  
2-(1-Iodoalkyl)oxiranes, **69**, 10  
2-Iodoaniline, copper iodide catalysed reaction with enolates, **67**, 244  
2-Iodobenzamide, Ni(0)-catalysed reaction with *N,N'*-disubstituted thioureas, **66**, 145  
reaction with *o*-acylhomoveratrylic acid, **67**, 379  
2'-Iodo-2'-deoxyformycin, **70**, 242  
3'-Iodo-3'-deoxyformycin, **70**, 242  
2-Iodobenzofuran, copper catalysed homocoupling, **67**, 18  
6-Iodo-6-deoxy-D-galactopyranose, formation of radicals and coupling to pyridines, **68**, 348  
5-Iodo-2'-deoxyuridine, alkenylation reactions, **62**, 342  
5-Iodo-3',5'-di-*O*-acetyl-2'-deoxyuridine, coupling with alkynes, **62**, 327  
2(2'-Iodoethyl)-1,4-dioxaheptane, synthesis, **69**, 59

- 2-Iodo-3-hydroxypyridine, conversion to furo[3,2-*b*]pyridines, **62**, 319
- 5-Iodomethyl-2,2-dimethyl-1,3-dioxane, precursor to carboacyclic C-nucleosides, **68**, 41
- 2-Iodomethyl-1,4-dioxane, **69**, 56
- 2-Iodomethyloxetane, preparation, **69**, 13
- 3-Iodomethyloxetane, preparation, **69**, 13
- 2-Iodomethyloxiranes, preparation from tertiary alcohols, **69**, 9
- 2-Iodomethylpiperidine, radical reactions, **69**, 111
- 2-Iodo-4-methylquinoline, coupling reactions, **62**, 307  
homocoupling with Pd, **62**, 411
- 2-Iodomethyltetrahydrofuran, synthesis, **69**, 26
- 4-Iodo-2-methylthieno[2,3-*d*]pyrimidine, coupling with alkynes, **66**, 229
- 4-Iodo-2-methylthiopyrimidine, stannylation, **62**, 352
- N,N*-Iodomethyl-trimethylsilyloxyamine, in nucleoside synthesis, **69**, 130
- Iodomethyltrimethylsilyloxyethyl ether, in nucleoside synthesis, **69**, 130
- Iodomethyltrimethylsilyloxyethyl sulfide, in nucleoside synthesis, **69**, 130
- 5-Iodo-1-methyluracil, coupling with alkynes, **62**, 320
- Iodonium ylides, from diazo compounds, **65**, 171
- 3-Iodopropionic acid, reaction with thiocarbamates, **66**, 149
- 2-Iodopurines, coupling with stannanes, **62**, 345
- 6-Iodopurine, coupling with alkynes, **62**, 325
- 2-Iodopyridine, coupling with 1-phenylpropargylalcohol, **62**, 318  
coupling with phenylethynyl copper/palladium, **62**, 396  
reaction with organomercury compounds, **62**, 399
- 3-Iodopyridine, reaction with styrene, **62**, 307  
coupling with propargyl alcohol, **62**, 318  
palladium catalysed coupling to glycal derivatives, **68**, 344
- 7-Iodo-4*H*-pyrido[1,2-*a*]pyrimidine, reaction with carbon monoxide, **63**, 207
- 2-Iodopyrimidine, coupling with alkenes, **62**, 311
- 4-Iodopyrimidine, coupling with alkenes, **62**, 311  
coupling with alkynes, **62**, 315, **62**, 320  
homocoupling with Pd, **62**, 411
- 5-Iodopyrimidine, coupling to styrene and ethyl acrylate, **62**, 308
- Iodosobenzene, reaction with sulfur trioxide, **69**, 63
- 8-Iodo-4-(tetrahydropyran-2yloxy)pyrazolo[1,5-*a*]1,3,5-triazine, **70**, 303
- Iodotetrathiafulvalene, **62**, 285
- 3-Iodotriazine, coupling with alkynes, **62**, 324
- $\alpha$ -Iodo- $\alpha,\beta$ -unsaturated lactones, preparation, **69**, 66
- 5-Iodouracil, palladium-mediated coupling with furanoid glycals, **68**, 366
- 5-Iodouridine, coupling with alkylzinc chlorides, **62**, 379
- Ipalbidine, **67**, 247
- Ipalbine, **67**, 248
- Isatin, reaction with 2,3-diaminoquinazoline to give indolotriazino-quinazolinones, **61**, 294  
reaction product with thiobenzhydrazide, ring chain tautomerism, **66**, 45  
in preparation of thieno[2,3-*c*]acridines, **70**, 144
- Isoacronycine, **70**, 138
- Isoascidemin, **70**, 104
- D-Isoascorbic acid, in preparation of butanetriols, **67**, 397  
in preparation of 1',2'-seco-AZT, **67**, 400
- Isobenzothiazolone, heat in dimethyl formamide to give 2-amino-1,3-benzothiazin-4-ones, **66**, 146
- 3-Isobutyryl-2*H*-1-benzopyran-2-one, reaction with anhydrides, **65**, 301
- N*-2-Isobutyryl-2',3'-seco-guanosine, use in preparation of nucleosides, **67**, 407
- Isochrysohermidin, **67**, 6
- Isocoformycin, **70**, 233
- 2-Isocyanato-1-cyclopentanecarboxylic acids, cyclisation, **69**, 382
- Isoferenulins, *see* 1,3-dimethyl-6-azalumazines
- Isogravacridone chloride, **70**, 146
- Isoindolo-1,3,4-benzotriazepinones, **64**, 230
- 3-Isonitrosopyrazolo[5,1-*b*]quinazolin-2,9-dione, precursor to [1,2,4]triazino[6,1-*b*]quinazolin-10-one, **61**, 265

- Isonoracronycine, **70**, 138
- 2-Isopropenylbenzofuran, reaction with maleic anhydride, **63**, 369  
reaction with tetracyanoethylene, **63**, 371
- 2-Isopropenylfuran, reaction with acetylenic esters, **63**, 341
- 3-Isopropenyl-1-methylindole, reaction with tetracyanoethylene, **63**, 375
- 3-Isopropenyltropolone, oxidation, **64**, 101
- N*-Isopropylbenzenesulfonamides, ring chain tautomerism, **66**, 55
- 4-Isopropylcoumarin, **65**, 320
- N*-Isopropyl-2-cyanobenzamides, ring chain tautomerism, **66**, 55
- O*-Isopropylfagaranine, synthesis, **67**, 358
- (Isopropylideneamino)guanidinium iodide, ring chain tautomerism, **66**, 31
- 2-Isopropylidene-1-cyclopentanone, reaction with carbon disulfide, **69**, 381
- 1-Isopropylidene-4,4-dimethyl-1,3,4,4a-tetrahydro[1,3]oxazino[3,4-*a*]quinolin-3-one, reduction of 5,6 double bond, **70**, 35
- 2',3'-*O*-Isopropylideneformycin, reaction with diethyl azodicarboxylate, **70**, 245
- (*R*)2,3-*O*-Isopropylidene glyceraldehyde, precursor to amino-4*H*-pyrans, **62**, 34
- 2,3-*O*-Isopropylidene-D-glyceraldehyde, **68**, 253  
coupling with 2-trimethylsilylbenzothiazole, **70**, 194  
formation of pyridinolol, **70**, 175
- 9-(2',3'-*O*-Isopropylideneglycerolyl)-8-azaadenine, **69**, 175
- 9-(2',3'-*O*-Isopropylideneglycerolyl)-8-azahypoxanthine, **69**, 175
- 9-(2',3'-*O*-Isopropylideneglycerolyl)-8-azapurines, **69**, 176
- 2,3-*O*-Isopropylidene-β-D-ribofuranosyl acetic acid, reaction with aminoguanidine, **68**, 326
- 2',3'-*O*-Isopropylidene showdomycin, **68**, 247
- cis,trans*-2-Isopropyl-5-iodo-1,3-dioxanes, conformations, **69**, 236
- 2-Isopropyl-5-substituted-1,3-dioxanes, conformations, **69**, 234
- 4-Isopropyl-*p*-tropoquinone, coupling with 5-hydroxyhinokitiol, **64**, 118
- Isoquino[3,4-*b*]acridines, **70**, 97
- (1-Isoquinolinylamino) methylenemalononitrile, ring chain tautomerism, **66**, 58
- 2-(Isoquinolin-5'-yl)benzanilides, cyclisation, **70**, 109
- 3-(Isoquinolin-1-yl)-1-*threo*-1,2-dihydroxypropanoate, reaction with methyl lithium, **70**, 211
- 1-(5-Isoquinolylimino)-1,3,4,4a, 5,10-hexahydro[1,3]thiazino[3,4-*b*]isoquinoline, **70**, 40
- 1-Isoquinolinyltriflate, coupling with stannanes, **62**, 341  
arylation, **62**, 364
- Isoretronecanol, **67**, 234
- Isothiazoles, **65**, **70**; **67**, 252
- Isothiazolium salts, reaction with formamides, **66**, 146
- Isothiazolo[4,5-*d*]pyrimidin-3-yl *C*-nucleosides, **70**, 254
- 3-Isothiazolyl *C*-nucleosides, preparation, **68**, 306
- Isothiocyanates of acrylic acids, reaction with amines, **66**, 152
- 4-Isothiocyanato-4-methylpentan-2-one, reaction with glycine, **64**, 48
- 3-Isoxazinyll *C*-nucleosides, **68**, 384
- Isoxazoles, ring opening to enamines, **67**, 215  
synthesis via enamines, **67**, 250  
isoxazole-5-acetic acid, **64**, 19
- Isoxazole[3,4-*c*]coumarins, **65**, 309  
isoxazolidines, photochemical ring transformation, **69**, 358
- Isoxazolidin-5-ones, ring chain tautomerism, **64**, 292
- Δ<sup>2</sup>-Isoxazoline-*N*-oxides, **65**, 179
- Isoxazoline-5-spirocyclopropanes, rearrangement, **67**, 276
- Isoxazolopyrazolotriazines, **61**, 298
- Isoxazolo[5',4':4,5]pyrimido[6,1-*c*][1,2,4]triazines, **61**, 241
- Isoxazolo[3,2-*b*]quinazolinone, **68**, 217
- Isoxazoloquinones, **67**, 251
- Isoxazolotroponeoximes, **66**, 374
- Isoxazolotropones, **64**, 104, **64**, 115  
reaction with 1,2-diaminoethane, **66**, 363  
nmr spectra, **66**, 288  
aromaticity, **66**, 308  
catalytic hydrogenation, **66**, 336
- Isoxazolotropylium ions, electron density calculated by molecular orbital methods, **66**, 379

- $\beta$ -Isoxazolylalanines, from 1,3-dipolar cycloaddition with acetamidomalones, **64**, 20
- 3-Isoxazolyl carbocyclic C-nucleosides, preparation, **68**, 292
- 5-Isoxazolyl carbocyclic C-nucleosides, preparation, **68**, 292
- 3-Isoxazolyl C-nucleosides, preparation by cycloadditions, **68**, 290
- 4-Isoxazolyl C-nucleosides, preparations, **68**, 297
- 4-Isoxazolyl reverse C-nucleosides, preparation, **68**, 294
- 5-Isoxazolyl reverse C-nucleosides, preparation, **68**, 294
- Junosidine, **70**, 138
- $\alpha$ -Kainic acid, **64**, 7
- Ketenes, cycloaddition to enamines, **67**, 215
- Ketene-S,S-hemiacetal, condensation with arylcyanates, **66**, 133
- Ketenimines, **64**, 181
- $\beta$ -Ketoethynyl(phenyl)iodonium triflates, reaction with sodium *p*-toluenesulfinate, **69**, 30
- Ketone *N*-(2-aminoethyl)hydrazones, ring chain tautomerism, **66**, 31
- Ketone bisthiocarbonohydrazones, gas phase ring chain tautomerism, **66**, 34
- Ketone 2,4-dialkylthiosemicarbazones, ring chain tautomerism, **66**, 52
- Ketone 2-methylthiosemicarbazones, ring chain tautomerism, **66**, 52
- Ketone 2-substituted thiosemicarbazones, ring chain tautomerism, **66**, 50
- Ketone thioacylhydrazones, ring chain tautomerism, **66**, 44
- Ketone thiobenzoylhydrazones, ring chain tautomerism, **66**, 44
- Ketone thiocarbonomonohydrazones, ring chain tautomerism, **66**, 33
- Ketone thiosemicarbazones, ring chain tautomerism, **66**, 51
- Kinamycin alkaloids, **67**, 238
- Kinuramine, **70**, 120
- Kuanomiamines A-D, **70**, 116
- synthesis, **70**, 120
- $\beta$ -Lactams, formation of spiro derivatives, **65**, 30
- via carbene reactions, **65**, 101
- $\gamma$ -Lactams, synthesis via iodonium salts, **69**, 30
- Lactim ethers, reaction with active methylene compounds, **67**, 212
- $\alpha$ -Lactones, **65**, 134
- $\gamma$ -Lactones, formation via iodonium ylides, **69**, 19
- Laurusin *see* 3-( $\beta$ -D-ribofuranosyl)-pyrazolo[4,3-*b*]pyrimidin-7-one
- Lepidinium trifluoroacetate, in preparation of lepidin-2-yl homo C-nucleoside, **70**, 206
- $\alpha$ - and  $\beta$ -Lepidin-2-yl C-nucleosides, **70**, 205
- Lepidin-2-yl homo C-nucleoside, **70**, 206
- Leucettidine, *see* 6-[(1'S)-1'-hydroxypropyl]-3-methylpteridine-2,4-dione
- Leukoindigo *see* 6,6'-dihydroxyindigo
- Lissoclines A and B, **70**, 112
- Lithiated 2-chloro-3-cycloalkylideneaminopyridines, reaction with *O*-ethyl thiocarboxylates, **65**, 51
- Lithiated tetrathiafulvalenes, reactions, **62**, 277
- acylation, **62**, 277
- reaction with chalcogens, **62**, 280
- reaction with halogenating agents, **62**, 288
- reaction with halophosphines, **62**, 288
- reaction with mercuric halides, **62**, 290
- reaction with chlorosilanes, **62**, 290
- reaction with chlorostannanes, **62**, 290
- Lithiated triphenyliminophosphoranes, **64**, 166
- 2-Lithiobenzothiophene, oxidative coupling, **67**, 18
- Lithio 2,6-dichloroimidazo[1,2-*a*]pyridine, ribosylation, **70**, 199
- 2-Lithiofuran, as precursor to 2,2'-bifuran, **67**, 8
- 2-Lithioimidazoles, oxidation, **67**, 29
- 2-Lithioindole, in preparation of indol-2-yl acyclo C-nucleosides, **70**, 171
- 4-Lithiomethylene pyrimidines, reaction with glycosyl halides, **68**, 374
- 2-Lithiomethylquinoline, reaction with 2-chlorobenzonitrile, **68**, 213
- 2-Lithiopyridines, reaction with aldehydo-sugar derivatives, **68**, 348

- 3-Lithiopyridines, reaction with *aldehyde-sugar* derivatives, **68**, 351
- 2-Lithiopyrimidine from 2-stannylpyrimidine, **62**, 354
- 5-Lithiopyrimidines, reaction with *aldehyde sugars*, **68**, 377
- 2-Lithiopyrrole, transition metal coupling, **67**, 5
- 3-Lithiopyrrole, precursor of 3,3'-bipyrroles, **67**, 6
- 9-Lithiotelluroxenthenes, **63**, 31
- Lithium diisopropylamide, in lithiation of nucleosides, **69**, 142
- Lithium triphenylsilylacetylide, reaction with amides, **67**, 213
- Luminol, chemiluminescence, **61**, 176
- Luteolin, synthesis, **69**, 52
- 2,3-Lutidine, photochlorination and conversion to dihydrothienopyridines, **68**, 183
- 3,4-Lutidine, photochlorination and conversion to dihydrothienopyridines, **68**, 183
- 2-( $\alpha$ -D-Lyxofuranosyl)-4,5-dihydro-1,3,4-thiadiazole, **68**, 335
- 4-( $\alpha,\beta$ -D-Lyxopyranosyl)imidazoline-2-thione, preparation, **68**, 281
- 2-( $\beta$ -D-Lyxopyranosyl)indol-4-one, preparation, **70**, 168
- Macrocycl
- Macrocyclic diamines, **64**, 216
- Magnesium salt of monoethyl malonate, reaction with methylthiodihydropyrrolidinium salts, **67**, 212
- D-Malate, synthesis, **68**, 145
- Maleic acid, reaction with thioureas to give 2-imino-5,6-dihydro-1,3-thiazin-4-ones, **66**, 154
- Malonyl-2-aminopyridine, structure **63**, 117 synthesis, **63**, 137 nitrosation, **63**, 188 reaction with diazonium compounds, **63**, 189
- Maniawamycins A and B, synthesis via cyclic sulfates, **68**, 155
- D-Mannonolactone, starting material in synthesis of *seco*-nucleosides, **67**, 422
- D-Mannose thiosemicarbazones, ring chain tautomerism, **66**, 20
- (+)-Maritidine, synthesis, **69**, 59
- Menthyl (s)-3-(2-pyridylsulfinyl)acrylate, in synthesis of showdomycin, **68**, 244
- 2-Mercapto-N-alkylbenzamides, precursor to 1,3-benzothiazin-4-ones, **66**, 143
- 4-Mercapto-5-alkyl-2,6-dimethylpyrimidine, bromination and cyclisation to thieno[2,3-*d*]pyrimidines, **65**, 237
- 3-Mercaptoalkyl isocyanides, cyclisation, **69**, 384
- 2-Mercaptobenzamides, precursor to 2-substituted-1,3-benzothiazin-4-ones, **66**, 143 reaction of zinc salts and benzotrichloride, **66**, 143 reaction with aldehydes to give 2,3-dihydro-1,3-benzothiazin-4-ones, **66**, 156
- 2-Mercaptobenzhydrazide, reaction with cyanogen **66**, 144
- 2-Mercaptobenzimidazole, reaction with acryloyl chlorides, **66**, 165 reaction with 4-benzylideneoxazol-5-ones **66**, 166 reaction with 2-chlorobenzoic acid or 2-chloronicotinic acid, **66**, 167
- 2-Mercaptobenzoic acid reaction with ethyl cyanofornate, **66**, 140 reaction with cyanogen to give bis(1,3-benzothiazin-4-ones), **66**, 140 reaction with malononitrile, **66**, 140 reaction with cyanates, **66**, 141 reaction with carbodiimides, cyanamides, dialkylcyanamides, cyanourea, cyanothiourea, **66**, 141
- 2-Mercaptobenzothiazole, reduction by Raney nickel to 2,2'-bibenzothiazole, **67**, 40
- 2-Mercaptoimidazoles, synthesis, **69**, 36 reaction with  $\alpha$ -haloketones, **69**, 280
- 2-Mercapto-1*H*-imidazo[4,5-*b*]pyridine, reaction with 2-chlorobenzoic or 2-chloronicotinic acids, **66**, 167
- $\alpha$ -Mercaptoketones, reaction with liquid HCN, **67**, 34
- N-(2-Mercapto-1-methylimidazol-5-yl)-N'-methyl urea, **61**, 34

- 9-Mercapto-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 210  
alkylation and acylation, **63**, 210  
reaction with isocyanates, **63**, 211
- 2-Mercaptonicotinic acids, reaction with carbodiimides to give 2-imino-1,3-pyridothiazin-4-one, **66**, 163
- 2-Mercapto-1,3,4-oxadiazole, **64**, 194
- 2-Mercaptooxazolotropone, UV spectra, **66**, 301
- 2-Mercaptophenyltriazole, from 1,3-benzthiazin-4-ones and hydrazines, **66**, 178
- 3-Mercaptopropionic acid amides, reaction with azomethines to give 2,3,5,6-tetrahydro-1,3-thiazin-4-ones, **66**, 154  
reaction with aldehydes and ketones, **66**, 155
- 11-Mercaptopyrido[1,2-*b*]cinnolin-6-ium hydroxide, reduction, **69**, 99  
alkylation with ethyl bromoacetate, **69**, 106
- 3-Mercaptopyrrole, **65**, 55
- 2-Mercaptoquinoline acids, reaction with cyanoamides and cyanothioureas to give 2-imino-1,3-quinolinothiazin-4-ones, **66**, 163
- 2-Mercaptothiazoles, synthesis, **69**, 44
- 2-Mercaptothiazolo[*c*]tropone, alkylation and oxidation, **66**, 360
- 2-Mercapto-4,5-di-*p*-tolyl-imidazole, reaction with  $\alpha$ -halo carboxylic acids, **69**, 283
- 2-Mercaptotriazoles, in preparation of thiazolo[3,2-*b*][1,2,4]triazoles, **69**, 317  
reaction with dimedone and bromine, **69**, 321  
reaction with haloacetoacetic ethyl esters, **69**, 322  
reaction with epoxyphosphonates, **69**, 322
- Meridine, **70**, 100
- ( $\pm$ )-Meserbrine, synthesis, **67**, 230
- 1-(Mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole, nucleoside preparation, **69**, 142
- Methacryloyl thiourea, thermal cyclisation to 5,6-dichloro-2-imino-1,3-thiazin-4-ones, **66**, 152
- 5,8-Methano-3,1-benzoxazine-2,4-diones, synthesis, **69**, 374
- 5,8-Methano-2*H*-1,3-benzoxazin-4-one, synthesis, **69**, 379
- 5,8-Methano-2*H*-3,1-benzoxazin-4-ones, **69**, 380
- 1',2'-*seco*-2',3'-Methanonucleosides, synthesis, **67**, 402
- 5,8-Methano-*r*-4-phenylimino-*c*-4a,c5,6,7,8-*c*-8a-hexahydro-4*H*-1,3-benzoxazine, conformations, **69**, 410
- 5,8-Methano-*r*-4-phenylimino-*c*-4a,c5,8-*c*-8a-tetrahydro-4*H*-1,3-benzoxazine, conformations, **69**, 410
- diexo*-Methanoquinazolinédiones, **69**, 394
- 2-Methoxyacridine-9-carboxaldehyde, in synthesis of pyridoacridines, **70**, 119
- 6-Methoxyadenine, alkylation to give acylonucleosides, **68**, 9
- cis,trans*-2-Methoxy-5-alkyloxanes, conformational equilibria, **69**, 223
- 5-Methoxy-2-anisylloxazole, [3+2]cycloaddition with 2,3-di-*O*-benzyl-D-glyceraldehyde, **68**, 305
- (*E*)-2'-Methoxy-1-benzenesulfonyl-3-vinylindole, reaction with 1,4-benzoquinones, **63**, 362
- (*Z*)-2-Methoxy-1-benzenesulfonyl-3-vinylindole, reaction with diethyl azidodicarboxylate, **63**, 385
- 6-Methoxybenzo[*c*]phenanthridines, synthesis, **67**, 360
- 1-Methoxybenzo[*c*]pyrilium-4-olate, generation and reaction with dipolarophiles, **65**, 361  
reaction with carbonyls, **65**, 362
- 5-Methoxybenzo[*f*]-1,4-thiazepine, loss of sulfur, **65**, 50
- 10-Methoxybenzotrothiazine, oxidation, **66**, 352
- 2-(4-Methoxybenzylamino)-1-(4-*r*-phenacyl)pyridinium bromide, ring chain tautomerism, **66**, 63
- 2-Methoxy-3-bromotropones, reaction with *o*-aminophenol, **64**, 108
- 3-Methoxycarbonylcoumarin, as dienophile with Lewis acid catalysis, **65**, 350
- 2-Methoxycarbonylcyclanones, thiobenzoylhydrazones-ring chain tautomerism, **66**, 46
- 5-Methoxycarbonyl-4-methylnicotinic acid, reaction with oxalyl chloride, **68**, 192
- 4-Methoxycarbonyl-5-phenyl-1,3,2-dioxathiolane 2,2-dioxide, reaction with ammonium bromide, **68**, 146
- 2-(*o*-Methoxycarbonylphenyl)pyridine, reaction with *O*-tosylhydroxylamine, **69**, 114



- 3-Methoxycarbonyl-2-pyrone, cycloaddition with trimethylenemethane, **65**, 330
- 5-Methoxycarbonyl-2-pyrone, photosensitised reaction with acrylonitrile, **65**, 325  
cycloaddition with 1,1-diethoxyethylene, **65**, 334  
reaction with 2,3-dihydrofuran, **65**, 334  
reaction with 3,4-dimethoxy- and 3,4-dibenzyloxyfurans, **65**, 334  
reaction with isoprene, **65**, 334  
reaction with 1-ethoxycarbonyl-1*H*-azepine, **65**, 336  
reaction with p-benzoquinone, **65**, 342  
reaction with cyclopropanone ketal, **65**, 341  
reaction with conjugated olefins (as 2*π*-dienophile), **65**, 348  
reaction with 2-ethoxybutadiene, **65**, 350  
reaction with isoprene, **65**, 350
- 4-(Methoxycarbonyl)thiophen-3-yl urea, cyclisation, **65**, 263
- (*E*)-5-(2-Methoxycarbonylvinyl)uracil, preparation, **69**, 164
- 2-Methoxycoumaran-3-ones, preparation from *o*-hydroxyacetophenones, **69**, 19
- 2-Methoxy-3,6-diaryl-2*H*-pyrans, **62**, 27
- 2-Methoxy-1,3-dioxane, conformational energies, **69**, 236
- β*-Methoxyethyltosylamide, reaction with iodonium triflate, **69**, 28
- 5-(1-Methoxyethyl)uridine from 5-chloromercuryuridine, **62**, 403
- 11-Methoxy-1,2,4,6,7,11b-hexahydro[1,3]oxazino[4,3-*a*]isoquinoline, antitumor activity, **70**, 75
- 4(5)-Methoxyimidazole, Pd(0) catalysed allylation, **66**, 91
- Methoxy-5-iodopyrimidines, coupling with methyl acrylate, **62**, 309
- 2-Methoxy-3-methoxycarbonyltropone, reaction with phenylhydrazine, **64**, 105
- 3-[(Methoxymethyl)amino]pyrido[4,3-*e*][1,2,4]triazine, synthesis from 3-aminopyrido[4,3-*e*][1,2,4]triazine, **61**, 219
- 2-Methoxy-3-(3-methyl-2-butenyl)-4H-pyrido[1,2-*a*]pyrimidin-4-one, oxidation, **63**, 181
- Methoxy-1-methylcycloheptapyrazol-8-ones, **64**, 112
- cis/trans*-2-Methoxy,4-methyl-1,3-dioxane, rotamers, **69**, 248
- 4-Methoxy-6-methyl-3-oxidopyrylium ylide, from kojic acid, **65**, 359  
reaction with *N*-phenylmaleimide, **65**, 359  
reaction with dimethyl acetylene dicarboxylate, **65**, 359  
reaction with acrylonitrile, **65**, 359  
(*o*-Methoxymethylphenyl)diazomethane, decomposition, **65**, 144
- 4-Methoxy-5-methyl-2-pyrimidinone, in preparation of acyclonucleosides, **68**, 77
- 2-Methoxy-3-methylquinone, Nenitzescu reaction with urethanes, **67**, 235
- 2-Methoxymethylthieno[2,3-*d*]pyrimidin-4(3*H*)-one, **66**, 209
- 7-Methoxymitomycin precursor, **65**, 11
- 11-Methoxynoracronycine, **70**, 127
- 2-Methoxyoxane, conformations, **69**, 220  
calculated conformational equilibria, **69**, 225
- 4-*p*-Methoxyphenyl-5-methoxycarbonyl-1,3,2-dioxathiolane 2,2-dioxide, instability, **68**, 153
- 3-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl]thieno[3,2-*d*]pyrimidine-2,4-dione, **66**, 258
- N*-Methoxyphenylpropionamide, oxidative cyclisation, **69**, 56
- 5-(4'-Methoxyphenyl)-2-(3'-pyridyl)oxazole, **64**, 189
- 2-Methoxy-2*H*-pyran, aromatisation, **62**, 68  
conversion to benzene derivatives, **62**, 93
- 2-Methoxy-4*H*-pyran, ring opening transformations, **62**, 86
- 3-Methoxypyridazine, dimerisation, **67**, 59
- 2-Methoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 184
- 3-Methoxy-2-(*D*-ribofuranosyl)acrylate esters, reaction with urea derivatives, **68**, 367
- 3-Methoxy-2-(*D*-ribofuranosyl)acrylate, in preparation of pseudouridine, **68**, 359
- 3-Methoxy-2-(*D*-ribofuranosyl)acrylonitrile, reaction with urea derivatives, **68**, 367
- N*-Methoxytetrahydroquinoline, synthesis, **69**, 56
- 2-Methoxy-1,2,4,5-tetroxane, conformations, **69**, 257
- 3-Methoxythiocarbonylamino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 249

- 2-Methoxy-3,5,7-tribromotropone, reaction with *o*-aminophenol, **64**, 108  
*trans*-2-(2-Methoxyvinyl)benzofuran, cycloaddition reactions, **63**, 342, **63**, 372  
3-(2-Methoxyvinyl)-1-phenylsulfonylindole, reaction with *N*-phenylmaleimide, **63**, 363  
Methyl 3-acetoxy-2-methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylate, **63**, 133  
3-Methylacetylacetone, alkylation with  $\alpha,\varphi$ -dihaloalkanes, **67**, 216  
Methyl 3-acetylaminothiophene-2-carboxylates, reaction with primary amines to thieno[3,2-*d*]pyrimidines, **66**, 236  
*de-N*-Methylacronycine, **70**, 127  
3-Methyl acrylate, 1,3-dipolar cycloaddition to metallated azomethine ylides, **64**, 8  
Methyl acrylate, Pd catalysed reaction with anilines, **67**, 214  
*cis*-2-Methyl-5-alkyl-5-hydroxy-1,3-dioxanes, intramolecular hydrogen bonding, **69**, 242  
*cis,trans*-2-Methyl-5-alkylmercaptotoxanes, conformational equilibria, **69**, 224  
*trans*-3,4*a*-*H*-2-Methyl-3-alkylperhydropyrido[1,2-*c*]pyrimidines, <sup>1</sup>H NMR spectra and conformations, **70**, 26  
Methyl 5-alkyl-1-phenyl-1,2,4-triazole-3-carboxylate, **64**, 197  
Methyl-L-amicetoside, in preparation of acyclonucleosides, **68**, 64  
Methyl 5-amino-4-benzylthieno[2,3-*d*]pyrimidin-2-one-6-carboxylate, **66**, 218  
Methyl 5-amino-2-(4-chlorophenyl)-4-phenylthieno[2,3-*d*]pyrimidine-6-carboxylate, **66**, 217  
2-(2-Methylaminoethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline, **70**, 42  
2-(*N*-Methylaminoethyl)-3-nitrobenzaldoxime, ring chain tautomerism **66**, 36  
5-Methylaminomethylene-1,3-dioxan-4,6-dione, conformations, **69**, 247  
1-Methyl-*trans*-2-amino-3,4,4*a*, 5,6,7,8,8*a*-octahydroquinazoline, conformations, **69**, 407  
3-Methyl-*trans*-2-amino-3,4,4*a*, 5,6,7,8,8*a*-octahydroquinazoline, conformations, **69**, 407  
2-*N*-Methylaminooxane, conformations, **69**, 220  
2-Methyl-1-aminopyridinium salts, acylation, **68**, 201  
Methyl 4-aminothiophene-3-carboxylate, cyclisation with formamide **65**, 262  
4-(*N*-Methylanilino)pent-3-en-2-one, irradiation **67**, 239  
6-Methylantranilic acid, in synthesis of quino[*a*]acridones, **70**, 91  
*Cis* and *trans*-*N*-Methyl-3-aryl-4-carboxymethylisoquinol-1-ones, synthesis, **67**, 372  
Methyl *N*-aryl-3-cyano-4-ethyl-2-oxopyridazin-5-carboxylate, reaction with sulfur and base, **68**, 188  
Methyl 2-aryl-2,3-dihydrobenzofuran-3-carboxylates, formation, **69**, 69  
3-Methyl-2-(*N*-arylimino)-2,3,6,7-tetrahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-ones, UV spectra, **70**, 24  
infrared spectroscopy, **70**, 24  
*N*-Methylalaphyllidine, **70**, 127  
bicyclo-*N*-Methylalaphylline, **70**, 127  
*O*-Methylated-5-iodouracil, reaction with tetrahydropyranyl protected copper derivatives of propargyl alcohol, **62**, 397  
Methyl 2-benzamido-2-deoxy-5,6-*O*-isopropylidene-4-*O*-methylsulfonyl- $\beta$ -D-glucopyranoside, cyclisation, **70**, 188  
11-Methylbenzazinetropylium ions, ring cleavage, **66**, 387  
5(6)-Methylbenzimidazole, Pd(0) catalysed allylation, **66**, 93  
Methyl benzofuran-4-carboxylate, **63**, 341  
2-Methylbenzo[*f*]indole-4,9-dione, synthesis, **67**, 244  
*nor*-6-Methylbenzo[*c*]phenanthridine, synthesis, **67**, 360  
6-Methylbenzo[*c*]phenanthridines, synthesis, **67**, 379  
8-Methyl-4*H*-1-benzopyran-4-ones, arylation to flavones, **65**, 305  
Methyl benzothietane-2-carboxylate, **65**, 161  
Methyl 2-benzoylamino-3-dimethylaminopropenoate, reaction with barbituric acid, **64**, 54  
conversion to pyrido[1,2-*a*]quinoline, **64**, 58  
reaction with 1,4-naphthoquinone, **64**, 50  
Methyl-4,6-*O*-benzylidene-2,3-dimethoxy- $\alpha$ -D-glucopyranoside, conformations, **69**, 251

- Methyl 4,6-*O*-benzylidene- $\alpha$ -D-glucopyranoside, conversion to cyclic sulfates, **68**, 114
- 1'-Methyl-1,2'-bibenzimidazole, from benzimidazole and 1-methylbenzimidazole-2-sulfonic acid, **67**, 37
- 3'-Methyl-4,5'-biisoxazole, **67**, 24
- 3-Methylbiopterin, **70**, 268
- 3-Methyl-3-(2-bromoethyl)-1,3,4,6-tetrahydro-7*H*-[1,4]oxazino[1,3-*b*]isoquinoline-1,4-diones, **70**, 55
- 1-Methyl-3-bromomethyl-7-methoxypyrazolo[4,3-*d*]pyrimidine, in preparation of acyclo 1-methylformycin, **70**, 247
- Methyl-3-bromo-3-phenyl-2-hydroxypropionate, synthesis via ring opening of cyclic sulfates, **68**, 146
- 3-Methyl-2-*t*-butyl-6,7,8,9-tetrahydropyrido[1,2-*a*]pyrimidin-4-one, **63**, 236
- Methyl *N*-carbobenzyloxy-pyrrolidin-3-one-2-carboxylate, **65**, 107
- 1-Methyl- $\beta$ -carboline, **64**, 56
- r*-4-Methyl,*cis*-5-chloro,*trans*-6-methyl-1,3-dioxane, conformation, **69**, 238
- Methyl 3-cyano-4-imino-6-methyl-4*H*-quinolizine-1-carboxylate, reaction with carboxylic anhydrides, **68**, 185
- Methyl 2-cyano(3-methylthienopyrimidin-2-ylidene)acetates, **66**, 200
- 1-(and 2-)Methylcycloheptapyrazol-4-ones, **64**, 112
- 5-Methylcytosine, Pd(0) catalysed allylation, **66**, 111
- 3-Methyl-*cis*-decahydroquinazoline, conformations, **69**, 405
- Methyl 2-deoxy-3,5-di-*O*-*p*-toluoyl-D-*erythro*-pentofuranoside, reaction with trimethylsilyl derivatives of hydantoin, **68**, 79
- 1-Methyl-2'-deoxypseudouridine, **68**, 370 inhibition of P815 tumour cells, **68**, 371
- 3-Methyl-2'-deoxypseudouridine, **68**, 370
- 1-*O*-Methyl-2-deoxy-D-ribofuranose, precursor in *seco*-nucleoside synthesis, **67**, 417
- Methyl 2,2-dialkyl-4-oxo-1,3-dioxolan-5-carboxylate, **65**, 184
- Methyl 2,5-diamino-thieno[2,3-*d*]pyrimidine-6-carboxylate, **66**, 218
- Methyl 3,3-diazido-2-cyanoacrylate, **67**, 248 precursor to 1,2,3-triazoles, **67**, 260
- Methyl 2-diazo-3-oxobutyrate, copper catalysed decomposition in presence of aldehydes and ketones, **65**, 184
- [1-(1-Methyl-2,2-dibromocyclopropyl)ethylidene]hydroxylamine, **65**, 124
- Methyl-2,3-dideoxy-3-fluoro-5-*O*-(4-phenylbenzoyl)- $\beta$ -D-*erythro*-pentofuranoside, reaction with 5-nitouracil, **69**, 195
- 2-Methyl-2,3-dihydro-1,3-benzothiazin-4-one, oxidation, **66**, 172
- Methyl dihydrobenzothiophene-3-carboxylate, **65**, 165
- 1-Methyl-3,4-dihydro- $\beta$ -carboline, reaction with ethyl ethoxymethyleneacetoacetate, **68**, 213
- 9-Methyl-3,4-dihydro- $\beta$ -carboline, conversion to triazinopyridoindole, **61**, 212
- 1-Methyl-3,4-dihydro- $\beta$ -carboline-3-carboxylate, **64**, 56
- 2-Methyl-1,2-dihydroisoquinoline, **67**, 384
- Methyl 3,4-dihydro-2-methyl-5-thiomethylthieno[3,4-*d*]pyrimidin-4-one-7-carboxylate, **66**, 248 antiallergic activity, **66**, 273
- 9-Methyl-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrimidin-2-one, **63**, 242
- N*-Methyl-6,7-dimethoxy-1,3-isoquinolinedione, **67**, 385
- Methyl 2,4-dimethoxy-6-methylpyrimidine-5-carboxylate, lithiation and reaction with acetylenes, **68**, 195
- 2-[*N*-Methyl-2-(2',4'-dinitrophenyl)amino]oxane, UV spectra and conformations, **69**, 227
- 2-Methyl-1,3-dioxane, conformational energies, **69**, 236
- 4-Methyl-1,3,2-dioxathiolane 2-oxide, synthesis, **68**, 106
- Methyl 2,7-dioxo-5,5-diphenyl-3-methyl-1,4-diazabicyclo[3,3,0]octane-8-carboxylate, **65**, 110
- Methyl-2,6-diphenylpyridinium perchlorate, **62**, 51

- 4-Methyl-2,6-diphenylpyrylium tetrafluoroborate, reactions with diazoalkanes, **65**, 292
- Methylene-3-azapyrylium salts, formation of anhydrobases, **64**, 355
- Methylenebenzothiazolines, **65**, 191
- Methylene-bridged bisoxazines, **69**, 354
- (*R*)-2-Methylene cyclopropane acetic acid, synthesis via cyclic sulfites, **68**, 136
- 4-Methylene-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrimidines, **63**, 169
- ring opening, **63**, 239
- 4-Methylene-3,4-dihydro-4*H*-pyrido[1,2-*a*]pyrimidine, X-ray structure, **62**, 121
- exo*-Methylene-1,3-dioxanes, ring inversion, **69**, 259
- 2-Methylenedioxiols, **65**, 183
- 3,4-Methylenedioxyacetophenone, in the synthesis of benzo[*c*]phenanthridine alkaloids, **67**, 352
- (3',4'-Methylenedioxy)-3,4-dimethoxychalcone, in nitidine synthesis, **67**, 350
- 2-(3,4-Methylenedioxyphenyl)ethylamine, condensation with *D*-ribonolactone, **68**, 69
- 3-(3,4-Methylenedioxyphenyl)propionate, starting material for synthesis of nitidine, **67**, 350
- Methylenediphosphiranes, **65**, 171
- 6,7-Methylene-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylate, **63**, 205
- Methylenephosphiranes, **65**, 170
- Methylene pyrazoles, hydration, **64**, 294
- 6-Methylene-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 157
- Methylenethiaranes, **65**, 161
- Methyl 3-ethoxycarbonylaminothiophene-2-carboxylate, reaction with ethyl chloroformate to give thieno[3,2-*d*]pyrimidines, **66**, 238
- O*-Methylfagaranine, synthesis **67**, 352; **67**, 362; **67**, 364; **67**, 374
- 2-Methylfevenulone, preparation and antibiotic activity, **61**, 252
- 2-Methyl-3[2-(4'-(4-fluorobenzoyl)piperazin-1-yl)ethyl]pyrido[1,2-*a*]pyrimidin-4-one, biological activity, **63**, 245
- Methyl 5-fluoro-4-trifluoromethanesulfonyloxy-2,3-dihydro-1-methyl-7-oxo-1*H*, 7*H*-pyrido[3,2,1-*ij*]cinnoline-8-carboxylate, reaction with 3-tributylstannyl-2-cyclohexen-1-one, **69**, 104
- 1-Methylformycin, **70**, 240
- 2-Methylformycin, **70**, 240
- 4-Methylformycin, **70**, 240
- 6-Methylformycin, **70**, 240
- 2-Methyl-4-formyl-1,2-dihydroisoquinoline, synthesis, **67**, 384
- Methyl 3(2*H*)-furanone-2-carboxylate, **65**, 138
- N*-Methylfuro[2,3-*c*]acridin-6-one, **70**, 151
- 2-Methylfurotropone, reaction with primary amines, **64**, 116
- 2-Methylglyoxal-1-oxime, condensation with 2-amino-2-( $\beta$ -*D*-ribofuranosyl)acetonitrile derivatives, **68**, 379
- O*-Methylhalfordinol, *see* 5-(4'-methoxyphenyl)-2-(3'-pyridyl)oxazole
- trans*-3,4*a*-*H*-3-Methyl-1,3,4,4*a*, 5,6-hexahydropyrido[1,2-*a*][1,3]oxazin-1-one, catalytic hydrogenation, **70**, 34
- 6-Methylhexahydropyridopyrimidin-4-ones, configuration, **63**, 111
- 3-Methyl-1,3,4,6,7,11*b*-hexahydropyrimido[6,1-*a*]isoquinolines,  $^{13}\text{C}$  NMR spectra and conformations, **70**, 30
- 2-Methyl-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinoline,  $^1\text{H}$  NMR spectra and conformations, **70**, 27
- 3-Methyl-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2,4-dione,  $^1\text{H}$  NMR spectra and conformations, **70**, 28
- 3-Methyl-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-one,  $^1\text{H}$  NMR spectra and conformations, **70**, 28
- 2-Methyl-2,3,4,4*a*, 5,6-hexahydro-1*H*-pyrimido[1,6-*a*]quinoline, **70**, 65
- $^1\text{H}$  NMR spectra and conformations, **70**, 27
- (2*S*,5*S*)-*trans*-2-Methyl-5-hexanolide, synthesis via cyclic sulfites, **68**, 133
- N*-Methyl-2-hydroxy-1-cycloalkancarboxamides, reaction with aldehydes and ketones, **69**, 369
- 1-Methyl-3-hydroxymethyloctahydroquinazolin-4-ones, **69**, 389

- anhydro*-2-Methyl-4-hydroxy-5,6,7,8-tetrahydropyrido[1,2-*b*]pyridazinium hydroxide, reaction at position 3, **69**, 102
- 2-Methylimidazo[1,2-*a*]pyrimidine, **63**, 230
- 6-Methylimidazo[2,1-*b*]thiazole, **69**, 288
- 6-Methylimidazo[2,1-*b*]thiazole-5-carboxylic acid, **69**, 298
- 2-Methylimidazotropone, *N*-alkylation, **66**, 348
- 2-(*N*-Methylimino)-3-nitroso-2,3-dihydrothiazole, cyclisation, **69**, 324
- 2-*N*-Methyliminooctahydro-2*H*-3,1-benzoxazines, mass spectra, **69**, 441
- 2-*N*-Methylimino-*cis* and *trans*-ocahydro-2*H*-3,1-oxazines, conformations, **69**, 408
- 2-*N*-Methylimino-*cis* and *trans*-ocahydro-2*H*-3,1-thiazines, conformations, **69**, 408
- (*E*)-Methyl indole-2-acrylate, reaction with diethyl azidodicarboxylate, **63**, 385
- N*-Methylindole-4,5-dicarboxylic anhydride, **63**, 373
- 1-Methylindole-4,7-dicarboxylic ester, **63**, 345
- 1-(1-Methyl-2-indolyl)-1-(*N*-methyl-2'-pyrrolyl)ethene, reaction with dimethyl acetylene dicarboxylate, **63**, 351
- 2-(1-Methyl-2-indolyl)propene, dimerisation, **63**, 350
- O*<sup>6</sup>-Methylinosine, cyanomethylation, **62**, 345
- 2-Methylisocarbostyryl-4-aldehyde, synthesis **67**, 384
- 1-Methylisochromane, conformations, **69**, 229
- Methyl 3-isocyanato-2-thiophenecarboxylate, reaction with ethyl glycinate, **65**, 258
- 1-Methylisoquinoline, reaction with benzenesulfonyl azide, **68**, 216
- s*-Methylisothiazolidine-3-carboxylic acid, **64**, 23
- 3-Methyl-isoxazolin-5-one, Pd(0)-catalysed reaction with cinnamyl ethyl carbonate, **66**, 84
- anhydro*-2-Methyl-3-mercapto-4-hydroxy-5,6,7,8-tetrahydro[1,2-*b*]pyridazinium hydroxide, **69**, 105
- Methyl-E-3-(methoxycarbonyl)methoxypropenoate, reaction with 2-amino-6-chloropurine, **67**, 414
- Methyl 4-(methoxyphenyl)-3,6-dioxo-3,4,5,6-tetrahydro-2*H*-1,4-oxazine carboxylate, **65**, 190
- 1-Methyl-3-[1-(*m*-methoxyphenyl)ethyl]perhydropyridazine, reaction with formaldehyde, **69**, 117
- 3-Methyl-5-methoxy-2-phenyl-2,4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidine-1-thione, **70**, 66,68
- N*-Methyl-2-(2-methoxyvinyl)indole, reaction with acrylonitrile **63**, 377
- reaction with diethyl azidodicarboxylate, **63**, 385
- Methyl *N*-methylglycinate, precursor to imidazoles, **64**, 18
- 3-Methyl-6-(1-methylhydrazino)uracil, precursor of pyrido[4,3-*c*] [1,2,4]triazines, **61**, 241
- Methyl 5-methyl-2-hydroxyindolizine-3-dithiocarboxylate, **68**, 211
- Methyl 1-methylimidazole-5-carboxylate, **64**, 18
- Methyl 3-methylimidazo[2,1-*b*]thiazole-6-carboxylate, reduction, **69**, 295
- Methyl 2-methyl-3-propyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylate, **63**, 135
- 1-Methyl-2-methylthio-2-pyrroline, as a dienophile, **70**, 198
- 2-Methyl-2*H*-naphtho[1,8-*c,d*]thiophene, **65**, 163
- N*-Methylnaphthylformamides, in the synthesis of benzo[*c*]phenanthridine alkaloids, **67**, 353
- 2-Methylnicotinic acid, reaction with phosphorus oxychloride and dimethyl formamide, **68**, 192
- 4-Methylnicotinic acid, reaction with thionyl chloride, **68**, 192
- 2-Methyl-4-nitroimidazole, catalytic hydrogenation in acetic anhydride, **61**, 12
- 4-Methyl-5-nitroimidazole, coupling with mercury chloride salt, **69**, 140
- 3-Methyl-2-(4-nitrophenyl)-4-phenyl-1,3-oxazolium-5-olate, in preparation of pyrroles, **67**, 425
- 6-Methyl-4-(4'-nitrophenyl)-2-phenylquinazoline, **64**, 217
- 1-Methyl-5-nitro-2-(2'-pyrimidyl)imidazole, metabolism of, **61**, 31
- 4-Methyl-6-nitroso-3-phenylpyridinediol-hydrolysis to hydroxyazabenzquinone, **61**, 143

- N*-Methyl-2-(2-nitrovinyl)indole, reaction with acrylonitrile, **63**, 377  
 reaction with maleic acid, **63**, 373  
 de-*N*-Methylnoracronycine, **70**, 127  
*N*-Methyl-*cis*-octahydro-2*H*-3,1-benzoxazine, conformations, **69**, 405  
 Methyl 1,3-oxazin-2-one-4-carboxylate, **64**, 33  
 Methyl oxazolidin-2-one-3-carboxylate, **64**, 21  
 Methyl 3-oxobutanoate, reaction with thiobenzhydrazide, ring chain tautomerism, **66**, 46  
 3-(1-Methyl-5-oxo-1,5-dihydropyrrol-3-yl)acrolein, **65**, 120  
 2-Methyl-7-oxo-3,7-dihydro-1,2,4-triazolo[3,2-*c*][1,2,4]triazine, **61**, 286  
 5-Methyl-5-oxo-1,3,5-dioxaphosphorinane, synthesis from tris(hydroxyethyl)phosphine, **61**, 64  
 Methyl *trans*-4*a*,8-*H*-1-oxo-1,3,4,4*a*,7,8-hexahydropyrido[1,2-*c*][1,3]oxazine-8-carboxylate, hydrolysis, **70**, 37  
 Methyl 1-oxo-1,3,4,4*a*,7,8-hexahydropyrido[1,2-*c*][1,3]oxazine-8-carboxylate, deuteration, **70**, 36  
 2-(and 3)-Methylloxolane, **65**, 142  
 Methyl 3-oxooxepane-2-carboxylate, **65**, 158  
 Methyl 3-oxooxocane-2-carboxylate, **65**, 159  
 Methyl 2-oxo-2*H*-pyrido[1,2-*a*]pyrimidine-4-acetate, **63**, 126  
 6-Methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetate, X-ray analysis, **63**, 120  
 6-Methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-acrylates, thermal rearrangement, **63**, 231  
 6-Methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylates, hydrolysis, **63**, 173  
 2-Methyl-4-oxopyrido[1,2-*a*]pyrimidine-7-carboxylate, condensation with aldehydes, **63**, 187  
 2-Methyl-4-oxo-4*H*-pyrido[1,2-*a*]pyrimidine-9-carboxylic acid, **63**, 133  
 1-Methyl-4-oxo-4,5,6,7-tetrahydro-6,6-dimethyl-1,3-benzoxazole, **65**, 181  
 3-Methyl-1-oxo-12*H*-1,2,4-triazepino-[3',4':3,4][1,2,4]triazino[5,6-*b*]indole, **61**, 294  
 3-Methyl-5-oxo-12*H*-1,2,4-triazepino-[4',3':2,3][1,2,4]triazino[5,6-*b*]indole, **61**, 295  
 4-Methylperhydropyrido[1,2-*a*][1,3]oxazines, quaternisation, **70**, 35  
*cis*-4*a*, 5-*H*-5-Methyl-perhydropyrido[1,2-*c*][1,3]oxazine, NMR spectroscopy and conformations, **70**, 11  
*trans*-4*a*, 5-*H*-5-Methyl-perhydropyrido[1,2-*c*][1,3]oxazine, NMR spectroscopy and conformations, **70**, 11  
*cis*-4*a*, 8-*H*-8-Methyl-perhydropyrido[1,2-*c*][1,3]oxazine, NMR spectroscopy and conformations, **70**, 11  
*trans*-4*a*,8-*H*-8-Methyl-perhydropyrido[1,2-*c*][1,3]oxazine, NMR spectroscopy and conformations, **70**, 11  
 1-Methylperhydropyrido[1,2-*b*]pyridazine, conformation, **69**, 93  
 ionisation potential, **69**, 93  
 low temperature <sup>13</sup>C NMR spectroscopy, **69**, 95  
 2-Methylperhydropyrido[1,2-*c*]pyrimidine, dipole moments, **70**, 22  
<sup>1</sup>H NMR spectra and conformations, **70**, 25  
 1-Methylperhydropyrido[1,2-*c*]pyrimidin-3-one, **70**, 45  
 2-Methylperhydropyrido[1,2-*a*]pyrimidin-3-ones, Bohlmann bands in infrared spectra, **70**, 24  
*trans*-3,4*a*-*H*-3-Methylperhydropyrido[1,2-*c*][1,3]thiazine, infrared spectroscopy, **70**, 18  
<sup>1</sup>H NMR spectroscopy, **70**, 18  
*trans*-,4*a*-,5-*H*-5-Methylperhydropyrido[1,2-*c*][1,3]thiazine, infrared spectroscopy, **70**, 18  
<sup>1</sup>H NMR spectroscopy, **70**, 18  
*cis*-4*a*-,8-*H*-8-Methylperhydro[1,2-*c*][1,3]thiazine, infrared spectroscopy, **70**, 18  
 1-Methylperhydro-2,4-quinazolinone, **69**, 392  
 6-Methylphenanthridine, reaction with benzenesulfonyl azide, **68**, 216  
*cis*-2-Methyl-4-phenoxy-1,3-dioxanes, conformations, **69**, 239  
 2-Methyl-3-phenoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, nitration, **63**, 192  
 3-Methyl-7-phenoxy-pyrrolo[*b*]tropone, resistance to hydrolysis, **66**, 345  
 4-(*N*-Methyl-*N*-phenylamino)thieno[3,2-*d*]pyrimidine, **66**, 248

- Methyl 2-*O*-(phenylcarbamoyl)- $\alpha$ -D-glucopyranoside, cyclisation, **70**, 186
- 2-Methyl-2-phenyl-1,3-dioxanes, conformation of phenyl substituent, **69**, 241
- Methyl phenylglycinate, condensation with 4-chloroquinoline-3-carboxylate, **64**, 57
- 5-Methyl-6-phenylimidazo[2,1-*b*]thiazole, oxidation, **69**, 296
- Methyl 2-phenyl-5-(4-nitrophenyl)furan-3-carboxylate, **65**, 149
- cis*-1,4*a*-*H*-*trans*-5*H*-5-Methyl-1-phenylperhydro[1,2-*c*][1,3]thiazine, infra-red spectroscopy, **70**, 18
- 2-Methyl,*r*-2-phenyl, *cis*-5-phenyl-1,3-dioxane, conformational equilibria, **69**, 239
- 2-Methyl-4-phenyl-3*H*-pyrido[1,2-*b*]pyridazin-3-one, reduction, **69**, 100
- 2-Methyl-7-phenyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 136  
reaction with aromatic aldehydes, **63**, 201  
electrochemistry, **63**, 238
- 3-Methyl-1-phenylthieno[2,3-*d*]pyrimidin-2,4(1*H*, 3*H*)-diones, **65**, 246
- 1-Methylphthalazine, reaction with dimethyl acetylene dicarboxylate, **69**, 120
- 3-(2-Methyl-2-propenyl)thieno[3,4-*d*]pyrimidin-2(1*H*)-thione-4-one, **66**, 262
- 2-Methyl-4(1-propenyl)thieno[2,3-*d*]pyrimidine, **66**, 229
- 1-Methylpseudouridine, *see* 1-methyl-5-( $\beta$ -D-ribofuranosyl)uracil
- acyclo* 1-Methylpseudouridines, **68**, 378
- Methyl-4*H*-pyrans, **62**, 21
- Methyl-4*H*-pyran-2,6-dicarboxylate, **62**, 102
- 6-Methyl-2*H*-pyran-2-one, as pyrylium triflate in reaction with silyloxydienes, **65**, 350
- 2-Methylpyrazine, reaction with nitriles, **68**, 206
- 3-Methylpyrazolo[*d*]tropone, **64**, 102
- 3-(and 4-)Methyl-5-pyrazolone, Pd(0) catalysed allylation, **66**, 86
- N*-Methylpyridazinium iodide, reaction with dimethyl acetylenedicarboxylate, **68**, 208
- 3-Methylpyridine-2-thione, reaction of dianion with benzophenone, **68**, 206
- 2-(6-Methylpyridinylamino)methylenemalononitrile, ring chain tautomerism, **66**, 56
- 6-Methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, configuration and spectra, **63**, 110-1  
nitration, **63**, 188
- 2-Methylpyridotropolones, condensation with aldehydes, **66**, 361
- 4-Methylpyrimidine trifluoroacetate, reaction with saccharide free radicals, **68**, 364
- N*-Methyl-pyrimidin-5-yl triflate, coupling to alkenes, **62**, 311
- Methylpyrones, photosensitised reactions, **65**, 325
- 4-Methyl-2-pyrone, reaction with methyl magnesium iodide, **65**, 295
- Methyl 2-pyrone-5-carboxylate, decarboxylation, **62**, 28  
precursor to 2*H*-pyrans, **62**, 65  
photosensitised cycloaddition to 2,3-dihydrofurans, **65**, 325  
photosensitised cycloaddition to 3,4-dihydro-2*H*-pyrans, **65**, 325
- 1-Methylpyrrole, precursor to bipyrazoles, **67**, 22
- N*<sup>6</sup>-(*N*-Methyl-2-pyrrolidinylidene)adenine, Pd(0) catalysed allylation, **66**, 120
- 6-Methylpyrrolo[3,2-*d*]pyrimidin-4-one, *C*-ribosylation, **70**, 220
- 3-Methylpyrrolo[*b*]tropone, bromination, **66**, 332
- N*-Methylpyrrolo[*c*]tropone, 1:2-cycloadduct with diethyl acetylene dicarboxylate, **66**, 364
- 2-Methylpyrrolo[*b*]tropone, Mannich base and reduction, **66**, 361
- 2-(1-Methylpyrrol-2-yl)propene, reaction with diethyl azidodicarboxylate, **63**, 383
- 2-Methylquinazolin-4-one, reaction with dimethyl acetylenedicarboxylate, **68**, 215
- 2-Methylquinoline, reaction with two moles of dimethyl acetylenedicarboxylate, **68**, 214  
reaction with benzenesulfonyl azide, **68**, 216  
oxidative dimerisation to 2,2'-dimethyl-4,4'-biquinoline, **67**, 54
- 4-Methylquinoline, reaction with thionyl chloride, **68**, 208
- 2-Methylquinoxaline, reaction with tetrachloro-*o*-benzoquinone, **68**, 212  
reaction with two moles of dimethyl acetylenedicarboxylate, **68**, 214

- 1-Methylquinoxalinium iodide, precursor of [1,2,4]triazino[5,6-*b*]quinoxalines, **61**, 270
- Methyl  $\alpha$ -rhodinoside, in preparation of acyclonucleosides, **68**, 64
- S-Methyl 1-( $\beta$ -D-ribofuranosyl)dithiocarbonate, free radical coupling with *N*-ethylmaleimide, **68**, 240
- Methyl 2-( $\beta$ -D-ribofuranosyl)-2-oxoacetate, condensation with semicarbazides, **68**, 390
- 1-Methyl-6-( $\beta$ -D-ribofuranosyl)pyrrolidino [3,2-*c*]pyridine, preparation, **70**, 198
- 1-Methyl-5-( $\beta$ -D-ribofuranosyl)uracil, **68**, 360  
isolation from fermentation broth of *Streptomyces platensis*, **68**, 226
- 3-Methyl-5-( $\beta$ -D-ribofuranosyl)uracil, **68**, 360  
isolation from fermentation broth of *Nocardia lactamdurans*, **68**, 226
- N*-Methylseverifoline, **70**, 127
- 2-Methylshowsomycin, synthesis, **68**, 236
- 2-Methyl-4-styrylthieno[2,3-*d*]pyrimidine, **66**, 226
- 3-Methyl-substituted 4-oxo-4a,5,6,7,8,8a-hexahydroquinazolines, conformations, **69**, 416
- 5-Methyl-5-(4'-substituted-phenyl)-1,3-dioxane, conformational equilibria, **69**, 239
- Methyl substituted tetrahydro-1,3-oxazines, conformations, **69**, 401
- 1-Methyl-3-substituted-thieno[3,2-*d*]pyrimidinediones, **66**, 254
- 2-Methyl-3-substituted-thieno[3,2-*d*]pyrimidin-4-one, **66**, 236
- N*-Methyl-*N'*-sulfonatequinoxalinotropylium ions, tautomerism to sultone, **66**, 384
- 2(2-Methylsulfonyloxypentitol-1-yl)pyridines, cyclisation, **68**, 341
- 3-(2-Methylsulfonyloxypentitol-1-yl)pyridines, acid catalysed cyclisation, **68**, 344
- 2-Methyl-2*H*-tellurachromenes, **63**, 27
- 3-Methyl-2*H*-tellurachromenes, **63**, 27
- 2-Methyltellurachromylium salts, condensation with aldehydes, **63**, 51
- 2-Methyltellurapyrylium cations, reaction with dimethylformamide dimethyl acetal, **63**, 51
- 2-Methyltellurapyrylium salts, condensation with aldehydes to give Te containing cyanine dyes, **63**, 52
- 4-Methyltellurapyrylium tetrafluoroborate, **63**, 43
- 2-Methyltellurochromanone, **63**, 22
- 2-Methyltellurocinnamic acid, **63**, 32
- 3-Methyl tetrahydroindol-4-ones, formation, **67**, 246
- N*-Methyltetrahydronaphthylamines, in the synthesis of benzo[*c*]phenanthridine alkaloids, **67**, 353
- Methyl 2,3,4,5-tetrahydro-3-oxothiophene-2-carboxylate, **66**, 245
- 2-Methyl-3,4,5,6-tetrahydro-4a*H*-pyridazino[1,6-*a*]quinolin-4-one, **69**, 104
- 6-Methyl-6,7,8,9-tetrahydro-4*H*-pyrido [1,2-*a*]pyrimidin-4-ones, reaction with iminium salts, **63**, 219
- 9-Methyl-6,7,8,9-tetrahydro-4*H*-pyrido [1,2-*a*]pyrimidin-4-ones, **63**, 179
- 3-(1-Methyl-1,2,3,6-tetrahydropyrid-4-yl)indoles, cyclisation, **63**, 348
- 4-Methyl-1,6,7,11*b*-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinoline, **70**, 65
- Methyl 2,2,4,4-tetramethylthietane-1,1-dioxide-3-carboxylate, **65**, 161
- Methyl tetrathiafulvalenecarboxylate, hydrolysis **62**, 262  
decarboxylation, **62**, 265
- N*-(1-Methyl-5-tetrazolyl)benzohydrazonoyl bromide, reaction with sodium acetate, **63**, 324
- 9-Methyl-3-(1*H*-tetrazolyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 147
- 5-Methyl-2-(1-*arabino*-tetritol-1-yl)benzimidazole, antitumor activity, **70**, 185
- 2-Methyl-5-(D-*arabino*-tetritol-1-yl)pyrazine, **68**, 381
- 2-Methyl-6-(D-*arabino*-tetritol-1-yl)pyrazine, **68**, 381
- 3-Methyltetric acid, Pd(0)-catalysed allylation, **66**, 80
- 5-Methylthiazolo[3,2-*b*][1,2,4]triazole-2-thiol, **69**, 327
- 3-Methylthieno[3,2-*d*]pyrimidin-2,4-diones, **66**, 236
- 7-Methylthieno[2,3-*d*]pyrimidin-2(1*H*)-4(3*H*)-diones, **66**, 236



- 4-Methylthieno[2,3-*d*]pyrimidine, oxidation to aldehyde, **66**, 219
- 6-Methylthieno[2,3-*d*]pyrimidine, preparation and Reissert reactions, **66**, 229
- Reissert reaction, **65**, 252,
- 2-Methylthieno[3,2-*d*]pyrimidines, reaction with furfural, **65**, 259
- 2-Methylthieno[2,3-*d*]pyrimidin-4(3*H*)-one, **66**, 208
- reaction with aromatic aldehydes, **65**, 251
- 3-Methylthieno[2,3-*d*]pyrimidin-2(3*H*)-ones, **65**, 243, **66**, 209, **66**, 212
- 2-Methylthieno[*b*]tropolone, photochemical [4+2]cyclisation, **66**, 329
- 4(and 8-)Methylthieno[*b*]tropones, **64**, 94
- Methyl 3-(thien-2-yl)amino-2-cyano-3-methylthioacrylates, **66**, 200
- N*-Methyl-3-thioacetylpyrrole, alkylation and Diels-Alder reaction, **63**, 361
- $\alpha$ -Methylthio amide, Pummerer-type rearrangement, **69**, 33
- 4(*N*-Methylthioamido)tetrathiafulvalene, **62**, 279
- 2-Methylthio-3-arylthienopyrimido-4-imines, **65**, 243
- 4-Methylthiobutan-1-ol, reaction with chlorpurine, **69**, 156
- 2-Methylthio-6,7-dihydro-4*H*-pyrimido [6,1-*a*]isoquinoline-4-ones, reaction with amines **70**, 44
- Methylthiodihydropyrrolidinium salts, reaction with magnesium salt of monoethyl malonate, **67**, 212
- 2-Methylthio-9,10-dimethoxy-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinoline-4-ones, reaction with Raney nickel **70**, 46
- 1-Methylthio-4,4*a*,5,6,7,8-hexahydro-3*H*-pyrido[1,2-*a*]pyrimidine, condensation with anthranilic acids, **70**, 52
- 3-Methyl-2-thiohydantoin, by hydrolysis of 5-amino-2-mercapto-1-methylimidazole, **61**, 32
- 4-Methylthio-1-hydroxymethyl-9,10-dimethoxy-1,6,7,11*b*-tetrahydro-2*H*-[1,3]oxazino[4,3-*a*]isoquinolinium iodide, **70**, 38
- Methylthio-5-iodopyrimidines, coupling with methyl acrylate, **62**, 309
- 6-Methylthiopurines, Ni catalysed substitution by Grignard reagents, **62**, 385
- 6-Methylthiopurine nucleosides, Ni catalysed substitution by Grignard reagents, **62**, 386
- Methylthiopyrazoles, **67**, 253
- 2-Methylthiopyridine, Ni catalysed reaction with phenylmagnesium bromide, **62**, 384
- 4-(Methylthio)pyrido[1,2-*a*]pyrimidinium iodide, **63**, 205
- 3-Methylthiopyrido[2,3-*e*][1,2,4]triazine, preparation from 2-amino-3-hydrazinopyridine, **61**, 214
- 4-Methylthiopyrimidines, **67**, 311
- 3-Methylthiopyrrolidinone, formation, **69**, 33
- 4-Methylthio-7-( $\beta$ -D-ribofuranosyl)thieno[3,2-*d*]pyrimidine, **66**, 251
- 4-Methylthio-7-( $\beta$ -D-ribofuranosyl)thieno[3,4-*d*]pyrimidine, reactions, **66**, 269
- 1-Methylthio-4,4*a*,5,10-tetrahydro-3*H*-[1,3]thiazino[3,4-*b*]isoquinolinium iodide, **70**, 40
- 2-(and 4-)Methylthiothieno[3,2-*d*]pyrimidine, **66**, 252
- 5-(and 6)-Methyl-2-thiouracil, Pd(0) catalysed allylation, **66**, 111
- 2-Methyl-5,6-di-*p*-tolylimidazo[2,1-*b*]thiazole-3(2*H*)-one, **69**, 283
- 2-Methyl-1-tosylindole, **69**, 29
- Methyl-5-*O*-tosyl-2,3-*O*-isopropylidene- $\beta$ -D-ribofuranoside, reaction with adenine, **68**, 76
- 2-Methyl-1-tosylpyrrole, **69**, 28
- 3-Methyl[1,2,4]triazino[4,3-*a*]permidin-4(1*H*)one, **61**, 265
- 4-Methyl-1,2,4-triazoline-3,5-dione, **67**, 121
- reaction with vinylsulfoxyallenes, **67**, 123
- reaction with cyclooctatetraene and iron tricarbonyl, **67**, 128
- reaction with naphthalene and phenanthrene, **67**, 130
- irradiation in benzene, **67**, 130
- reaction with adamantanone azine and diaryl acetylenes, **67**, 164
- reaction with pyrido[1,2-*a*]azepinone, **67**, 164
- reaction with 3-methylimidazo[1,2-*a*]pyridines, **67**, 165
- reaction with vinylcyclopropenes, **67**, 169
- oxidation of (3-phenyl-2-propenyl)hydrazine, **67**, 171

- nucleophilic addition to *N*-methylpyrrole, **67**, 174
- Michael reaction with 1-acetylimidazo [1,5-*a*]pyridine, **67**, 175
- Methyl-2,3,4-tri-*O*-benzyl- $\alpha$ -D-glucopyranoside, precursor of acyclonucleosides, **68**, 47
- 6-Methyl-3,9,9-tribromopyrido[1,2-*a*]pyrimidin-4-one, **63**, 189
- 2-Methyl-4-trifluoromethylthieno[2,3-*d*]pyrimidine, **66**, 226
- 3-Methyl-2-[*N*-(2,4,6-trimethylphenyl imino)-2,3,6,7-tetrahydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one, <sup>1</sup>H NMR spectra and conformations, **70**, 29
- Methyl trimethylsilyldiazoacetate, decomposition in presence of benzaldehyde and dimethyl fumarate, **65**, 148
- 1-Methyltryptamine, reaction with 1-chlorobut-1-en-3-one, **67**, 232
- 6-Methyluracil, Pd(0) catalysed allylation, **66**, 107
- 2-Methyl-3-vinylbenzo[*b*]thiophene, reaction with tetracyanoethylene, **63**, 380
- 3-Methyl-2-vinylbenzo[*b*]thiophene, reaction with tetracyanoethylene, **63**, 380
- 1-Methyl-2-vinylindole, dimerisation, **63**, 350
- 2-(2-Methylvinyl)indole, Diels-Alder reaction, **63**, 377
- 1-(1-Methyl-2-vinylindol-3-yl)-4-phenyl-1,2,4-triazolidine-3,5-dione, **63**, 384
- 3-Methyl-5-vinylisoxazole, reaction with dienophiles, **63**, 382
- Methyl vinyl ketone, Pd catalysed reaction with anilines, **67**, 214
- N*-Methyl-2-vinylpyrrole, reaction with dimethyl acetylene dicarboxylate, **63**, 344
- reaction with methyl propiolate, **63**, 345
- Diels-Alder reactions, **63**, 360
- reaction with diethyl azidodicarboxylate, **63**, 383
- Metronidazole- see 1-(2'-hydroxyethyl)-2-methyl-4-nitroimidazole
- Micrococci, **67**, 25
- Mitomycin, **64**, 173
- analogs, **65**, 8
- Mitosene, synthesis, **67**, 235
- Mixed 1,3,2,4-/1,2,3,5-dithiadiazolylum salts, **62**, 236
- sequential heterocyclic ring synthesis, **62**, 236
- X-ray diffraction, **62**, 237
- physical properties, **62**, 237
- D-Monalumazine, **70**, 275
- D-Monapterin, see 2-amino-6-(D-threo-tetritol-1-yl)pteridin-4-one
- L-Monapterin, see 2-amino-6-(L-threo-tetritol-1-yl)pteridin-4-one
- (- ) and (+ )-Monoacetate of *cis*-cyclopent-2-ene-1,4-diol, Pd(0) catalysed allylation, **66**, 121-3
- 2-Monoaroylcoumaran-3-ones, synthesis, **69**, 20
- Monoazanaphthoquinone, **61**, 149
- reactions, **61**, 152
- spectra, **61**, 154
- Mono-1,3,2,4-dithiadiazolylum salts, **62**, 195
- Monoformyltetraselenotetrafulvalene, **62**, 293
- 1-Monomethyl ester of (2*E*,4*Z*)-3,2,4-hexadienedioic acid, ring chain tautomerism, **66**, 59
- ( $\pm$ )-Monomorphine, **65**, 129
- ( $\pm$ )-Monomorphine I, synthesis, **69**, 122
- Monosaccharide acylhydrazones, preparation of 1,3,4-oxadiazole acyclo C-nucleosides, **68**, 333
- 2-Monosubstituted oxanes, calculated conformation equilibria, **69**, 225
- 1-Morpholinocyclohexene, cycloaddition with isocyanates, **69**, 385
- 2-(*N*-Morpholino)-1,4-naphthoquinone, reaction with dimethyl acetylene dicarboxylate, **65**, 7
- Morpholinones via carbene reactions, **65**, 189
- MTAD see 4-methyl-1,2,4-triazoline-3,5-dione
- Multi-1,2,3,5-dithiadiazolyl radicals, **62**, 222, **62**, 239
- X-ray structure, **62**, 223
- electron spin resonance spectra, **62**, 223
- magnetic susceptibility, **62**, 226
- conductivity, **62**, 227
- electronic properties, **62**, 240
- 1,2,3,5-/1,3,2,4-Multidithiadiazolyl radicals, **62**, 239
- electronic properties, **62**, 240

- Multi-1,2,3,5-dithiadiazolylum salts, **62**, 195  
from amidines and sulfur dichloride, **62**, 220  
from nitriles and ammonium chloride-sulfur dichloride, **62**, 220  
anionic metathesis, **62**, 221  
electrochemistry, **62**, 221  
X-ray structure, **62**, 222
- Multi-1,3,2,4-dithiazolylum salts-  
preparation from multi-cyano  
compounds and dithianitronium salts,  
**62**, 227  
initiators in polymerisations, **62**, 228  
metathesis, **62**, 228  
addition reactions, **62**, 228  
electrochemistry, **62**, 229  
X-ray diffraction, **62**, 229
- Multi-1,3,2,4-dithiazolyl radicals, **62**, 229  
X-ray diffraction, **62**, 232  
electron spin resonance spectroscopy, **62**,  
233  
electronic properties, **62**, 233  
oxidation, **62**, 235  
rearrangement, **62**, 235
- (+)Muscarine, **65**, 138
- Muscopyridine, preparation from 2,6-  
dichloropyridine, **62**, 387
- (±)-Myrtine, synthesis, **67**, 286
- Myxothiazole, **67**, 35
- Naphthaleno[*b*][1,7]phenanthrolines, **70**, 103
- Naphth[2,3-*b*]imidazo[2,1-*b*]thiazole-5,10-  
dienones, **69**, 287
- Naph[2,3-*c*]isoxazoloquinone, **67**, 251
- Naphtho[2,1-*b*]furan-2(1*H*)-spiro-1'-(2*H*)-  
naphthalene-2'-ones, synthesis, **69**, 25
- 2-Naphthol, condensation with 5-  
aminoquinolines, **70**, 103
- Naphtho[2,1-*b*][1,8]phenanthrolines, **70**, 110
- Naphtho[1,2-*b*]tellurachromanone, **63**, 20
- 3,5-Naphtho-1-telluracyclohexane, **63**, 4
- Naphthothiophenes, **65**, 62
- β-Naphthylamine, oxidation, **69**, 57
- N-α-Naphthyl diazoacetamide,  
decomposition, **65**, 122
- 1-Naphthyl isocyanates, starting materials for  
the synthesis of benzo[*c*]phenanthridine  
alkaloids, **67**, 369
- 2-Naphthylthieno[2,3-*d*]pyrimidines, **66**, 215
- 1-(1-Naphthyl)-1,2,3-triazoles, photolysis,  
**65**, 123
- Naphthyridines, from enamines derived  
from aminopyridines, **67**, 297
- 1,5-Naphthyridines, **65**, 51; **67**, 297
- 1,6-Naphthyridines, **68**, 190
- 1,8-Naphthyridines, preparation from 4*H*-  
pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 120,  
**67**, 297
- 7,8-Naphthyridine-2,4-diols, **63**, 231
- 1,6-Naphthyridones, **67**, 297
- Necatorone, **70**, 123
- Nemertelline, neurotoxin isolated from sea  
worms, **67**, 52
- Neoacrimarines C and D, **70**, 127
- Neoamphimedine, **70**, 108
- Neocallactine acetate, synthesis, **70**, 120
- D-Neolumazine, **70**, 275
- D-Neopterin, *see* 2-amino-6-(D-erythro-  
tetritol-1-yl)pteridin-4-one
- L-Neopterin, *see* 2-amino-6-(L-erythro-  
tetritol-1-yl)pteridin-4-one
- Neplanocins, antitumor agents, **69**, 157
- Ninhydrin- product with 1,3-dicarbonyls, ring  
chain tautomerism, **66**, 62
- Nitidine, **67**, 345  
activity against P388 and L1210 cell lines,  
**67**, 347  
antimalarial activity, **67**, 348  
synthesis, **67**, 350 **67**, 365; **67**, 383
- 3-Nitro-5-(alditol-1-yl)pyrroles, preparation,  
**68**, 255
- Nitroalkenes, Michael reaction with  
enaminones, **67**, 226
- o*-Nitroaniline, oxidative cyclisation, **69**, 43
- 2-Nitro-*t*-anilines, conversion to  
benzimidazole-*N*-oxides, **65**, 14
- 7-Nitroanthranil, reaction with hydrazine  
hydrate, **67**, 26
- 1-Nitroanthroquinone, reaction with  
*o*-phenylenediamine, **70**, 107
- 2-Nitro-4-azidocarbonylphenylpyrrolidine,  
thermolysis, **65**, 29
- O*-Nitrobenzaldehyde azine, reduction by  
triethyl phosphite, **67**, 26
- 3-Nitrochromone, reaction with  
diazoalkanes, **65**, 321
- 3-Nitrocoumarin, reaction with  
diazomethane, **65**, 319
- 1-Nitro-1,2-dideoxyhept-1-enitol, in synthesis  
of pyrazoles, **67**, 425

- 1-Nitro-6,6a, 7,8,9,10-hexahydro-5*H*-pyrido[1,2-*c*][1,2,3]thiazolo[1,5-*a*]pyrimidine, **70**, 52
- 9-Nitro-2-hydroxy-4-oxo-4*H*-pyrido[1,2-*a*]]pyrimidine-3-carboxylate-reaction, **63**, 175  
reduction, **63**, 177
- 3-Nitro-9-hydroxy-4*H*-pyrido[1,2-*a*]]pyrimidin-4-ones, nitration, **63**, 206
- 2-Nitroimidazole, preparation of acyclonucleosides, **69**, 144
- 4(5)-Nitroimidazoles, Pd(0) catalysed allylation, **66**, 90  
reduction to 4(5)-aminoimidazoles, **61**, 7  
reduction by palladium charcoal, **61**, 8  
reduction by stannous chloride or catalysis in acetic anhydride, **61**, 12
- 5-(6)-Nitroimidazole, Pd(0) catalysed alkylation, **66**, 93
- 4-Nitro-5-imidazolecarboxylic acid as a source of 4-amino-5-imidazolecarboxylic acid, **61**, 10
- 2-Nitroiodobenzene diacetate, oxidative cyclisation, **69**, 47
- Nitromethane- C-anion reaction with pyrylium salts, **62**, 58  
reaction with formaldehyde and amino acids, **64**, 31
- 8a-Nitromethyl-*cis*-octahydroquinazolinone, **69**, 387
- 3-Nitro-2-methyl-4*H*-pyrido[1,2-*a*]]pyrimidin-4-ones, **63**, 250
- 3-Nitro-6-methyl-4*H*-pyrido[1,2-*a*]]pyrimidin-4-one, **63**, 188
- 9-Nitro-4-oxo-1,6,7,8-tetrahydro[1,2-*a*]]pyrimidine-3-carboxylate, **63**, 214  
(*p*-Nitrophenyl)chlorodiazirine, flash photolysis, **65**, 147
- 4-(*p*-Nitrophenyl)-9,10-dimethoxy-6,7-dihydro-2*H*-pyrido[6,1-*a*]isoquinoline, reduction, **70**, 43
- 6-*p*-Nitrophenylimidazo[2,1-*b*]thiazole, **69**, 291
- 1-(*p*-Nitrophenyl)-3-methylperhydro[1,2-*c*][1,3]oxazines, ORD curves, **70**, 8
- syn*-2-(*p*-Nitrophenyl)octahydro-3-methyl-2*H*-1,3-benzoxazines, conformations, **69**, 405
- anti*-2-(*p*-Nitrophenyl)octahydro-3-methyl-2*H*-1,3-benzoxazines, conformations, **69**, 405
- 2-Nitrophenylpyrrolidines, cyclisation, **65**, 15  
*N*-(2-Nitrophenyl)tetrahydroisoquinolines, conversion to annelated benzimidazole-*N*-oxides, **65**, 14
- 4-(4-Nitrophenyl)-1,2,4-triazoline-3,5-dione, **67**, 121
- 5-(4-Nitrophenyl)-2-vinylfuran, reaction with acetylene dicarboxylates, **63**, 341  
reaction with methyl propiolate, **63**, 341
- 2-Nitropyrido[1,2-*b*]cinnolinium-11-olate, reduction, **69**, 106
- 3-Nitro-4*H*-pyrido[1,2-*a*]]pyrimidin-4-ones, **63**, 150  
reduction, **63**, 177
- Nitropyrolo[*b*]tropolones, ring contraction to nitroindoles, **66**, 369
- Nitrosoenaminones, from nitrosyl chloride and enaminones, **67**, 258
- 3-(*N*-Nitroso-2-piperidyl)propionic acid, reduction, **69**, 114
- Nitrosotropolone, reaction to anion, **66**, 346  
reaction with ethylenediamine to give pyridazotropone, **66**, 375  
reaction with bifunctional synthons, **64**, 90
- 5-Nitouracils, dehydrative cyclisation to 6-substituted-3-methyl-7-azalumazines, **61**, 249  
preparation of acylconucleosides, **69**, 195
- 2-( $\beta$ -Nitrovinyl)furan, reaction with ethyl acrylate, **63**, 371
- $\beta$ -Nitrovinylindoles, Diels-Alder reactions, **63**, 363
- $\beta$ -Nitrovinyl-*N*-methypyrroles, Diels-Alder reactions, **63**, 360
- Noracronycine, **70**, 127
- (+) and (-)-5'-Noraristeromycin, **66**, 122
- Noravicine, synthesis, **67**, 372
- Norbornadiene, reaction with thiazyl chloride, **62**, 148  
cycloadditions with isocyanates, **69**, 379  
cycloadditions with thiobenzoyl isocyanate, **69**, 384
- diendo* and *diexo*-Norbornane-fused-1,3-oxazines, **69**, 354
- diendo*-Norbornane-fused quinazolinones, **69**, 390
- diexo*-Norbornane-fused quinazolinones, **69**, 390
- diendo* and *diexo*-Norbornane-3-hydroxy-2-carboxamides, cyclisation, **69**, 372

- Norchelilutine, synthesis, **67**, 366  
(+)-5'-Nor-2'-deoxyaristeromycin, **66**, 122  
(-)-5'-Nor-2'-deoxyaristeromycin, **66**, 122  
Nordercitin, **70**, 116  
Norfagaronine, synthesis, **67**, 372  
Nor-nitidine, synthesis, **67**, 351; **67**, 360;  
**67**, 372  
    quaternisation to nitidine, **67**, 351  
Norsanguilutine, synthesis, **67**, 366  
Norsegoline, **70**, 112  
1',2'-*seco*-Nucleosides, synthesis, **67**, 397,  
**68**, 1  
2',3'-*seco*-Nucleosides, **68**, 1  
(-)-Nupharamine, synthesis, **69**, 122
- Ocaperidone, X-ray diffraction study, **63**, 121  
    synthesis, **63**, 198  
(2s,3<sub>R</sub>,4<sub>E</sub>)-2-Octadecanoylamino-4-  
    octadecene-1,3-diol, synthesis via azide  
    ring opening of cyclic sulfate, **68**, 159  
Octahydro-3,3'-bi-1,2-benzisoxazole, **67**, 27  
Octahydrobenzophenanthroline, **70**, 91  
Octahydro-2H-1,3-benzoxazines,  
    preparation, **69**, 367  
    conformations, **69**, 404  
*cis*-Octahydro-2H-3,1-benzoxazine-2-thione,  
    X-ray structure, **69**, 424  
Octahydrocarbazole, **67**, 247  
Octahydrocarbazole-4-ones, **67**, 246  
*cis*-fused Octahydro-1H-  
    cyclopentapyrimidine-2,4-diones, EI  
    mass spectra, **69**, 446  
*cis*-Octahydro-3-hydroxymethyl-4H-1,3-  
    benzoxazin-4-one, X-ray structure,  
    **69**, 430  
Octahydroimidazo[4,5-*e*]thiazolo[3,2-*b*]  
    [1,2,4]triazin-3,7-diones, **61**, 306  
Octahydroindolo[2,3-*a*]quinolizines, **64**, 61  
*diexo*-1,2,3,4,4a,5,8,8a-Octahydro-5,8-  
    methano-3,1-benzoxazines,  
    conformations, **69**, 407  
(4 $\alpha$ ,5 $\alpha$ ,8 $\alpha$ ,8 $\alpha$ )-Octahydro-5,8-methano-  
    2H-3,1-benzoxazine-2-thione, X-ray  
    structure, **69**, 428  
(4 $\alpha$ ,5 $\beta$ ,8 $\beta$ ,8 $\alpha$ )-Octahydro-5,8-methano-  
    2H-3,1-benzoxazine-2-thione, X-ray  
    structure, **69**, 427  
*cis*-Octahydro-1-methyl-2H-3,1-  
    benzoxazine-2-thione, X-ray structure,  
    **69**, 426
- cis*-N-(Octahydro-1-methyl-2H-3,1-  
    benzothiazin-2-ylidene)benzeneamine,  
    X-ray structure, **69**, 435  
*cis*-and *trans*-Octahydro-2H-3,1-  
    benzoxazines, EI fragmentation, **69**, 444  
*cis*-Octahydro-3-methyl-2H-3,1-  
    benzoxazine-2-one, X-ray structure,  
    **69**, 425  
*cis*-N-(Octahydro-1-methyl-2H-3,1-  
    benzoxazin-2-ylidene)benzeneamine, X-  
    ray structure, **69**, 426  
(2 $\alpha$ ,4 $\alpha$ ,8 $\alpha\beta$ )-Octahydro-1-methyl-  
    2-(4-nitrophenyl)-2H-3,1-benzoxazine,  
    X-ray structure, **69**, 423  
(2 $\alpha$ ,4 $\alpha$ ,8 $\alpha\beta$ )-Octahydro-2-(4-nitrophenyl)-  
    2H-3,1-benzoxazine, X-ray structure,  
    **69**, 422  
(2 $\alpha$ ,4 $\alpha\beta$ ,8 $\alpha\beta$ )-Octahydro-2-(4-nitrophenyl)-  
    4(1H)-quinazolinone, X-ray structure,  
    **69**, 436  
(2 $\alpha$ ,4 $\alpha$ ,8 $\alpha\alpha$ )-Octahydro-2-phenyl-4H-3,1-  
    benzoxazin-4-one, X-ray structure,  
    **69**, 430  
(4 $\alpha$ ,4 $\alpha\alpha$ ,5 $\alpha$ ,8 $\alpha$ ,8 $\alpha\beta$ )-Octahydro-4-phenyl-5,8-  
    methano-2H-3,1-benzoxazine-2-thione,  
    X-ray structure, **69**, 429  
*cis*-Octahydro-1-phenylmethyl-2H-3,1-  
    benzoxazine, X-ray structure, **69**, 421  
Octahydroquinazolin-4-ones, conformations,  
    **69**, 413  
*cis* and *trans*-Octahydroquinazolin-4(1H)-  
    ones, synthesis, **69**, 389  
Octahydroquino[3,2-*a*]acridine, **70**, 97  
Octahydroquinolino[*b*]quinoline, **70**, 99  
*manno*-2-Octulosonic acid, preparation via  
    cyclic sulfites, **68**, 138  
2-Octynylpyridines, from 2-bromopyridines  
    and 1-octyn-1-ylzinc chloride, **62**, 376  
Oligothiophenes, **67**, 11  
Orellamine- *see* 3,3',4,4'-tetrahydroxy-2,2'-  
    bipyridine bisN,N'-oxide  
Orelline, toxic constituent of mushrooms,  
    **67**, 52  
Orinapterin, *see* 2-amino-6-(1-*threo*-1',2'-  
    dihydroxypropyl)pteridin-4-one  
Otonecine, synthesis, **67**, 325  
7-Oxabicyclo[2,2,1]heptanes, from  
    diazodiketones and dimethyl acetylene  
    dicarboxylate, **65**, 205  
Oxabicyclo[2,2,1]hept-5-ene-2,3-  
    dicarboxamide, **70**, 172

- 9-Oxabicyclo[4,2,1]nonanes, via tandem cyclisation/intermolecular cycloadditions, **65**, 208  
from decomposition of diazoketones, **65**, 214
- 8-Oxabicyclo[3,2,1]octanes, from intramolecular reactions of carbenes from diazoketones and 1,4-dicarbonyl fragments, **65**, 206  
via transannular cyclisation, **65**, 215
- Oxabicyclooctene carboxylate, **65**, 344
- Oxabicyclooctenones, **65**, 325
- 2-Oxa-1,4-butanediol diacetate, in nucleoside synthesis, **69**, 137
- 1-Oxacepham via carbene reactions, **65**, 188
- 1,2-Oxachalcogenolium chloride, **63**, 28
- 1,3,5-Oxadiazinium salts, **64**, 357  
reactions, **64**, 359
- 2*H*-1,3,4-Oxadiazin-2-ones from aroyl- $\alpha$ -(diazoacyl)hydrazines, **65**, 196
- 1,2,5-Oxadiazole-*N*-oxides, preparation, **69**, 43
- 1,3,4-Oxadiazoles, **64**, 194
- 1,3,4-Oxadiazole acyclo *C*-nucleosides, **68**, 333
- 1,3,4-Oxadiazole *C*-nucleosides, **68**, 331
- 1,3,4-Oxadiazole reverse *C*-nucleosides, **68**, 331
- [1,2,4]Oxadiazolo[5,4-*d*][1,5]benzothiazepines, **63**, 82
- 1,2,4-Oxadiazolo[2,3-*b*][1,3]oxazines, by cycloaddition of nitrile oxides with dihydrooxazines, **69**, 454
- Oxadiazolothieno[2,3-*d*]pyrimidines, **66**, 216
- N*-(1,2,4-Oxadiazol-3-yl)-enaminone, reaction with sodium ethoxide, **67**, 313
- 1,2,3-Oxadiazol-4-yl *C*-nucleoside lactols, **68**, 328
- 1,2,4-Oxadiazol-5-yl *C*-nucleosides, **68**, 329
- (Oxane-2-yl)methyl radicals, conformations, **69**, 229
- Oxanosine, analog synthesis, **69**, 137
- Oxapenams, **65**, 181
- $\lambda^5$ -1,2-Oxaphosphetanes, **65**, 173
- 1,3-Oxaphospholanes, via addition of primary phosphines to  $\alpha$ -oxides followed by reaction with ketones and aldehydes, **61**, 62
- 1,3,2-Oxaphospholidines, **64**, 183
- 1,3-Oxaphosphorinanes, via addition of primary phosphines to allyl alcohols followed by reaction with aldehydes and ketones, **61**, 61
- 1-Oxa-2-sila-3-cyclobutenes, **65**, 173  
from diazo(disilacyl)methylketones, **65**, 198
- 1-Oxa-2-silacyclopentenes, from siloxyalkylidenecarbene, **65**, 187
- Oxasilacyclopentenes, **65**, 187
- Oxaspiropentanes, **65**, 134
- 1,2-Oxatellurolium chloride, **63**, 29
- 1,2-Oxatellurolium methanesulfonate, **63**, 29
- 1,2,3-Oxathiazole 2,2-dioxide, **68**, 91
- 1,2,3-Oxathiazole 2-oxide, **68**, 91  
conformational study, **68**, 91
- 1,3,4-Oxathiazol-5-yl *C*-nucleosides, **68**, 338  
1,4-Oxathiocines, loss of sulfur and oxygen, **65**, 82  
from carbenoids and 2,5-dichlorothiophenes, **65**, 194
- Oxathioles, from carbenes and carbon-sulfur double bonds, **65**, 185
- Oxathiolotropothione, **64**, 119
- 1,3-Oxathiones, from diazoketones and carbon disulfide, **65**, 185
- Oxatricyloalkanones, **65**, 356
- 1,3-Oxazepines, from pyrylium salts, **65**, 307
- 1,4-Oxazepines via rearrangement of dimorpholinocarbene, **65**, 194
- 1,3-Oxazines, **64**, 208
- 1-(3 and 4)-Oxazines, via carbene reaction, **65**, 188
- 1,3-Oxazine-2,6-dione-4-carboxylic acid, **64**, 33
- 1,3-Oxazine-2-thiones, **69**, 364
- 4*H*-1,3-Oxazinium salts, **64**, 347
- [1,3]Oxazino[4,3-*a*]isoquinolin-2-ones, **70**, 58  
hydrolysis, **70**, 31
- Oxazinomycin, *see* 5-( $\beta$ -D-ribofuranosyl)-1,3-oxazine-2,4-dione,
- 1,3-Oxazin-6-ones, **67**, 306  
thermolysis, **67**, 307  
from acylimides and Meldrum's acid, **67**, 307
- 1,3-Oxazin-4-onium salts, **64**, 361
- Oxazino[6,5-*e*]pyrido[1,2-*a*]pyrimidinone, **63**, 20
- [1,3]Oxazino[3,4-*a*]quinolin-3-ones, **70**, 58  
hydrolysis, **70**, 31
- 1,3-Oxazin-6-yl acyclo *C*-nucleosides, **68**, 387
- 1,3-Oxazin-5-yl carbocyclic *C*-nucleosides, **68**, 387

- 1,2-Oxazin-3-yl *C*-nucleoside, **68**, 384  
1,3-Oxazin-2-yl *C*-nucleosides, **68**, 387  
Oxaziridines, **64**, 183  
Oxazofurin, *see* 4-carboxamido-2- $\beta$ -ribofuranosyloxazole  
1,3-Oxazolidines, equilibrium constants in ring chain tautomerism, **66**, 13  
Oxazolidines, ring chain tautomerism by solid state nmr, **66**, 8  
Oxazolidin-4-ones, **67**, 249  
*spiro*-Oxazolidin-4-ones, **67**, 249  
Oxazolidin-5-ones, **67**, 249  
    thermolysis, **67**, 306  
Oxazolines, **65**, 181  
Oxazolin-5-yl *acyclo-C*-nucleosides, preparation, **68**, 305  
Oxazolium tropylium salt, condensation with benzothiazolium salts, **66**, 361  
1,3-Oxazolo[2,3-*b*][1,3]benzoxazinones, **64**, 57  
1,3-Oxazol-2-one, **64**, 190  
1,3-Oxazol-5-ones, **64**, 190  
Oxazolo[5,4-*d*]pyrido[1,2-*a*]pyrimidinone, **63**, 201  
7 *H*-Oxazolo[5,4:3,4]pyrido[1,2-*a*]pyrimidin-4-one, **63**, 207  
Oxazolo[3,2-*c*]pyrimidines, **64**, 48  
Oxazolotropones, mass spectra, **66**, 305  
Oxazolo[4,5-*b*]tropones, **64**, 109  
Oxazolo[5,4-*b*]tropones, **64**, 107  
Oxazolotropylium salts, reaction with amines, **66**, 383  
1,3-Oxazol-2-thiones, **64**, 191  
Oxazol-5-yl *acyclo C*-nucleosides, preparation, **68**, 305  
2-Oxazolyl *acyclo C*-nucleosides, preparation, **68**, 301  
4-Oxazolyl *acyclo C*-nucleosides, preparation, **68**, 302  
2-Oxazolyl carbocyclic *C*-nucleosides, **68**, 300  
5-Oxazolyl homo *C*-nucleosides, **68**, 299  
2-Oxazolyl *C*-nucleosides, preparations, **68**, 297  
(*s*)-4-Oxazolyl reverse *C*-nucleosides, preparation, **68**, 300  
Oxecephams, by radical reactions, **65**, 199  
1,2-Ox-4-enes, ring inversion, **69**, 259  
1,3-Ox-4-enes, ring inversion, **69**, 259  
1,4-Ox-4-enes, ring inversion, **69**, 259  
Oxepines, from pyrylium salts and diazoalkanes, **65**, 292  
Oxepino[2,3-*d*]isoxazoles, **65**, 160  
Oxepinotropones, **64**, 115  
    NMR spectra, **66**, 293  
    UV spectra, **66**, 299  
    reaction with hydrazine, **66**, 335  
Oxepinotropylium ions, aromaticity, **66**, 323  
    intermediate in reaction of oxepinotropones with malononitrile, **66**, 343  
    ring contraction, **66**, 388  
4-Oxidopyrido[1,2-*b*]pyridazinium zwitterions, **69**, 116  
3-Oxidopyrylium salts, reaction with electron deficient dipolarophiles, **65**, 355  
Oximinophenols, oxidation to spiro-isoxazoles, **69**, 41  
Oxindoles, **65**, 122  
*O*-(3-Oxoacyl)hydroxylamines, ring chain tautomerism, **64**, 292  
3-Oxoaldehyde-dioximes, ring chain tautomerism, **66**, 21  
3-Oxoaldehyde monothioacylhydrazones, ring chain tautomerism, **66**, 46  
*N*-(3-Oxoalkyl)-*N'*-acylhydrazines, ring chain tautomerism, **64**, 293  
*N*-(3-Oxoalkyl)thioureas, ring chain tautomerism, **64**, 292  
2-Oxo-4-amino-1,3,4,6,7,11*b*-2-*H*-pyrimido[6,1-*a*]iosquinolines, **70**, 68  
9-Oxo-benzo[*b*]cyclohept[*e*][1,4]oxazinone, **64**, 89  
4-Oxo-4 *H*-1-benzopyrans, reaction with cuprates, **65**, 302  
    oxidation, **69**, 72  
2-Oxo-1,2'-bibenzimidazole, from 2-chlorobenzimidazole, **67**, 37  
4-(and 5)-Oxocarboxylic acids, ring chain tautomerism, **66**, 62  
4-Oxochromene-3-carbaldehydes, cyclisation with bisnucleophiles, **65**, 185  
4-(2'-Oxocycloalkyl)-3,4-dihydro-3-methyl-2*H*-1,3-benzoxazin-2-ones, **69**, 363  
2-Oxo-1-cyclohexanecarboxamide, reaction with aldehydes, **69**, 391  
2-Oxo-1,4,4*a*,5,8,8*a*-decahydro-5,8-methano-2*H*-3,1-benzoxazines, EI fragmentation, **69**, 442  
Oxodiazolidine, annelation to  $\beta$ -lactams, **65**, 181  
3-Oxo-3,4-dihydro-2 *H*-1-benzopyrans, **65**, 156

- 1-Oxo-dihydro-de-*N*-methylacronycine, **70**, 127
- 2-Oxo-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrimidines, **63**, 165
- 2-Oxo-2,5-dihydropyrido[1,2-*b*][1,2,4]triazine-4-oxide, synthesis, **61**, 211
- 1-Oxo-3,6-dihydro-1,2-thiazines, rearrangement, **64**, 345
- Oxoformycin B, **70**, 235
- 3-*ara*-Oxoformycin B, **70**, 236
- Oxoformycin, *see* 7-amino-3- $\beta$ -D-ribofuranosylpyrazolo[4,3-*d*]pyrimidin-5-one
- 2-Oxoglutaric acid, ring chain tautomerism, **64**, 259
- diendo*-2-Oxo-1,4,4*a*,5,8,8*a*-hexahydro-5,8-methano-3,1-benzoxazines, conformations, **69**, 412
- diendo*-and *diexo*-fused-4-Oxo-4*a*,5,6,7,8,8*a*-hexahydro-1*H*-5,8-methanoquinazoline-2-thiones, conformations, **69**, 416
- 2-Oxo-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolines,  $^{13}\text{C}$  NMR spectra and conformations, **70**, 30
- reduction, **70**, 42
- 1-Oxo-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrimido[6,1-*a*]quinolines, reduction, **70**, 42
- 4-Oxoisoaxazolo[5,4-*b*]pyridines, via enamines, **67**, 293
- trans*-4*a*, 5-*H*-8-Oxo-5-methylperhydropyrido[1,2-*b*][1,2]oxazines, conformation, **69**, 92
- 2-Oxo-octahydro-2*H*-1,3-benzoxazines, conformations, **69**, 410
- 2-Oxo-octahydro-2*H*-3,1-benzoxazines, conformations, **69**, 410
- fragmentation, **69**, 441
- diendo*-2-Oxo-octahydro-5,8-methano-1,3-benzoxazines, conformations, **69**, 412
- diendo*-2-Oxo-octahydro-5,8-methano-3,1-benzoxazines, conformations, **69**, 412
- 2-Oxo-octahydro-5,8-methano-2*H*-3,1-benzoxazines, EI fragmentation, **69**, 442
- 3-Oxo-2-oxabicyclo[2,2,2]oct-5-enes, **65**, 334
- 6-Oxo-6*H*-1,3-oxazin-3-ium-4-olate, cycloaddition, **63**, 141
- 2-Oxoperhydropyrido[1,2-*b*]pyridazine,  $\text{pK}_a$  values, **69**, 93
- 1-Oxoperhydropyrido[1,2-*a*]pyrimidine-8-carboxylates, **70**, 73
- 5-Oxoperhydro-1,4-thiazine-3-carboxylic acid, **64**, 34
- 5-Oxopipicolonic acids, **65**, 126
- O*-(3-Oxopropyl)-*N*-benzoylhydroxylamine, ring chain tautomerism, **64**, 292
- 7-Oxopyrido[3,2,1-*i,j*]cinnoline-8-carboxylates, **69**, 115
- hydrolysis, **69**, 106
- 7-Oxopyrido[3,2,1-*i,j*]cinnoline-3,3,8-tricarboxylates, **69**, 117
- 11-Oxopyrido[1,2-*b*]cinnolin-6-ium hydroxide inner salts, **69**, 121
- 1-Oxopyrido[1,2-*c*][1,3]oxazinium chloride, **70**, 56
- 2-Oxo-2*H*-pyrido[1,2-*a*]pyrimidine, spectra, **63**, 109
- 4-Oxo-4*H*-pyrido[1,2-*a*]pyrimidines, biological activities, **63**, 104
- stereochemistry, **63**, 82
- spectra, **63**, 109
- 4-Oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetic acid, **63**, 146
- 4-Oxo-4*H*-pyrido[1,2-*a*]pyrimidine-3-carboxylic acids, zinc and silver coordination equilibria, **63**, 106
- mass spectra, **63**, 121
- preparation, **63**, 144
- by hydrolysis of esters, **63**, 193
- conversion to amides, **63**, 194
- 4-Oxo-4*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylates, **63**, 207
- 6-Oxo-6*H*-pyrido[1,2-*a*]pyrimidine-7-carboxylate, **63**, 159
- 6-Oxo-6*H*-pyrido[1,2-*a*]pyrimidine-8-carboxylate, **63**, 162
- (6-Oxo-6*H*-pyrido[1,2-*a*]pyrimidin-7-yl)acrylate, **63**, 162
- 2(2-Oxo-2*H*-pyrido[1,2-*a*]pyrimidin-3-yl)-3,4-dihydroquinoxalin-2-one, **63**, 128
- (*E*)-3-(2-Oxo-2*H*-pyrido[1,2-*a*]pyrimidin-4-yl)prop-2-enoate, **63**, 127
- 4-Oxo-1,3-pyridothiazines, **66**, 162
- 1-Oxopyrido[1,2-*b*][1,2]thiazine, **69**, 113
- 2-Oxopyrimidines, **67**, 311
- 4-Oxo-pyrimidine-5-carboxylates, reaction with methyl 2-mercaptoacetate, **66**, 217
- (*R*)-5-Oxopyrrolidine-2-carboxylic acid, **64**, 6
- 7-Oxoquino[8,7-*b*][1,10]phenanthroline, **70**, 106
- 2-Oxo-4-substituted-1,3,4,6,7,11*b*-2-*H*-pyrimido[6,1-*a*]isoquinolines, **70**, 68



- 2-Oxo-tetrahydrocarbazoles, formation, **67**, 246
- 4-Oxo-tetrahydrocarbazoles, formation, **67**, 246
- 4-Oxo-4,5,6,7-tetrahydro-6,6-dimethyl-1,3-benzoxathiole-2-thione, **65**, 185
- 6-Oxo-5,6,7,8-tetrahydroflavone, in preparation of pyrano[3,2-*a*]acridines, **70**, 137
- 7-Oxo-5,6,7,8-tetrahydroflavone, condensation with ethyl anthranilate, **70**, 125  
in synthesis of pyranacridines, **70**, 139
- 4-Oxo-4,5,6,7-tetrahydroindoles, **70**, 139
- 7-Oxo-1,2,3,7-tetrahydropyrido[3,2,1-*i,j*]cinnoline-8-carboxylates, N-alkylation, **69**, 101
- 6-Oxo-1,2,3,4-tetrahydro-6*H*-pyrido[1,2-*a*]pyrimidine-9-alkanoate, **63**, 163
- 2-Oxo-2*H*-6,7,8,9-tetrahydropyrido[1,2-*a*]pyrimidines, **63**, 132
- 4-Oxo-4*H*-6,7,8,9-tetrahydropyrido[1,2-*a*]pyrimidines, **63**, 132
- 4-Oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidine-3-acetates (and carboxylates), conformational analysis, **63**, 112
- 6-Oxo-2,3,4,6-tetrahydro[1,2,4]triazino[5,6-*c*]isoquinoline-3-thione, **61**, 231
- 3-Oxo-2,3,4,10-tetrahydro[1,2,4]triazino[5,6-*b*]quinoline, **61**, 224
- 4-(Oxothieno[3,2-*d*]pyrimidin-2-ylidene)acetates, **66**, 242
- 2-Oxo-4-thiono-1,2,3,4-tetrahydroquinazolin-2-one, precursor of triazinoquinolines, **61**, 267
- 2-Oxo-4-thiopyrimidine-5-carbonitrile, reaction with methyl chloroacetate, **66**, 218
- 4-Oxo-2-thioxopyrazolo[1,5-*a*]1,3,5-triazin-3-yl *C*-nucleosides, **70**, 302
- 2-Oxo-4-thioxo-1,3,4,6,7,11*b*-2-*H*-pyrimido[6,1-*a*]iosquinolines, **70**, 64, 68
- 4-Oxo-2-thioxothieno[3,2-*d*]pyrimidines, **65**, 258
- 6-Oxo-2,3*a*,6*a*-triazephenalene-3-thione, **63**, 229
- cis* and *trans*-2-Oxo-2-(2-vinylcyclopropyl)acetates, **65**, 160
- 1-Oxo-3-vinylperhydropyrido[1,2-*c*][1,3]oxazine-4-carboxylate, rearrangement, **70**, 38
- 2,3,7,8-Oxygenated benzo[*c*]phenanthridines, synthesis, **67**, 376
- 2,3,7,8-Oxygenated benzo[*c*]phenanthridin-6-ones, synthesis, **67**, 379
- 2,3,8,9-Oxygenated benzo[*c*]phenanthridin-6-ones, synthesis, **67**, 379
- 5-Oxygenated indoles, synthesis, **69**, 33
- Oxynitidine, synthesis, **67**, 367; **67**, 382; **67**, 385
- Palladium(II) catalysis for alkenyl substitution, **62**, 307
- Pantherinine, **70**, 112
- Pelletierine, *N*-formylation, **67**, 286
- Penams, ring expansion, **69**, 78
- Penciclovir, *see* 9-[4-hydroxy-3-(hydroxymethyl)-butyl]guanine
- 9-(*D*-manno-Pentitol-1-yl)acridine-1,8-dione, **70**, 210
- 3-(*D*-manno-Pentitol-1-yl)indoles, cyclisation, **70**, 168
- 2-(*D*-galacto-Pentitol-1-yl)indol-4-one, dehydrative cyclisation, **70**, 168
- 2-(*D*-manno-Pentitol-1-yl)pyrrole, **68**, 254  
use in synthesis of 2-( $\alpha$ -*D*-arabinopyranosyl)pyrroles, **68**, 247
- 2-*D*-gluco-Pentitol-1-yl)pyrroles, use in synthesis of 2-( $\alpha$ -*D*-arabinofuranosyl)pyrroles, **68**, 247
- 2-(*D*-gluco-Pentitol-1-yl)-4,5,6,7-tetrahydroindol-4-one, acid catalysed cyclodehydration, **70**, 167
- 2-(*D*-manno-Pentitol-1-yl)-4,5,6,7-tetrahydroindol-4-one, acid catalysed cyclodehydration, **70**, 167
- 2-(Penta-*O*-acetyl-pentitol-1-yl)-1-nitroethene, 1,3-dipolar cycloadditions, **68**, 258
- 2-(Penta-*O*-acetyl-*D*-gluco-pentitol-1-yl)pyrimido[4,5-*d*]pyrimidine, **70**, 262
- 1,3,3,4,5-Pentamethyl(2*H*)1,2,4-triazolidine, lack of ring chain tautomerism, **66**, 28
- Pentane-2,4-dione, condensation product with thiosemicarbazide- ring chain tautomerism, **64**, 304  
condensation product with benzamidrazinium iodides, ring chain tautomerism, **64**, 304

- Pentane-2,4-dione 2,4-dimethylthiosemicarbazone, ring chain tautomerism, **66**, 26
- Pentane-2,4-dione 2-methyl (and 2,4-dimethyl)thiosemicarbazones, ring chain tautomerism, **66**, 53
- Pentane-2,4-dione monothiobenzoylhydrazone, ring chain tautomerism, **66**, 46
- Pentane-2,4-dione oxime thiobenzoylhydrazone, ring chain tautomerism, **66**, 49
- Pentane-2,4-dione reaction product with 4-phenylsemicarbazide, ring chain tautomerism, **66**, 38
- reaction product with aminoguanidinium nitrate, ring chain tautomerism, **66**, 38
- reaction product with benzamidrazonium iodide, ring chain tautomerism, **66**, 38
- Pentane-2,4-dione thiophenylacetylhydrazone, ring chain tautomerism, **66**, 49
- 4-Pentenoic acid, conversion to lactones, **69**, 27
- 4-(*D*-galacto-Pentitol-1-yl)-2-phenyl-1,2,3-triazole, intramolecular cyclodehydration, **68**, 319
- 3-(*D*-Pentitol-1-yl)pyrazoles, acid-catalysed cyclodehydration, **68**, 265
- 2-(Pentitol-1-yl)-pyridines, dehydrative cyclisation, **68**, 346
- 2-(*D*-galacto-Pentitol-1-yl)pyrroles, precursor to 2( $\alpha$ - and  $\beta$ -*lyxo*-pyranosyl)pyrroles, **68**, 247
- Pentodialdofuranose 4-nitrophenylhydrazones, reaction with reactive alkenes, **68**, 272
- 3-(Pentofuranosyl)pyrazoles, preparation, **68**, 265
- 2-( $\beta$ -*D*-Pentopyranosyl)imidazo[4,5-*b*]pyridines, preparation, **70**, 201
- Pentostatin, acyclonucleoside analogue, **69**, 133
- 4-*N*-Pentylproline, **64**, 10
- 2-(4-Pentynyl)-5-phenylpyrimidine, cyclisation, **63**, 126
- Perchlorocyclobutanone, nucleophilic reaction with amines to enamines, **67**, 217
- Perfluoroalkenes, reaction with 1,3-dicarbonylenolates to give fluorinated 2H-pyrans, **62**, 28
- Perfluoroalkyl biphenylsulfides, **64**, 324
- (Perfluoroalkyl)dibenzotellurophenium salts, nitration, **64**, 327
- sulfonation, **64**, 328
- spectra, **64**, 329
- S*-(and *Se*)-(Perfluoroalkyl)dibenzothiophenium salts, **64**, 326
- thermolysis, **64**, 328
- sulfonation, **64**, 328
- nitration, **64**, 327
- properties, **64**, 328
- spectra, **64**, 329
- 5-Perfluoroalkyl-1-methyl-2-ethoxycarbonylpyrrolidin-3-ones, **64**, 10
- Perfluoro-3-diazopentane-2,5-dione, photolysis, **65**, 152
- (Perfluoroisopropylidene)thiocarboxamides, **69**, 383
- Perhydroazulenes, **65**, 356
- Perhydro-3,1-benzothiazine-2-thiones, **69**, 381
- 3,1-Perhydrobenzoxazine, synthesis, **69**, 353, 359
- Perhydrobenzoxazines, ring chain tautomerism, **66**, 12
- 3,1-Perhydrobenzoxazine-2,4-diones, synthesis, **69**, 373
- 1,3-Perhydrobenzoxazin-2-ones, **69**, 363
- cis*-or *trans*-3,1-Perhydrobenzoxazine-2-thione, ring opening with methyl iodide, **69**, 452
- Perhydrocyclopenta[*e*]thiazine-2-thione, **69**, 381
- (-)-Perhydrohistrionicotoxin, synthesis, **67**, 275; **67**, 276
- 2-(*trans*-Perhydroisoquinolin-3-yl)ethyl propionate, from hydrolysis of oxazinoisoquinolines, **70**, 31
- Perhydro-1,3,4-oxadiazines, ring chain tautomerism, **66**, 17
- Perhydro[3,2,1-*ij*][3,1]oxazines, conformations, **70**, 9
- (+)-*cis*-4*a*,5*a*-*H*-Perhydro[1,3]oxazino[3,4-*b*]isoquinoline, NMR and conformations, **70**, 12
- (-)-*cis*-4*a*,9*a*-*H*-Perhydro[1,3]oxazino[3,4-*b*]isoquinoline, NMR and conformations, **70**, 12
- r*-4*a*, *c*-5*a*,*t*-9*a*-*H*-Perhydro[1,3]oxazino[3,4-*b*]isoquinolines, protonation constants, **70**, 6

- r-4a, t-5a, c-9a-H-Perhydro[1,3]oxazino [3,4-b]isoquinolines, protonation constants, **70**, 6
- Perhydropyrido[1,2-c][1,3]benzoxazines, theoretical conformational study, **70**, 6
- r-4a, c-11a, c-11b-Perhydropyrido[1,2-c][1,3]benzoxazines, theoretical conformational study, **70**, 7
- r-4a, t-11a, t-11b-Perhydropyrido[1,2-c][1,3]benzoxazines, theoretical conformational study, **70**, 7
- Bohlmann bands and conformation, **70**, 9
- r-4a, c-11a, t-11b-Perhydropyrido[1,2-c][1,3]benzoxazines, theoretical conformational study, **70**, 7
- r-4a, t-11a, c-11b-Perhydropyrido[1,2-c][1,3]benzoxazines, theoretical conformational study, **70**, 7
- Perhydropyrido[1,2-b][1,2]oxazines, reductive N-O bond cleavage, **69**, 96
- Perhydropyrido[1,2-c][1,3]oxazine, dipole moments, **70**, 8
- theoretical conformational study, **70**, 6
- infrared spectra, **70**, 8
- <sup>1</sup>H NMR spectra, **70**, 9
- <sup>15</sup>N NMR spectra, **70**, 17
- hydrolysis, **70**, 31
- Perhydropyrido[1,2-b][1,2]oxazin-8-ones, synthesis, **69**, 97
- Perhydropyrido[1,2-b]pyridazine, **69**, 99
- pK<sub>a</sub> values, **69**, 93
- alkylation and acylation, **69**, 101
- reaction with isocyanates, **69**, 101
- Perhydropyrido[1,2-b]pyridazin-2-one, **69**, 114
- reduction, **69**, 99
- alkylation and acylation, **69**, 101
- reaction with isocyanates, **69**, 101
- Perhydropyrido[1,2-a]pyrimidine, ring opening, **63**, 240
- Perhydropyrido[1,2-c]pyrimidine, Bohlmann bands in infrared spectra, **70**, 24
- <sup>1</sup>H NMR spectra and conformations, **70**, 24
- Perhydropyrido[1,2-a]pyrimidin-4-one, **63**, 180
- Perhydropyrido[1,2-a]pyrimidin-6-ones, **63**, 165, **63**, 169
- Perhydropyrido[1,2-c][1,3]thiazine, dipole moments, **70**, 18
- <sup>1</sup>H NMR spectroscopy, **70**, 19
- <sup>13</sup>C NMR spectroscopy, **70**, 20
- Perhydropyrido[1,2-b][1,2]thiazine-1,1-dioxide, **69**, 111, 112
- reduction, **69**, 99
- Perhydropyrimidin-4-one-6-carboxylic acid, **64**, 32
- Perhydropyrimido[1,2-a]pyrimidin-2-one, deuterium exchange, **63**, 173
- trans-fused-Perhydroquinazolines, synthesis, **69**, 385
- Perhydro-2,4-quinazolinedione, **69**, 392
- cis-Perhydroquinazolin-2-ones, conformations, **69**, 407
- Perhydroquinazolinon-2-ones, synthesis, **69**, 386
- Perhydroquinazolinon-2-thiones, synthesis, **69**, 386
- Perhydro-s-tetrazine-3-thione, ring chain tautomerism, **66**, 34
- Perhydro-1,4-thiazine-3-carboxylic acid 1-oxide, **64**, 34
- Perhydro-1,3-thiazine-2,4-diones, preparation, **69**, 382
- Petrosamine, **70**, 108
- N-Phenacylbenzoisothiazol-3-one, cyclisation to 2-benzoyl-2,3-dihydro-1,3-benzothiazin-4-one, **66**, 159
- 3-Phenacylbenzthiazolium cations, ring chain tautomerism, **64**, 289
- 3-Phenacylidene-3-acetyl coumarin, **65**, 318
- 2-Phenacylisoquinolinium bromide as precursor to [1,2,4]triazino[3,4-a]isoquinolines, **61**, 229
- 3-Phenacylquinazolinone, conversion to pyrrolo[2,3-a]quinazolinone, **68**, 192
- Phenanthrene, **65**, 48
- Phenanthridine, synthesis via boron compounds, **62**, 362
- Phenanthro[9,10-b]furan, **65**, 140
- 1,10-Phenanthroline, epoxidation, **70**, 120
- Phencyclidine, oxidation, **69**, 74
- Phenols, oxidation with hypervalent iodine, **69**, 6
- Phenol substituted tetrathiafulvalenes, copolymerisation with poly(p-chloromethylstyrene), **62**, 259
- Phenothiazines, loss of sulfur, **65**, 57
- from o-thioanilines and cyclohexane-1,3-diones, **67**, 309
- Phenoxathiins, desulfuration, **65**, 59
- 2-(Phenoxy)phenyltellurium trichloride, **63**, 35

- 2-Phenoxy pyridines, **62**, 9  
2-Phenylacetylbenzoic acid, ring chain tautomerism, **64**, 259  
Phenylacetylene, reaction with iodonium ylide from 2-hydroxy-1,4-naphthoquinone, **69**, 18  
*N*-Phenylacetylhydrazones of benzylacetaldehyde, ring chain tautomerism, **64**, 299  
1-Phenyl-4-(alditol-1-yl)-1,2,3-triazoles, **68**, 322  
1-Phenyl-5-(alditol-1-yl)-1,2,3-triazoles, **68**, 322  
2-Phenyl-6-amino-6*H*-cycloheptoxazoles, reaction with, *p*-toluidine, **64**, 137  
9-(Phenylaminomethylene)-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, Vilsmeier-Haack formylation and separation of isomers, **63**, 222  
5-Phenylamino-5-phenylimino-2,4,6-triisopropyl-1,3,5-dioxaphosphorinanes, by reaction of 1,3,5-dioxaphosphorinanes with phenylazide, **61**, 66  
2-(Phenylamino)phenyltellurium trichloride, **63**, 35  
2-Phenylamino-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, reaction with ethyl chloroformate, **63**, 186  
9-(Phenylamino)tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, uv spectra and tautomerism, **63**, 109  
conformations, **63**, 114  
2-Phenylazetidine, **64**, 184  
2-Phenylaziridines, as a precursor to pyrido[1,2,4]triazines, **61**, 210  
Phenylbenzofuranpropionic acid, cyclisation to dibenzofurotropones, **64**, 95  
1-Phenyl-5-benzofuryl-4-arylo-1*H*-pyrazolo[5,1-*c*]imidazoles, **63**, 321  
2-Phenyl-1,3-benzothiazin-4-one, **66**, 143  
formation, protonation and stability of dioxane complex of ion, **66**, 170  
hydrolysis, **66**, 175  
reaction with Grignard reagents, **66**, 179  
Phenylbenzoxepines, **65**, 322  
2'-Phenyl-2,5'-bioxazole, **67**, 32  
Phenylboronic acid, Pd catalysed phenylation of bromoheterocycles, **62**, 359  
2-Phenyl-6-bromoimidazo[2,1-*b*][1,3,4]thiadiazole, reaction with phenylmercaptan, **69**, 312  
1-Phenyl-8-bromoimidazo[1,2-*b*]-s-triazolo[3,4-*f*]pyridazine, **63**, 299  
1-[2-*O*-(1-Phenylcarbamoyl)-*D*-glucopyranosyl]piperidine, cyclisation, **70**, 186  
6-Phenylcarbamoyl-2-methyl-3-phenylpyrazolo[5,1-*c*][1,2,4]triazole, **63**, 316  
2-Phenylcycloheptapyrazole-3,8-dione, **64**, 105  
2-Phenylcyclohepta[*d*]thiazol-4-one, **64**, 125  
2-Phenylcyclohepta[*d*]thiazol-8-one, **64**, 125  
*N*-(1-Phenylcyclohexyl)piperidone, synthesis, **69**, 74  
5-Phenyl-1,3,5-diazaphosphorinanes, oxides, sulfates and selenides- conformations of, **61**, 82  
5-Phenyl-2-(1,1-dibutylamyl)-1,3,2,5-dioxaboraphorinane, **61**, 93  
*N*-Phenyl-3,5-dicyano-4-methylpyridazin-2-one, preparation of pyridopyridazine, **68**, 186  
4-Phenyl-5-diethylphosphonyl-1,3,2-dioxathiolane 2,2,-dioxide, instability, **68**, 153  
2-Phenyl-2,3-dihydro-1,3-benzothiazin-2-one, reduction, **66**, 182  
2-Phenyl-2,5-dihydroisobenzofuran, **65**, 138  
4-Phenyl-2,3-dihydro-1*H*-pyrido[1,2-*c*]pyrimidine-1,3-dione, reaction with amines and POCl<sub>3</sub>, **70**, 44  
3-Phenyl-1,9*a*-dihydro-2*H*-pyrido[1,2-*b*][1,2,4]triazines, preparation from pyridinium-*N*-imine with 2-phenylazirine, **61**, 210  
2-Phenyl-2,3-dihydro-1*H*-pyrimido[1,6-*a*]quinoline-1,3-dione, reaction with sulfonyl chloride, **70**, 47  
4-Phenyl-9,10-dimethoxy-6,7-dihydro-2*H*-pyrimido[6,1-*a*]isoquinoline, **70**, 62  
2-Phenyl-3-dimethylaminofuran, **65**, 151  
2-Phenyl-1,3-dioxane, conversion to oxazinium salts, **64**, 345  
2-Phenyl-1,3-dioxanyl carbanion, conformations, **69**, 244  
4-Phenyl-1,3-dioxanyl carbanion, conformations, **69**, 244  
3-Phenyl-2,4-dioxo-1,3,4,6,7,11*b*-hexahydropyrimido[6,1-*a*]isoquinolines, <sup>13</sup>C NMR spectra and conformations, **70**, 30

- 4-Phenyl-4-[[*N,N*-di(2-propyl)amino]ethyl]-3-amino-4,4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one, **70**, 65
- 4-Phenyl-4-[[*N,N*-di(2-propyl)amino]ethyl]perhydro[1,2-*c*]pyrimidine-1,3-dione, **70**, 65
- m*-Phenylenediamine, condensation with 2-formylcyclohexanone, **70**, 91
- p*-Phenylenediamine, reaction with 2-chlorobenzoic acid, **70**, 93
- O*-Phenylene sulfite, kinetics of hydrolysis, **68**, 94
- 5-(2-Phenylethenyl)uridine, **62**, 400
- 3-Phenyl-6-*p*-fluorophenylimidazo[2,1-*b*]thiazole-2-acetic acid, X-ray structure, **69**, 301
- 1-Phenyfuro[2,3-*d*]oxazolidin-5-yl acyclo C-nucleoside, **70**, 186
- 2-Phenyl-4-(2'-furyl)-5-nitro-6-methyl-1,3-dioxanes, conformations, **69**, 233
- 3-Phenyl-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2,4-dione, <sup>1</sup>H NMR spectra and conformations, **70**, 28
- cis* and *trans*-3,4*a*-*H*-3-Phenylhydropyrido[1,2-*c*][1,3]oxazin-6-ones, Cotton effects, **70**, 8
- N*-Phenyl-1-hydroxymethyl-1,2,4,6,7,11*b*-hexahydro[1,3]thiazino[4,3-*a*]isoquinolin-4-imines, <sup>13</sup>C NMR spectroscopy, **70**, 20
- Phenyl(hydroxymethyl)phosphine, as a precursor to 1,3,5-diazaphosphorinanes, **61**, 73
- 1-Phenylimidazoles, from reaction of nitrobenzene and enamines, **67**, 258
- 2-Phenylimidazo[2,1-*b*]thiazole, halogenation, **69**, 293
- 6-Phenylimidazo[2,1-*b*]thiazole, reaction with bromine, **69**, 291
- X-ray structure, **69**, 300
- 2-Phenylimino-4*H*-3,1-benzoxazin-4-ones, EI mass spectra, **69**, 446
- 2-*N*-Phenylimino-1,4,4*a*,5,8,8*a*-decahydro-2*H*-3,1-benzothiazines, fragmentation, **69**, 441
- 2-*N*-Phenylimino-1,4,4*a*,5,8,8*a*-decahydro-2*H*-3,1-benzoxazines, fragmentation, **69**, 441
- 2-*N*-Phenylimino-1,4,4*a*,5,8,8*a*-decahydro-5,8-methano-2*H*-3,1-benzoxazines, EI fragmentation, **69**, 441
- 4-(Phenylimino)-1-hydroxymethyl-9,10-dimethoxy-1,2,4,6,7,11*b*-hexahydro[1,3]oxazino[4,3-*a*]isoquinoline, **70**, 38
- 2-*N*-Phenylimino-octahydro-2*H*-1,3-benzothiazines, conformations, **69**, 409
- 2-*N*-Phenylimino-octahydro-2*H*-3,1-benzothiazines, thermal rearrangement, **69**, 441
- 2-*N*-Phenylimino-octahydro-2*H*-1,3-benzoxazines, conformations, **69**, 409
- 2-*N*-Phenylimino-octahydro-2*H*-3,1-benzoxazines, thermal rearrangement, **69**, 441
- 2-*N*-Phenylimino-octahydrocyclopent[*d*][1,3]oxazines, **69**, 441
- 2-*N*-Phenylimino-octahydrocyclopent[*e*][1,3]oxazine, mass spectra, **69**, 442
- 2-*N*-Phenylimino-octahydro-5,8-methano-2*H*-3,1-benzoxazines, fragmentation, **69**, 441
- 2-(*N*-Phenylimino)-Δ<sup>3</sup>-1,3,4-oxadiazoline, synthesis, **69**, 42
- 2-*N*-Phenylimino-perhydro-1,3-oxazines, mass spectra, **69**, 441
- 4-*N*-Phenylimino-3-phenyl-1,3-benzothiazin-2-one, ring cleavage, **66**, 176
- 2-*N*-Phenylimino-3-phenyl-1,3-benzothiazin-4-one, hydrolysis, **66**, 176
- 2-*N*-Phenylimino-4-phenylcyclopent[*e*][1,3]oxazine, conformations, **69**, 409
- Phenylidiodane, as a nitrene source, **69**, 11
- Phenylidodonium bis(phenylsulfonyl)methylide, thermolysis in carbon disulfide, **69**, 63
- decomposition to give carbenoids, **69**, 35
- Phenylidodonium sulfate, reaction with alkenes, **69**, 63
- 3-Phenylisoserine, synthesis, **68**, 146
- stereoselective synthesis, **68**, 151
- 2-Phenylisoxazo[*d*]tropone, **66**, 384
- 3-(8-Phenylmenthyloxycarbonyl)chromone, asymmetric Diels-Alder reaction with 1,3-diketones, **65**, 351
- 5-Phenyl-2-mercaptotriazole, reaction with chloroacetone, **69**, 318
- reaction with α-haloketones, **69**, 318
- reaction with 3-bromoacetyl coumarin, **69**, 320

- 4-Phenyl-5-methoxycarbonyl-1,3,2-dioxathiolane 2,2-dioxide, instability, **68**, 153
- 2-Phenyl-5-methoxy-1,3-dioxanes, equilibration of isomers, **69**, 238
- r*-2-Phenyl, *cis*-3-methoxy, *cis*-6-methyl-oxan-4-one, conformations, **69**, 227
- r*-2-Phenyl, *cis*-4-methyl, *cis*-6-dimethyl-1,3-dioxanes, acid catalysed conformations, **69**, 240
- 3-Phenylmethylene-4*H*-1-benzothiopyran-4-one, reaction with 2-aminothiophenol, **63**, 96
- 2-Phenyl-6-methylpyridines, reaction with chloroacetate, **66**, 217
- cis*-7*a*,10*b*-*H*-1-Phenyl-7*a*-methyl-5,6,7,8,9,10,10*b*-3*H*-pyrido[3,2,1-*ij*][3,1]benzoxazines, formation, **70**, 8
- 2-Phenyl-5-methylpyrrocoline, **68**, 210
- 1-Phenyl-3-methylthio-indol-2(3*H*)one, preparation, **69**, 33
- 3-Phenyl-2-naphthoquinone, **61**, 149 spectra, **61**, 154
- E-(1-Phenyl)-2-nitropropane, cycloadducts with enamines- ring chain tautomerism, **66**, 60
- 6-Phenyl-5-nitrosoimidazo[2,1-*b*]thiazole, **69**, 292
- N*-2-(5-Phenyl-1,3,4-oxadiazolyl)benzohydrazonyl bromide, cyclisation, **63**, 297
- 3-Phenyl-1,2,3-oxathiazole 2-oxides, potential energy surface, **68**, 92
- 3-Phenyl-1,2,3-oxathiazolidine 2-oxide, potential energy surface, **68**, 92
- 2-Phenyloxazole[3,2-*f*]xanthine, electron densities, **69**, 275
- 2-Phenyloxazolidin-5-one, **64**, 22
- 2-Phenyl-5(4*H*)oxazolone, **64**, 50
- 3-(1-Phenyl-3-oxobutyl)-4-hydroxycoumarin, ring chain tautomerism, **64**, 283
- 2-Phenyl-4-oxo-4*a*,5,8,8*a*-tetrahydroquinazoline-2(1*H*)-thiones, conformations, **69**, 416
- 3-Phenylperhydropyrido[1,2-*c*][1,3]oxazine, NMR spectra, **70**, 11
- cis*-3,4*a*-*H*-3-Phenylperhydropyrido[1,2-*c*][1,3]oxazin-1-one, electrochemical oxidation, **70**, 36
- cis*-3,4*a*-*H*-3-Phenylperhydropyrido[1,2-*c*][1,3]oxazin-6-one, separation of epimers, **70**, 39
- 3-Phenylperhydropyrido[1,2-*c*][1,3]oxazin-6-ones, reduction of C3 epimers, **70**, 34
- 3-Phenylperhydropyrido[1,2-*c*]pyrimidines, <sup>1</sup>H NMR spectra and conformations, **70**, 25
- cis*-1,4*a*-*H*-1-Phenylperhydropyrido[1,2-*c*][1,3]thiazine, infrared spectroscopy, **70**, 18
- <sup>1</sup>H NMR spectroscopy, **70**, 18
- 1-Phenyl-4-phenyl-3-(1-*threo*-tritol-1-yl)pyrazolin-5-one, synthesis, **68**, 273
- 2-Phenyl-3-*i*-propylindazole, **65**, 173
- Phenyl(propynyl)iodonium triflate, conversion to dihydropyrroles, **69**, 28
- 2-Phenyl-5-propynylthiotriazole, cyclisation, **69**, 324
- 1-Phenylpyrazolo[4,3-*b*][1,5]benzothiazepin-10(9*H*)-one, **63**, 76
- 1-Phenylpyrazolo[3,4-*e*]pyrrolo[2,1-*c*][1,2,4]triazine, preparation from 4-amino-1-phenyl-5(pyrrolo-1-yl)pyrazole, **61**, 296
- N*-(3-Phenylpyrazol-5-yl)hydrazonoyl chloride, nitrilimine formation and cycloaddition, **63**, 310
- nitrilimine formation and cycloaddition to active methylenes, **63**, 311
- reaction with potassium cyanide, **63**, 329
- N*-(3-Phenyl-5-pyrazolyl)-*C*-(2-methoxyphenyl)carbamoylehydrazonoyl chloride, cyclisation, **63**, 303
- 2-Phenyl-4*H*-pyridazine[4,5-*c*]-1,3,4-thiadiazine-8(7*H*)-ones, **63**, 326
- 2-Phenylpyridine, **62**, 12
- from 2-methylthiopyridine and phenylmagnesium bromide, **62**, 384
- 3-Phenylpyridino[2,1-*c*]-1,2,4-triazole, **63**, 296
- cis*-7*a*,10*b*-*H*-1-Phenyl-5,6,7,7*a*, 8,9,10,10*b*-3*H*-pyrido[3,2,1-*ij*][3,1]benzoxazines, formation, **70**, 8
- 2-Phenyl-4*H*-pyrido[2,1-*a*]phthalazine-4-thione, **69**, 117
- 2-Phenylpyrido[1,2-*b*]pyridazinium-4-olate, photoinduced ring transformation, **69**, 108
- 2-Phenylpyrido[1,2-*a*]pyrimidinium perchlorate, **63**, 125

- 3-Phenylpyrido[2,3-*e*][1,2,4]triazine-synthesis from 3-acylhydrazino-2-aminopyridines, **61**, 214
- 3-Phenylpyrido[3,2-*e*][1,2,4]triazine, catalytic reduction and by lithium aluminium hydride, **61**, 216
- 3-Phenylpyrido[3,4-*e*][1,2,4]triazine, reduction, **61**, 218
- 1-Phenylpyrido[2,1-*f*][1,2,4]triazin-5-ium-3-olate, **61**, 220
- 4-Phenyl-2-{4-[4-(2-pyrimidinyl)piperazin-1-yl]butyl}-2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*][1,3]oxazine, absolute configuration, **70**, 17
- 2-Phenylpyrrolo[2,3-*b*]pyrazine, preparation from 2-methylpyrazine, **68**, 206
- 2-Phenylpyrrolotropone, mass spectrum, **66**, 306
- 3-Phenylselenopropylamine, formation of enamines with cyclic 1,3-diones, **67**, 232
- cis*-3,4*a*, 5,6-*H*-3-Phenyl-5-substituted-6-formylperhydropyrido[1,2-*c*][1,3]thiazin-1-ones, reductive desulfurisation, **70**, 39
- cis*-1,11*b*-*H*-1-Phenyl-3-substituted 2,3,4,6,7,11*b*-hexahydro-1*H*-pyrimido[6,1-*a*]isoquinolines, **70**, 70
- trans*-7-Phenylsulfonyl-1-azobicyclo[4,2,0]octan-8-one, **65**, 104
- 4-Phenylsulfonylpyridine, reaction with aryl Grignard reagents, **62**, 405
- 4-Phenylsulfonyl-tetrahydropyran-2-one, conformations, **69**, 228
- 2-Phenyl-1-telluracyclohexa-2,5-dione, **63**, 17
- 1-Phenyltelluroniacyclohexane, structure, **63**, 11
- 3-Phenyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones- reduction, **63**, 180
- cis*-2-Phenyl-4*a*,5,6,7,8,8*a*-tetrahydroquinazolin-4-(3*H*)-ones, conformations, **69**, 419
- 1-Phenyl-3-( $\beta$ -D-*lyxo*-tetritol-1-yl)flavazoles, acid catalysed cyclodehydration, **70**, 288
- 2-Phenyl-4-(D-*arabino*-tetritol-1-yl)-1,2,3-triazole, **68**, 320
- 3-Phenylthiazolo[3,2-*a*]benzimidazole, synthesis, **69**, 47
- 2-Phenylthiazolo[3,2-*b*]-s-triazole, **69**, 325
- 3-Phenylthieno[2,3-*d*]pyrimidin-2,4-diones, allylation, **66**, 223
- 3-Phenylthieno[2,3-*d*]pyrimidin-2-one, **66**, 209
- 3-Phenylthieno[2,3-*d*]pyrimidin-4-one-2-thione, **66**, 195
- 6-Phenylthieno[*c*]tropylium salts, reduction, **66**, 382
- 1-Phenyl-2-thioaldonoylhydrazines, condense with benzaldehyde, **68**, 335
- 2-Phenylthiobenzimidazole, thermolysis to 1,2'-bibenzimidazole, **67**, 37
- 2-(Phenylthio)phenyltellurium trichloride, **63**, 35
- 2-(Phenylthio)pyridines, **62**, 9
- 1-Phenyl-2-(thio-D-talonoyl)hydrazine, reaction with benzaldehyde, **68**, 335
- 4-Phenyl-3-thioxo-2,3-dihydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one, **70**, 44
- 1-Phenyl-2-thioxo-2,3-dihydro-1*H*-1,2,4-triazolo[2,3-*b*]indazole, **64**, 197
- 2-Phenyl-1-thioxoperhydropyrido[1,2-*c*]pyrimidin-3-one, **70**, 67
- 1-Phenyl-3-( $\beta$ - and  $\alpha$ -D-threofuranosyl)flavazoles, **70**, 288
- 1-Phenyltriazoles, **65**, 123
- 4-Phenyl-1,2,4-triazoline-3,5-dione, as a dienophile, **67**, 122
- reaction with allylidene cyclopropanes to give spiro compounds, **67**, 123
- reaction with 1,3-dimethoxy-1,3-butadiene, **67**, 123
- reaction with triphenyl azapentadiene, **67**, 125
- reaction with conjugated dienes, **67**, 125
- reaction with 5,5-dimethoxy-1,3-cyclopentadiene, **67**, 127
- reaction with 1,2,3,4,5,6-hexafluoro-5,6-dichloro-1,3-cyclohexadiene, **67**, 127
- reaction with tropones, **67**, 127
- with *cis*-cyclononatetraene, **67**, 128
- reaction with anthracene, perylene and naphtho[1,2,3,4-*c*]chrysene, **67**, 130
- paracyclophane, **67**, 130
- reaction with styrene and  $\alpha$ -bromovinylpyridine, **67**, 131
- reaction with vinylheterocycles, **67**, 131
- reaction with benzylidene ketones, **67**, 133
- reaction with heterocycles, isopyrazoles and 2,6-dimethoxythiophene, **67**, 135

- reaction with thieno[3,4-*c*]isothiazole, **67**, 136
- reaction with dihydropyridines, **67**, 136
- reaction with *N*-alkyl-2-pyridones, **67**, 137
- reaction with oxepins, **67**, 137
- reaction with 1,3-oxazepines, **67**, 138
- reaction with 2,3-dihydro-1,2(1*H*)-diazepines and triazepines, **67**, 138
- adducts of steroidal 5,7-dienes, **67**, 140
- protection of vitamin D analogues, **67**, 142
- isolation of diterpenes, **67**, 145
- isolation of unstable 1,3,6,6-heptatetraenes, **67**, 145
- trapping unstable 1-acyloxyenamines, **67**, 146
- trapping benzene oxides, isoindenes and trimethylene cyclopentanes, **67**, 146
- silica gel supported material to separate mixtures of natural products, **67**, 147
- reaction with Dewar benzene and dihydrofulvalene, **67**, 149
- reaction with dihydro-1,4-dioxane, **67**, 149
- 1,2-addition to adamantylidene adamantane, **67**, 149
- 1,2-cycloaddition to tetramethoxyallene and diphenylketene, **67**, 151
- ene reactions with olefins, **67**, 152
- ene reactions with vinylsilanes, **67**, 154
- ene reactions with  $\alpha,\beta$ -unsaturated ketones, **67**, 155
- ene reactions with 5-methylfuran-2(3*H*)-one, **67**, 156
- cycloaddition to bicyclo[1,1,0]butanes, **67**, 157
- [4+2]cycloaddition to allenylcyclopropanes, **67**, 159
- reaction with mesoionic oxazoles, **67**, 160
- reaction with vinyl azides, **67**, 160
- reaction with azomethine imines, **67**, 161
- reaction with vinyl ethers and 1-phenyl-4-vinylpyrazole, **67**, 161
- reaction with aryl or diaryldiazomethanes, **67**, 162
- reaction with diazoacetates, **67**, 162
- reaction with *N,N*-disubstituted hydrazines, **67**, 165
- reaction with arylthioxodithianes, **67**, 165
- reaction with 2-alkylidene-1,3-oxathiole, **67**, 165
- formation of hetero spiranes with tetraacetylene, **67**, 166
- cycloaddition to strained bicycloalkenes, **67**, 168
- reaction with 1,2-diphenylcyclopropene derivatives, **67**, 169
- reaction with semibullvalenes, **67**, 169
- oxidative properties, **67**, 171
- nucleophilic addition to  $\beta$ -diketones, **67**, 173
- Michael addition to 2,4-diphenylthiazolone and 4-oxypyrimidines, **67**, 174
- nucleophilic addition to 2-methylindole and 2,3-dimethylindole, **67**, 174
- reaction with 1,3,5-trimethoxybenzene, **67**, 175
- addition to *N,N*-dimethylaniline, **67**, 176
- [8+2]cycloaddition with trimethylene-8,8-dithiaheptafulvene, heptalene and 3*aH*-indene, **67**, 179
- as a mimic of singlet oxygen, **67**, 190
- as a spin trap, **67**, 190
- N*-[3-Phenyl-5-(1,2,4-triazolyl)]benzohydrazonoyl bromide hydrobromide- cyclisation, **63**, 304
- 2-Phenyl-4,4*a*-trichloro-2,3,4,4*a*-tetrahydro-1*H*-pyrimido[1,6-*a*]quinoline-1,3-dione, **70**, 47
- 3-Phenyl-7,7,11-trimethyl-8*H*-benzopyrano[4,3-*e*]imidazo[1,2-*b*][1,2,4]triazine, **61**, 305
- 2-Phenyl-2,4,6-trimethyl-1,3-dioxanes, conformational equilibria, **69**, 239
- 3-Phenyl-2,5,6-trimethylthienopyrimidin-4-one, diuretic activity, **66**, 234
- 6-Phenyl-2,4,6-trioxohexanoic acids, ring chain tautomerism, **64**, 283
- 1-Phenyl-4-vinylpyrazole, reaction with dimethyl acetylene dicarboxylate, **63**, 356
- reaction with tetracyanoethylene, **63**, 381
- reaction with diethyl azidodicarboxylate, **63**, 388
- 1-Phenyl-5-vinylpyrazole, reaction with dimethyl acetylene dicarboxylate, **63**, 357
- reaction with tetracyanoethylene, **63**, 381
- reaction with diethyl azidodicarboxylate, **63**, 389
- reaction as a diene with 1,2,4-triazole-3,5-dione, **63**, 389
- N*-Phenyl-2-vinylpyrroles, reaction with dimethyl acetylene dicarboxylate, **63**, 344
- reaction with methyl propiolate, **63**, 345



- Phenylzinc, reaction with bromoheterocycles, **62**, 377
- Phleomycins, **67**, 35
- Phloroglucinol, condensation with 6-methylanthranilic acid, **70**, 91
- Phosphaadamantane, preparation, **61**, 76  
alkylation, **61**, 77
- 1-Phospha-3,5-dioxa-4-aryl bicyclo[2,2,2]heptanes, rearrangement on heating with sulfur in benzene, **61**, 67
- 1,2-bis-(Phosphino)ethane, reaction with cyclic sulfates, **68**, 163
- 1,2,4-Phosphodioxenes, from photolysis of phosphoryldiazoketones, **65**, 197
- O*-Phthalaldehyde, ring chain tautomerism, **64**, 284
- Phthalanes, ring chain tautomerism, **66**, 19
- Phthalazines, **64**, 220  
reaction with dimethyl acetylene dicarboxylate, **69**, 120
- Phthalazinedione, preparation from phthalic hydrazide, **61**, 158
- Diels-Alder reaction with cyclooctadiene, **61**, 165
- Diels-Alder reaction with tropone, **61**, 165
- Diels-Alder reaction with aromatic compounds, **61**, 165
- Diels-Alder reaction with perylene, **61**, 165
- Diels-Alder reaction with *N*-alkyl-2-pyridine, **61**, 166
- as a protecting group for 1,3-dienes, **61**, 166
- reaction with ergosterol derivatives, **61**, 168
- reaction with styrene, **61**, 172
- 1,2-reaction with indene, **61**, 172
- hydrolysis, **61**, 172
- with 3-aminocrotonate, **61**, 172
- flash vacuum pyrolysis of 1,4-adducts to give benzocyclobutanedione, **61**, 173
- Phthalazin-5-yl *C*-nucleosides, **70**, 216
- O*-Phthaloyl dichlorides, ring chain tautomerism, **66**, 62
- 2-(and 3-)Picolinines, from triflates of 2- and 3-hydroxypyridine and trimethylaluminum, **62**, 371  
reaction with phenacyl bromide, **68**, 210
- Picolinic acid ethyl ester *N*-amminium salts as precursors to pyrido[2,1-*f*][1,2,4]triazines, **61**, 221
- Picrasidines, isolation and structure, **61**, 178  
spectra, **61**, 180
- Pinacolone thiocarbonomono-hydrazone, ring chain tautomerism, **66**, 33
- Pipecolates, from *L*-asparagine, **64**, 28
- Piperazine-2,5-diones, **64**, 32
- Piperazinones, from dichlorocarbene with ketones and diamines, **65**, 188
- 4-Piperazinothieno[3,2-*d*]pyrimidine, **66**, 248
- 4-Piperazinoylthieno[2,3-*b*][1,5]benzothiazepines, **63**, 72
- 10-Piperazinoylthieno[3,2-*b*][1,5]benzothiazepines, **63**, 72  
biological activity, **63**, 72
- Piperidine, oxidation by iodosobenzene, **69**, 74
- 2-Piperidinecarboxylic acid, oxidation, **69**, 74
- 5-Piperidinobenzo[*b*]thiepin, **65**, 47
- 3-Piperidinoindolizine, **62**, 315
- Piperidinoxazines, **65**, 23
- Piperidinopropionamidoximines, oxidation to pyrido[1,2-*a*]pyrimidines, **63**, 169
- 2-Piperidino-3,4,5,6-tetrahydropyridine, **65**, 132
- 2-Piperidone, from  $\alpha$ -methylthio amides, **69**, 54
- Piperidone acyclo *C*-nucleosides, **68**, 351
- 3-[(2-Piperidyl)methyl]perhydropyrido[1,2-*a*][1,3]oxazines, **70**, 59
- 4-(2-Piperidylmethyl)perhydropyrido[1,2-*c*][1,3]oxazines, reaction with isothiocyanates, **70**, 37
- Pirenperone, 2-methyl-3[2-{4'-(4-fluorobenzoyl)piperazin-1-yl}ethyl]pyrido[1,2-*a*]pyrimidin-4-one
- N*-Pivaloylhydrazone of acetylpinacolone, ring chain tautomerism, **64**, 301
- endo*-2-Pivaloyl-*endo*-8-hydroxybicyclo[3,3,0]octanes, ring chain tautomerism, **66**, 62
- Plakinidines A, B and C, **70**, 104, 142
- Podophyllotoxin, **65**, 348
- Poly-*O*-acetyl aldehyde-sugar *N,N'*-diphenylformazans, cyclisation with lead tetraacetate, **68**, 340
- 4-(Poly-*O*-acetylalditol-1-yl)-2-methylimidazoles, synthesis, **68**, 288

- 1-(Poly-*O*-acetylalditol-1-yl)-2-nitroethenes, cycloaddition reactions to hydrazones of aromatic aldehydes, **68**, 273  
cycloaddition reactions with diazoalkanes, **68**, 276
- 3-(Poly-*O*-acetylalditol-1-yl)pyrazoles, preparation, **68**, 273
- 4-(Poly-*O*-acetylalditol-1-yl)pyrazolines, synthesis, **68**, 276
- 4-(Poly-*O*-acetylalditol-1-yl)pyrimido[4,5-*c*]pyrazines, **70**, 216
- 3-(Poly-*O*-acetylalditol-1-yl)pyrroles, preparation, **68**, 258
- Poly-*O*-acetyl-benzothiazol-2-yl acyclo *C*-nucleosides, preparation, **70**, 194
- Polypyrrole, **67**, 2  
synthesis, **67**, 7
- Polystyryl diphenylphosphane resin, **64**, 173
- Polytetrahydrofurans, synthesis, **68**, 144
- Polythiophene, **67**, 2; **67**, 10
- (-)-Porantheridine, **70**, 75
- Porphycenes, **67**, 6
- Potassium 2,4-dichlorobenzoate, in synthesis of pyrido[2,3-*a*]acridines, **70**, 90
- Potassium thieno[3,4-*d*]pyrimidin-4(1*H*)-one-2-thiolate, **66**, 257
- Prelog-Djerassi lactonic acid, synthesis, **67**, 262
- Primapterin, *see* 2-amino-7-(1-*erythro*-1',2'-dihydroxypropyl)pteridin-4-one
- Prodigiosin, **67**, 6
- 1-Proline-*N*-oxalic anhydride, **64**, 46
- 9-[(Propargyloxy)methyl]adenine, **69**, 144
- 9-[(Propargyloxy)methyl]hypoxanthine, preparation, **69**, 144
- 2-(Propargylsulfinyl)tropones, rearrangement to 3-acylthienotropones, **64**, 100
- Propargylthiotropone, rearrangement to thienotropone, **64**, 99
- 2-(2-Propenyl)-3-aminonaphthoquinone, cyclisation, **67**, 244
- 2-Propenylcyclohexanol, conversion to spirooxetanes, **69**, 14
- 3-(*trans*-1-Propenyl)-3,6-dihydrocyclobut[*c*]-2-coumarins, **65**, 328
- 2-(1-Propenyl)indole, reaction with methyl propiolate, **63**, 351
- 3-(2-Propenyl)-*N*-substituted indoles, Diels-Alder reactions, **63**, 363
- 2-(Prop-1-en-2-yl)thiophene, reaction with di-*t*-butyl azidodicarboxylate, **63**, 388
- $\beta$ -Propiolactone, reaction with thioureas and thioamidrazones to give 1,3-thiazin-4-ones, **66**, 154
- 3-Propionyl-2*H*-1-benzopyran-2-ones, reaction with anhydrides, **65**, 301
- 3-Propionylthieno[2,3-*d*]pyrimidin-4(3*H*)-one, **66**, 206
- 6-(di-*n*-Propylamino)-6,7-dihydro-1*H*-3*H*-5*H*-pyrido[3,2,1-*i,j*][3,1]benzoxazine-3-one, biological activity, **70**, 75
- 3-*N*-Propylbiopterin, **70**, 275
- 1-(2-Propylidene)benzamidrazone hydroiodide, ring chain tautomerism, **66**, 28
- 5(2-Propynylsulfoxido)pyrimidine, conversion to thieno[3,2-*d*]pyrimidines, **66**, 245
- Propynylthiophenylamino-1,2,4-triazines, pyrolysis, **63**, 85
- 5(2-Propynylthio)pyrimidine, conversion to 1,3,6-trimethylthieno[3,2-*d*]pyrimidin-2,4-dione, **66**, 245
- 3-Propynylthio-5-substituted 1,2,4-triazoles, formation and cyclisation, **69**, 323
- 3-Propynylthio-1,2,4-triazoles, cyclisation, **69**, 323
- N*-Protected-5-aza-2-oxabicyclo[2,2,1]heptanes, **64**, 42
- N*-Protected pyrrole-2-carboxaldehyde, reaction with ethyl  $\alpha$ -amino- $\beta$ , $\beta$ -diethylpropionate, **64**, 41
- Protoberberine alkaloids, transformation to benzo[*c*]phenanthridines, **67**, 381
- Pseudoisocytidine, **68**, 357  
synthesis, **68**, 367  
preparation from 1,3-dimethylpseudouridine, **68**, 369
- ara*-Pseudoisocytidine, **68**, 370
- acyclo*Pseudoisocytidine, **68**, 378
- D-arabino*-Pseudoisocytidine, synthesis, **68**, 367
- ara*-Pseudouridine, **68**, 370
- Pseudouridine, *see* 5-( $\beta$ -D-ribofuranosyl)uracil
- $\alpha$ -Pseudouridine, conformation and crystal structure, **68**, 358
- Pseudouridine 5'-diphosphate, biological activity, **68**, 359

- Pseudouridine 5'-monophosphate, biological activity, **68**, 359
- Pseudouridine 5'-palmitate, biological activity, **68**, 359
- Pseudouridine triacetate, methylation, **68**, 360
- PTAD 4-phenyl-1,2,4-triazoline-3,5-dione
- (+)-Pulegone, in synthesis of 1,3-oxazines, **69**, 357
- (-)-Pumiliotoxin, synthesis, **69**, 122
- Purine nucleoside, alkylation, **62**, 348
- Purine nucleoside phosphorylase, inhibition by purine acyclonucleosides, **69**, 155 *see* Puromycin analogs, synthesis, **67**, 406
- 2H-Pyranamines, **65**, 307
- 4H-Pyran-2-carboxylic acids, **62**, 64
- catalytic hydrogenation, **62**, 75
- 4H-Pyran-crowns, **62**, 68
- 4H-Pyran-3,5-dicarboxaldehydes, **62**, 23
- 4H-Pyran-2,6-dicarboxylic acid, inhibition of tetrahydridipicolinate N-succinyl transferase, **62**, 121
- 4H-Pyran-3,5-diketone, reduction, **62**, 86
- cycloaddition to tetrahydropyridine-*N*-oxide, **62**, 109
- Pyrano[2,3-*a*]acridin-2-ones, **70**, 124
- Pyranoaminopyridines, preparation from pyrans, **62**, 105, **62**, 107
- Pyranofoline, **70**, 138
- Pyranones, via Michael addition of active methylenes to enamines, **67**, 265
- 2-Pyranones, **67**, 262
- 2H-Pyran-2-ones, **64**, 33
- Pyranooxazolinones, preparation from 4H-pyrans, **62**, 106
- Pyranopyrimidines, preparation from pyrans, **62**, 103
- Pyrano[2,3-*d*]pyrimidines, **64**, 212
- Pyrano[2,3-*d*]pyrimidin-3-ylureas, **64**, 212
- 2( $\alpha$ - and  $\beta$ -*lyxo*-Pyranosyl)pyrroles, preparation, **68**, 247
- Pyrano[2,3-*e*][1,2,4]triazines, **61**, 234
- Pyrano[3,4-*e*][1,2,4]triazines, **61**, 233
- Pyrano[4,3-*e*][1,2,4]triazines, **61**, 233
- Pyranotropolone, **64**, 126
- 2H-Pyrans, preparation from 1,3-diketones and Knoevenagel reaction, **62**, 25
- cycloaddition, **62**, 107
- preparation from ketones and dimedones, **62**, 26
- preparation from alkenic acetylenes, **62**, 40
- preparation from ( $2\pi+2\pi+2\pi$ ) cycloaddition of two acetylenic and one carbonyl moieties, **62**, 41
- preparation by photoisomerisation, **62**, 46
- preparation by cobalt catalysed cycloadditions, **62**, 41
- molybdenum complexes, **62**, 91
- photooxidation, **62**, 73
- cleavage, **62**, 84
- stability and valence bond tautomerism, **62**, 111
- theoretical studies, **62**, 111
- spectra, **62**, 113
- synthesis by addition of nucleophiles to pyrylium salts, **65**, 285
- (4H)-Pyrans, **62**, 21, **62**, 29
- theoretical studies, **62**, 112
- NMR and IR spectra, **62**, 113
- aromatisation, **62**, 68
- hydrogenation, **62**, 75
- via Diels-Alder reactions, **62**, 43
- spirocycles, **62**, 43
- manganese complex, **62**, 91
- conversion to pyridines, **62**, 95
- cycloaddition reactions, **62**, 109
- synthesis by addition of nucleophiles to pyrylium salts, **65**, 285
- 2-(Pyran-4-ylidene)-1,3-dithiols, **65**, 291
- (Pyran-4-ylidene)phosphoranes, **65**, 316
- 4H-Pyran-4-yl phosphonium salts, **62**, 62
- 2H-Pyran-5-sulfone, **62**, 28
- (4H-Pyran-5-yl)triphenylphosphonium salts, preparation of bipyrans, **65**, 315
- Pyrazine bis-homo *C*-nucleoside, **68**, 380
- Pyrazine-2-carboxylic acid, **67**, 63
- Pyrazine *C*-nucleosides, **68**, 379
- Pyrazinoditropone, **66**, 375
- (2-Pyrazinyl)methylenemalononitrile, ring chain tautomerism, **66**, 58
- Pyrazofurin 5'-phosphate, antiviral activity, **68**, 263
- Pyrazofurin B, *see* 5-carboxamido-4-hydroxy-3-( $\alpha$ -D-ribofuranosyl)pyrazole
- Pyrazofurin, *see* 5-carboxamido-4-hydroxy-3-( $\beta$ -D-ribofuranosyl)pyrazole
- Pyrazole reverse *C*-nucleosides, preparation, **68**, 272
- Pyrazole-3-carboxylic acid, **64**, 18
- Pyrazole-3,4-dicarboxylic acids, oxidative degradation products of pyrazolotropolones, **66**, 367

- Pyrazole-di-*N*-oxides, from oxidation of dioximes of  $\beta$ -diketones, **69**, 40  
 Pyrazolepyranone, **65**, 309  
 Pyrazoles, from 1,3-diketones and hydrazino bis(iminophosphoranes), **64**, 191  
 Pyrazolo[1,5-*a*]azocines, **65**, 134  
 Pyrazolo[3,4-*c*][1,5]benzothiazepines, **63**, 76  
 Pyrazolo[4,3-*b*][1,5]benzothiazepines, **63**, 75  
 Pyrazolo[4,3-*b*][1,4]-benzothiazines, **67**, 257  
 Pyrazolopyrans, **62**, 22  
 Pyrazolo[1,5-*a*]pyrimidines, from enamines, **67**, 317  
 Pyrazolopyrimidinotriazines, **61**, 300  
     Pyrazolo[4,3-*d*]pyrimidin-5-yl *C*-nucleosides, **70**, 247  
 Pyrazolo[1,2-*a*]pyridines, preparation, **68**, 201  
 Pyrazolo[1,5-*a*]pyridine, **68**, 217  
 Pyrazolo[1,5-*a*]pyridine-4,7-diones, preparation from pyrazoles and acetylenes, **61**, 183  
 Pyrazolo[4',3':5,6]pyrido[2,3-*b*][1,5]benzothiazepines, **63**, 91  
 Pyrazolo[3',4':4,5]pyrido[6,1-*a*]phthalazine, **64**, 236  
 Pyrazolo[3',4':4,5]pyrido[6,1-*a*]pyrimidines, **64**, 236  
 Pyrazolo[1,5-*a*]pyrido[3,4-*e*]pyrimidines, synthesis, **68**, 190  
 Pyrazolo[1,5-*a*]pyrido[3,4-*e*]pyrimidine-7-oxide, synthesis, **68**, 191  
 Pyrazolo[2'-*a*]pyrido[2,1-*c*][1,2,4]triazinedium dibromide, **61**, 300  
 Pyrazolo[3,2-*c*]pyrido[4,3-*e*][1,2,4]triazine oxides, preparation and reduction, **61**, 300  
 Pyrazolothiazines, **67**, 257  
 Pyrazolo[5,1-*c*]as-triazine, **63**, 303  
 Pyrazolo[5,1-*c*][1,2,4]triazines, **63**, 316  
 Pyrazolo[5',1':3,4][1,2,4]triazino[1,6-*a*]indole, X-ray structure, **61**, 310  
 Pyrazolo[1,5-*c*]as-triazin-7-one, **63**, 328  
 Pyrazolo[5',1':3,4][1,2,4]triazino[5,6-*d*]pyrimidine, **61**, 300  
 Pyrazolo[5',1':3,4][1,2,4]triazino[6,5-*f*][1,3,4]thiadiazopine hydrochloride, **61**, 302  
 Pyrazolo[1,5-*f*]1,3,5-triazin-8-yl *acyclo C*-nucleosides, **70**, 303  
 Pyrazolo[5,1-*c*][1,2,4]triazoles, **63**, 285  
 Pyrazolo[1,5-*c*][1,2,4]-triazoles, **63**, 301  
 Pyrazolotroponehydrazones, cyclisation with carboxylic acids, **66**, 377  
 Pyrazolotropones, **64**, 103, **64**, 105  
     X-ray diffraction, **66**, 286  
     NMR spectra, **66**, 288  
     UV spectra, **66**, 295  
     IR spectra, **66**, 302  
     aromaticity, **66**, 308  
     ironcarbonyl complexes, **66**, 331  
     catalytic hydrogenation, **66**, 336  
     failure to react with phenylhydrazines, **66**, 338  
     *N*-alkylation, **66**, 348  
 3-Pyrazolyl *acyclo C*-nucleosides, preparation, **68**, 273  
 4-Pyrazolyl *acyclo C*-nucleosides, preparation, **68**, 276  
 Pyrazol-4-yl homo *C*-nucleosides, preparation, **68**, 270  
 3-Pyrazolyl *C*-nucleosides, preparation, **68**, 267, 394  
 Pyrazolylpyrazolines, dehydrogenation to bipyrazoles, **67**, 21  
 Pyridazinedione, 1,2-addition to styrene, **61**, 171  
 Pyridazin-3-ones, **67**, 310  
 4*H*-Pyridazino[6,1-*a*]isoquinolines, **69**, 119  
 Pyridazino[6,1-*a*]isoquinolin-2-one, **69**, 119  
 4-Pyridazinones, **67**, 310  
 Pyridazino[2,3-*b*][1,2,4]triazines, **61**, 234  
 Pyridazino[2,3-*e*][1,2,4]triazines, **61**, 268  
 Pyridazino[4,5-*e*][1,2,4]triazines, herbicidal activity, **61**, 235  
 Pyridazino[6,1-*c*][1,2,4]triazines, **61**, 234  
 3(6)-Pyridazinyl *acyclo C*-nucleosides, **68**, 354  
 4(5)-Pyridazinyl *acyclo C*-nucleosides, **68**, 354  
 3(6)-Pyridazinyl *C*-nucleosides, **68**, 354  
 4(5)-Pyridazinyl *C*-nucleosides, **68**, 354  
 Pyridin-2-(3*H*)-one, from  $\alpha$ -methylthio amides, **69**, 54  
 Pyridine-*N*-oxides, from enamines, **67**, 272  
     synthesis via enamines, **67**, 250  
 Pyridine-2-thione, Pd(0) catalysed allylation, **66**, 101  
     Pd(0) catalysed allylation with acetates of geraniol, nerol and linalool, **66**, 102  
 Pyridinium betaines, **64**, 28  
 Pyridinium-*N*-imines, reaction with  $\alpha$ -halogenounsaturated esters to give pyrido[1,2-*b*][1,2,4]triazines, **61**, 211

- Pyridinium ylides, 1,3-dipolar cycloaddition reactions with dimethyl acetylene dicarboxylate, **65**, 113
- Pyridindolol, *see* 1-[(1R)-2-dihydroxyethyl]-3-hydroxymethyl-9-*H*-pyrido[4,3-*b*]indole [*n*](2, 6-Pyridinophanes), preparation from 2,6-dichloropyridine, **62**, 386
- N*-(2-Pyridinyl)acylacetamides, cyclisation with phosphorus pentasulfide, **63**, 126
- Pyrido[2,3,4-*kl*]acridines, synthesis, **70**, 120
- Pyrido[2,3-*a*]acridine, **70**, 92
- Pyrido[3,2-*a*]acridines, **70**, 93
- Pyrido[3,2-*b*]acridones, **70**, 97
- Pyrido[2,1-*d*][1,5]benzothiazepines, **63**, 86
- Pyrido[2,3-*b*][1,5]benzothiazepines, **63**, 83
- Pyrido[3,2-*b*][1,5]benzothiazepines, **63**, 84
- Pyrido[3,2-*c*][1,5]benzothiazepines, **63**, 85
- Pyrido[3,2,1-*i,j*][3,1]benzoxazin-1,3-diones, hydrolysis, **70**, 31
- Pyrido[3,2,1-*ij*][3,1]benzoxazin-3-ones, hydrolysis, **70**, 31
- Pyrido[3,2,1-*i,j*]cinnoline-3,3,8-tricarboxylate, hydrolysis, **69**, 107
- Pyrido[1,2-*b*]cinnolinium-11-olate, HOMO coefficients, **69**, 94
- UV spectroscopy, **69**, 94
- reduction, **69**, 100
- nitration, **69**, 102
- reaction with phosphorus pentasulfide, **69**, 102
- methylation, **69**, 105
- Pyrido[2,1-*a*]isoquinolinium salts, **65**, 50
- 2-Pyridone, **62**, 12
- Pd(0) catalysed allylation, **66**, 100
- reaction with vinylogous acid halides, **67**, 210
- 4-Pyridones, from enamines and diketenes, **67**, 271
- Pyrido-oxadiazoles, synthesis, **69**, 43
- Pyrido[2,1-*a*]phthalazinium-7-olate, HOMO coefficients on *O* and *N*(6), **69**, 94
- methylation, **69**, 105
- Pyrido[3,2-*g*]pteridines, **67**, 419
- Pyrido[2,3-*b*]pyrazines, **64**, 54; **67**, 306
- Pyrido[1,2-*b*]pyridazine-3-carboxylate, **69**, 116
- 3*H*-Pyrido[1,2-*b*]pyridazin-3-ones, **69**, 118
- Pyrido[1,2-*b*]pyridazino[3,4-*e*][1,2,4]triazines, **61**, 309
- Pyrido[1,2-*a*]pyridines, **64**, 51
- Pyrido[1',2':1,2-*a*]pyrido[4,5-*e*]-1,4-diazepine-2,6-dione, **63**, 250
- Pyrido[3,2-*d*]pyrimidine, preparation **64**, 54, **67**, 297, **68**, 200
- Pyrido[1,2-*a*]pyrimidines, **64**, 52
- Pyrido[2,3-*d*]pyrimidines, **64**, 54, **67**, 297
- Pyrido[1,2-*c*]pyrimidinium chloride, X-ray structure, **70**, 30
- 2*H*-Pyrido[1,2-*a*]pyrimidin-2-ones, spectra, **63**, 112
- 4*H*-Pyrido[1,2-*a*]pyrimidin-4-ones, solubilities, **63**, 106
- spectra, **63**, 112
- calculation of base strength, **63**, 106
- reduction, **63**, 176
- correlation of partition coefficient and *R<sub>m</sub>* values, **63**, 107
- chromatography, **63**, 107
- Vilsmeier-Haack formylation, **63**, 190
- physical properties, **63**, 108
- UV/visible spectroscopy, **63**, 109
- X-ray diffraction, **63**, 112
- IR spectroscopy, **63**, 112
- Pyrido[1,2-*a*]pyrimidine-4,6-diones, **63**, 157
- 2*H*-Pyrido[1,2-*a*]pyrimidine-2-ones, **63**, 126
- 2*H*-Pyrido[1,2-*a*]pyrimidine-2-thiones, **63**, 126
- 6*H*-Pyrido[1,2-*a*]pyrimidine-6-thione, **63**, 160
- Pyrido[1,2-*a*]pyrimidinium cation, ring chain tautomerism, **66**, 56
- Pyrido[1,2-*a*]pyrimidinium salts, hydrolysis, **63**, 169
- Pyrido[1,2-*a*]pyrimidin-3-yl *C*-nucleosides, **70**, 261
- Pyrido[1,2-*f*]pyrimido[4,5-*d*]pyrimidine, **64**, 232
- Pyrido[1',2':1,2]pyrimido[4,5-*b*]quinazolin-12-one, **63**, 202
- 12*H*-Pyrido[1',2':1,2]pyrimido[4,5-*b*]quinolin-12-one, **63**, 202
- Pyrido[3,2-*e*]pyrimido[2,1-*c*][1,2,4]triazine, preparation and biological activity, **61**, 241
- Pyrido[1,2-*b*]pyrrolo[2,3-*e*][1,2,4]triazine, **61**, 310
- Pyrido[1,2-*a*]quinolines, **64**, 58
- Pyrido[3,4-*c*]quinoline, synthesis, **68**, 186
- Pyrido[2,1-*b*][1,3]thiazines, **67**, 306
- 4*H*-Pyrido[2,1-*b*][1,3]thiazin-4-one, synthesis and rearrangement, **63**, 159

- Pyrido[1,2-*a*]thieno[2,3-*d*]pyrimidine-2-carboxylate, **63**, 200
- Pyridotriazines, **62**, 12
- Pyrido[1,2-*a*][1,3,5]triazines, **64**, 222, **65**, 197
- Pyrido[1,2-*b*][1,2,4]triazines, **61**, 210
- Pyrido[2,1-*c*][1,2,4]triazines, **61**, 212
- Pyrido[2,1-*f*][1,2,4]triazines, **61**, 219
- Pyrido[2,3-*c*][1,2,4]triazines, **61**, 214
- Pyrido[3,2-*e*][1,2,4]triazines, **61**, 215
- Pyrido[3,4-*e*][1,2,4]triazines, **61**, 217
- Pyrido[4,3-*e*][1,2,4]triazines, **61**, 219
- Pyrido[2,1-*f*][1,2,4]triazin-5-ium-1-olates, preparation and methylation, **61**, 221
- Pyrido[2,1-*f*][1,2,4]triazin-9-ium salts, **61**, 222
- Pyrido[1,2-*d*][1,2,4]triazin-4-thiones, **61**, 213
- Pyrido[2,1-*f*][1,2,4]triazinium-1-thiolates, preparation and methylation, **61**, 222
- Pyrido[2,3-*e*][1,2,4]triazolo[3,4-*c*][1,2,4]triazine-1-oxides, **61**, 306
- Pyrido[*b*]tropolone- ring contraction to 7-quinolinic acid, **66**, 369
- Pyridotropolone, **64**, 127
- Pyridotropolone-*N*-oxide, **66**, 350
- Pyridotropones, mass spectra, **66**, 305
- tautomerism, **66**, 310
- formation of dioximes, **66**, 338
- N*-alkylation, **66**, 348
- N*-oxides, **66**, 350
- cyclocondensation with *o*-phenylenediamine, **66**, 362
- Fischer indole synthesis, **66**, 363
- Pyridoxal-5-phosphate-ethylenediamine solutions, ring chain tautomerism, **66**, 24
- 2(6)-Pyridyl *acyclo* C-nucleosides, **68**, 348
- 3(5)-Pyridyl *acyclo* C-nucleosides, **68**, 351
- 4-Pyridyl *acyclo* C-nucleosides, **68**, 352
- 3-(2-Pyridylamino)acroleins, hydrolysis products of pyrimido[1,2-*a*]pyridinium salts, **63**, 169
- 3-(2-Pyridyl)-2,1-benzisoxazoles, photolysis, **69**, 121
- 5-(4-Pyridyl)benzo[*a*][2,7]naphthyridin-4-one, in synthesis of amphimedine, **70**, 122
- 2(6)-Pyridyl carbocyclic C-nucleosides, **68**, 348
- 2-(2-Pyridylcarbonyl)-benzoic acids, ring chain tautomerism, **64**, 260
- 2-(2-Pyridylcarbonyl)biphenyl-2'-carboxamides, ring chain tautomerism, **64**, 267
- 8-(2-Pyridylcarbonyl)naphthoic acids, ring chain tautomerism, **64**, 261
- 2-Pyridylcopper, preparation and use, **62**, 397
- 1-(2-Pyridyl)-3,5-dinitro-2-pyridone, reaction with ethyl sodioacetoacetate to give 2-oxo-2,5-dihydropyrido[1,2-*b*][1,2,4]triazine-4-oxide, **61**, 211
- 2(6)-Pyridyl *homo* C-nucleosides, **68**, 346
- C-(2-Pyridyl)hydrazonoyl bromide, 1,3-dipolar cycloadditions, **63**, 308
- 2-Pyridyl isocyanate, precursor in synthesis of bipyridines, **67**, 51
- 2(6)-Pyridyl C-nucleosides, **68**, 341
- 3(5)-Pyridyl C-nucleosides, **68**, 343
- 4-Pyridyl C-nucleosides, **68**, 346
- 3-(2-Pyridyl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 143
- 1-(2-Pyridyl)pyrrolinone, **63**, 230
- Pyridylquinolines, from bromoquinolines and pyridylzincs, **62**, 381
- 2(6)-Pyridyl reverse C-nucleosides, **68**, 348
- 4-Pyridyl thioglycosides, photorearrangement, **68**, 344
- 3-Pyridyltriflate, coupling with alkynes, **62**, 319
- 3-Pyridylzinc chloride, coupling with 2-bromopyridine, **67**, 50
- Pyridylzinc halides, **62**, 382
- acylation, **62**, 383
- Pyrimidine, dimerisation by reaction on palladium on charcoal, **67**, 61
- Pyrimidine acyclonucleosides, preparation, **68**, 59
- 5-Pyrimidineboronic acid, arylation, **62**, 368
- Pyrimidine-4-carboxylate copper salt, pyrolysis, **67**, 61
- Pyrimidine-*N*-oxide- from enaminoxones, **67**, 313
- Pyrimidin-2-one, Pd(0) catalysed allylation, **66**, 102
- Pd(0) catalysed reaction with vinyl epoxides, **66**, 105
- Pyrimidin-4-ones, reaction with aldohexopyranoses, **68**, 365
- N*-1-Pyrimidine substituted acyclonucleosides, **68**, 56
- N*-1,*N*-3-bis-Pyrimidine substituted acyclonucleosides, **68**, 56
- Pyrimidin-2-thione, Pd(0) catalysed allylation on sulfur, **66**, 105

- 2-Pyrimidinyl *acyclo* C-nucleosides, **68**, 376  
 4(6)-Pyrimidinyl *acyclo* C-nucleosides, **68**, 377  
 5-Pyrimidinyl *acyclo* C-nucleosides, **68**, 377  
 (2-Pyrimidinylamino)  
   methylenemalononitrile, ring chain  
   tautomerism, **66**, 58  
 4(6)-Pyrimidinyl carbocyclic C-nucleosides, **68**, 374  
 5-Pyrimidinyl carbocyclic C-nucleosides, **68**, 375  
 4-Pyrimidinyl 2,3-dibenzyloxycyclobutyl C-nucleoside, **68**, 374  
 4(6)-Pyrimidinyl homo C-nucleosides, **68**, 374  
 5-Pyrimidinyl homo C-nucleosides, **68**, 374  
 5-Pyrimidinyl-mercuric acetates, reaction with unsaturated sugar derivatives, **68**, 366  
 (Pyrimidin-4-yl)methylene phosphoranes, reaction with aldehyde-sugar derivatives, **68**, 374  
 5-Pyrimidin-5-yl C-nucleosides, **68**, 365  
 2-Pyrimidinyl C-nucleosides, **68**, 363  
 4(6)-Pyrimidinyl C-nucleosides, **68**, 364  
 4(6)-Pyrimidinyl reverse C-nucleosides, **68**, 375  
 2-(and 4-)Pyrimidinyltriflates, coupling with stannanes, **62**, 341  
 Pyrimidinyltriflates, coupling with zinc reagents, **62**, 379  
 Pyrimido[4,5-*b*][1,5]benzothiazepines, **63**, 86  
 Pyrimido[5,4-*c*][1,5]benzothiazepines, **63**, 87  
 Pyrimido[4,5-*b*]indole, **67**, 238  
 Pyrimido[4,3-*d*]pyridazines, by cyclisation of arylazo groups with adjacent methyl groups and dimethylformamide dimethylacetal, **68**, 204  
 Pyrimido[4',5':4,5]pyrimido[6,1-*a*]phthalazine, **64**, 235  
 Pyrimido[4,5-*b*]quinolines, **64**, 206  
 Pyrimido[4,5-*f*][1,3,5-triazepin-4-yl *acyclo* C-nucleosides, **70**, 307  
 Pyrimido[4,5-*d*]1,2,3-triazines, preparation from aminopyrimidines, **68**, 197  
 Pyrimido[1,2-*b*][1,2,4]triazines, **61**, 238  
 Pyrimido[1,6-*b*][1,2,4]triazines, **61**, 239  
 Pyrimido[2,1-*c*][1,2,4]triazines, **61**, 240  
 Pyrimido[4,5-*e*][1,2,4]triazines, **61**, 242  
 Pyrimido[5,4-*e*][1,2,4]triazines, **61**, 247  
 Pyrimido[6,1-*c*][1,2,4]triazines, **61**, 241  
 Pyrimido[5,4-*e*][1,2,4]triazinediones, hydration, **61**, 260  
 Pyrimido[5,4-*e*][1,2,4]triazine-5-(6*H*)-one, **61**, 251  
 Pyrimido-1,2,3-triazine-*N*-oxide, **68**, 197  
 Pyrimido[3',2':2,3][1,2,4]triazino[5,6-*b*]indole-2,4-diones, **61**, 294  
 Pyrimido[4,5-*e*][1,2,4]triazoline, **64**, 235  
 Pyrimidotropones, **64**, 104  
   IR spectra, **66**, 304  
 Pyrroles, synthesis via enaminones, **67**, 224  
 Pyrrolidines, from enaminones, **67**, 230  
   oxidation by iodosobenzene, **69**, 74  
 2-Pyrrolidine carboxylic acid, oxidation, **69**, 74  
*cis* and *trans*-Pyrrolidine-2,4-dicarboxylic acid, **64**, 12  
 Pyrrolidinobenzothiazines, **65**, 24  
 2-Pyrrolidino-3-cyanovinylanthraquinone, **65**, 30  
 1-Pyrrolidinocyclopentene, inverse cycloaddition with 1,2,4-triazin-4-yl C-nucleosides, **70**, 197  
 Pyrrolidinonaphthalenes, cyclisation, **65**, 23  
 Pyrrolidinooxazines, **65**, 23  
 4-Pyrrolidino-3-penten-2-one, reaction with ketenes, **67**, 262  
 2-Pyrrolidinylbenzoquinones, photocyclisation, **65**, 10  
 2-Pyrrolidinylbenzo[*b*]thiophene, reaction with dimethyl acetylene dicarboxylate, **65**, 7  
 2-[2-(1-Pyrrolidinyl)ethyl]2,3,4,4a-hexahydro-1*H*-pyrimido[6,1-*a*]quinolin-1-one, reaction with P<sub>4</sub>S<sub>10</sub>, **70**, 46  
 2-Pyrrolidinylthiophene, reaction with dimethyl acetylene dicarboxylate, **65**, 7  
 3-Pyrrolidinylthiophene, reaction with dimethyl acetylene dicarboxylate, **65**, 7  
 D,L-*threo*-1-Pyrroline derivatives, reaction with pyridyl-2-ylmethyl lithium, **68**, 347  
 Pyrrolizidine-synthesis via enaminones, **67**, 234  
 Pyrrolizidine acid chloride, **67**, 233  
 Pyrrolizines, **65**, 123  
 Pyrrolo[2,3,4-*kl*]acridines, synthesis, **70**, 142  
 Pyrrolo[2,3-*c*]acridine, **70**, 140  
 Pyrrolo[1,2-*a*]azepines, **64**, 47  
 Pyrrolobenzazepines, **65**, 133  
 Pyrrolo[4,3,2-*fg*][3]benzazocine, **64**, 60  
 Pyrrolo[2,1-*c*][1,4]benzothiazepines, **64**, 59  
 Pyrrolo[2,1-*d*][1,5]benzothiazepine-6-carboxylic acid, **63**, 67

- Pyrrolo[2,1-*d*][1,5]benzothiazepine-5,5-dioxide, **63**, 65
- Pyrrolo[2,3-*h*][1,4]benzothiazines, **64**, 58
- Pyrrolo[3,4-*c*][1,5]benzothiazepines, **63**, 65
- Pyrrolo[2,1-*d*][1,5]benzothiazepin-7(6*H*)-ones, **63**, 66
- Pyrrolo[2,1-*b*][1,3]benzoxazines, **64**, 59
- Pyrrolodiazine, **65**, 113
- Pyrroloditropylum salts, reduction, **66**, 382
- Pyrrolo[2',3':4,5]-furo[3,2-*c*]pyridines, **64**, 204
- Pyrrolo[1,2-*a*]indole, **64**, 59
- Pyrroloindoles, **65**, 3
- Pyrrolo[4,3,2-*i,j*]isoquinoline, **64**, 208
- Pyrrolo[1,2-*b*]isoquinoline-5,10-diones, from phthalic anhydride and pyrroles, **61**, 181
- from 1,2,3,4-tetrahydroisoquinoline-1,4-dione and sulfonyl ketene thioacetals, **61**, 182
- reactions, **61**, 185
- Pyrrolones, by flash vacuum pyrolysis of enamines, **67**, 228
- Pyrrolo[2,1-*c*][1,4]oxazepines, **64**, 47
- Pyrrolo[2,1-*c*]oxazines, **64**, 47
- Pyrrolooxazines, **65**, 23
- Pyrrolo[3,2-*d*]oxazin-3-yl *C*-nucleosides, **70**, 293
- Pyrrolophenanthridines, via base treatment of bromoenamines, **67**, 291
- via Claisen rearrangements of enamines, **67**, 292
- Pyrrolo[3,4-*b*]pyran, **64**, 42
- Pyrrolo[1,2-*a*]pyrazines, **64**, 45
- Pyrrolo[2,3-*e*]pyrazine, **64**, 188
- Pyrrolo[1,2-*a*]pyrazoles, **64**, 43
- Pyrrolo[1,2-*b*]pyridazines, from 2-methylpyridazines and phenacyl bromides, **68**, 211
- Pyrrolopyridazine-*N*-oxides, **68**, 198
- Pyrrolo[2,3-*c*]pyridines, **64**, 41
- Pyrrolo[3,2-*b*]pyridines, via enamines, **67**, 294
- Pyrrolo[3,4-*b*]pyridines, **67**, 293
- 1-Pyrrolo[2,3-*b*]pyridine magnesium bromide, reaction with *aldehydo*-sugars, **70**, 198
- Pyrrolo[3,2-*b*]pyridones, **67**, 293
- Pyrrolo[3,4-*c*]pyrido[2,3-*d*]pyrimidines, **64**, 7
- Pyrrolo[1,2-*c*]pyrimidines, from 2-picolines and phenacyl bromides, **68**, 211
- Pyrrolo[2,3-*d*]pyrimidine, preparation, **68**, 199
- preparation by cyclisation of vicinal alkyl acylamines, **68**, 201
- by cyclisation of anils of aminopyrimidines, **68**, 203
- Pyrrolopyrimidine, Pd(0) catalysed reaction with (-)monoacetate of cis cyclopent-2-ene-1,4-diol, **66**, 123
- Pyrrolo[1,2-*a*]pyrimidines, **64**, 45
- Pyrrolo[2,3-*d*]pyrimidines, **65**, 121
- Pyrrolo[3,2-*d*]pyrimidinediones, preparation from uracil, **68**, 204
- Pyrrolo[1,2-*a*]pyrimidinones, **63**, 165
- Pyrrolo[2,3-*d*]pyrimidin-7-yl *C*-nucleosides, **70**, 218
- Pyrrolo[1,2-*a*]quinazolines, from 4-methylquinazolines and phenacyl bromides, **68**, 211
- Pyrrolo[1,2-*c*]quinazolin-1-ones, **64**, 219
- Pyrrolo[2,3-*d*]quinazolinone, preparation, **68**, 199
- Pyrrolo[3,2-*c*]quinolines, **64**, 57
- Pyrrolo[3,2-*b*]quinoline, synthesis from aminoquinolines, **68**, 198
- trans*-Pyrroloquinoline, conversion to enantiomerically pure *cis* isomer, **65**, 19
- Pyrrolo[1,2-*a*]quinoxalines, from 3-methylquinoxalines and phenacyl bromides, **68**, 211
- Pyrrolo[2,1-*c*]quinoxalin-2-ones, **64**, 219
- Pyrrolo[2,1-*c*][1,4]thiazepines, **64**, 47
- Pyrrolo[1,2-*a*]1,2,5-triazines, from 2-methyltriazines and phenacyl bromides, **68**, 211
- Pyrrolo[1,5-*d*]1,2,4-triazin-8-yl *C*-nucleosides, **70**, 296
- Pyrrolotropones, **64**, 97, **64**, 109, **64**, 118
- UV spectra, **66**, 295
- basicity, **66**, 330
- mass spectra, **66**, 305
- photoelectron spectra, **66**, 307
- amination by silylamines, **66**, 338
- chlorination, **66**, 340
- N*-hydroxymethylation and *N*-hydroxyalkylation, **66**, 349
- Pyrrolotropothiones, **66**, 372
- Pyrrolo[*c*]tropylium ions, <sup>1</sup>H NMR spectra, **66**, 315
- reduction, **66**, 381



- UV spectrum, **66**, 315  
aromaticity, **66**, 323  
reaction with Grignard reagents, **66**, 383  
dimer, **66**, 386  
Pyrrolo[*c*]tropylum salts, **64**, 131  
Pyrrol-2-yl *acyclo* C-nucleosides, **68**, 254  
cyclodehydration, **68**, 247  
2(5)-Pyrrolyl *acyclo* C-nucleosides,  
preparation, **68**, 256  
5-(2-Pyrrolylcarbonyl)pyrimidine, **62**, 339  
1-Pyrrolyl magnesium bromide, reaction with  
2,3-*O*-isopropylidene-D-glyceraldehyde,  
**68**, 253  
1-(Pyrrol-1-ylmethyl)indan-2-one, **65**, 129  
3-Pyrrolyl C-nucleosides, preparation and  
biological activities, **68**, 249  
Pyrrolyl potassium, reaction with  
ethoxymethylenemalonic acid, **67**, 235  
2-Pyrones, photosensitised cycloaddition  
reactions, **65**, 325  
high pressure reaction with dienophiles,  
**65**, 332  
reaction with cyclopropenone ketal, **65**, 341  
reaction with p-benzoquinone, **65**, 342  
reaction with benzocyclobutene, **65**, 343  
reaction with cyclooctatetraene-maleic  
anhydride adduct, **65**, 343  
reaction with cyclopropenone ketal, **65**, 365  
4-Pyrones, reaction with  
dimethylsulfoxonium methylide, **65**, 321  
2-Pyrone(s)lactate, reaction with  
benzylvinylether, **65**, 337  
Pyronotropones, **66**, 394  
Prylium perchlorate, reaction with  
organolithiums, **62**, 52  
reaction with organomagnesium reagents,  
**62**, 53  
reaction with organocopper reagents, **62**, 55  
reaction with organotitanium reagents,  
**62**, 56  
reaction with organozirconium reagents,  
**62**, 56  
reaction with amines, **62**, 59  
Prylium tetrafluoroborate, reaction with  
active methylenes **65**, 290  
  
Quinazoline, dimerisation with aqueous  
cyanide, **67**, 67  
Quinazolinium salts, **65**, 26  
  
Quinazolino[2,3-*d*][1,5]benzothiazepines,  
**63**, 96  
4(3*H*)-Quinazolinones, **64**, 215  
palladium catalysed dimerisation to 4,4'-  
dihydroxy-2,2'-biquinazoline, **67**, 66  
reaction with sodium naphthalenide, **67**, 67  
from enaminones, **67**, 314  
preparation, **69**, 74  
Quinazolinotriazinoindoles, **61**, 294  
Quinazolin-8-yl C-nucleosides, **70**, 260  
Quinazolin-8-yl *acyclo* C-nucleosides, **70**, 260  
Quino[3,2-*c*]acridine, **70**, 107  
Quino[*a*]acridones, synthesis, **70**, 91  
Quino[3,2-*a*]acridone, **70**, 93  
Quino[2,3-*b*][1,5]benzothiazepines, **63**, 92  
Quino[4,3-*b*][1,5]benzothiazepin-6(5*H*)-  
ones, **63**, 92  
Quinoline-5,6-diones, synthesis, **67**, 279  
Quinoline-5,8-diones, synthesis, **67**, 279  
Quinoline-2-sulfoxides, reaction with  
Grignards to give 2,2'-biquinolines,  
**67**, 53  
Quinolinic acid, from quinolinotropolones,  
**66**, 367  
Quinolin-5-ones, synthesis, **67**, 279  
Quinolinones, **65**, 73  
Quinolinotropones, IR spectra, **66**, 302  
(2-Quinolinylamino)methylenemalononitrile,  
ring chain tautomerism, **66**, 58  
Quinolinygold compounds, thermolysis to  
2,2'-biquinolines, **67**, 53  
2-Quinoliny triflate, coupling with stannanes,  
**62**, 341  
8-Quinoliny triflate-coupling with stannanes  
**62**, 341  
2-Quinolones, from cyclic enaminones and  
 $\alpha,\beta$ -unsaturated esters, **67**, 279  
2-(2-Quinolylcarbonyl)benzoyl chloride, ring  
chain tautomerism, **66**, 62  
Quinonediazides, decomposition, **65**, 118  
Quino[8,7-*b*][1,10]phenanthroline, **70**,  
106  
Quinoxalino[2,3-*b*][1,5]benzothiazepines,  
**63**, 97  
Quinoxalinotropones, **64**, 110, **64**, 128  
1,4-addition reactions with active  
methylenes, **66**, 335  
bridged adduct with aniline, **66**, 336  
reaction with hydrazine to give tetracyclic  
products, **66**, 336

- reduction with metal hydrides, **66**, 337  
 mono and di-*N*-oxides, **66**, 351  
 Quinoxalotropylium salts, **64**, 137
- (R)-Reticuline, synthesis, **68**, 153  
 Reumycin, preparation, **61**, 256  
   silylation, **61**, 259  
   alkaline hydrolysis, **61**, 259  
   source, **61**, 262  
   effect on electron transport, **61**, 262  
   carcinostatic activity, **61**, 262  
 D-Rhamnitol, in synthesis of EHNA, **68**, 63  
 D-(and L)-Rhamnose, in synthesis of EHNA, **68**, 63  
 Rhodanine, *see* thiazol-4-one-2-thione  
 Ribavirin, *see* 3-carboxamido-1-( $\beta$ -D-ribofuranosyl)-1,2,4-triazole  
 Ribavarin analogues, synthesis, **67**, 408  
 6-(N-D-Ribitylanilino)uracil, in synthesis of riboflavins, **67**, 418  
 $\beta$ -D-Ribofuranosylacetylenes, reaction with disubstituted 1,2,4,5-tetrazines, **68**, 354  
 D-Ribofuranosylacetic acid derivatives, decarboxylation, **70**, 206  
 8- $\beta$ -D-Ribofuranosyladenine, *see* 7-amino-2- $\beta$ -D-ribofuranosylimidazo[4,5-*d*]pyrimidine,  
 C- $\beta$ -D-Ribofuranosylalkynes, cycloaddition reactions, **68**, 318  
 2- $\beta$ -D-Ribofuranosylbenzoxazole, **70**, 190  
 5-( $\beta$ -D-Ribofuranosyl)cytosine, **68**, 367  
 3-Ribofuranosyl-2-ethoxy-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 153  
 $\beta$ -D-Ribofuranosylformimidate, reaction with 2-aminophenol, **70**, 190  
 2- $\beta$ -D-Ribofuranosylfuran, reaction with dimethylacetylene dicarboxylate, **70**, 215  
 4[*N*-( $\beta$ -D-Ribofuranosyl)formylamino]thiophene 3-carboxamide, **66**, 271  
 5-( $\beta$ -D-Ribofuranosyl)furans, conversion to 2-( $\beta$ -D-ribofuranosyl)pyrroles, **68**, 247  
 3-(D-Ribofuranosyl)glutarimide derivatives, **68**, 344  
 3- $\beta$ -D-Ribofuranosylindazole, **70**, 178  
 5- $\beta$ -Ribofuranosylisoxazole, preparation, **68**, 291  
 2-( $\beta$ -D-Ribofuranosyl)maleimide, **68**, 226  
   isolation, **68**, 233  
   structure determination, **68**, 234  
   spectra, **68**, 234  
   biosynthesis, **68**, 234  
   antibiotic activity, **68**, 234  
   isomerisation to isoshowdomycin, **68**, 235  
   synthesis and biological activity, **68**, 235  
   synthesis of  $^{14}\text{C}$ -showdomycin, **68**, 236  
    $\alpha$ -D-arabinofuranosyl analog, **68**, 237  
    $\alpha$ -D-lyxofuranosyl analog, **68**, 237  
   tetraoxetanose analog, **68**, 238  
 2-(D-Ribofuranosyl)malonic ester, reaction with urea derivatives, **68**, 367  
 C- $\beta$ -D-Ribofuranosylnitromethane, in synthesis of indolyl-4-yl C-nucleosides, **70**, 169  
 3-( $\beta$ -D-Ribofuranosyl)-1,2,4-oxadiazole C-nucleosides, **68**, 329  
 5-( $\beta$ -D-Ribofuranosyl)-1,3,4-oxathiazol-2-one, thermolysis reactions, **68**, 305  
 5-( $\beta$ -D-Ribofuranosyl)1,3-oxazin-2,4-dione, isolation from *Streptomyces candidus*, **68**, 385  
   rearrangement with ammonia, **68**, 386  
 5-( $\beta$ -D-Ribofuranosyl)-1,3-oxazine-2,5-dione, **68**, 226  
 3-( $\beta$ -D-Ribofuranosyl)propiolate esters, cyclocondensation with guanidine, **68**, 365  
 3- $\beta$ -D-Ribofuranosylphthalimides, preparation, **70**, 173  
 3- $\beta$ -Ribofuranosylpyrazolo[3,4-*e*]oxazin-5,7-dione, **70**, 293  
 3- $\beta$ -Ribofuranosylpyrazolo[4,3-*d*]oxazine-5,7-dione, in synthesis of formamycin B, **70**, 293  
 3- $\beta$ -D-Ribofuranosylpyrazolo[4,3-*d*]pyrimidine-5,7-dione, **70**, 231  
 6- $\beta$ -D-Ribofuranosylpyrazolo[3,4-*d*]pyrimidin-4-one, **70**, 229  
 3- $\beta$ -D-Ribopyranosylpyrazolo[1,5-*a*]pyrimidin-7-one, **70**, 228  
 3-( $\beta$ -D-Ribofuranosyl)-pyrazolo[4,3-*b*]pyrimidin-7-one, **68**, 226  
 3- $\beta$ -D-Ribofuranosylpyrazolo[4,3-*d*]pyrimidin-7-one, **70**, 230  
 8-( $\beta$ -D-Ribofuranosyl)pyrazolo[1,5-*a*]1,3,5-triazin-4-one, **70**, 302  
 7- $\beta$ -D-Ribofuranosyl[3,2-*d*]pyrimidin-4(3*H*)-one, **70**, 226  
 2-( $\beta$ -D-Ribofuranosyl)pyrroles, **68**, 247  
 7 $\beta$ -D-Ribofuranosyl-3*H*, 5*H*-pyrrolo[3,2-*d*]pyrimidin-4-one, **70**, 221

- 5-( $\beta$ -D-Ribofuranosyl)tetrazoles, reaction with 2-chloro-3-nitropyridine, **70**, 203
- 2- $\beta$ -D-Ribofuranosylthiazolidine, **68**, 307
- 1-(and 3-)( $\beta$ -D-Ribofuranosyl)thieno[3,2-*d*]pyrimidin-2,4-diones, **66**, 250
- 3- $\beta$ -D-Ribofuranosylthieno[2,3-*d*]pyrimidin-4-one, **66**, 223  
anticancer activity, **66**, 233
- 7- $\beta$ -D-Ribofuranosylthieno[3,2-*d*]pyrimidin-4(3*H*)-ones, antiprotozoal activity, **66**, 254
- 1- $\beta$ -D-Ribofuranosylthieno[3,4-*d*]pyrimidin-4(1*H*)-ones, **66**, 256  
hydrolytic ring opening, **66**, 271
- $\beta$ -D-Ribofuranosylthioformimidate, condensation with 5-benzyloxy-4-hydrazinopyrimidine, **70**, 257
- C- $\beta$ -D-Ribofuranosylthioformimidates, in synthesis of 2-imidazolyl C-nucleosides, **68**, 277
- C-2-deoxy- $\alpha,\beta$ -D-Ribofuranosylthioformimidates, in synthesis of 2-imidazolyl C-nucleosides, **68**, 277
- 4-( $\beta$ -D-Ribofuranosyl)-5-thioxo-1,2,4-triazole, **68**, 324
- 5-( $\beta$ -D-Ribofuranosyl)1,2,4-triazine C-nucleoside, **68**, 390
- 6-( $\beta$ -D-Ribofuranosyl)1,2,4-triazine-3-dione, **68**, 390
- 6-( $\beta$ -D-Ribofuranosyl)1,2,4-triazine-3-thione, **68**, 390
- 3-( $\beta$ -D-Ribofuranosyl)-1,2,4-triazolo[4,3-*a*]pyrazine, **70**, 282
- 5-( $\beta$ -D-Ribofuranosyl)uracil, **68**, 226, 357  
isomerisation to  $\alpha$ -pseudouridine, **68**, 358
- D-Ribonolactone, use in preparing acyclonucleosides, **68**, 69
- D-Ribono-1,4-lactones, reaction with heterocyclic lithio compounds, **70**, 199
- aldehydo-D-Ribose semicarbazone, in synthesis of anapterin, **70**, 272
- D-Ribouronoyldiazomethane glycoside, reaction with benzynes, **70**, 179
- Risperidine, structure, **63**, 105  
assay of blood levels, **63**, 108  
X-ray diffraction, **63**, 121
- (+)-Rosaramicin Aglycone, synthesis, **67**, 263
- Rutacidone, **70**, 146  
oxidation to gravacridonol, **70**, 149  
Rutacidone epoxide, **70**, 146
- [bis(Salicylidene)ethylenediamine] manganese (III) complex, **69**, 8
- Sangivamycin, in preparation of nucleosides, **67**, 405
- Sanguilutine, synthesis, **67**, 365
- Sanguinarine, **67**, 345  
biological activity, **67**, 347  
synthesis, **67**, 383
- Sapphyrins, **67**, 6, **67**, 9
- Saramycetic acid, **67**, 35
- Saturated 1,3-benzoxazine-2,4-diones, synthesis, **69**, 372
- Saxitonin, synthesis, **67**, 214
- (-)-Sedacryptine, **70**, 75
- (-)-Sedamine, **70**, 75
- ( $\pm$ )-Sedridine, **70**, 75
- Selenazofurin, **68**, 298, 307  
antiviral activity, **68**, 311
- Selono-3-coumaranone, **65**, 171
- 2(and 3)-Selenopheneboronic acid, use for selenophenylation, **62**, 363
- L-Serine, conversion to cyclic sulfamidites, **68**, 121
- L-Serine methyl ester, precursor to oxazolidin-2-ones, **64**, 21
- Sesbanimide, ring chain tautomerism, **64**, 275
- Severifoline, **70**, 127
- Shermilamines A,B and C, **70**, 115
- Showdomycin, *see*, 2-( $\beta$ -D-ribofuranosyl)maleimide
- Showdomycin acetate, synthesis, **68**, 239
- Silacyclobutane, reaction with singlet methylene, **65**, 170
- 1,2,4-Siladioxenes, from photolysis of silyldiazoketones with ketones, **65**, 197
- 2-Siloxazolidin-5-ones, **64**, 27
- Silver pyrazolate, chlorination to 4,4'-dichloro-1,3(5)-bipyrazole, **67**, 21
- N-Silylated iminophosphoranes, reaction with activated chloro and nitroheterocycles, **64**, 165
- $\alpha$ -Silylaziridine, synthesis via cyclic sulfites, **68**, 157

- Silyl ketene acetals, conversion to  $\alpha$ -aminoketones, **69**, 11
- Sodium cyanoborohydride, reduction of cyclic sulfates, **68**, 164
- Sodium tetrathiafulvalenethiolate, preparation, alkylation and acylation, **62**, 267
- Spiroazindoles, **65**, 101
- Spiro[benzoxazole-2'-(3*H*),4(1*H*)pyrazolo[5,1-*c*][1,2,4]triazines], preparation and antibiotic activity, **61**, 302
- Spirocyclic 4*H*-pyrans, hydrolysis, **62**, 87
- Spiro[2,3]cyclohexan-3-one, photolysis, **65**, 153
- 5-Spirocyclopropyl- $\Delta^{a\beta}$ -butenolides, **65**, 153
- Spirodioxoles, **65**, 183
- Spiroisochromanediones, **65**, 362
- Spiropyrazolinequinones, disproportionation, **66**, 393
- 2-Spirothieno[2,3-*d*]pyrimidine-4(3*H*)-thiones, **66**, 203
- Sporidesmin-A, synthesis, **69**, 49
- S<sub>RN</sub>1 reactions-synthesis of benzo[*c*]phenanthrines, **67**, 378
- Stannylated heterocycles, acylation, **62**, 349
- 5-Stannylated-2-pyrimidinones, coupling reactions, **62**, 355
- 6-Stannylated uridines, **62**, 356
- coupling with alkynes, **62**, 356
- Stannylation of heterocycles, **62**, 349
- Stannylation of pyrimidines by decarboxylation of stannyl carboxylates, **62**, 352
- 3-Stannylazines, cross coupling reaction, **62**, 349
- 2-Stannylimidazole, preparation of heterocyclic ketones, **62**, 340
- Stannylpyrimidines, coupling reactions, **62**, 351
- 2-Stannylpyrimidines, reaction with acid chlorides, **62**, 355
- 5-Stannylpyrimidines, conversion to ketones, **62**, 355
- 3-Stannylquinoline, homocoupling, **62**, 349
- Stelletamine, **70**, 116
- Stille synthesis of unsymmetrical biheterocycles, **67**, 3
- Streptozocin, decomposition in dimethyl sulfoxide, **68**, 305
- decomposition, **70**, 280
- synthesis, **70**, 181
- Styrene, conversion to aziridines, **69**, 13
- 3-( $\beta$ -Styryl)-2,1-benzisoxazoles, from oxidative cyclisation of *o*-aminochalcones, **69**, 40
- 3-Styrylisoxazolo-tropones, **64**, 102
- 5-Styrylpyrazole-4-carboxylic acid, cyclisation, **64**, 95
- 3-Styrylpyrazolo-tropones, **64**, 102
- 2-Substituted-5-(alditol-1-yl)-3-methoxyoxazolidines, preparation, **68**, 305
- 2-Substituted 3-amino-4-cyano-2,4*a*, 5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-ones, reaction with acyl chlorides, **70**, 49
- 2-(Substituted amino)-9,10-dimethoxy-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinoline-4-ones, alkylation, **70**, 44
- 4-(Substituted amino)-5-fluoro-7-oxo-3,7-dihydro-2*H*-pyrido[3,2,1-*ij*][2,1]benzoxazine-8-carboxylic acids, as antimicrobial agents, **69**, 123
- 4-(Substituted amino)-5-fluoro-7-oxo-1,2,3,7-tetrahydro-pyrido[3,2,1-*ij*][2,1]benzoxazine-8-carboxylic acids, as antimicrobial agents, **69**, 123
- 6-Substituted-2-aminopurines, Pd(0) catalytic allylation, **66**, 117
- 4-Substituted-aminothieno[3,2-*d*]pyrimidines, **66**, 245
- 4-Substituted-aminothieno[3,4-*d*]pyrimidines, **66**, 265
- 2-(Substituted-aryl)-substituted octahydro-1,3,2*H*-benzoxazines, mass spectrometry, **69**, 440
- 2-(Substituted-aryl)-substituted octahydro-3,1,2*H*-benzoxazines, mass spectrometry, **69**, 440
- 2-Substituted 4-*t*-butyldimethylsilyloxybenzopyrans, **65**, 293
- 3-Substituted 1-cyano-9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-*a*]isoquinolines, **70**, 70
- 2-Substituted-4-cyano-3-imino-2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidine-1-ones, **70**, 67
- reduction, **70**, 43
- 6-Substituted-3,4-diaryl(or 3-heteroaryl-4-aryl)-1-methyl-1,2,3,4-tetrahydro-s-tetrazines, ring chain tautomerism, **66**, 34

- 3-Substituted-5,6-dihydro-4*H*-imidazo [2,1-*b*]thiazoles, synthesis from  $\alpha$ -tosyloxyacetophenones, **69**, 46
- 7-Substituted 6,7-dihydro-1*H*, 3*H*, 5*H*-pyrido[3,2,1-*ij*][3,1]benzoxazines, **70**, 56
- 6-Substituted 9-(1-ethoxyethyl)purines, base-catalysed hydrolysis, **68**, 57
- 5-Substituted 2(5*H*)-furanones, from 2-(trimethylsilyloxy)furan, **69**, 65
- 3-Substituted 1,3,4,4*a*, 5,6-hexahydro-[1,3]oxazino[3,4-*a*]isoquinoline-1-one, **70**, 56
- 2-Substituted 2,3,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidine-1,3-diones, **70**, 67
- N*-Substituted-2-hydroxy-1-carboxamides, cyclisation, **69**, 369
- 6-(and 7-)Substituted 2-hydroxychromane-4-ones, ring chain tautomerism, **64**, 276
- 1-Substituted-2-(2-hydroxyethyl)piperidines, from reductive ring opening of perhydropyridooxazines, **70**, 32
- 3-Substituted-2-imino-1-cyclopentanedithiocarbamic acids, **69**, 381
- 1-(Substituted imino)-9,10-dimethoxy-1,2,4,6,7,11*b*-hexahydro [1,3]oxazino[4,3-*a*]isoquinoline, reaction with  $P_4S_{10}$ , **70**, 62
- 1-(Substituted imino)-9,10-dimethoxy-1,2,4,6,7,11*b*-hexahydro [1,3]thiazino[4,3-*a*]isoquinoline, **70**, 62
- 4-(Substituted imino)-1,2,4,5,6,11*b*-hexahydro[1,3]thiazino [4,3-*a*]isoquinolines, electrochemical reduction, **70**, 41
- 4-(Substituted imino)-1,2,4,6,7,11*b*-hexahydro[1,3]thiazino [4,3-*a*]isoquinolines, **70**, 61
- 1-(Substituted imino)-1,3,4,4*a*, 5,10-hexahydro[1,3]thiazino[3,4-*b*]isoquinolines, **70**, 61
- r*-4*a*, *t*-5, *c*-8-*H*-8-Substituted-5-methylperhydropyrido[1,2-*b*] [1,2]oxazine, conformation, **69**, 92
- 5-Substituted-1,3,4-oxadiazolin-2-ones, synthesis by oxidation of carbo-*t*-butoxyhydrazones, **69**, 42
- 2-Substituted oxanes,  $^{13}C$  chemical shifts, **69**, 224
- 1-Substituted 4-phenyl-4-[2-(*N,N*-di(2-propylamino)-4,4*a*, 5,6,7,8-hexahydro-3*H*-pyrido[1,2-*c*]pyrimidin-3-ones, **70**, 63
- 2-Substituted-5-phenyl-6*H*-1,3,4-thiadiazine, conversion to pyrazoles, **65**, 66
- 6-Substituted 4-phenyl-2-thioxothieno [2,3-*d*]pyrimidines, **66**, 198
- N*-Substituted pyrazoles, **65**, 66
- 6-Substituted 2-pyrones, **65**, 301
- 3-Substituted (1*H*, 3*H*)-quinazoline-2,4-diones, EI mass spectra, **69**, 446
- N*-Substituted 1,2,3,4-tetrahydroquinoline-8-carboxamides, **70**, 32
- 3-Substituted thieno[3,2-*d*]pyrimidin-2,4-diones, **66**, 236
- 3-Substituted thieno[3,4-*d*]pyrimidin-2(1*H*),4-diones, alkylation at *N*-1, **66**, 268
- 2-Substituted thieno[2,3-*d*]pyrimidin-4(3*H*)-ones, **66**, 202
- 2-Substituted thieno[3,2-*d*]pyrimidin-4(3*H*)-thiones, **66**, 244
- aldehyde*-Sugar *S*-alkylhydrazonocarbdithiolates, reaction with bromine, **68**, 337
- aldehyde*-Sugar lepidin-2-yl hydrazones, cyclisation with iron(III) chloride, **70**, 209
- 5'-Sulfamoyltiazofurin, **68**, 309
- Sulfatobetaines, **68**, 154
- 3-Sulphenyl-2-pyrone, cycloadditions, **65**, 340
- Sulfinyldioxycyclobutene, reaction with diazomethane, **68**, 128
- 3-Sulfinyl-2-pyrone, reaction with 1,1-dimethoxyethylene, **65**, 340
- 3'-Sulfonyloxypyrimidin-5-yl *C*-nucleosides, **68**, 373
- 5'-Sulfonyloxypyrimidin-5-yl *C*-nucleosides, **68**, 373
- 3-Sulfonyl-2-pyrone, reaction with chiral alkylvinyl ethers, **65**, 338
- reaction with dioxoles, **65**, 338
- Sulfur dichloride, reaction with ammonium chloride, **62**, 149
- reaction with amidines, **62**, 150
- Suzuki synthesis of unsymmetrical biheterocycles, **67**, 3
- (-)-Swainsonine, synthesis, **69**, 122

- Tallysomyins, **67**, 35  
Tantazoles, **67**, 35  
Tandem aza-Wittig/6- $\pi$ -electrocyclisations, **64**, 178  
    quinoline synthesis, **64**, 206  
    isoquinoline synthesis, **64**, 206  
    to give 1,5-diaza-1,3,5-triazines, **64**, 214  
    to give 1-oxa-5-aza-1,3,5-triazines, **64**, 214  
    to give quinazolines, **64**, 217  
    to give 1,3,5-benzotriazepines, **64**, 228  
Tandem cyclisation/intermolecular cycloadditions, **65**, 208  
Tautomerism of aminoimidazoles, by  $^1\text{H}$  nmr, **61**, 45  
    by IR spectroscopy, **61**, 47  
    by AM1 calculations, **61**, 51  
Tautomerism of 2*H*-pyrans, **62**, 77  
Tellurachromanones, **63**, 20  
    reaction with halogens, **63**, 22  
2*H*-Tellurachromenes, **63**, 24, **63**, 43  
    oxidation, **63**, 26  
    photolysis to indene, **63**, 28  
4*H*-Tellurachromenes, **63**, 25  
    salt formation, **63**, 28  
Tellurachromones, **63**, 31  
    reduction, **63**, 32  
    reactions, **63**, 33  
    spectral data, **63**, 33  
1-Telluracyclohexa-2,5-diene, **63**, 15  
1-Telluracyclohexa-2,5-diene-4-ones, reduction, **63**, 15  
    reaction, **63**, 16  
    from 1,5-bis(trimethylsilyl)penta-1,4-diyne-3-one, **63**, 16  
    conversion to thiones, **63**, 18  
    oxidation, **63**, 19  
    structure and spectra, **63**, 20  
1-Telluracyclohexan-1,1-dioxide, **63**, 5  
1-Telluracyclohexane, **63**, 2-3  
    conformation, **63**, 11  
    NMR, **63**, 11  
    oxidation, **63**, 5  
1-Telluracyclohexane-3,5-dione, **63**, 2, **63**, 6  
    conformation, **63**, 9  
1-Telluracyclohexane-3,5-dione-1,1-dichlorides, **63**, 6  
1-Telluracyclohexan-4-one, **63**, 4  
1-Telluracyclohex-3-enes, **63**, 13  
Telluraflavone, **63**, 2  
    reaction with Lawesson's reagent, **63**, 32  
Telluraisochromanone, **63**, 2  
Telluraisochroman-1-(and 3-)-one, **63**, 54  
Telluraisochromone, **63**, 2  
4*H*-Tellurapyranes, protonation, **63**, 43  
1-Tellurapyranylidinomalonitriles, **63**, 18  
1-Tellurapyranyl-4*H*-tellurapyrones, **63**, 18  
4-Tellurapyranyl-4*H*-tellurapyrones, charge transfer complexes, **63**, 19  
Tellurapyrylium salts, **63**, 17  
Tellura[3,2-*b*]thiophene, **63**, 27  
Telluraxanthene, **63**, 35  
    oxidation, **63**, 39, **63**, 43, **63**, 44  
Telluraxanthene-10,10-diacetate, **63**, 40  
9-Telluraxanthenoles, **63**, 40  
Telluraxanthone, **63**, 38  
Telluro-3-coumaranones, **65**, 171  
4,4- $\text{d}_2$ -Tellurocyclohexane, **63**, 4  
3,3,5,5- $\text{d}_4$ -Tellurocyclohexane, **63**, 4  
10-Telluroniaanthracene perchlorate, **63**, 37  
    reactions, **63**, 44  
Telluronium salts, **63**, 23  
Tellurosulfides, **63**, 32  
3,2':5',3'-Terthiophene, synthesis, **69**, 35  
1,4,5,6-Tetraacetoxy-3-oxahexane, in *seco*-nucleoside synthesis, **67**, 414  
Tetra-*o*-acetyl-*aldehyde*-L-arabinose, cyclocondensation with L-cysteine, **70**, 189  
Tetra-*O*-acetyl-galactaric acid 1,4-bis(4-arylthiosemicarbazide), dehydrocyclization, **68**, 337  
Tetra-*O*-acetyl galactaroyl-1,4-bis(acylhydrazides), cyclisation, **68**, 333  
Tetra-*O*-acetyl galactaroyl chloride, reaction with anthranilic acid, **67**, 430  
5-(Tetra-*O*-acetyl- $\beta$ -D-galactopyranosyl)tetrazole, reaction with 2-chloropyrimidine, **70**, 259  
2,3,4,5,6-Tetra-*O*-acetyl-D-gluconoyl isothiocyanate, **70**, 307  
Tetraacetylguanosine, in preparation of acylonucleosides, **68**, 6  
3-Tetra-*O*-acetyl-D-*arabino*-tetritol-1-yl)-4-ethoxycarbonyl-2,5-dimethyl-2-nitropyrrole, deesterification, **70**, 167  
4-(Tetra-*O*-acetyl-D-*arabino*-tetritol-1-yl)imidazoline-2-thione, **70**, 191  
7-(Tetra-*O*-acetyl-D-*arabino*-tetritol-1-yl)thiazolo[3,4-*c*]oxazole, preparation, **70**, 189

- 2,4,4,6-Tetraalkyl-1,3-dioxan-2-ylum ions, conformations, **69**, 244
- 2,3,4,5-Tetraalkyl-imidazo[2,1-*b*]thiazoles, **69**, 280
- 4,4',5,5'-Tetraarylbi-1,2,4-triazole, **67**, 42
- 2,4,4,6-Tetraaryl-4*H*-pyrans, conversion to 4*H*-thiopyrans, **62**, 100
- theoretical studies, **62**, 113
- 2,2',6,6'-Tetra-*t*-butyltellurapyranyl-4*H*-tellurapyrone, **63**, 19
- Tetrachlorobenzimidazoles, **65**, 16
- trans-syn-cis*-1,2,5,6-Tetrachloro-1,4-dioxane, conformations, **69**, 254
- cis/trans*-2,3,5,6-Tetrachloro-1,4-dioxane, conformations, **69**, 254
- trans-anti-trans*-2,3,5,6-Tetrachloro-1,4-dioxane, conformations, **69**, 254
- 2,2,3,3-Tetrachloro-1,4-dioxane, conformations, **69**, 254
- cis-anti-cis*-2,3,5,6-Tetrachloro-1,4-dioxane, conformations, **69**, 254
- 1,1,2,2-Tetrachloro-1 $\alpha$ ,2 $\alpha$ ,2 $\alpha$ ,3 $\beta\alpha$ -tetrahydro-3*H*-cyclobuta[*c*]chromen-3-one, **65**, 327
- 4,4',5,5'-Tetracyano-2,2'-biimidazole, **67**, 29
- Tetracyano-1,4-dithiin, reaction with sodium cyanide, **65**, 249
- Tetraethyl-1-acetamido-4-hydroxybutane-1,1,3,3-tetracarboxylate, **64**, 12
- Tetrahalotetrathiafulvalenes, **62**, 287
- Tetrahydroazepines, **65**, 134
- Tetrahydrobenzimidazoles, from cyclodehydration of  $\alpha$ -nitroso enaminones, **67**, 258
- Tetrahydrobenzo[*f*]carbazoles, **67**, 238
- 3a,4,5,6-Tetrahydrobenzofuran-4,5-dicarboxylic acid anhydride, **63**, 359
- 7,8,9,10-Tetrahydrobenzo[*c*]phenanthridin-6(5*H*)-ones, in the synthesis of benzo[*c*]phenanthridine alkaloids, **67**, 369
- 8,9,10,11-Tetrahydrobenzo[*b*][1,10]phenanthroline-7(12*H*)one, **70**, 105
- Tetrahydrobenzo[*f*]pyrrolo[1,2-*b*]isoquinoline, **64**, 61
- Tetrahydrobenzothieno[2,3-*d*]pyrimidines, antibacterial activity, **66**, 234
- 4,5,6,7-Tetrahydrobenzoxazoles, from reaction of dimedone iodonium ylide with acetonitriles, **69**, 39
- 5,6,7,8-Tetrahydrobiopterin, **70**, 266
- 3,4,5,6-Tetrahydro-2,3-bipyridine, ring chain tautomerism, **64**, 289
- trans*-Tetrahydrocarbazol-4(5*H*)-ones, **67**, 239
- 2,3,6,7-Tetrahydro-1*H*-1,4-diazepines, **64**, 227
- 4,5,6,7-Tetrahydrofuran-4-ones, in preparation of dihyrofuro[2,3-*c*]acridines, **70**, 150
- Tetrahydrofuro[2,3-*b*][1]benzopyran-4-one, **65**, 312
- $\alpha$ -Tetrahydrofurylidene ketones, **67**, 222
- Tetrahydro-2a-hydroxycyclobuta[*c*][1]benzopyran-3-one, **65**, 328
- 1a,4a,5,6-Tetrahydro-6-hydroxy-5-[(2*R*)-1,2-dihydroxyethyl]-*cis*-furo[2,3-*d*]imidazol-3-one, **70**, 181
- 3a,5,6,6a-Tetrahydro-6-hydroxy-5-[(2*R*)-1,2-dihydroxyethyl]-*cis*-furo[2,3-*d*]oxazol-2-one, **70**, 187
- Tetrahydroimidazo[1,2-*a*]pyridines, **67**, 295
- Tetrahydroimidazo[2,3-*c*]pyridines, **64**, 48
- Tetrahydroindeno[1,2-*b*]-1,4-oxazin-3(2*H*)-ones, **65**, 189
- Tetrahydroindole-2-acetic acids, from enaminones and 4-hydroxy-2-butenolide, **67**, 246
- Tetrahydroindoles, from cyclic enaminones, **67**, 227
- from keto carbenes and enaminones, **67**, 245
- 1,2,3,4-Tetrahydroisoquinoline, oxidation, **69**, 74
- preparation, **69**, 74
- 2-(Tetrahydroisoquinolinol-1-yl)ethanols, epimerisation, **70**, 34
- Tetrahydroisoquinoline-3-yl *C*-nucleosides, **70**, 211
- (4 $\beta$ ,4 $\alpha$ ,7 $\alpha\beta$ )-Tetrahydro-4-methyl-3-phenylcyclopent[*d*][1,3]oxazine, X-ray structure, **69**, 432
- 1,2,3,4-Tetrahydrooxanthenes, preparation, **69**, 72
- Tetrahydrooxazepines, **65**, 102
- Tetrahydrooxazines, ring chain tautomerism by solid state nmr, **66**, 8
- Tetrahydro-1,3-oxazines, ring chain tautomerism thermodynamics, **66**, 13
- epimeric equilibria, **69**, 401

- ring-chain tautomerism, **69**, 399  
ring-chain tautomerism, **69**, 447  
hydrolysis, **69**, 450  
1,6,7,11b-Tetrahydro-2*H*,  
4*H*[1,3]oxazino[4,3-*a*]isoquinolines,  
reductive ring opening, **70**, 32  
conformations by X-ray crystallography,  
**70**, 18  
mass spectroscopy, **69**, 440  
1,6,7,11b-Tetrahydro-2*H*[1,3]oxazino[4,3-*a*]  
isoquinolin-4-ones, mass spectroscopy,  
**69**, 440  
Tetrahydro-1,3-oxazin-2-ones, reduction, **69**,  
454  
synthesis, **69**, 361  
Tetrahydro-1,3-oxazin-4-ones, preparation,  
**69**, 369  
reduction, **69**, 454  
1,2,3,4-Tetrahydro-4-oxo- $\beta$ -carbolines, **67**,  
244  
6,7,8,9-Tetrahydro-4-oxo-4*H*-pyrido[1,2-*a*]  
pyrimidine-3-carbonitrile, **63**, 196  
6,7,8,9-Tetrahydro-4-oxo-4*H*-pyrido[1,2-*a*]  
pyrimidine-3-carboxamide-preparation  
by amination of esters, **63**, 193  
quaternisation, **63**, 183  
6,7,8,9-Tetrahydro-4-oxo-4*H*-pyrido[1,2-*a*]  
pyrimidine-3-carboxylic acid,  
decarboxylation, **63**, 193  
reaction with carbon disulfide, **63**, 220  
Tetrahydropyrazines, from ring expansion of  
imidazolidines, **65**, 188  
1,2,4,10-Tetrahydro-3*H*-pyrazolo[3,4-*c*]  
[1,5]benzothiazepin-3-ones, **63**, 76  
3,4,5,6-Tetrahydro-4*aH*-pyridazino[1,6-*a*]  
quinoline, **69**, 114  
reduction, **69**, 100  
3,4,5,6-Tetrahydropyridines, **64**, 202  
1,2,3,6-Tetrahydropyridine-2-carboxylic acid,  
**64**, 28  
1,4,10,11-Tetrahydropyrido[3,2-*b*]  
[1,5]benzothiazepine-5,5-dioxide,  
**63**, 84  
3,5,6,7-Tetrahydro-1*H*-pyrido[3,2,1-*ij*]  
[3,1]benzothiazine-1,3-dithione, **70**, 62  
3,5,6,7-Tetrahydro-1*H*-pyrido[3,2,1-*ij*]  
[3,1]benzothiazine-3-thiones, **70**, 62  
1,5,6,7-Tetrahydro-3*H*-pyrido[3,2,1-*ij*]  
[3,1]benzothiazin-3-ones, **70**, 61  
3,4,5,6-Tetrahydro-1*H*-pyrido[3,2,1-*ij*]  
[3,1]benzoxazine-3,7-dione, acetal  
formation, **70**, 38  
3,5,6,7-Tetrahydro-1*H*-pyrido[3,2,1-*ij*]  
[3,1]benzoxazine-1,3-dione, reaction  
with amines, **70**, 32  
reaction with P<sub>4</sub>S<sub>10</sub>, **70**, 62  
1,5,6,7-Tetrahydro-3*H*-pyrido[3,2,1-*ij*]  
[3,1]benzoxazin-3-one, **70**, 56  
6,10,11,11*a*-Tetrahydropyrido[1,2-*c*]  
[1,3]benzoxazin-6-one, enantiomer  
separation, **70**, 39  
1,2,3,4-Tetrahydro-9*H*-pyrido[3,4-*b*]indole,  
from tryptophan, **64**, 55  
5,6,7,8-Tetrahydro-1*H*-pyrido[1,2-*c*]  
pyrimidines, **70**, 66  
5,6,7,8-Tetrahydro-1*H*-pyrido[1,2-*c*]  
pyrimidin-1-ones, **70**, 66  
6,7,8,9-Tetrahydro-4*H*-pyrido[1,2-*a*]  
pyrimidin-4-ones, chromatography,  
**63**, 107  
formylation, **63**, 190  
preparation by decarboxylation, **63**, 192  
spectra, **63**, 112  
preparation, **63**, 136, **63**, 176  
reaction with halogens, **63**, 213  
reaction with nitrites, **63**, 213  
reaction with aldehydes, **63**, 215  
acylation, **63**, 217, **63**, 222  
reaction with dimethylformamide and  
phosphoryl chloride, **63**, 218  
reaction with dimethylformamide  
dimethylacetal, **63**, 218  
reaction with phosgene imminium chloride,  
**63**, 220  
reaction with isocyanates, **63**, 221  
photochemistry, **63**, 234  
spectral data, **63**, 118  
Tetrahydropyrido[1,2-*a*]pyrimidines, **67**, 297  
1,6,7,8-Tetrahydro-4*H*-pyrido[1,2-*a*]  
pyrimidin-4-ones, reduction, **63**, 180  
6,7,8,9-Tetrahydro-4*H*-pyrido[1,2-*a*]  
pyrimidin-4-ones, **69**, 108  
1,2,3,4-Tetrahydro-6*H*-pyrido[1,2-*a*]  
pyrimidin-6-ones, **63**, 160, **63**, 162  
Tetrahydropyrimidines, from enamines,  
**67**, 314  
3,4,6,7-Tetrahydro-2*H*-pyrimido[6,1-*a*]  
isoquinolin-2,4-dione, **70**, 69  
1,6,7,11*b*-*H*-2,7-Tetrahydro-2*H*-  
pyrimido[6,1-*a*]isoquinolin-2-ones,  
Bohlmann bands in infrared spectra,  
**70**, 24



- E- and Z-3,4,6,7-Tetrahydro-2H-pyrimido[6,1-*a*]isoquinolin-4-one, **70**, 68
- 1,2,3,4-Tetrahydropyrimido [4',5':5,6][1,2,4]triazino[4,3-*b*]indazole-2,4-dione, **61**, 305
- 1,2,4,10-Tetrahydro-3H-pyrrolo[3,4-*c*] [1,5]benzothiazepin-3-ones, **63**, 65
- 5,6,7,8-Tetrahydroquinazolines, reduction, **69**, 385
- Tetrahydroquinolines, **64**, 49
- 1,2,3,4-Tetrahydroquinoline, reaction with rhenium sulfide to give biquinolines, **67**, 53
- 1,2,3,4-Tetrahydroquinoline-8-carboxylic acid, **70**, 56  
from hydrolysis of  
pyridobenzoxazindiones, **70**, 31
- 3-[2-(1,2,3,4-Tetrahydroquinolyl) propylamine, **69**, 99
- Tetrahydro-1,2,5-thiadiazines, loss of sulfur, **65**, 69
- 2,3,5,6-Tetrahydro-1,3-thiazin-4-one, oxidation, **66**, 174
- 4,5,6,7-Tetrahydrothiazolo[3,2-*a*] pyrimidines, synthesis, **69**, 46
- Tetrahydrothiophene, loss of sulfur, **65**, 71
- Tetrahydrothiopyrans, extrusion of sulfur, **65**, 54
- 3,4,4a,5-Tetrahydro[1,2,4]triazino[6,1-*c*] benzoxazines, preparation and X-ray structure, **61**, 271
- 2,3,4,6-Tetrahydro[1,2,4]triazino[5,6-*c*] cinnoline-3-ones, **61**, 236
- 3,3a,4,5-Tetrahydro[1,2,4]triazolo[3,4-*d*] [1,5]benzothiazepines, **63**, 80
- 3,3',4,4'-Tetrahydroxy-2,2'-bipyridine-bis-*N,N'*-oxide, toxin from mushrooms and synthesis, **62**, 407
- 2,4,5,7-Tetraketooctane, oxidative cyclisation to pyrones, **69**, 49
- Tetrakis(alkylchalcogeno)tetrathiafulvalenes, **62**, 270, **62**, 282
- Tetrakis(ethyltelluro)tetrathiafulvalene, **62**, 282
- Tetrakis(methyltelluro)tetrathiafulvalene, **62**, 282
- Tetrakis(methylthio)tetrathiafulvalene, **62**, 285
- Tetrakis(vinylthio)tetrathiafulvalenes, **62**, 270
- Tetralithiotetraselenafulvalene, **62**, 293  
alkylation, **62**, 294  
reaction with dialkyl or diaryldisulfides, **62**, 295
- Tetralithiotetrathiafulvalene, reactions, **62**, 282
- $\alpha$ -Tetralone pyrrolidine enamine, reaction with dimethyl acetylene dicarboxylate, **65**, 4
- 2,2,4,5-Tetramethyl-5-alkyl-1,3-dioxanes, conformations by <sup>1</sup>H NMR, **69**, 239
- 4,4',5,5'-Tetramethyl-2,2'-biimidazole, **67**, 29
- 3,3',5,5'-Tetramethyl-4,4'-bipyrazole, coordination chemistry, **67**, 23
- Tetramethyl-4,4'-bipyrazole, **67**, 24
- 2,2,3,6-Tetramethyl-5-chloro-1,3-dioxan, conformation, **69**, 233
- Tetramethyl 2,3-dimethoxy-6,11a-dihydropyrido[1,2-*c*] [1,3]benzothiazine-8,9,10,11-tetracarboxylate, **70**, 62
- 2,3,5,6-Tetramethyl-1,4-dioxane, isomers, **69**, 255
- Tetramethyl-1,3,2-dioxathiolane 2,2-dioxide, pinacol type rearrangement, **68**, 127, 132
- 2,2,5,5-Tetramethyl-3,4-dioxathiolane, **65**, 165
- Tetramethyl 6-methyl-11*bH*-pyrido[2,1-*a*] phthalazine-1,2,3,4-tetracarboxylate, **69**, 120
- 2,2',4,4'-Tetramethyloxetane-3-carboxylate, **65**, 136
- 2,2,6,6-Tetramethylpiperidin-4-one, reaction with dichlorocarbenes, **65**, 125
- 2,2,4,6-Tetramethyl-2H-pyran, **65**, 286, **65**, 295  
reaction with acetylenic diesters, **62**, 108  
reaction with organometallic reagents, **62**, 85
- 3,3,5,5-Tetramethyl-1,2,4,5-tetroxane, conformations, **69**, 256
- 2,2,4,4-Tetramethylthietan-3-one, **65**, 162
- 1,3,5,7-*cis*-Tetraoxadecalins, conformations by NMR, **69**, 251
- 4,4',5,5'-Tetraphenyl-2,2'-biimidazole, **67**, 29
- 4,4',5,5'-Tetraphenyl-2,2'-bioxazoles, preparation and X-ray structure, **67**, 32
- Tetraphenyl-4,4'-bipyrazole, **67**, 243'-
- 5,5',6,6'-Tetraphenyl-3,3'-bi-1,2,4-triazine, X-ray structure, **67**, 69

- 4,4,5,5-Tetraphenyl-1,3,2-dioxathiolane 2-oxide, thermal rearrangement, **68**, 124  
 photolysis, **68**, 126  
 Tetraphenylporphinatomanganese(III) chloride, as catalyst in oxidation of dienones with iodosobenzenes, **69**, 8  
 2,2,4,6-Tetraphenyl-2*H*-pyrans, **65**, 295  
 2,4,4,6-Tetraphenyl-4*H*-pyran, electrophilic substitutions, **62**, 89  
   Vielsmeier-Haack reactions, **62**, 89  
   X-ray structure, **62**, 115  
 2,3,4,5-Tetraphenyl-4*H*-pyran, Vielsmeier-Haack reactions, **62**, 89  
 Tetraphenylstannane, use in phenylation reactions, **62**, 341  
 (±)-Tetraponerine-T4 alkaloid, **70**, 46  
 Tetraponerine-T8 alkaloid, **70**, 46  
 Tetraselenafulvalenes, lithiation, **62**, 292  
*cis,trans*-3,4,4,5-Tetrasubstituted oxanes, H-H coupling constants, **69**, 224  
 2,2,4,6-Tetrasubstituted-2*H*-pyrans, **65**, 295  
   reaction with organometallic reagents, **62**, 84  
   reaction with acetylenic diesters, **62**, 93  
 2,4,4,6-Tetrasubstituted 4*H*-pyrans, **62**, 67  
   cleavage to cyclohexanones, **62**, 94  
 Tetrasubstituted pyrroles from enaminones and keto carbenes, **67**, 227  
 2,3,5,6-Tetrasubstituted pyrylium salts, conversion to 4*H*-pyrans, **62**, 55  
   reaction with  $\alpha$ -diketones, **62**, 56  
   reaction with alkoxides, **62**, 62  
 Tetrasubstituted pyrylium salts, reaction with amines, **65**, 306  
 Tetrathiacyclophane, ring contraction, **65**, 80  
 Tetrathiafulvalenes, photochemical dimerisation, **62**, 252  
   tetrathiation, **62**, 255  
   S-oxidation, **62**, 252  
   substituent effects on lithiation, **62**, 256  
   *cis/trans* isomerisation, **62**, 252  
   reaction with butyl lithium, **62**, 253  
   reaction with free radicals, **62**, 256  
   cycloadditions, **62**, 257  
   dienophile in hetero-Diels-Alder reactions, **62**, 257  
 Tetrathiafulvalenecarboxylic acids, conversion to acid chlorides, **62**, 262  
   preparation, **62**, 279  
   decarboxylation, **62**, 265  
   ester formation via cesium salts, **62**, 262  
   reduction, **62**, 264  
 Tetrathiafulvalene-fused-1,3-dithiol-2-ones, phosphite coupling, **62**, 267  
 Tetrathiafulvalenetetrathiolate anion, **62**, 284  
 Tetrathiafulvalenethiobenzoate, hydrolysis, **62**, 267  
 Tetrathiafulvalenyllithium, preparation, **62**, 253  
   disproportionation of multilithium species, **62**, 254  
 Tetrathianes, loss of sulfur, **65**, 82  
 Tetrathiofulvalenisocyanate, preparation from acid chloride, **62**, 264  
 1,2,4,5-Tetrazines, reaction with ambiphilic carbenes, **65**, 174  
 1,2,4,5-Tetrazine C-nucleosides, **68**, 394  
 Tetrazole C-nucleosides, **68**, 339  
 Tetrazole carbocyclic C-nucleosides, **68**, 339  
 Tetrazolo-1,3-benzothiazin-4-ones, **66**, 168  
 Tetrazolo[5,1-*d*][1,5]benzothiazepines, **63**, 83  
 Tetrazolo[1,5-*b*]isoquinoline-5,10-diones, by thermolysis of 2,2-diazo-1,3-indanedione, **61**, 184  
   alkaline hydrolysis, **61**, 188  
 Tetrazolotetrazepines, **66**, 35  
 1,2,3,4-Tetrazolo[5',1':6,1][1,2,4]triazino[4,5-*b*]indole, **61**, 303  
 3-(1*H*-Tetrazol-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 248  
 3-(1*H*-Tetrazol-5-yl)-9-(dimethylcarbamoylthio)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, **63**, 197  
*N*-(5-Tetrazolyl)hydrazones, bromination, **63**, 284  
   chlorination, **63**, 286  
 3-(5-Tetrazolyl)-4*H*-pyrido[1,2-*a*]pyrimidines, alkylation, **63**, 197  
 3-(1*H*-Tetrazol-5-yl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-ones, **63**, 146  
 3-(1*H*-Tetrazol-5-yl)thieno[2,3-*d*]pyrimidin-4(3*H*)-ones, **66**, 199  
 2-(*D*-Tetritol-1-yl)benzimidazoles, heating with zinc(II) chloride, **70**, 182  
 2-(*D-arabino*-Tetritol-1-yl)benzo[*f*]quinoxaline, **70**, 291  
 3-(*D-arabino*-Tetritol-1-yl)cinnoline, **70**, 215  
 2-(*D-arabino*-Tetritol-1-yl)-5-(2-deoxy-*D-arabino*-tetritol-1-yl)pyrazine, **68**, 383

- 2-(*primo*-Tetritol-1-yl)imidazole, acid catalysed cyclisation, **68**, 278 synthesis, **68**, 283
- 4-(*D-arabino*-Tetritol-1-yl)imidazolidin-2-one, preparation, **68**, 288
- 5-(*D-arabino*-Tetritol-1-yl)-imidazo[2,1-*b*]thiazolium olate, reaction with 2-bromophenylacetic acid, **70**, 191
- (4-*D-arabino*-Tetritol-1-yl)oxazole-2-thione, **68**, 316
- 3-(*D-manno*-Tetritol-1-yl)pyrrolo[2,3-*b*]pyridine, preparation, **70**, 198
- 3-(*D-arabino*-Tetritol-1-yl)-1,5,6,7-tetrahydroindol-4-ones, preparation, **70**, 172
- 6-(Tetritol-1-yl)-1,2,4-triazines, cyclodehydration, **68**, 391
- Tetrodotoxin, structure, **69**, 351
- 2-( $\alpha$ - or  $\beta$ -*D*-Tetrofuranosyl)benzimidazoles, preparation, **70**, 183
- Tetronic acid, **67**, 221
- Pd(0) catalysed allylation, **66**, 79
- s*-Tetroxane, conformations, **69**, 256
- Thehaplosine, **70**, 148
- 11-Thiabenz[*a*]fluorene, **63**, 358
- Thiabicyclo[3,1,0]hexanes, **65**, 163
- 1-Thia-2*a*, 5*a*-diazacenaphthene, **63**, 228
- 1,3,5-Thiadiazepinones, extrusion of sulfur, **65**, 52
- Thiadiazide dioxide, **65**, 27
- 1,2,6-Thiadiazines, loss of sulfur, **65**, 62
- 1,3,5-Thiadiazines, conversion to imidazoles, **65**, 69
- 6*H*-1,3,4-Thiadiazines, ring contraction to pyrazoles, **65**, 62
- 1,2,5-Thiadiazole 1,1-dioxide, **68**, 91
- 1,2,5-Thiadiazole 1-oxide, **68**, 91
- 1,3,4-Thiadiazoline acyclo *C*-nucleosides, **68**, 335
- 1,3,4-Thiadiazoline *C*-nucleosides, **68**, 335
- 1,3,4-Thiadiazolidin-2-iminium cation, **66**, 52
- 1,3,4-Thiadiazolines, olefin formation, **65**, 40
- ring chain tautomerism, **66**, 44
- Thiadiazolium betaines, reaction with acetic anhydride to give 1,3-thiazin-4-ones, **66**, 139
- 1,3,4-Thiadiazolo[2,3-*c*][1,2,4]triazinium cations, **64**, 195
- 1,3,4-Thiadiazolo[2,3-*c*][1,2,4]triazinium-7-imide, **64**, 223
- [1,2,5]Thiadiazolotroponoids, **64**, 115
- Thiadisphosphetane, **65**, 75
- Thiangazole, **67**, 35
- Thiaphorphines, loss of sulfur, **65**, 76
- Thiatropocin, *see* [1,2]oxathiolotropothione
- 1,4-Thiazepins, from carbene ring expansion, **65**, 193
- Thiazetidine, ring transformation by diethylaminopropyne to 2-imino-1,3-thiazin-4-ones, **66**, 139
- 1,2-Thiazetidine-1,1-dioxide, **64**, 5
- 1,3-Thiazines, loss of sulfur to give pyrroles, **65**, 55
- 4*H*-1,3-Thiazines- thermolysis to 2*H*-thiazine, **65**, 24
- 1,4-Thiazines, from enamines, **67**, 226
- 1,3-Thiazinium salts, **67**, 308
- 1,2,4,6,7,11*b*-[1,3]Thiazino[4,3-*a*]isoquinolin-4-imines, <sup>1</sup>H NMR spectroscopy, **70**, 20
- 1,3-Thiazin-4-ones, hydrolysis, **66**, 175
- biological activity, **66**, 185
- 1,3-Thiazinones, from diazo compounds and isothiazolones, **65**, 190
- 1,3-Thiazin-2-yl acyclo *C*-nucleosides, **68**, 389
- 1,3-Thiazin-6-yl *C*-nucleosides, **68**, 389
- Thiazofurin acyclic analogues, preparation, **69**, 150
- Thiazole, coupling with 2-trimethylsilylthiazole to give 2,2'-bithiazole, **67**, 33
- 1,2,4-Thiazole homo *C*-nucleosides, **68**, 326
- Thiazole-4,5-dicarboxylic acid, from thienotropolones, **66**, 367
- Thiazole-1,1-dioxides, ring enlargement to 1,3-thiazin-4-ones, **66**, 139
- 1,3-Thiazole-2-thiones, **64**, 191
- 4(R)-Thiazolidinecarboxylic acid, from L-cystine, **64**, 24
- 2-Thiazolidine-4-carboxylic acid, **64**, 25
- Thiazolidine-2,4-dicarboxylic acid, from cystine and glyoxylic acid, **64**, 24
- Thiazolidines, ring chain tautomerism, **66**, 43
- 1,2-Thiazolidinones, loss of sulfur, **65**, 73
- Thiazolidinothieno[2,3-*d*]pyrimidines, **66**, 215
- Thiazolin-5-ones, **64**, 25
- 1,3-Thiazolium-4-olates, ring contraction, **65**, 74
- 1,2-Thiazolium salts, rearrangement to pyrroles, **65**, 56

- Thiazolo[2,3-*d*][1,5]benzothiazepines, **63**, 79
- Thiazol-4-one-2-thione, Pd(0) catalysed reaction with cinnamyl ethyl carbonate, **66**, 86
- Thiazolopyrimidines, via thermal cyclization of enaminones, **67**, 315
- Thiazolo[2,3-*b*]pyrimidines, **64**, 48
- Thiazolo[5,4-*b*]pyrimido[6,1-*a*]isoquinolin-5-ones, preparation, **70**, 48
- Thiazolo[2,3-*b*]quinolinone, preparation, **69**, 457
- Thiazolo[2,3-*b*][1,3,4]thiadiazine, **64**, 221
- Thiazolo[2,3-*b*][1,3,4]thiadiazoles, **64**, 196
- Thiazolo-1,3-thiazin-4-ones, **66**, 166
- Thiazolo[3',2':2,3][1,2,4]triazino[5,6-*b*]indoles, **61**, 288
- biological activity, **61**, 290
- Thiazolo[3',4':2,3][1,2,4]triazino[5,6-*b*]indoles, **61**, 290
- Thiazolo[2,3-*c*]-1,2,4-triazole, **63**, 296
- Thiazolo[2,3-*c*]triazole, **63**, 285
- Thiazolo[3,2-*b*][1,2,4]triazole, preparation, **69**, 326
- alkylation at *N*-1, **69**, 327
- bromination, **69**, 329
- spectra, **69**, 330
- spectral comparison with thiazolo[2,3-*c*][1,2,4]triazoles, **69**, 330
- mass spectral data, **69**, 332
- biological properties, **69**, 33
- Thiazolotropolone, aromaticity, **66**, 357
- Thiazolotropolone amide, dehydration to nitrile, **66**, 360
- Thiazolotropone, ir spectra, **66**, 302
- 4-(2-Thiazolyl)aminoisoxazoles, cyclisation, **69**, 286
- 2-Thiazolyl C-nucleoside, preparation, **68**, 308
- 2-Thiazolylhydrazones of aromatic aldehydes, oxidative cyclisation, **69**, 46
- Thiazyl chloride, precursor of dithiadiazolium cations, **62**, 146
- ring expansions, **62**, 147
- reaction with S<sub>8</sub> and SCl<sub>2</sub>, **62**, 147
- reaction with norbornadiene, **62**, 148
- reaction with nitriles, **62**, 148
- in situ* preparation from ammonium chloride and sulfur dichloride, **62**, 149
- reaction with tetrachloroethylene, **62**, 152
- Thiazyl trichloride, reaction with thioamides, **62**, 300
- Thieno[2,3-*c*]acridines, **70**, 144
- Thieno[2,3-*b*][1,5]benzothiazepines, **63**, 71
- Thieno[3,2-*b*][1,5]benzothiazepines, **63**, 72
- Thieno[3,4-*b*][1,5]benzothiazepines, **63**, 73
- Thieno[3,4-*c*][1,5]benzothiazepines, **63**, 74
- Thieno[2,3-*b*][1,5]benzothiazepin-4(5*H*)-one, reaction with piperazines, **63**, 72
- Thieno[3,2-*b*][1,5]benzothiazepin-10(9*H*)-one, **63**, 72
- Thienoditropones, **64**, 118
- Thienomycin, **65**, 108
- Thieno[3,2-*c*][1,5] or [1,6]naphthyridines, **62**, 363
- Thieno[*c*]naphthyridines, **62**, 363
- Thieno[2,3-*d*]oxazin-4-ones, transformation to thieno[2,3-*d*]pyrimidin-4-ones, **66**, 218
- Thieno[3,2-*d*]-1,3-oxazin-4-ones, rearrangement to thieno[3,4-*d*]pyrimidines, **66**, 267
- Thieno[2,3-*d*]oxazinones, reaction with amines, **65**, 244
- Thienopyridines, from *N*-allyl-*N*-thiophenylaminones, **67**, 293
- Thieno[3,4-*b*]pyridine, synthesis, **68**, 186
- Thieno[4,3-*b*]pyridine, synthesis, **68**, 186
- Thieno[2,3-*b*]pyridine-5-carboxylates, synthesis, **67**, 292
- Thieno[3,2-*b*]pyridone, from 3-amino-2-methoxycarbonylthiophene, **67**, 293
- Thieno[3,2-*d*]pyrimidines, physical properties and biological activities, **66**, 254
- reaction with electrophilic reagents, **65**, 256
- biological activity, **65**, 267
- Thieno[2,3-*d*]pyrimidines, bromination, nitration, formylation at C-6, **66**, 224
- metal complexes, **66**, 230
- properties, spectra, **65**, 237, **66**, 231
- biological activity, **65**, 266
- nitration, **65**, 250
- reduction, **65**, 252
- Thieno[3,4-*d*]pyrimidines, biological activity, **65**, 268
- physical properties and biological activities, **66**, 272
- Thieno[2,3-*d*]pyrimidin-2(1*H*),4(3*H*)-diones, **65**, 246
- mass spectra, **65**, 237
- from uracils, **65**, 238

- reaction with phosphoryl chloride, **65**, 253  
synthesis, **66**, 195  
analgesic activity, **66**, 232
- Thieno[3,2-*d*]pyrimidine-2,4-(1*H*,3*H*)-  
diones, reaction with phosphoryl  
trichloride, **65**, 260, **69**, 198
- Thieno[3,4-*d*]pyrimidin-2,4-(1*H*,3*H*)-dione,  
**65**, 263, **66**, 258  
reaction with phosphoryl trichloride, **65**,  
266  
mass spectra, **65**, 237
- Thieno[3,2-*d*]pyrimidine-2,4-dione-7-  
carbaldehyde, **66**, 245
- Thieno[2,3-*d*]pyrimidin-2(1*H*),4(3*H*)-  
dithiones, **65**, 248, **66**, 204
- Thienopyrimidin-4(3*H*)-ones, **66**, 236  
conversion to chloro analog, **66**, 221  
hydrolytic cleavage, **66**, 226  
silylation, **66**, 223
- Thieno[2,3-*d*]pyrimidin-4(3*H*)-one,  
bromination and nitration, **65**, 250  
methylation, **65**, 253  
thionyl chloride/dimethylformamide, **65**,  
254  
synthesis, **66**, 195  
analgesic activity, **66**, 232
- Thieno[2,3-*d*]pyrimidin-2(1*H*)-one, **65**, 243,  
**66**, 197  
methylation, **65**, 252  
silylation, **65**, 253  
reaction with phosphoryl chloride, **65**, 253
- Thieno[3,2-*d*]pyrimidin-4(3*H*)-ones, **65**, 256  
alkylation, **65**, 260  
reactions with phosphorus trichloride and  
phosphorus tribromide, **65**, 260  
chlorination, **66**, 248  
alkylation on *N*-3, **66**, 248
- Thieno[3,4-*d*]pyrimidin-4(3*H*)-one, **65**, 262  
electrophilic halogenation, **65**, 264  
reaction with phosphorus pentasulfide,  
**65**, 265  
alkylation, **65**, 265
- Thienopyrimidin-4-one-2(1*H*)-thiones, **66**,  
241
- Thieno[2,3-*d*]pyrimidin-2(1*H*)-one-4(3*H*)-  
thiones, **66**, 209, **65**, 247
- Thieno[2,3-*d*]pyrimidin-4(3*H*)-one-2(1*H*)-  
thiones, **65**, 247, **66**, 198, **66**, 201  
synthesis, **66**, 195
- Thieno[2,3-*d*]pyrimidin-2(1*H*)-thione,  
alkylation, **65**, 254
- Thieno[2,3-*d*]pyrimidin-4(3*H*)-thiones, **65**,  
248, **66**, 209, **66**, 219
- Thieno[3,2-*d*]pyrimidine-4(3*H*)-thione,  
alkylation, **65**, 261  
reaction with phosphoryl trichloride, **65**,  
261
- N*-(Thieno[2,3-*d*]pyrimidin-2-yl)cyanamides,  
**66**, 200
- 7β-(Thienopyrimidin-2-  
ylthioacetamido)cephalosporanic acids,  
antibacterials, **66**, 234
- Thieno[3,4-*c*]quinolinone, synthesis, **68**, 186
- Thieno[ ]tellurapyrones, **63**, 31
- Thieno[2,3-*e*][1,2,4]triazino[4,3-*b*]  
[1,2,4]triazines, **61**, 298
- Thienotropolones, p*K*<sub>a</sub> values, **66**, 330  
chromium tricarbonyl complexes, **66**, 331
- Thienotropone, **65**, 97
- Thieno[*b*]tropone, calculation of electronic  
spectra, **66**, 301  
mass spectra, **66**, 306
- Thieno[*c*]tropones, IR spectra, **66**, 304  
mass spectrum, **66**, 306  
Raman spectra, **66**, 307  
aromaticity, **66**, 308  
photochemistry, **66**, 329  
basicity, **66**, 331  
reaction with active methylene compounds,  
**66**, 339
- S,S*-dioxides, **66**, 352  
bromination, nitration and sulfonation,  
**66**, 354  
reaction with sulfur ylides, **66**, 364  
antioxidants, **66**, 392
- Thieno[*c*]tropylium ions, electrochemical  
reductions, **66**, 382  
reaction with phenyllithium, **66**, 385  
reaction with malononitrile, **66**, 383
- Thieno[*c*]tropylium salts, **64**, 131
- Thienotropylium ions <sup>1</sup>H NMR, **66**, 314  
UV spectra, **66**, 319  
theoretical studies, **66**, 319  
metal complexes, **66**, 379  
hydrolysis, **66**, 381
- 3-(2-Thienyl)allyl phenylpropiolates,  
intramolecular reactions, **63**, 393
- 3-(3-Thienyl)allyl phenylpropiolates,  
intramolecular reactions, **63**, 393
- 3-(Thien-2-yl)amino-2-cyano-3-  
methylthioacrylonitriles, **66**, 200

- 1,4-di(3-Thienyl)-1,4-butanedione, conversion to furans, **69**, 22
- N*-(2-Thienyl)chloroformamides, reaction with *N*-cyanomorpholine, **65**, 241
- 1-(2-Thienyl)cyclooct-1-ene, Diels-Alder reactions, **63**, 366
- 2,5-di(3-Thienyl)furan, preparation, **69**, 22
- 2-(2-Thienyl)glyoxal-1-*N*-carbamoylhydrazones, bromination, **63**, 288
- 4-(2-Thienyl)imidazoles, synthesis, **69**, 36
- 2-Thienylstannanes, use in preparation of thieno[3,2-*c*][1,5] or [1,6]naphthyridines, **62**, 363
- 2-(2-Thienylthio)-1-piperazinecarboxanilide, precursor to thienyl[2,3-*b*][1,5]benzothiazepines, **63**, 72
- Thiepins, sulfur elimination, **65**, 45
- Thietanes, **65**, 75
- loss of sulfur to give cyclopropanes, **65**, 76
- Thietanones, **65**, 162
- “Thiiradialene”, **65**, 161
- 3-Thioacetyl-1-methylpyrrole, alkylation and cycloaddition reactions **63**, 347, **63**, 373
- 2-Thiobarbituric acid, Pd(0) catalysed allylation, **66**, 116
- 1-Thiobenzoylhydrazinopyranose, ring chain tautomerism, **66**, 45
- Thiobenzoylisocyanate, [2+4]cycloaddition with 1-morpholinocyclohexene, **66**, 150
- condensation with ethyl sodiocyanoacetate, **66**, 133
- Thiobenzoylketenes, cycloadditions with diisopropylcarbodiimide, **66**, 139
- 2-Thiocarbonylphenylpyrrolidines, cyclisation, **65**, 24
- Thiocarbonyl ylides, as reaction intermediates, **65**, 110
- 4-Thiocarboxamidothiazol-2-yl *C*-nucleosides, **68**, 310
- Thiochroman-4-ones, reaction with diethyl diazomalonate, **65**, 168
- $\alpha$ -Thiocyanoacetophenones, as intermediates in synthesis of 2-hydroxythiazoles, **69**, 44
- 2-Thiocyanobenzoyl chloride, acid catalysed cyclisation to 2-chlorobenzo-1,3-thiazin-4-ones, **66**, 144
- 3-Thiocyanobenzoyl chloride, cyclisation with phosphorus pentachloride to 2-chloro-5,6-dichloro-1,3-thiazin-4-ones, **66**, 149
- cis/trans*-fused 2-Thiodecahydroquinazolines, EI mass spectra, **69**, 445
- Thiolactams, reaction with bromomethyl ketones, **67**, 211
- 3-Thiomethylpyrazolotropones, **64**, 105
- 2-Thio-5-(*o*-nitrobenzyl)-6-azauracil, precursor to [1,2,4]triazino[5,6-*b*][quinolines, **61**, 224
- 4-Thiono-1,3-oxazine, *S*-alkylation to 3-azapyrylium salts, **64**, 350
- 2(or 3)-Thiopheneboronic acid, Pd catalysed thiophenylation of halopyridines, **62**, 358
- Thiophene-2,3-dicarbohydroxamates, Lossen rearrangement, **65**, 247
- Thiopheno[2,3-*c*]thiophenes, **65**, 166
- 2-Thiopseudouridine, **68**, 367, 375
- 2-Thiopseudouridine acetate, **68**, 369
- 2*H*-Thiopyrans, from [4+2] cycloadditions of thioenaminones with dienophiles, **67**, 267
- 4*H*-Thiopyrans, from [4+2] cycloadditions of thioenaminones with dienophiles, **67**, 267
- Thiopyrano[3,4-*c*]pyridazine, preparation, **68**, 195
- Thiopyranotropone, **64**, 100
- 2-(Thiopyridine)-*N*-(2,5-anhydro-aldonate), photolysis, **70**, 205
- 2-Thiopyridine-1-(2,3-benzoyloxycyclobutanoate), photoirradiation, **68**, 348
- 2-Thiopyridone-*N*-(2,5-anhydro-3-deoxy)-*D*-allonoate, photolysis, **70**, 193
- 2-Thiopyrimidines, **67**, 311
- 4-Thiopyrimidines, from enamines and acyl isothiocyanates, **67**, 310
- Thiotropocin,  $^{13}\text{C}$  NMR, **66**, 293
- $^1\text{H}$  NMR, **66**, 288
- UV spectra, **66**, 300
- mass spectra, **66**, 307
- 3-Thio-2,3,5-triphenyl-1,4,3-oxathiaphospholane, from rearrangement of 5-thiono-2,4,5,6-tetraphenyl-1,3,5-dioxaphosphorinane, **61**, 65
- 2-Thiouracil, Pd(0) catalysed allylation, **66**, 111
- 2-Thioureidoglucopyranoses, **70**, 181
- 2-Thioxo-1,2'-bibenzimidazole, from benzimidazole-2-thione, **67**, 37
- 2-Thioxo-2,3-dihydroquinazolidin-4(1*H*)-one, EI mass spectra, **69**, 445

- 2-Thioxo-2,3-dihydro[1,2,4]triazino [6,5-*c*]isoquinolin-6-one, **61**, 232
- 3-Thioxofuro[2,3-*d*]imidazol-6-yl acyclo C-nucleosides, ring opening, **70**, 182
- 4-Thioxo-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrimido[6,1-*a*]isoquinolin-2-one, reaction with mercury salts, **70**, 46
- 2-Thioxooctahydro-2*H*-1,3-benzoxazines, conformations, **69**, 410
- 2-Thioxooctahydro-2*H*-3,1-benzoxazines, conformations, **69**, 410  
fragmentation **69**, 441
- cis*-fused 2-Thioxooctahydro-1*H*-cyclopentapyrimidin-4-one, EI mass spectra, **69**, 445
- diendo*-2-Thioxooctahydro-5,8-methano-1,3-benzoxazines, conformations, **69**, 412
- diendo*-2-Thioxooctahydro-5,8-methano-3,1-benzoxazines, conformations, **69**, 412
- trans*-fused 2-Thioxo-1,2,3,4,4*a*,5,8,8*a*-octahydroquinazolines, EI mass spectra, **69**, 445
- 2-Thioxo-5-oxazolidinyl reverse C-nucleosides, preparation, **68**, 301
- 1-Thioxo-3-oxo-hexahydropyrido[1,2-*c*]pyrimidines, **70**, 73
- 2-Thioxoperhydro-1,3-benzoxazine, **69**, 365
- 2-Thioxoperhydro-1,3-oxazin-4-ones, isomerisation, **69**, 382
- 1-Thioxoperhydropyrido[1,2-*c*]pyrimidin-3-one, **70**, 67
- 2,4-Thioxoperhydroquinazoline, **69**, 396
- 4-Thioxopyrazolo[1,5-*a*][1,3,5-triazin-3-yl C-nucleosides, **70**, 302
- 4-Thioxopyrimidine-5-carbonitriles, reaction with alkylating agents, **66**, 217
- 2-Thioxotetrahydrooxazines, synthesis, **69**, 364
- 4-Thioxothieno[3,2-*d*]pyrimidines, **65**, 257
- 3-Thioxo-1,2,4-triazolo[3',4':6,1][1,2,4]triazino[4,5-*b*]indazole, **61**, 303
- D,L-Threonine, reaction with formaldehyde to give oxazolidinecarboxylate, **64**, 22
- 2',3'-*seco*-Thymidine analogues, synthesis, **67**, 410
- Thymine, Pd(0) catalysed allylation, **66**, 107  
in presence of trisodium triphenylphosphine trisulfonate, **66**, 111
- ara*-Tiazofurin, *see* 2-β-D-arabinofuranosyl-4-carboxamidothiazole
- Tiazofurin, *see* 4-carboxamido-2-β-D-ribofuranosylthiazole
- Tiazofurin-5'-monophosphate, **68**, 309
- Tiazofurin-5'-triphosphate, **68**, 309
- Tin compounds in coupling reactions, **62**, 330
- Tirandamycin A, synthesis, **67**, 263
- [β-(*p*-Toluenesulfonyl)alkylidene]carbenes, conversion to 2-cyclopentenones, **69**, 30
- 1-*O*-*p*-Toluenesulfonyl-2,3-*O*-isopropylidene-D-glycerol, **69**, 175
- 1-*p*-Toluenesulfonyl-3-vinylindole, reaction with tetracyanoethylene, **63**, 374
- 3-*p*-Toluenethio-2-pyrone, preparation and oxidation, **65**, 305
- p*-Toluidine derivatives of *N*-Cbz-L-Th, aziridine synthesis, **64**, 3
- 2-*o*-Toluidinothieno[3,2-*d*]pyrimidin-4-one, **66**, 248
- 9-(*p*-Tolyl)-9-azidotelluroxanthene, thermolysis, **63**, 46
- 11-(*p*-Tolyl)dibenzo[*b,f*][1,4]tellurazepine, **63**, 46
- [*N*-(*p*-Tolylsulfonyl)imino]phenyliodinane, decomposition and reaction with olefins, **69**, 11
- 5'-(4-Tolylsulfonyloxy)pseudouridine, **68**, 370
- 9-(*p*-Tolyl)-10-telluroniaanthracene, **63**, 37  
reactions with nucleophiles, **63**, 45
- 9-(*p*-Tolyl)-telluroxanthanol, reduction, **63**, 37
- 9-(*p*-Tolyl)-telluroxenthenes, **63**, 37
- Tosylhydrazonouracil sodium salt, thermolysis, **65**, 121
- α-Tosyloxyacetophenones, conversion to imidazothiazoles, **69**, 46  
conversion to imidazothiadiazoles, **69**, 47
- 2-(α-Tosyloxy)acylphenyl benzoates, cyclisation to coumaran-3-one dimethylacetals, **69**, 19
- α-Tosyloxyketones, preparation, **69**, 4  
precursors for 3-substituted benzofurans, **69**, 19
- 3-Tosyloxy-1,2-propanediol, as precursor of acylonucleosides, **68**, 16
- N*-Tosyl-2-vinylpyrrole, reaction with tetrabromocyclopropane, **63**, 360
- Toyocamycin, in preparation of nucleosides, **67**, 405

- Toxoflavin *see* xanthothricin
- Transannular oxidative cyclisation reactions  
to give bicyclic ethers, **69**, 61
- ( $\pm$ )-Trachelanthamidine, **65**, 110; **67**, 234
- Trequinsen, as antihypertensive, **70**, 3
- Triacetic acid lactone, *see* 4-hydroxy-6-methyl-2-pyrone
- 1,2,3-Triacetoxy-1-methoxypropane,  
reaction with pertrimethylsilyl  
derivatives of *N*-benzoyladenine, **68**, 60
- 2',3',5'-Tri-*O*-acetyl pseudouridine, **68**, 391
- 7-(2',3',5'-Tri-*O*-acetyl- $\beta$ -D-  
ribofuranosyl)thieno[3,2-*d*]pyrimidin-  
4(3*H*)-one, conversion to thione, **66**, 250,  
**66**, 269
- 2,2,5-Trialkyl-1,3-dioxanes, conformations,  
**69**, 240
- 2-Trialkylsilyloxy-4*H*-pyran, oxidative  
decomposition, **62**, 74  
bromination, **62**, 90  
conversion to pyrones, **62**, 95
- 2,4,5-Triamino-6-hydroxypyrimidine, **69**, 170
- 2,4,6-Triaminopyrimidin-4-one,  
condensation with *aldehydo*-5-deoxy-L-  
arabinose semicarbazone, **70**, 272
- 2,5,6-Triaminopyrimidin-4-one, in  
preparation of dictyopterin, **70**, 268
- 2,4,5-Triarylimidazoles, oxidation, **67**, 28
- 2,4,6-Triarylpyrylium perchlorates, ring  
conversion to 2*H*-pyrans, **62**, 56
- 2,4,6-Triarylpyrylium salts, reaction with  
alcohols, **65**, 310  
reaction with  
tris(dimethylamino)phosphine, **65**,  
316
- 6,8,9-Triazaflavin *see* 6,8,9-triazaisoalloxazine
- 3,5,7-Triaza-7-phosphaadamantane,  
synthesis, **61**, 75
- s*-Triazines, **64**, 223
- 1,2,4-Triazines, **64**, 34
- 1,3,5-Triazine *C*-nucleosides, **68**, 394
- 1,2,4-Triazine homo *C*-nucleosides, **68**, 391
- [1,2,4]Triazino[4,3-*a*]azepines, **61**, 282
- 1,3,5-Triazino[1,2-*a*]benzimidazole, **64**, 221
- [1,2,4]Triazino[3,4-*c*][1,4]benzothiazines, **61**,  
274
- [1,2,4]Triazino[6,1-*c*][1,4]benzothiazines, **61**,  
274
- [1,2,4]Triazino[6,5-*b*][1,4]benzothiazines, **61**,  
274
- [1,2,4]Triazino[4,3-*c*]benzo[1,2,3]triazines,  
**61**, 275
- [1,2,4]Triazino[3,4-*c*][1,4]benzoxazines, **61**,  
272
- [1,2,4]Triazino[6,1-*c*][1,4]benzoxazines, **61**,  
271
- [1,2,4]Triazino[5,6-*c*]cinnolines, **61**, 236
- [1,2,4]Triazino[4,3-*a*][1,4]diazepines,  
preparation and biological activity, **61**,  
284
- [1,2,4]Triazino[4,3-*d*][1,4]diazepines, **61**, 286
- [1,2,4]Triazino[5,6-*b*][1,4]diazepines, **61**, 284
- [1,2,4]Triazino[6,1-*d*][1,3,5]dioxazines, **61**,  
281
- [1,2,4]Triazinoisoalloxazines, **61**, 270
- Triazino[5,6-*c*]isocoumarines, **61**, 234
- [1,2,4]Triazino[2,3-*b*]isoquinolines, **61**, 231
- [1,2,4]Triazino[3,2-*a*]isoquinolines, **61**, 229
- [1,2,4]Triazino[3,4-*a*]isoquinolines, **61**, 229
- [1,2,4]Triazino[5,6-*c*]isoquinolines, **61**, 231
- [1,2,4]Triazino[6,1-*a*]isoquinolines, **61**, 230
- [1,2,4]Triazino[6,5-*c*]isoquinolines, **61**, 232
- [1,2,4]Triazino[6,1-*a*]isoquinolinium-1-oate,  
photolysis, **61**, 230
- [1,2,4]Triazinoloponeoximine, **66**, 375
- [1,2,4]Triazino[6,5-*f*][1,7]naphthyridines, **61**,  
232
- 1,2,4-Triazin-6-one, **64**, 35
- [1,2,4]Triazino[4,3-*d*][1,3,4]oxadiazines, **61**,  
279
- [1,2,4]Triazino[5,6-*e*][1,3,4]oxadiazines, **61**,  
279
- [1,2,4]Triazino[6,5-*e*][1,2,3]oxathiazines, **61**,  
281
- [1,2,4]Triazino[4,3-*a*]perimidine, **61**, 264
- [1,2,4]Triazino[4,3-*f*]phenanthridines,  
synthesis and fungicidal activity, **61**, 229
- [1,2,4]Triazino[3,4-*a*]phthalazines, **61**, 236
- 2*H*[1,2,4]Triazino[3,4-*c*]phthalazin-3(4*H*)-  
one, **61**, 237 1,2,4-Triazino[3,4-*a*]  
phthalazin-3-yl acyclo *C*-nucleosides,  
**70**, 218
- 1,2,4-Triazino[1,5-*a*]pyridin-2-yl *C*-  
nucleosides, **70**, 203
- 1,2,4-Triazino[4,3-*a*]pyridin-3-yl *C*-  
nucleosides, **70**, 203
- 1,2,4-Triazino[1,5-*a*]pyridin-2-yl acyclo *C*-  
nucleosides, **70**, 204
- 1,2,4-Triazino[4,3-*a*]pyridin-3-yl acyclo *C*-  
nucleosides, **70**, 203



- Triazinopyridoindole, **61**, 212  
 [1,2,4]Triazino[1,6-*c*]quinazolines, **61**, 265  
 [1,2,4]Triazino[4,3-*c*]quinazolines, **61**, 267  
 [1,2,4]Triazino[6,1-*b*]quinazolines, **61**, 265  
 [1,2,4]Triazino[3,2-*b*]quinazoline-3,10-dione, thiation, **61**, 309  
 [1,2,4]Triazino[6,1-*b*]quinazoline-4,10-diones, **61**, 265  
 [1,2,4]Triazino[6,1-*b*]quinazoline-10-one, **61**, 265  
 [1,2,4]Triazino[2,3-*a*]quinolines, **61**, 263  
 [1,2,4]Triazino[3,2-*b*]quinolines, **61**, 263  
 [1,2,4]Triazino[3,4-*b*]quinolines, **61**, 264  
 [1,2,4]Triazino[4,3-*a*]quinolines, **61**, 224, **61**, 263  
 1,2,3-Triazino[4,5-*c*]quinolines, preparation from aminoquinolines, **68**, 197  
 [1,2,4]Triazino[5,6-*c*]quinolines, **61**, 226  
     biological and spectral features, **61**, 227  
 [1,2,4]Triazino[5,6-*f*]quinolines, **61**, 228  
 [1,2,4]Triazino[6,5-*c*]quinolines, **61**, 227  
 [1,2,4]Triazino[4,3-*a*]quinolin-2-yl acyclo *C*-nucleosides, **70**, 209  
 [1,2,4]Triazino[5,6-*b*]quinoxalines, **61**, 270  
 [1,2,4]Triazino[5,6-*b*]quinoxaline-1,2,4-tri-*N*-oxides, preparation from *o*-azidoloquinoxalines, **61**, 270  
 [1,2,4]Triazino[4,3-*b*][1,2,4,5]tetrazines, **61**, 281  
 [1,2,4]Triazino[3,4-*b*][1,3,4]thiadiazines, fungicidal and light sensitive photographic materials, **61**, 280  
 [1,2,4]Triazino[5,6-*e*][1,3,4]thiadiazines, **61**, 280  
 [1,2,4]Triazino[3',4':2,3][1,3,4]thiadiazino[5,6-*c*]cinnolin-9-one, **61**, 280  
 [1,2,4]Triazino[3,2-*b*][1,3]thiazines, **61**, 273  
 [1,2,4]Triazino[3,4-*b*][1,3]thiazines, **61**, 273  
 [1,2,4]Triazino[4,3-*b*][1,2,4]triazepines, **61**, 286  
 [1,2,4]Triazino[4,3-*d*][1,2,4]triazepines, **61**, 287  
 1,3,5-Triazino[1,2-*b*][1,2,4]triazines, **61**, 278  
 1,3,5-Triazino[2,1-*c*][1,2,4]triazines, **61**, 278  
 1,3,5-Triazino[2,1-*f*][1,2,4]triazines, **61**, 278  
 [1,2,4]Triazino[4,3-*b*][1,2,4]triazines, **61**, 276  
 [1,2,4]Triazino[6,5-*e*][1,2,4]triazines, **61**, 277  
 Triazino[4,3-*b*][1,2,4]triazolo[3,4-*f*]pyridazine, **61**, 235  
 1,2,4-Triazinotroponone, **64**, 110  
 Triazinotropones, reaction with cyclopropenes, **66**, 368  
 1,2,4-Triazin-6-yl acyclo *C*-nucleosides, **68**, 393  
 1,2,4-Triazin-6-yl carbocyclic *C*-nucleosides, **68**, 392  
 1,2,4-Triazin-6-yl homo *C*-nucleosides, **68**, 392  
 1,2,4-Triazin-5-yl *C*-nucleosides, **68**, 390  
 1,2,4-Triazin-6-yl *C*-nucleosides, **68**, 391  
 1,2,3-Triazoles, from [3+2]-cycloaddition of azidoarenes to enaminones, **67**, 259  
 1,2,4-Triazole, **64**, 25  
     Pd(0) catalysed allylation, **66**, 91  
     1,2,3-Triazole *C*-nucleosides, **68**, 318  
     1,2,4-Triazole *C*-nucleosides, **68**, 324  
     1,2,4-Triazole carbocyclic *C*-nucleosides, **68**, 326  
     1,2,3-Triazole homo *C*-nucleosides, **68**, 319  
     1,2,4-Triazole-5-thione, Pd(0) catalysed allylation, **66**, 91  
     1,2,4-Triazolidine-3-thione, ring chain tautomerism, **66**, 26, **66**, 51  
     protonation, **66**, 52  
     1,2,4-Triazoline-3,5-diones, by oxidations of urazoles, **67**, 120  
     use in detecting conjugated dienes, **67**, 189  
 Triazolinedione ylides, from diazo compounds and 4-phenyl-1,2,4-triazoline-3,5-dione, **67**, 183  
 [1,2,4]Triazolo[5,1-*d*][1,5]benzothiazepines, **63**, 81  
 [1,2,4]Triazolo[3,4-*d*][1,5]benzothiazepines, **63**, 79  
*s*-Triazolo[3,4-*b*]benzothiazole, **63**, 325  
 Triazolo-1,3-benzothiazolin-4-ones, **66**, 167  
 1,2,4-Triazolo-bridgehead heterocycles, synthesis, **69**, 46  
 1,2,4-Triazolo[5,1-*b*]indazoles, **64**, 197  
 1*H*-1,2,4-Triazoloindazole, **64**, 229  
 1,2,4-Triazolo[3,4-*b*]oxadiazoles, **63**, 297  
 1,2,4-Triazolo[5,1-*b*][1,3,4]oxadiazoles, synthesis, **69**, 279  
 1,2,4-Triazolo[3,4-*b*][1,3]oxazines, by cycloaddition of nitrilimines with dihydrooxazines, **69**, 454  
 1*H* [1,2,4]Triazolo[4,3-*a*]perimidine-3-carboxylate, **61**, 265  
 1,2,3-Triazolopyridines, **67**, 296  
 1,2,4-Triazolo[4,3-*a*]pyridin-3-yl *C*-nucleosides, **70**, 202

- 1,2,4-Triazolo[1,5-*c*]pyrimidine, **64**, 212  
 1,2,4-Triazolo[1,5-*a*]pyrimidin-2-yl *C*-nucleosides, **70**, 257  
 1,2,4-Triazolo[1,5-*c*]pyrimidin-2-yl *C*-nucleosides, **70**, 257  
 1,2,3-Triazolo[1,5-*c*]pyrimidin-3-yl *C*-nucleosides, **70**, 256  
 1,2,4-Triazolo[4,3-*c*]pyrimidin-3-yl *C*-nucleosides, **70**, 257  
 1,2,4-Triazolo[1,5-*a*]pyrimidin-2-yl pyranose *C*-nucleoside, **70**, 256  
 [1,2,4]Triazolo[4',3':3,4]pyrimido[2,1-*c*][1,2,4]triazines, **61**, 241  
 [1,2,4]Triazolo[4,3-*b*]pyrimido[5,4-*e*][1,2,4]triazines, **61**, 307  
 1,2,4-Triazolo[4,3-*d*]tetrazoles, **63**, 298  
 Triazothiadiazines, **65**, 67  
 1,2,4-Triazolo[5,1-*b*][1,3,4]thiadiazoles, **69**, 334  
     spectral data, **69**, 335  
 Triazolotriazines, **64**, 197  
 Triazolo[5,1-*c*][1,2,4]triazines, **63**, 316  
 [1,2,4]Triazolo[3,4,6,1][1,2,4]triazino[4,3-*a*]benzimidazoles, **61**, 306  
 Triazolotriazinoindoles, **61**, 293  
 [1,2,4]Triazolo[3',4'-*f*][1,2,4]triazino[4,5-*a*]indoles, **61**, 293  
 [1,2,4]Triazolo[3',4':3,4][1,2,4]triazin *o*[5,6-*b*]indoles, **61**, 291  
 [1,2,4]Triazolo[4',3':2,3][1,2,4]triazin *o*[5,6-*b*]indoles, **61**, 291  
 1,2,4-Triazolo[3,4-*f*]  
     1,2,4-triazin-3-yl *C*-nucleoside, **70**, 298  
 1,2,4-Triazolo[3,4-*f*]1,2,4-triazin-3-yl acyclo *C*-nucleosides, **70**, 301  
 1,2,4-Triazolo[1,2-*a*][1,2,4]triazole,  
     decomposition product of 4-phenyl-  
     1,2,4-triazoline-3,5-dione, **67**, 170  
 Triazolotroponeimines, **66**, 376  
 Triazolotropones, tautomerism, **66**, 310  
     catalytic hydrogenation, **66**, 336  
     *N*-alkylation, **66**, 348  
     *N*-amination, **66**, 350  
 1,2,3-Triazol-4-yl *C*-nucleosides, **68**, 318  
 Tri-*O*-benzoyl-*D*-ribofuranosyl chloride, in  
     preparation of pseudouridine, **68**, 358  
 5-(2,3,5,-Tri-*O*-benzoyl- $\beta$  (and  $\alpha$ )-*D*-  
     ribofuranosyl)-4-  
     (formylamino)thiophene-3-carboxylate,  
     reaction with formamidine acetate, **66**,  
     256  
 5-(Tri-*O*-benzoyl- $\beta$ -*D*-ribofuranosyl)-1,3,4-  
     oxathiazol-2-one, **68**, 338  
 7-(2,3,5,-Tri-*O*-benzoyl- $\beta$ -*D*-  
     ribofuranosyl)thieno[3,4-*d*]pyrimidin-  
     4(3*H*)-one, **66**, 258  
 7-(2,3,5,-Tri-*O*-benzoyl- $\beta$ -*D*-  
     ribofuranosyl)thieno[3,4-*d*]pyrimidin-  
     4(3*H*)-thione, **66**, 269  
 2,3,5-Tri-*O*-benzyl-*D*-arabinofuranose,  
     reaction with pyrrolopyridine  
     magnesium bromide, **70**, 198  
 2,3,5-Tri-*O*-benzyl-*D*-arabinose, in  
     nucleoside synthesis, **67**, 396  
 1,3,5-Tribromobenzene, reaction with  
     anthranilic acid, **70**, 91  
 6,8,10-Tribromobenzo[*b*]tropoxazine,  
     hydrolysis, **64**, 90  
 2,5,7-Tribromopyrrolo[*b*]tropolone, **66**, 332  
 3,9,9-Tribromo-6,7,8,9-tetrahydro-4*H*-  
     pyrido[1,2-*a*]pyrimidin-4-one, **63**, 213  
 2-Tributylstannylindole, reaction with *N*-  
     protected 2-lithioindoles, **67**, 13  
 Tributylstannyltetrathiafulvalenes, **62**, 290  
     Stille reactions, **62**, 290  
 Tricarbonyl cyclobutadiene iron, annulation  
     to tropone, **64**, 144  
 Tricarbonyliron cyclobutadiene fused  
     tropones, NMR spectra, **66**, 288  
     UV spectra, **66**, 300  
     mass spectrum, **66**, 307  
     <sup>13</sup>C NMR, **66**, 293  
 2-Trichloroacetylbenzoyl chlorides, ring  
     chain tautomerism, **64**, 262  
 1,1,4-Trichloro-2,3-diazabutadiene, **63**, 286  
 2,2,3-Trichloro-1,4-dioxane, conformations,  
     **69**, 254  
*trans-syn*-1,2,5-Trichloro-1,4-dioxane,  
     conformations, **69**, 254  
 bis(2,4,6-Trichlorophenyl)malonates,  
     reaction with 3-aryl-2-methyl-4-  
     quinazolones, **68**, 214  
 2,4,6-Trichloropyrimidine, Ni-catalysed  
     reaction with Grignard reagents, **62**, 391  
     monocoupling with stannanes, **62**, 333  
 2',3',5'-Trichlorotrideoxy-2',3'-*seco*-uridine,  
     synthesis, **67**, 410  
 2,5,6-Tricyanothieno[2,3-*d*]pyrimidine-2-  
     thiolate, **65**, 249  
 Tricyclo[3.2.10<sup>2.7</sup>]oct-3-ene, **69**, 118  
 4-*O*-Triflate-2-oxo-1-2*H*-1-benzopyran, Pd-  
     catalysed coupling, **65**, 305

- 5-Trifloxy-1,3-dimethyluracil, methylation by methylaluminium, **62**, 371
- 2-Trifluoroacetyl-*t*-anilines, cyclisation to pyrrolooxazines, **65**, 22
- N*-(2-Trifluoroacetylphenyl)pyrrolidines, cyclisation to pyrroloquinazolines, **65**, 21
- 3-Trifluoroacetylpropionic acid, ring chain tautomerism, **64**, 259
- 3-Trifluoro-2-diazopropionate anion, Rh(II)-derived carbenoid reaction with nitrile, **65**, 179
- 5-Trifluoromethanesufonyluridine triacetate, coupling with stannanes, **62**, 343
- Trifluoromethyl acyclonucleosides, **68**, 56
- 5-Trifluoromethyl-3,3'-bi-1,2,4-oxadiazole, **67**, 45
- Trifluoromethyl biphenylselenides, **64**, 324
- Trifluoromethyl biphenylsulfides, **64**, 324
- Trifluoromethyl biphenyl telluride, **64**, 326
- Se(Trifluoromethyl)dibenzoselenophenium 3-sulfonates, trifluoromethylation agents, **64**, 331
- Se(Trifluoromethyl)dibenzoselenophenium triflate, trifluoromethylating agent, **64**, 329
- Te(Trifluoromethyl)dibenzotellurophenium triflate, **64**, 326
- salts, **64**, 327
- nitration, **64**, 327
- trifluoromethylating agents, **64**, 329
- S-(Trifluoromethyl)dibenzothiophenium-3-sulfonates, trifluoromethylating agents, **64**, 331
- trifluoromethylation of  $\beta$ -ketoesters and  $\beta$ -diketones, **64**, 331
- trifluoromethylation of lithium phenylacetylide, **64**, 332
- trifluoromethylation of enol trimethylsilyl ethers, **64**, 332
- trifluoromethylation of enamines, **64**, 332
- trifluoromethylation of pyrroles, **64**, 333
- trifluoromethylation of thiolates, **64**, 333
- trifluoromethylation of halide anions, **64**, 334
- trifluoromethylation in combination with boron Lewis acids, **64**, 335
- kinetic studies, **64**, 338
- S-(Trifluoromethyl)diphenylsulfonium triflate, **64**, 326
- trifluoromethylating agents, **64**, 329
- 6-Trifluoromethyl-4-methoxycarbonyl-2-pyrone, cycloaddition with acetylene, **65**, 343
- 2,4,6-Trifluoromethyl-2-methyl-2*H*-pyran, platinum complexes, **62**, 92
- metal complexes, **62**, 110
- S-(Trifluoromethyl)phenoxathiirium triflate, **64**, 326
- 6-Trifluoromethyl-2*H*-pyran-2-one, **65**, 337
- 2-Trifluoromethylpyridine, from 2-iodopyridine and bis(trifluoromethyl)mercury, **62**, 395
- 4-Trifluoromethyl quinoline, preparation from enamines, **67**, 278
- Se-(Trifluoromethyl)selenophenium-3-sulfonates, trifluoromethylating agents, **64**, 331
- Trifluoromethyl substituted pyridines, synthesis, **67**, 269
- 3,6-bis-(Trifluoromethyl)tetrazine, inverse Diels-Alder reaction with formimides, **68**, 390
- 2-Triflyloxyquinoline, reaction with trialkylaluminums, **62**, 371
- 5-Triflyloxyuracil, coupling with alkenes and alkynes, **62**, 311
- Trihydrobenzo[c]phenanthridines, synthesis, **67**, 374
- {6,7,8-Trihydro-8-hydroxy-3- $\beta$ -D-ribofuranosyl}imidazo[4,5-*d*]1,3-diazepine, **70**, 233
- 3-(D-*erythro*-1,2,3-Trihydroxypropyl)benzo[g]flavazole, **70**, 291
- 2,4,6-Triisopropyl-1,3,5-dioxaphosphorinane, reaction with aldehydes, **61**, 66
- Trimethine tellurapyrylium dyes, **63**, 49
- Trimethylbipyrroles, **67**, 22
- 2,2,6-Trimethylchromane-3,4-dione, condensation with formamidine to pyrano[3,4-*e*][1,2,4]triazines, **61**, 233
- Trimethyldibenzofuran-1,2,3-tricarboxylate, **63**, 343
- 2,2,4-Trimethyl-2,4-dihydro-1*H*,6*H*imidazo[1',2':1,6][1,2,4]triazino[3,4-*a*]isoindol-1,6-dione, preparation and X-ray structure, **61**, 296
- 2,2,4-Trimethyl-1,2-dihydroquinoline, reaction with formaldehyde, **70**, 17

- 2,2,6-Trimethyl-4-(2'-furyl)-5-nitro-1,3-dioxanes, conformations, **69**, 233
- 2,4,5-Trimethylimidazole, reaction with dichlorocarbene, **65**, 187
- 2,4,6-Trimethyl-4-isopropylpyran, **65**, 286
- 1,3,6-Trimethyl-5-nitouracil, reaction with aldehydes, **68**, 205
- 2,2,6-Trimethyloxane, simulated  $^{13}\text{C}$  NMR spectra, **69**, 229
- 2-{*N*-(2,4,6-Trimethylphenyl)-*N*methyl imino}-6,7-dihydro-4*H*-pyrimido[6,1-*a*]isoquinolin-4-one,  $^1\text{H}$  NMR spectra and conformations, **70**, 30
- 1,3,6-Trimethyl-2-phenylpyrrolo[*d*]tropylum ions, condensation of 6-methyl group with aldehydes, **66**, 385
- 2,4,4-Trimethyl-5-phenyl-1-thioxo-3-oxo-2,3,4,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidine, reaction with Lawesson's reagent, **70**, 46
- 2,4,6-Trimethylpyridinium perchlorate, reaction with methyl magnesium halides, **65**, 286
- reaction with organocuprates, **65**, 287
- 5,5,7-Trimethyl-1*H*,3*H*,5*H*-pyrido[3,2,1-*i,j*][3,1]benzoxazines, mass spectroscopy, **70**, 17
- 2,4,6-Trimethylpyrylium tetrafluoroborate, reaction with diazoalkenes, **65**, 291
- N,O*-bis-Trimethylsilyl-*N*-acetylcytosine, in preparation of acyclonucleosides, **68**, 60
- bis(Trimethylsilyl)adenine, preparation of acyclonucleosides, **68**, 15
- 2-Trimethylsilylazoles, in preparation of acyclonucleosides, **68**, 69
- bis(Trimethylsilyl)-5-benzyluracil, preparation of acyclonucleosides, **68**, 18
- O*-Trimethylsilylcytosine, Pd(0) catalysed allylation, **66**, 127
- Trimethylsilyldiazomethane, decomposition, **65**, 172
- Trimethylsilylethoxymethyltetra-thiafulvalene, source of selenyl anion, **62**, 268
- O*-Trimethylsilylethylguanine, **66**, 118
- bis(Trimethylsilyl)guanine, preparation of acyclonucleosides, **68**, 15
- tris(Trimethylsilyl)guanine, preparation of acyclonucleosides, **68**, 15
- reaction with alkylating agents to give *diseco* nucleosides, **68**, 46
- N*-Trimethylsilyliminophosphorane, reaction with 2-acyloxybenzoyl chloride, **64**, 210
- 2-Trimethylsilylmethylallyl acetate, as an equivalent of trimethylenemethane for cycloadditions to coumarins, **65**, 329
- bis-*O*-Trimethylsilyl-5-nitouracil, condensation with 1,3-diacetoxy-1-methoxypropane, **68**, 60
- 2-Trimethylsilyloxy-1,3-diazabutadienes, reaction with morpholinocyclohexene, **69**, 388
- 2,3-bis(Trimethylsilyloxy)-1,1-dimethoxypropane, alkylation of purines to give acyclonucleosides, **68**, 60
- 2-(Trimethylsilyloxy)furan, oxidation, **69**, 65
- conversion to 3-acetoxybenzofuran-2-one, **69**, 65
- 2-Trimethylsilyloxy-4-methoxy-1,3-butadiene, reaction with sugar azomethines, **68**, 351
- 2-(1-Trimethylsilyloxyvinyl)furan, Diels-Alder reaction, **63**, 359
- reaction with diethyl azodicarboxylate, **63**, 382
- 2-(1-Trimethylsilyloxyvinyl)thiophene, Diels-Alder reaction, **63**, 366
- reaction with *N*-phenylmaleimide, **63**, 366
- reaction with olefins, **63**, 379
- 2-Trimethylsilylpyridine, reaction with aldehydo-sugar derivatives, **68**, 349
- N*-(Trimethylsilyl)pyridinium triflate, **62**, 3
- 2-Trimethylsilylthiazole, coupling with thiazole to give 2,2'-bithiazole, **67**, 33
- 2-Trimethylsilylthio-1,3-diazabutadienes, reaction with morpholinocyclohexene, **69**, 388
- bis(Trimethylsilyl)thymine, preparation of acyclonucleosides, **68**, 18
- bis-*O*-Trimethylsilyluracils, in preparation of acyclonucleosides, **68**, 60
- 2-Trimethylstannylbenzofuran, copper induced homocoupling, **67**, 18
- Trimethyltetra-thiafulvene, lithiation, **62**, 256
- 2,5,5-Trimethylthiazolidine-4-carboxylic acid, **64**, 25
- 2,4,6-Trimethylthieno[2,3-*d*]pyrimidines, **65**, 237, **66**, 229
- 1,3,6-Trimethylthieno[3,2-*d*]pyrimidin-2,4-dione, **66**, 245
- 1,3,6-Trimethyluracil, reaction with dimethylformamide dimethylacetal and dienophiles, **68**, 209

- 8,9,10-Trinorborn-5-en-2-ol, in preparation of imidazo[1,5-*a*]pyridin-3-yl carbocyclic C-nucleosides, **70**, 200
- 2,8,9-Trioxa-1-borata-4-phospha-6,7-benzobicyclo[3,3,3]nonane, synthesis from phenyl phosphine, salicylic anhydride, phenylboric acid anhydride and triethylamine, **61**, 91
- s*-Trioxane, conformations, **69**, 255
- 1,2,4-Trioxane, conformations, **69**, 256  
ring inversion, **69**, 258
- Triphenyl-*N*-acyliminophosphorane, **64**, 166
- 2,4,6-Triphenyl-3-azapyrylium perchlorate, reactions, **64**, 353
- Triphenylbipyrzoles, **67**, 22
- 6,6,7-Triphenyl-6,7-dihydrodibenzo[*b,d*]thiepin, **65**, 169
- 1,2,4-Triphenylimidazo[2,1-*b*]oxazoles, **69**, 273
- 2,5,5-Triphenyl-1,3-oxathiolan-4-one, extrusion of sulfur and carbon dioxide, **65**, 40
- Triphenylphosphine, reaction with organic azides, **64**, 160
- 1-(Triphenylphosphoranylidene)benzotriazole, formation of aziridines, **64**, 183  
formation of pyridines, **64**, 202  
formation of imidazoles, **64**, 192
- 2-(Triphenylphosphoranylideneamino)cinnamate, reaction with aroyl chlorides, **64**, 190
- $\alpha$ -(Triphenylphosphoranylidene)toluene, reaction with activated nitriles, **64**, 166
- 2,4,6-Triphenyl-4*H*-pyran, cleavage, **62**, 87
- 2,4,6-Triphenylpyrylium perchlorate, **62**, 51
- 2,4,6-Triphenylpyrylium tetrafluoroborate, uv spectrum, **62**, 56
- Triple layer cyclophanes, **65**, 78
- Triquinanes, synthesis, **67**, 277
- Tris(benzazino)troplium salts, ring contraction, **66**, 387
- Tris(2-benzothiazolyl)phosphine, reaction with aryl lithiums, **67**, 40
- Tris(hydroxyethyl)phosphine, conversion to 5-methyl-5-oxo-1,3,5-dioxaphosphorinane with formaldehyde, **61**, 64
- Tris(hydroxymethyl)phosphine as a source of heterocycles, **61**, 92
- Tris( $\alpha$ -hydroxy- $\beta,\beta,\beta$ -trichloroethyl)phosphine, reaction with phenyltrichlorosilane to give bicyclo adducts, **61**, 64
- Tris(oxymethyl)phosphine, as a precursor to 5-aminomethyl-1,3-diphenyl-1,3,5-diazaphosphorinane, **61**, 72
- Tris(pyrazol-1-yl)methane, flash vacuum pyrolysis, **67**, 21
- Triquinobenzene, **70**, 91
- 3,4,5-Trisubstituted 2-amino-3-cyano-4*H*-pyrans, conversion to pyramines, **62**, 71
- 2,2,5-Trisubstituted 1,3-dioxane-4,6-diones, conformations, **69**, 245
- 2,3,6-Trisubstituted imidazo[2,1-*b*]thiazoles, **69**, 285
- 2,5,6-Trisubstituted imidazo[2,1-*b*]thiazoles, **69**, 282
- 2,4,6-Trisubstituted-2*H*-pyrans, reaction with organometallic reagents, **62**, 84
- 2,3,5-Trisubstituted pyrroles, formation via iminophosphoranes, **64**, 187
- 2,3,6-Trisubstituted pyrylium salts, conversion to 4*H*-pyrans, **62**, 55
- 2,4,6-Trisubstituted pyrylium salts, reaction with organometallics, **65**, 285
- Trithiolanone, reaction with dichlorocarbene, **65**, 185
- 5,10-di-(*perythro*-Trititol-1-yl)-bisoxazolo[3,4-*a*:3',4'-*d*]pyrazine-3,8-dione, **70**, 280
- Tropanes, via carbene reactions on *N*-(methoxycarbonyl)pyrrole, **65**, 202
- Tropinooxepine, valence tautomerism, **66**, 311
- Tropolone, reactions, **66**, 327  
acidity, **66**, 330  
tautomerism, **66**, 309  
polarographic reduction, **66**, 311  
*O*-alkylation, **66**, 343
- $\gamma$ -Tropolone-2-chloroallylether, Claisen rearrangement, **66**, 393
- Tropone, basicity, **66**, 331  
reaction with diazomethane, **64**, 112  
cycloaddition with nitrile oxides, **64**, 115  
reaction with diphenylnitrilimine, **64**, 113
- Tropone 2,7-bis(thioether), rearrangement to dithienotropone, **64**, 100

- Tropone tricarbonyliron complex, reaction with diphenylnitrilimine, **64**, 113  
reactions with 3-phenylsydnone, **64**, 114
- Troponeimine, derivatives, **66**, 338  
spectra, **66**, 376
- Troponefuroxan, isomerisation by nmr, **66**, 293
- Troponoids, photochemical reaction, **66**, 329
- p*-Tropoquinone, condensation with 1,2,4,5-tetraaminobenzene, **64**, 118  
reactions, **64**, 110
- Tropothiones, preparation and spectra, **66**, 372  
*S*-alkylation, **66**, 372  
enzymatic acidity, **66**, 389
- Tropylidene quinones, **66**, 386
- Tropylium ions, NMR spectra, **66**, 315  
UV spectra, **66**, 315  
IR spectra, **66**, 319  
aromaticity, **66**, 320  
stability, **66**, 324  
polarographic reduction, **66**, 327  
reaction with nucleophiles, **66**, 379
- Tsuji-Trost reaction, palladium (0) catalysed allylation of nucleophiles, **66**, 74  
mechanism, **66**, 75  
use of mixed carbonates, **66**, 76  
use of vinyloxydes, **66**, 76  
stereochemistry, **66**, 76
- Tubercidin, in preparation of nucleosides, **67**, 405
- Tyrian purple *see* 6,6'-dibromoindigo
- 3-(2-Ulos-1-yl)indoles, preparation, **70**, 172
- Uracil, Pd(0) catalysed allylation, **66**, 107  
Pd(0) catalysed allylation in presence of trisodium triphenylphosphine trisulfonate, **66**, 111
- 2-Ureido-2-deoxyaldopyranoses, preparation, **68**, 285
- Uridine, use in preparation of nucleosides, **67**, 407
- 1',2'-*seco*-Uridine, synthesis, **67**, 397  
use in synthesis of ribavarin analogues, **67**, 408
- Urothione *see* 2-amino-7-((2'*S*)-1',2'-dihydroxyethyl)-6-(methylthio)thieno[2',3':2,3]pyrazino[6,5-*d*]pyrimidine
- Utalins, **64**, 117  
X-ray structure, **66**, 287  
mass spectra, **66**, 307
- Valeranone, **65**, 356
- Valiolactone, synthesis, **68**, 139
- Valiolamine, synthesis, **68**, 158
- Varamines A and B, **70**, 112
- Verrucarol, **65**, 350
- ( $\pm$ )-Vindoline, **67**, 232
- ( $\pm$ )-Vindorosine, synthesis, **67**, 230; **67**, 232
- Vinologous imines of amino acids, 1,5-electrocyclisation, **64**, 38
- N*-Vinylamides, **66**, 179
- Vinyl azide, cycloaddition to olefins, **67**, 217
- N*-Vinylaziridines, base catalysed isomerisation, **67**, 226  
photolysis, **67**, 230
- 3-Vinylbenzofuran, Diels-Alder reactions, **63**, 360  
reaction with 4-phenyl-1,2,4-triazole-3,5-dione, **63**, 382
- 2-Vinylbenzo[*b*]thiophene, reaction with dimethyl acetylene dicarboxylate, **63**, 354  
reaction with maleic anhydride, **63**, 367
- 3-Vinylbenzo[*b*]thiophene, reaction with benzyne **63**, 358  
reaction with maleic anhydride, **63**, 367  
reaction with tetracyanoethylene, **63**, 371
- Vinylcarbodiimides, **66**, 188
- 1-Vinylcyclopentanol, oxidation to spirooxiranes, **69**, 9
- Vinylcyclopropanes, **65**, 145
- 2-Vinyl-*N,N*-dialkylanilines, cyclisation, **65**, 3
- $\alpha$ -Vinyl- $\alpha$ -diazoesters, vinylcarbenoid formation, **65**, 106
- N*-Vinyl enamines, photolysis, **67**, 230
- 4-Vinylethylene sulfite, synthesis, **68**, 107
- Vinylfurans, intramolecular Diels-Alder reactions, **63**, 391
- 2-Vinylfuran, reaction with dimethyl acetylene dicarboxylate, **63**, 341  
dimerisation, **63**, 370  
reaction with methyl propiolate, **63**, 341  
high pressure reaction with dimethyl malonate, **63**, 320  
reaction with maleic anhydride, **63**, 359  
reaction with tetrabromocyclopropene, **63**, 359

- Vinylglycine, reaction with  
tribromoformaldoxime, **64**, 20
- Vinylidenephosphirane, **65**, 170
- 1-Vinylimidazole-2-thiones, intramolecular  
cyclisation, **69**, 283
- N*-Vinyliminophosphoranes, **64**, 166  
reaction with  $\alpha$ -bromoketones, **64**, 187  
reaction with aromatic isocyanates, **64**, 188  
reaction with isonitriles, **64**, 188  
reaction with  $\alpha,\beta$ -unsaturated ketones,  
**64**, 203
- 2-Vinylindole, cycloaddition reactions,  
**63**, 348  
reaction with methyl propiolate, **63**, 350  
Diels-Alder reaction, **63**, 363  
reaction with tetracyanoethylene, **63**, 375  
acid catalysed reaction with  $\alpha,\beta$ -  
unsaturated ketones, **63**, 378
- 3-Vinylindole, cycloaddition reactions,  
**63**, 348  
reaction with acrylonitrile, ethyl acetate  
and cinnamaldehyde, **63**, 375  
Diels-Alder reaction, **63**, 362  
asymmetric Diels-Alder reaction, **63**, 378  
intramolecular Diels-Alder reaction, **63**,  
394
- 2(2-Vinyloxyethyl)pyridine, reaction with  
bromine, **70**, 53
- 4-Vinylpyrazole, Diels-Alder reactions, **63**,  
368
- 5-Vinylpyrazole, Diels-Alder reactions, **63**,  
368
- 2-Vinylpyridine, **63**, 357  
reaction with *N*-phenylmaleimide, **63**, 368  
reaction with diethyl azidodicarboxylate,  
**63**, 390  
conversion to imidazolines by reaction with  
chlorocarbenes, **65**, 116
- 4-Vinylpyridine, 1:3 adduct with *N*-  
phenylmaleimide, **63**, 368
- Vinylpyridinium salts, reduction to  
enaminones, **67**, 217
- 2-Vinylpyrrole, reaction with diethyl  
diazoacetate, **63**, 383
- N*-Vinylpyrroles, synthesis, **67**, 235
- 2-Vinylthiophene, reaction with dimethyl  
acetylene dicarboxylate, **63**, 352  
Diels-Alder reaction, **63**, 366  
dimerisation, **63**, 378  
reaction with methyl acrylate, **63**, 379  
reaction with methyl propiolate, **63**, 352  
reaction with 1,4-benzoquinone, **63**, 366  
polymerisation, **63**, 353  
reaction with tetrabromocyclopropene,  
**63**, 366  
reaction with 4-phenyl-1,2,4-triazole-3,5-  
dione, **63**, 386
- 3-Vinylthiophene, reaction with dimethyl  
acetylene dicarboxylate, **63**, 354  
reaction with methyl propiolate, **63**, 354
- Virginiamycin  $M_2$ , synthesis, **67**, 264
- Xanthine oxidase, in preparation of 6-  
deoxyacyclovir, **69**, 135
- Xanthone, synthesis from 2-  
aryliodonobenzoates, **69**, 54  
Xanthothricin, isolation **61**, 247  
naturally occurring metabolite of 7-  
azapteridine **61**, 247  
synthesis **61**, 250  
stimulator of oxidation in mitochondria  
**61**, 261  
source **61**, 262
- 3'- $\alpha$ -D-Xylofuranosylimidazo[4,5-  
*d*]pyrimidine, **70**, 249
- 5-( $\beta$ -Xylofuranosyl)uracil, **68**, 367
- Yohimboid alkaloids, synthesis **67**, 287
- Yukocitrine, **70**, 138
- Zinc alkyls, coupling to halogenated  
heterocycles, **62**, 375
- Zincation of haloheterocycles, **62**, 381

This Page Intentionally Left Blank



ISBN 0-12-020770-2

